PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lew, DP; Waldvogel, FA				Lew, DP; Waldvogel, FA			Osteomyelitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FOREIGN-BODY INFECTION; STAPHYLOCOCCUS-AUREUS; THERAPEUTIC CONSIDERATIONS; CLINICAL FEATURES; DIABETIC-PATIENTS; TOTAL HIP; BONE; FOOT; OSTEOPOROSIS; REPLACEMENT		UNIV HOSP GENEVA,DEPT MED,MED CLIN 2,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva	Lew, DP (corresponding author), UNIV HOSP GENEVA,DEPT MED,DIV INFECT DIS,24 RUE MICHELI DU CREST,CH-1211 GENEVA 14,SWITZERLAND.							Belmatoug N, 1996, J INFECT DIS, V174, P414, DOI 10.1093/infdis/174.2.414; Boxma H, 1996, LANCET, V347, P1133, DOI 10.1016/S0140-6736(96)90606-6; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; Charnley J, 1972, Clin Orthop Relat Res, V87, P167, DOI 10.1097/00003086-197209000-00020; CHUARD C, 1991, J INFECT DIS, V163, P1369; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; D'Hoore K, 1993, Acta Orthop Belg, V59, P306; DAROUICHE RO, 1994, ARCH INTERN MED, V154, P753, DOI 10.1001/archinte.154.7.753; DELLINGER EP, 1988, ARCH SURG-CHICAGO, V123, P333; DRANCOURT M, 1993, ANTIMICROB AGENTS CH, V37, P1214, DOI 10.1128/AAC.37.6.1214; ECKARDT JJ, 1994, CLIN ORTHOP RELAT R, V298, P229; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P712, DOI 10.1001/jama.273.9.712; FISCHER B, 1996, J ORTHOPAED RES, V14, P1914; GENTRY LO, 1991, ANN INTERN MED, V114, P986, DOI 10.7326/0003-4819-114-11-986; GOLD RH, 1991, AM J ROENTGENOL, V157, P365, DOI 10.2214/ajr.157.2.1853823; GOLD RH, 1995, SKELETAL RADIOL, V24, P563; GORDON L, 1988, J BONE JOINT SURG AM, V70A, P377, DOI 10.2106/00004623-198870030-00009; GRANINGER W, 1995, EUR J CLIN MICROBIOL, V14, P643, DOI 10.1007/BF01690746; GRAYSON ML, 1995, JAMA-J AM MED ASSOC, V273, P721, DOI 10.1001/jama.273.9.721; GREEN SA, 1991, ORTHOP CLIN N AM, V22, P515; Greene C, 1996, MICROBIOL-UK, V142, P2153, DOI 10.1099/13500872-142-8-2153; GRMEK M, 1983, MALADIES AUBE CIVILI, P190; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HERMANN M, 1988, J INFECT DIS, V158, P693; HILL C, 1981, LANCET, V1, P795; HOWARD CB, 1994, J BONE JOINT SURG BR, V76B, P311, DOI 10.1302/0301-620X.76B2.8113300; Hudson MC, 1995, MICROB PATHOGENESIS, V19, P409, DOI 10.1006/mpat.1995.0075; Jauregui, 1995, DIAGNOSIS MANAGEMENT; Klenerman L, 1991, Acta Orthop Belg, V57, P19; Lew D P, 1995, Drugs, V49 Suppl 2, P100; LEW DP, 1996, HOSP EPIDEMIOLOGY IN, P731; LIDWELL OM, 1982, BRIT MED J, V285, P10, DOI 10.1136/bmj.285.6334.10; MACKOWIAK PA, 1978, JAMA-J AM MED ASSOC, V239, P2772, DOI 10.1001/jama.239.26.2772; MADER JT, 1992, CLIN INFECT DIS, V15, pS155, DOI 10.1093/clind/15.Supplement_1.S155; MANION SS, 1995, DIAGNOSIS MANAGEMENT, P325; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MATHES SJ, 1982, NEW ENGL J MED, V306, P294, DOI 10.1056/NEJM198202043060509; MORRISON WB, 1993, RADIOLOGY, V189, P251, DOI 10.1148/radiology.189.1.8204132; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; NELSON CL, 1993, CLIN ORTHOP RELAT R, V295, P96; NELSON JD, 1996, CLIN TOPICS INFECT D, V4, P64; NEWMAN LG, 1992, DIABETES CARE, V15, P1527, DOI 10.2337/diacare.15.11.1527; NORDEN C, 1992, CLIN INFECT DIS, V15, pS177, DOI 10.1093/clind/15.Supplement_1.S177; NORDEN CW, 1988, REV INFECT DIS, V10, P103; NORDEN CW, 1991, REV INFECT DIS, V13, pS842; OYEN WJG, 1990, J NUCL MED, V31, P403; PAPINEAU LJ, 1979, INT ORTHOP, V3, P165; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; PATZAKIS MJ, 1974, J BONE JOINT SURG AM, VA 56, P532, DOI 10.2106/00004623-197456030-00010; PIROFSKY JG, 1993, SPINE, V18, P1926, DOI 10.1097/00007632-199310000-00036; PROCTOR RA, 1995, CLIN INFECT DIS, V20, P95, DOI 10.1093/clinids/20.1.95; REESE JH, 1995, DIAGNOSIS MANAGEMENT, P425; SCHAAD HJ, 1994, ANTIMICROB AGENTS CH, V38, P1703, DOI 10.1128/AAC.38.8.1703; SOWA DT, 1987, ORTHOP CLIN N AM, V18, P257; TANG C, 1993, J INFECTION, V26, P89, DOI 10.1016/0163-4453(93)97064-5; TORDA AJ, 1995, CLIN INFECT DIS, V20, P320, DOI 10.1093/clinids/20.2.320; TUMEH SS, 1991, RHEUM DIS CLIN N AM, V17, P559; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P198, DOI 10.1056/NEJM197001222820406; WALDVOGEL FA, 1980, NEW ENGL J MED, V303, P360, DOI 10.1056/NEJM198008143030703; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P316, DOI 10.1056/NEJM197002052820606; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P260, DOI 10.1056/NEJM197001292820507; WEILAND AJ, 1984, J BONE JOINT SURG AM, V66A, P181, DOI 10.2106/00004623-198466020-00004; WIDMER AF, 1992, CLIN INFECT DIS, V14, P1251, DOI 10.1093/clinids/14.6.1251; ZIMMERLI W, 1984, J CLIN INVEST, V73, P1191, DOI 10.1172/JCI111305	64	478	502	1	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	1997	336	14					999	1007		10.1056/NEJM199704033361406	http://dx.doi.org/10.1056/NEJM199704033361406			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR385	9077380				2022-12-28	WOS:A1997WR38500006
J	Aggeli, A; Bell, M; Boden, N; Keen, JN; Knowles, PF; McLeish, TCB; Pitkeathly, M; Radford, SE				Aggeli, A; Bell, M; Boden, N; Keen, JN; Knowles, PF; McLeish, TCB; Pitkeathly, M; Radford, SE			Responsive gels formed by the spontaneous self-assembly of peptides into polymeric beta-sheet tapes	NATURE			English	Article							SUPRAMOLECULAR CHEMISTRY; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; PROTEIN; STABILITY; FILAMENTS; DOMAIN; ALPHA	Molecular self-assembly is becoming an increasingly popular route to new supramolecular structures and molecular materials(1-7). The inspiration for such structures is commonly derived from self-assembling systems in biology. Here we show that a biological motif, the peptide beta-sheet, can be exploited in designed oligopeptides that self-assemble into polymeric tapes and with potentially useful mechanical properties. We describe the construction of oligopeptides, rationally designed or based on segments of native proteins, that aggregate in suitable solvents into long, semi-flexible beta-sheet tapes. These become entangled even at low volume fractions to form gels whose viscoelastic properties can be controlled by chemical (pH) or physical (shear) influences. We suggest that it should be possible to engineer a wide range of properties in these gels by appropriate choice of the peptide primary structure.	UNIV LEEDS,CTR SELF ORGANISING MOL SYST,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,SCH CHEM,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT PHYS,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV OXFORD,OXFORD CTR MOL SCI,OXFORD OX1 3QT,ENGLAND; UNIV OXFORD,NEW CHEM LAB,OXFORD OX1 3QT,ENGLAND	University of Leeds; University of Leeds; University of Leeds; University of Leeds; University of Oxford; University of Oxford				McLeish, Tom/0000-0002-2025-0299; Radford, Sheena/0000-0002-3079-8039	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aggeli A, 1996, BIOCHEMISTRY-US, V35, P16213, DOI 10.1021/bi960891g; BALL P, 1994, NATURE, V371, P202, DOI 10.1038/371202a0; Berg RH, 1996, NATURE, V383, P505, DOI 10.1038/383505a0; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; CHIRGADZE YN, 1973, BIOPOLYMERS, V12, P1337, DOI 10.1002/bip.1973.360120610; Choo DW, 1996, MACROMOLECULES, V29, P355, DOI 10.1021/ma950703e; CLARK AH, 1987, ADV POLYM SCI, V83, P57; CLAUSEN TM, 1992, J PHYS CHEM-US, V96, P474, DOI 10.1021/j100180a086; Doi M., 1988, THEORY POLYM DYNAMIC; Ferry J.D., 1980, VISCOELASTIC PROPERT; GAY NJ, 1991, FEBS LETT, V291, P87, DOI 10.1016/0014-5793(91)81110-T; GEISLER N, 1993, J STRUCT BIOL, V110, P205, DOI 10.1006/jsbi.1993.1023; GUO H, 1994, J PHYS CHEM-US, V98, P7104, DOI 10.1021/j100080a002; HANABUSA K, 1994, J CHEM SOC CHEM COMM, P2683, DOI 10.1039/c39940002683; KAMLET MJ, 1983, J ORG CHEM, V48, P2877, DOI 10.1021/jo00165a018; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; LOKEY RS, 1995, NATURE, V375, P303; Mayo KH, 1996, PROTEIN SCI, V5, P1301, DOI 10.1002/pro.5560050709; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; Muller A, 1996, NATURE, V383, P296, DOI 10.1038/383296a0; Nyrkova IA, 1996, J PHYS II, V6, P1411, DOI 10.1051/jp2:1996139; OTZEN DE, 1995, BIOCHEMISTRY-US, V34, P5718, DOI 10.1021/bi00017a003; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; STOCK HT, 1995, J CHEM SOC CHEM COMM, P2063, DOI 10.1039/c39950002063; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; TAKUMI T, 1993, NEWS PHYSIOL SCI, V8, P175; Vegners R, 1995, J Pept Sci, V1, P371, DOI 10.1002/psc.310010604; YANG JJ, 1994, BIOCHEMISTRY-US, V33, P7345, DOI 10.1021/bi00189a040; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334	33	750	777	5	299	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					259	262		10.1038/386259a0	http://dx.doi.org/10.1038/386259a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069283				2022-12-28	WOS:A1997WP00300045
J	Giardiello, FM; Brensinger, JD; Petersen, GM; Luce, MC; Hylind, LM; Bacon, JA; Booker, SV; Parker, RD; Hamilton, SR				Giardiello, FM; Brensinger, JD; Petersen, GM; Luce, MC; Hylind, LM; Bacon, JA; Booker, SV; Parker, RD; Hamilton, SR			The use and interpretation of commercial APC gene testing for familial adenomatous polyposis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY ANGIOGRAPHY; DIAGNOSIS; IMPACT; COLI; ECHOCARDIOGRAPHY; APPROPRIATENESS; IDENTIFICATION; MANAGEMENT; LINKAGE; LOCUS	Background The use of commercially available tests for genes linked to familial cancer has aroused concern about the impact of these tests on patients. Familial adenomatous polyposis is an autosomal dominant disease caused by a germ-line mutation of the adenomatous polyposis coli (APC) gene that causes colorectal cancer if prophylactic colectomy is not performed. We evaluated the clinical use of commercial APC gene testing. Methods We assessed indications for APC gene testing, whether informed consent was obtained and genetic counseling was offered before testing, and the interpretation of the results through telephone interviews with physicians and genetic counselors in a nationwide sample of 177 patients from 125 families who underwent testing during 1995. Results Of the 177 patients tested, 83.0 percent had clinical features of familial adenomatous polyposis or were at risk for the disease - both valid indications for being tested. The appropriate strategy for presymptomatic testing was used in 79.4 percent (50 of 63 patients). Only 18.6 percent (33 of 177) received genetic counseling before the test, and only 16.9 percent (28 of 166) provided written informed consent. In 31.6 percent of the cases the physicians misinterpreted the test results. Among the patients with unconventional indications for testing, the rate of positive results was only 2.3 percent (1 of 44). Conclusions Patients who underwent genetic tests for familiar adenomatous polyposis often received inadequate counseling and would have been given incorrectly interpreted results. Physicians should be prepared to offer genetic counseling if they order genetic tests. (C) 1997, Massachusetts Medical Society.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21205 USA; LABCORP, DEPT MOL BIOL, RES TRIANGLE PK, NC USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA063721, U01CA053801, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA63721, CA53801, CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BROWN ML, 1995, J NATL CANCER I, V87, P1131, DOI 10.1093/jnci/87.15.1131; BULOW S, 1987, DAN MED BULL, V34, P1; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; CARTER MA, 1995, J NCI MONOGRAPHS, V17, P119; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; COHEN MM, 1994, AM J HUM GENET, V55, pR1; Collins FS, 1996, J CLIN ONCOL, V14, P1738; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; GOLDMAN L, 1980, CIRCULATION, V62, P680, DOI 10.1161/01.CIR.62.4.680; GOLDMAN L, 1983, AM J MED, V75, P49, DOI 10.1016/0002-9343(83)91167-1; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Holtzman N A, 1996, Oncology (Williston Park), V10, P57; HOLTZMANN NA, 1995, JNCI-J NATL CANCER I, V17, P95; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KAHN KL, 1988, ANN INTERN MED, V109, P664, DOI 10.7326/0003-4819-109-8-664; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MCDONALD IG, 1988, J CLIN EPIDEMIOL, V41, P151, DOI 10.1016/0895-4356(88)90089-3; *NIH DOE WORK GROP, 1996, INT PRINC TASK FORC; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Petersen G M, 1996, Oncology (Williston Park), V10, P89; Petersen G M, 1995, J Natl Cancer Inst Monogr, P67; PETERSEN GM, 1991, GASTROENTEROLOGY, V100, P1658, DOI 10.1016/0016-5085(91)90666-9; PETERSEN GM, 1995, SEMIN COLON RECTAL S, V6, P55; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SPIRIO L, 1992, AM J HUM GENET, V51, P92; WERTZ DC, 1994, JAMA-J AM MED ASSOC, V272, P875, DOI 10.1001/jama.272.11.875	29	346	354	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					823	827		10.1056/NEJM199703203361202	http://dx.doi.org/10.1056/NEJM199703203361202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN371	9062090				2022-12-28	WOS:A1997WN37100002
J	Gerber, MA; Tanz, RR; Kabat, W; Dennis, E; Bell, GL; Kaplan, EL; Shulman, ST				Gerber, MA; Tanz, RR; Kabat, W; Dennis, E; Bell, GL; Kaplan, EL; Shulman, ST			Optical immunoassay test for group A beta-hemolytic streptococcal pharyngitis - An office-based, multicenter investigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GROUP-A STREPTOCOCCI; THROAT SWABS; RHEUMATIC-FEVER; CULTURE METHODS; STREP-A; DIAGNOSIS; ASSAYS; OIA	Objective.-To compare the accuracy of an optical immunoassay (OIA) for the rapid diagnosis of group A streptococcal pharyngitis with blood agar plate (BAP) culture. Design.-Blinded comparison with criterion standard. Setting.-A total of 6 private pediatricians' offices, 3 in Connecticut and 3 in Chicago, Ill. Patients.-A total of 2113 consecutive patients with acute pharyngitis, 983 in Connecticut and 1130 in Chicago. Main Outcome Measures.-The sensitivities and specificities of OIA and BAP culture (both performed and interpreted in the office) were determined using a research laboratory's interpretation of a combination of BAP culture and Todd-Hewitt broth (THB) culture of transport tube pledget as criterion standard. Results.-Among patients in Connecticut, the sensitivities of the OIA and BAP culture were 94% and 89%, respectively (P=.004), while the specificities were 96% and 99%, respectively (P=.001), Among patients in Chicago, the sensitivities of the OIA and BAP culture were 79% and 72%, respectively (P<.001), while the specificities were 89% and 99%, respectively (P<.001). In each of the 6 pediatricians' offices, the OIA was more sensitive than the BAP culture. Combining the data from Connecticut and Chicago, the overall sensitivities of the OIA and BAP culture were 84% and 78%, respectively (P<.001), while the specificities were 93% and 99%, respectively (P<.001). Conclusions.-The results of this comprehensive office-based investigation suggest that with adequately trained personnel, negative OIA test results may not always need to be routinely confirmed with BAP cultures.	UNIV CONNECTICUT,SCH MED,DEPT PEDIAT,FARMINGTON,CT 06032; NORTHWESTERN UNIV,DEPT PEDIAT,SCH MED,EVANSTON,IL 60208; CHILDRENS MEM HOSP,CHICAGO,IL 60614; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455	University of Connecticut; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Minnesota System; University of Minnesota Twin Cities	Gerber, MA (corresponding author), CONNECTICUT CHILDRENS MED CTR,282 WASHINGTON ST,HARTFORD,CT 06106, USA.							ANHALT JP, 1992, J CLIN MICROBIOL, V30, P2135, DOI 10.1128/JCM.30.8.2135-2138.1992; *COMM INF DIS, 1994, 1994 REDB, P430; DAJANI A, 1995, PEDIATRICS, V96, P758; DALE JC, 1994, J CLIN MICROBIOL, V32, P2698, DOI 10.1128/JCM.32.11.2698-2701.1994; DALY JA, 1994, J CLIN MICROBIOL, V32, P531, DOI 10.1128/JCM.32.2.531-532.1994; DELLALATTA P, 1994, PEDIATR INFECT DIS J, V13, P742, DOI 10.1097/00006454-199408000-00013; FRIES SM, 1995, J PEDIATR-US, V126, P933, DOI 10.1016/S0022-3476(95)70213-X; GERBER MA, 1990, J CLIN MICROBIOL, V28, P1463, DOI 10.1128/JCM.28.6.1463-1464.1990; GERBER MA, 1989, PEDIATR INFECT DIS J, V8, P820, DOI 10.1097/00006454-198911000-00032; HARBECK RJ, 1993, J CLIN MICROBIOL, V31, P839, DOI 10.1128/JCM.31.4.839-844.1993; HEITER BJ, 1995, J CLIN MICROBIOL, V33, P1408, DOI 10.1128/JCM.33.5.1408-1410.1995; RODDEY OF, 1995, J PEDIATR-US, V126, P931, DOI 10.1016/S0022-3476(95)70212-1; ROE M, 1995, J CLIN MICROBIOL, V33, P1551, DOI 10.1128/JCM.33.6.1551-1553.1995; Schlager TA, 1996, ARCH PEDIAT ADOL MED, V150, P245, DOI 10.1001/archpedi.1996.02170280015002; SCHWARTZ B, 1994, JAMA-J AM MED ASSOC, V271, P234, DOI 10.1001/jama.271.3.234; SHULMAN ST, 1994, PEDIATR INFECT DIS J, V13, P567, DOI 10.1097/00006454-199406000-00034; STEVENS DL, 1995, EMERG INFECT DIS, V1, P69, DOI 10.3201/eid0103.950301; TANZ RR, 1994, PATHOGENIC STREPTOCO, P6; WEGNER DL, 1992, JAMA-J AM MED ASSOC, V267, P695, DOI 10.1001/jama.267.5.695	19	80	81	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					899	903		10.1001/jama.277.11.899	http://dx.doi.org/10.1001/jama.277.11.899			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062328				2022-12-28	WOS:A1997WM77400033
J	Aguzzi, A				Aguzzi, A			Neuro-immune connection in spread of prions in the body?	LANCET			English	Editorial Material							SCRAPIE; MICE				Aguzzi, A (corresponding author), UNIV ZURICH HOSP,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND.		Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; KIMBERLIN RH, 1980, J GEN VIROL, V51, P183, DOI 10.1099/0022-1317-51-1-183; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lasmezas CI, 1996, J VIROL, V70, P1292; MURAMOTO T, 1993, J VIROL, V67, P6808, DOI 10.1128/JVI.67.11.6808-6810.1993; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762	11	62	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					742	743		10.1016/S0140-6736(97)22011-8	http://dx.doi.org/10.1016/S0140-6736(97)22011-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074567				2022-12-28	WOS:A1997WN12400002
J	Goodman, R				Goodman, R			Child mental health: Who is responsible? An overextended remit	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE				Goodman, R (corresponding author), INST PSYCHIAT,DEPT CHILD & ADOLESCENT PSYCHIAT,LONDON SE5 8AF,ENGLAND.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BIRD HR, 1988, ARCH GEN PSYCHIAT, V45, P1120; BRANDENBURG NA, 1990, J AM ACAD CHILD PSY, V29, P76, DOI 10.1097/00004583-199001000-00013; Department of Health, 1995, HDB CHILD AD MENT HL; NHS Health Advisory Service, 1995, CHILD AD MENT HLTH S; Rapoport Judith L., 1989, OBSESSIVE COMPULSIVE; Taylor E, 1991, EPIDEMIOLOGY CHILDHO; *WHO, 1978, PRIM HLTH CAR; World Health Organisation, 1993, ICD 10 CLASSIFICATIO	9	18	18	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					813	814		10.1136/bmj.314.7083.813	http://dx.doi.org/10.1136/bmj.314.7083.813			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN646	9081004	Green Published			2022-12-28	WOS:A1997WN64600035
J	Lendon, CL; Ashall, F; Goate, AM				Lendon, CL; Ashall, F; Goate, AM			Exploring the etiology of Alzheimer disease using molecular genetics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E POLYMORPHISM; ISOFORM-SPECIFIC BINDING; BETA-PROTEIN; MISSENSE MUTATION; EPSILON-4 ALLELE; S182 GENE; CHROMOSOME 14Q24.3; SENILE PLAQUES; TYPE-4 ALLELE		WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; ST LOUIS UNIV, SCH MED, ST LOUIS, MO USA	Washington University (WUSTL); Washington University (WUSTL); Saint Louis University				Goate, Alison/0000-0002-0576-2472	NIA NIH HHS [AG00634] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1992, J NEUROCHEM, V59, P2328; BACHMAN DL, 1992, NEUROLOGY, V42, P115, DOI 10.1212/WNL.42.1.115; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Boteva K, 1996, LANCET, V347, P130, DOI 10.1016/S0140-6736(96)90261-5; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; BROOKS WS, 1995, NEUROSCI LETT, V199, P183, DOI 10.1016/0304-3940(95)12046-7; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; Campion D, 1996, J MED GENET, V33, P661, DOI 10.1136/jmg.33.8.661; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; DAVIS KL, 1993, NEUROLOGY, V43, pS52; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FIDANI L, 1992, HUM MOL GENET, V1, P165, DOI 10.1093/hmg/1.3.165; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gearing M, 1996, ANN NEUROL, V39, P395, DOI 10.1002/ana.410390320; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOATE AM, 1989, LANCET, V1, P352; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HALTIA M, 1994, NEUROLOGY, V36, P862; HARDY J, 1993, LANCET, V342, P737; HARDY J, 1997, 1997 KEYST S MOL MEC; HENDRIE HC, 1995, ANN NEUROL, V37, P118, DOI 10.1002/ana.410370123; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hutton M, 1996, NEUROREPORT, V7, P801, DOI 10.1097/00001756-199602290-00029; Isoe K, 1996, ACTA NEUROL SCAND, V93, P133; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; Katzman R, 1996, NEUROLOGY, V46, P889; KAWAMATA J, 1994, J NEUROL NEUROSUR PS, V57, P1414, DOI 10.1136/jnnp.57.11.1414; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LAMPE TH, 1994, ANN NEUROL, V36, P368, DOI 10.1002/ana.410360308; Lee Virginia M.-Y., 1995, P41, DOI 10.1016/B978-012286965-5/50005-4; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; LIPPA CF, 1995, NEUROLOGY, V45, P97, DOI 10.1212/WNL.45.1.97; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MANN DMA, 1986, NEUROPATH APPL NEURO, V12, P447, DOI 10.1111/j.1365-2990.1986.tb00053.x; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; MARDER K, 1994, NEUROLOGY, V44, P1330, DOI 10.1212/WNL.44.7.1330; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MORRIS JC, 1991, GERIATRICS, V46, P47; MULLAN M, 1992, NAT GENET, V2, P340, DOI 10.1038/ng1292-340; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MULLAN M, 1993, NEUROBIOL AGING, V14, P407, DOI 10.1016/0197-4580(93)90099-W; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NEE LE, 1983, ARCH NEUROL-CHICAGO, V40, P203, DOI 10.1001/archneur.1983.04050040033004; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OSUNTOKUN BO, 1995, ANN NEUROL, V38, P463, DOI 10.1002/ana.410380319; PerezTur J, 1995, NEUROREPORT, V7, P297; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; PFLIEGERBRUSS S, 1995, LANCET, V346, P1040, DOI 10.1016/S0140-6736(95)91724-1; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; Prihar G, 1996, NEUROREPORT, V7, P1680, DOI 10.1097/00001756-199607080-00031; ROBAKIS NK, 1987, LANCET, V1, P384; ROCH JM, 1992, J BIOL CHEM, V267, P2214; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1991, AM J HUM GENET, V49, P511; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; SORBI S, 1995, LANCET, V346, P439, DOI 10.1016/S0140-6736(95)92809-X; SORBI S, 1995, ANN NEUROL, V38, P124, DOI 10.1002/ana.410380120; STCLAIR D, 1994, NEUROSCI LETT, V176, P45, DOI 10.1016/0304-3940(94)90867-2; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; TANAHASHI H, 1995, LANCET, V346, P440, DOI 10.1016/S0140-6736(95)92810-3; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TANZI RE, 1992, AM J HUM GENET, V51, P273; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; VAN BROECKHOVEN C, 1992, NAT GENET, V2, P335, DOI 10.1038/ng1292-335; Van Broeckhoven C, 1995, NAT GENET, V11, P230; VAN BROECKHOVEN C, 1994, NEUROSCI LETT, V169, P179, DOI 10.1016/0304-3940(94)90385-9; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; vanDuijn CM, 1996, J NEUROL NEUROSUR PS, V60, P478, DOI 10.1136/jnnp.60.5.478; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wang JZ, 1996, NAT MED, V2, P871, DOI 10.1038/nm0896-871; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z; ZHOU Z, 1993, P NATL ACAD SCI USA, V90, P8098	129	219	232	2	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					825	831		10.1001/jama.277.10.825	http://dx.doi.org/10.1001/jama.277.10.825			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM082	9052714				2022-12-28	WOS:A1997WM08200037
J	Collee, JG; Bradley, R				Collee, JG; Bradley, R			BSE: A decade on .2.	LANCET			English	Review							CREUTZFELDT-JAKOB-DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; PRION PROTEIN; SCRAPIE; MICE; TRANSMIT; UK	Predicted numbers vary widely but the most authoritative estimate is that about 6950 cases of BSE will occur in cattle in the UH during 1997-2001 if new infections via feed have ceased as expected and if 10% maternal transmission occurs in the last half-year of the maternal incubation period. This assumes no culling or premature slaughter. Agreed cull strategies would reduce these numbers considerably and accelerate the observed rate of decline of the disease, but there is no scientific necessity for any cull. Bovine products that were banned as specified bovine offals in 1989/90 and as specified bovine materials by successive legislation are now excluded from the food and feed chains. As this second of the two-part article on BSE shows, there has been slippage in some of our control measures, but public and animal health are adequately protected if the legislation that has been evolved is enforced along present lines. Meanwhile, for human beings, bovine milk is safe to drink and beef is safe to eat.	CENT VET LAB, ADDLESTONE, SURREY, ENGLAND		Collee, JG (corresponding author), UNIV EDINBURGH, SCH MED, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.							Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; [Anonymous], 1995, BRIT MED J, V311, P1415, DOI 10.1136/bmj.311.7017.1415a; BATEMAN D, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91828-0; Bignell J, 1996, LANCET, V348, P602, DOI 10.1016/S0140-6736(05)64804-0; BRITTON TC, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91827-2; Brown P, 1996, BRIT MED J, V312, P790, DOI 10.1136/bmj.312.7034.790; Collee JG, 1996, LANCET, V347, P917, DOI 10.1016/S0140-6736(96)91408-7; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; DAVIES PTG, 1993, LANCET, V342, P680, DOI 10.1016/0140-6736(93)91787-M; DEARMOND S, 1995, BRAIN PATHOL, V5, P77, DOI 10.1111/j.1750-3639.1995.tb00579.x; DELASNERIELAUPRETRE N, 1995, LANCET, V346, P898, DOI 10.1016/S0140-6736(95)92735-2; Deslys JP, 1996, LANCET, V347, P1332, DOI 10.1016/S0140-6736(96)90979-4; Finkel E, 1996, LANCET, V348, P326; Foncin JF, 1996, LANCET, V347, P1332, DOI 10.1016/S0140-6736(96)90979-4; FRASER H, 1992, J GEN VIROL, V73, P1891, DOI 10.1099/0022-1317-73-8-1891; FRASER H, 1994, TRANSMISSIBLE SPONGI, P145; Garland T, 1996, LANCET, V348, P610, DOI 10.1016/S0140-6736(05)64821-0; Goldmann W, 1996, NATURE, V382, P32, DOI 10.1038/382032b0; HADLOW WJ, 1982, J INFECT DIS, V146, P657, DOI 10.1093/infdis/146.5.657; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; HOINVILLE LJ, 1995, VET REC, V136, P312, DOI 10.1136/vr.136.13.312; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; KIMBERLIN RH, 1988, J GEN VIROL, V69, P2953, DOI 10.1099/0022-1317-69-12-2953; Krakauer DC, 1996, NATURE, V380, P675, DOI 10.1038/380675a0; KULCZYCKI J, 1991, EUR J EPIDEMIOL, V7, P501, DOI 10.1007/BF00143129; Lee KH, 1996, LANCET, V348, P887, DOI 10.1016/S0140-6736(96)24039-5; MIDDLETON DJ, 1993, VET REC, V132, P545, DOI 10.1136/vr.132.22.545; *NAT CJD SURV UN D, 1994, CREUTZF JAK DIS SURV; PRUSINER SB, 1995, SCI AM, V272, P48, DOI 10.1038/scientificamerican0195-48; SAWCER SJ, 1993, LANCET, V341, P642, DOI 10.1016/0140-6736(93)90414-C; SCOTT JR, 1993, VET MICROBIOL, V34, P305, DOI 10.1016/0378-1135(93)90055-C; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SMITH PEM, 1995, LANCET, V346, P898, DOI 10.1016/S0140-6736(95)92734-4; Stekel DJ, 1996, NATURE, V381, P119, DOI 10.1038/381119a0; TAYLOR KC, 1991, VET REC, V129, P522; *WHO, 1996, WHO CONS CLIN NEUR C; Wickham EA, 1996, BRIT MED J, V312, P988, DOI 10.1136/bmj.312.7037.988; Will R, 1996, BRIT MED J, V313, P833; Will RG, 1996, LANCET, V348, P955, DOI 10.1016/S0140-6736(96)24040-1; WILL RG, 1996, SURVEILLANCE PRION D, P119; Young GR, 1996, LANCET, V348, P610, DOI 10.1016/S0140-6736(05)64822-2; Zerr I, 1996, LANCET, V348, P846, DOI 10.1016/S0140-6736(96)08077-4; 1996, LANCET, V348, P835	46	69	73	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	1997	349	9053					715	721		10.1016/S0140-6736(96)08496-6	http://dx.doi.org/10.1016/S0140-6736(96)08496-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078212				2022-12-28	WOS:A1997WM08000044
J	Nightingale, SL				Nightingale, SL			Over-the-counter test system for drugs of abuse approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					703	703						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042830				2022-12-28	WOS:A1997WK02600010
J	DiRocco, M; Patrini, C; Rimini, A; Rindi, G				DiRocco, M; Patrini, C; Rimini, A; Rindi, G			A 6-month-old girl with cardiomyopathy who nearly died	LANCET			English	Article									G GASLINI INST CHILDREN,CARDIAC UNIT,I-16147 GENOA,ITALY; UNIV PAVIA,INST HUMAN PHYSIOL,I-27100 PAVIA,ITALY	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Pavia	DiRocco, M (corresponding author), G GASLINI INST CHILDREN,PEDIAT DIV 2,I-16147 GENOA,ITALY.		rimini, alessandro/AAA-9439-2021	rimini, alessandro/0000-0002-2545-9235				BAKKER HD, 1991, J INHERIT METAB DIS, V14, P75, DOI 10.1007/BF01804393; Burch M, 1996, ARCH DIS CHILD, V74, P479, DOI 10.1136/adc.74.6.479; Loew D, 1996, INT J CLIN PHARM TH, V34, P47; RINDI G, 1994, J INHERIT METAB DIS, V17, P667, DOI 10.1007/BF00712009; RINDI G, 1992, P 1 INT C VIT BIOF L	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					616	616		10.1016/S0140-6736(96)10338-X	http://dx.doi.org/10.1016/S0140-6736(96)10338-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057735				2022-12-28	WOS:A1997WK91500013
J	Amano, M; Chihara, K; Kimura, K; Fukata, Y; Nakamura, N; Matsuura, Y; Kaibuchi, K				Amano, M; Chihara, K; Kimura, K; Fukata, Y; Nakamura, N; Matsuura, Y; Kaibuchi, K			Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase	SCIENCE			English	Article							GTP-BINDING-PROTEIN; SIGNAL-TRANSDUCTION; CATALYTIC DOMAINS; GENE-PRODUCT; GROWTH; RAS; CELLS; INVOLVEMENT; REGULATOR; GTPASES	The small guanosine triphosphatase (GTPase) Rho is implicated in the formation of stress fibers and focal adhesions in fibroblasts stimulated by extracellular signals such as lysophosphatidic acid (LPA). Rho-kinase is activated by Rho and may mediate some biological effects of Rho. Microinjection of the catalytic domain of Rho-kinase into serum-starved Swiss 3T3 cells induced the formation of stress fibers and focal adhesions, whereas microinjection of the inactive catalytic domain, the Rho-binding domain, or the pleckstrin-homology domain inhibited the LPA-induced formation of stress fibers and focal adhesions. Thus, Rho-kinase appears to mediate signals from Rho and to induce the formation of stress fibers and focal adhesions.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; KYOTO UNIV,FAC MED,DEPT ANAT 2,KYOTO 606,JAPAN; NATL INST HLTH,DEPT VIROL 2,TOKYO 162,JAPAN	Nara Institute of Science & Technology; Kyoto University			Kimura, Kazushi/ABB-4007-2020; Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524; Fukata, Yuko/0000-0001-7724-8643				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AMANO M, UNPUB; Bussey H, 1996, SCIENCE, V272, P224, DOI 10.1126/science.272.5259.224; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RAPP UR, 1991, ONCOGENE, V6, P495; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1994, ONCOGENE, V9, P273; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	36	919	960	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1308	1311		10.1126/science.275.5304.1308	http://dx.doi.org/10.1126/science.275.5304.1308			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036856				2022-12-28	WOS:A1997WK64400043
J	Lindner, KH; Dirks, B; Strohmenger, HU; Prengel, AW; Lindner, IM; Lurie, KG				Lindner, KH; Dirks, B; Strohmenger, HU; Prengel, AW; Lindner, IM; Lurie, KG			Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation	LANCET			English	Article							HIGH-DOSE EPINEPHRINE; ORGAN BLOOD-FLOW; CARDIOPULMONARY-RESUSCITATION; CARDIAC-ARREST	Background Studies in animals have suggested that intravenous vasopressin is associated with better vital-organ perfusion and resuscitation rates than is epinephrine in the treatment of cardiac arrest. We did a randomised comparison of vasopressin with epinephrine in patients with ventricular fibrillation in out-of-hospital cardiac arrest. Methods 40 patients in ventricular fibrillation resistant to electrical defibrillation were prospectively and randomly assigned epinephrine (1 mg intravenously; n=20) or vasopressin (40 U intravenously; n=20) as primary drug therapy for cardiac arrest, The endpoints of this double-blind study were successful resuscitation (hospital admission), survival for 24 h, survival to hospital discharge, and neurological outcome (Glasgow coma scale). Analyses were by intention to treat, Findings Seven (35%) patients in the epinephrine group and 14 (70%) in the vasopressin group survived to hospital admission (p=0.06). At 24 h, four (20%) epinephrine-treated patients and 12 (60%) vasopressin-treated patients were alive (p=0.02). Three (15%) patients in the epinephrine group and eight (40%) in the vasopressin group survived to hospital discharge (p=0.16). Neurological outcomes were similar (mean Glasgow coma score at hospital discharge 10.7 [SE 3.8] vs 11.7 [1.6], p=0.78). Interpretation In this preliminary study, a significantly larger proportion of patients treated with vasopressin than of those treated with epinephrine were resuscitated successfully from out-of-hospital ventricular fibrillation and survived for 24 h, Based upon these findings, larger multicentre studies of vasopressin in the treatment of cardiac arrest are needed.	UNIV ULM,DEPT ANESTHESIOL & CRIT CARE MED,ULM,GERMANY; UNIV MINNESOTA,DIV CARDIOVASC,DEPT MED,MINNEAPOLIS,MN 55455	Ulm University; University of Minnesota System; University of Minnesota Twin Cities								BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; CUMMINS RO, 1993, ANN EMERG MED, V22, P37, DOI 10.1016/S0196-0644(05)80247-1; DITCHEY RV, 1988, CIRCULATION, V78, P382, DOI 10.1161/01.CIR.78.2.382; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2199; *EUR RES COUNC WOR, 1993, BRIT MED J, V306, P1589; LINDNER KH, 1993, ANESTH ANALG, V77, P427; LINDNER KH, 1992, ANESTHESIOLOGY, V77, P662, DOI 10.1097/00000542-199210000-00008; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; Lindner KH, 1996, ANN INTERN MED, V124, P1061, DOI 10.7326/0003-4819-124-12-199606150-00006; LINDNER KH, 1990, CHEST, V97, P1458, DOI 10.1378/chest.97.6.1458; LINDNER KH, 1996, BRIT HEART J, V75, P145; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; TEASDALE G, 1974, LANCET, V2, P81; Woodhouse SP, 1995, RESUSCITATION, V30, P243, DOI 10.1016/0300-9572(95)00890-X	14	260	273	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					535	537		10.1016/S0140-6736(97)80087-6	http://dx.doi.org/10.1016/S0140-6736(97)80087-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048792				2022-12-28	WOS:A1997WJ51200011
J	Meller, VH; Wu, KH; Roman, G; Kuroda, MI; Davis, RL				Meller, VH; Wu, KH; Roman, G; Kuroda, MI; Davis, RL			roX1 RNA paints the X chromosome of male Drosophila and is regulated by the dosage compensation system	CELL			English	Article							DNA TOPOISOMERASE-II; MUSHROOM BODIES; SEXUAL-DIFFERENTIATION; CATALYTIC SUBUNIT; TRANSFORMER GENE; NUCLEAR MATRIX; XIST GENE; MELANOGASTER; EXPRESSION; PROTEIN	The Drosophila roX1 gene is X-linked and produces RNAs that are male-specific, somatic, and preferentially expressed in the central nervous system. These RNAs are retained in the nucleus and lack any significant open reading frame. Although all sexually dimorphic characteristics in Drosophila were thought to be controlled by the sex determination pathway through the gene transformer (tra), the expression of roX1 is independent of tra activity. Instead, the dosage compensation system is necessary and sufficient for the expression of roX1. Consistent with a potential function in dosage compensation, roX1 RNAs localize specifically to the male X chromosome. This localization occurs even when roX1 RNAs are expressed from autosomal locations in X-to-autosome translocations. The novel regulation and subnuclear localization of roX1 RNAs makes them candidates for an RNA component of the dosage compensation machinery.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute			Roman, Gregg/W-1586-2019; Davis, Ronald/J-4998-2013	Roman, Gregg/0000-0003-1519-4699; Davis, Ronald/0000-0002-5986-7608				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN CM, 1994, NUCLEIC ACIDS RES, V22, P3620, DOI 10.1093/nar/22.17.3620; BURTIS KC, 1991, EMBO J, V10, P2577, DOI 10.1002/j.1460-2075.1991.tb07798.x; Burtis KC, 1993, CURR OPIN CELL BIOL, V5, P1006, DOI 10.1016/0955-0674(93)90085-5; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DONG S, 1994, GENOMICS, V23, P540, DOI 10.1006/geno.1994.1541; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FOSTER JL, 1988, J BIOL CHEM, V263, P1676; Franke A, 1996, DEVELOPMENT, V122, P2751; FUKUNAGA A, 1975, GENETICS, V81, P135; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; GRIFFINSHEA R, 1982, DEV BIOL, V91, P325, DOI 10.1016/0012-1606(82)90039-2; Han PL, 1996, J NEUROBIOL, V31, P88, DOI 10.1002/(SICI)1097-4695(199609)31:1<88::AID-NEU8>3.0.CO;2-B; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; HILFIKER A, 1994, EMBO J, V13, P3542, DOI 10.1002/j.1460-2075.1994.tb06661.x; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; Lucchesi JC, 1996, BIOESSAYS, V18, P541, DOI 10.1002/bies.950180705; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; McDowell KA, 1996, MECH DEVELOP, V57, P113, DOI 10.1016/0925-4773(96)00517-5; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MELLER VH, 1995, J CELL SCI, V108, P1651; MELLER VH, 1994, J CELL BIOL, V126, P1331, DOI 10.1083/jcb.126.6.1331; MUKHERJEE AS, 1965, NATURE, V207, P785, DOI 10.1038/207785a0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NICKERSON JA, 1989, P NATL ACAD SCI USA, V86, P177, DOI 10.1073/pnas.86.1.177; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; PALMER MJ, 1993, GENETICS, V134, P545; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RASTELLI L, 1995, MECH DEVELOP, V53, P1; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; UCHIDA S, 1981, JPN J GENET, V56, P523, DOI 10.1266/jjg.56.523; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	67	232	235	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					445	457		10.1016/S0092-8674(00)81885-1	http://dx.doi.org/10.1016/S0092-8674(00)81885-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038336	Bronze			2022-12-28	WOS:A1997WJ69100005
J	Meyerowitz, EM				Meyerowitz, EM			Genetic control of cell division patterns in developing plants	CELL			English	Review							SHOOT APICAL MERISTEM; CONTROLLING FLOWER DEVELOPMENT; FLORAL HOMEOTIC GENES; MAIZE HOMEOBOX GENE; ARABIDOPSIS-THALIANA; ECTOPIC EXPRESSION; VEGETATIVE SHOOT; BOX GENE; FATE; ROOT				Meyerowitz, EM (corresponding author), CALTECH,DIV BIOL 15629,PASADENA,CA 91125, USA.		Meyerowitz, Elliot M/A-7118-2009					ALVAREZ J, 1994, ARABIDOPSIS ATLAS MO, P254; Angenent GC, 1996, TRENDS PLANT SCI, V1, P228; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARTON MK, 1993, DEVELOPMENT, V119, P823; BENFEY PN, 1993, DEVELOPMENT, V119, P57; Bossinger G, 1996, DEVELOPMENT, V122, P1093; BOSSINGER G, 1992, PLANT J, V2, P311, DOI 10.1111/j.1365-313X.1992.00311.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; Chuck G, 1996, PLANT CELL, V8, P1277, DOI 10.1105/tpc.8.8.1277; CLARK SE, 1993, DEVELOPMENT, V119, P397; Clark SE, 1996, DEVELOPMENT, V122, P1567; CLARK SE, 1995, DEVELOPMENT, V121, P2057; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; CRONE W, 1993, AM J BOT, V80, P1419, DOI 10.2307/2445671; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Doerner P, 1996, NATURE, V380, P520, DOI 10.1038/380520a0; DOLAN L, 1994, DEVELOPMENT, V120, P2465; DOLAN L, 1993, DEVELOPMENT, V119, P71; DOONAN JH, 1991, PLANT J, V1, P129; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Elliott RC, 1996, PLANT CELL, V8, P155, DOI 10.1105/tpc.8.2.155; FERREIRA P, 1994, PLANT MOL BIOL, V26, P1289, DOI 10.1007/BF00016475; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; FRANCIS D, 1995, PHYSIOL PLANTARUM, V93, P365, DOI 10.1111/j.1399-3054.1995.tb02241.x; FURNER IJ, 1992, DEVELOPMENT, V115, P755; FURNER IJ, 1993, PLANT J, V4, P917, DOI 10.1046/j.1365-313X.1993.04060917.x; GAISER JC, 1995, PLANT CELL, V7, P333, DOI 10.1105/tpc.7.3.333; GOODMAN HM, 1995, P NATL ACAD SCI USA, V92, P10831, DOI 10.1073/pnas.92.24.10831; Hall LN, 1996, NEW PHYTOL, V132, P533, DOI 10.1111/j.1469-8137.1996.tb01873.x; HARA N, 1995, J PLANT RES, V108, P115, DOI 10.1007/BF02344315; Hareven D, 1996, CELL, V84, P735, DOI 10.1016/S0092-8674(00)81051-X; INGRAM GC, 1995, PLANT CELL, V7, P1501, DOI 10.1105/tpc.7.9.1501; IRISH VF, 1992, DEVELOPMENT, V115, P745; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jackson D, 1996, CURR BIOL, V6, P917, DOI 10.1016/S0960-9822(02)00625-5; JACOBS TW, 1995, ANNU REV PLANT PHYS, V46, P317, DOI 10.1146/annurev.pp.46.060195.001533; JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; Klucher KM, 1996, PLANT CELL, V8, P137, DOI 10.1105/tpc.8.2.137; Laux T, 1996, DEVELOPMENT, V122, P87; LEVIN JZ, 1995, PLANT CELL, V7, P529, DOI 10.1105/tpc.7.5.529; LEYSER HMO, 1992, DEVELOPMENT, V116, P397; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; MCCONNELL JR, 1995, DEV GENET, V16, P358, DOI 10.1002/dvg.1020160409; MEINKE DW, 1995, ANNU REV PLANT PHYS, V46, P369, DOI 10.1146/annurev.pp.46.060195.002101; MEYEROWITZ EM, 1991, DEVELOPMENT S, V1, P157; Running MP, 1996, DEVELOPMENT, V122, P1261; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; Satina S, 1941, AM J BOT, V28, P862, DOI 10.2307/2436864; Satina S, 1940, AM J BOT, V27, P895, DOI 10.2307/2436558; Scheres B, 1996, PLANT PHYSIOL, V111, P959, DOI 10.1104/pp.111.4.959; SCHERES B, 1995, DEVELOPMENT, V121, P53; SCHNEEBERGER RG, 1995, GENE DEV, V9, P2292, DOI 10.1101/gad.9.18.2292; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; Shaul O, 1996, CRIT REV PLANT SCI, V15, P97, DOI 10.1080/713608129; SHERIDAN WF, 1995, DEV GENET, V16, P291, DOI 10.1002/dvg.1020160402; SIEBURTH LE, 1995, PLANT CELL, V7, P1249, DOI 10.1105/tpc.7.8.1249; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; Smith LG, 1996, DEVELOPMENT, V122, P481; SMITH LG, 1992, DEVELOPMENT, V116, P21; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; SZYMKOWIAK EJ, 1993, PLANT J, V4, P1, DOI 10.1046/j.1365-313X.1993.04010001.x; SZYMKOWIAK EJ, 1992, PLANT CELL, V4, P1089, DOI 10.1105/tpc.4.9.1089; TALBERT PB, 1995, DEVELOPMENT, V121, P2723; TILNEYBASSETT RAE, 1986, J PLANT RES, V108, P407; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; Vincent CA, 1995, CURR BIOL, V5, P1449, DOI 10.1016/S0960-9822(95)00282-X; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0; WILKINSON MD, 1995, PLANT CELL, V7, P1485, DOI 10.1105/tpc.7.9.1485; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	75	248	264	2	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					299	308		10.1016/S0092-8674(00)81868-1	http://dx.doi.org/10.1016/S0092-8674(00)81868-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039256	Bronze			2022-12-28	WOS:A1997WG47900002
J	Ginzberg, E; Ostow, M				Ginzberg, E; Ostow, M			Managed care - A look back and a look ahead	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Ginzberg, E (corresponding author), COLUMBIA UNIV,NEW YORK,NY 10027, USA.							Bodenheimer T, 1996, NEW ENGL J MED, V335, P1601, DOI 10.1056/NEJM199611213352112; *CONGR BUDG OFF, 1997, EC BUDG OUTL 1998 20, P126; Cowan CA, 1996, HEALTH CARE FINANC R, V17, P157; ECKHOLM E, 1994, NY TIMES        1218, P1; EHTEREDGE L, 1996, HLTH AFF MILLWOOD, V15, P93; Levit KR, 1996, HEALTH CARE FINANC R, V17, P205	6	53	53	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	1997	336	14					1018	1020		10.1056/NEJM199704033361411	http://dx.doi.org/10.1056/NEJM199704033361411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR385	9077385				2022-12-28	WOS:A1997WR38500011
J	Han, J; Jiang, Y; Li, Z; Kravchenko, VV; Ulevitch, RJ				Han, J; Jiang, Y; Li, Z; Kravchenko, VV; Ulevitch, RJ			Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation	NATURE			English	Article							PROTEIN; CELLS; GENE; BIOSYNTHESIS; ENDOTOXIN; THREONINE; PROMOTER	For cells of the innate immune system to mount a host defence response to infection, they must recognize products of microbial pathogens such as lipopolysaccharide (LPS), the endotoxin secreted by Gram-negative bacterial, These cellular responses require intracellular signalling pathways, such as the four MAP kinase (MAPK) pathways(2-6). In mammalian cells the MAPK p38 is thought to play an important role in the regulation of cellular responses during infection through its effects on the expression of proinflammatory molecules(7-9). One means of understanding the role of p38 in these responses is to identify proteins with functions regulated by p38-catalysed phosphorylation, Here we demonstrate a link between the p38 pathway and a member of the myocyte-enhancer factor 2 (MEF2) group of transcription factors, We found that in monocytic cells, LPS increases the transactivation activity of MEF2C(10-12) through p38-catalysed phosphorylation, One consequence of MEF2C activation is increased c-jun gene transcription. Our results show that p38 may influence host defence and inflammation by maintaining the balance of c-Jun protein consumed during infection.			Han, J (corresponding author), Scripps Res Inst, DEPT IMMUNOL, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Han, J/G-4671-2010; Ulevitch, Richard J/Q-3393-2017					Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; MORRISON DC, 1994, J ENDOTOXIN RES, V1, P71; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SHIN HS, 1996, MOL CELL BIOL; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	27	660	705	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	1997	386	6622					296	299		10.1038/386296a0	http://dx.doi.org/10.1038/386296a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069290				2022-12-28	WOS:A1997WP00300055
J	Bodner, C; Ross, S; Douglas, G; Little, J; Legge, J; Friend, J; Godden, D				Bodner, C; Ross, S; Douglas, G; Little, J; Legge, J; Friend, J; Godden, D			The prevalence of adult onset wheeze: Longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							ASTHMA		UNIV ABERDEEN,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen			Little, Julian/AAR-6117-2020	Little, Julian/0000-0001-5026-5531				DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; HAHN DL, 1994, J FAM PRACTICE, V38, P373; LITTLEJOHNS P, 1989, THORAX, V44, P797, DOI 10.1136/thx.44.10.797; ROSS S, 1992, BRIT MED J, V305, P545, DOI 10.1136/bmj.305.6853.545; Strachan DP, 1996, BRIT MED J, V312, P1195	5	31	32	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					792	793		10.1136/bmj.314.7083.792	http://dx.doi.org/10.1136/bmj.314.7083.792			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080997	Green Published			2022-12-28	WOS:A1997WN64600025
J	Holland, KG; Ahrens, TJ				Holland, KG; Ahrens, TJ			Melting of (Mg,Fe)(2)SiO4 at the core-mantle boundary of the Earth	SCIENCE			English	Article							CHEMICAL-COMPOSITION; TEMPERATURE; (MG,FE)SIO3-PEROVSKITE; CONSTRAINTS; RADIATION; VELOCITY	The lower mantle of the Earth is believed to be largely composed of (Mg,Fe)O (magnesiowustite) and (Mg,Fe)SiO3 (perovskite). Radiative temperatures of single-crystal Olivine [(Mg-0.9,Fe-0.1)(2)SiO4] decreased abruptly from 7040 +/- 315 to 4300 +/- 270 kelvin upon shock compression above 80 gigapascals. The data indicate that an upper bound to the solidus of the magnesiowustite and perovskite assemblage at 4300 +/- 270 kelvin is 130 +/- 3 gigapascals. These conditions correspond to those for partial melting at the base of the mantle, as has been suggested occurs within the ultralow-velocity zone beneath the central Pacific.			Holland, KG (corresponding author), CALTECH, SEISMOL LAB, LINDHURST LAB EXPT GEOPHYS, PASADENA, CA 91125 USA.							Ahrens TJ, 1996, AIP CONF PROC, V370, P3; AHRENS TJ, 1982, HIGH PRESSURE RES GE, P579; Ahrens TJ., 1987, METHODS EXP PHYS, V24, P185, DOI 10.1016/S0076-695X(08)60587-6; AHRENS TJ, 1995, HDB PHYSICAL CONSTAN, V2; ALLEGRE CJ, 1995, EARTH PLANET SC LETT, V134, P515, DOI 10.1016/0012-821X(95)00123-T; Boehler R, 1996, ANNU REV EARTH PL SC, V24, P15, DOI 10.1146/annurev.earth.24.1.15; BOHELER R, 1996, ADV MAT 96, P159; BONESS DA, 1993, PHYS REV LETT, V71, P2931, DOI 10.1103/PhysRevLett.71.2931; BOSLOUGH MB, 1989, REV SCI INSTRUM, V60, P3711, DOI 10.1063/1.1140480; BOSLOUGH MB, 1985, J APPL PHYS, V58, P3394, DOI 10.1063/1.335756; Brown J. M., 1988, Shock Waves in Condensed Matter 1987. Proceedings of the American Physical Society Topical Conference, P119; Brown J. M., 1987, HIGH PRESS RES MINER, P373; GARNERO EJ, 1995, PHYS EARTH PLANET IN, V91, P161, DOI 10.1016/0031-9201(95)03039-Y; GARNERO EJ, 1993, GEOPHYS RES LETT, V20, P1843, DOI 10.1029/93GL02009; HEINZ DL, 1994, SCIENCE, V264, P279, DOI 10.1126/science.264.5156.279; JACKSON I, 1983, EARTH PLANET SC LETT, V62, P91, DOI 10.1016/0012-821X(83)90073-0; JEANLOZ R, 1986, ANNU REV EARTH PL SC, V14, P377, DOI 10.1146/annurev.ea.14.050186.002113; Jeanloz R., 1977, HIGH PRESSURE RES, P439; KNITTLE E, 1989, GEOPHYS RES LETT, V16, P421, DOI 10.1029/GL016i005p00421; LYZENGA G, 1982, THESIS CALTECH; LYZENGA GA, 1980, GEOPHYS RES LETT, V7, P141, DOI 10.1029/GL007i002p00141; LYZENGA GA, 1983, J GEOPHYS RES, V88, P2431, DOI 10.1029/JB088iB03p02431; Mao H.-K, 1973, YB CARNEGIE I WASHIN, V72, P554; MAO MK, 1972, SCIENCE, V176, P403; Presnall D. C., 1995, HDB PHYSICAL CONSTAN, V2, P248; PRESNALL DC, 1993, J GEOPHYS RES, V98, P1977; RINGWOOD AE, 1991, GEOCHIM COSMOCHIM AC, V55, P2083, DOI 10.1016/0016-7037(91)90090-R; SHEN GY, 1995, J GEOPHYS RES-SOL EA, V100, P17699, DOI 10.1029/95JB01864; SVENDSEN B, 1989, PHYS REP, V180, P333, DOI 10.1016/0370-1573(89)90092-6; SWEENEY JS, P US JAP SEM 96 HIGH; SYONO Y, 1981, SCIENCE, V214, P177, DOI 10.1126/science.214.4517.177; WEIDNER DJ, 1986, CHEM PHYSICS TERREST, P251, DOI DOI 10.1007/978-1-4612-4928-3_7; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; YANG W, 1996, THESIS CALTECH, pCH4; ZERR A, 1994, NATURE, V371, P506, DOI 10.1038/371506a0; ZERR A, 1993, SCIENCE, V262, P553, DOI 10.1126/science.262.5133.553	36	71	72	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1623	1625		10.1126/science.275.5306.1623	http://dx.doi.org/10.1126/science.275.5306.1623			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054352				2022-12-28	WOS:A1997WN12300040
J	deLeval, MR				deLeval, MR			Human factors and surgical outcomes: A Cartesian dream	LANCET			English	Editorial Material											deLeval, MR (corresponding author), GREAT ORMOND ST HOSP CHILDREN,CARDIOTHORAC UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.							DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914; Hawkins FH., 1993, HUMAN FACTORS FLIGHT, V2nd ed; HOLLNAGEL E, 1993, HUMAN RELIABILITY AN; ICAO, 1993, 247 ICAO; Mainzer K., 1994, THINKING COMPLEXITY; MCINTYRE N, 1983, BRIT MED J, V287, P1919, DOI 10.1136/bmj.287.6409.1919; REASON J, 1994, HUMAN ERROR MED; Reason J.T., 1990, HUMAN ERRORS	8	30	30	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					723	725		10.1016/S0140-6736(96)11327-1	http://dx.doi.org/10.1016/S0140-6736(96)11327-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078214				2022-12-28	WOS:A1997WM08000046
J	Culyer, AJ				Culyer, AJ			The rationing debate - Maximising the health of the whole community - The case for	BRITISH MEDICAL JOURNAL			English	Article											Culyer, AJ (corresponding author), UNIV YORK,DEPT ECON & RELATED STUDIES,YORK YO1 5DD,N YORKSHIRE,ENGLAND.								0	18	18	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					667	669		10.1136/bmj.314.7081.667	http://dx.doi.org/10.1136/bmj.314.7081.667			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066486	Green Published			2022-12-28	WOS:A1997WL41800037
J	Rizzoli, R; Bonjour, JP				Rizzoli, R; Bonjour, JP			Hormones and bones	LANCET			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; REPLACEMENT THERAPY; MASS ACCUMULATION; HIP-FRACTURES; ESTROGEN; PREDICTION; RISK; DENSITOMETRY; DENSITY; DISEASE				Rizzoli, R (corresponding author), UNIV HOSP,WHO,COLLABORATING CTR OSTEOPOROSIS & BONE DIS,DEPT INTERNAL MED,DIV BONE DIS,CH-1211 GENEVA 14,SWITZERLAND.							Albright F, 1941, J AMER MED ASSOC, V116, P2465, DOI 10.1001/jama.1941.02820220007002; AMMANN P, IN PRESS J CLIN INVE; BARRETTCONNOR E, 1995, AM J MED, V98, pS3, DOI 10.1016/S0002-9343(05)80037-3; BLACK DM, 1992, J BONE MINER RES, V7, P639; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; BONJOUR JP, 1994, BONE MINERAL RES, V8, P205; CLARK AP, 1992, OSTEOPOROSIS INT, V2, P195, DOI 10.1007/BF01623926; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; Davies MC, 1995, CLIN ENDOCRINOL, V43, P741, DOI 10.1111/j.1365-2265.1995.tb00544.x; DRINKWATER BL, 1984, NEW ENGL J MED, V311, P277, DOI 10.1056/NEJM198408023110501; Hans D, 1996, LANCET, V348, P511, DOI 10.1016/S0140-6736(95)11456-4; JACOBS S, 1996, DRUGS AGING, V8, P13; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; Kanis JA, 1996, OSTEOPOROSIS INT, V6, P256, DOI 10.1007/BF01622743; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LINDSAY R, 1993, LANCET, V341, P801, DOI 10.1016/0140-6736(93)90571-W; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MELTON LJ, 1993, J BONE MINER RES, V8, P1227; PRIOR JC, 1990, NEW ENGL J MED, V323, P1221, DOI 10.1056/NEJM199011013231801; Schurch MA, 1996, J BONE MINER RES, V11, P1935; SEEMAN E, 1992, J BONE MINER RES, V7, P1467; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756-3282(93)90081-K; WASNICH R, 1993, AM J MED, V95, pS6, DOI 10.1016/0002-9343(93)90374-X; WHITCROFT SIJ, 1992, CLIN ENDOCRINOL, V36, P15, DOI 10.1111/j.1365-2265.1992.tb02896.x	32	42	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR	1997	349			1			S20	S23		10.1016/S0140-6736(97)90007-6	http://dx.doi.org/10.1016/S0140-6736(97)90007-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL568	9057775				2022-12-28	WOS:A1997WL56800008
J	Robertson, EJ				Robertson, EJ			Development - Left-right asymmetry	SCIENCE			English	Editorial Material											Robertson, EJ (corresponding author), HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0	4	5	5	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1280	1280		10.1126/science.275.5304.1280	http://dx.doi.org/10.1126/science.275.5304.1280			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9064786				2022-12-28	WOS:A1997WK64400032
J	Hager, KM; Hajduk, SL				Hager, KM; Hajduk, SL			Mechanism of resistance of African trypanosomes to cytotoxic human HDL	NATURE			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN SERUM-RESISTANT; BRUCEI-RHODESIENSE; IDENTIFICATION; HAPTOGLOBIN; PROTEIN; CLONES; LYSIS; GENE	Trypanosoma brucei brucei the causative agent of ngana in cattle, is non-infectious to humans because of its sensitivity to the cytolytic activity of normal human serum(1). The toxin in normal human serum is human haptoglobin-related protein (Hpr)(2-5) which is found either as an apolipoprotein associated with a minor subclass of high-density lipoprotein (HDL), named trypanosome lytic factor (TLF1)(6-8), or as an unstable, high-molecular-mass protein complex known as TLF2 (refs 5, 9-12). TLF-mediated lysis of T. b. brucei requires binding, internalization and lysosomal targeting(13). The human sleeping-sickness trypanosome, Trypanosoma brucei rhodesiense is resistant to TLF. Our studies reveal that resistant trypanosomes fail to endocytose TLF yet continue to bind TLF through cell-surface receptors. On the basis of these results, we conclude that one mechanism of resistance of human sleeping-sickness trypanosomes to human serum is decreased internalization of receptor-bound TLF.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham								BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3208; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; DEGREEF C, 1994, MOL BIOCHEM PARASIT, V68, P277, DOI 10.1016/0166-6851(94)90172-4; DEGREEF C, 1989, MOL BIOCHEM PARASIT, V36, P169, DOI 10.1016/0166-6851(89)90189-8; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; HAWKING F, 1976, T  SOC TROP MED HYG, V90, P504; Hoare C, 1972, TRYPANOSOMES MAMMALS; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; Laveran A, 1902, CR HEBD ACAD SCI, V134, P735; LORENZ P, 1994, MOL BIOCHEM PARASIT, V64, P153, DOI 10.1016/0166-6851(94)90143-0; MATHIEUDAUDE F, 1994, EXP PARASITOL, V78, P1, DOI 10.1006/expr.1994.1001; MOORE DR, 1995, EXP PARASITOL, V81, P216, DOI 10.1006/expr.1995.1111; ORTIZ JC, 1994, J PARASITOL, V80, P550, DOI 10.2307/3283190; OVERATH P, 1994, PARASITOL TODAY, V10, P53, DOI 10.1016/0169-4758(94)90393-X; OWEN JS, 1987, BIOCHEM SOC T, V15, P478, DOI 10.1042/bst0150478; PRIEST JM, 1994, MOL BIOCHEM PARASIT, V65, P294; Raper J, 1996, J EXP MED, V183, P1023, DOI 10.1084/jem.183.3.1023; RICKMAN L, 1980, T ROY SOC TROP MED H, V74, P817, DOI 10.1016/0035-9203(80)90214-X; RIFKIN MR, 1994, MOL BIOCHEM PARASIT, V66, P211, DOI 10.1016/0166-6851(94)90148-1; RIFKIN MR, 1978, P NATL ACAD SCI USA, V75, P3450, DOI 10.1073/pnas.75.7.3450; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; SMITH AB, 1995, P NATL ACAD SCI USA, V92, P10262, DOI 10.1073/pnas.92.22.10262; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; SMITH AB, MOL BIOCH PARASITOL; TOMLINSON S, 1995, MOL BIOCHEM PARASIT, V70, P131, DOI 10.1016/0166-6851(95)00019-W; TYTLER E, 1995, MOL BIOCHEM PARASIT, V62, P9	27	50	53	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					823	826		10.1038/385823a0	http://dx.doi.org/10.1038/385823a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039915				2022-12-28	WOS:A1997WK57000055
J	Goldhaber, SZ; Grodstein, F; Stampfer, MJ; Manson, JE; Colditz, GA; Speizer, FE; Willett, WC; Hennekens, CH				Goldhaber, SZ; Grodstein, F; Stampfer, MJ; Manson, JE; Colditz, GA; Speizer, FE; Willett, WC; Hennekens, CH			A prospective study of risk factors for pulmonary embolism in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; VENOUS THROMBOSIS; FACTOR-V; WEIGHT; FIBRINOGEN; OBESITY; MEN	Objective.-To investigate risk factors for pulmonary embolism in women. Design.-Prospective study based on biennial, mailed questionnaires. Setting.-Nurses' Health Study with 16 years of follow-up from 1976 to 1992. Patients.-A group of 112 822 women aged 30 to 55 years in 1976, free from diagnosed cardiovascular disease or cancer at baseline. Overall, there were 1 619 770 person-years of follow-up. Measurements.-Based on self-report and medical records, we documented 280 cases of pulmonary embolism, of which 125 were primary (no identified antecedent cancer, trauma, surgery, or immobilization). information on height, weight, cigarette smoking, hypertension, diabetes, and hypercholesterolemia was collected by questionnaire. Results.-In multivariate analysis, obesity, cigarette smoking, and hypertension were independent predictors of pulmonary embolism. Specifically, obese women (body mass index greater than or equal to 29.0 kg/m(2)) had an increased risk of primary pulmonary embolism (multivariate relative risk=2.9; 95% confidence interval [CI], 1.5-5.4). Heavy cigarette smokers also had an increased risk of primary pulmonary embolism. The relative risk (RR) of primary pulmonary embolism was 1.9 (95% CI, 0.9-3.7) for women currently smoking 25 to 34 cigarettes per day and 3.3 (95% CI, 1.7-6.5) for those smoking 35 cigarettes or more daily as compared with never smokers. Hypertension, even after adjustment for body mass index, was also associated with an increased risk of primary pulmonary embolism (RR=1,9; 95% CI, 1.2-2.8), High serum cholesterol levels (RR=1.1;95% CI, 0.62-1.8) and diabetes (RR=0.7; 95% CI, 0.3-1.9) did not appear to be related to primary pulmonary embolism. Conclusion.-These prospective data indicate that obesity, cigarette smoking, and hypertension are associated with increased risk of pulmonary embolism in women. Control of these risk factors will decrease risks of pulmonary embolism as well as coronary heart disease.	BRIGHAM & WOMENS HOSP,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Goldhaber, SZ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40935] Funding Source: Medline; NHLBI NIH HHS [HL 24074, HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COX DR, 1972, J R STAT SOC B, V34, P187; GOLDHABER SZ, 1983, AM J MED, V74, P1023, DOI 10.1016/0002-9343(83)90805-7; GOLDHABER SZ, 1993, PREVENTION VENOUS TH; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Hirsch DR, 1996, AM HEART J, V131, P1145, DOI 10.1016/S0002-8703(96)90089-7; KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P223, DOI 10.1001/jama.271.3.223; PRIMROSE JN, 1992, THROMB HAEMOSTASIS, V68, P396; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROTHMAN KJ, 1979, PHS PUBLICATION; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320	22	440	455	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					642	645		10.1001/jama.277.8.642	http://dx.doi.org/10.1001/jama.277.8.642			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039882				2022-12-28	WOS:A1997WJ49800032
J	Schubert, I; Oud, JL				Schubert, I; Oud, JL			There is an upper limit of chromosome size for normal development of an organism	CELL			English	Article							MINICHROMOSOME; CENTROMERE	A clearly definable upper tolerance limit for chromosome arm length has been found. As a rule we postulate that, for normal development of an organism, the longest chromosome arm must not exceed half of the average length of the spindle axis at telophase. Above this length, fertility and viability of the carrier individuals become severely impaired due to increasingly incomplete separation of the longest chromatids during mitosis, resulting finally in the loss of DNA. The experimental work that points to a limit in genome plasticity has been carried out on a series of field bean lines with karyotypes of considerable variation in length of individual chromosomes.	UNIV AMSTERDAM,BIOCENTRUM AMSTERDAM,INST MOL CELL BIOL,NL-1098 SM AMSTERDAM,NETHERLANDS	University of Amsterdam	Schubert, I (corresponding author), INST PLANT GENET & CROP PLANT RES,CORRENSSTR 3,D-06466 GATERSLEBEN,GERMANY.		Schubert, Ingo/AAF-5882-2020	Schubert, Ingo/0000-0002-6300-2068				Adames KA, 1996, CELL MOTIL CYTOSKEL, V34, P13; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; NIWA O, 1989, EMBO J, V8, P3045, DOI 10.1002/j.1460-2075.1989.tb08455.x; OUD JL, 1992, J CELL SCI, V103, P847; SCHRIEVERSCHWEMMER G, 1993, CYTOGENET CELL GENET, V64, P122, DOI 10.1159/000133567; SCHUBERT I, 1986, BIOL ZBL, V105, P9; SCHUBERT I, 1982, BIOL ZBL, V101, P793; Schubert I., 1991, Chromosome engineering in plants: genetics, breeding, evolution. Part A., P113; SCHUBERT I, 1990, BIOL ZBL, V109, P207; Schubert I., 1991, FABIS Newsletter, P14; VISCHER NOE, 1994, BINARY-COMPUT MICROB, V6, P160; VISSER TD, 1994, SCANNING, V16, P198, DOI 10.1002/sca.4950160403	13	72	73	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					515	520		10.1016/S0092-8674(00)81891-7	http://dx.doi.org/10.1016/S0092-8674(00)81891-7			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038342	Bronze			2022-12-28	WOS:A1997WJ69100011
J	Zwijsen, RML; Wientjens, E; Klompmaker, R; vanderSman, J; Bernards, R; Michalides, RJAM				Zwijsen, RML; Wientjens, E; Klompmaker, R; vanderSman, J; Bernards, R; Michalides, RJAM			CDK-independent activation of estrogen receptor by cyclin D1	CELL			English	Article							HUMAN-BREAST-CANCER; RETINOBLASTOMA PROTEIN; RESPONSIVE ELEMENT; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; HORMONE RECEPTOR; GENE-PRODUCT; EXPRESSION; PHOSPHORYLATION; ONCOGENE	Both cyclin D1 and estrogens have an essential role in regulating proliferation of breast epithelial cells. We show here a novel role for cyclin D1 in growth regulation of estrogen-responsive tissues by potentiating transcription of estrogen receptor-regulated genes. Cyclin D1 mediates this activation independent of complex formation to a CDK partner. Cyclin D1 activates estrogen receptor-mediated transcription in the absence of estrogen and enhances transcription in its presence. The activation of estrogen receptor by cyclin D1 is not inhibited by anti-estrogens. A direct physical binding of cyclin D1 to the hormone binding domain of the estrogen receptor results in an increased binding of the receptor to estrogen response element sequences, and upregulates estrogen receptor-mediated transcription. These results highlight a novel role for cyclin D1 as a CDK-independent activator of the estrogen receptor.	NETHERLANDS CANC INST,ANTONI VAN LEEUWENHOEK HUIS,DEPT MOL CARCINOGENESIS,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	Zwijsen, RML (corresponding author), NETHERLANDS CANC INST,ANTONI VAN LEEUWENHOEK HUIS,DEPT TUMOR BIOL,PLESMANLAAN 121,NL-1066 CX AMSTERDAM,NETHERLANDS.			Bernards, Rene/0000-0001-8677-3423				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; DEFRIEND DJ, 1994, CANCER RES, V54, P408; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUBIK D, 1988, J BIOL CHEM, V263, P12705; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAMMIE GA, 1991, ONCOGENE, V6, P439; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MIGLIACCIO A, 1991, J STEROID BIOCHEM, V38, P407, DOI 10.1016/0960-0760(91)90328-3; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; REEVES SA, 1995, BIOTECHNIQUES, V18, P18; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHUURING E, 1992, ONCOGENE, V7, P355; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WANG YL, 1991, MOL ENDOCRINOL, V5, P1707, DOI 10.1210/mend-5-11-1707; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WILTSCHKE C, 1995, TRENDS ENDOCRIN MET, V6, P77, DOI 10.1016/1043-2760(95)00005-3; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; ZHANG QX, 1993, CANCER RES, V53, P5882; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; ZWILJSEN R, 1996, MOL CELL BIOL, V16, P2554	50	597	618	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					405	415		10.1016/S0092-8674(00)81879-6	http://dx.doi.org/10.1016/S0092-8674(00)81879-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039267	Bronze, Green Published			2022-12-28	WOS:A1997WG47900013
J	Briggs, A; Sculpher, M				Briggs, A; Sculpher, M			Markov models of medical prognosis - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							DECISION				Briggs, A (corresponding author), UNIV OXFORD WOLFSON COLL,INST HLTH SCI,HLTH ECON RES CTR,OXFORD OX2 6UD,ENGLAND.		Briggs, Andrew/ABA-9009-2020	Briggs, Andrew/0000-0002-0777-1997; Sculpher, Mark/0000-0003-3746-9913				Briggs AH, 1996, BRIT MED J, V312, P1321, DOI 10.1136/bmj.312.7042.1321; MICHAELS JA, 1993, EUR J VASCULAR SURG, V7, P136, DOI 10.1016/S0950-821X(05)80753-4; SHARPLES LD, 1996, TRANSPLANTATION, V62, P1; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409	4	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					354	355		10.1136/bmj.314.7077.354a	http://dx.doi.org/10.1136/bmj.314.7077.354a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040334	Green Published			2022-12-28	WOS:A1997WF86100040
J	Zuckerman, JN; Sabin, C; Craig, FM; Williams, A; Zuckerman, AJ				Zuckerman, JN; Sabin, C; Craig, FM; Williams, A; Zuckerman, AJ			Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: Randomised double blind dose-response study	BRITISH MEDICAL JOURNAL			English	Article							PRE-S-REGION; VIRUS SURFACE-ANTIGEN; HBV COAT PROTEIN; ANTIBODY-RESPONSE; CARE WORKERS; IMMUNOGENICITY; REVACCINATION; EFFICACY; NONRESPONSIVENESS; COMPONENTS	Objective: To evaluate the immunogenicity and reactogenicity of a new triple S recombinant hepatitis B vaccine in a cohort of healthy people in whom currently licensed hepatitis B vaccines had persistently not induced an immune response. Design: Single centre, randomised, double blind, dose-response study. Setting: Research vaccine evaluation centre at a teaching hospital. Subjects: 100 healthcare workers aged 18-70 years with a history of failure to seroconvert after at least four doses of a licensed hepatitis B vaccine containing the S component. Intervention: Each subject was randomly allocated two doses of 5, 10, 20, or 40 mu g of a new hepatitis B vaccine two months apart Main outcome measures: Immunogenicity of the four doses. Seroconversion and seroprotection were defined as an antibody titre > 10 IU/l and > 100 IU/l respectively against an international antibody standard. Results: 69 subjects seroconverted after a single dose of the vaccine. After the booster vaccination one other subject seroconverted, bringing the overall seroconversion rate to 70%. Fifteen subjects given 5 mu g of vaccine, 19 given 10 mu g, 16 given 20 mu g, and 20 given 40 mu g seroconverted. Seroconversion rates in the four antigen dose groups were 60% (15/25), 76% (19/25), 64% (16/25), and 80% (20/25). After the booster dose there was no significant dose-response effect on the overall seroconversion rate, although the small sample size meant that a clinically important dose-response could not be ruled out. Conclusion: A single dose of 20 mu g of the vaccine was as effective as two doses of either 40 mu g or 20 mu g of this vaccine formulation in terms of seroconversion, seroprotection, and geometric mean titres.	ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND; MEDEVA SCI & REGULATORY AFFAIRS,LEATHERHEAD KT22 7PQ,SURREY,ENGLAND; ROYAL FREE HOSP,SCH MED,WHO,COLLABORATING CTR RES & REFERENCE VIRAL DIS,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; World Health Organization	Zuckerman, JN (corresponding author), ROYAL FREE HOSP,SCH MED,ACAD UNIT TRAVEL MED & VACCINES,LONDON NW3 2PF,ENGLAND.		Sabin, Caroline/C-2464-2008	Sabin, Caroline/0000-0001-5173-2760				ALBERTI A, 1988, LANCET, V1, P1421; ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103; *BMA, 1995, COD PRACT IMPL UK HE; BOAG F, 1991, INT J STD AIDS, V2, P318, DOI 10.1177/095646249100200502; CRAVEN DE, 1986, ANN INTERN MED, V105, P356, DOI 10.7326/0003-4819-105-3-356; DIENSTAG JL, 1984, ANN INTERN MED, V101, P34, DOI 10.7326/0003-4819-101-1-34; EDDLESTON A, 1990, LANCET, V335, P1142, DOI 10.1016/0140-6736(90)91138-Z; FERRARI C, 1989, J CLIN INVEST, V84, P1314, DOI 10.1172/JCI114299; GERLICH W, 1990, VACCINE, V8, P563; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; JILG W, 1988, J MED VIROL, V24, P377, DOI 10.1002/jmv.1890240404; JILG W, 1984, LANCET, V2, P1174; KLINKERT MQ, 1986, J VIROL, V58, P522, DOI 10.1128/JVI.58.2.522-525.1986; KRUSKALL MS, 1992, J EXP MED, V175, P495, DOI 10.1084/jem.175.2.495; LEGLER K, 1983, DEV BIOL STAND, V54, P179; M Arif, 1988, VIRAL HEPATITIS LIVE, P714; MILICH DR, 1985, P NATL ACAD SCI USA, V82, P8168, DOI 10.1073/pnas.82.23.8168; MILICH DR, 1985, SCIENCE, V228, P1195, DOI 10.1126/science.2408336; MILICH DR, 1991, SEMIN LIVER DIS, V11, P93, DOI 10.1055/s-2008-1040428; MILICH DR, 1986, J IMMUNOL, V137, P315; NEURATH AR, 1984, SCIENCE, V224, P392, DOI 10.1126/science.6200931; PRINCE AM, 1991, LANCET, V338, P61, DOI 10.1016/0140-6736(91)90059-X; PRINCE AM, 1984, J MED VIROL, V15, P399; SAMANTA H, 1989, VACCINE, V7, P69, DOI 10.1016/0264-410X(89)90013-3; SHOUVAL D, 1994, VACCINE, V12, P1453, DOI 10.1016/0264-410X(94)90155-4; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; WESTMORELAND D, 1990, EPIDEMIOL INFECT, V104, P499, DOI 10.1017/S0950268800047506; WOOD RC, 1993, JAMA-J AM MED ASSOC, V270, P2935, DOI 10.1001/jama.270.24.2935; YAP I, 1992, VACCINE, V10, P439, DOI 10.1016/0264-410X(92)90391-V; YAP I, 1995, J GASTROEN HEPATOL, V10, P51, DOI 10.1111/j.1440-1746.1995.tb01047.x; YONEYAMA T, 1988, J GEN VIROL, V69, P1931, DOI 10.1099/0022-1317-69-8-1931; ZUCKERMAN JN, 1992, BRIT MED J, V305, P1158, DOI 10.1136/bmj.305.6862.1158	32	94	105	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					329	333		10.1136/bmj.314.7077.329	http://dx.doi.org/10.1136/bmj.314.7077.329			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040320	Green Published			2022-12-28	WOS:A1997WF86100024
J	Baker, DJ; Reboli, AC				Baker, DJ; Reboli, AC			Cutaneous cryptococcosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Baker, DJ (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CAMDEN,NJ 08103, USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	1997	336	14					998	998		10.1056/NEJM199704033361405	http://dx.doi.org/10.1056/NEJM199704033361405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR385	9077379				2022-12-28	WOS:A1997WR38500005
J	[Anonymous]				[Anonymous]			World medical association declaration of Helsinki - Recommendations guiding physicians in biomedical research involving human subjects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																			0	590	605	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					925	926						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062334				2022-12-28	WOS:A1997WM77400039
J	He, X; SaintJeannet, JP; Wang, YS; Nathans, J; Dawid, I; Varmus, H				He, X; SaintJeannet, JP; Wang, YS; Nathans, J; Dawid, I; Varmus, H			A member of the frizzled protein family mediating axis induction by Wnt-5A	SCIENCE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; XENOPUS-LAEVIS EMBRYOS; SPEMANN ORGANIZER; EXPRESSION; DOMAINS; HOMOLOG; PATTERN; TISSUE; XWNT-8; GENES	In Xenopus laevis embryos, the Wingless/Wnt-1 subclass of Wnt molecules induces axis duplication, whereas the Wnt-5A subclass does not. This difference could be explained by distinct signal transduction pathways or by a lack of one or more Wnt-5A receptors during axis formation. Wnt-5A induced axis duplication and an ectopic Spemann organizer in the presence of hFz5, a member of the Frizzled family of seven-transmembrane receptors. Wnt-5A/hFz5 signaling was antagonized by glycogen synthase kinase-3 and by the amino-terminal ectodomain of hFz5. These results identify hFz5 as a receptor for Wnt-5A.	NCI,NIH,BETHESDA,MD 20892; NICHHD,NIH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Howard Hughes Medical Institute; Johns Hopkins University				Nathans, Jeremy/0000-0001-8106-5460				Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DU SJ, 1995, MOL CELL BIOL, V15, P2625; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GERHART J, 1989, DEVELOPMENT, V107, P37; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOON RT, 1993, DEVELOPMENT, P85; MOON RT, 1993, DEVELOPMENT, V119, P97; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; WOLDA SL, 1993, DEV BIOL, V155, P46, DOI 10.1006/dbio.1993.1005; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060	29	402	421	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1652	1654		10.1126/science.275.5306.1652	http://dx.doi.org/10.1126/science.275.5306.1652			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054360	Green Submitted			2022-12-28	WOS:A1997WN12300048
J	Post, SG; Whitehouse, PJ; Binstock, RH; Bird, TD; Eckert, SK; Farrer, LA; Fleck, LM; Gaines, AD; Jeungst, ET; Karlinsky, H; Miles, S; Murray, TD; Quaid, KA; Relkin, NR; Roses, AD; StGeorgeHyslop, PH; Sachs, GA; Steinbock, B; Truschke, EF; Zinn, AB				Post, SG; Whitehouse, PJ; Binstock, RH; Bird, TD; Eckert, SK; Farrer, LA; Fleck, LM; Gaines, AD; Jeungst, ET; Karlinsky, H; Miles, S; Murray, TD; Quaid, KA; Relkin, NR; Roses, AD; StGeorgeHyslop, PH; Sachs, GA; Steinbock, B; Truschke, EF; Zinn, AB			The clinical introduction of genetic testing for Alzheimer disease - An ethical perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRECURSOR PROTEIN GENE; E TYPE-4 ALLELE; APOLIPOPROTEIN-E; MISSENSE MUTATIONS; HUNTINGTON DISEASE; EPSILON-4 ALLELE; ONSET; RISK; LOCUS; CHROMOSOME-1	Objective.-Primary caregivers should be aware of recent progress in the genetics of Alzheimer disease (AD) and of the clinical and ethical considerations raised regarding the introduction of genetic testing for purposes of disease prediction and susceptibility (risk) analysis in asymptomatic individuals and diagnosis in patients who present clinically with dementia, This statement addresses arguments for and against clinical genetic testing. Participants.-The 20 participants were selected by the investigators (S.G.P., T.H.M., A.B.Z,, and P.J.W.) to achieve balance in the areas of genetics, counseling, ethics, and public policy, and to include leadership from related consensus projects. The consensus group met twice in closed meetings and carried on extensive correspondence over 2 years (1995-1997). The project was supported by the National Human Genome Research Institute of the National Institutes of Health. Evidence.-All 4 involved chromosomes were discussed in group meetings against a background of information from several focus group sessions with AD-affected families. The focus groups comprised volunteers identified by the Cleveland Area Chapter of the Alzheimer's Disease and Related Disorders Association and represented a variety of ethnic populations. Consensus Process.-The first draft was written in April 1996 by the principal investigator (S.G.P.) after the consensus group had met twice. The draft was mailed to all consensus group members 3 times over 6 months for extensive response and redrafting by the principal investigator until all members were satisfied. Conclusions.-Except for autosomal dominant early-onset families, genetic testing in asymptomatic individuals is unwarranted. Use of APOE genetic testing as a diagnostic adjunct in patients already presenting with dementia may prove useful but it remains under investigation. The premature introduction of genetic testing and possible adverse consequences are to be avoided.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT GENET, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT EPIDEMIOL & STAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT ANTHROPOL, CLEVELAND, OH 44106 USA; UNIV HOSP CLEVELAND, ALZHEIMER CTR, CLEVELAND, OH 44106 USA; VET AFFAIRS MED CTR, DEPT NEUROL, SEATTLE, WA 98108 USA; ALZHEIMERS DIS & RELATED DISORDERS ASSOC, CLEVELAND AREA CHAPTER, CLEVELAND, OH USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; MICHIGAN STATE UNIV, CTR ETH & HUMANITIES LIFE SCI, E LANSING, MI 48824 USA; RIVERVIEW HOSP, ALZHEIMERS DIS RES PROGRAM, PORT COQUITLAM, BC, CANADA; UNIV MINNESOTA, CTR BIOMED ETH, MINNEAPOLIS, MN 55455 USA; SUNY ALBANY, COLL HUMANITIES & FINE ARTS, DEPT PHILOSOPHY, ALBANY, NY 12222 USA; ALZHEIMERS DIS & RELATED DISORDERS ASSOC, CHICAGO, IL USA; INDIANA UNIV, MED CTR, DEPT MED & MOL GENET, INDIANAPOLIS, IN USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT NEUROL & NEUROSCI, NEW YORK, NY 10021 USA; DUKE UNIV, MED CTR, DEPT NEUROL & NEUROBIOL, DURHAM, NC USA; UNIV TORONTO, CTR RES NEURODEGENERAT DIS, TORONTO, ON, CANADA; UNIV CHICAGO, MED CTR, DEPT MED, CHICAGO, IL 60637 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University; Michigan State University; University of Minnesota System; University of Minnesota Twin Cities; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Indiana University System; Indiana University-Purdue University Indianapolis; Cornell University; NewYork-Presbyterian Hospital; Duke University; University of Toronto; University of Chicago; University of Chicago Medical Center	Post, SG (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, CTR BIOMED ETH, CLEVELAND, OH 44106 USA.		Farrer, Lindsay/AAS-1035-2020	Juengst, Eric/0000-0002-8374-5774; Farrer, Lindsay/0000-0001-5533-4225	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001092] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HGO1092-01A1] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		*ALZH DIS ASS DIS, 1995, CAUT URG ALZH GEN TE; ANNAS GJ, 1995, AM J PUBLIC HEALTH, V85, P1196, DOI 10.2105/AJPH.85.9.1196; BARINAGA M, 1995, SCIENCE, V268, P1845, DOI 10.1126/science.7604254; BIRD TD, 1995, ANN NEUROL, V38, P141, DOI 10.1002/ana.410380204; Bird TD, 1996, ANN NEUROL, V40, P932, DOI 10.1002/ana.410400619; BIRD TD, 1995, ANN NEUROL, V38, P2, DOI 10.1002/ana.410380103; Birge SJ, 1996, J AM GERIATR SOC, V44, P865, DOI 10.1111/j.1532-5415.1996.tb03749.x; BLUMENTHAL D, 1992, JAMA-J AM MED ASSOC, V268, P3344, DOI 10.1001/jama.268.23.3344; Breitner JCS, 1996, LANCET, V347, P1184, DOI 10.1016/S0140-6736(96)90642-X; BREITNER JCS, 1991, ANN INTERN MED, V115, P601, DOI 10.7326/0003-4819-601; Brodaty H, 1995, ALZ DIS ASSOC DIS, V9, P182; Buchanan AE, 1990, DECIDING OTHERS ETHI; BUTLER RN, 1994, GERIATRICS, V49, P10; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; FARRER LA, 1995, JAMA-J AM MED ASSOC, V274, P1627, DOI 10.1001/jama.1995.03530200063039; FARRER LA, 1995, ANN NEUROL, V38, P797, DOI 10.1002/ana.410380515; Geldmacher DS, 1996, NEW ENGL J MED, V335, P330, DOI 10.1056/NEJM199608013350507; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOSTIN L, 1998, JAMA-J AM MED ASSOC, V270, P2487; HARPER PS, 1992, AM J HUM GENET, V50, P460; HENDEE WR, 1990, JAMA-J AM MED ASSOC, V263, P2790; HOWARD R, 1995, INT J GERIATR PSYCH, V10, P147, DOI 10.1002/gps.930100210; HUGGINS M, 1990, AM J HUM GENET, V47, P4; Hutton M, 1996, NEUROREPORT, V7, P801, DOI 10.1097/00001756-199602290-00029; Juengst Eric T, 1995, Genome Sci Technol, V1, P21, DOI 10.1089/gst.1995.1.21; Kakulas BA, 1996, LANCET, V348, P483, DOI 10.1016/S0140-6736(05)64588-6; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARLINSKY H, 1994, ALZ DIS ASSOC DIS, V8, P116, DOI 10.1097/00002093-199408020-00008; LAMPE TH, 1994, ANN NEUROL, V36, P368, DOI 10.1002/ana.410360308; LANNFELT L, 1995, AM J HUM GENET, V56, P332; Lapham EV, 1996, SCIENCE, V274, P621, DOI 10.1126/science.274.5287.621; Lautenschlager NT, 1996, NEUROLOGY, V46, P641, DOI 10.1212/WNL.46.3.641; LENNOX A, 1994, ALZ DIS ASSOC DIS, V8, P126, DOI 10.1097/00002093-199408020-00009; LEVYLAHAD E, 1995, ANN NEUROL, V38, P678, DOI 10.1002/ana.410380420; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MAYEUX R, 1995, AM J PUBLIC HEALTH, V85, P1280, DOI 10.2105/AJPH.85.9.1280; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; Mehlman MJ, 1996, AM J HUM GENET, V58, P393; MORRIS JC, 1994, CLIN GERIATR MED, V10, P257, DOI 10.1016/S0749-0690(18)30345-8; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; Nelkin D., 1994, PUBLIC UNDERST SCI, V3, P25, DOI DOI 10.1088/0963-6625/3/1/002; PerezTur J, 1995, NEUROREPORT, V7, P297; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; Quaid K A, 1992, J Genet Couns, V1, P277, DOI 10.1007/BF00962825; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6; REUBEN DB, 1988, J AM GERIATR SOC, V36, P1135, DOI 10.1111/j.1532-5415.1988.tb04403.x; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Roses AD, 1996, NEW ENGL J MED, V335, P1996; ROSES AD, 1996, 5 INT C ALZH DIS REL; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SESHADRI S, 1995, ARCH NEUROL-CHICAGO, V52, P1074, DOI 10.1001/archneur.1995.00540350068018; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Turney J, 1996, LANCET, V347, P1087, DOI 10.1016/S0140-6736(96)90283-4; UHLMANN WR, 1996, AM J HUM GENET, V58, P393; Van Broeckhoven C, 1995, NAT GENET, V11, P230; VANDUIJN CM, 1994, GENET EPIDEMIOL, V11, P539, DOI 10.1002/gepi.1370110609; Whitehouse PJ, 1996, NEW ENGL J MED, V335, P1997; WIENER JM, 1994, SHARING BURDEN STRAT; WIENER JM, 1996, HDB AGING SOCIAL SCI, P51; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001	75	168	170	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					832	836		10.1001/jama.277.10.832	http://dx.doi.org/10.1001/jama.277.10.832			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM082	9052715				2022-12-28	WOS:A1997WM08200038
J	Glantz, SA; Fox, BJ; Lightwood, JM				Glantz, SA; Fox, BJ; Lightwood, JM			Tobacco litigation issues for public health and public policy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							WILLIAMSON DOCUMENTS; LAWYER CONTROL		UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Glantz, SA (corresponding author), UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,BOX 0124,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Annas GJ, 1997, NEW ENGL J MED, V336, P304, DOI 10.1056/NEJM199701233360421; BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P248, DOI 10.1001/jama.274.3.248; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P241, DOI 10.1001/jama.274.3.241; CALIFANO JA, 1994, JAMA-J AM MED ASSOC, V272, P1217; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P469; FRANCE M, 1996, BUSINESS WEEK   1223; FREEDMAN A, 1996, WALL STREET J   0826, pA2; FREEDMAN AM, 1996, WALL ST J       0126, pA1; FRNACE M, 1996, BUSINESS WEEK   1007, P150; Glantz SA, 1996, CIRCULATION, V94, P596, DOI 10.1161/01.CIR.94.4.596; Glantz SA, 1996, AM J PUBLIC HEALTH, V86, P156, DOI 10.2105/AJPH.86.2.156; GLANTZ SA, 1987, CIRCULATION, V76, P746, DOI 10.1161/01.CIR.76.4.746; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; Glantz SA, 1996, CIGARETTE PAPERS, P219; GREEN S, 1976, CIGARETTE SMOKING CA; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HARRIS J, IN PRESS TOBACCO CON; *HLTH CAR FIN ADM, 1995, HLTH CAR FIN REV; HWANG S, 1996, WALL STREET J   0418, pB14; INGERSOL B, 1996, WALL STREET J   1219, pA16; KLUGER R, 1996, NY TIMES        0407, P28; MAXWELL J, 1995, TOBCCO REPORTER  APR, P14; MOORE S, 1994, JAMA-J AM MED ASSOC, V272, P1171, DOI 10.1001/jama.272.15.1171; PHELPS D, 1996, MINNEAPOLIS STA 0314, pA1; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; TODD JS, 1995, JAMA-J AM MED ASSOC, V274, P256, DOI 10.1001/jama.274.3.256; US Department of Health Education and Welfare, 1964, SMOK HLTH REP ADV CO; WAGNER S, 1971, CIGARETTE COUNTRY TO; WEINSTEIN H, 1996, LOS ANGELES TIM 0910, pD1; WEISER B, 1996, WASHINGTON POST 1208, P14; WEISER B, 1996, WASHINTON POST  1208, P28; 1996, FED REG         0828, V60, P44615	32	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					751	753		10.1001/jama.277.9.751	http://dx.doi.org/10.1001/jama.277.9.751			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042849				2022-12-28	WOS:A1997WK02600036
J	English, T				English, T			Personal paper: Medicine in the 1990s needs a team approach	BRITISH MEDICAL JOURNAL			English	Article								Health care increasingly emphasises the team approach in which doctors, nurses, and other health workers adapt and develop new skills. Before changes of this kind are widely accepted, however, there must be clarity about the training, status, authority working relationships, career structure, and remuneration of those who undertake responsibilities well beyond their traditional roles.			English, T (corresponding author), UNIV CAMBRIDGE ST CATHARINES COLL,CAMBRIDGE CB2 1RL,ENGLAND.							*AUD COMM, 1996, ACC DES IMPR ACC EM; *CENTR CONS SPEC C, 1996, TOM FUT ROL CONS; *CLIN STAND ADV GR, 1995, URG EM ADM HOSP; Department of Health and Social Security, 1986, NEIGHB NURS FOC CAR; Greenhalgh & Company, 1994, INT JUN DOCT NURS RE; READ S, 1995, CATCHING TIDE NEW VO; *ROYAL COLL NURS, 1994, ACC EM CHALL BOUND; *UK CENTR COUNC, 1990, REP POSTR ED PRACT P; United Kingdom Central Council, 1992, SCOP PROF PRACT	9	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					661	663		10.1136/bmj.314.7081.661	http://dx.doi.org/10.1136/bmj.314.7081.661			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066483	Green Published			2022-12-28	WOS:A1997WL41800033
J	Martin, RM; Hilton, SR; Kerry, SM; Richards, NM				Martin, RM; Hilton, SR; Kerry, SM; Richards, NM			General practitioners' perceptions of the tolerability of antidepressant drugs: A comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; DEPRESSION; METAANALYSIS; DISCONTINUATION; PSYCHIATRISTS; PRESCRIPTION; MANAGEMENT; EFFICACY; RATES	Objective: To examine inceptions and discontinuations of antidepressants in general practice. Design: An observational study analysing data from an ongoing cross sectional postal survey, Every three months a representative sample of 250 doctors recorded prescribing activity for four weeks. This provided 4000 general practitioner weeks of recording per year. Setting: A representative panel of general practitioners in England, Wales, and Scotland. Subjects: Patients who began a new course of an antidepressant or had their treatment stopped or changed by the general practitioner between 1 July 1990 and 30 June 1995. Main outcome measures: Numbers of patients prescribed a new course of antidepressant; numbers discontinuing treatment; the ratio of antidepressant discontinuations to antidepressant inceptions; reasons for discontinuation; proportion of switches to another antidepressant Results: There were 13 619 inceptions and 3934 discontinuations of selective serotonin reuptake inhibitors and tricyclic antidepressants during the study. The number of newly prescribed courses of antidepressants increased by 116%, mostly due to an increase in prescribing of serotonin reuptake inhibitors. The ratio of total discontinuations to inceptions was significantly lower for serotonin reuptake inhibitors (22%) than for tricyclic antidepressants (33%), Differences persisted when controlled for age and sex of patients and severity of depression. However, there was more switching away from selective serotonin reuptake inhibitors when they failed (72%) than from tricyclic antidepressants (58%). Conclusions: Selective serotonin reuptake inhibitors are less likely than tricyclic antidepressants to be discontinued. A prospective study is needed in general practice to assess the implications of differences in discontinuation rates and switches on clinical and economic outcomes.	COMPUFILE LTD,SEND,WOKING GU23 7EF,SURREY,ENGLAND		Martin, RM (corresponding author), ST GEORGE HOSP,SCH MED,DIV GEN PRACTICE & PRIMARY CARE,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.							ANDERSON IM, 1994, J PSYCHOPHARMACOL, V8, P238, DOI 10.1177/026988119400800407; ANDERSON IM, 1995, BMJ-BRIT MED J, V310, P1433, DOI 10.1136/bmj.310.6992.1433; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; *BRIT ASS PSYCH, 1993, J PSYCHOPHARMACOL, V7, P19; BROWN WA, 1995, J CLIN PSYCHIAT, V56, P30; BURGESS I, 1990, HORIZONS, V4, P433; *CENTR STAT OFF, 1995, REG TRENDS, V30; COHN CK, 1990, J CLIN PSYCHIAT, V51, P28; Donoghue J, 1996, BRIT MED J, V313, P861; Donoghue J. M., 1996, British Journal of Psychiatry, V168, P164, DOI 10.1192/bjp.168.2.164; EDWARDS JG, 1994, BRIT J PSYCHIAT, V164, P387, DOI 10.1192/bjp.164.3.387; EDWARDS JG, 1992, BRIT MED J, V304, P1644, DOI 10.1136/bmj.304.6843.1644; *EFF HLTH CAR, 1993, TREATM DEPR PRIM CAR; *GEN MED SERV COMM, 1993, BAS STAT ENGL WAL NA; HARRISON G, 1994, BRIT MED J, V309, P1280, DOI 10.1136/bmj.309.6964.1280; ISACSSON G, 1994, BRIT MED J, V309, P1546, DOI 10.1136/bmj.309.6968.1546; JOHNSON DAW, 1973, BRIT MED J, V2, P18, DOI 10.1136/bmj.2.5857.18; *JOINT FORM COMM, 1995, BRIT NAT FORM, V29, P165; JONSSON B, 1994, BRIT J PSYCHIAT, V164, P665, DOI 10.1192/bjp.164.5.665; LADER M, 1988, BRIT J PSYCHIAT, V153, P51, DOI 10.1192/S0007125000297298; MacDonald TM, 1996, BRIT MED J, V313, P860; MADDOX JC, 1994, J PSYCHOPHARMACOL, V8, P48, DOI 10.1177/026988119400800108; Martin R, 1995, BRIT MED J, V311, P1645, DOI 10.1136/bmj.311.7020.1645; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199400910-00008; OBRIEN JT, 1994, BRIT J PSYCHIAT, V165, P411, DOI 10.1192/bjp.165.3.411a; OLFSON M, 1993, AM J PSYCHIAT, V150, P571; OWENS D, 1994, BRIT MED J, V309, P1281, DOI 10.1136/bmj.309.6964.1281; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; *PRESCR PRIC AUTH, 1995, DEPR ANT PACT REP; RAMCHANDANI P, 1995, BRIT MED J, V311, P751, DOI 10.1136/bmj.311.7007.751b; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P113, DOI 10.1192/bjp.147.2.113; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P119, DOI 10.1192/bjp.147.2.119; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; THOMPSON C, 1989, Human Psychopharmacology, V4, P91, DOI 10.1002/hup.470040204; 1993, BRIT MED J, V306, P1124	37	88	91	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					646	651		10.1136/bmj.314.7081.646	http://dx.doi.org/10.1136/bmj.314.7081.646			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WL418	9066479	Green Published			2022-12-28	WOS:A1997WL41800027
J	Martineau, A; White, M; Bhopal, R				Martineau, A; White, M; Bhopal, R			No sex differences in immunisation rates of British south Asian children: The effect of migration?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE, DEPT EPIDEMIOL & PUBL HLTH, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Newcastle University - UK	Martineau, A (corresponding author), WANSBECK GEN HOSP, ASHINGTON NE63 9JJ, NORTHD, ENGLAND.		White, Martin J. R./G-2410-2010; Martineau, Adrian R/A-3083-2010					BHOPAL RS, 1988, COMMUNITY MED, V10, P215; BOOTH BE, 1994, BRIT MED J, V309, P1259, DOI 10.1136/bmj.309.6964.1259; CHEN LC, 1981, POPUL DEV REV, V7, P55, DOI 10.2307/1972764; Naik V A, 1991, J Postgrad Med, V37, P216; Waldron I, 1987, World Health Stat Q, V40, P194	5	12	12	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 1	1997	314	7081					642	643		10.1136/bmj.314.7081.642	http://dx.doi.org/10.1136/bmj.314.7081.642			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WL418	9066476	Green Published			2022-12-28	WOS:A1997WL41800023
J	New, B				New, B			The rationing debate - Defining a package of healthcare services the NHS is responsible for - The case for	BRITISH MEDICAL JOURNAL			English	Article											New, B (corresponding author), KINGS FUND POLICY INST,LONDON W1M 0AN,ENGLAND.							KLEIN R, 1994, HEALTH POLICY, V27, P103, DOI 10.1016/0168-8510(94)90075-2; NEW B, 1996, RATIONING NHS PRINCI	2	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					503	505						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056805				2022-12-28	WOS:A1997WJ41900035
J	Kirwan, JF; Potamitis, T; ElKasaby, H; HopeRoss, MW; Sutton, GA				Kirwan, JF; Potamitis, T; ElKasaby, H; HopeRoss, MW; Sutton, GA			Lesson of the week - Microbial keratitis in intensive care	BRITISH MEDICAL JOURNAL			English	Review							EYE INFECTIONS		KINGSTON HOSP,ROYAL EYE UNIT,KINGSTON THAMES KT2 7QB,SURREY,ENGLAND; BIRMINGHAM & MIDLAND EYE HOSP,BIRMINGHAM B3 2NS,W MIDLANDS,ENGLAND									Farrell M, 1993, Intensive Crit Care Nurs, V9, P137, DOI 10.1016/0964-3397(93)90055-3; HILTON E, 1983, LANCET, V1, P1318; KATZ J, 1977, ARCH OPHTHALMOL-CHIC, V95, P449; Liesegang T.J., 1988, CORNEA, P217; MILLIKEN J, 1988, CRIT CARE MED, V16, P233, DOI 10.1097/00003246-198803000-00005; OMMESLAG D, 1987, CRIT CARE MED, V15, P80, DOI 10.1097/00003246-198701000-00017	6	27	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					433	434		10.1136/bmj.314.7078.433	http://dx.doi.org/10.1136/bmj.314.7078.433			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040392	Green Published			2022-12-28	WOS:A1997WH29500035
J	Levine, AJ				Levine, AJ			p53, the cellular gatekeeper for growth and division	CELL			English	Review							WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; CYCLE ARREST; GENE; MICE; MUTATIONS; CELLS				Levine, AJ (corresponding author), PRINCETON UNIV,LEWIS THOMAS LAB,DEPT MOL BIOL,PRINCETON,NJ 08544, USA.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BOND JA, 1995, CANCER RES, V55, P2404; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GOGA A, 1995, ONCOGENE, V11, P791; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIN J, 1995, COLD SPRING HARB SYM, V49, P215; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MIYASHITA T, 1995, CELL, V80, P293; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sun XF, 1996, ONCOGENE, V13, P407; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	55	6415	6641	10	727	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					323	331		10.1016/S0092-8674(00)81871-1	http://dx.doi.org/10.1016/S0092-8674(00)81871-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039259	Bronze			2022-12-28	WOS:A1997WG47900005
J	Martinez, BM; Domingo, P				Martinez, BM; Domingo, P			Acute eosinophilic pneumonia associated with tenidap	BRITISH MEDICAL JOURNAL			English	Letter											Martinez, BM (corresponding author), UNIV AUTONOMA BARCELONA,HOSP SANTA CREU & SANT PAU,DEPT INTERNAL MED,E-08193 BARCELONA,SPAIN.		Domingo, Pere/AAP-7571-2021; Domingo, Pere/CAF-3577-2022	Domingo, Pere/0000-0003-1138-5770; 				ALLEN JN, 1989, NEW ENGL J MED, V321, P569, DOI 10.1056/NEJM198908313210903; GOODWIN SD, 1992, ARCH INTERN MED, V152, P1521, DOI 10.1001/archinte.152.7.1521; KHALIL H, 1993, ARCH INTERN MED, V153, P1649, DOI 10.1001/archinte.153.14.1649; UMEKI S, 1992, ARCH INTERN MED, V152, P1913, DOI 10.1001/archinte.152.9.1913	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					349	349		10.1136/bmj.314.7077.349	http://dx.doi.org/10.1136/bmj.314.7077.349			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040330	Green Published			2022-12-28	WOS:A1997WF86100036
J	Wang, J; Whetsell, M; Klein, JR				Wang, J; Whetsell, M; Klein, JR			Local hormone networks and intestinal T cell homeostasis	SCIENCE			English	Article							INTRAEPITHELIAL LYMPHOCYTES; THYROTROPIN; EXPRESSION; MOUSE; RECEPTOR; THYMUS; GENE; IDENTIFICATION; HETEROGENEITY; EPITHELIUM	Neuroendocrine hormones of the hypothalamus-pituitary-thyroid axis can exert positive or negative immunoregulatory effects on intestinal lymphocytes, Small intestine epithelial cells were found to express receptors for thyrotropin-releasing hormone (TRH) and to be a primary source of intestine-derived thyroid-stimulating hormone (TSH). The gene for the TSH receptor (TSH-R) was expressed in intestinal T cells but not in epithelial cells, which suggested a hormone-mediated link between lymphoid and nonhematopoietic components of the intestine, Because mice with congenitally mutant TSH-R (hyt/hyt mice) have a selectively impaired intestinal T cell repertoire, TSH may be a key immunoregulatory mediator in the intestine.	UNIV TULSA,DEPT BIOL SCI,TULSA,OK 74104; UNIV TULSA,MERVIN BOVAIRD CTR STUDIES MOL BIOL & BIOTECHNOL,TULSA,OK 74104	University of Tulsa; University of Tulsa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035566, R23DK035566] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35566, R01 DK035566] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOISMENU R, 1994, SCIENCE, V266, P1253, DOI 10.1126/science.7973709; FARR A, 1991, J HISTOCHEM CYTOCHEM, V39, P645, DOI 10.1177/39.5.2016514; GREEN RP, 1988, P NATL ACAD SCI USA, V85, P5592, DOI 10.1073/pnas.85.15.5592; GURR J, 1983, P NATL ACAD SCI USA, V80, P2121; HAMAD M, 1994, IMMUNOLOGY, V82, P611; HARBOUR DV, 1989, MOL CELL ENDOCRINOL, V64, P229, DOI 10.1016/0303-7207(89)90150-0; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; KLEIN JR, 1990, P SOC EXP BIOL MED, V195, P329; KLEIN JR, 1994, MUCOSAL IMMUNOLOGY I, P33; KOMANO K, 1995, P NATL ACAD SCI USA, V92, P6147; KRUGER TE, 1989, J IMMUNOL, V142, P744; LABRIE F, 1990, HORMONES MOL DIS, P261; MOSLEY RL, 1992, J IMMUNOL METHODS, V156, P19; MOSLEY RL, 1994, INT IMMUNOL, V6, P231, DOI 10.1093/intimm/6.2.231; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; PEKONEN F, 1978, ENDOCRINOLOGY, V103, P1668, DOI 10.1210/endo-103-5-1668; PELLETIER G, 1974, J CELL BIOL, V62, P185, DOI 10.1083/jcb.62.1.185; SATOH T, 1994, NEUROPEPTIDES, V27, P195, DOI 10.1016/0143-4179(94)90070-1; SMITH EM, 1983, P NATL ACAD SCI-BIOL, V80, P6010, DOI 10.1073/pnas.80.19.6010; Stein S A, 1991, Thyroid, V1, P257, DOI 10.1089/thy.1991.1.257; STEIN SA, 1994, MOL ENDOCRINOL, V8, P129, DOI 10.1210/me.8.2.129; STICKNEY DG, 1994, BLOOD, V84, P3034, DOI 10.1182/blood.V84.9.3034.bloodjournal8493034; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; VIDAL K, 1993, J IMMUNOL METHODS, V166, P63, DOI 10.1016/0022-1759(93)90329-6; WANG J, 1994, SCIENCE, V265, P1860, DOI 10.1126/science.8091211; Wang J, 1996, INT IMMUNOL, V8, P231, DOI 10.1093/intimm/8.2.231; WANG J, 1995, CELL IMMUNOL, V161, P299, DOI 10.1006/cimm.1995.1040; XIA W, 1995, ENDOCRINOLOGY, V136, P3146	28	103	110	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1937	1939		10.1126/science.275.5308.1937	http://dx.doi.org/10.1126/science.275.5308.1937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072972				2022-12-28	WOS:A1997WQ51300047
J	Brugada, R; Tapscott, T; Czernuszewicz, GZ; Marian, AJ; Iglesias, A; Mont, L; Brugada, J; Girona, J; Domingo, A; Bachinski, LL; Roberts, R				Brugada, R; Tapscott, T; Czernuszewicz, GZ; Marian, AJ; Iglesias, A; Mont, L; Brugada, J; Girona, J; Domingo, A; Bachinski, LL; Roberts, R			Identification of a genetic locus for familial atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STROKE	Background Atrial fibrillation, the most common sustained cardiac-rhythm disturbance, affects over 2 million Americans and accounts for one third of all strokes in patients over 65 years of age. The molecular basis for atrial fibrillation is unknown, and palliative therapy is used to control the ventricular rate and prevent systemic emboli. We identified a family of 26 members of whom 10 had atrial fibrillation that segregated as an autosomal dominant disease. We subsequently identified two additional families in which the disease was linked to the same locus. Methods We screened the human genome with 300 polymorphic dinucleotide-repeat markers using an unconventional strategy of pooling the DNA samples into two groups (affected and unaffected), which reduced the sample size by approximately 90 percent, before performing linkage analysis to map the locus. This made it possible to identify potential loci within a few weeks. Results The lod scores for markers D10S569 and D10S607, located at 10q22-q24, were 3.60 in Family 1. The disease locus in Families 2 and 3 was also linked to the same markers, with lod scores of 6.02 and 5.35 for markers D10S569 and D10S607, respectively, when data on all three families were combined. Haplotype analysis of the three families showed that the locus was between D10S1694 and D10S1786, an interval of 11.3 centimorgans. Conclusions Identification of the gene for familial atrial fibrillation will help to elucidate the molecular basis of the disease and provide insights into acquired forms. The strategy of pooling DNA samples for analysis is more time and cost effective than conventional screening and should accelerate the process of gene mapping in the future. (C) 1997, Massachusetts Medical Society.	BAYLOR COLL MED, DEPT CARDIOL, HOUSTON, TX 77030 USA; UNIV BARCELONA, HOSP CLIN, DEPT CARDIOL, CARDIAC ARRHYTHMIA SERV, BARCELONA, SPAIN; HOSP MATERNO INFANTIL VALL HEBRON, DEPT CARDIOL, BARCELONA, SPAIN	Baylor College of Medicine; University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitari Vall d'Hebron			Mont, Lluís/AAO-9518-2021	Mont, Lluís/0000-0002-8115-5906; Marian, AJ/0000-0002-1252-7120; BRUGADA, JOSEP/0000-0002-5662-8302	NHLBI NIH HHS [P50-HL313-01, T32-HL-07706] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007706] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS GW, 1994, ARCH INTERN MED, V154, P1443, DOI 10.1001/archinte.154.13.1443; ANTMAN E, 1993, J AM COLL CARDIOL, V22, P1830; BEYER F, 1993, Z KARDIOL, V82, P674; BULLRICH F, 1995, CYTOGENET CELL GENET, V70, P250, DOI 10.1159/000134045; DURAND JB, 1995, CIRCULATION, V92, P3387, DOI 10.1161/01.CIR.92.12.3387; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; GUYER M, 1992, SCIENCE, V258, P67; HOEHE M, 1989, American Journal of Human Genetics, V45, pA143; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; Ott J., 1991, ANAL HUMAN GENETIC L; Scott DA, 1996, AM J HUM GENET, V59, P385; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; YANGFENG TL, 1990, P NATL ACAD SCI USA, V87, P1516, DOI 10.1073/pnas.87.4.1516	15	403	418	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	1997	336	13					905	911		10.1056/NEJM199703273361302	http://dx.doi.org/10.1056/NEJM199703273361302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP832	9070470				2022-12-28	WOS:A1997WP83200002
J	Boyartchuk, VL; Ashby, MN; Rine, J				Boyartchuk, VL; Ashby, MN; Rine, J			Modulation of Ras and a-factor function by carboxyl-terminal proteolysis	SCIENCE			English	Article							GTP-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; STE14 GENE; ISOPRENOID MODIFICATION; MATING PHEROMONE; SHUTTLE VECTORS; AMINO-ACIDS; YEAST; METHYLATION; METHYLTRANSFERASE	Prenylated proteins contain a covalently linked cholesterol intermediate near their carboxyl-termini. Maturation of most prenylated proteins involves proteolytic removal of the last three amino acids. Two genes in Saccharomyces cerevisiae, RCE1 and AFC1, were identified that appear to be responsible for this processing, The Afc1 protein is a zinc protease that participates in the processing of yeast a-factor mating pheromone. The Reel protein contributes to the processing of both Ras protein and a-factor. Deletion of both AFC1 and RCE1 resulted in the loss of proteolytic processing of prenylated proteins. Disruption of RCE1 led to defects in Ras localization and signaling and suppressed the activated phenotype associated with the allele RAS2(val19).	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA; ACACIA BIOSCI INC, RICHMOND, CA 94806 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035827] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35827] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; ASHBY MN, 1995, METHOD ENZYMOL, V250, P235; ASHBY MN, 1993, YEAST, V9, P907, DOI 10.1002/yea.320090810; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; BOYARTCHUCK VL, UNPUB; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HEILMEYER LMG, 1992, P NATL ACAD SCI USA, V89, P9554, DOI 10.1073/pnas.89.20.9554; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KOHL NE, 1995, J CELL BIOCHEM, P145; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MARR RS, 1990, J BIOL CHEM, V265, P20057; MITSUZAWA H, 1989, GENETICS, V123, P739; Parish CA, 1996, BIOCHEMISTRY-US, V35, P8473, DOI 10.1021/bi960603g; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; WHISTLER JL, 1996, THESIS U CALIFORNIA	51	295	313	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	1997	275	5307					1796	1800		10.1126/science.275.5307.1796	http://dx.doi.org/10.1126/science.275.5307.1796			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065405				2022-12-28	WOS:A1997WP05600043
J	Covinsky, KE; Fortinsky, RH; Palmer, RM; Kresevic, DM; Landefeld, CS				Covinsky, KE; Fortinsky, RH; Palmer, RM; Kresevic, DM; Landefeld, CS			Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons	ANNALS OF INTERNAL MEDICINE			English	Article						depression; age factors; activities of daily living; outcome assessment (health care); health status	FUNCTIONAL STATUS; MAJOR DEPRESSION; DISABILITY; CARE; IMPACT; SYMPTOMATOLOGY; VALIDATION; MORBIDITY; MORTALITY; PATIENT	Background: Older patients often have poor health status outcomes after hospitalization. Symptoms of depression are common in hospitalized older persons and may be a risk factor for these poor outcomes. Objective: To determine whether symptoms of depression predict worse health status outcomes in acutely ill, older medical patients, independent of health status and severity of illness at hospital admission. Design: Prospective cohort study. Setting: Medical service of a teaching hospital. Patients: 572 hospitalized medical patients older than 70 years of age. Measurements: 15 symptoms of depression, health status, and severity of illness were measured at admission. The main outcome was dependence in basic activities of daily living at discharge and 30 and 90 days after discharge. Other outcome measures were dependence in instrumental activities of daily living, fair or poor global health status, and poor global satisfaction with life. Results: The median number of symptoms of depression on admission was 4. Patients with 6 or more symptoms on admission (n = 196) were more likely than patients with 0 to 2 symptoms (n = 181) to be dependent in basic activities of daily living (odds ratio, 2.47 [95% Cl, 1.58 to 3.86]) after controlling for demographic characteristics and severity of illness. At each subsequent time point, patients with more symptoms of depression on admission were more likely to be dependent in basic activities of daily living. This association persisted after adjustment for dependence in basic activities of daily living, severity of illness, and demographic characteristics on admission. The odds ratios comparing patients who had 6 or more symptoms with those who had 0 to 2 symptoms were 3.23 (Cl, 1.76 to 5.95) at discharge, 3.45 (Cl, 1.81 to 6.60) 30 days after discharge, and 2.15 (Cl, 1.15 to 4.03) 90 days after discharge. At each time point, patients with 6 or more symptoms of depression were more likely to have more dependence in instrumental activities of daily living, worse global health status, and less satisfaction with life. Conclusions: Symptoms of depression identified a vulnerable group of hospitalized older persons. The health status of patients with more symptoms of depression was after hospitalization. This association was not attributable to health status or severity of illness on admission. The temporal sequence and magnitude of this association, its consistency over time with different measures, and its independence from the severity of the somatic illness strongly support a relation between symptoms of depression on admission and subsequent health status outcomes.	VET AFFAIRS MED CTR, CLEVELAND, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Covinsky, KE (corresponding author), UNIV HOSP CLEVELAND, DIV GEN INTERNAL MED & HLTH CARE RES, 11100 EUCLID AVE, CLEVELAND, OH 44106 USA.				NATIONAL INSTITUTE ON AGING [K08AG000714, P60AG010418] Funding Source: NIH RePORTER; NIA NIH HHS [AG-10418-03, 1K08AG00714-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P323; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; BLAZER D, 1989, NEW ENGL J MED, V320, P164, DOI 10.1056/NEJM198901193200306; BLUMENTHAL MD, 1975, ARCH GEN PSYCHIAT, V32, P985; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BRUCE ML, 1994, AM J PSYCHIAT, V151, P716; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; Caine E.D., 1994, DIAGNOSIS TREATMENT, P21; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CRAIG TJ, 1983, AM J PSYCHIAT, V140, P598; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Dunham N C, 1994, Arch Fam Med, V3, P676, DOI 10.1001/archfami.3.8.676; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; GALLO JJ, 1994, J GERONTOL, V49, pP251, DOI 10.1093/geronj/49.6.P251; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GORDON HS, 1995, ARCH INTERN MED, V155, P2465, DOI 10.1001/archinte.155.22.2465; GURLAND BJ, 1988, INT J GERIATR PSYCH, V3, P163, DOI 10.1002/gps.930030304; HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037/0033-2909.113.3.472; IMBODEN JB, 1961, JAMA-J AM MED ASSOC, V178, P1182, DOI 10.1001/jama.1961.73040520003003a; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOENIG HG, 1988, INT J PSYCHIAT MED, V18, P17; KOENIG HG, 1988, J AM GERIATR SOC, V36, P699, DOI 10.1111/j.1532-5415.1988.tb07171.x; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; MCVEY LJ, 1989, ANN INTERN MED, V110, P79, DOI 10.7326/0003-4819-110-1-79; MORLEY JE, 1988, ANN INTERN MED, V109, P890, DOI 10.7326/0003-4819-109-11-890; MOSSEY JM, 1990, J GERONTOL, V45, pM163, DOI 10.1093/geronj/45.5.M163; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SAS Institute, 1990, SAS PROC GUID VERS 6; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	42	162	163	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					417	+		10.7326/0003-4819-126-6-199703150-00001	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM530	9072926				2022-12-28	WOS:A1997WM53000001
J	Gluud, C; Krogsgaard, K				Gluud, C; Krogsgaard, K			Would you trust a surrogate respondent?	LANCET			English	Editorial Material											Gluud, C (corresponding author), COPENHAGEN UNIV HOSP,INST PREVENT MED,HS KOMMUNEHOSP,DK-1399 COPENHAGEN,DENMARK.		Gluud, Christian/AAY-1027-2021; Gluud, Christian/HGB-3191-2022	Gluud, Christian/0000-0002-8861-0799; Krogsgaard, Kim/0000-0002-7153-9287				BOISSEL JP, 1992, EUR J CLIN PHARMACOL, V43, P235, DOI 10.1007/BF02333016; Farrow D C, 1990, Epidemiology, V1, P370, DOI 10.1097/00001648-199009000-00006; HOFMAN A, 1991, INT J EPIDEMIOL, V20, pS72, DOI 10.1093/ije/20.Supplement_2.S72; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; Weiss A, 1996, J CLIN EPIDEMIOL, V49, P1187, DOI 10.1016/0895-4356(96)00134-5; Wilson GAM, 1996, ANAESTHESIA, V51, P1005, DOI 10.1111/j.1365-2044.1996.tb14991.x	6	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					665	666		10.1016/S0140-6736(05)60131-6	http://dx.doi.org/10.1016/S0140-6736(05)60131-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078195				2022-12-28	WOS:A1997WM08000005
J	Daneholt, B				Daneholt, B			A look at messenger RNP moving through the nuclear pore	CELL			English	Review							EXPORT; TRANSLOCATION; PARTICLE				Daneholt, B (corresponding author), KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOL BIOL,S-17177 STOCKHOLM,SWEDEN.							AlzhanovaEricsson AT, 1996, GENE DEV, V10, P2881, DOI 10.1101/gad.10.22.2881; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FRANKE WW, 1974, CELL NUCLEUS, V1, P219; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KISELEVA E, 1994, EMBO J, V13, P6052, DOI 10.1002/j.1460-2075.1994.tb06952.x; Kiseleva E, 1996, J MOL BIOL, V260, P304, DOI 10.1006/jmbi.1996.0401; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; Mehlin Hans, 1993, Trends in Cell Biology, V3, P443, DOI 10.1016/0962-8924(93)90034-X; MICHAEL WM, 1995, CELL, V83, P415; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Pante N, 1996, CRIT REV BIOCHEM MOL, V31, P153, DOI 10.3109/10409239609106583; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5	20	125	129	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					585	588		10.1016/S0092-8674(00)81900-5	http://dx.doi.org/10.1016/S0092-8674(00)81900-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054498	Bronze			2022-12-28	WOS:A1997WM41300004
J	Kohler, S; Delwiche, CF; Denny, PW; Tilney, LG; Webster, P; Wilson, RJM; Palmer, JD; Roos, DS				Kohler, S; Delwiche, CF; Denny, PW; Tilney, LG; Webster, P; Wilson, RJM; Palmer, JD; Roos, DS			A plastid of probable green algal origin in apicomplexan parasites	SCIENCE			English	Article							ELONGATION-FACTOR-TU; PLASMODIUM-FALCIPARUM; TOXOPLASMA-GONDII; EXTRACHROMOSOMAL DNAS; PHYLOGENETIC ANALYSIS; SEQUENCES; PLANT; EVOLUTION; MALARIA; GENE	Protozoan parasites of the phylum Apicomplexa contain three genetic elements: the nuclear and mitochondrial genomes characteristic of virtually all eukaryotic cells and a 35-kilobase circular extrachromosomal DNA. In situ hybridization techniques were used to localize the 35-kilobase DNA of Toxoplasma gondii to a discrete organelle surrounded by four membranes. Phylogenetic analysis of the tufA gene encoded by the 35-kilobase genomes of coccidians T. gondii and Eimeria tenella and the malaria parasite Plasmodium falciparum grouped this organellar genome with cyanobacteria and plastids, showing consistent clustering with green algal plastids. Taken together, these observations indicate that the Apicomplexa acquired a plastid by secondary endosymbiosis, probably from a green alga.	UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA	University of Pennsylvania; Indiana University System; Indiana University Bloomington; MRC National Institute for Medical Research; Yale University			Delwiche, Charles F/C-6549-2008; Palmer, Jeffrey/P-6747-2014; Denny, Paul/B-8431-2013	Delwiche, Charles F/0000-0001-7854-8584; Palmer, Jeffrey/0000-0002-4626-2220; Denny, Paul/0000-0002-5051-1613; Roos, David Siker/0000-0001-6725-4089	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031808, U19AI031808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052857] Funding Source: NIH RePORTER; Medical Research Council [MC_U117532072] Funding Source: Medline; NIAID NIH HHS [AI-31808] Funding Source: Medline; NIGMS NIH HHS [GM-52857] Funding Source: Medline; MRC [MC_U117532072] Funding Source: UKRI	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; BECKERS CJM, 1995, J CLIN INVEST, V95, P367, DOI 10.1172/JCI117665; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; COUSINEAU B, 1992, GENE, V120, P33, DOI 10.1016/0378-1119(92)90006-B; DELWICHE CF, 1995, MOL PHYLOGENET EVOL, V4, P110, DOI 10.1006/mpev.1995.1012; DEPAMPHILIS CW, 1990, NATURE, V348, P337, DOI 10.1038/348337a0; DODGE JD, 1989, SYST ASSOC SPEC VOL, V38, P207; FEAGIN JE, 1992, NUCLEIC ACIDS RES, V20, P879, DOI 10.1093/nar/20.4.879; FEAGIN JE, 1995, EXP PARASITOL, V80, P430, DOI 10.1006/expr.1995.1055; FEAGIN JE, 1994, ANNU REV MICROBIOL, V48, P81, DOI 10.1146/annurev.mi.48.100194.000501; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FICHERA ME, 1995, ANTIMICROB AGENTS CH, V39, P1530, DOI 10.1128/AAC.39.7.1530; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; GARDNER MJ, 1994, MOL BIOCHEM PARASIT, V66, P221, DOI 10.1016/0166-6851(94)90149-X; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; HACKSTEIN JHP, 1995, PARASITOL RES, V81, P207; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; Hillis DM., 1996, MOL SYSTEMATICS, V2nd; HOWE CJ, 1992, J THEOR BIOL, V158, P199, DOI 10.1016/S0022-5193(05)80718-0; HRAZDINA G, 1992, ANNU REV PLANT PHYS, V43, P241, DOI 10.1146/annurev.pp.43.060192.001325; JOSEPH JT, 1989, MOL CELL BIOL, V9, P3621, DOI 10.1128/MCB.9.9.3621; Katz LA, 1996, J MOL EVOL, V43, P453, DOI 10.1007/BF02337517; Kim JH, 1996, SYST BIOL, V45, P363, DOI 10.2307/2413570; LEVINE ND, 1988, J PROTOZOOL, V35, P518, DOI 10.1111/j.1550-7408.1988.tb04141.x; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; LUDWIG W, 1993, ANTON LEEUW INT J G, V64, P285, DOI 10.1007/BF00873088; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MCFADDEN GI, 1995, TRENDS ECOL EVOL, V12, P12; MORRISSETTE NS, 1994, EXP PARASITOL, V79, P445, DOI 10.1006/expr.1994.1106; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; PALMER JD, 1985, ANNU REV GENET, V19, P325, DOI 10.1146/annurev.ge.19.120185.001545; PUKRITTAYAKAMEE S, 1994, ANTIMICROB AGENTS CH, V38, P511, DOI 10.1128/AAC.38.3.511; READ M, 1994, EUR J BIOCHEM, V220, P513, DOI 10.1111/j.1432-1033.1994.tb18650.x; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SIDDALL ME, 1992, PARASITOL TODAY, V8, P90, DOI 10.1016/0169-4758(92)90244-V; VAIDYA AB, 1989, MOL BIOCHEM PARASIT, V35, P3614; VAN DER STRAETEN D, 1991, PLANT CELL, V3, P719, DOI 10.2307/3869253; VanDePeer Y, 1996, P NATL ACAD SCI USA, V93, P7732, DOI 10.1073/pnas.93.15.7732; WILSON RJM, 1994, INFECT AGENT DIS, V3, P29; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648	43	558	581	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1485	1489		10.1126/science.275.5305.1485	http://dx.doi.org/10.1126/science.275.5305.1485			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045615				2022-12-28	WOS:A1997WM08100048
J	Goldstein, DS; Holmes, C; Cannon, RO; Eisenhofer, G; Kopin, IJ				Goldstein, DS; Holmes, C; Cannon, RO; Eisenhofer, G; Kopin, IJ			Sympathetic cardioneuropathy in dysautonomias	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORTHOSTATIC HYPOTENSION; PLASMA NOREPINEPHRINE; AUTONOMIC FAILURE; INNERVATION; HUMANS; DIHYDROXYPHENYLGLYCOL; NEUROSECRETION; RESPONSES; CATECHOLS; HEART	Background The classification of dysautonomias has been confusing, and the pathophysiology obscure, We examined sympathetic innervation of the heart in patients with acquired, idiopathic dysautonomias using thoracic positron-emission tomography and assessments of the entry rate of the sympathetic neurotransmitter norepinephrine into the cardiac venous drainage (cardiac norepinephrine spillover). We related the laboratory findings to signs of sympathetic neurocirculatory failure (orthostatic hypotension and abnormal blood-pressure responses associated with the Valsalva maneuver), central neural degeneration, and responsiveness to treatment with levodopa-carbidopa (Sinemet). Methods Cardiac scans were obtained after intravenous administration of 6-[F-18]fluorodopamine in 26 patients with dysautonomia. Fourteen had sympathetic neurocirculatory failure - three with no signs of central neurodegeneration (pure autonomic failure), two with parkinsonism responsive to treatment with levodopa-carbidopa, and nine with central neurodegeneration unresponsive to treatment with levodopa-carbidopa (the Shy-Drager syndrome). The rates of cardiac norepinephrine spillover were estimated on the basis of concentrations of intravenously infused [H-3]norepinephrine during catheterization of the right side of the heart. Results Patients with pure autonomic failure or parkinsonism and sympathetic neurocirculatory failure had no myocardial 6-[F-18]fluorodopamine-derived radioactivity or cardiac norepinephrine spillover, indicating loss of myocardial sympathetic-nerve terminals, whereas patients with the Shy-Drager syndrome had increased levels of 6-[F-18]fluorodopamine-derived radioactivity, indicating intact sympathetic terminals and absent nerve traffic, Patients with dysautonomia who did not have sympathetic neurocirculatory failure had normal levels of 6-[F-18]fluorodopamine-derived radioactivity in myocardium and normal rates of cardiac norepinephrine spillover. Conclusions The results of 6-[F-18]fluorodopamine positron-emission tomography and neurochemical analyses support a new clinical pathophysiologic classification of dysautonomias, based on the occurrence of sympathetic neurocirculatory failure, signs of central neurodegeneration, and responsiveness to levodopa-carbidopa. (C) 1997, Massachusetts Medical Society.	NINCDS, CARDIOL BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Goldstein, DS (corresponding author), NINCDS, CLIN NEUROSCI BRANCH,NIH,BLDG 10,RM 6N252, 10 CTR DR, MSC-1424, BETHESDA, MD 20892 USA.		Eisenhofer, Graeme/AAU-9829-2021	Eisenhofer, Graeme/0000-0002-8601-9903				BANNISTER R, 1993, CLIN AUTONOMIC DISOR, P517; EISENHOFER G, 1992, CIRCULATION, V85, P1775, DOI 10.1161/01.CIR.85.5.1775; Eisenhofer G, 1996, CIRCULATION, V93, P1667, DOI 10.1161/01.CIR.93.9.1667; GOLDING DW, 1991, BIOL CELL, V73, P157, DOI 10.1016/0248-4900(91)90098-8; Goldstein DS, 1996, CLIN AUTON RES, V6, P17, DOI 10.1007/BF02291401; GOLDSTEIN DS, 1993, J AM COLL CARDIOL, V22, P1961, DOI 10.1016/0735-1097(93)90786-Z; GOLDSTEIN DS, 1989, ANN NEUROL, V26, P558, DOI 10.1002/ana.410260410; GOLDSTEIN DS, 1991, J HYPERTENS, V9, P417, DOI 10.1097/00004872-199105000-00005; GOLDSTEIN DS, 1990, CIRCULATION, V81, P1606, DOI 10.1161/01.CIR.81.5.1606; GOLDSTEIN DS, 1991, J AUTONOM NERV SYST, V36, P85; GOLDSTEIN DS, 1991, J AUTONOM NERV SYST, V34, P17, DOI 10.1016/0165-1838(91)90005-N; Goldstein DS, 1995, ANN NY ACAD SCI, V771, P570, DOI 10.1111/j.1749-6632.1995.tb44711.x; GOLDSTEIN DS, IN PRESS CLIN AUTON; HOLMES C, 1994, J CHROMATOGR B, V653, P131, DOI 10.1016/0378-4347(93)E0430-X; JOHNSON RH, 1966, Q J MED, V35, P276; JOHNSON RH, 1984, NEUROCARDIOLOGY INTE, V13, P113; KACHI T, 1988, NEUROLOGY, V38, P1091, DOI 10.1212/WNL.38.7.1091; KVETNANSKY R, 1992, J PHARMACOL EXP THER, V261, P899; Low PA., 1993, CLIN AUTONOMIC DISOR, P728; Martin Thomas F. J., 1994, Current Opinion in Neurobiology, V4, P626, DOI 10.1016/0959-4388(94)90002-7; MATHIAS CJ, 1995, CLIN AUTON RES, V5, P307, DOI 10.1007/BF01819025; Meredith I T, 1991, Clin Auton Res, V1, P187, DOI 10.1007/BF01824986; MEREDITH IT, 1992, HYPERTENSION, V19, P628, DOI 10.1161/01.HYP.19.6.628; Oppenheimer D., 1988, AUTONOMIC FAILURE TX, P451; OPPENHEIMER DR, 1980, J NEUROL SCI, V46, P393, DOI 10.1016/0022-510X(80)90064-7; REA RF, 1990, AM J PHYSIOL, V258, pR982, DOI 10.1152/ajpregu.1990.258.4.R982; ROSE CP, 1994, AM J PHYSIOL, V266, pH1386, DOI 10.1152/ajpheart.1994.266.4.H1386; Saito F, 1992, Rinsho Shinkeigaku, V32, P1238; Schatz IJ, 1996, ANN INTERN MED, V125, P74, DOI 10.7326/0003-4819-125-1-199607010-00012; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; WALLIN BG, 1993, CLIN AUTONOMIC DISOR, P243; ZIEGLER MG, 1977, NEW ENGL J MED, V296, P293, DOI 10.1056/NEJM197702102960601	32	234	238	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					696	702		10.1056/NEJM199703063361004	http://dx.doi.org/10.1056/NEJM199703063361004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041100	Bronze			2022-12-28	WOS:A1997WL41900004
J	Nightingale, SL				Nightingale, SL			Proposal for treatment use of investigational devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V61, P66954	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					703	703						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042830				2022-12-28	WOS:A1997WK02600007
J	Everson, SA; Lynch, JW; Chesney, MA; Kaplan, GA; Goldberg, DE; Shade, SB; Cohen, RD; Salonen, R; Salonen, JT				Everson, SA; Lynch, JW; Chesney, MA; Kaplan, GA; Goldberg, DE; Shade, SB; Cohen, RD; Salonen, R; Salonen, JT			Interaction of workplace demands and cardiovascular reactivity in progression of carotid atherosclerosis: Population based study	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; INTIMA-MEDIA THICKNESS; CYNOMOLGUS MONKEYS; ULTRASOUND; ARTERY; MEN	Objective: To examine the combined influence of workplace demands and changes in blood pressure induced by stress on the progression of carotid atherosclerosis. Design: Population based follow up study of unestablished as well as traditional risk factors for carotid atherosclerosis, ischaemic heart disease, and other outcomes. Setting: Eastern Finland. Subjects: 591 men aged 42-60 who were fully employed at baseline and had complete data oil the measures of carotid atherosclerosis, job demands, blood pressure reactivity, and covariates. Main outcome measures: Change in ultrasonographically assessed intima-media thickness of the right and left common carotid arteries from baseline to 4 year follow up. Results: Significant interactions between workplace demands and str ess induced reactivity were observed for all measures of progression (P < 0.04). Men with large changes in systolic blood pressure (20 mm Hg or greater) in anticipation of a maximal exercise test and with high job demands had 10-40% greater progression of mean (0.138 v 0.123 mm) and maximum (0.320 v 0.261 mm) intima-media thickness and plaque height (0.347 v 0.264) than men who were less reactive and had fewer job demands. Similar results were obtained after excluding men with prevalent ischaemic heart disease at baseline. Findings were strongest among men with at least 20% stenosis or non-stenotic plaque at baseline. In this subgroup reactive men with high job demands had more than 46% greater atherosclerotic progression than the others. Adjustment for atherosclerotic risk factors did not alter the results. Conclusions: Men who showed stress induced blood pressure reactivity and who reported high job demands experienced the greatest atherosclerotic progression, showing the association between dispositional risk characteristics and contextual determinants of disease and suggesting that behaviourally evoked cardiovascular reactivity may have a role in atherogenesis.	UNIV CALIF SAN FRANCISCO, PREVENT SCI GRP, SAN FRANCISCO, CA 94105 USA; UNIV KUOPIO, PUBL HLTH RES INST, FIN-70211 KUOPIO, FINLAND	University of California System; University of California San Francisco; University of Eastern Finland	Everson, SA (corresponding author), INST PUBL HLTH, HUMAN POPULAT LAB, BERKELEY, CA 94704 USA.		Kaplan, George/AAJ-2398-2020; Everson-Rose, Susan A/L-7582-2017; Lynch, John W/A-4797-2008; Tanaka, Gohichi/A-1684-2010	Lynch, John W/0000-0003-2781-7902; Everson-Rose, Susan/0000-0002-9839-2537	NHLBI NIH HHS [HL 44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; EVANS GW, 1996, CIRCULATION, V93, P629; Everson SA, 1996, HYPERTENSION, V27, P1059, DOI 10.1161/01.HYP.27.5.1059; KAPLAN JR, 1991, CIRCULATION, V84, P23; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; KARASEK RA, 1988, AM J PUBLIC HEALTH, V78, P910, DOI 10.2105/AJPH.78.8.910; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; Lovallo WR, 1992, INDIVIDUAL DIFFERENC, P165; LYNCH JL, IN PRESS ARTERIOSCLE; LYNCH JL, IN PRESS AM J PUBLIC; Manuck S B, 1994, Int J Behav Med, V1, P4, DOI 10.1207/s15327558ijbm0101_2; MANUCK S B, 1990, Annals of Behavioral Medicine, V12, P17, DOI 10.1207/s15324796abm1201_2; MANUCK SB, 1989, PSYCHOSOM MED, V51, P306, DOI 10.1097/00006842-198905000-00005; MANUCK SB, 1983, PSYCHOSOM MED, V45, P95, DOI 10.1097/00006842-198305000-00002; Rose G, 1982, CARDIOVASCULAR SURVE; SALONEN JT, 1989, ANN MED, V21, P227, DOI 10.3109/07853898909149939; SALONEN JT, 1993, LANCET, V341, P1158, DOI 10.1016/0140-6736(93)93184-3; SALONEN JT, 1993, CIRCULATION, V87, P56; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SALONEN R, 1993, INT CONGR SER, V1018, P301; *SAS I, 1990, SAS US GUID; SCHNALL PL, 1994, ANNU REV PUBL HEALTH, V15, P381, DOI 10.1146/annurev.pu.15.050194.002121; SIEGRIST J, 1990, SOC SCI MED, V31, P1127, DOI 10.1016/0277-9536(90)90234-J; WIKSTRAND J, 1994, J INTERN MED, V236, P555, DOI 10.1111/j.1365-2796.1994.tb00845.x	25	181	187	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					553	558		10.1136/bmj.314.7080.553	http://dx.doi.org/10.1136/bmj.314.7080.553			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK215	9055713	Green Submitted, Green Published			2022-12-28	WOS:A1997WK21500022
J	Franke, TF; Kaplan, DR; Cantley, LC				Franke, TF; Kaplan, DR; Cantley, LC			PI3K: Downstream AKTion blocks apoptosis	CELL			English	Review							PROTEIN-KINASE-B		BETH ISRAEL DEACONESS MED CTR,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Franke, TF (corresponding author), MCGILL UNIV,MONTREAL NEUROL INST,CTR NEURONAL SURVIVAL,3801 UNIV ST,MONTREAL,PQ H3A 2B4,CANADA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM041890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DMELLO SR, 1997, IN PRESS J NEUROSCI; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; KAUFFMANNZEH A, 1997, IN PRESS NATURE; KHWAJA A, 1997, IN PRESS EMBO J; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KULIK G, 1997, IN PRESS MOL CELL BI; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	20	1332	1388	0	67	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					435	437		10.1016/S0092-8674(00)81883-8	http://dx.doi.org/10.1016/S0092-8674(00)81883-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038334	Bronze			2022-12-28	WOS:A1997WJ69100003
J	Rabeneck, L; McCullough, LB; Wray, NP				Rabeneck, L; McCullough, LB; Wray, NP			Ethically justified, clinically comprehensive guidelines for percutaneous endoscopic gastrostomy tube placement	LANCET			English	Article							PERSISTENT VEGETATIVE STATE; MEDICAL FUTILITY; COMPLICATIONS; INTERVENTIONS; WITHDRAWAL; NUTRITION; CACHEXIA	Guidelines for the placement of percutaneous endoscopic gastrostomy (PEG) tubes are not available. We developed a decision-making algorithm by integrating the medical and ethical dimensions of the decision. According to our algorithm, physicians should not offer PEG tubes to patients with anorexia-cachexia syndromes. For patients with permanent vegetative states, physicians should offer and recommend against the procedure. For patients who have dysphagia without other deficits in quality of life, physicians should offer and recommend the procedure. For the the remaining patients who have dysphagia with other deficits in quality of life, the physician's role is to provide nondirective counselling regarding the short and long-term consequences of a trial of PEG tube feeding.	BAYLOR COLL MED,CTR MED ETH & HLTH POLICY,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,DEV HOUSTON FIELD PROGRAM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT VET AFFAIRS,HLTH SERV RES,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine								ANNAS GJ, 1994, NEW ENGL J MED, V330, P1542, DOI 10.1056/NEJM199405263302120; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; GIBSON SE, 1992, ANN OTO RHINOL LARYN, V101, P46, DOI 10.1177/000348949210100113; GILLON R, 1993, J MED ETHICS, V19, P67, DOI 10.1136/jme.19.2.67; GRANT JP, 1993, ANN SURG, V217, P168, DOI 10.1097/00000658-199302000-00011; HORTON WL, 1991, AM J GASTROENTEROL, V86, P168; HULL MA, 1993, LANCET, V341, P869, DOI 10.1016/0140-6736(93)93072-9; LARSON DE, 1987, GASTROENTEROLOGY, V93, P48, DOI 10.1016/0016-5085(87)90312-X; MCCORMICK RA, 1974, JAMA-J AM MED ASSOC, V229, P172, DOI 10.1001/jama.229.2.172; MILLER R E, 1989, Surgical Endoscopy, V3, P186, DOI 10.1007/BF02171543; MITCHELL KR, 1993, J MED ETHICS, V19, P71, DOI 10.1136/jme.19.2.71; *MULT TASK FORC PV, 1994, NEW ENGL J MED, V330, P1572; *MULT TASK FORC PV, 1994, NEW ENGL J MED, V330, P1499; NELSON KA, 1994, J CLIN ONCOL, V12, P213, DOI 10.1200/JCO.1994.12.1.213; Norton B, 1996, BRIT MED J, V312, P13, DOI 10.1136/bmj.312.7022.13; PARK RHR, 1992, BRIT MED J, V304, P1406, DOI 10.1136/bmj.304.6839.1406; PISTERS PWT, 1993, CRIT REV CL LAB SCI, V30, P223, DOI 10.3109/10408369309084669; Rabeneck L, 1996, J GEN INTERN MED, V11, P287, DOI 10.1007/BF02598270; RAHA SK, 1994, AGE AGEING, V23, P162, DOI 10.1093/ageing/23.2.162; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949	20	134	137	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					496	498		10.1016/S0140-6736(96)07369-2	http://dx.doi.org/10.1016/S0140-6736(96)07369-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040591				2022-12-28	WOS:A1997WH38900045
J	Murphy, DJ; Hope, PL; Johnson, A				Murphy, DJ; Hope, PL; Johnson, A			Neonatal risk factors for cerebral palsy in very preterm babies: Case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT INFANTS; CRANIAL ULTRASOUND; WESTERN-AUSTRALIA; HEMORRHAGE; LEUKOMALACIA; PREDICTION; LESIONS; NEWBORN; TRENDS; EVENTS	Objective: To identify neonatal risk factors for cerebral palsy among very preterm babies and in particular the associations independent of the coexistence of antenatal and intrapartum factors. Design: Case-control study. Setting: Oxford health region. Subjects: Singleton babies born between 1984 and 1990 at less than 39 weeks' gestation who survived to discharge from hospital: 59 with cerebral palsy and 234 randomly selected controls without cerebral palsy. Main outcome measures: Adverse neonatal factors expressed as odds ratios and 95% confidence intervals. Results: Factors associated with an increased risk of cerebral palsy after adjustment for gestational age and the presence of previously identified antenatal and intrapartum risk factors were patent ductus arteriosus (odds ratio 2.3; 95% confidence interval 1.2 to 4.5), hypotension (2.3; 1.3 to 4.7), blood transfusion (4.8; 2.5 to 9.3), prolonged ventilation (4.8; 2.5 to 9.0), pneumothorax (3.5; 1.6 to 7.6), sepsis (3.6; 1.8 to 7.4), hyponatraemia (7.9; 2.1 to 29.6) and total parenteral nutrition (5.5; 2.8 to 10.5). Seizures were associated with an increased risk of cerebral palsy (10.0; 4.1 to 24.7), as were parenchymal damage (32; 12.4 to 84.4) and appreciable ventricular dilatation (5.4; 3.0 to 9.8) detected by cerebral ultrasound. Conclusion: A reduction in the Tate of cerebral palsy in very preterm babies requires an integrated approach to management throughout the antenatal intrapartum, and neonatal periods.	ST MICHAELS HOSP, DEPT OBSTET & GYNAECOL, BRISTOL BS2 8EG, AVON, ENGLAND; JOHN RADCLIFFE HOSP, DEPT PAEDIAT, OXFORD OX3 9DU, ENGLAND; RADCLIFFE INFIRM, NATL PERINATAL EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND	University of Oxford; Radcliffe Infirmary; University of Oxford				Murphy, Deirdre/0000-0001-6074-6718; Johnson, Anne/0000-0003-1330-7100				BOZYNSKI MEA, 1988, DEV MED CHILD NEUROL, V30, P342; CALVERT SA, 1987, ACTA PAEDIATR SCAND, V76, P254, DOI 10.1111/j.1651-2227.1987.tb10456.x; COOKE RWI, 1987, ARCH DIS CHILD, V62, P931, DOI 10.1136/adc.62.9.931; DEVRIES LS, 1988, AM J DIS CHILD, V142, P732, DOI 10.1001/archpedi.1988.02150070046023; DEVRIES LS, 1985, LANCET, V2, P137; ESCOBAR GJ, 1991, ARCH DIS CHILD, V66, P204, DOI 10.1136/adc.66.2.204; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GRAHAM M, 1987, LANCET, V2, P593; GRAZIANI LJ, 1986, PEDIATRICS, V78, P88; Grether JK, 1996, J PEDIATR-US, V128, P407, DOI 10.1016/S0022-3476(96)70292-5; JOHNSON A, 1989, COMMUNITY MED, V11, P352; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; LOW JA, 1986, AM J OBSTET GYNECOL, V155, P750, DOI 10.1016/S0002-9378(86)80013-8; MARLOW N, 1988, ARCH DIS CHILD-FETAL, V63, P1131, DOI 10.1136/adc.63.10_Spec_No.1131; Murphy DJ, 1996, ARCH DIS CHILD-FETAL, V74, pF105, DOI 10.1136/fn.74.2.F105; MURPHY DJ, 1995, LANCET, V346, P1449, DOI 10.1016/S0140-6736(95)92471-X; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1995, PEDIATRICS, V95, P263; NORUSSIS MJ, 1985, SPSS ADV STAT GUIDE; O'Shea M, 1992, Paediatr Perinat Epidemiol, V6, P352, DOI 10.1111/j.1365-3016.1992.tb00775.x; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PIDCOCK FS, 1990, J PEDIATR-US, V116, P417, DOI 10.1016/S0022-3476(05)82836-7; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; POWELL TG, 1988, DEV MED CHILD NEUROL, V30, P19, DOI 10.1111/j.1469-8749.1988.tb04722.x; SINHA SK, 1990, ARCH DIS CHILD-FETAL, V65, P1017, DOI 10.1136/adc.65.10_Spec_No.1017; SOLA A, 1992, LANCET, V340, P1363; STANLEY FJ, 1988, AM J OBSTET GYNECOL, V158, P89, DOI 10.1016/0002-9378(88)90784-3; VANDEBOR M, 1992, PEDIATRICS, V90, P196; WATKINS AMC, 1989, EARLY HUM DEV, V19, P103, DOI 10.1016/0378-3782(89)90120-5; WEINDLING AM, 1985, BRIT J OBSTET GYNAEC, V92, P1218, DOI 10.1111/j.1471-0528.1985.tb04865.x; WEISGLASKUPERUS N, 1992, EARLY HUM DEV, V31, P131, DOI 10.1016/0378-3782(92)90040-N	32	123	128	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 8	1997	314	7078					404	408		10.1136/bmj.314.7078.404	http://dx.doi.org/10.1136/bmj.314.7078.404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040385	Green Published			2022-12-28	WOS:A1997WH29500027
J	Cullinan, P; Acquilla, S; Dhara, VR				Cullinan, P; Acquilla, S; Dhara, VR			Respiratory morbidity 10 years after the Union Carbide gas leak at Bhopal: A cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METHYL ISOCYANATE; EXPOSURE	Objective: To examine the role of exposure to the 1984 Bhopal gas leak in the development of persistent obstructive airways disease. Design: Cross sectional survey. Setting: Bhopal, India. Subjects: Random sample of 454 adults stratified by distance of residence from the Union Carbide plant. Main outcome measures: Self reported respiratory symptoms; indices of lung function measured by simple spirometry and adjusted for age, sex, and height according to Indian derived regression equations. Results: Respiratory symptoms were significantly more common and lung function (percentage predicted forced expiratory volume in one second (FEV(1)), forced vital capacity (FVC), forced expiratory now between 25% and 75% of vital capacity (FEF(25-75)), and FEV(1)/FVC ratio) was reduced among those reporting exposure to the gas leak. The frequency of symptoms fell as exposure decreased (as estimated by distance lived from the plant), and lung function measurements displayed similar trends. These findings were not wholly accounted for by confounding by smoking or literacy, a measure of socioeconomic status. Lung function measurements were consistently lower in those reporting symptoms. Conclusion: Our results suggest that persistent small airways obstruction among survivors of the 1984 disaster may be attributed to gas exposure.	UNIV NEWCASTLE UPON TYNE, DEPT EPIDEMIOL & PUBL HLTH, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; AGCY TOX SUBST & DIS REGISTRY, ATLANTA, GA 30333 USA	Newcastle University - UK; Centers for Disease Control & Prevention - USA	Cullinan, P (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, DEPT OCCUPAT & ENVIRONM MED, LONDON SW3 6LR, ENGLAND.							ANDERSSON N, 1990, BRIT J IND MED, V47, P553; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BARKER DJP, 1992, FETAL INFANT ORIGINS, P150; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; *CARB CORP, 1985, BHOP METH IS INC INV; Cullinan P, 1996, NATL MED J INDIA, V9, P5; DARKE CHRISTOPHER S., 1958, THORAX, V13, P327, DOI 10.1136/thx.13.4.327; GALEA M, 1964, CAN MED ASSOC J, V91, P345; HARKONEN H, 1983, AM REV RESPIR DIS, V128, P890; *IND COUNC MED RES, 1985, HLTH EFF EXP TOX GAS; KAMAT SR, 1992, ENVIRON HEALTH PERSP, V97, P241, DOI 10.2307/3431360; RASTOGI SK, 1988, INDIAN J EXP BIOL, V26, P161; SINGH MP, 1987, J HAZARD MATER, V17, P1, DOI 10.1016/0304-3894(87)85039-2; UDWADIA FE, 1987, J ASSOC PHYSICIAN I, V36, P454; VIJAYAN V K, 1989, Indian Journal of Medical Research Section B, V90, P407; VIJAYAN VK, 1995, RESP MED, V89, P105, DOI 10.1016/0954-6111(95)90192-2; WEILL H, 1987, B EUR PHYSIOPATH RES, V23, P587	17	52	53	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 1	1997	314	7077					338	342		10.1136/bmj.314.7077.338	http://dx.doi.org/10.1136/bmj.314.7077.338			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040323	Green Published			2022-12-28	WOS:A1997WF86100029
J	Wagner, RM; Schleicher, DG				Wagner, RM; Schleicher, DG			The spectrum and spatial distribution of cyanogen in comet Hale-Bopp (C/1995 O1) at large heliocentric distance	SCIENCE			English	Article								Optical spectra of comet Hale-Bopp (C/1995 O1) at a heliocentric distance of 6.45 astronomical units showed emission from cyanogen gas. The spatial distribution of cyanogen was considerably more diffuse and extended compared to the spatial profile of the dust or grains which were sharply peaked near the center. This behavior is consistent with comets at smaller heliocentric distances suggesting the same or a similar formation mechanism, A cyanogen gas production rate of (1.2 +/- 0.3) x 10(26) molecules per second was derived. A model band profile derived from fluorescence equilibrium calculations for the comet's heliocentric velocity and distance agrees with the observed band profile.	LOWELL OBSERV,FLAGSTAFF,AZ 86001		Wagner, RM (corresponding author), OHIO STATE UNIV,DEPT ASTRON,174 W 18TH AVE,COLUMBUS,OH 43210, USA.							AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; BUS SJ, 1991, SCIENCE, V251, P774, DOI 10.1126/science.251.4995.774; COCHRAN AL, COMMUNICATION; COCHRAN AL, 1996, B AM ASTRON SOC, V28, P1093; Fitzsimmons A, 1996, MON NOT R ASTRON SOC, V278, pL37, DOI 10.1093/mnras/278.2.L37; GREEN D, 1995, 6191 IAU; HALE A, 1995, 6187 IAU; KLEINE M, 1994, ASTROPHYS J, V436, P885, DOI 10.1086/174966; RANDALL CA, UNPUB; RANDALL CE, 1992, B AM ASTRON SOC, V24, P1002; Schleicher DG, 1997, SCIENCE, V275, P1913, DOI 10.1126/science.275.5308.1913; SCHLEICHER DG, 1983, THESIS U MARYLAND; WAGNER RM, 1987, ASTROPHYS J, V322, P544, DOI 10.1086/165749; WAGNER RM, 1992, ASTR SOC P, V23, P160; WYCKOFF S, 1985, NATURE, V316, P241, DOI 10.1038/316241a0	15	12	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1918	1920		10.1126/science.275.5308.1918	http://dx.doi.org/10.1126/science.275.5308.1918			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072965				2022-12-28	WOS:A1997WQ51300040
J	Glick, SM				Glick, SM			Unlimited human autonomy - A cultural bias?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Glick, SM (corresponding author), BEN GURION UNIV NEGEV,IL-84105 BEER SHEVA,ISRAEL.							Etzioni A., 1998, ESSENTIAL COMMUNITAR; FRANCIS CM, 1992, TRANSCULTURAL DIMENSIONS IN MEDICAL ETHICS, P175; HAMEL R, 1995, REIGN AUTONOMY IS EN, P75; JAKOBOVITS I, 1959, JEWISH MED ETHICS; *WORLD MED ASS, 1975, DECL TOK TORT OTH CR	5	74	74	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	1997	336	13					954	956		10.1056/NEJM199703273361312	http://dx.doi.org/10.1056/NEJM199703273361312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP832	9070480				2022-12-28	WOS:A1997WP83200012
J	Mittal, RK; Balaban, DH				Mittal, RK; Balaban, DH			Mechanisms of disease: The esophagogastric junction	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOWER ESOPHAGEAL SPHINCTER; GASTROESOPHAGEAL JUNCTION; CRURAL DIAPHRAGM; HIATUS-HERNIA; NITRIC-OXIDE; REFLUX ESOPHAGITIS; ACHALASIA; RELAXATION; PRESSURE; OPOSSUM				Mittal, RK (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, DIV GASTROENTEROL & HEPATOL, BOX 10013, CHARLOTTESVILLE, VA 22906 USA.		Mittal, Ravinder/ABH-2171-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051604] Funding Source: NIH RePORTER; NIDDK NIH HHS [R-29-DK-45027, R01-DK-51604] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHULER SM, 1985, AM J PHYSIOL, V249, pG586, DOI 10.1152/ajpgi.1985.249.5.G586; BIANCANI P, 1987, AM J PHYSIOL, V253, pG760, DOI 10.1152/ajpgi.1987.253.6.G760; BOULANT J, 1994, GASTROENTEROLOGY, V107, P1059, DOI 10.1016/0016-5085(94)90230-5; BOYLE JT, 1985, GASTROENTEROLOGY, V88, P723, DOI 10.1016/0016-5085(85)90143-X; CHUNG SA, 1987, AM J PHYSIOL, V252, pG301, DOI 10.1152/ajpgi.1987.252.3.G301; COHEN S, 1971, NEW ENGL J MED, V284, P1053, DOI 10.1056/NEJM197105132841902; DARIAN GB, 1989, J APPL PHYSIOL, V66, P2579, DOI 10.1152/jappl.1989.66.6.2579; DELATTRE JF, 1985, ANAT CLIN, V7, P271, DOI 10.1007/BF01784644; DENT J, 1983, GASTROENTEROLOGY, V84, P453; DENT J, 1988, GUT, V29, P1020, DOI 10.1136/gut.29.8.1020; DODDS WJ, 1981, AM J PHYSIOL, V240, pG290, DOI 10.1152/ajpgi.1981.240.4.G290; EASTWOOD GL, 1975, GASTROENTEROLOGY, V69, P146; GALMICHE JP, 1990, DIGEST DIS SCI, V35, P649, DOI 10.1007/BF01540415; GAUMNITZ EA, 1995, GASTROENTEROLOGY, V109, P789, DOI 10.1016/0016-5085(95)90386-0; Goldblum JR, 1996, GASTROENTEROLOGY, V111, P648, DOI 10.1053/gast.1996.v111.pm8780569; GOYAL RK, 1975, J CLIN INVEST, V55, P1119, DOI 10.1172/JCI108013; HEINE KJ, 1993, J GASTROINTEST MOTIL, V5, P89; HOLLOWAY RH, 1986, GASTROENTEROLOGY, V90, P924, DOI 10.1016/0016-5085(86)90869-3; INGELFINGER FJ, 1958, PHYSIOL REV, V38, P533; KAHRILAS PJ, 1986, GASTROENTEROLOGY, V91, P897, DOI 10.1016/0016-5085(86)90692-X; KATZKA DA, 1995, AM J GASTROENTEROL, V90, P280; KLEIN WA, 1993, GASTROENTEROLOGY, V105, P1362, DOI 10.1016/0016-5085(93)90140-8; LANGMAN J, 1975, MED EMBRYOLOGY, P305; LIEBERMANNMEFFERT D, 1979, GASTROENTEROLOGY, V76, P31; LIN SZ, 1995, AM J PHYSIOL-GASTR L, V268, pG320, DOI 10.1152/ajpgi.1995.268.2.G320; LIU JB, 1992, RADIOLOGY, V184, P721, DOI 10.1148/radiology.184.3.1509056; LIU JQ, IN PRESS AM J PHYSL; MARTIN CJ, 1992, AM J PHYSIOL, V263, pG551, DOI 10.1152/ajpgi.1992.263.4.G551; MEARIN F, 1993, EUR J CLIN INVEST, V23, P724, DOI 10.1111/j.1365-2362.1993.tb01292.x; MILLER LS, 1993, GASTROENTEROLOGY, V105, P31, DOI 10.1016/0016-5085(93)90007-Y; Mittal RK, 1987, GASTROENTEROLOGY, V92, P130, DOI 10.1016/0016-5085(87)90849-3; MITTAL RK, 1990, AM J PHYSIOL, V258, pG624, DOI 10.1152/ajpgi.1990.258.4.G624; MITTAL RK, 1995, GASTROENTEROLOGY, V109, P601, DOI 10.1016/0016-5085(95)90351-8; MITTAL RK, 1995, GASTROENTEROLOGY, V108, pA168; MITTAL RK, 1988, J CLIN INVEST, V81, P1182, DOI 10.1172/JCI113433; Mittal RK, 1996, GASTROENTEROLOGY, V111, P378, DOI 10.1053/gast.1996.v111.pm8690202; MITTAL RK, 1988, GASTROENTEROLOGY, V95, P593, DOI 10.1016/S0016-5085(88)80003-9; MITTAL RK, 1995, GASTROENTEROLOGY, V109, P1547, DOI 10.1016/0016-5085(95)90643-6; MONGES H, 1978, J PHYSIOL-PARIS, V74, P541; PASRICHA PJ, 1995, NEW ENGL J MED, V332, P774, DOI 10.1056/NEJM199503233321203; PASRICHA PJ, 1995, NEW ENGL J MED, V333, P75; PATERSON WG, 1994, GASTROENTEROLOGY, V107, P1736, DOI 10.1016/0016-5085(94)90814-1; PENAGINI R, 1996, GASTROENTEROLOGY S, V110, pA227; PETERS JH, 1995, J AM COLL SURGEONS, V180, P385; ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304; SENGUPTA A, 1987, AM J ANAT, V180, P342, DOI 10.1002/aja.1001800404; SINGARAM C, 1994, GASTROENTEROLOGY, V106, pA566; SLOAN S, 1992, ANN INTERN MED, V117, P977, DOI 10.7326/0003-4819-117-12-977; SLOAN S, 1991, GASTROENTEROLOGY, V100, P596, DOI 10.1016/0016-5085(91)80003-R; THOR KBA, 1987, ACTA CHIR SCAND, V153, P25; Tlottrup A, 1990, Gut, V31, P17, DOI 10.1136/gut.31.1.17; VANTRAPPEN G, 1980, GASTROENTEROLOGY, V79, P144; YAMATO S, 1992, LIFE SCI, V50, P1263, DOI 10.1016/0024-3205(92)90326-K; ZIEGLER K, 1990, ENDOSCOPY, V22, P1, DOI 10.1055/s-2007-1012776; [No title captured]	55	372	396	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	1997	336	13					924	932		10.1056/NEJM199703273361306	http://dx.doi.org/10.1056/NEJM199703273361306			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP832	9070474				2022-12-28	WOS:A1997WP83200006
J	Park, HW; Boduluri, SR; Moomaw, JF; Casey, PJ; Beese, LS				Park, HW; Boduluri, SR; Moomaw, JF; Casey, PJ; Beese, LS			Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution	SCIENCE			English	Article							GERANYLGERANYLTRANSFERASE TYPE-I; AWAMORI VAR X100; ALPHA-SUBUNIT; 2.2-ANGSTROM RESOLUTION; METAL REQUIREMENTS; KINETIC MECHANISM; PEPTIDE-BINDING; CDNA CLONING; FARNESYL; EXPRESSION	Protein farnesyltransferase (FTase) catalyzes the carboxyl-terminal lipidation of Ras and several other cellular signal transduction proteins, The essential nature of this modification for proper function of these proteins has led to the emergence of FTase as a target for the development of new anticancer therapy. Inhibition of this enzyme suppresses the transformed phenotype in cultured cells and causes tumor regression in animal models. The crystal structure of heterodimeric mammalian FTase was determined at 2.25 angstrom resolution. The structure shows a combination of two unusual domains: a crescent-shaped seven-helical hairpin domain and an alpha-alpha barrel domain, The active site is formed by two clefts that intersect at a bound zinc ion. One cleft contains a nine-residue peptide that may mimic the binding of the Ras substrate: the other cleft is lined with highly conserved aromatic residues appropriate for binding the farnesyl isoprenoid with required specificity.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710	Duke University; Duke University			beese, lorena/G-4993-2010	Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM46372, GM52382] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372, R37GM052382, R01GM052382] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESHIN A, 1992, J BIOL CHEM, V267, P19291; ALESHIN AE, 1994, J MOL BIOL, V238, P575, DOI 10.1006/jmbi.1994.1316; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; *BIOS TECHN, 1993, INSIGHT, V2; BOGUSKI MS, 1992, NEW BIOL, V4, P408; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BUKHTIYAROV YE, 1995, J BIOL CHEM, V270, P19035, DOI 10.1074/jbc.270.32.19035; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Fu HW, 1996, J BIOL CHEM, V271, P28541, DOI 10.1074/jbc.271.45.28541; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Huang CC, 1997, J BIOL CHEM, V272, P20; JAININ J, 1988, J MOL BIOL, V204, P155; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JONES TA, 1993, O VERSION 5 9 MANUAL; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KNIGHT S, 1989, THESIS SWEDISH U AGR; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Nicholls A., 1992, GRASP GRAPHICAL REPR; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STRADLEY SJ, 1993, BIOCHEMISTRY-US, V32, P12586, DOI 10.1021/bi00210a006; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; YING WL, 1994, J BIOL CHEM, V269, P470; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	58	309	327	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1800	1804		10.1126/science.275.5307.1800	http://dx.doi.org/10.1126/science.275.5307.1800			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065406				2022-12-28	WOS:A1997WP05600044
J	Amdur, RJ; Biddle, C				Amdur, RJ; Biddle, C			Institutional review board approval and publication of human research results	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine if journals' instructions for authors require that manuscripts being considered for publication indicate that studies involving human subjects had appropriate institutional review board (IRB) approval. Design.-A descriptive study of the ethical guidelines published in the Instructions for Authors sections of the 102 English-language biomedical research journals listed in the 1995 Abridged Index Medicus. Intervention.-Literature review. Main Outcome Measure.-Policy regarding IRB approval of studies that involve human subjects. Results.-Of the 102 journals surveyed, 48 (47%) require IRB approval of studies involving human subjects as a prerequisite for publication, and 25 (24%) do not present or refer the author to any information related to human research ethics. Of the remaining journals, 15 (15%) referred authors to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, 3 (3%) to the Declaration of Helsinki, and 10 (10%) simply indicated that informed consent should be obtained. There was only 1 medical specialty (anesthesiology) in which all the representative journals presented the same ethical requirement. In the 48 journals that clearly required IRB approval of studies, 37 (77%) documented IRB approval with a statement in the manuscript, 7 (15%) required a separate signed statement from the author, and 4 (8%) did not mention a method of documentation. Conclusions.-The results of this study suggest that about half of the 102 English-language biomedical research journals listed in the 1995 Abridged Index Medicus do not publish guidelines indicating that IRB approval of studies involving human research subjects is a requirement for publication. The manner in which publication requirements related to ethical standards are presented in biomedical research journals is extremely variable.	DARTMOUTH HITCHCOCK MED CTR, LEBANON, NH 03766 USA	Dartmouth College								[Anonymous], 1997, JAMA-J AM MED ASSOC, V277, P925; [Anonymous], 1997, JAMA, V277, P927; [Anonymous], 1996, JAMA-J AM MED ASSOC, V276, P1691; BLACKBALL Y, 1980, HASTINGS CTR REP APR, P20; CAELLEIGH AS, 1993, ACAD MED, V68, pS23, DOI 10.1097/00001888-199309000-00030; DEBAKEY L, 1978, ENCY BIOETHICS, P188; *INSTR AUTH, 1995, CAN MED ASSOC J, V153, P57; *NAT LIBR MED, 1995, NIH PUBL; RELMAN AS, 1990, HASTINGS CENT REP, V20, P23, DOI 10.2307/3563157; 1997, NEW ENGL J MED, V336, P316; 1996, JAMA-J AM MED ASSOC, V275, P6; 1991, FED REG         0618, V56, P28003; 1996, NURS RES         JAN, P9; 1996, ANESTH ANALG     APR; 1994, J CLIN ENDOCR METAB, V79, pA25; 1996, CLIN PHARMACOL THER, V59, pA5; 1996, J CLIN INVEST, V97, pR1; 1996, AM J MED SCI, V312, P194; 1996, RADIOLOGY, V199, pA45	19	63	63	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					909	914		10.1001/jama.277.11.909	http://dx.doi.org/10.1001/jama.277.11.909			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062330				2022-12-28	WOS:A1997WM77400035
J	Brandjes, DPM; Buller, HR; Heijboer, H; Huisman, MV; deRijk, M; Jagt, H; tenCate, JW				Brandjes, DPM; Buller, HR; Heijboer, H; Huisman, MV; deRijk, M; Jagt, H; tenCate, JW			Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis	LANCET			English	Article							THERAPY	Background Post-thrombotic syndrome varies from mild oedema to incapacitating swelling with pain and ulceration. We investigated the rate of post-thrombotic syndrome after a first episode of deep-vein thrombosis and assessed the preventive effect of direct application of a sized-to-fit graded compression stocking. Methods Patients with a first episode of venogram-proven proximal deep-vein thrombosis were randomly assigned no stockings (the control group) or made-to-measure graded compression elastic stockings for at least 2 years. Post-thrombotic syndrome was assessed with a standard scoring system that combined clinical characteristics and objective leg measurements. Patients were assessed every 3 months during the first 2 years, and every 6 months thereafter for at least 5 years. The cumulative incidence of mild-to-moderate post-thrombotic syndrome was the primary outcome measure. Findings Of the 315 consecutive outpatients considered for inclusion, 44 were excluded and 77 did not consent to take part, 194 patients were randomly assigned compression stockings (n=96) or no stockings (n=98). The median follow-up was 76 months (range 60-96) in both groups. Mild-to-moderate post-thrombotic Syndrome (score greater than or equal to 3 plus one clinical sign) occurred in 19 (20%) patients in the stocking group and in 46 (47%) control-group patients (p<0.001). 11 (11%) patients in the stocking group developed severe post-thrombotic syndrome (score greater than or equal to 4), compared with 23 (23%) patients in the control group (p<0.001). In both groups, most cases of post-thrombotic syndrome occurred within 24 months of the acute thrombotic event. Interpretation About 60% of patients with a first episode of proximal deep-vein thrombosis develop post-thrombotic syndrome within 2 years. A sized-to-fit compression stocking reduced this rate by about 50%.	SLOTERVAART HOSP,DEPT MED,AMSTERDAM,NETHERLANDS	Slotervaart Hospital	Brandjes, DPM (corresponding author), UNIV AMSTERDAM,ACAD MED CTR F4237,CTR HEMOSTAS THROMBOS ATHEROSCLEROS & INFLAM RES,NL-1105 AZ AMSTERDAM,NETHERLANDS.							Altman DG, 1991, PRACTICAL STAT MED R, P365; ANNING ST, 1976, PATHOLOGY SURG VEINS, P110; [Anonymous], 1994, HAEMOSTASIS S1; [Anonymous], 1988, PHLEBOLOGIE; BAUER G, 1942, ACTA CHIR SCAND S74, V86, P1; BROWSE NL, 1980, BRIT MED J, V281, P1167, DOI 10.1136/bmj.281.6249.1167; CORNWALL JV, 1986, BRIT J SURG, V73, P693, DOI 10.1002/bjs.1800730905; GIDOROV J, 1989, ARCH INTERN MED, V149, P1841; GJORES J E, 1956, Acta Chir Scand Suppl, V206, P1; HAEGER K, 1968, ANGIOLOGY, V19, P439, DOI 10.1177/000331976801900801; HELDAL M, 1993, J INTERN MED, V234, P71, DOI 10.1111/j.1365-2796.1993.tb00707.x; HOAK JC, 1992, INTERNAL MED, P1285; KAKKAR VV, 1985, AM J SURG, V150, P54; LENSING AWA, 1994, HEMOSTASIS THROMBOSI, P1297; ROGERS LQ, 1990, AM J MED, V88, P389, DOI 10.1016/0002-9343(90)90494-X; SHULL KC, 1979, ARCH SURG-CHICAGO, V114, P1304; SKENE A, 1992, BRIT MED J, V305, P1118; WIDMER LK, 1985, VASA-J VASCULAR DIS, V14, P264	18	644	665	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					759	762		10.1016/S0140-6736(96)12215-7	http://dx.doi.org/10.1016/S0140-6736(96)12215-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074574	Green Submitted			2022-12-28	WOS:A1997WN12400009
J	Thybo, H; Perchuc, E				Thybo, H; Perchuc, E			The seismic 8 degrees discontinuity and partial melting in continental mantle	SCIENCE			English	Article							LOW-VELOCITY ZONE; STRUCTURE BENEATH; LEHMANN DISCONTINUITY; NORTH-AMERICA; EUROPE; LITHOSPHERE; THICKNESS; EURASIA	Strong, scattered reflections beyond 8 degrees (8 degrees.) offset are characteristic features of all high-resolution seismic sections from the continents. The reflections identify a low-velocity zone below approximately 100 kilometers depth beneath generally stratified mantle. This zone may be caused by partial melting, globally initiated at equal depth in the continental mantle. Solid state is again attained at the Lehmann discontinuity in cold, stable areas, whereas the zone extends to near the 400-kilometer discontinuity in hot, tectonically active areas. Thus, the depth to the Lehmann discontinuity may be an indicator of the thermal state of the continental mantle.	POLISH ACAD SCI,INST GEOPHYS,PL-01452 WARSAW,POLAND	Polish Academy of Sciences; Institute of Geophysics of the Polish Academy of Sciences	Thybo, H (corresponding author), UNIV COPENHAGEN,INST GEOL,OSTER VOLDGADE 10,DK-1350 COPENHAGEN K,DENMARK.		Thybo, Hans/B-9292-2008; Perchuć, Edward/HHZ-0836-2022; Perchuc, Edward/O-5797-2015	Thybo, Hans/0000-0002-3945-8065; 				ANDERSON DL, 1990, CONTINENTAL MANTLE, P1; Ansorge J., 1973, Zeitschrift fur Geophysik, V39, P385; *BABEL WORK GROUP, 1991, GEOPHYSICAL RES LETT, V18, P645; BADAL J, 1996, GEOPHYS J INT, V124, P91; BECHTEL TD, 1990, NATURE, V343, P636, DOI 10.1038/343636a0; BOWMAN JR, 1990, GEOPHYS J INT, V101, P411, DOI 10.1111/j.1365-246X.1990.tb06578.x; BURDICK LJ, 1981, J GEOPHYS RES, V86, P5926, DOI 10.1029/JB086iB07p05926; DEYSARKAR SK, 1976, J GEOPHYS RES, V81, P3619, DOI 10.1029/JB081i020p03619; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; FUCHS K, 1971, GEOPHYS J ROY ASTR S, V23, P417, DOI 10.1111/j.1365-246X.1971.tb01834.x; Fuchs K., 1982, GEODYNAMICS SERIES, V8, P81; FUCHS K, 1983, TECTONOPHYSICS, V56, P1; GAHERTY JB, 1995, SCIENCE, V268, P1468, DOI 10.1126/science.268.5216.1468; GIVEN JW, 1980, J GEOPHYS RES, V85, P7183, DOI 10.1029/JB085iB12p07183; HALES AL, 1991, GEOPHYS J INT, V105, P355, DOI 10.1111/j.1365-246X.1991.tb06718.x; Hartley R, 1996, EARTH PLANET SC LETT, V137, P1, DOI 10.1016/0012-821X(95)00185-F; HAUSER F, 1990, 902 U KARLSR GEOPH I; HILL DP, 1972, GEOL SOC AM BULL, V83, P1639, DOI 10.1130/0016-7606(1972)83[1639:CAUMSO]2.0.CO;2; Hirn A., 1973, Zeitschrift fur Geophysik, V39, P363; IYER HM, 1969, J GEOPHYS RES, V74, P4409, DOI 10.1029/JB074i017p04409-02; JEFFREYS H, 1936, MON NOT R ASTRON S S, V3, P401; KARATO S, 1992, GEOPHYS RES LETT, V19, P2255, DOI 10.1029/92GL02603; KENNETT BLN, 1991, GEOPHYS J INT, V105, P429, DOI 10.1111/j.1365-246X.1991.tb06724.x; LAMBECK K, 1990, GEOPHYS J INT, V103, P451, DOI 10.1111/j.1365-246X.1990.tb01784.x; LAMBERT IB, 1968, NATURE, V219, P1240, DOI 10.1038/2191240a0; LAMBERT IB, 1970, SCIENCE, V169, P764, DOI 10.1126/science.169.3947.764; Lehmann I., 1959, ANN GEOPHYS, V15, P93; Lehmann Inge, 1964, B SEISMOL SOC AM, V54, P123; LELIWAKOPYSTYNS.J, 1984, CONSTITUTION EARTHS, P171; MALONE S, COMMUNICATION; MASSE RP, 1973, B SEISMOL SOC AM, V63, P911; MAVKO GM, 1980, J GEOPHYS RES, V85, P5173, DOI 10.1029/JB085iB10p05173; Mayer-Rosa D., 1973, Zeitschrift fur Geophysik, V39, P395; MECHIE J, 1993, PHYS EARTH PLANET IN, V79, P269, DOI 10.1016/0031-9201(93)90151-X; MOHOROVICIC A, 1909, JB METEOROL OBS ZAGR, V9, P1; NIAZI M, 1965, J GEOPHYS RES, V70, P4633, DOI 10.1029/JZ070i018p04633; Perchuc E, 1996, TECTONOPHYSICS, V253, P227, DOI 10.1016/0040-1951(95)00057-7; POUPINET G, IN PRESS; PRIESTLEY K, 1994, GEOPHYS J INT, V118, P369, DOI 10.1111/j.1365-246X.1994.tb03968.x; ROMANOWICZ BA, 1982, J GEOPHYS RES, V87, P6865, DOI 10.1029/JB087iB08p06865; ROMNEY C, 1962, B SEISMOL SOC AM, V52, P1057; SATO H, 1989, J GEOPHYS RES-SOLID, V94, P5689, DOI 10.1029/JB094iB05p05689; SHEARER PM, 1990, NATURE, V344, P121, DOI 10.1038/344121a0; VANHEIJST HJ, 1994, GEOPHYS J INT, V118, P333, DOI 10.1111/j.1365-246X.1994.tb03965.x; VIDALE JE, 1995, GEOPHYS RES LETT, V22, P2557, DOI 10.1029/95GL02663; WALCK MC, 1984, GEOPHYS J ROY ASTR S, V76, P697, DOI 10.1111/j.1365-246X.1984.tb01918.x; WYLLIE PJ, 1980, J GEOPHYS RES, V85, P6902, DOI 10.1029/JB085iB12p06902; WYLLIE PJ, 1995, J GEODYN, V20, P429, DOI 10.1016/0264-3707(95)00023-3; ZENG R, 1995, PURE APPL GEOPHYS, V145, P423; ZIELHUIS A, 1994, SCIENCE, V265, P79, DOI 10.1126/science.265.5168.79	50	192	203	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1626	1629		10.1126/science.275.5306.1626	http://dx.doi.org/10.1126/science.275.5306.1626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054353				2022-12-28	WOS:A1997WN12300041
J	Hasdai, D; Garratt, KN; Grill, DE; Lerman, A; Holmes, DR				Hasdai, D; Garratt, KN; Grill, DE; Lerman, A; Holmes, DR			Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; RECEIVING THROMBOLYTIC THERAPY; CIGARETTE-SMOKING; ARTERY DISEASE; BYPASS-SURGERY; CASS REGISTRY; PTCA REGISTRY; HEART-DISEASE; RISK FACTOR; ANGIOPLASTY	Background Cigarette smoking is known to be deleterious to patients with coronary artery disease, but the effect of smoking on the clinical outcome of percutaneous coronary revascularization is unknown. Methods Patients who had undergone successful percutaneous coronary revascularization at the Mayo Clinic between 1979 and 1995 were divided into nonsmokers (n=2009), former smokers (those who had stopped smoking before the procedure, n=2259), quitters (those who stopped smoking after the procedure, n=435), and persistent smokers (those who smoked before and after the procedure, n=734). Results The maximal follow-up was 16 years (mean [+/-SD], 4.5+/-3.4). The nonsmokers and former smokers had similar base-line characteristics and outcomes. The quitters and persistent smokers were younger than the nonsmokers and former smokers and had more favorable clinical and angiographic characteristics. In analyses adjusted for confounding base-line characteristics, the persistent smokers had a greater relative risk of death (1.76 [95 percent confidence interval, 1.37 to 2.26]) and of Q-wave infarction (2.08 [95 percent confidence interval, 1.16 to 3.72]) than the nonsmokers. The quitters and persistent smokers were less likely than the nonsmokers to undergo additional percutaneous coronary procedures (relative risk, 0.80 [95 percent confidence interval, 0.64 to 0.98] and 0.67 [95 percent confidence interval, 0.56 to 0.81], respectively) or coronary bypass surgery (relative risk, 0.72 [95 percent confidence interval, 0.54 to 0.95] and 0.68 [95 percent confidence interval, 0.54 to 0.86], respectively). The persistent smokers were also at greater risk for death than the quitters (relative risk, 1.44 [95 percent confidence interval, 1.02 to 2.11]). Conclusions Patients who continued to smoke after successful percutaneous coronary revascularization were at greater risk for Q-wave infarction and death than nonsmokers. The cessation of smoking either before or after percutaneous revascularization was beneficial. Patients undergoing percutaneous revascularization should be encouraged to stop smoking. (C) 1997, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN,DIV INTERNAL MED & CARDIOVASC DIS,ROCHESTER,MN 55905	Mayo Clinic								ARORA RR, 1990, CATHETER CARDIO DIAG, V19, P17, DOI 10.1002/ccd.1810190106; BARBASH GI, 1995, J AM COLL CARDIOL, V26, P1222, DOI 10.1016/0735-1097(95)00299-5; BARBASH GI, 1993, CIRCULATION, V87, P53, DOI 10.1161/01.CIR.87.1.53; BARBASH GI, 1995, EUR HEART J, V16, P313; BARRY J, 1989, JAMA-J AM MED ASSOC, V261, P398, DOI 10.1001/jama.261.3.398; BELL MR, 1990, J AM COLL CARDIOL, V16, P553, DOI 10.1016/0735-1097(90)90342-M; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CAVENDER JB, 1992, J AM COLL CARDIOL, V20, P287, DOI 10.1016/0735-1097(92)90092-2; *CTR CHRON DIS PRE, 1989, DHHS PUBLICATION CDC; DETRE K, 1995, CIRCULATION, V91, P2868, DOI 10.1161/01.CIR.91.12.2868; EMOND M, 1994, CIRCULATION, V90, P2645, DOI 10.1161/01.CIR.90.6.2645; FOLTS JD, 1982, CIRCULATION, V65, P465, DOI 10.1161/01.CIR.65.3.465; FRIEDMAN GD, 1979, NEW ENGL J MED, V300, P213, DOI 10.1056/NEJM197902013000501; GALAN KM, 1988, AM J CARDIOL, V61, P260, DOI 10.1016/0002-9149(88)90927-7; GORDON T, 1974, LANCET, V2, P1345; GRINES CL, 1995, CIRCULATION, V91, P298, DOI 10.1161/01.CIR.91.2.298; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; HOLMES DR, 1987, PERCUTANEOUS TRANSLU, P35; MARTIN JL, 1984, AM J CARDIOL, V54, P56, DOI 10.1016/0002-9149(84)90303-5; MYLER RK, 1987, CATHETER CARDIO DIAG, V13, P1, DOI 10.1002/ccd.1810130102; PENN A, 1981, CANCER RES, V41, P588; POWELL JT, 1994, BRIT MED J, V308, P607, DOI 10.1136/bmj.308.6929.607; ROSENBERG L, 1985, NEW ENGL J MED, V313, P1511, DOI 10.1056/NEJM198512123132404; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RYAN TJ, 1993, CIRCULATION, V88, P2987, DOI 10.1161/01.CIR.88.6.2987; UNDERWOOD MJ, 1993, BMJ-BRIT MED J, V306, P1047, DOI 10.1136/bmj.306.6884.1047; VLIETSTRA RE, 1986, JAMA-J AM MED ASSOC, V255, P1023, DOI 10.1001/jama.255.8.1023; Voors AA, 1996, CIRCULATION, V93, P42, DOI 10.1161/01.CIR.93.1.42; Waters D, 1996, CIRCULATION, V94, P614, DOI 10.1161/01.CIR.94.4.614; WEINTRAUB WS, 1985, AM J CARDIOL, V55, P669, DOI 10.1016/0002-9149(85)90133-X	31	172	191	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					755	761		10.1056/NEJM199703133361103	http://dx.doi.org/10.1056/NEJM199703133361103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM640	9052653				2022-12-28	WOS:A1997WM64000003
J	Rollman, BL; Mead, LA; Wang, NY; Klag, MJ				Rollman, BL; Mead, LA; Wang, NY; Klag, MJ			Medical specialty and the incidence of divorce	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYSICIANS; PERSONALITY; STUDENTS; MARRIAGE; DISEASE		JOHNS HOPKINS MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine	Rollman, BL (corresponding author), UNIV PITTSBURGH,MED CTR,PITTSBURGH,PA 15213, USA.			Wang, Nae-Yuh/0000-0001-6513-9730	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042734] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42734] Funding Source: Medline; PHS HHS [A601760] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM BOARD MED SPEC, 1990, ABMS COMP CERT MED S; Derdeyn AP, 1978, INT J PSYCHIAT MED, V9, P297; DOHERTY WJ, 1989, JAMA-J AM MED ASSOC, V261, P2374, DOI 10.1001/jama.261.16.2374; EISENBERG L, 1989, JAMA-J AM MED ASSOC, V261, P2401, DOI 10.1001/jama.261.16.2401; ELLIOT FR, 1979, SOC SCI MED-MED SOC, VA13, P57, DOI 10.1016/0160-7979(79)90008-0; GABBARD GO, 1989, JAMA-J AM MED ASSOC, V261, P2378, DOI 10.1001/jama.261.16.2378; GABBARD GO, 1985, JAMA-J AM MED ASSOC, V254, P2926, DOI 10.1001/jama.254.20.2926; Gabbard GO, 1988, MED MARRIAGES; GARVEY M, 1979, J CLIN PSYCHIAT, V40, P129; GLICK ID, 1984, JAMA-J AM MED ASSOC, V251, P1855, DOI 10.1001/jama.251.14.1855; GOUGH HG, 1977, J MED EDUC, V52, P541; KIRCHNER M, 1979, MED ECON, V56, P33; KRITZER H, 1967, J MED EDUC, V42, P47; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; MCGRATH E, 1977, J MED EDUC, V52, P293; MONK MA, 1973, JOHNS HOPKINS MED J, V133, P19; *NAT CTR HLTH STAT, 1991, DHHS PUBL, V3; *OFF MED ALUMN AFF, 1990, J HOPK MED AL DIR; PAIVA REA, 1971, J MED EDUC, V46, P281; PAIVA REA, 1977, PSYCHOL REP, V41, P747, DOI 10.2466/pr0.1977.41.3.747; ROSE KD, 1972, CALIF MED, V116, P95; SCHUMACHER CF, 1964, J MED EDUC, V39, P278; THOMAS CB, 1980, JOHNS HOPKINS MED J, V147, P137; THOMAS CB, 1974, JOHNS HOPKINS MED J, V134, P251; THOMAS CB, 1951, B JOHNS HOPKINS HOSP, V89, P419; VAILLANT GE, 1972, NEW ENGL J MED, V287, P372, DOI 10.1056/NEJM197208242870802; YUFIT RI, 1969, ARCH GEN PSYCHIAT, V20, P89; ZELDOW PB, 1991, ACAD MED, V66, P283, DOI 10.1097/00001888-199105000-00012	28	51	51	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					800	803		10.1056/NEJM199703133361112	http://dx.doi.org/10.1056/NEJM199703133361112			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM640	9052662				2022-12-28	WOS:A1997WM64000012
J	Ross, GW; Abbott, RD; Petrovitch, H; Masaki, KH; Murdaugh, C; Trockman, C; Curb, JD; White, LR				Ross, GW; Abbott, RD; Petrovitch, H; Masaki, KH; Murdaugh, C; Trockman, C; Curb, JD; White, LR			Frequency and characteristics of silent dementia among elderly Japanese-American men - The Honolulu-Asia aging study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE CERAD; MULTI-INFARCT DEMENTIA; MILD SENILE DEMENTIA; NEUROPSYCHOLOGICAL ASSESSMENT; INFORMANT QUESTIONNAIRE; COGNITIVE DECLINE; STROKE; CONSORTIUM; DIAGNOSIS; ESTABLISH	Objective.-To determine the frequency of unrecognized dementia in a group of men found to have dementia by population survey, and to identify factors associated with the failure of a family informant to recognize significant memory impairment. Design and Setting.-The Honolulu-Asia Aging Study, a population-based study of dementia among elderly Japanese-American men living on the island of Oahu, Hawaii, Data for this study were from the dementia prevalence survey, 1991-1993. Study Participants.-A total of 191 noninstitutionalized men with dementia who had a reliable family informant. Main Outcome Measures.-Failure of family informants to recognize a problem with thinking or memory in subjects with dementia, Results.-A total of 21% of family informants failed to recognize a problem with memory among subjects subsequently found to have dementia, Among subjects with very mild dementia, 52% of family informants failed to recognize a significant memory problem compared with 13% among more severely demented subjects. Of the subjects with dementia whose family informants did recognize a memory problem, 53% failed to receive a medical evaluation for this problem. For all family informants, increasing age, fewer years of education, less severe dementia, fewer behavioral complications, fewer functional disabilities, and better performance on certain tests of memory and language were significantly associated with the family informant's failure to recognize a problem with memory, When the family informants were wives living with husbands, less severe dementia, fewer behavioral complications, fewer functional disabilities, and intact remote memory were associated with unrecognized dementia. Conclusions.-Unrecognized dementia was common in our population, especially among mild cases. Cognitive screening programs for the elderly and public education policies designed to increase awareness of early signs of dementia are needed if interventions for individuals with potentially treatable dementias are to be implemented.	DEPT VET AFFAIRS,HONOLULU,HI; UNIV VIRGINIA,DIV BIOSTAT,CHARLOTTESVILLE,VA; UNIV HAWAII,JOHN A BURNS SCH MED,DEPT MED,HONOLULU,HI 96822; KUAKINI MED CTR,HONOLULU ASIA AGING STUDY,HONOLULU,HI; NIA,BETHESDA,MD 20892; UNIV ARIZONA,COLL NURSING,TUCSON,AZ 85721	University of Virginia; University of Hawaii System; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Arizona					NIA NIH HHS [N01-AG-4-2149] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG042149] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERG L, 1988, MT SINAI J MED, V55, P87; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BRONNER LL, 1995, NEW ENGL J MED, V333, P1392, DOI 10.1056/NEJM199511233332106; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; CHIU HC, 1992, NEUROLOGY, V42, P473; COOPER PJ, 1993, J SAFETY RES, V24, P9, DOI 10.1016/0022-4375(93)90047-Q; CUMMINGS JL, 1992, DEMENTIA CLIN APPROA, P1; Dooneief G, 1996, NEUROLOGY, V46, P1746, DOI 10.1212/WNL.46.6.1746; DRICKAMER MA, 1992, NEW ENGL J MED, V326, P947, DOI 10.1056/NEJM199204023261410; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAVES AB, 1992, ALZHEIMERS DIS ADV C, P113; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hasegawa K., 1983, AGING EIGHTIES, P207; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; Henon H, 1996, NEUROLOGY, V47, P852, DOI 10.1212/WNL.47.3.852-a; HOSMER DW, 1989, APPL LOGISTIC REGRES; ISHIDA D, 1995, TRANSCULTURAL NURSIN, P317; JACOBS DM, 1995, NEUROLOGY, V45, P957, DOI 10.1212/WNL.45.5.957; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; KAGAN A, 1994, STROKE, V25, P1170, DOI 10.1161/01.STR.25.6.1170; MASUR DM, 1994, NEUROLOGY, V44, P1427, DOI 10.1212/WNL.44.8.1427; MCDERMOTT JF, 1973, PEOPLE CULTURES HAWA; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; MCGLONE J, 1990, ARCH NEUROL-CHICAGO, V47, P1189, DOI 10.1001/archneur.1990.00530110043015; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MEYER JS, 1989, J AM GERIATR SOC, V37, P549, DOI 10.1111/j.1532-5415.1989.tb05688.x; MEYER JS, 1986, JAMA-J AM MED ASSOC, V256, P2203, DOI 10.1001/jama.256.16.2203; MORRIS JC, 1988, PSYCHOPHARMACOL BULL, V24, P641; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; MOSS MB, 1986, ARCH NEUROL-CHICAGO, V43, P239, DOI 10.1001/archneur.1986.00520030031008; PECK JC, 1982, ANN INTERN MED, V97, P231; Preston SH, 1994, DEMOGRAPHY AGING, P1; REISBERG B, 1987, J CLIN PSYCHIAT, V48, P9; RUBIN EH, 1989, ARCH NEUROL-CHICAGO, V46, P379, DOI 10.1001/archneur.1989.00520400033016; SAGAR HJ, 1988, BRAIN, V111, P525, DOI 10.1093/brain/111.3.525; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; White L, 1996, JAMA-J AM MED ASSOC, V276, P955, DOI 10.1001/jama.276.12.955; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742	42	154	161	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					800	805		10.1001/jama.277.10.800	http://dx.doi.org/10.1001/jama.277.10.800			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM082	9052709				2022-12-28	WOS:A1997WM08200032
J	Julian, DG; Camm, AJ; Frangin, G; Janse, MJ; Munoz, A; Schwartz, PJ; Simon, P				Julian, DG; Camm, AJ; Frangin, G; Janse, MJ; Munoz, A; Schwartz, PJ; Simon, P			Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT	LANCET			English	Article							ANTIARRHYTHMIC THERAPY; SUDDEN-DEATH; ARRHYTHMIAS; SURVIVORS; ISCHEMIA; EFFICACY; DESIGN	Background Ventricular arrhythmias are a major cause of death after myocardial infarction, especially in patients with poor left-ventricular function. Previous attempts to identify and suppress arrhythmias with various antiarrhythmic drugs failed to reduce or actually increase mortality. Amiodarone is a powerful antiarrhythmic drug with several potentially beneficial actions, and has shown benefit in several small-scale studies. We postulated that this drug might reduce mortality in patients at high risk of death after myocardial infarction because of impaired ventricular function, irrespective of whether they had ventricular arrhythmias. Methods The European Myocardial Infarct Amiodarone Trial (EMIAT) was a randomised double-blind placebo-controlled trial to assess whether amiodarone reduced ail-cause mortality (primary endpoint) and cardiac mortality and arrhythmic death (secondary endpoints) in survivors of myocardial infarction with a left-ventricular ejection fraction (LVEF) of 40% or less. Intention-to-treat and on-treatment analyses were done. Findings EMIAT enrolled 1486 patients (743 in the amiodarone group, 743 in the placebo group). Median follow-up was 21 months. All-cause mortality (103 deaths in the amiodarone group, 102 in the placebo group) and cardiac mortality did not differ between the two groups. However, in the amiodarone group, there was a 35% risk reduction (95% CI 0-58, p=0.05) in arrhythmic deaths. Interpretation Our findings do not support the systematic prophylactic use of amiodarone in all patients with depressed left-ventricular function after myocardial infarction. However, the lack of proarrhythmia and the reduction in arrhythmic death support the use of amiodarone in patients for whom antiarrhythmic therapy is indicated.	ST GEORGE HOSP, SCH MED, LONDON SW17 0RE, ENGLAND; NETHERHALL GARDENS, LONDON, ENGLAND; SANOFI RECH, F-34082 MONTPELLIER, FRANCE; UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN & EXPTL CARDIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS; UNIV PAVIA, DEPT CARDIOL, I-27100 PAVIA, ITALY	St Georges University London; Sanofi-Aventis; Sanofi France; University of Amsterdam; Academic Medical Center Amsterdam; University of Pavia			Schwartz, Peter J/J-4267-2016	Schwartz, Peter J/0000-0003-0367-1048				AKHTAR M, 1990, CIRCULATION, V81, P1123, DOI 10.1161/01.CIR.81.3.1123; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BASHIR Y, 1992, AM HEART J, V124, P1233, DOI 10.1016/0002-8703(92)90405-K; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; Camm AJ, 1996, CIRCULATION, V93, P1043; Camm AJ, 1996, EUR HEART J, V17, P354; CAMM AJ, 1993, AM J CARDIOL, V72, pF95, DOI 10.1016/0002-9149(93)90970-N; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; COX DR, 1972, J R STAT SOC B, V34, P187; DUSMAN RE, 1990, CIRCULATION, V82, P51, DOI 10.1161/01.CIR.82.1.51; ELLENBOGEN KA, 1985, AM HEART J, V110, P376, DOI 10.1016/0002-8703(85)90159-0; FARRELL TG, 1991, J AM COLL CARDIOL, V18, P687, DOI 10.1016/0735-1097(91)90791-7; FURBERG CD, 1983, AM J CARDIOL, V52, pC32, DOI 10.1016/0002-9149(83)90629-X; GOTTLIEB SH, 1987, CIRCULATION, V75, P792, DOI 10.1161/01.CIR.75.4.792; GOTTLIEB SS, 1994, J AM COLL CARDIOL, V23, P560, DOI 10.1016/0735-1097(94)90736-6; GREENBERG HM, 1995, BRIT HEART J, V74, P631; HARRIS L, 1983, CIRCULATION, V67, P45, DOI 10.1161/01.CIR.67.1.45; HOHNLOSER SH, 1994, ANN INTERN MED, V121, P529, DOI 10.7326/0003-4819-121-7-199410010-00009; *IMP RES GROUP, 1984, J AM COLL CARDIOL, V4, P1148; JANSE MJ, 1989, PHYSIOL REV, V69, P1049, DOI 10.1152/physrev.1989.69.4.1049; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MARTINO E, 1987, CLIN ENDOCRINOL, V26, P227, DOI 10.1111/j.1365-2265.1987.tb00781.x; MEYER BJ, 1993, AM HEART J, V125, P996, DOI 10.1016/0002-8703(93)90106-J; MOSS AJ, 1979, CIRCULATION, V60, P998, DOI 10.1161/01.CIR.60.5.998; NEWNHAM HH, 1988, AUST NZ J MED, V18, P37, DOI 10.1111/j.1445-5994.1988.tb02237.x; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PITT B, 1982, ANN NY ACAD SCI, V382, P218, DOI 10.1111/j.1749-6632.1982.tb55219.x; RUBERMAN W, 1977, NEW ENGL J MED, V297, P750, DOI 10.1056/NEJM197710062971404; SCHWARTZ PJ, 1994, EUR HEART J, V15, P620, DOI 10.1093/oxfordjournals.eurheartj.a060557; SCHWARTZ PJ, 1994, EUR HEART J, V15, P721; SCHWARTZ PJ, 1994, CIRCULATION, V89, P2892; SCHWARTZ PJ, 1992, CIRCULATION, V85, P171; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; WALDO AL, 1995, AM J CARDIOL, V75, P1023, DOI 10.1016/S0002-9149(99)80717-6; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; WILSON JS, 1991, AM HEART J, V121, P158, DOI 10.1016/0002-8703(91)90969-O; YUSUF S, 1993, AM J CARDIOL, V72, pF51, DOI 10.1016/0002-9149(93)90963-D	39	767	805	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	1997	349	9053					667	674		10.1016/S0140-6736(96)09145-3	http://dx.doi.org/10.1016/S0140-6736(96)09145-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078197	Green Submitted			2022-12-28	WOS:A1997WM08000007
J	Mohl, DA; Gober, JW				Mohl, DA; Gober, JW			Cell cycle-dependent polar localization of chromosome partitioning proteins in Caulobacter crescentus	CELL			English	Article							UNIT-COPY MINIPLASMIDS; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; P1 PLASMID; TRANSCRIPTIONAL ACTIVATOR; BACTERIAL CHROMOSOME; GEL-ELECTROPHORESIS; DAUGHTER CELLS; F-PLASMID; REPLICATION	In the bacterium C. crescentus, the cellular homologs of plasmid partitioning proteins, ParA and ParB, localize to both poles of the predivisional cell following the completion of DNA replication. pare binds to DNA sequences adjacent to the origin of replication suggesting that this region of the genome is tethered to the poles of the cell at a specific time in the cell cycle. Increasing the cellular levels of ParA and ParB disrupts polar localization and results in defects in both cell division and chromosome partitioning. These results suggest that ParA and ParB are involved in partitioning newly replicated chromosomes to the poles of the predivisional cell and may function as components of a bacterial mitotic apparatus.	UNIV CALIF LOS ANGELES,MOL BIOL INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Mohl, DA (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90095, USA.				NIGMS NIH HHS [GM48417] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUSTIN S, 1983, J MOL BIOL, V169, P373, DOI 10.1016/S0022-2836(83)80056-4; AUSTIN S, 1983, J MOL BIOL, V169, P353, DOI 10.1016/S0022-2836(83)80055-2; BEGG KJ, 1991, NEW BIOL, V3, P475; DARN M, 1994, J MOL BIOL, V236, P1289; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; DINGWALL A, 1989, P NATL ACAD SCI USA, V86, P119, DOI 10.1073/pnas.86.1.119; ELY B, 1988, GENE, V68, P323, DOI 10.1016/0378-1119(88)90035-2; EVINGER M, 1977, J BACTERIOL, V132, P294, DOI 10.1128/JB.132.1.294-301.1977; GERDES K, 1986, J MOL BIOL, V190, P269, DOI 10.1016/0022-2836(86)90001-X; GOBER JW, 1995, MICROBIOL REV, V59, P31, DOI 10.1128/MMBR.59.1.31-47.1995; GOMES SL, 1984, J MOL BIOL, V178, P551, DOI 10.1016/0022-2836(84)90238-9; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARCZYNSKI GT, 1992, J MOL BIOL, V226, P959, DOI 10.1016/0022-2836(92)91045-Q; MARTIN KA, 1987, P NATL ACAD SCI USA, V84, P8544, DOI 10.1073/pnas.84.23.8544; MEISENZAHL AC, 1997, IN PRESS J BACTERIOL; MORI H, 1989, J BIOL CHEM, V264, P15535; MYSLIWIEC TH, 1991, J BACTERIOL, V173, P1911, DOI 10.1128/jb.173.6.1911-1919.1991; Nanninga N., 1985, MOL CYTOLOGY ESCHERI, P161; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; POINDEXTER JS, 1964, BACTERIOL REV, V28, P231, DOI 10.1128/MMBR.28.3.231-295.1964; ROTHFIELD LI, 1994, CELL, V77, P963, DOI 10.1016/0092-8674(94)90435-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDHAUSER TJ, 1989, PLASMID, V21, P99, DOI 10.1016/0147-619X(89)90053-X; Sharpe ME, 1996, MOL MICROBIOL, V21, P501, DOI 10.1111/j.1365-2958.1996.tb02559.x; SHARPE ME, 1995, P NATL ACAD SCI USA, V92, P8630, DOI 10.1073/pnas.92.19.8630; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wake RG, 1995, ANNU REV GENET, V29, P41; WATANABE E, 1992, MOL GEN GENET, V234, P346, DOI 10.1007/BF00538693; WEBB CD, 1997, CELL; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; WINGROVE JA, 1993, GENE DEV, V7, P1979, DOI 10.1101/gad.7.10.1979; Wingrove JA, 1996, SCIENCE, V274, P597, DOI 10.1126/science.274.5287.597; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014	44	302	306	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					675	684		10.1016/S0092-8674(00)81910-8	http://dx.doi.org/10.1016/S0092-8674(00)81910-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054507				2022-12-28	WOS:A1997WM41300013
J	Goldman, J				Goldman, J			ABC of clinical haematology - Chronic myeloid leukaemia	BRITISH MEDICAL JOURNAL			English	Review											Goldman, J (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON,ENGLAND.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					657	660		10.1136/bmj.314.7081.657	http://dx.doi.org/10.1136/bmj.314.7081.657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066482	Green Published			2022-12-28	WOS:A1997WL41800031
J	Harrison, KA				Harrison, KA			The importance of the educated healthy woman in Africa	LANCET			English	Editorial Material							DEVELOPING-COUNTRIES; NIGERIA				Harrison, KA (corresponding author), UNIV PORT HARCOURT,DEPT OBSTET & GYNAECOL,POB 44,PORT HARCOURT,NIGERIA.							BRABIN L, 1995, LANCET, V345, P300, DOI 10.1016/S0140-6736(95)90281-3; EKWEMPU CC, 1990, LANCET, V336, P56, DOI 10.1016/0140-6736(90)91573-S; EVANS I, 1995, LANCET, V346, P1046, DOI 10.1016/S0140-6736(95)91733-0; FLEMING AF, 1989, T ROY SOC TROP MED H, V83, P441, DOI 10.1016/0035-9203(89)90241-1; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HARRISON KA, 1989, BRIT J OBSTET GYNAEC, V96, P1, DOI 10.1111/j.1471-0528.1989.tb01567.x; Harrison KA, 1996, J ROY SOC MED, V89, P361, DOI 10.1177/014107689608900701; HARRISON KA, 1989, BRIT J OBSTET GYNAEC, V96, P1121, DOI 10.1111/j.1471-0528.1989.tb03399.x; HARRISON KA, 1985, BR J OBSTET GYNAE S5, V92, P61; HARRISON KA, 1985, BR J OBSTET GYNAE S5, V92, P13; HARRISON KA, 1985, BR J OBSTET GYNAE S5, V92, P72; HARRISON KA, 1985, BR J OBSTET GYNAE S5, V92, P86; Harrison KA, 1996, YB ROYAL COLL OBSTET, P33; HARRISON KA, 1985, BR J OBSTET GYNAE S5, V92, P100; MARTIN TC, 1995, STUD FAMILY PLANN, V26, P187, DOI 10.2307/2137845; MURPHY M, 1981, J BIOSOC SCI, V13, P139, DOI 10.1017/S0021932000013304; Nelson EAS, 1996, LANCET, V348, P1642, DOI 10.1016/S0140-6736(96)06389-1; NEWBY R, 1995, LANCET, V346, P1493, DOI 10.1016/S0140-6736(95)92513-9; OWA JA, 1992, LANCET, V340, P732, DOI 10.1016/0140-6736(92)92273-I; Pereira C, 1996, BRIT J OBSTET GYNAEC, V103, P508, DOI 10.1111/j.1471-0528.1996.tb09797.x; ROOTH G, 1979, LANCET, V2, P1170; RUNCIE RA, 1990, 6 ECA SILV JUB LECT, P1; SUMMERS L, 1992, SCI AM           AUG, P108; TAHZIB F, 1983, BRIT J OBSTET GYNAEC, V90, P387, DOI 10.1111/j.1471-0528.1983.tb08933.x; *UN, 1995, WORLDS WOM 1995 TREN; World Health Organisation, 1989, PREV TREATM OBST FIS; 1981, LANCET, V1, P1402; 1994, LANCET, V344, P1377; 1987, LANCET, V1, P255	29	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					644	647		10.1016/S0140-6736(97)02192-2	http://dx.doi.org/10.1016/S0140-6736(97)02192-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057747				2022-12-28	WOS:A1997WK91500044
J	McMurray, J; Murdoch, D				McMurray, J; Murdoch, D			Calcium-antagonist controversy: The long and short of it?	LANCET			English	Editorial Material											McMurray, J (corresponding author), UNIV GLASGOW,GLASGOW G12 8QQ,LANARK,SCOTLAND.		mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				Aursnes Vvar I. Litleskare, 1995, Blood Pressure, V4, P157, DOI 10.3109/08037059509077588; BRAUN S, 1996, J AM COLL CARDIOL, V27, P7; CAVIS BR, 1996, AM J HYPERTENS, V9, P342; Dargie HJ, 1996, LANCET, V348, P488, DOI 10.1016/S0140-6736(05)64663-6; Furberg CD, 1996, CIRCULATION, V93, P1475; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GLASSER SP, 1991, JAMA-J AM MED ASSOC, V265, P1550, DOI 10.1001/jama.265.12.1550; GOLDSTEIN RE, 1991, CIRCULATION, V83, P52, DOI 10.1161/01.CIR.83.1.52; Gong LS, 1996, J HYPERTENS, V14, P1237, DOI 10.1097/00004872-199610000-00013; Jick H, 1996, PHARMACOTHERAPY, V16, P321; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P62; WATERS D, 1991, CIRCULATION, V84, P2598, DOI 10.1161/01.CIR.84.6.2598; Yusuf S, 1996, AM J CARDIOL, V77, P421, DOI 10.1016/S0002-9149(97)89376-9; Yusuf S, 1996, EUR HEART J, V17, P16, DOI 10.1093/eurheartj/17.suppl_F.16	15	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					585	586		10.1016/S0140-6736(05)61561-9	http://dx.doi.org/10.1016/S0140-6736(05)61561-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057725				2022-12-28	WOS:A1997WK91500003
J	Hubbard, WB				Hubbard, WB			Planetary science - Neptune's deep chemistry	SCIENCE			English	Editorial Material											Hubbard, WB (corresponding author), UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA.							Ancilotto F, 1997, SCIENCE, V275, P1288, DOI 10.1126/science.275.5304.1288; Bishop J, 1995, SPACE SCI S, P427; FEGLEY MB, 1988, ASTROPHYS J, V324, P625; Gautier D, 1995, SPACE SCI S, P547; Hubbard WB, 1995, SPACE SCI S, P109; HUBBARD WB, 1980, ICARUS, V44, P676, DOI 10.1016/0019-1035(80)90136-0; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; ROSS M, 1981, NATURE, V292, P435, DOI 10.1038/292435a0	8	32	32	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1279	1280		10.1126/science.275.5304.1279	http://dx.doi.org/10.1126/science.275.5304.1279			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9064785				2022-12-28	WOS:A1997WK64400031
J	Farnet, CM; Bushman, FD				Farnet, CM; Bushman, FD			HIV-1 cDNA integration: Requirement of HMG I(Y) protein for function of preintegration complexes in vitro	CELL			English	Article							IMMUNODEFICIENCY-VIRUS INTEGRATION; SITE-SPECIFIC RECOMBINATION; DNA-BINDING DOMAIN; RETROVIRAL DNA; CIRCULAR DNA; CDC2 KINASE; VIRAL-DNA; PHAGE-MU; INVITRO; SEQUENCE	We present data indicating that a host protein is important for function of HIV-1 preintegration complexes (PICs) in vitro. PICs partially purified from infected cells were subjected to gel filtration in 600 mM KCl, which removed a factor required for integration without fully disrupting PICs. Addition of an extract from uninfected cells restored activity. Fractionation of the complementing activity yielded HMG IM, a nonhistone chromosomal protein important for transcriptional control and chromosomal architecture. Complementing activity could be isolated from PICs, and activity could be depleted from such fractions with an antibody against HMG IM. Recombinant HMG IM also complemented salt-stripped complexes. The finding that a host protein is required for integration by HIV PICs parallels findings in several well-studied transposition and site-specific recombination systems.			Farnet, CM (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,LA JOLLA,CA 92024, USA.		Farnet, Chris/ABE-5463-2021	Farnet, Chris/0000-0003-4927-198X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037489, R01AI034786] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 34786, R01 AI 37489] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berg DE, 1989, MOBILE DNA; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUSHMAN FD, 1990, J VIROL, V64, P5645, DOI 10.1128/JVI.64.11.5645-5648.1990; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DENG D, 1996, NATURE, V381, P661; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; ELTON TS, 1986, ANAL BIOCHEM, V157, P53, DOI 10.1016/0003-2697(86)90195-8; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FAMET C, 1996, P NATL ACAD SCI USA, V93, P9742; FAMET CM, 1991, J VIROL, V65, P1910; FAMET CM, 1996, AIDS SA, V10, P3; FAMET CM, 1990, P NATL ACAD SCI USA, V87, P4164; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUJIWARA T, 1989, P NATL ACAD SCI USA, V86, P3065, DOI 10.1073/pnas.86.9.3065; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; Harlow E., 1988, ANTIBODIES LAB MANUA; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KANAAR R, 1986, BIOCHIM BIOPHYS ACTA, V866, P170, DOI 10.1016/0167-4781(86)90114-4; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Lavoie BD, 1996, CELL, V85, P761, DOI 10.1016/S0092-8674(00)81241-6; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MERKER P, 1993, COLD SPRING HARB SYM, V58, P505, DOI 10.1101/SQB.1993.058.01.057; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; Nash Howard A., 1996, P149; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PAULL TT, 1994, BIOCHIMIE, V76, P992, DOI 10.1016/0300-9084(94)90024-8; REEVES R, 1993, J BIOL CHEM, V268, P21137; Reeves R, 1996, BIOCHEMISTRY-US, V35, P5063, DOI 10.1021/bi952424p; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANDERS C, 1974, BIOCHEM SOC T, V546, P546; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; Stevens SW, 1996, J VIROL, V70, P6459, DOI 10.1128/JVI.70.9.6459-6462.1996; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON JF, 1987, CELL, V50, P901, DOI 10.1016/0092-8674(87)90516-2; VARMUS H, 1989, MOBILE DNA, P53; VINCENT KA, 1990, NUCLEIC ACIDS RES, V18, P6045, DOI 10.1093/nar/18.20.6045; VINK C, 1990, J VIROL, V64, P5626, DOI 10.1128/JVI.64.11.5626-5627.1990; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	64	267	283	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					483	492		10.1016/S0092-8674(00)81888-7	http://dx.doi.org/10.1016/S0092-8674(00)81888-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038339	Bronze			2022-12-28	WOS:A1997WJ69100008
J	Klemm, RD; Austin, RJ; Bell, SP				Klemm, RD; Austin, RJ; Bell, SP			Coordinate binding of ATP and origin DNA regulates the ATPase activity of the origin recognition complex	CELL			English	Article							REPLICATION ORIGINS; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL REPLICATION; FUNCTIONAL ELEMENTS; YEAST; INITIATION; ORC; PROTEINS; SUBUNITS	The Origin Recognition Complex (ORC) is a six-protein assembly that specifies the sites of DNA replication initiation in S. cerevisiae. Origin recognition by ORC requires ATP. Here, we demonstrate that two subunits, Orc1p and Orc5p, bind ATP and that Orc1p also hydrolyzes ATP. ATP binding and hydrolysis by Orc1p are both regulated by origin DNA in a sequence-specific manner. ATP binding to Orc1p, but not ATP hydrolysis, is responsible for the ATP dependence of the ORC-origin interaction, indicating that ATP is a cofactor that locks ORC on origin DNA. These data demonstrate that occupancy of the Orc1p ATP-binding site has a profound effect on ORC function and that ATP hydrolysis by Orc1p has the potential to drive transitions between different functional states of ORC.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)				Bell, Stephen/0000-0002-2876-610X	NIGMS NIH HHS [(GM18170), (GM52339)] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1992, ANNU REV GENET, V26, P447; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	41	203	205	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1997	88	4					493	502		10.1016/S0092-8674(00)81889-9	http://dx.doi.org/10.1016/S0092-8674(00)81889-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038340	Bronze			2022-12-28	WOS:A1997WJ69100009
J	vandeVen, CJM				vandeVen, CJM			Nasogastric enteral feeding in hyperemesis gravidarum!	LANCET			English	Editorial Material							HUMAN CHORIONIC-GONADOTROPIN; PREGNANCY; NAUSEA				vandeVen, CJM (corresponding author), UNIV MICHIGAN,CS MOTT CHILDRENS HOSP,DIV MATERNAL FETAL MED,ANN ARBOR,MI 48109, USA.							Barclay B A, 1990, Nutr Clin Pract, V5, P153, DOI 10.1177/0115426590005004153; GROSS S, 1989, AM J OBSTET GYNECOL, V160, P906, DOI 10.1016/0002-9378(89)90307-4; Hsu JJ, 1996, OBSTET GYNECOL, V88, P343, DOI 10.1016/0029-7844(96)00174-3; JARNFELTSAMSIOE A, 1983, GYNECOL OBSTET INVES, V16, P221; KAUPPILA A, 1979, BMJ-BRIT MED J, V1, P1670, DOI 10.1136/bmj.1.6179.1670; OBRIEN B, 1995, BIRTH-ISS PERINAT C, V22, P93, DOI 10.1111/j.1523-536X.1995.tb00566.x; SINGER AJ, 1991, AM J GASTROENTEROL, V86, P1695; SMITH CV, 1981, AM J OBSTET GYNECOL, V141, P180, DOI 10.1016/S0002-9378(16)32588-1; SOULES MR, 1980, OBSTET GYNECOL, V55, P696; Walsh JW, 1996, AM J PHYSIOL-GASTR L, V270, pG506, DOI 10.1152/ajpgi.1996.270.3.G506	10	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					445	446		10.1016/S0140-6736(05)61177-4	http://dx.doi.org/10.1016/S0140-6736(05)61177-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040568				2022-12-28	WOS:A1997WH38900003
J	Burgess, DL; Jones, JM; Meisler, MH; Noebels, JL				Burgess, DL; Jones, JM; Meisler, MH; Noebels, JL			Mutation of the Ca2+ channel beta subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (lh) mouse	CELL			English	Article							SENSITIVE CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; ELECTROPHYSIOLOGICAL PROPERTIES; THALAMIC NEURONS; SKELETAL-MUSCLE; RAT-BRAIN; ALPHA(1)-SUBUNIT; ALPHA-1-SUBUNIT; IDENTIFICATION; DEFICIENCY	Ca2+ channel beta subunits regulate voltage-dependent calcium currents through direct interaction with alpha(1) subunits. The beta- and alpha(1)-binding motifs are conserved, and all beta subunits can stimulate current amplitude, voltage dependence, and kinetics when coexpressed with various alpha(1) subunits. We used a positional candidate approach to determine that the ataxia and seizures in the lethargic (lh) mouse arise from mutation of the beta-subunit gene Cchb4 on mouse chromosome 2. A four-nucleotide insertion into a splice donor site results in exon skipping, translational frameshift, and protein truncation with loss of the alpha(1)-binding site. The lethargic phenotype is the first example of a mammalian neurological disease caused by an inherited defect in a non-pore-forming subunit of a voltage-gated ion channel.	UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Burgess, DL (corresponding author), BAYLOR COLL MED,DEPT NEUROL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Tuluc, Petronel/C-2527-2011	Noebels, Jeffrey/0000-0002-2887-0839	NIGMS NIH HHS [GM24872] Funding Source: Medline; NINDS NIH HHS [NS29709, NS34509] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034509, R01NS029709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVANZINI G, 1989, J PHYSIOL-LONDON, V416, P111, DOI 10.1113/jphysiol.1989.sp017752; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; CASTELLANO A, 1994, BIOCHEM SOC T, V22, P483, DOI 10.1042/bst0220483; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; CHIN HM, 1995, GENOMICS, V28, P592, DOI 10.1006/geno.1995.1196; COULTER DA, 1989, J PHYSIOL-LONDON, V414, P587, DOI 10.1113/jphysiol.1989.sp017705; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Dickie MM, 1964, MOUSE NEWS LETT, V30, P31; DUNG HC, 1977, TRANSPLANTATION, V23, P39, DOI 10.1097/00007890-197701000-00007; DUNG HC, 1971, TEX REP BIOL MED, V29, P273; DUNG HC, 1972, TEX REP BIOL MED, V30, P23; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HIDAKA Y, 1987, J CLIN INVEST, V80, P1409, DOI 10.1172/JCI113219; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; HUGENARD JR, 1992, J NEUROSCI, V12, P3804; HUGUENARD JR, 1994, J NEUROSCI, V14, P5485; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P205, DOI 10.1113/jphysiol.1984.sp015153; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; *MOUS GEN INF JACK, 1996, MOUS GEN DAT MGD 3 1; Murakami M, 1996, EUR J BIOCHEM, V236, P138, DOI 10.1111/j.1432-1033.1996.t01-1-00138.x; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; Noebels J.L., 1982, NEUROSCIENCE, V7, P159; NOEBELS JL, 1979, SCIENCE, V204, P1334, DOI 10.1126/science.572084; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; SANKILA EM, 1992, NAT GENET, V1, P109, DOI 10.1038/ng0592-109; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; Sidman RL, 1965, CATALOG NEUROLOGICAL, P34; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SOUTHARD JL, 1973, MOUSE NEWS LETT, V49, P32; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VU TH, 1988, J IMMUNOL, V141, P3654; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; Wiser O, 1996, FEBS LETT, V379, P15, DOI 10.1016/0014-5793(95)01475-6; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	54	349	358	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					385	392		10.1016/S0092-8674(00)81877-2	http://dx.doi.org/10.1016/S0092-8674(00)81877-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039265	Bronze			2022-12-28	WOS:A1997WG47900011
J	Wardrope, J				Wardrope, J			Bed shortages - Hospitals need support for coping with emergency work	BRITISH MEDICAL JOURNAL			English	Letter											Wardrope, J (corresponding author), NO GEN HOSP NHS TRUST,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					369	369						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040340				2022-12-28	WOS:A1997WF86100047
J	Bergqvist, D; Jendteg, S; Johansen, L; Persson, U; Odegaard, K				Bergqvist, D; Jendteg, S; Johansen, L; Persson, U; Odegaard, K			Cos of long-term complications of deep venous thrombosis of the lower extremities: An analysis of a defined patient population in Sweden	ANNALS OF INTERNAL MEDICINE			English	Article							VEIN THROMBOSIS; PROPHYLAXIS	Background: Little information is available on the epidemiology and economic effect of long-term complications developing after deep venous thrombosis. Objective: To determine the extent of, timing of, and treatment costs associated with long-term complications developing after deep venous thrombosis of the lower extremities. Design: 15-year retrospective cohort study. Setting: County hospital in Sweden. Patients: 257 patients with deep venous thrombosis and 241 age- and sex-matched controls without deep venous thrombosis. Measurements: Data on use of health care resources and costs of inpatient and outpatient care, pharmaceutical agents, and treatment of complications. Results: After 15 years of follow-up, 35% of the patients with thrombosis and 57% of the controls were alive. Two hundred forty-two complications were reported among the patients with thrombosis, and 25 similar events were reported among the controls. The average expected present value of the health care cost of treating complications of thrombosis was estimated to be about $4659 in the patients with thrombosis and $375 in the controls. In controls, primary deep venous thrombosis cost about $6000; thus, the additional long-term health care cost of post-thrombotic complications is about 75% of the cost of primary deep venous thrombosis. Conclusions: The economic effect of post-thrombotic complications is considerable. The use of measures to prevent thromboembolism and its long-term complications are justified on both clinical and economic grounds.	CENT HOSP SKOVDE, DEPT SURG, S-54185 SKOVDE, SWEDEN; UNIV UPPSALA HOSP, DEPT SURG, S-75185 UPPSALA, SWEDEN; INST HLTH ECON, S-22002 LUND, SWEDEN	Uppsala University; Uppsala University Hospital								BAUER G, 1942, ACTA CHIR SCAND S74, V86, P1; BERGQVIST D, 1993, HAEMOSTASIS, V23, P15; BERGQVIST D, 1988, WORLD J SURG, V12, P349, DOI 10.1007/BF01655669; BERGQVIST D, 1983, POSTOPERATIVE THROMB; BEYTH RJ, 1995, ARCH INTERN MED, V155, P1031, DOI 10.1001/archinte.155.10.1031; Hartunian NS, 1981, INCIDENCE EC COSTS M; KAKKAR VV, 1985, AM J SURG, V150, P54; LINDHAGEN A, 1985, ACTA MED SCAND, V217, P389; NELZEN O, 1994, PERSPECTIVES VASCULA, V7, P33; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203	12	198	199	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					454	457		10.7326/0003-4819-126-6-199703150-00006	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM530	9072931				2022-12-28	WOS:A1997WM53000006
J	Coley, CM; Barry, MJ; Fleming, C; Fahs, MC; Mulley, AG				Coley, CM; Barry, MJ; Fleming, C; Fahs, MC; Mulley, AG			Early detection of prostate cancer .2. Estimating the risks, benefits, and costs	ANNALS OF INTERNAL MEDICINE			English	Article							DIGITAL RECTAL EXAMINATION; MEDICARE PROVIDE REIMBURSEMENT; LONG-TERM SURVIVAL; QUALITY-OF-LIFE; RADICAL PROSTATECTOMY; CONSERVATIVE MANAGEMENT; DECISION-ANALYSIS; FOLLOW-UP; TREATMENT STRATEGIES; INFORMED CONSENT	Purpose: To evaluate the potential benefits, harms, and economic consequences of digital rectal examination and measurement of prostate-specific antigen (PSA) for the early detection of prostate cancer. Data Sources: Relevant studies were identified from a MEDLINE search (1966 to 1995), reviews, bibliographies of retrieved articles, author files, and abstracts. Study Selection: Probabilities for individual clinical outcomes were derived from various sources, including the largest screening study of community volunteers to date, analyses of Medicare claims, and recently published meta-analyses of the outcomes of alternative treatment strategies. Cost estimates were based on the 1992 Medicare fee schedule. Data Extraction: A cost-effectiveness model for onetime digital rectal examination and PSA measurement was constructed to examine the possible outcomes. Results: If a favorable set of assumptions is used, one-time digital rectal examination and PSA measurement may increase average life expectancy by approximately 2 weeks at a reasonable marginal cost for men who are between 50 and 69 years of age. Considerable iatrogenic illness would occur. If less favorable assumptions are used, the estimated net benefit would decrease and cost-effectiveness ratios would dramatically increase. Even if favorable assumptions are used, the model suggests that screening adds only a few days to the average life expectancy of men who are older than 69 years of age. If the assumptions are less favorable, older men are harmed. Conclusions: The model suggests that screening may be reasonable in younger men if optimistic assumptions consistent with existing observational data are made. The lack of direct evidence showing a net benefit of screening for prostate cancer seems to mandate more clinician-patient discussion for this procedure than for many other routine tests.	MASSACHUSETTS GEN HOSP, MED PRACTICES EVALUAT CTR, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; CUNY MT SINAI SCH MED, DEPT COMMUNITY MED, NEW YORK, NY 10029 USA; HLTH OUTCOMES ASSOCIATES, VANCOUVER, WA 98685 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					AHRQ HHS [HS-08397] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008397] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAMI HO, 1994, LANCET, V343, P958, DOI 10.1016/S0140-6736(94)90071-X; ADOLFSSON J, 1993, CANCER-AM CANCER SOC, V72, P310, DOI 10.1002/1097-0142(19930715)72:2<310::AID-CNCR2820720203>3.0.CO;2-T; ADOLFSSON J, 1992, BRIT J UROL, V69, P183, DOI 10.1111/j.1464-410X.1992.tb15493.x; ADOLFSSON J, 1991, J UROLOGY, V146, P96, DOI 10.1016/S0022-5347(17)37722-4; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; ASBELL SO, 1988, INT J RADIAT ONCOL, V15, P1307, DOI 10.1016/0360-3016(88)90225-8; AUS G, 1993, BRIT J UROL, V71, P457, DOI 10.1111/j.1464-410X.1993.tb15992.x; AUS G, 1994, SCAND J UROL NEPHROL, P1; BARRY MJ, 1995, UROLOGY, V46, P445, DOI 10.1016/S0090-4295(99)80255-6; BARRY MJ, 1995, UROLOGY, V46, P277, DOI 10.1016/S0090-4295(99)80208-8; BECK JR, 1994, J UROLOGY, V152, P1894, DOI 10.1016/S0022-5347(17)32409-6; BRENDLER CB, 1993, J UROLOGY, V149, P1001, DOI 10.1016/S0022-5347(17)36279-1; BYAR DP, 1981, UROLOGY, V17, P7; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P1691, DOI 10.1001/jama.270.14.1691; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Coley CM, 1997, ANN INTERN MED, V126, P394, DOI 10.7326/0003-4819-126-5-199703010-00010; COLLINS GN, 1993, BRIT J UROL, V71, P460, DOI 10.1111/j.1464-410X.1993.tb15993.x; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; EGAWA S, 1993, UROLOGY, V42, P520, DOI 10.1016/0090-4295(93)90261-8; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; FOWLER FJ, 1995, UROLOGY, V45, P1007, DOI 10.1016/S0090-4295(99)80122-8; GARNICK MB, 1993, ANN INTERN MED, V118, P804, DOI 10.7326/0003-4819-118-10-199305150-00008; GEORGE NJR, 1988, LANCET, V1, P494; GRAVERSEN PH, 1990, UROLOGY, V36, P493, DOI 10.1016/0090-4295(90)80184-O; HAHN DL, 1993, J FAM PRACTICE, V37, P432; HANKS G E, 1988, NCI (National Cancer Institute) Monographs, P75; HANKS GE, 1994, INT J RADIAT ONCOL, V28, P39, DOI 10.1016/0360-3016(94)90139-2; JOHANSSON JE, 1994, UROLOGY, V43, P138, DOI 10.1016/0090-4295(94)90032-9; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; JONES GW, 1992, CANCER, V70, P307, DOI 10.1002/1097-0142(19920701)70:1+<307::AID-CNCR2820701319>3.0.CO;2-N; JONIER M, 1994, BR J UROL, V74, P352; KANTOFF PW, 1994, J CLIN ONCOL, V12, P2243, DOI 10.1200/JCO.1994.12.11.2243; KAPLAN ID, 1994, UROLOGY, V43, P634, DOI 10.1016/0090-4295(94)90177-5; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LEE JM, 1993, NEW ENGL J MED, V328, P438, DOI 10.1056/NEJM199302113280613; LITTRUP PJ, 1993, CA-CANCER J CLIN, V43, P134, DOI 10.3322/canjclin.43.3.134; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; Love R R, 1985, Med Decis Making, V5, P263, DOI 10.1177/0272989X8500500303; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LuYao GL, 1996, J NATL CANCER I, V88, P166, DOI 10.1093/jnci/88.3-4.166; MARK DH, 1994, J UROLOGY, V152, P896, DOI 10.1016/S0022-5347(17)32602-2; MARSHALL KG, 1993, CAN FAM PHYSICIAN, V39, P2385; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; METTLIN C, 1993, CA-CANCER J CLIN, V43, P83, DOI 10.3322/canjclin.43.2.83; MOLD JW, 1992, J FAM PRACTICE, V34, P561; MOSKOVITZ B, 1987, UROL INT, V42, P49, DOI 10.1159/000281849; *NAT CTR HLTH STAT, 1986, DHHS PUBL; OESTERLING JE, 1993, UROL CLIN N AM, V20, P687; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; PAULSON DF, 1982, J UROLOGY, V128, P502, DOI 10.1016/S0022-5347(17)53016-5; RICHIE JP, 1993, UROLOGY, V42, P365, DOI 10.1016/0090-4295(93)90359-I; RILEY G, 1987, INQUIRY-J HEALTH CAR, V24, P233; SCHRODER FH, 1993, BRIT MED J, V306, P407, DOI 10.1136/bmj.306.6875.407; Simpson K. N., 1993, J UROL S, V149, p413A; SOX HC, 1994, NEW ENGL J MED, V330, P1589, DOI 10.1056/NEJM199406023302208; SOX HC, 1994, AM J PREV MED, V10, P187, DOI 10.1016/S0749-3797(18)30589-0; STEIN A, 1992, J UROLOGY, V147, P942, DOI 10.1016/S0022-5347(17)37429-3; STEINECK G, 1991, SCAND J UROL NEPHROL, P121; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; THOMPSON IM, 1994, UROLOGY, V43, P41, DOI 10.1016/0090-4295(94)90217-8; *US C OFF TECHN AS, 1995, COST EFF PROST CANC; US Preventive Services Task Force United States. Office of Disease Prevention Health Promotion, 1996, GUID CLIN PREV SERV, P89; WALSH PC, 1993, ANN INTERN MED, V119, P948, DOI 10.7326/0003-4819-119-9-199311010-00015; WALSH PC, 1994, UROLOGY, V44, P463, DOI 10.1016/S0090-4295(94)80039-1; WALSH PC, 1987, CANCER, V60, P526, DOI 10.1002/1097-0142(19870801)60:3+<526::AID-CNCR2820601515>3.0.CO;2-9; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WHITMORE WF, 1991, CANCER, V67, P1091, DOI 10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J; ZINCKE H, 1994, J CLIN ONCOL, V12, P2254, DOI 10.1200/JCO.1994.12.11.2254	74	143	143	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					468	479		10.7326/0003-4819-126-6-199703150-00010	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM530	9072935				2022-12-28	WOS:A1997WM53000010
J	Darling, MRN				Darling, MRN			Elective or selective caesarean delivery of the small baby?	LANCET			English	Editorial Material							PRETERM				Darling, MRN (corresponding author), ROTUNDA HOSP,DUBLIN 1,IRELAND.							COLLINS R, 1836, PRACTICAL TREATISE M; Gilbert R, 1996, ARCH DIS CHILD, V75, P465, DOI 10.1136/adc.75.6.465; Grant A, 1996, BRIT J OBSTET GYNAEC, V103, P1197, DOI 10.1111/j.1471-0528.1996.tb09628.x; LAMONT RF, 1983, BMJ-BRIT MED J, V286, P454, DOI 10.1136/bmj.286.6363.454; NARAYAN H, 1994, BRIT J OBSTET GYNAEC, V101, P936, DOI 10.1111/j.1471-0528.1994.tb13034.x	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					666	666		10.1016/S0140-6736(05)60132-8	http://dx.doi.org/10.1016/S0140-6736(05)60132-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078196				2022-12-28	WOS:A1997WM08000006
J	Chawengsaksophak, K; James, R; Hammond, VE; Kontgen, F; Beck, F				Chawengsaksophak, K; James, R; Hammond, VE; Kontgen, F; Beck, F			Homeosis and intestinal tumours in Cdx2 mutant mice	NATURE			English	Article							GENE-EXPRESSION; MOUSE; DISRUPTION; EPITHELIUM; NEOPLASIA; PATTERN; MIN	In Drosophila, disturbing the expression of the homeobox gene caudal causes a severe disruption in body segmentation and global body patterning(1). There are three mouse homologues of Drosophila caudal: Cdx1 (ref. 2), Cdx2 (ref. 3) and Cdx4 (ref. 4). We have generated a null mutation of murine Cdx2 by homologous recombination. Cdx2 homozygote null mutants die between 3.5 and 5.5 days post coitum (d.p.c.). Cdx2 heterozygote mutants exhibit a variable phenotype, with many showing tail abnormalities or stunted growth. Skeletal analysis demonstrates a homeotic shift of vertebrae and compatible malformations of the ribs. Within the first three months of life, 90% of Cdx2 heterozygotes develop multiple intestinal adenomatous polyps, particularly in the proximal colon. These polyps occasionally contain areas of true metaplasia. In contrast to the surrounding intestinal epithelium, the neoplastic cells do not express Cdx2 from the remaining allele, These results suggest that Cdx2 mutation is the primary event in the genesis of some intestinal tumours.	QUEEN ELIZABETH HOSP,DEPT MED,WOODVILLE,SA 5011,AUSTRALIA; UNIV MELBOURNE,HOWARD FLOREY INST EXPT PHYSIOL & MED,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Florey Institute of Neuroscience & Mental Health; University of Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute			Chawengsaksophak, Kallayanee/G-4427-2014	Chawengsaksophak, Kallayanee/0000-0001-9401-2122				BECK F, 1995, DEV DYNAM, V204, P217; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chawengsaksophak K, 1996, GENOMICS, V34, P270, DOI 10.1006/geno.1996.0286; DUBOULE D, 1995, CURR OPIN GENET DEV, V5, P525, DOI 10.1016/0959-437X(95)90058-O; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HC, 1995, AM J PATHOL, V147, P586; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GERMAN MS, 1994, GENOMICS, V24, P403, DOI 10.1006/geno.1994.1639; INOUYE M, 1976, Congenital Anomalies, V16, P171; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; Kontgen Frank, 1993, V225, P878; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; RUBIN H, 1985, CANCER RES, V45, P2935; SABRAMANIAN V, 1995, CELL, V83, P641; SLACK JMW, 1985, J THEOR BIOL, V114, P463, DOI 10.1016/S0022-5193(85)80179-X; SZABO P, 1994, DEVELOPMENT, V120, P1651; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	23	524	545	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					84	87		10.1038/386084a0	http://dx.doi.org/10.1038/386084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052785				2022-12-28	WOS:A1997WL74600056
J	Smirnakis, SM; Berry, MJ; Warland, DK; Bialek, W; Meister, M				Smirnakis, SM; Berry, MJ; Warland, DK; Bialek, W; Meister, M			Adaptation of retinal processing to image contrast and spatial scale	NATURE			English	Article							TIGER SALAMANDER; GANGLION-CELLS; VISUAL-CORTEX; NEURONS; RABBIT; FIELD	Owing to the limited dynamic range of a neuron's output, neural circuits are faced with a trade-off between encoding the full range of their inputs and resolving gradations among those inputs. For example, the ambient light level varies daily over more than nine orders of magnitude(1), whereas the firing rate of optic nerve fibres spans less than two(2). This discrepancy is alleviated by light adaptation(3): as the mean intensity increases, the retina becomes proportionately less sensitive. However, image statistics other than the mean intensity also vary drastically during routine visual processing. Theory predicts that an efficient visual encoder should adapt its strategy not only to the mean, but to the full shape of the intensity distribution(4-6). Here we report that retinal ganglion cells, the output neurons of the retina, adapt to both image contrast-the range of light intensities-and to spatial correlations within the scene, even at constant mean intensity. The adaptation occurs on a scale of seconds, one hundred times more slowly than the immediate light response, and involves 2-5-fold changes in the firing rate. It is mediated within the retinal network: two independent sites of modulation after the photoreceptor cells appear to be involved. Our results demonstrate a remarkable plasticity in retinal processing that may contribute to the contrast adaptation of human vision(7).	HARVARD UNIV,DEPT PHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DIV HLTH SCI & TECHNOL,BOSTON,MA 02215; NEC RES INST,PRINCETON,NJ 08540	Harvard University; Harvard University; Harvard University; Harvard Medical School; NEC Corporation				Meister, Markus/0000-0003-2136-6506				ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; BARLOW HB, 1963, NATURE, V200, P1345, DOI 10.1038/2001345a0; BARLOW HB, 1981, PROC R SOC SER B-BIO, V212, P1, DOI 10.1098/rspb.1981.0022; BARLOW HB, 1963, NATURE, V200, P1347, DOI 10.1038/2001347a0; BLAKEMORE C, 1969, J PHYSIOL-LONDON, V203, P237, DOI 10.1113/jphysiol.1969.sp008862; BLOOMFIELD SA, 1992, J NEUROPHYSIOL, V68, P711, DOI 10.1152/jn.1992.68.3.711; BRAINARD DH, 1989, COLOR RES APPL, V14, P23, DOI 10.1002/col.5080140107; COPENHAGEN DR, 1985, J PHYSIOL-LONDON, V369, P161, DOI 10.1113/jphysiol.1985.sp015894; DACHEUX RF, 1982, J NEUROSCI, V2, P1486; DAWIS SM, 1981, VISION RES, V21, P1427, DOI 10.1016/0042-6989(81)90250-9; DEWEESE M, 1995, NUOVO CIMENTO D, V17, P733, DOI 10.1007/BF02451830; GIASCHI D, 1993, J NEUROPHYSIOL, V70, P2024, DOI 10.1152/jn.1993.70.5.2024; HARE WA, 1990, J PHYSIOL-LONDON, V421, P223, DOI 10.1113/jphysiol.1990.sp017942; HO WA, 1988, VISION RES, V28, P1287, DOI 10.1016/0042-6989(88)90059-4; LAUGHLIN S, 1981, Z NATURFORSCH C, V36, P910; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; MEISTER M, 1995, SCIENCE, V270, P1207, DOI 10.1126/science.270.5239.1207; NUBOER JFW, 1983, J COMP PHYSIOL, V151, P353, DOI 10.1007/BF00623910; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; RUSHTON WAH, 1965, PROC R SOC SER B-BIO, V162, P20, DOI 10.1098/rspb.1965.0024; SAKAI HM, 1987, J NEUROPHYSIOL, V58, P1329, DOI 10.1152/jn.1987.58.6.1329; SCHIETING S, 1987, VISION RES, V27, P277, DOI 10.1016/0042-6989(87)90190-8; Shapley R.M., 1984, PROG RETIN RES, V3, P263, DOI [DOI 10.1016/0278-4327(84)90011-7, 10.1016/0278-4327(84)90011-7]; SHAPLEY RM, 1978, J PHYSIOL-LONDON, V285, P275, DOI 10.1113/jphysiol.1978.sp012571; VANSTEVENINCK RRD, 1994, P IEEE C SYST MAN CY, P302; VICTOR JD, 1987, J PHYSIOL-LONDON, V386, P219, DOI 10.1113/jphysiol.1987.sp016531; Wang J.-L., 1995, Society for Neuroscience Abstracts, V21, P1644; WERBLIN F, 1988, VISUAL NEUROSCI, V1, P317, DOI 10.1017/S0952523800001978	28	330	336	1	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					69	73		10.1038/386069a0	http://dx.doi.org/10.1038/386069a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052781				2022-12-28	WOS:A1997WL74600052
J	Marini, JC; Gerber, NL				Marini, JC; Gerber, NL			Osteogenesis imperfecta rehabilitation and prospects for gene therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GROWTH-HORMONE; SHORT CHILDREN; MUTATION; STABILITY; AXIS		NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT REHABIL MED,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	Marini, JC (corresponding author), NICHHD,HERITABLE DISORDERS BRANCH,BLDG 10,RM 9S241,BETHESDA,MD 20892, USA.			Gerber, Lynn/0000-0001-7525-680X				BINDER H, 1984, ARCH PHYS MED REHAB, V65, P537; BLECK EE, 1981, CLIN ORTHOP RELAT R, V159, P111; Byers Peter H., 1993, P317; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CHARNAS LR, 1993, NEUROLOGY, V43, P2603, DOI 10.1212/WNL.43.12.2603; COHN DH, 1990, AM J HUM GENET, V46, P591; Fedde K. N., 1996, American Journal of Human Genetics, V59, pA15; FILIE JD, 1993, HUM MUTAT, V2, P380, DOI 10.1002/humu.1380020510; Folio M. R., 1983, PEABODY DEV MOTOR SC; GERBER LH, 1990, CLIN ORTHOP RELAT R, V251, P254; HASKINS M, 1991, AM J HUM GENET, V49, pA435; Kielty Cay M., 1993, P103; Marini J C, 1988, Adv Pediatr, V35, P391; MARINI JC, 1993, AM J MED GENET, V45, P261, DOI 10.1002/ajmg.1320450223; MARINI JC, 1993, J CLIN ENDOCR METAB, V76, P251, DOI 10.1210/jc.76.1.251; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; Wang Q, 1996, J CLIN INVEST, V97, P448, DOI 10.1172/JCI118434; Willing MC, 1996, AM J HUM GENET, V59, P799; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763	21	35	37	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					746	750		10.1001/jama.277.9.746	http://dx.doi.org/10.1001/jama.277.9.746			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042848				2022-12-28	WOS:A1997WK02600035
J	Andersson, PB; Waubant, E; Goodkin, DE				Andersson, PB; Waubant, E; Goodkin, DE			How should we proceed with disease-modifying treatments for multiple sclerosis?	LANCET			English	Editorial Material											Andersson, PB (corresponding author), UNIV CALIF SAN FRANCISCO,MT ZION MULTIPLE SCLEROSIS CTR,SAN FRANCISCO,CA 94115, USA.							DEAN G, 1994, NEUROEPIDEMIOLOGY, V13, P1, DOI 10.1159/000110351; FISCHER JS, 1996, MULTIPLE SCLEROSIS A, P123; GOODKIN DE, 1995, ANN NEUROL, V37, P30, DOI 10.1002/ana.410370108; JOHNSON KP, 1996, MULTIPLE SCLEROSIS A, P289; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LAROCCA NG, 1996, MULTIPLE SCLEROSIS A, P145; RUDICK RA, 1996, MULTIPLE SCLEROSIS A, P223	7	20	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					586	587		10.1016/S0140-6736(05)61562-0	http://dx.doi.org/10.1016/S0140-6736(05)61562-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057726				2022-12-28	WOS:A1997WK91500004
J	Heagerty, AM				Heagerty, AM			Industry-sponsored research	LANCET			English	Editorial Material											Heagerty, AM (corresponding author), UNIV MANCHESTER,DEPT MED,MANCHESTER M13 9WL,LANCS,ENGLAND.			Heagerty, Anthony/0000-0002-9043-2119				Blumenthal D, 1996, NEW ENGL J MED, V334, P368, DOI 10.1056/NEJM199602083340606; ETZKOWITZ H, 1991, MINERVA, V29, P133, DOI 10.1007/BF01096406; SWANN C, 1996, TOBACCO PRODUCTS RES; THOMSON AL, 1973, HALF CENTURY MED RES, P212; WEBSTER A, 1992, SOCIOLOGY, V28, P123; 1987, LANCET, V28, P257	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					588	588		10.1016/S0140-6736(05)61563-2	http://dx.doi.org/10.1016/S0140-6736(05)61563-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057727				2022-12-28	WOS:A1997WK91500005
J	Bean, AJ; Seifert, R; Chen, YA; Sacks, R; Scheller, RH				Bean, AJ; Seifert, R; Chen, YA; Sacks, R; Scheller, RH			Hrs-2 is an ATPase implicated in calcium-regulated secretion	NATURE			English	Article							SENSITIVE FUSION PROTEIN; SYNAPTIC VESICLE DOCKING; TRANSMITTER RELEASE; DOMAIN; CELLS; HYDROLYSIS; MECHANISM; TRANSPORT; SNAP-25; ZINC	Associations between proteins present on neurotransmitter-containing vesicles and on the presynaptic membrane are thought to underlie docking and fusion of synaptic vesicles with the plasma membrane, which are obligate steps in regulated neurotransmission(1-4). SNAP-25 resides on the plasma membrane and interacts with syntaxin (a plasma membrane t-SNARE) and VAMP (a vesicle V-SNARE)(1-9) to form a core protein complex thought to be an intermediate in a biochemical pathway that is essential for vesicular transport. We have now characterized a protein, Hrs-2, that interacts with SNAP-25. The binding of Hrs-2 to SNAP-25 is inhibited by calcium in the physiological concentration range that supports synaptic transmission. Furthermore, Hrs-2 binds and hydrolyses nucleoside triphosphates with kinetics that suggest that ATP is the physiological substrate for this enzyme. Hrs-2 is expressed throughout the brain and is present in nerve terminals. Moreover, recombinant Hrs-2 inhibits calcium-triggered H-3-noradrenaline release from permeabilized PC12 cells. Our results suggest a role for Hrs-2 in regulating secretory processes through calcium- and nucleotide-dependent modulation of vesicle-trafficking protein complexes.	STANFORD UNIV,HOWARD HUGHES MED INST,DEPT CELLULAR & MOL PHYSIOL,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University			Seifert, Roland/G-3189-2013					BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MORGAN A, 1994, J BIOL CHEM, V269, P29347; NISHIMURA M, 1988, BRIT J PHARMACOL, V93, P430, DOI 10.1111/j.1476-5381.1988.tb11450.x; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WANG YX, 1990, PFLUG ARCH EUR J PHY, V415, P582, DOI 10.1007/BF02583509; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945	26	111	115	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					826	829		10.1038/385826a0	http://dx.doi.org/10.1038/385826a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039916				2022-12-28	WOS:A1997WK57000056
J	Heath, I				Heath, I			Threat to social justice	BRITISH MEDICAL JOURNAL			English	Article											Heath, I (corresponding author), CAVERSHAM GRP PRACTICE,KENTISH TOWN HLTH CTR,LONDON NW5 2AJ,ENGLAND.							Benzeval M, 1995, TACKLING INEQUALITIE; Galbraith John K., 1996, GOOD SOC HUMANE AGEN; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; Heath I., 1995, MYSTERY GEN PRACTICE; Hutton W., 1996, STATE WERE; *LOND INT ZON INC, 1997, DEV ED ANN REP 1995; Mathie T, 1997, BRIT J GEN PRACT, V47, P3; *MED PRACT COMM, 1996, RESP WHIT PAP CHOIC; *MIN HLTH, 1994, CMD6502; *NHS EX, 1995, PRIOR PLANN GUID 199; Pringle M, 1996, BRIT MED J, V313, P1026; *SECR STAT HLTH, 1996, PRIM CAR DEL FUT; *SECR STAT HLTH, 1996, NAT HLTH SERV SERV A; *SECR STAT HLTH, 1996, PRIM CAR FUT CHOIC O; STOTT NCH, 1994, BMJ-BRIT MED J, V309, P971, DOI 10.1136/bmj.309.6960.971; Westin S, 1995, FAM PRACT, V12, P394, DOI 10.1093/fampra/12.4.394	16	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					598	599		10.1136/bmj.314.7080.598	http://dx.doi.org/10.1136/bmj.314.7080.598			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055725	Green Published			2022-12-28	WOS:A1997WK21500036
J	Savage, COS; Harper, L; Adu, D				Savage, COS; Harper, L; Adu, D			Primary systemic vasculitis	LANCET			English	Article							WEGENERS GRANULOMATOSIS; MICROSCOPIC POLYARTERITIS; CLASSIFICATION; ANCA; NOMENCLATURE; DISEASE; NODOSA		UNIV BIRMINGHAM, SCH MED, RENAL IMMUNOL LAB, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Birmingham	Savage, COS (corresponding author), QUEEN ELIZABETH HOSP, RENAL UNIT, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND.							ADU D, 1995, CURRENT DIAG PATHOL, V2, P732; ADU D, 1995, CURR DIAG PATHOL, V2, P73; ADU D, 1993, OXFORD TXB RHEUMATOL, P846; [Anonymous], 1995, Clin Exp Immunol, V101 Suppl 1, P29; BROUWER E, 1993, J EXP MED, V177, P905, DOI 10.1084/jem.177.4.905; CARVALHO D, 1996, CARDIOVASC PATHOL, V5, P350; CHURG A, 1991, SYSTEMIC VASCULITIDE; CHURG J, 1989, MODERN PATHOL, V2, P144; Cochrane C G, 1973, Adv Immunol, V16, P185, DOI 10.1016/S0065-2776(08)60298-9; DAGATI V, 1986, AM J KIDNEY DIS, V7, P95, DOI 10.1016/S0272-6386(86)80062-2; DAVSON J, 1948, Q J MED, V17, P175; ESNAULT VLM, 1993, KIDNEY INT, V43, P1329, DOI 10.1038/ki.1993.186; EXLEY AR, IN PRESS ARTHRITIS R; FALK RJ, 1990, KIDNEY INT, V38, P998, DOI 10.1038/ki.1990.304; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; GASKIN G, 1992, OXFORD TXB CLIN NEPH, P612; GORDON M, 1993, Q J MED, V86, P779; Griffith ME, 1996, CLIN EXP IMMUNOL, V103, P253, DOI 10.1046/j.1365-2249.1996.d01-629.x; GROSS WL, 1993, CLIN EXP IMMUNOL, V91, P1; Gross Wolfgang L., 1994, Current Opinion in Rheumatology, V6, P11, DOI 10.1097/00002281-199401000-00003; GUILLEVIN L, 1994, ANN RHEUM DIS, V53, P334, DOI 10.1136/ard.53.5.334; Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1065; JAYNE DRW, 1993, ADV EXP MED BIOL, V336, P469; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; KALLENBERG CGM, 1991, IMMUNOL TODAY, V12, P61, DOI 10.1016/0167-5699(91)90159-Q; Kettritz R, 1995, Clin Exp Immunol, V101 Suppl 1, P12; LANHAM JG, 1991, SYSTEMIC VASCULITIDE, P101; LIE JT, 1994, ARTHRITIS RHEUM-US, V37, P181, DOI 10.1002/art.1780370205; LUQMANI RA, 1994, Q J MED, V87, P671; PALL AA, 1994, SPRINGER SEMIN IMMUN, V16, P23; PORGES AJ, 1994, J IMMUNOL, V153, P1271; ReinholdKeller E, 1996, QJM-MON J ASSOC PHYS, V89, P15, DOI 10.1093/oxfordjournals.qjmed.a030133; REINHOLDKELLER E, 1994, ARTHRITIS RHEUM, V37, P919, DOI 10.1002/art.1780370622; RICHTER C, 1995, CLIN EXP IMMUNOL, V101, P2; SAVAGE CO, 1995, CURR DIAG PATHOL, V2, P256; SAVAGE COS, 1985, Q J MED, V56, P467; SCOTT DGI, 1994, BRIT J RHEUMATOL, V33, P897; SNELLER MC, 1995, ARTHRITIS RHEUM, V38, P608, DOI 10.1002/art.1780380505; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; Stegeman CA, 1996, NEW ENGL J MED, V335, P16, DOI 10.1056/NEJM199607043350103; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; ZEEK PM, 1952, AM J CLIN PATHOL, V22, P777; ZHAO MH, 1995, CLIN EXP IMMUNOL, V99, P49	45	165	172	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 22	1997	349	9051					553	558		10.1016/S0140-6736(97)80118-3	http://dx.doi.org/10.1016/S0140-6736(97)80118-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048802				2022-12-28	WOS:A1997WJ51200041
J	Stockton, D; Davies, T; Day, N; McCann, J				Stockton, D; Davies, T; Day, N; McCann, J			Retrospective study of reasons for improved survival in patients with breast cancer in East Anglia: Earlier diagnosis or better treatment?	BRITISH MEDICAL JOURNAL			English	Article							PROGRAM	Objectives: To investigate the recent fall in mortality from breast cancer in England and Wales, and to determine the relative contributions of improvements in treatment and earlier detection of tumours. Design: Retrospective study of all women with breast cancer registered by the East Anglian cancer registry and diagnosed between 1982 and 1989. Subjects: 3965 patients diagnosed 1982-5 compared with 4665 patients diagnosed 1986-9, in three age groups 0-49, 50-64, greater than or equal to 65 years, with information on stage at diagnosis and survival. Main outcome measures: Three year relative survival rates by time period, age group, and stage; relative hazard ratios for each time period and age group derived from Cox's proportional hazards model, adjusted for single year of age and stage. Results: Survival improved in the later time period, although there was little stage specific improvement. The proportion of early stage tumours increased especially in the 50-64 year age group, and adjustment for stage accounted for over half of the improvement in survival in women aged under 65 years. Conclusion: Over half of the drop in mortality in women aged under 65 years seems to be attributable to earlier detection of tumours, which has been observed since the mid-1980s. This could have resulted from an increase in breast awareness predating the start of the breast screening programme.			Stockton, D (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,E ANGLIAN CANC INTELLIGENCE UNIT,DEPT COMMUNITY MED,CAMBRIDGE CB2 2SR,ENGLAND.							ALEXANDER FE, 1994, BRIT J CANCER, V70, P542, DOI 10.1038/bjc.1994.342; BERAL V, 1995, LANCET, V345, P1642, DOI 10.1016/S0140-6736(95)90151-5; CHOUILLET AM, 1994, BRIT MED J, V308, P168, DOI 10.1136/bmj.308.6922.168; COX DR, 1972, J R STAT SOC B, V34, P187; *EARL BREAST CANC, 1992, LANCET, V339, P1; Forrest APM, 1987, BREAST CANC SCREEN R, V3rd, P102; HAKULINEN T, 1985, COMPUT PROG BIOMED, V19, P197, DOI 10.1016/0010-468X(85)90011-X; *KINGS FUND, 1986, BRIT MED J, V293, P496; NAB HW, 1994, BRIT J CANCER, V70, P285, DOI 10.1038/bjc.1994.293; QUINN M, 1995, BRIT MED J, V311, P1391, DOI 10.1136/bmj.311.7017.1391; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; *YORKSH CANC ORG, 1995, CANC REG REP SER, V3	12	68	70	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					472	475		10.1136/bmj.314.7079.472	http://dx.doi.org/10.1136/bmj.314.7079.472			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056796	Green Published			2022-12-28	WOS:A1997WJ41900024
J	Hoffbrand, V; Provan, D				Hoffbrand, V; Provan, D			ABC of clinical haematology - Macrocytic anaemias	BRITISH MEDICAL JOURNAL			English	Review											Hoffbrand, V (corresponding author), ROYAL FREE HOSP,POND ST,LONDON NW3 2QG,ENGLAND.		Provan, Drew/AAF-2766-2021	Provan, Drew/0000-0002-5110-8455					0	50	52	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					430	433		10.1136/bmj.314.7078.430	http://dx.doi.org/10.1136/bmj.314.7078.430			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040391	Green Published			2022-12-28	WOS:A1997WH29500034
J	Garner, P				Garner, P			Industry can damage your health - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material											Garner, P (corresponding author), UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,INT HLTH DIV,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND.			Garner, Paul/0000-0002-0607-6941				BRAVERMAN H, 1974, LABOR MONOPOLY CAPIT, P45; MCMICHAEL AJ, 1993, PLANETARY OVERLOAD G, P13; WEIR D, 1988, BHOPAL SYNDROME PEST, pR9; *WHO, 1992, OUR PLAN OUR HLTH RE, P175; *WORLD BANK, 1993, WORLD DEV REP 1993 I, V6, P95	5	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					342	342		10.1136/bmj.314.7077.342	http://dx.doi.org/10.1136/bmj.314.7077.342			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040324	Green Published			2022-12-28	WOS:A1997WF86100030
J	Lloyd, BW				Lloyd, BW			A randomised controlled trial of dictating the clinic letter in front of the patient	BRITISH MEDICAL JOURNAL			English	Article							COMMUNICATION				Lloyd, BW (corresponding author), N MIDDLESEX HOSP,LONDON N18 1QX,ENGLAND.							DAMIAN D, 1991, LANCET, V338, P923, DOI 10.1016/0140-6736(91)91782-P; RAWAL J, 1993, BRIT MED J, V307, P1044, DOI 10.1136/bmj.307.6911.1044; RYLANCE G, 1992, ARCH DIS CHILD, V67, P622, DOI 10.1136/adc.67.5.622; TATTERSALL R, 1990, DIABETIC MED, V7, P917, DOI 10.1111/j.1464-5491.1990.tb01330.x	4	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					347	348		10.1136/bmj.314.7077.347	http://dx.doi.org/10.1136/bmj.314.7077.347			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040328	Green Published			2022-12-28	WOS:A1997WF86100034
J	Radford, JA; Eardley, A; Woodman, C; Crowther, D				Radford, JA; Eardley, A; Woodman, C; Crowther, D			Follow up policy after treatment for Hodgkin's disease: Too many clinic visits and routine tests? A review of hospital records	BRITISH MEDICAL JOURNAL			English	Article								Objective: To examine the effectiveness of routine clinic review in detecting relapse after treatment for Hodgkin's disease. Design: Review of hospital records. Setting: Regional centre for cancer treatment and research. Subjects: 210 patients with Hodgkin's disease recruited to a chemotherapy trial protocol between 1984 and the end of 1990 who had achieved a complete or partial remission after treatment. Main outcome measures: The number of clinic visits made by patients over the period of observation, the number of relapses occurring during that time, and the route by which relapse was detected. Results: The 210 patients generated 2512 outpatient reviews, and 37 relapses were detected. Thirty relapses (81%) were diagnosed in patients who described symptoms, which in 15 cases had resulted in an earlier appointment being arranged. In only four cases (11%; 95% confidence interval 4% to 25%) was relapse detected as a result of routine physical examination or investigation of a patient who did not have symptoms. Conclusions: Relapse of Hodgkin's disease after treatment is usually detected as a result of the investigation of symptoms rather than by routine screening of asymptomatic patients. It is therefore proposed that the frequency of routine follow up visits should be reduced and greater emphasis placed on patient education. This should underline the importance of symptoms and encourage patients to arrange an earlier appointment if these develop.			Radford, JA (corresponding author), CHRISTIE HOSP NHS TRUST,CANC RES CAMPAIGN,DEPT MED ONCOL,MANCHESTER M20 4BX,LANCS,ENGLAND.		Radford, John A/N-1331-2015	Radford, John A/0000-0001-7898-2786				ANDERSEN PK, 1993, SMOOTHING NELSON AAL, P229; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; RADFORD JA, 1995, J CLIN ONCOL, V13, P2379, DOI 10.1200/JCO.1995.13.9.2379; WEEKS JC, 1991, J CLIN ONCOL, V9, P1196, DOI 10.1200/JCO.1991.9.7.1196	4	81	81	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					343	346		10.1136/bmj.314.7077.343a	http://dx.doi.org/10.1136/bmj.314.7077.343a			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040326	Green Published			2022-12-28	WOS:A1997WF86100032
J	Crovisier, J; Leech, K; BockeleeMorvan, D; Brooke, TY; Hanner, MS; Altieri, B; Keller, HU; Lellouch, E				Crovisier, J; Leech, K; BockeleeMorvan, D; Brooke, TY; Hanner, MS; Altieri, B; Keller, HU; Lellouch, E			The spectrum of comet Hale-Bopp (C/1995 O1) observed with the Infrared Space Observatory at 2.9 astronomical units from the sun	SCIENCE			English	Article							INTERSTELLAR SILICATE MINERALOGY; AIRBORNE SPECTROPHOTOMETRY; EMISSION FEATURES; WATER-VAPOR; P/HALLEY; MICRONS; SIMULATION; 2.8-MU-M; OLIVINE; GRAINS	Comet Hale-Bopp (C/1995 O1) was observed at wavelengths from 2.4 to 195 micrometers with the Infrared Space Observatory when the comet was about 2.9 astronomical units (AU) from the sun, The main observed volatiles that sublimated from the nucleus ices were water, carbon monoxide, and carbon dioxide in a ratio (by number) of 10:6:2. These species are also the main observed constituents of ices in dense interstellar molecular clouds; this observation strengthens the links between cometary and interstellar material. Several broad emission features observed in the 7- to 45-micrometer region suggest the presence of silicates, particularly magnesium-rich crystalline olivine. These features are similar to those observed in the dust envelopes of Vega-type stars.	EUROPEAN SPACE AGCY, DIV ASTROPHYS, ISO SCI OPERAT CTR, E-28080 VILLAFRANCA DASTI, SPAIN; CALTECH, JET PROP LAB, PASADENA, CA 91109 USA; MAX PLANCK INST AERON, D-37189 KATLENBURG DUHM, GERMANY	European Space Agency; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Max Planck Society	Crovisier, J (corresponding author), OBSERV PARIS, F-92195 MEUDON, FRANCE.			Altieri, Bruno/0000-0003-3936-0284				BENKHOFF J, 1995, ICARUS, V114, P348, DOI 10.1006/icar.1995.1067; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; BOCKELEEMORVAN D, 1995, ICARUS, V116, P18, DOI 10.1006/icar.1995.1111; BOCKELEEMORVAN D, 1989, ASTRON ASTROPHYS, V216, P278; BOCKELEEMORVAN D, 1987, ASTRON ASTROPHYS, V181, P169; BOCKELEEMORVAN D, IN PRESS IAU S, V178; BOCKELEEMORVAN D, 1990, ASTEROIDS COMETS MET, V3, P263; BREGMAN JD, 1987, ASTRON ASTROPHYS, V187, P616; BROOKE TY, 1989, ASTROPHYS J, V336, P971, DOI 10.1086/167068; CAMPINS H, 1989, ASTROPHYS J, V341, P1059, DOI 10.1086/167563; Capria MT, 1996, PLANET SPACE SCI, V44, P987, DOI 10.1016/0032-0633(96)00016-5; COLANGELI L, 1995, ASTRON ASTROPHYS, V293, P927; COMBES M, 1988, ICARUS, V76, P44; Crovisier J, 1996, ASTRON ASTROPHYS, V315, pL385; CROVISIER J, 1992, LES HOUCHES, P221; CROVISIER J, 1994, ASTEROIDS COMETS MET, P149; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; dHendecourt L, 1996, ASTRON ASTROPHYS, V315, pL365; DORSCHNER J, 1995, ASTRON ASTROPHYS, V300, P503; ESPINASSE S, 1991, ICARUS, V92, P350, DOI 10.1016/0019-1035(91)90058-2; GLACCUM W, 1987, ASTRON ASTROPHYS, V187, P635; GRADY CA, 1993, IN PRESS ASTROPHYS J, V418; HANNER MS, 1994, ASTROPHYS J, V425, P274, DOI 10.1086/173984; Hayward TL, 1997, SCIENCE, V275, P1907, DOI 10.1126/science.275.5308.1907; HERTER T, 1987, ASTRON ASTROPHYS, V187, P629; HUEBNER WF, 1992, ASTROPHYS SPACE SCI, V195, P1, DOI 10.1007/BF00644558; JAGER C, 1994, ASTRON ASTROPHYS, V292, P641; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; KESSLER MF, 1996, ASTRON ASTROPHYS, V315, pL38; KNACKE RF, 1993, ASTROPHYS J, V418, P440, DOI 10.1086/173405; KOIKE C, 1993, MON NOT R ASTRON SOC, V264, P654, DOI 10.1093/mnras/264.3.654; KOIKE C, 1992, MON NOT R ASTRON SOC, V255, P248, DOI 10.1093/mnras/255.2.248; LAWLER ME, 1989, ICARUS, V80, P225, DOI 10.1016/0019-1035(89)90135-8; Lemke D, 1996, ASTRON ASTROPHYS, V315, pL64; MUMMA MJ, 1986, SCIENCE, V232, P1523, DOI 10.1126/science.232.4757.1523; Mumma MJ, 1996, SCIENCE, V272, P1310, DOI 10.1126/science.272.5266.1310; MUMMA MJ, 1987, ASTRON ASTROPHYS, V187, P419; MUMMA MJ, 1988, FORMATION EVOLUTION; SCHLEICHER DG, 1988, ASTROPHYS J, V331, P1058, DOI 10.1086/166622; TOKUNAGA AT, 1987, ASTRON ASTROPHYS, V187, P519; Waelkens C, 1996, ASTRON ASTROPHYS, V315, pL245; Waters LBFM, 1996, ASTRON ASTROPHYS, V315, pL361; WEAVER HA, 1996, B AM ASTRON SOC, V28, P1094; WEAVER HA, 1988, FORMATION EVOLUTION; Whittet DCB, 1996, ASTRON ASTROPHYS, V315, pL357	46	468	469	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1904	1907		10.1126/science.275.5308.1904	http://dx.doi.org/10.1126/science.275.5308.1904			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072960				2022-12-28	WOS:A1997WQ51300035
J	Noji, H; Yasuda, R; Yoshida, M; Kinosita, K				Noji, H; Yasuda, R; Yoshida, M; Kinosita, K			Direct observation of the rotation of F-1-ATPase	NATURE			English	Article							ESCHERICHIA-COLI; F1-ATPASE; FORCE; MOLECULE; SUBUNITS; MOTOR	Cells employ a variety of linear motors, such as myosin(1-3), kinesin(4) and RNA polymerase(5), which move along and exert force on a filamentous structure. But only one rotary motor has been investigated in detail, the bacterial flagellum(6) (a complex of about 100 protein molecules(7)). We now show that a single molecule of F-1-ATPase acts as a rotary motor, the smallest known, by direct observation of its motion. A central rotor of radius similar to 1 nm, formed by its gamma-subunit, turns in a stator barrel of radius similar to 5nm formed by three alpha- and three beta-subunits(8). F-1-ATPase, together with the membrane-embedded proton-conducting unit F-0, forms the H+-ATP synthase that reversibly couples transmembrane proton flow to ATP synthesis/hydrolysis in respiring and photosynthetic cells(9,10). It has been suggested that the gamma-subunit of F-1-ATPase rotates within the alpha beta-hexamer(11), a conjecture supported by structural(8), biochemical(12,13) and spectroscopic(14) studies. We attached a fluorescent actin filament to the gamma-subunit as a marker, which enabled us to observe this motion directly. In the presence of ATP, the filament rotated for more than 100 revolutions in an anticlockwise direction when viewed from the 'membrane' side. The rotary torque produced reached more than 40 pN nm(-1) under high load.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN; KEIO UNIV, FAC SCI & TECHNOL, DEPT PHYS, YOKOHAMA, KANAGAWA 223, JAPAN	Tokyo Institute of Technology; Keio University			Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AIZAWA S, 1991, ADV MICROB PHYSL, V32, P110; BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KAGAWA Y, 1966, J BIOL CHEM, V241, P2467; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MIYATA H, 1995, BIOPHYS J, V68, pS286; Noji H, 1996, J BIOENERG BIOMEMBR, V28, P451, DOI 10.1007/BF02113988; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SASE I, 1995, BIOPHYS J, V69, P323, DOI 10.1016/S0006-3495(95)79937-4; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	24	1865	1916	11	364	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	1997	386	6622					299	302		10.1038/386299a0	http://dx.doi.org/10.1038/386299a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069291				2022-12-28	WOS:A1997WP00300056
J	Gall, MA; Hougaard, P; BorchJohnsen, K; Parving, HH				Gall, MA; Hougaard, P; BorchJohnsen, K; Parving, HH			Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY ALBUMIN EXCRETION; GLYCEMIC CONTROL; PIMA-INDIANS; MICROALBUMINURIA; PROGRESSION; PROTEINURIA; NIDDM; COMPLICATIONS; PREVALENCE; CAPTOPRIL	Objective: To evaluate putative risk factors for the development of incipient diabetic nephropathy (persistent microalbuminuria) and overt diabetic nephropathy (persistent macroalbuminuria) in patients with non-insulin dependent diabetes. Design: Prospective, observational study of a cohort of white, non-insulin dependent diabetic patients followed for a median period of 5.8 years. Setting: Outpatient clinic in tertiary referral centre. Subjects: 191 patients aged under 66 years with noninsulin dependent diabetes and normoalbuminuria (urinary albumin excretion rate < 30 mg/24 h) who attended the clinic during 1987. Main outcome measures: Incipient and overt diabetic nephropathy. Results: Fifteen patients were lost to follow up. Thirty six of the 176 remaining developed persistent microalbuminuria (30-299 mg/24 h in two out of three consecutive 24 hour urine collections) and five developed persistent macroalbuminuria (greater than or equal to 300 mg/24 h in two out of three consecutive collections) during follow up. The five year cumulative incidence of incipient diabetic nephropathy was 23% (95% confidence interval 17% to 30%). Cox's multiple stepwise regression analysis revealed the following risk factors for the development of incipient or overt diabetic nephropathy: increased baseline log urinary albumin excretion rate (relative risk 11.1 (3.4 to 35.9); P<0.0001); male sex (2.6 (1.2 to 5.4); P < 0.02); presence of retinopthy (2.4 (1.3 to 4.7); P < 0.01); increased serum cholesterol concentration (1.4 (1.1 to 1.7); P < 0.01); haemoglobin A(1c) concentration (1.2 (1.0 to 1.4); P < 0.05); and age (1.07 (1.02 to 1.12); P < 0.01). Known duration of diabetes, body mass index, arterial blood pressure, serum creatinine concentration, pre-existing coronary heart disease, and history of smoking were not risk factors. Conclusion: Several potentially modifiable risk factors predict the development of incipient and overt diabetic nephropathy in normoalbuminuric patients with non-insulin dependent diabetes.	UNIV COPENHAGEN, GLOSTRUP HOSP, CTR PREVENT MED, DK-2600 GLOSTRUP, DENMARK; NOVO NORDISK AS, STAT, DK-2880 BAGSVAERD, DENMARK	University of Copenhagen; Novo Nordisk	Gall, MA (corresponding author), STENO DIABET CTR, DK-2820 GENTOFTE, DENMARK.							Andersen P. K., 2012, STAT MODELS BASED CO; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; CHRISTENSEN CK, 1984, DIABETIC NEPHROPATHY, V3, P92; CLOSE CF, 1995, BMJ-BRIT MED J, V311, P973; COX DR, 1972, J R STAT SOC B, V34, P187; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; FRIER BM, 1977, DIABETES, V26, P369; GALL MA, 1993, DIABETOLOGIA, V36, P1071, DOI 10.1007/BF02374501; GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303; GALL MA, 1991, DIABETOLOGIA, V34, P655, DOI 10.1007/BF00400995; HOTHERNIELSEN O, 1988, DIABETES CARE, V11, P531, DOI 10.2337/diacare.11.7.531; JOHN L, 1994, DIABETES CARE, V17, P888, DOI 10.2337/diacare.17.8.888; KATTERMANN R, 1984, J CLIN CHEM CLIN BIO, V22, P245; KLEIN R, 1995, DIABETES, V44, P916, DOI 10.2337/diabetes.44.8.916; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1995, DIABETIC MED, V12, P482, DOI 10.1111/j.1464-5491.1995.tb00528.x; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOORHEAD JF, 1982, LANCET, V2, P1309; MORTENSEN HB, 1980, J CHROMATOGR, V182, P325, DOI 10.1016/S0378-4347(00)81481-4; NELSON RG, 1993, DIABETOLOGIA, V36, P998, DOI 10.1007/BF02374490; NELSON RG, 1995, DIABETES CARE, V18, P182, DOI 10.2337/diacare.18.2.182; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P550, DOI 10.1530/acta.0.1000550; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; PARVING HH, 1995, BRENNER RECTORS KIDN, P1864; POWRIE JK, 1994, BRIT MED J, V309, P1608, DOI 10.1136/bmj.309.6969.1608; RAVID M, 1995, KIDNEY INT, V47, P907, DOI 10.1038/ki.1995.135; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; SCHMITZ A, 1994, DIABETOLOGIA, V37, P1251, DOI 10.1007/BF00399799; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Ullmann R, 1976, Med Lab (Stuttg), V29, P137; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI GC, 1982, LANCET, V1, P1430; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; YIP J, 1993, BRIT MED J, V306, P1235	38	288	305	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	1997	314	7083					783	788		10.1136/bmj.314.7083.783	http://dx.doi.org/10.1136/bmj.314.7083.783			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080995	Green Published			2022-12-28	WOS:A1997WN64600022
J	Nowack, R; Birck, R; vanderWoude, FJ				Nowack, R; Birck, R; vanderWoude, FJ			Mycophenolate mofetil for systemic vasculitis and IgA nephropathy	LANCET			English	Article							GRANULOMATOSIS		UNIV HEIDELBERG,KLINIKUM MANNHEIM,DEPT MED 3,FAC CLIN MED,D-68135 MANNHEIM,GERMANY	Ruprecht Karls University Heidelberg								*EUR MYC MOF COOP, 1995, LANCET, V345, P1321; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; GALLA JH, 1995, KIDNEY INT, V47, P377, DOI 10.1038/ki.1995.50; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; VANDERWOUDE FJ, 1995, NEPHROL DIAL TRANSPL, V10, P1112, DOI 10.1093/ndt/10.7.1112	5	138	145	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					774	774		10.1016/S0140-6736(05)60198-5	http://dx.doi.org/10.1016/S0140-6736(05)60198-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074580				2022-12-28	WOS:A1997WN12400015
J	Pitt, B; Segal, R; Martinez, FA; Meurers, G; Cowley, AJ; Thomas, I; Deedwania, PC; Ney, DE; Snavely, DB; Chang, PI				Pitt, B; Segal, R; Martinez, FA; Meurers, G; Cowley, AJ; Thomas, I; Deedwania, PC; Ney, DE; Snavely, DB; Chang, PI			Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)	LANCET			English	Article							CONVERTING ENZYME-INHIBITION; II RECEPTOR ANTAGONISTS; ANGIOTENSIN; MORTALITY; HYDRALAZINE; BRADYKININ; ENALAPRIL; EXERCISE; CHYMASE; HUMANS	Background To determine whether specific angiotensin ii receptor blockade with losartan offers safety and efficacy advantages in the treatment of heart failure over angiotensin-converting-enzyme (ACE) inhibition with captopril, the ELITE study compared losartan with captopril in older heart-failure patients. Methods We randomly assigned 722 ACE inhibitor naive patients (aged 65 years or more) with New York Heart Association (NYHA) class Ii-IV heart failure and ejection fractions of 40% or less to double-blind losartan (n=352) titrated to 50 mg once daily or captopril (n=370) titrated to 50 mg three times daily, for 48 weeks. The primary endpoint was the tolerability measure of a persisting increase in serum creatinine of 26.5 mu mol/L or more (greater than or equal to 0.3 mg/dL) on therapy; the secondary endpoint was the composite of death and/or hospital admission for heart failure; and other efficacy measures were total mortality, admission for heart failure, NYHA class, and admission for myocardial infarction or unstable angina. Findings The frequency of persisting increases in serum creatinine was the same in both groups (10.5%). Fewer losartan patients discontinued therapy for adverse experiences (12.2% vs 20.8% for captopril, p=0.002). No losartan-treated patients discontinued due to cough compared with 14 in the captopril group. Death and/or hospital admission for heart failure was recorded in 9.4% of the losartan and 13.2% of the captopril patients (risk reduction 32% [95% CI -4% to +55%], p=0.075). This risk reduction was primarily due to a decrease in ail-cause mortality (4.8% vs 8.7%; risk reduction 46% [95% CI 5-69%], p=0.035). Admissions with heart failure were the same in both groups (5.7%), as was improvement in NYHA functional class from baseline. Admission to hospital for any reason was less frequent with losartan than with captopril treatment (22.2% vs 29.7%). Interpretation in this study of elderly heart-failure patients, treatment with losartan was associated with an unexpected tower mortality than that found with captopril. Although there was no difference in renal dysfunction, losartan was generally better tolerated than captopril and fewer patients discontinued losartan therapy. A further trial, evaluating the effects of losartan and captopril on mortality and morbidity in a larger number of patients with heart failure, is in progress.	INST MED LA PAZ,CORDOBA,ARGENTINA; KRANKENHAUS VINZENTINUM,RUHPOLDING,GERMANY; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT CARDIOVASC MED,NOTTINGHAM NG7 2UH,ENGLAND; SLIDELL MEM HOSP & MED CTR,MED RES INST,SLIDELL,LA; UNIV CALIF SAN FRANCISCO,VA MED CTR,CARDIOL SECT,FRESNO,CA; MERCK RES LABS,W POINT,PA	University of Nottingham; University of California System; University of California San Francisco; University of California San Francisco at Fresno; Merck & Company	Pitt, B (corresponding author), UNIV MICHIGAN HOSP,DIV CARDIOL,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.		Arnold, Malcolm/G-2869-2011					*AC INF RAM EFF AI, 1993, LANCET, V342, P812; ALDIGIER JC, 1993, J CARDIOVASC PHARM, V21, P289, DOI 10.1097/00005344-199302000-00015; APPLEFELD MM, 1986, AM J MED, V80, P73, DOI 10.1016/0002-9343(86)90149-X; BRASCH H, 1993, HYPERTENSION, V22, P699, DOI 10.1161/01.HYP.22.5.699; CHALMERS D, 1987, BRIT J CLIN PHARMACO, V24, P343, DOI 10.1111/j.1365-2125.1987.tb03179.x; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; *CONSENSUS TRIAL S, 1987, NEW ENGL J MED, V316, P1429; CROZIER I, 1995, CIRCULATION, V91, P691, DOI 10.1161/01.CIR.91.3.691; FONAROW GC, 1992, J AM COLL CARDIOL, V19, P842, DOI 10.1016/0735-1097(92)90529-V; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GAVRAS I, 1992, KIDNEY INT, V42, P1020, DOI 10.1038/ki.1992.383; GOTTLIEB SS, 1993, CIRCULATION, V88, P1602, DOI 10.1161/01.CIR.88.4.1602; *GRUPP IT STUD SOP, 1994, LANCET, V343, P1115; *ISIS 4, 1995, LANCET, V345, P669; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; Klinger G., 1997, Journal of the American College of Cardiology, V29, p205A; LACOURCIERE Y, 1994, J HYPERTENS, V12, P1387; MINISI AJ, 1993, CIRCULATION, V87, P240, DOI 10.1161/01.CIR.87.1.240; MIURA S, 1994, J HYPERTENS, V12, P1177; PACKER M, 1986, NEW ENGL J MED, V315, P847, DOI 10.1056/NEJM198610023151402; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PITT B, 1995, CARDIOVASC DRUG THER, V9, P693, DOI 10.1007/BF00878552; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; *SOLVD INV, 1991, NEW ENGL J MED, V325, P293; *SOLVD INV, 1992, NEW ENGL J MED, V327, P685; STAFFORD RS, 1996, CIRCULATION, V94, P1; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; URATA H, 1994, J HYPERTENS, V12, pS17; URATA H, 1990, J BIOL CHEM, V265, P22348; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6	31	1316	1360	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					747	752		10.1016/S0140-6736(97)01187-2	http://dx.doi.org/10.1016/S0140-6736(97)01187-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074572				2022-12-28	WOS:A1997WN12400007
J	Schultz, W; Dayan, P; Montague, PR				Schultz, W; Dayan, P; Montague, PR			A neural substrate of prediction and reward	SCIENCE			English	Article							MONKEY DOPAMINE NEURONS; PREFRONTAL CORTEX; SELF-STIMULATION; BACTERIAL CHEMOTAXIS; BEHAVIORAL REACTIONS; CEREBRAL-CORTEX; NETWORK MODEL; RESPONSES; MIDBRAIN; BRAIN	The capacity to predict future events permits a creature to detect, model, and manipulate the causal structure of its interactions with its environment. Behavioral experiments suggest that learning is driven by changes in the expectations about future salient events such as rewards and punishments. Physiological work has recently complemented these studies by identifying dopaminergic neurons in the primate whose fluctuating output apparently signals changes or errors in the predictions of future salient and rewarding events. Taken together, these findings can be understood through quantitative theories of adaptive optimizing control.	BAYLOR COLL MED, DIV NEUROSCI, CTR THEORET NEUROSCI, HOUSTON, TX 77030 USA; UNIV FRIBOURG, INST PHYSIOL, CH-1700 FRIBOURG, SWITZERLAND; MIT, DEPT BRAIN & COGNIT SCI, CTR BIOL & COMPUTAT LEARNING, CAMBRIDGE, MA 02139 USA	Baylor College of Medicine; University of Fribourg; Massachusetts Institute of Technology (MIT)			anand, amit/A-7222-2009; Jansen, Heiko T./A-5770-2008; schultz, wolfram/H-8958-2016	Jansen, Heiko T./0000-0003-0178-396X; schultz, wolfram/0000-0002-8530-4518; Dayan, Peter/0000-0003-3476-1839				[Anonymous], 1996, NEURO DYNAMIC PROGRA; AOSAKI T, 1994, J NEUROSCI, V14, P3969; BARTO AG, 1983, IEEE T SYST MAN CYB, V13, P834, DOI 10.1109/TSMC.1983.6313077; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bellman R., 1957, DYNAMIC PROGRAMMING; BENINGER RJ, 1983, SCIENCE, V220, P1304, DOI 10.1126/science.6857251; BENINGER RJ, 1983, BRAIN RES REV, V6, P173, DOI 10.1016/0165-0173(83)90038-3; BENINGER RJ, 1989, BRAIN RES BULL, V23, P365, DOI 10.1016/0361-9230(89)90223-2; BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; BERG HC, 1975, NATURE, V254, P389, DOI 10.1038/254389a0; Berns GS, 1996, RES PER NEUROSCI, P101; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; Church R. M., 1989, CONT LEARNING THEORI, P41; CORBETT D, 1980, BRAIN RES, V185, P1, DOI 10.1016/0006-8993(80)90666-6; DAMASIO AR, 1994, DESCARTES ERROR; DAYAN P, 1992, MACH LEARN, V8, P341, DOI 10.1007/BF00992701; DAYAN P, 1994, MACH LEARN, V14, P295; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; Dickinson A., 1980, CONT ANIMAL LEARNING; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; FREUND TF, 1984, NEUROSCIENCE, V13, P1189, DOI 10.1016/0306-4522(84)90294-X; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; GALLISTEI CR, 1990, ORG LEARNING; GIBBON J, 1991, LEARN MOTIV, V22, P3, DOI 10.1016/0023-9690(91)90015-Z; GOLDMANRAKIC PS, 1989, P NATL ACAD SCI USA, V86, P9015, DOI 10.1073/pnas.86.22.9015; Graybiel AM, 1995, CURR OPIN NEUROBIOL, V5, P733, DOI 10.1016/0959-4388(95)80100-6; Graybiel Ann M., 1995, Trends in Neurosciences, V18, P60, DOI 10.1016/0166-2236(95)93871-T; GROSSBERG S, 1972, Mathematical Biosciences, V15, P253, DOI 10.1016/0025-5564(72)90038-7; GROSSBERG S, 1989, NEURAL NETWORKS, V2, P79, DOI 10.1016/0893-6080(89)90026-9; GROSSBERG S, 1982, PSYCHOL REV, V89, P529, DOI 10.1037/0033-295X.89.5.529; GROSSBERG S, 1992, COGNITIVE BRAIN RES, V1, P3, DOI 10.1016/0926-6410(92)90003-A; Hollerman J., 1996, Society for Neuroscience Abstracts, V22, P1388; Houk JC, 1995, MODELS INFORMATION P, P249; Howard RonaldA., 1960, DYNAMIC PROGRAMMING; JAAKKOLA T, 1994, NEURAL COMPUT, V6, P1185, DOI 10.1162/neco.1994.6.6.1185; Kamin L. J., 1969, PUNISHMENT AVERSIVE, P279, DOI DOI 10.2105/AJPH.2006.090910; KOOB GF, 1992, SEMIN NEUROSCI, V4, P139; LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; Mackintosh N. J, 1983, CONDITIONING ASS LEA; MACKINTOSH NJ, 1975, PSYCHOL REV, V82, P276, DOI 10.1037/h0076778; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; Mirenowicz J, 1996, NATURE, V379, P449, DOI 10.1038/379449a0; MIRENOWICZ J, 1994, J NEUROPHYSIOL, V72, P1024, DOI 10.1152/jn.1994.72.2.1024; Montague P. R., 1994, Advances in neural information processing systems 6., P598; Montague P. R., 1993, ADV NEURAL INFORMATI, V5, P969; MONTAGUE PR, 1995, NATURE, V377, P725, DOI 10.1038/377725a0; MONTAGUE PR, 1994, LEARN MEMORY, V1, P1; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; MONTAGUE PR, IN PRESS NEURAL NETW; MONTAGUE PR, IN PRESS COMPANION C; MOORE JW, 1986, BEHAV BRAIN RES, V21, P143, DOI 10.1016/0166-4328(86)90092-6; MORA F, 1977, SCIENCE, V197, P1387, DOI 10.1126/science.897677; Olds J., 1977, DRIVES REINFORCEMENT; Pavlov I.P., 1927, CONDITIONED REFLEXES; PEARCE JM, 1980, PSYCHOL REV, V87, P532, DOI 10.1037/0033-295X.87.6.532; PERRETT SP, 1993, J NEUROSCI, V13, P1708; PHILLIPS AG, 1975, BRAIN RES, V85, P13, DOI 10.1016/0006-8993(75)90998-1; PHILLIPS AG, 1979, PSYCHOPHARMACOLOGY, V62, P79, DOI 10.1007/BF00426039; PHILLIPS AG, 1976, BRAIN RES, V104, P221, DOI 10.1016/0006-8993(76)90615-6; Quartz S. R., 1992, Society for Neuroscience Abstracts, V18, P1210; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; REAL LA, 1991, SCIENCE, V253, P980, DOI 10.1126/science.1887231; Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; ROMO R, 1990, J NEUROPHYSIOL, V63, P592, DOI 10.1152/jn.1990.63.3.592; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SCHULTZ W, 1990, J NEUROPHYSIOL, V63, P607, DOI 10.1152/jn.1990.63.3.607; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SCHULTZ W, 1986, J NEUROPHYSIOL, V56, P1439, DOI 10.1152/jn.1986.56.5.1439; SERVANSCHREIBER D, 1990, SCIENCE, V249, P892, DOI 10.1126/science.2392679; Skinner BF, 1938, BEHAV ORGANISMS EXPT; SMITH Y, 1994, J COMP NEUROL, V344, P1, DOI 10.1002/cne.903440102; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; SPUDICH JL, 1975, P NATL ACAD SCI USA, V72, P710, DOI 10.1073/pnas.72.2.710; Sutton R. S., 1988, Machine Learning, V3, P9, DOI 10.1023/A:1022633531479; Sutton R. S., 1987, P 9 ANN C COGN SCI S; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; SUTTON RS, 1989, LEARNING COMPUTATION; TESAURO G, 1995, COMMUN ACM, V38, P58, DOI 10.1145/203330.203343; TSANG N, 1973, SCIENCE, V181, P60, DOI 10.1126/science.181.4094.60; WHITE NM, 1992, ANNU REV PSYCHOL, V43, P443; Wickens JR, 1996, NEUROSCIENCE, V70, P1, DOI 10.1016/0306-4522(95)00436-M; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; WISE RA, 1982, BEHAV BRAIN SCI, V5, P39, DOI 10.1017/S0140525X00010372; WISE RA, 1992, SYNAPSE, V10, P247, DOI 10.1002/syn.890100307; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; WISE RA, 1989, NEUROPHARMACOLOGICAL; [No title captured]	91	5398	5459	23	622	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	1997	275	5306					1593	1599		10.1126/science.275.5306.1593	http://dx.doi.org/10.1126/science.275.5306.1593			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WN123	9054347	Green Submitted			2022-12-28	WOS:A1997WN12300029
J	Spirito, P; Seidman, CE; McKenna, WJ; Maron, BJ				Spirito, P; Seidman, CE; McKenna, WJ; Maron, BJ			Medical progress - The management of hypertrophic cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEFT-VENTRICULAR HYPERTROPHY; SUB-AORTIC STENOSIS; PROGRAMMED ELECTRICAL-STIMULATION; DIMENSIONAL ECHOCARDIOGRAPHIC ASSESSMENT; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; MYOCARDIAL PERFUSION ABNORMALITIES; ASYMMETRIC SEPTAL HYPERTROPHY; MITRAL-VALVE REPLACEMENT; CORONARY-ARTERY DISEASE; SUDDEN CARDIAC DEATH		BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; ST GEORGE HOSP, SCH MED, DEPT CARDIOL SCI, LONDON SW17 0RE, ENGLAND; MINNEAPOLIS HEART INST FDN, MINNEAPOLIS, MN USA	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; St Georges University London; Minneapolis Heart Institute Foundation	Spirito, P (corresponding author), OSPED ST ANDREA, SERV CARDIOL, VIA VENETO 197, I-19100 LA SPEZIA, ITALY.		McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460	Telethon [0860C] Funding Source: Medline	Telethon(Fondazione Telethon)		[Anonymous], 1989, NEW ENGL J MED, V321, P406; Betocchi S, 1996, AM J CARDIOL, V78, P451, DOI 10.1016/S0002-9149(96)00336-0; BETOCCHI S, 1985, CIRCULATION, V72, P1001, DOI 10.1161/01.CIR.72.5.1001; Betocchi S, 1996, AM J CARDIOL, V77, P498, DOI 10.1016/S0002-9149(97)89344-7; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; BONOW RO, 1985, CIRCULATION, V72, P853, DOI 10.1161/01.CIR.72.4.853; BONOW RO, 1981, CIRCULATION, V64, P787, DOI 10.1161/01.CIR.64.4.787; CANEDO MI, 1980, AM J CARDIOL, V45, P848, DOI 10.1016/0002-9149(80)90131-9; CANNAN CR, 1995, CIRCULATION, V92, P2488, DOI 10.1161/01.CIR.92.9.2488; CANNON RO, 1991, CIRCULATION, V83, P1660, DOI 10.1161/01.CIR.83.5.1660; CANNON RO, 1992, CIRCULATION, V85, P1039, DOI 10.1161/01.CIR.85.3.1039; CANNON RO, 1985, CIRCULATION, V71, P234, DOI 10.1161/01.CIR.71.2.234; CANNON RO, 1989, CIRCULATION, V79, P766, DOI 10.1161/01.CIR.79.4.766; CECCHI F, 1995, J AM COLL CARDIOL, V26, P1529, DOI 10.1016/0735-1097(95)00353-3; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CHMIELEWSKI CA, 1977, AM HEART J, V93, P91, DOI 10.1016/S0002-8703(77)80177-4; COHEN LS, 1967, CIRCULATION, V35, P847, DOI 10.1161/01.CIR.35.5.847; COHN LH, 1992, AM J CARDIOL, V70, P657, DOI 10.1016/0002-9149(92)90208-G; COOLEY DA, 1971, ARCH SURG-CHICAGO, V103, P606; COOPER MM, 1987, ANN THORAC SURG, V44, P370, DOI 10.1016/S0003-4975(10)63795-2; DEROSE JJ, 1994, PROG CARDIOVASC DIS, V36, P475, DOI 10.1016/S0033-0620(94)80054-5; DILSIZIAN V, 1993, J AM COLL CARDIOL, V22, P796, DOI 10.1016/0735-1097(93)90193-5; Duck H J, 1984, Z Gesamte Inn Med, V39, P437; EPSTEIN SE, 1981, CIRCULATION, V64, P437, DOI 10.1161/01.CIR.64.3.437; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; FANANAPAZIR L, 1992, CIRCULATION, V86, P730, DOI 10.1161/01.CIR.86.3.730; FANANAPAZIR L, 1991, AM J CARDIOL, V67, P169, DOI 10.1016/0002-9149(91)90440-V; FAY WP, 1990, J AM COLL CARDIOL, V16, P821, DOI 10.1016/S0735-1097(10)80328-6; FIDDLER GI, 1978, AM J CARDIOL, V42, P793, DOI 10.1016/0002-9149(78)90099-1; FLAMM MD, 1968, CIRCULATION, V38, P846, DOI 10.1161/01.CIR.38.5.846; FRANK S, 1968, CIRCULATION, V37, P759, DOI 10.1161/01.CIR.37.5.759; FRENNEAUX MP, 1989, J AM COLL CARDIOL, V13, P1521, DOI 10.1016/0735-1097(89)90342-2; FURLAN AJ, 1984, STROKE, V15, P282, DOI 10.1161/01.STR.15.2.282; GEIBEL A, 1987, AM J CARDIOL, V60, P738, DOI 10.1016/0002-9149(87)90399-7; GILLIGAN DM, 1992, CIRCULATION, V85, P2140, DOI 10.1161/01.CIR.85.6.2140; GILLIGAN DM, 1991, AM J CARDIOL, V68, P766, DOI 10.1016/0002-9149(91)90651-Z; GILLIGAN DM, 1993, J AM COLL CARDIOL, V21, P1672, DOI 10.1016/0735-1097(93)90386-F; GILLIGAN DM, 1994, AM J CARDIOL, V73, P312, DOI 10.1016/0002-9149(94)90241-0; GOODWIN JF, 1970, LANCET, V1, P731; GOSSELINK ATM, 1992, JAMA-J AM MED ASSOC, V267, P3289, DOI 10.1001/jama.267.24.3289; GREENE HL, 1993, AM J CARDIOL, V72, P280; GRIGG LE, 1992, J AM COLL CARDIOL, V20, P42, DOI 10.1016/0735-1097(92)90135-A; HANRATH P, 1980, AM J CARDIOL, V45, P1258, DOI 10.1016/0002-9149(80)90487-7; HARRIS L, 1983, CIRCULATION, V67, P45, DOI 10.1161/01.CIR.67.1.45; HARRISON DC, 1964, CIRCULATION, V29, P84, DOI 10.1161/01.CIR.29.1.84; Hassenstein P, 1975, Thoraxchir Vask Chir, V23, P496; HENRY WL, 1975, AM J CARDIOL, V35, P337, DOI 10.1016/0002-9149(75)90025-9; HERIC B, 1995, J THORAC CARDIOV SUR, V110, P195, DOI 10.1016/S0022-5223(05)80026-1; HESS OM, 1986, CIRCULATION, V74, P530, DOI 10.1161/01.CIR.74.3.530; IWASE M, 1987, J AM COLL CARDIOL, V9, P1099, DOI 10.1016/S0735-1097(87)80313-3; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; JOSEPH S, 1972, BRIT HEART J, V34, P974; KLUES HG, 1991, CIRCULATION, V84, P1188, DOI 10.1161/01.CIR.84.3.1188; Kofflard MJ, 1996, J AM COLL CARDIOL, V28, P197, DOI 10.1016/0735-1097(96)00103-9; KOFFLARD MJ, 1993, AM J CARDIOL, V72, P939, DOI 10.1016/0002-9149(93)91111-T; KUCK KH, 1988, EUR HEART J, V9, P177, DOI 10.1093/oxfordjournals.eurheartj.a062472; LEVER HM, 1989, CIRCULATION, V79, P580, DOI 10.1161/01.CIR.79.3.580; LEWIS JF, 1989, J AM COLL CARDIOL, V13, P36, DOI 10.1016/0735-1097(89)90545-7; LORELL BH, 1982, CIRCULATION, V65, P499, DOI 10.1161/01.CIR.65.3.499; LOUIE EK, 1986, J AM COLL CARDIOL, V8, P57, DOI 10.1016/S0735-1097(86)80092-4; LOUIE EK, 1994, PROG CARDIOVASC DIS, V36, P275, DOI 10.1016/S0033-0620(05)80036-2; MACRAE CA, 1995, J CLIN INVEST, V96, P1216, DOI 10.1172/JCI118154; MARIAN AJ, 1995, CIRCULATION, V92, P1336, DOI 10.1161/01.CIR.92.5.1336; MARON BJ, 1976, CIRCULATION, V53, P9, DOI 10.1161/01.CIR.53.1.9; MARON BJ, 1978, CIRCULATION, V57, P1205, DOI 10.1161/01.CIR.57.6.1205; MARON BJ, 1994, J AM COLL CARDIOL, V24, P880, DOI 10.1016/0735-1097(94)90844-3; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; MARON BJ, 1995, CIRCULATION, V92, P2748, DOI 10.1161/01.CIR.92.9.2748; MARON BJ, 1993, AM J CARDIOL, V72, P970, DOI 10.1016/0002-9149(93)91117-Z; MARON BJ, 1981, AM J CARDIOL, V48, P252, DOI 10.1016/0002-9149(81)90604-4; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MARON BJ, 1978, AM J CARDIOL, V41, P1133, DOI 10.1016/0002-9149(78)90870-6; MARON BJ, 1986, NEW ENGL J MED, V315, P610, DOI 10.1056/NEJM198609043151003; MARON BJ, 1986, J AM COLL CARDIOL, V8, P545, DOI 10.1016/S0735-1097(86)80181-4; MARON BJ, 1979, AM J CARDIOL, V43, P1086, DOI 10.1016/0002-9149(79)90139-5; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; MARWICK TH, 1992, J AM COLL CARDIOL, V20, P1066, DOI 10.1016/0735-1097(92)90359-U; McCully RB, 1996, CIRCULATION, V94, P467, DOI 10.1161/01.CIR.94.3.467; MCDONALD K, 1988, EUR HEART J, V9, P893, DOI 10.1093/oxfordjournals.eurheartj.a062584; MCINTOSH CL, 1989, ANN THORAC SURG, V47, P236, DOI 10.1016/0003-4975(89)90277-4; MCINTOSH CL, 1988, CIRCULATION, V78, P487, DOI 10.1161/01.CIR.78.3.487; MCINTOSH CL, 1992, CIRCULATION, V86, P60; MCKENNA W, 1982, BRIT HEART J, V47, P177; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MCKENNA WJ, 1988, J AM COLL CARDIOL, V11, P147, DOI 10.1016/0735-1097(88)90181-7; MCKENNA WJ, 1981, BRIT HEART J, V46, P168; MCKENNA WJ, 1985, BRIT HEART J, V53, P412; MCKENNA WJ, 1980, AM J CARDIOL, V45, P1, DOI 10.1016/0002-9149(80)90212-X; MCKENNA WJ, 1984, AM J CARDIOL, V54, P802, DOI 10.1016/S0002-9149(84)80212-X; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; MORROW AG, 1975, CIRCULATION, V52, P88, DOI 10.1161/01.CIR.52.1.88; NICOD P, 1988, NEW ENGL J MED, V318, P1255, DOI 10.1056/NEJM198805123181907; NIENABER CA, 1990, J AM COLL CARDIOL, V15, P948, DOI 10.1016/0735-1097(90)90222-B; NIHOYANNOPOULOS P, 1992, J AM COLL CARDIOL, V19, P536, DOI 10.1016/S0735-1097(10)80268-2; Nishimura RA, 1996, J AM COLL CARDIOL, V27, P421, DOI 10.1016/0735-1097(95)00445-9; Nishimura RA, 1997, J AM COLL CARDIOL, V29, P435, DOI 10.1016/S0735-1097(96)00473-1; NUNAIN SO, 1995, CIRCULATION, V91, P2204, DOI 10.1161/01.CIR.91.8.2204; OGARA PT, 1987, CIRCULATION, V76, P1214, DOI 10.1161/01.CIR.76.6.1214; PASTERNAC A, 1982, CIRCULATION, V65, P778, DOI 10.1161/01.CIR.65.4.778; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; POLLICK C, 1982, NEW ENGL J MED, V307, P997, DOI 10.1056/NEJM198210143071607; POWELL AC, 1993, CIRCULATION, V88, P1083, DOI 10.1161/01.CIR.88.3.1083; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; Robbins RC, 1996, J THORAC CARDIOV SUR, V111, P586, DOI 10.1016/S0022-5223(96)70310-0; ROBINSON K, 1990, J AM COLL CARDIOL, V15, P1279, DOI 10.1016/S0735-1097(10)80014-2; ROSING DR, 1979, CIRCULATION, V60, P1208, DOI 10.1161/01.CIR.60.6.1208; SADOUL N, IN PRESS CIRCULATION; SANDERSON JE, 1977, BRIT HEART J, V39, P661; SAUMAREZ RC, 1995, CIRCULATION, V91, P2762, DOI 10.1161/01.CIR.91.11.2762; SCHAPIRA JN, 1978, CIRCULATION, V58, P850, DOI 10.1161/01.CIR.58.5.850; SCHOENDUBE FA, 1995, CIRCULATION, V92, P122, DOI 10.1161/01.CIR.92.9.122; SCHULTE HD, 1993, J THORAC CARDIOV SUR, V106, P709, DOI 10.1016/S0022-5223(19)33715-8; SCHWARTZ K, 1995, CIRCULATION, V91, P532, DOI 10.1161/01.CIR.91.2.532; Seidman CE, 1995, MOL CARDIOVASCULAR M, P193; SHAH PM, 1972, CIRCULATION, V45, P516, DOI 10.1161/01.CIR.45.3.516; SHAPIRO LM, 1983, BRIT HEART J, V50, P530; SHIRANI J, 1993, AM J CARDIOL, V72, P434, DOI 10.1016/0002-9149(93)91136-6; SIEGMAN IL, 1989, J AM COLL CARDIOL, V13, P1527, DOI 10.1016/0735-1097(89)90343-4; SIGWART U, 1995, LANCET, V346, P211, DOI 10.1016/S0140-6736(95)91267-3; Slade AKB, 1996, HEART, V75, P44, DOI 10.1136/hrt.75.1.44; SPIRITO P, 1984, CIRCULATION, V70, P984, DOI 10.1161/01.CIR.70.6.984; SPIRITO P, 1983, CIRCULATION, V67, P1100, DOI 10.1161/01.CIR.67.5.1100; SPIRITO P, 1994, CIRCULATION, V90, P2743, DOI 10.1161/01.CIR.90.6.2743; SPIRITO P, 1987, AM J CARDIOL, V60, P123, DOI 10.1016/0002-9149(87)90998-2; SPIRITO P, 1985, CIRCULATION, V72, P310, DOI 10.1161/01.CIR.72.2.310; SPIRITO P, 1995, CIRCULATION, V92, P1670; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; SPIRITO P, 1989, J AM COLL CARDIOL, V13, P820, DOI 10.1016/0735-1097(89)90222-2; SPIRITO P, 1990, J AM COLL CARDIOL, V15, P1521, DOI 10.1016/0735-1097(90)92820-R; SPIRITO P, 1987, J AM COLL CARDIOL, V9, P1013, DOI 10.1016/S0735-1097(87)80301-7; SPIRITO P, 1986, J AM COLL CARDIOL, V8, P537, DOI 10.1016/S0735-1097(86)80180-2; SPIRITO P, 1992, AM J CARDIOL, V69, P1217, DOI 10.1016/0002-9149(92)90939-V; SPIRITO P, 1987, AM J CARDIOL, V60, P1137, DOI 10.1016/0002-9149(87)90406-1; STEWART S, 1968, CIRCULATION, V37, P8, DOI 10.1161/01.CIR.37.1.8; TENBERG JM, 1994, CIRCULATION, V90, P1781, DOI 10.1161/01.CIR.90.4.1781; TENCATE FJ, 1983, CIRCULATION, V68, P1274, DOI 10.1161/01.CIR.68.6.1274; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; THOMPSON DS, 1980, BRIT HEART J, V44, P488; UDELSON JE, 1989, CIRCULATION, V79, P1052, DOI 10.1161/01.CIR.79.5.1052; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, CIRCULATION, V91, P2302, DOI 10.1161/01.CIR.91.9.2302; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WELLENS HJJ, 1985, CIRCULATION, V72, P1, DOI 10.1161/01.CIR.72.1.1; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; WILLIAMS WG, 1987, CIRCULATION, V76, P104; ZIPES DP, 1995, CIRCULATION, V91, P2115, DOI 10.1161/01.CIR.91.8.2115	152	688	749	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					775	785		10.1056/NEJM199703133361107	http://dx.doi.org/10.1056/NEJM199703133361107			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM640	9052657	Green Submitted, Green Published			2022-12-28	WOS:A1997WM64000007
J	Snowdon, DA; Greiner, LH; Mortimer, JA; Riley, KP; Greiner, PA; Markesbery, WR				Snowdon, DA; Greiner, LH; Mortimer, JA; Riley, KP; Greiner, PA; Markesbery, WR			Brain infarction and the clinical expression of Alzheimer disease - The nun study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VASCULAR DEMENTIA; NEUROFIBRILLARY TANGLES; CONSORTIUM; ESTABLISH; REGISTRY; PLAQUES; CERAD; POPULATION	Objective.-To determine the relationship of brain infarction to the clinical expression of Alzheimer disease (AD). Design.-Cognitive function and the prevalence of dementia were determined for participants in the Nun Study who later died. At autopsy, lacunar and larger brain infarcts were identified, and senile plaques and neurofibrillary tangles in the neocortex were quantitated, Participants with abundant senile plaques and some neurofibrillary tangles in the neocortex were classified as having met the neuropathologic criteria for AD. Setting.-Convents in the Midwestern, Eastern, and Southern United States. Participants.-A total of 102 college-educated women aged 76 to 100 years. Main Outcome Measures.-Cognitive function assessed by standard tests and dementia and AD assessed by clinical and neuropathologic criteria. Results.-Among 61 participants who met the neuropathologic criteria for AD, those with brain infarcts had poorer cognitive function and a higher prevalence of dementia than those without infarcts. Participants with lacunar infarcts in the basal ganglia, thalamus, or deep white matter had an especially high prevalence of dementia, compared with those without infarcts (the odds ratio [OR] for dementia was 20.7, 95% confidence interval [95% CI], 1.5-288.0). Fewer neuropathologic lesions of AD appeared to result in dementia in those with lacunar infarcts in the basal ganglia, thalamus, or deep white matter than in those without infarcts. In contrast, among 41 participants who did not meet the neuropathologic criteria for AD, brain infarcts were only weakly associated with poor cognitive function and dementia. Among all 102 participants, atherosclerosis df the circle of Willis was strongly associated with lacunar and large brain infarcts. Conclusion.-These findings suggest that cerebrovascular disease may play an important role in determining the presence and severity of the clinical symptoms of AD.	UNIV KENTUCKY,COLL MED,DEPT PREVENT MED,LEXINGTON,KY 40536; UNIV KENTUCKY,COLL MED,DEPT PATHOL,LEXINGTON,KY 40536; UNIV KENTUCKY,COLL MED,DEPT NEUROL,LEXINGTON,KY 40536; FAIRFIELD UNIV,SCH NURSING,FAIRFIELD,CT 06430; UNIV S FLORIDA,INST AGING,TAMPA,FL	University of Kentucky; University of Kentucky; University of Kentucky; Fairfield University; State University System of Florida; University of South Florida	Snowdon, DA (corresponding author), UNIV KENTUCKY,SANDERS BROWN CTR AGING,COLL MED,101 SANDERS BROWN BLDG,LEXINGTON,KY 40536, USA.				NATIONAL INSTITUTE ON AGING [P50AG005144, R01AG009862, K04AG000553] Funding Source: NIH RePORTER; NIA NIH HHS [KO4AG00553, 5P50AG05144, R01AG09862] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIERER LM, 1995, ARCH NEUROL-CHICAGO, V52, P81, DOI 10.1001/archneur.1995.00540250089017; BOURAS C, 1994, CEREB CORTEX, V4, P138, DOI 10.1093/cercor/4.2.138; BOWLER JV, 1995, BAILLIERE CLIN NEUR, V4, P357; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; CRYSTAL H, 1988, NEUROLOGY, V38, P1682, DOI 10.1212/WNL.38.11.1682; GARCIA JH, 1992, J NEUROL SCI, V109, P121, DOI 10.1016/0022-510X(92)90158-H; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KURIANSKY J, 1976, INT J AGING HUM DEV, V7, P343, DOI 10.2190/X45L-TWW7-WXXY-KA6K; LARSON EB, 1993, NEW ENGL J MED, V328, P203, DOI 10.1056/NEJM199301213280308; MARKESBERY WR, 1991, ALZ DIS ASSOC DIS, V5, P149, DOI 10.1097/00002093-199100520-00012; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; NAGY Z, 1995, DEMENTIA, V6, P21, DOI 10.1159/000106918; POTVIN AR, 1972, ARCH PHYS MED REHAB, V53, P476; POTVIN AR, 1972, ARCH PHYS MED REHAB, V53, P498; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; *SAS I INC, 1990, SAS STAT US GUID VER, P1024; *SAS I INC, 1958, ECONOMETRICA, V26, P24; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Tatemichi Thomas K., 1994, P123; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; WOLF PA, 1991, STROKE, V22, P312, DOI 10.1161/01.STR.22.3.312	26	1873	1929	1	83	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					813	817		10.1001/jama.277.10.813	http://dx.doi.org/10.1001/jama.277.10.813			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM082	9052711				2022-12-28	WOS:A1997WM08200034
J	Neuman, WR				Neuman, WR			Resurrection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					696	696						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042825				2022-12-28	WOS:A1997WK02600002
J	Camargo, CA; Stampfer, MJ; Glynn, RJ; Grodstein, F; Gaziano, JM; Manson, JE; Buring, JE; Hennekens, CH				Camargo, CA; Stampfer, MJ; Glynn, RJ; Grodstein, F; Gaziano, JM; Manson, JE; Buring, JE; Hennekens, CH			Moderate alcohol consumption and risk for angina pectoris or myocardial infarction in US male physicians	ANNALS OF INTERNAL MEDICINE			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; CHOLESTEROL	Background: Although previous studies have found that moderate alcohol intake decreases the risk for myocardial infarction, many clinicians question the validity of this finding. Furthermore, the relation of moderate drinking to the risk for other events, such as angina pectoris, is not known, Objective: To determine whether moderate alcohol in take decreases the risk for angina pectoris or myocardial infarction in apparently healthy men. Design: Prospective cohort study. Setting: United States. Participants: 22 071 apparently healthy male physicians who were 40 to 84 years of age between 1981 and 1984. Measurements: Responses to annual questionnaires. Results: Through 1994, 1368 cases of new-onset angina and 690 cases of myocardial infarction had been documented. In multivariate analyses that controlled for several potential confounders, alcohol intake was strongly and inversely associated with the risk for each event (P for trend < 0.001). Compare with men who consumed less than one drink per week, those who consumed one drink per day had relative risks of 0.69 (95% CI, 0.59 to 0.81) for angina and 0.65 (CI, 0.52 to 0.81) for myocardial infarction. These associations were seen when either nondrinkers or occasional drinkers were used as the reference group. Conclusions: Moderate drinking decreases the risk for angina pectoris and myocardial infarction in apparently heal-thy men.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, DIV PREVENT MED, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02215 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health			Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAMARGO CA, 1985, JAMA-J AM MED ASSOC, V253, P2854; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; COLDITZ GA, 1991, AM J CLIN NUTR, V54, P49, DOI 10.1093/ajcn/54.1.49; COX DR, 1972, J R STAT SOC B, V34, P187; *DIET GUID ADV COM, 1995, NUTR HLTH DIET GUID; *GALL POLL, 1992, GALL POLL NEWS SERV; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; Hennekens C.H., 1987, EPIDEMIOLOGY MED; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MIDANIK LT, 1988, BRIT J ADDICT, V83, P1019; *NAT I ALC AB ALC, 1993, 8 SPEC REP US C ALC; *NAT I ALC AB ALC, 1992, ALC AL MOD DRINK; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; ROSNER B, 1992, AM J EPIDEMIOL, V136, P1400, DOI 10.1093/oxfordjournals.aje.a116453; SHAPER AG, 1993, AM J PUBLIC HEALTH, V83, P799, DOI 10.2105/AJPH.83.6.799; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1993, AM J PUBLIC HEALTH, V83, P801, DOI 10.2105/AJPH.83.6.801; STEINBERG D, 1991, ANN INTERN MED, V114, P967, DOI 10.7326/0003-4819-114-11-967; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; World Health Organization, 1971, IHD REG REP 5 WORK G	24	106	108	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					372	375		10.7326/0003-4819-126-5-199703010-00005	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL104	9054281				2022-12-28	WOS:A1997WL10400005
J	Harris, J				Harris, J			The case against: What the principal objective of the NHS should really be	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL,CTR SOCIAL ETH & POLICY,LIVERPOOL,MERSEYSIDE,ENGLAND	University of Liverpool	Harris, J (corresponding author), UNIV MANCHESTER,INST MED LAW & BIOETH,MANCHESTER M13 9PL,LANCS,ENGLAND.								0	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					669	672		10.1136/bmj.314.7081.669	http://dx.doi.org/10.1136/bmj.314.7081.669			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066487	Green Published			2022-12-28	WOS:A1997WL41800038
J	Taddio, A; Katz, J; Ilersich, AL; Koren, G				Taddio, A; Katz, J; Ilersich, AL; Koren, G			Effect of neonatal circumcision on pain response during subsequent routine vaccination	LANCET			English	Article							FULL-TERM; INFANTS; CRY; EXPRESSION; ANESTHESIA; PREMATURE; NEWBORNS; STATES; SLEEP	Background Preliminary studies suggested that pain experienced by infants in the neonatal period may have long-lasting effects on future infant behaviour. The objectives of this study were to find out whether neonatal circumcision altered pain response at 4-month or 6-month vaccination compared with the response in uncircumcised infants, and whether pretreatment of circumcision pain with lidocaine-prilocaine cream (Emla) affects the subsequent vaccination response. Methods We used a prospective cohort design to study 87 infants, The infants formed three groups-uncircumcised infants, and infants who had been randomly assigned Emla or placebo in a previous clinical trial to assess the efficacy of Emla cream as pretreatment for pain in neonatal circumcision, Infants were Videotaped during vaccination done at the primary care physician's clinic, Videotapes were scored without knowledge of circumcision or treatment status by a research assistant who had been trained to measure infant facial action, cry duration, and visual analogue scale pain scores. Findings Birth characteristics and infant characteristics at the time of vaccination, including age and temperament scores, did not differ significantly among groups. Multivariate ANOVA revealed a significant group effect (p<0.001) in difference (vaccination minus baseline) values for percentage facial action, percentage cry time, and visual analogue scale pain scores, Univariate ANOVAs were significant for all outcome measures (p<0.05): infants circumcised with placebo had higher difference scores than uncircumcised infants for percentage facial action (136.9 vs 77.5%), percentage cry duration (53.8 vs 24.7%), and visual analogue scale pain scores (5.1 vs 3.1 cm). There was a significant linear trend on ail outcome measures, showing increasing pain scores from uncircumcised infants, to those circumcised with Emla, to those circumcised with placebo. Interpretation Circumcised infants showed a stronger pain response to subsequent routine vaccination than uncircumcised infants. Among the circumcised group, preoperative treatment with Emla attenuated the pain response to vaccination. We recommend treatment to prevent neonatal circumcision pain.	HOSP SICK CHILDREN, DEPT PAEDIAT, DIV CLIN PHARMACOL & TOXICOL, TORONTO, ON M5G 1X8, CANADA; TORONTO HOSP, DEPT PSYCHOL, TORONTO, ON, CANADA; UNIV TORONTO, FAC PHARM, DEPT BEHAV SCI & ANAESTHESIA, TORONTO, ON M5S 1A1, CANADA; UNIV TORONTO, FAC PHARM, DEPT HLTH ADM, TORONTO, ON M5S 1A1, CANADA; UNIV TORONTO, DEPT PAEDIAT, TORONTO, ON M5S 1A1, CANADA; UNIV TORONTO, FAC MED, TORONTO, ON M5S 1A1, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto			Koren, Gideon/AAG-7726-2019; Katz, Joel/HDO-1635-2022; Katz, Joel/J-7015-2014	Koren, Gideon/0000-0002-9234-0875; Katz, Joel/0000-0002-8686-447X				ALS H, 1994, JAMA-J AM MED ASSOC, V272, P853, DOI 10.1001/jama.272.11.853; Altman D.G., 1991, PRACTICAL STAT MED R; ANDERS TF, 1974, PSYCHOSOM MED, V36, P174, DOI 10.1097/00006842-197403000-00009; [Anonymous], 1989, PEDIATRICS, V84, P388; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; CAREY WB, 1978, PEDIATRICS, V61, P735; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; CRAIG KD, 1988, CAN J BEHAV SCI, V20, P442, DOI 10.1037/h0079934; DAHL JB, 1992, BRIT J ANAESTH, V69, P117, DOI 10.1093/bja/69.2.117; EMDE RN, 1971, PSYCHOSOM MED, V33, P491, DOI 10.1097/00006842-197111000-00002; FITZGERALD M, 1989, PAIN, V39, P31, DOI 10.1016/0304-3959(89)90172-3; GRUNAU RVE, 1994, PAIN, V56, P353, DOI 10.1016/0304-3959(94)90174-0; GRUNAU RVE, 1990, PAIN, V42, P295, DOI 10.1016/0304-3959(90)91142-6; GRUNAU RVE, 1987, PAIN, V28, P395, DOI 10.1016/0304-3959(87)90073-X; GRUNAU RVE, 1996, PEDIATR RES, V39, P266; HOWARD CR, 1996, ARCH PEDIAT ADOLESC, V150, P42; JOHNSTON CC, 1993, PAIN, V52, P201, DOI 10.1016/0304-3959(93)90132-9; KATZ J, 1993, MOTIV EMOTION, V17, P147, DOI 10.1007/BF00992218; KATZ J, 1994, PAIN, V59, P395, DOI 10.1016/0304-3959(94)90026-4; MARSHALL RE, 1982, EARLY HUM DEV, V7, P367, DOI 10.1016/0378-3782(82)90038-X; PHAROAH POD, 1994, ARCH DIS CHILD, V70, P264, DOI 10.1136/adc.70.4.264; SCHOEN EJ, 1990, NEW ENGL J MED, V322, P1308, DOI 10.1056/NEJM199005033221810; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; TADDIO A, 1995, LANCET, V345, P291, DOI 10.1016/S0140-6736(95)90278-3; TADDIO A, 1994, J PEDIATR-US, V124, P643, DOI 10.1016/S0022-3476(05)83150-6; TADDIO A, IN PRESS N ENGL J ME; Toffler W L, 1990, J Am Board Fam Pract, V3, P171; WELLINGTON N, 1993, PEDIATRICS, V92, P541; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	30	720	745	1	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	1997	349	9052					599	603		10.1016/S0140-6736(96)10316-0	http://dx.doi.org/10.1016/S0140-6736(96)10316-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK915	9057731	Green Submitted			2022-12-28	WOS:A1997WK91500009
J	Vaizey, CJ; Kamm, MA; Bartram, CI				Vaizey, CJ; Kamm, MA; Bartram, CI			Primary degeneration of the internal anal sphincter as a cause of passive faecal incontinence	LANCET			English	Article							NEUROGENIC FECAL INCONTINENCE; ENDOSONOGRAPHY; STIMULATION; MANOMETRY; SYMPTOMS; DAMAGE	Background Faecal incontinence is usually attributed to pelvic-floor denervation of striated muscle or direct sphincter trauma. We have identified a cause of passive faecal incontinence related to degeneration of the internal anal sphincter smooth muscle, in the absence of denervation, structural damage, external-sphincter weakness, or sensory abnormalities. Methods Patients were included on the basis of: passive faecal incontinence, no urge faecal incontinence, low anal pressure whilst at rest, normal anal-squeeze pressure, endosonographically confirmed circumferentially intact internal and external anal sphincters, and normal pudendal nerve terminal nerve latencies. In a second analysis done to assess the proportion of patients with this disorder, we recorded the cause of incontinence in consecutive patients seen during a 6-month period. Findings 45 patients (35 women, median age 63 years, range 23-80 years) fulfilled the diagnostic criteria. Median duration of symptoms was 2 years (3 months to 20 years). Nine of the 35 women were nulliparous. The median resting anal pressure was 40 cm water (16-56 cm water, normal >60 cm water). Endosonography revealed an internal sphincter that was thin and hyperechogenic, and had a poorly defined edge. The normal increase in the thickness of the internal anal sphincter with age was not seen, Anal-squeeze pressure, sensitivity, and pudendal nerve latencies were normal. In the second analysis the condition was identified in eight of 230 patients, representing 4% of new referrals. Interpretation Primary degeneration of the internal anal sphincter smooth muscle is a discrete clinical condition causing passive faecal incontinence.	ST MARKS HOSP,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London								BAETEN CGMI, 1995, NEW ENGL J MED, V332, P1600, DOI 10.1056/NEJM199506153322403; BARTOLO DCC, 1983, GASTROENTEROLOGY, V85, P68; BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; BURNETT SJD, 1991, INT J COLORECTAL DIS, V6, P2, DOI 10.1007/BF00703951; CARRARO PS, 1994, BRIT J SURG, V81, P140, DOI 10.1002/bjs.1800810151; CHERRY DA, 1988, SURG CLIN N AM, V68, P1217; CHRISTIANSEN J, 1992, ANN SURG, V215, P383, DOI 10.1097/00000658-199204000-00013; DELECHENAUT P, 1992, DIS COLON RECTUM, V35, P847, DOI 10.1007/BF02047871; ENGEL AF, 1995, INT J COLORECTAL DIS, V10, P152, DOI 10.1007/BF00298538; ENGEL AF, 1994, GUT, V35, P857, DOI 10.1136/gut.35.6.857; FELTBERSMA RJF, 1994, NETH J MED, V44, P182; JAMESON JS, 1994, BRIT J SURG, V81, P1689, DOI 10.1002/bjs.1800811143; KAMM MA, 1989, GUT, V30, P935, DOI 10.1136/gut.30.7.935; KAMM MA, 1990, DIS COLON RECTUM, V33, P419, DOI 10.1007/BF02156270; KAMM MA, 1994, LANCET, V344, P730, DOI 10.1016/S0140-6736(94)92213-6; KIFF ES, 1984, BRIT J SURG, V71, P614, DOI 10.1002/bjs.1800710817; LUBOWSKI DZ, 1988, GASTROENTEROLOGY, V95, P997, DOI 10.1016/0016-5085(88)90175-8; MILLER R, 1988, BRIT J SURG, V75, P44, DOI 10.1002/bjs.1800750116; PARKS AG, 1977, GUT, V18, P656, DOI 10.1136/gut.18.8.656; SPEAKMAN CTM, 1995, DIS COLON RECTUM, V38, P407, DOI 10.1007/BF02054231; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, CLIN RADIOL, V49, P368, DOI 10.1016/S0009-9260(05)81819-7; WILLIAMS NS, 1990, ANN ROY COLL SURG, V72, P108	23	121	123	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					612	615		10.1016/S0140-6736(96)09188-X	http://dx.doi.org/10.1016/S0140-6736(96)09188-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057734				2022-12-28	WOS:A1997WK91500012
J	LeBaron, CW; Chaney, M; Baughman, AL; Dini, EF; Maes, E; Dietz, V; Bernier, R				LeBaron, CW; Chaney, M; Baughman, AL; Dini, EF; Maes, E; Dietz, V; Bernier, R			Impact of measurement and feedback on vaccination coverage in public clinics, 1988-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNIZATION; PREVENTION; PRESCHOOL; CHILDREN	Objective.-To investigate whether a reported rise in vaccination coverage in Georgia public clinics during the period 1988 through 1994 was artifactual or real and, if real, to determine the extent to which the rise could be associated with a program of measurement and feedback. Design.-Examination of data from Georgia public clinics, doses-administered records, and National Health Interview Surveys. Setting/Participants.-Children attending Georgia public clinics. Intervention.-Measurement of vaccination coverage and feedback to providers. Main Outcome Measure.-Vaccination coverage rates. Results.-For the period 1988 through 1994, 136 004 Georgia public clinic vaccination records for children 21 to 23 months of age were reviewed. Median series-completion rates at public clinics rose from 53% to 89%, while indexes of under-vaccination fell: missed opportunities for simultaneous vaccination (6% to 0%), lost contact for more than 12 months (14% to 1%), and first vaccination more than 1 month late (19% to 8%). According to the independent doses-administered database, the proportion of children starting the primary series very late (greater than or equal to 12 months old) fell from 14% to 6%, and the series-completion index rose from 64% to 83%, suggesting that improvements could not be wholly ascribed to better clinic record keeping. In 1988, vaccination coverage of children 24 months of age in the National Health Interview Survey (NHIS) was 53%, identical to median public clinic coverage in Georgia; in 1993, NHIS coverage was 60%, while median public clinic coverage in Georgia was 90%, suggesting that the rise in coverage in Georgia public clinics exceeded national trends. Patterns within the coverage changes suggest an association with the process of measurement and feedback. Conclusions.-A marked increase in vaccination coverage occurred in Georgia public clinics associated with a program of annual measurement and feedback.	GEORGIA DIV PUBL HLTH,ATLANTA,GA		LeBaron, CW (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,MS E-52,ATLANTA,GA 30333, USA.							*ADV COMM IMM PRAC, 1996, MMWR-MORBID MORTAL W, V45, P219; Berwick DM, 1996, JAMA-J AM MED ASSOC, V275, P877, DOI 10.1001/jama.275.11.877; BUFFINGTON J, 1991, J GEN INTERN MED, V6, P204, DOI 10.1007/BF02598961; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P36; CHANEY M, 1995, MMWR-MORBID MORTAL W, V44, P323; *CTR DIS CONTR PRE, 1994, CLIN ASS SOFTW APPL; DIETRICH AJ, 1992, BRIT MED J, V304, P687, DOI 10.1136/bmj.304.6828.687; Dini E F, 1996, J Public Health Manag Pract, V2, P45; GANGAROSA RE, 1996, 124 ANN M AM PUBL HL, P108; Goldstein KP, 1996, JAMA-J AM MED ASSOC, V276, P56, DOI 10.1001/jama.276.1.56; HERBERT TM, 1996, ARCH PEDIAT ADOLES S, V150, P31; KOUIDES RW, 1993, AM J PREV MED, V9, P250, DOI 10.1016/S0749-3797(18)30723-2; MASSEY J, 1989, VITAL HLTH STAT 2, V110; MCDONALD RR, 1996, ATLANTA J CONST 0407, P1; Morrow R W, 1995, Arch Fam Med, V4, P165, DOI 10.1001/archfami.4.2.165; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; SCHLENKER TL, 1992, JAMA-J AM MED ASSOC, V267, P823, DOI 10.1001/jama.267.6.823; THOMPSON RS, 1995, JAMA-J AM MED ASSOC, V273, P1130, DOI 10.1001/jama.273.14.1130; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833	19	83	84	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					631	635		10.1001/jama.277.8.631	http://dx.doi.org/10.1001/jama.277.8.631			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039880				2022-12-28	WOS:A1997WJ49800030
J	Evans, RH; Mansel, RE; Borysiewicz, LK; Williams, BD				Evans, RH; Mansel, RE; Borysiewicz, LK; Williams, BD			Grand round - University Hospital of Wales, Cardiff - Pyrexia of unknown origin - The difficulty of establishing a diagnosis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ADULT STILLS DISEASE; JUVENILE RHEUMATOID-ARTHRITIS; SERUM FERRITIN; FOLLOW-UP; FEVER; INFECTION; THERAPY		UNIV WALES HOSP, DEPT MED, CARDIFF CF4 4XW, S GLAM, WALES	Cardiff University								AYDINTUG AO, 1992, J RHEUMATOL, V19, P431; BISAGNIFAURE A, 1992, J RHEUMATOL, V19, P1487; BUJAK JS, 1973, MEDICINE, V52, P431, DOI 10.1097/00005792-197309000-00007; BYWATERS EG, 1971, ANN RHEUM DIS, V30, P121, DOI 10.1136/ard.30.2.121; COLEBUNDERS R, 1984, ARCH INTERN MED, V144, P1880, DOI 10.1001/archinte.144.9.1880; CUSH JJ, 1987, ARTHRITIS RHEUM, V30, P186, DOI 10.1002/art.1780300209; GORDON SC, 1982, ANN INTERN MED, V97, P45, DOI 10.7326/0003-4819-97-1-45; HUANG SHK, 1980, CAN MED ASSOC J, V122, P1275; HURST NP, 1983, BMJ-BRIT MED J, V286, P605, DOI 10.1136/bmj.286.6365.605; KASHIWAGI H, 1994, INTERNAL MED, V33, P65, DOI 10.2169/internalmedicine.33.65; KHRAISHI M, 1991, J RHEUMATOL, V18, P1088; LARSON EB, 1984, MEDICINE, V63, P82, DOI 10.1097/00005792-198403000-00002; LARSON EB, 1982, MEDICINE, V61, P269, DOI 10.1097/00005792-198209000-00001; MAGADURJOLY G, 1995, ANN RHEUM DIS, V54, P587, DOI 10.1136/ard.54.7.587; MILLER ML, 1985, ARTHRITIS RHEUM, V28, P146, DOI 10.1002/art.1780280207; OHTA A, 1987, J RHEUMATOL, V14, P1139; PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001; PETERSDORF RG, 1992, ARCH INTERN MED, V152, P21, DOI 10.1001/archinte.152.1.21; POUCHOT J, 1991, MEDICINE, V70, P118, DOI 10.1097/00005792-199103000-00004; SCHWARZEYWILL M, 1992, ANN RHEUM DIS, V51, P683, DOI 10.1136/ard.51.5.683; STEFFE LA, 1983, JAMA-J AM MED ASSOC, V249, P2062, DOI 10.1001/jama.249.15.2062; Still GF., 1897, MED CHIR T, V80, P1; VANDEPUTTE LBA, 1991, BAILLIERE CLIN RHEUM, V5, P263, DOI 10.1016/S0950-3579(05)80283-3; VANREETH C, 1994, J RHEUMATOL, V21, P890; WOUTERS JMGW, 1988, ANN RHEUM DIS, V47, P764, DOI 10.1136/ard.47.9.764; WOUTERS JMGW, 1985, J RHEUMATOL, V12, P791; WOUTERS JMGW, 1986, ARTHRITIS RHEUM, V29, P415, DOI 10.1002/art.1780290316; WOUTERS JMGW, 1986, Q J MED, V61, P1055; YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424	29	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	1997	314	7080					583	586		10.1136/bmj.314.7080.583	http://dx.doi.org/10.1136/bmj.314.7080.583			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055721	Green Published			2022-12-28	WOS:A1997WK21500031
J	Colin, C; Geffroy, L				Colin, C; Geffroy, L			France - The health system: Reform wanted by government and expected by patients	LANCET			English	Article									REG AGCY HOSPITALISAT, BESANCON, FRANCE		Colin, C (corresponding author), UNIV LYON 1, F-69365 LYON, FRANCE.								0	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	1997	349	9054					791	792		10.1016/S0140-6736(97)01388-3	http://dx.doi.org/10.1016/S0140-6736(97)01388-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074590				2022-12-28	WOS:A1997WN12400044
J	Prince, A; Smolensky, P				Prince, A; Smolensky, P			Optimality: From neural networks to universal grammar	SCIENCE			English	Article							CONNECTIONIST SYSTEMS	Can concepts from the theory of neural computation contribute to formal theories of the mind? Recent research has explored the implications of one principle of neural computation, optimization, for the theory of grammar. Optimization over symbolic linguistic structures provides the core of a new grammatical architecture, optimality theory. The proposition that grammaticality equals optimality sheds light on a wide range of phenomena, from the gulf between production and comprehension in child language, to language learnability, to the fundamental questions of linguistic theory: What is it that the grammars of all languages share, and how may they differ?	RUTGERS STATE UNIV,RUTGERS CTR COGNIT SCI,NEW BRUNSWICK,NJ 08903; JOHNS HOPKINS UNIV,DEPT COGNIT SCI,BALTIMORE,MD 21218	Rutgers State University New Brunswick; Johns Hopkins University	Prince, A (corresponding author), RUTGERS STATE UNIV,DEPT LINGUIST,18 SEMINARY PL,NEW BRUNSWICK,NJ 08903, USA.							ARCHANGELI D, 1984, GROUNDED PHONOLOGY; BAHL LR, 1983, IEEE T PATTERN ANAL, V5, P179, DOI 10.1109/TPAMI.1983.4767370; BAUM LE, 1966, ANN MATH STAT, V37, P1559; BURZIO LUIGI, 1994, PRINCIPLES ENGLISH S; BYBEE JL, 1982, LANGUAGE, V58, P265, DOI 10.2307/414099; CHOMSKY N, 1981, LECTURES GOVT BINDIN; CHOMSKY N, 1968, SOUND PATTERN ENGLIS, pCH9; Chomsky Noam, 1968, SOUND PATTERN ENGLIS; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; CHOMSKY Noam, 1986, KNOWLEDGE LANGUAGE I; COHEN MA, 1983, IEEE T SYST MAN CYB, V13, P815, DOI 10.1109/TSMC.1983.6313075; DOLAN CP, 1989, THESIS U CALIFORNIA; GOLDEN RM, 1988, BIOL CYBERN, V59, P109, DOI 10.1007/BF00317773; Goldsmith J.A., 1993, LAST PHONOLOGICAL RU; GRIMSHAW J, IN PRESS LINGUIST IN; Hinton G. E., 1983, Proceedings of the IEEE Computer Society Conference on Computer Vision and Pattern Recognition, P448; HIRSCH MW, 1996, MATH PERSPECTIVES NE, P271; HOPFIELD JJ, 1984, P NATL ACAD SCI-BIOL, V81, P3088, DOI 10.1073/pnas.81.10.3088; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; Jakobson Roman, 1962, SELECTED WRITINGS, V1; KISSEBERTH CW, 1970, LINGUIST INQ, V1, P291; LEGENDRE G, 1990, P ANN C COGN SCI SOC, V12, P884; Legendre G., 1990, P ANN C COGN SCI SOC, V12, P388; LEGENDRE G, IN PRESS WORKING PAP; MCCARTHY J, INP RESS PROSODY MOR; MCCARTHY J, IN PRESS LINGUISTIC; MCCARTHY J, 1996, RUCCSTR32 RUTG U; McCarthy J.J., 1993, RUCCSTR3; McCarthy John J., 1993, YB MORPHOLOGY 1993, P79, DOI DOI 10.1007/978-94-017-3712-8_4; MCCLOSKEY M, 1991, PSYCHOL SCI, V2, P387, DOI 10.1111/j.1467-9280.1991.tb00173.x; NADAS A, 1996, MATH PERSPECTIVES NE, P603; Perlmutter, 1971, DEEP SURFACE STRUCTU; PERLMUTTER DM, 1983, STUDIES RELATIONAL G, V1; PIKE R, 1984, PSYCHOL REV, V9, P281; PIKE R, 1989, CONNECTION SCI, V1, P53; PINKER S, 1988, COGNITION, V28, P73, DOI 10.1016/0010-0277(88)90032-7; Pinker S., 1988, CONNECTIONS SYMBOLS; PLATE TA, 1994, THESIS U TORONTO; PRINCE A, IN PRESS LINGUISTIC; PRINCE A, 1993, RUCCSTR1 RUTG U; PRINCE A, 1991, NOTES CONNECTIONISM; Prince Alan, 1993, OPTIMALITY THEORY CO; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, P216; Samek-Lodovici Vieri., 1996, THESIS RUTGERS U NEW; SMOLENSKY P, 1988, BEHAV BRAIN SCI, V11, P1, DOI 10.1017/S0140525X00052432; Smolensky P, 1996, LINGUIST INQ, V27, P720; Smolensky P., 1986, PARALLEL DISTRIBUTED, V1, P194; SMOLENSKY P, 1996, MATH PERSPECTIVES NE, P245; SMOLENSKY P, 1996, MATH PERSPECTIVES NE, P453; SMOLENSKY P, 1983, P NAT C ART INT AAAI; Stampe D, 1979, DISSERTATION NATURAL; TESAR B, IN PRESS LINGUIST IN; TESAR B, IN PRESS LINGUA; Tesar Bruce., 1993, LEARNABILITY OPTIMAL; Tesar Bruce, 1996, LEARNABILITY OPTIMAL; TRANEL B, 1994, FRENCH LIAISON ELISI; TRUBETSKOI NS, 1939, PRINCIPLES PHONOLOGY; [No title captured]	59	134	136	3	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1604	1610		10.1126/science.275.5306.1604	http://dx.doi.org/10.1126/science.275.5306.1604			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WN123	9054349				2022-12-28	WOS:A1997WN12300031
J	Slooter, AJC; Tang, MX; vanDuijn, CM; Stern, Y; Ott, A; Bell, K; Breteler, MMB; Van Broeckhoven, C; Tatemichi, TK; Tycko, B; Hofman, A; Mayeux, R				Slooter, AJC; Tang, MX; vanDuijn, CM; Stern, Y; Ott, A; Bell, K; Breteler, MMB; Van Broeckhoven, C; Tatemichi, TK; Tycko, B; Hofman, A; Mayeux, R			Apolipoprotein E epsilon 4 and the risk of dementia with stroke - A population-based investigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARADIGM-BASED DIAGNOSIS; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; E POLYMORPHISM; HETEROGENEOUS POPULATION; CEREBROVASCULAR-DISEASE; ALLELE; PREVALENCE; ROTTERDAM; EDUCATION	Objective.-To investigate the association between the apolipoprotein E (APOE) genotypes and dementia in patients with stroke, defined as either vascular dementia (VaD) or Alzheimer disease with cerebrovascular disease (AD with CVD). Design and Setting.-Population-based, case-control study from Rotterdam, the Netherlands, and New York City. Participants.-A total of 187 patients with dementia and stroke were compared with 507 controls similar in age and ethnic group. Main Outcome Measures.-The APOE allele frequencies in patients and controls; the odds ratio of dementia with stroke, VaD, and AD with CVD, adjusted for age, sex, residency, and education; and the percent attributable risk related to the APOE epsilon 4 allele. Results.-Overall, patients with dementia and stroke had a higher APOE epsilon 4 allele frequency than controls. Compared with APOE epsilon 3 homozygote individuals, APOE epsilon 4 homozygotes had a 7-fold increased risk of dementia with stroke (OR=6.9; 95% CI, 1.6-29.4), while APOE epsilon 4 heterozygotes had nearly a 2-fold increase in risk (OR=1.8; 95% CI, 1.2-2.7). Risks associated with APOE epsilon 4 were elevated regardless of the subtype of dementia with stroke or age or sex. The percent attributable risk related to the APOE epsilon 4 allele among demented patients with stroke was 41% overall, 33% among those with VaD, and 44% among those with AD with CVD. Conclusion.-The APOE epsilon 4 allele is a genetic risk factor for dementia with stroke, including VaD and AD with CVD. This may imply shared genetic susceptibility to dementia associated with stroke and AD. Alternatively, the category of patients with dementia and stroke, including VaD as currently defined, may include patients with AD.	COLUMBIA UNIV, SCH PUBL HLTH, GERTRUDE H SERGIEVSKY CTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DEPT NEUROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, TAUB CTR ALZHEIMERS DIS RES, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY 10032 USA; ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS; UNIV ANTWERP, DEPT BIOCHEM, B-2020 ANTWERP, BELGIUM; FLANDER INTERUNIV, INST BIOTECHNOL, BORN BUNGE FDN, NEUROGENET LAB, ANTWERP, BELGIUM	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Erasmus University Rotterdam; University of Antwerp			Breteler, Monique M.B./J-5058-2014; Van Broeckhoven, Christine/M-7853-2019; Van Broeckhoven, Christine/G-8362-2017	Breteler, Monique M.B./0000-0002-0626-9305; Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665; Stern, Yaakov/0000-0001-7542-3241	NATIONAL INSTITUTE ON AGING [R35AG010963, P01AG007232] Funding Source: NIH RePORTER; NIA NIH HHS [AG07232, AG10963] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BETARD C, 1994, NEUROREPORT, V5, P1893, DOI 10.1097/00001756-199410000-00013; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; FRISONI GB, 1994, DEMENTIA, V5, P240, DOI 10.1159/000106730; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HIXSON J, 1991, J LIPID RES, V31, P545; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; KIDA E, 1995, BRAIN RES, V674, P341, DOI 10.1016/0006-8993(94)01467-V; KUUSISTO J, 1995, ARTERIOSCL THROM VAS, V15, P1280, DOI 10.1161/01.ATV.15.9.1280; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MAHIEUX F, 1995, REV NEUROL-FRANCE, V151, P231; MARDER K, 1995, ARCH NEUROL-CHICAGO, V52, P146, DOI 10.1001/archneur.1995.00540260050015; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRRA SS, 1996, ALZHEIMERS DIS CAUSE, P111; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; Pirttila T, 1996, ACTA NEUROL SCAND, V93, P352; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; SAKODA S, 1994, NEUROLOGY, V44, P2420, DOI 10.1212/WNL.44.12.2420; STENGARD JH, 1995, ACTA NEUROL SCAND, V92, P297; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; *US BUR CENS, 1991, CENS POP; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd	32	297	299	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					818	821		10.1001/jama.277.10.818	http://dx.doi.org/10.1001/jama.277.10.818			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM082	9052712				2022-12-28	WOS:A1997WM08200035
J	Stranc, LC; Evans, JA; Hamerton, JL				Stranc, LC; Evans, JA; Hamerton, JL			Chorionic villus sampling and amniocentesis for prenatal diagnosis	LANCET			English	Article							WEEKS GESTATION; WOMEN; RISK; ABNORMALITIES; DEFECTS; CHOICES; TRIAL; CVS		UNIV MANITOBA, FAC MED, DEPT HUMAN GENET, WINNIPEG, MB R3E 0W3, CANADA	University of Manitoba								[Anonymous], 1976, JAMA-J AM MED ASSOC, V236, P1471; BERNASCHEK G, 1995, PRENATAL DIAG, V15, P995, DOI 10.1002/pd.1970151103; BEVIS DCA, 1952, LANCET, V262, P395; Burke B M, 1993, Health Care Women Int, V14, P193; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; *CAN COLL MED GEN, 1993, J SOC OBSTET GYNAE S, V15, P16; CASTELLVIBEL S, 1995, PRENATAL DIAG, V15, P801, DOI 10.1002/pd.1970150903; CRANDALL BF, 1995, PRENATAL DIAG, V15, P339, DOI 10.1002/pd.1970150407; CUTILLO DM, 1994, PRENATAL DIAG, V14, P327, DOI 10.1002/pd.1970140502; DESNICK RJ, 1992, PRENATAL DIAG, V12, P357, DOI 10.1002/pd.1970120505; EIBEN B, 1994, PRENATAL DIAG, V14, P497, DOI 10.1002/pd.1970140615; Evans JA, 1996, LANCET, V347, P484, DOI 10.1016/S0140-6736(96)91131-9; EVANS MI, 1993, FETAL DIAGN THER, V8, P70, DOI 10.1159/000263875; EVANS MI, 1994, J REPROD MED, V39, P77; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; GRANT A, 1991, LANCET, V337, P1491; GRAY RGF, 1995, PRENATAL DIAG, V15, P486, DOI 10.1002/pd.1970150514; HAMERTON J, 1993, RES STUDIES ROAYL CO, V13, P1; HECKERLING PS, 1994, J CLIN EPIDEMIOL, V47, P1215, DOI 10.1016/0895-4356(94)90126-0; HSU LYF, 1984, PRENATAL DIAG, V4, P97, DOI 10.1002/pd.1970040708; Johnson JAM, 1996, FETAL DIAGN THER, V11, P85, DOI 10.1159/000264285; KYLE PM, 1994, ULTRASOUND OBST GYN, V4, P199, DOI 10.1046/j.1469-0705.1994.04030199.x; LAWSON HW, 1994, AM J OBSTET GYNECOL, V171, P1365, DOI 10.1016/0002-9378(94)90162-7; LEDBETTER DH, 1992, PRENATAL DIAG, V12, P317, DOI 10.1002/pd.1970120503; LIPPMAN A, 1992, PRENATAL DIAG, V12, P385, DOI 10.1002/pd.1970120508; NICOLAIDES K, 1994, LANCET, V344, P435, DOI 10.1016/S0140-6736(94)91769-8; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; SMIDTJENSEN S, 1991, PRENATAL DIAG, V11, P529, DOI 10.1002/pd.1970110808; SMIDTJENSEN S, 1992, LANCET, V340, P1237, DOI 10.1016/0140-6736(92)92946-D; TABOR A, 1986, LANCET, V1, P1287	30	22	22	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	1997	349	9053					711	714		10.1016/S0140-6736(96)08169-X	http://dx.doi.org/10.1016/S0140-6736(96)08169-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078211				2022-12-28	WOS:A1997WM08000043
J	Ott, M; Emiliani, S; VanLint, C; Herbein, G; Lovett, J; Chirmule, N; McCloskey, T; Pahwa, S; Verdin, E				Ott, M; Emiliani, S; VanLint, C; Herbein, G; Lovett, J; Chirmule, N; McCloskey, T; Pahwa, S; Verdin, E			Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTERLEUKIN-2 RECEPTOR EXPRESSION; INFECTED INDIVIDUALS; HIV-1 TAT; KAPPA-B; ACTIVATION; TYPE-1; GENE; PROMOTER; REPLICATION	Human immunodeficiency virus-type 1 (HIV-1) infection is characterized by a chronic state of immune hyperactivation in patients. Infection of human peripheral blood lymphocytes with HIV-1 in vitro resulted in increased interleukin-2 (IL-2) secretion in response to T cell activation via the CD3 and CD28 receptors. Expression of the HIV-1 transactivator Tat recapitulated this phenotype and was associated with increased IL-2 secretion in response to costimulation with CD3 plus CD28. IL-2 superinduction by Tat occurred at the transcriptional level, was mediated by the CD28-responsive element in the IL-2 promoter, and was exclusively dependent on the 29 amino acids encoded by the second exon of Tat.	PICOWER INST MED RES,MANHASSET,NY 11030; N SHORE UNIV HOSP,MANHASSET,NY 11030; NYU,SCH MED,MANHASSET,NY 11030	Northwell Health; Northwell Health; North Shore University Hospital; New York University			Verdin, Eric/AAB-7999-2019; Lovett, Jennie/S-2996-2016; Pahwa, Savita/AAA-4900-2019; Emiliani, Stéphane/O-2454-2017	Pahwa, Savita/0000-0002-4470-4216; Emiliani, Stéphane/0000-0001-7344-8429; Ott, Melanie/0000-0002-5697-1274; Lovett, Jennie/0000-0002-3710-9400; Verdin, Eric/0000-0003-3703-3183				ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Graziosi C, 1996, P NATL ACAD SCI USA, V93, P4386, DOI 10.1073/pnas.93.9.4386; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; HAFFAR OK, 1993, P NATL ACAD SCI USA, V90, P11094, DOI 10.1073/pnas.90.23.11094; KINTER AL, 1995, J IMMUNOL, V154, P2448; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OTT M, UNPUB; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; PURI RK, 1995, AIDS RES HUM RETROV, V11, P31, DOI 10.1089/aid.1995.11.31; PURVIS SF, 1992, CELL IMMUNOL, V144, P32, DOI 10.1016/0008-8749(92)90223-C; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; VACCA A, 1994, BIOCHEM BIOPH RES CO, V205, P467, DOI 10.1006/bbrc.1994.2689; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; WECHSLER AS, 1994, J IMMUNOL, V153, P2515; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	30	182	187	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1481	1485		10.1126/science.275.5305.1481	http://dx.doi.org/10.1126/science.275.5305.1481			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045614				2022-12-28	WOS:A1997WM08100047
J	Dunne, MJ; Kane, C; Shepherd, RM; Sanchez, JA; James, RFL; Johnson, PRV; AynsleyGreen, A; Lu, S; Clement, JP; Lindley, KJ; Seino, S; AguilarBryan, L				Dunne, MJ; Kane, C; Shepherd, RM; Sanchez, JA; James, RFL; Johnson, PRV; AynsleyGreen, A; Lu, S; Clement, JP; Lindley, KJ; Seino, S; AguilarBryan, L			Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELLS; SECRETION; CHANNELS		BAYLOR COLL MED,DEPT MED,DIV ENDOCRINOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV SHEFFIELD,DEPT BIOMED SCI,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; UNIV SHEFFIELD,DEPT SURG,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; UNIV LONDON,INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND; CHIBA UNIV,SCH MED,RES CTR PATHOGEN FUNGI & MICROBIAL TOXICOSIS,CHIBA 280,JAPAN; CHIBA UNIV,SCH MED,DIV MOL MED,CTR BIOMED SCI,CHIBA 280,JAPAN	Baylor College of Medicine; Baylor College of Medicine; University of Sheffield; University of Sheffield; University of London; University College London; Chiba University; Chiba University			Tuluc, Petronel/C-2527-2011	Sanchez, Jorge A./0000-0002-0057-435X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguilar-Bryan L, 1996, DIABETES REV, V4, P336; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; BRANDT AM, 1993, COMPOS STRUCT, V25, P51, DOI 10.1016/0263-8223(93)90150-O; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Lebrun P, 1996, J PHARMACOL EXP THER, V277, P156; Lindley KJ, 1996, ARCH DIS CHILD, V74, P373, DOI 10.1136/adc.74.5.373; PERMUTT MA, 1996, DIABETES REV, V4, P347; SEINO S, 1996, DIABETES REV, V4, P177	13	199	208	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					703	706		10.1056/NEJM199703063361005	http://dx.doi.org/10.1056/NEJM199703063361005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041101	Green Published			2022-12-28	WOS:A1997WL41900005
J	Bergelson, JM; Cunningham, JA; Droguett, G; KurtJones, EA; Krithivas, A; Hong, JS; Horwitz, MS; Crowell, RL; Finberg, RW				Bergelson, JM; Cunningham, JA; Droguett, G; KurtJones, EA; Krithivas, A; Hong, JS; Horwitz, MS; Crowell, RL; Finberg, RW			Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5	SCIENCE			English	Article							DECAY-ACCELERATING FACTOR; FIBER; INFECTION; DOMAIN; CELLS; ATTACHMENT; SEQUENCE; INTEGRIN; PROTEIN; VLA-2	A complementary DNA clone has been isolated that encodes a coxsackievirus and adenovirus receptor (CAR). When transfected with CAR complementary DNA, nonpermissive hamster cells became susceptible to coxsackie B virus attachment and infection. Furthermore, consistent with previous studies demonstrating that adenovirus infection depends on attachment of a viral fiber to the target cell, CAR-transfected hamster cells bound adenovirus in a fiber-dependent fashion and showed a 100-fold increase in susceptibility to virus-mediated gene transfer. Identification of CAR as a receptor for these two unrelated and structurally distinct viral pathogens is important for understanding viral pathogenesis and has implications for therapeutic gene delivery with adenovirus vectors.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10461; UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,DEPT CELL BIOL & ANAT,BIRMINGHAM,AL 35294; MED COLL PENN & HAHNEMANN UNIV,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19102	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Alabama System; University of Alabama Birmingham; Drexel University	Bergelson, JM (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV INFECT DIS,44 BINNEY ST,BOSTON,MA 02115, USA.		Finberg, Robert W/E-3323-2010		NCI NIH HHS [CA69703] Funding Source: Medline; NIAID NIH HHS [AI31628, AI35667] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031628, R01AI035667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAI M, 1994, J VIROL, V68, P5925, DOI 10.1128/JVI.68.9.5925-5932.1994; BERGELSON JM, 1993, J VIROL, V67, P6847, DOI 10.1128/JVI.67.11.6847-6852.1993; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; BERGELSON JM, UNPUB; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; CHROBOCZEK J, 1987, VIROLOGY, V161, P549, DOI 10.1016/0042-6822(87)90150-4; CLEMENTS GB, 1995, LANCET, V346, P221, DOI 10.1016/S0140-6736(95)91270-3; CROWELL RL, 1976, CELL MEMBRANE RECEPT, P179; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; GOLDMAN MJ, 1995, J VIROL, V69, P5951, DOI 10.1128/JVI.69.10.5951-5958.1995; Grist N., 1993, VIRAL INFECT HEART, V88, P23; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HORWITZ MS, 1996, VIROLOGY, V2, P2149; HSU KHL, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P271; HSU KHL, 1988, J VIROL, V62, P1647, DOI 10.1128/JVI.62.5.1647-1652.1988; Huang S, 1996, J VIROL, V70, P4502, DOI 10.1128/JVI.70.7.4502-4508.1996; IMRIE CW, 1977, GUT, V18, P53, DOI 10.1136/gut.18.1.53; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREMER EJ, 1995, BRIT MED BULL, V51, P31, DOI 10.1093/oxfordjournals.bmb.a072951; LONBERGHOLM K, 1976, NATURE, V259, P679, DOI 10.1038/259679a0; LONGIARU M, 1981, MOL CELL BIOL, V1, P208, DOI 10.1128/MCB.1.3.208; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9; Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567; MAPOLES JE, 1985, J VIROL, V55, P560, DOI 10.1128/JVI.55.3.560-566.1985; MARTIN AB, 1994, CIRCULATION, V90, P330, DOI 10.1161/01.CIR.90.1.330; Mayr GA, 1997, J VIROL, V71, P412, DOI 10.1128/JVI.71.1.412-418.1997; MELNICK JL, 1996, VIROLOGY, V2, P655; MUCKELBAUER JK, 1995, STRUCTURE, V3, P653, DOI 10.1016/S0969-2126(01)00201-5; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; RADNA RL, 1987, VIRUS RES, V8, P277, DOI 10.1016/0168-1702(87)90001-3; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SAVOIA MC, 1995, PRINCIPLES PRACTICE, V1, P799; SHAFREN DR, 1995, J VIROL, V69, P3873, DOI 10.1128/JVI.69.6.3873-3877.1995; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; TOMKO RP, 1994, CELLULAR RECEPTORS A, P75; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102	39	2360	2499	0	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1320	1323		10.1126/science.275.5304.1320	http://dx.doi.org/10.1126/science.275.5304.1320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036860				2022-12-28	WOS:A1997WK64400047
J	Gallin, JI; Smits, HL				Gallin, JI; Smits, HL			Managing the interface between medical schools, hospitals, and clinical research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To review how academic health centers are coping with the changing environment of health care delivery with special emphasis on the impact of the changing health care system on clinical research. Design.-In response to Health and Human Services Secretary Donna Shalala's 1995 mandated review of the National Institutes of Health (NIH) Warren Grant Magnuson Clinical Center, an NIH review team visited 30 health facilities and government-owned organizations throughout the country. The review team determined what strategies are used by academic health centers to survive and thrive in the changing health care marketplace. The findings have implications for the NIH Clinical Center as well as academic health centers. Conclusions.-Management strategies in successful academic health centers include streamlined governance structures whereby small groups of highly empowered group leaders allow institutions to move quickly and decisively; an active strategic planning process; close integration of hospital and medical school management; heavy investment in information systems; and new structures for patient care delivery. Successful centers are initiating discussions with third-party payers and are implementing new initiatives, such as establishing their own managed care organizations, purchasing physician practices, or owning hospitals. Other approaches include establishing revenue-generating centers for clinical research and new relations with industry. Attention to the infrastructure required to support the training and conduct of clinical research is essential for the future vitality of medical schools.	US DEPT HHS,US HLTH CARE FINANCING ADM,BETHESDA,MD		Gallin, JI (corresponding author), NIH,CTR CLIN,WARREN GRANT MAGNUSON CLIN CTR,BLDG 10,ROOM 2C128,BETHESDA,MD 20892, USA.							Alguire PC, 1996, ANN INTERN MED, V124, P321, DOI 10.7326/0003-4819-124-3-199602010-00007; DELLECAVE T, 1995, INFORM WEEK, V538, P62; *FED RES BANKS, 1995, FCA FUNCT COST PROF; FLEXNER A, 1925, MED ED COMP STUDY, P6; KELLEY W, 1991, CAREERS CLIN RES OBS; SHULTZ HJ, 1996, ANN INTERN MED, V124, P340; SMITS HL, 1996, OPPORTUNITY REVITALI; WEISSLER JC, 1994, CLIN RES, V42, P393	8	30	30	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					651	654						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039884				2022-12-28	WOS:A1997WJ49800034
J	Morrison, C; Woodward, M; Leslie, W; TunstallPedoe, H				Morrison, C; Woodward, M; Leslie, W; TunstallPedoe, H			Effect of socioeconomic group on incidence of, management of, and survival after myocardial infarction and coronary death; Analysis of community coronary event register	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; MORTALITY; WOMEN; RISK; MEN; INTERVENTION; SCOTLAND; OUTCOMES; PROJECT; FINLAND	Objective: To investigate tile effect of socioeconomic group (with reference t Design: Community coronary event register from 1985 to 1991. Setting: City of Glasgow north of the River Clyde, population 196 000. Subjects: 3991 men and 1551 women aged 25-64 years on the Glasgow MONICA coronary event register with definite or fatal possible or unclassifiable events according to the criteria of the World Health Organisation's MONICA project (monitoring trends and determinants in cardiovascular disease). Main outcome measures: Rate of coronary events; proportion of subjects reaching hospital alive; case fatality in admitted patients and in community overall. Results: Event rates increased with age for both sexes and were greater in men than women at all ages. The rate increased 1.7-fold in men and 2.4-fold in women from the least (Q1) to the most (Q4) deprived socioeconomic quarter. The socioeconomic gradient decreased with age and was steeper for women than men. The proportion treated in hospital (66%) decreased with age, was greater in women than men, and decreased in both sexes with increasing deprivation (age standardised odds ratio 0.82 for Q4 v Q1) Case fatality in hospital (20%) increased with age, was greater for women than men when age was standardised, and showed no strong socioeconomic pattern. Overall case fatality in the community (50%) increased with age, was similar between the sexes, and increased from Q1 to Q4 (age standardised odds ratio 1.12 in men, 1.18 in women). Conclusions: Socioeconomic group affects not only death rates from myocardial infarction but also event rates and chance of admission. This should be taken into account when different groups of patients are compared. Because social deprivation is associated with so many more deaths outside hospital, primary and secondary prevention are more likely than acute hospital care to reduce the socioeconomic variation in mortality.	UNIV READING, DEPT APPL STAT, READING RG6 6FN, BERKS, ENGLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CARDIOVASC EPIDEMIOL UNIT, DUNDEE DD1 9SY, SCOTLAND	University of Reading; University of Dundee	Morrison, C (corresponding author), ROYAL INFIRM, MONICA PROJECT, GLASGOW G31 2ER, LANARK, SCOTLAND.		Woodward, Mark/L-6817-2017; Woodward, Mark/D-8492-2015	Woodward, Mark/0000-0001-9800-5296				AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BOSMA H, 1995, INT J EPIDEMIOL, V24, P119, DOI 10.1093/ije/24.1.119; Capewell S, 1996, HEART, V76, P70, DOI 10.1136/hrt.76.1.70; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; Carstairs V., 1991, DEPRIVATION HLTH SCO; COBB LA, 1975, CIRCULATION, V52, P223; DEBACKER G, 1994, J EPIDEMIOL COMMUN H, V48, P344, DOI 10.1136/jech.48.4.344; *DEP HLTH, 1995, HLTH NAT VAR HLTH WH; GAFFNEY B, 1995, BRIT HEART J, V73, P385; GHALI JK, 1993, J NATL MED ASSOC, V85, P180; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; *GRP IT STUD STREP, 1986, LANCET, V1, P397; GRUBB NR, 1995, LANCET, V346, P417, DOI 10.1016/S0140-6736(95)92784-0; HAMMAR N, 1992, SCAND J WORK ENV HEA, V18, P178, DOI 10.5271/sjweh.1590; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; HEBERT PR, 1992, ARCH INTERN MED, V152, P2253, DOI 10.1001/archinte.152.11.2253; KATHLEEN E, 1994, AM J PUBLIC HEALTH, V84, P965, DOI 10.2105/AJPH.84.6.965; KESSON E, 1993, DEPRIVATION USE CHD; Leslie WS, 1996, HEART, V75, P195, DOI 10.1136/hrt.75.2.195; MAYNARD C, 1995, J NATL MED ASSOC, V87, P339; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; McLoone P., 1994, CARSTAIRS SCORES SCO; PEKKANEN J, 1995, BRIT MED J, V311, P589, DOI 10.1136/bmj.311.7005.589; Pell J, 1996, BRIT MED J, V313, P267, DOI 10.1136/bmj.313.7052.267; *REG GEN, 1993, ANN REP REG GEN BIRT; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1992, BRIT MED J, V305, P1554, DOI 10.1136/bmj.305.6868.1554; SMITH WCS, 1990, BRIT HEART J, V64, P295; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; TOFLER GH, 1993, AM J CARDIOL, V71, P1031, DOI 10.1016/0002-9149(93)90568-W; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; TUNSTALLPEDOE H, LANCET, V2, P833; VANDEWERF F, 1990, LANCET, V336, P71; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; WALDEN SM, 1990, ANN INTERN MED, V113, P337, DOI 10.7326/0003-4819-113-5-337; Watt G C, 1993, Health Bull (Edinb), V51, P407; *WHO, 1989, WORLD HLTH STAT ANN; WILHELMSEN L, 1996, CIRCULATION, V17, P1619; WILKINSON P, 1994, BRIT MED J, V309, P566, DOI 10.1136/bmj.309.6954.566; Woodward M, 1996, J EPIDEMIOL COMMUN H, V50, P570, DOI 10.1136/jech.50.5.570	42	143	143	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	1997	314	7080					541	546		10.1136/bmj.314.7080.541	http://dx.doi.org/10.1136/bmj.314.7080.541			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055711	Green Published			2022-12-28	WOS:A1997WK21500020
J	Perros, P; Henderson, AK; Carter, DC; Toft, AD				Perros, P; Henderson, AK; Carter, DC; Toft, AD			Lesson of the week - Are spontaneous hypoglycaemia, raised plasma insulin and C peptide concentrations, and abnormal pancreatic images enough to diagnose insulinoma?	BRITISH MEDICAL JOURNAL			English	Article							FACTITIOUS HYPOGLYCEMIA; TUMORS		ROYAL INFIRM,ENDOCRINE UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; LORN & ISL DIST GEN HOSP,DEPT MED,OBAN PA34 4HH,ARGYLL,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh				Perros, Petros/0000-0001-7320-5574				DOHERTY GM, 1991, SURGERY, V110, P989; FAJANS SS, 1989, ENDOCRIN METAB CLIN, V18, P45, DOI 10.1016/S0889-8529(18)30388-8; GILBEY SG, 1994, JOSLINS DIABETES MEL, P1000; Marks V, 1996, CLIN ENDOCRINOL, V44, P133, DOI 10.1046/j.1365-2265.1996.659478.x; MARKS V, 1993, BAILLIERE CLIN ENDOC, V7, P705, DOI 10.1016/S0950-351X(05)80215-0; MOORE NR, 1995, BRIT J RADIOL, V68, P341, DOI 10.1259/0007-1285-68-808-341; SCARLETT JA, 1977, NEW ENGL J MED, V297, P1029, DOI 10.1056/NEJM197711102971903; SENER A, 1995, DIABETIC MED, V12, P433, DOI 10.1111/j.1464-5491.1995.tb00509.x; TEALE JD, 1989, PRACTICAL DIABETES, V6, P177; VINIK AI, 1991, SURGERY, V109, P1	10	11	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					496	497		10.1136/bmj.314.7079.496	http://dx.doi.org/10.1136/bmj.314.7079.496			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056803	Green Published			2022-12-28	WOS:A1997WJ41900032
J	Hunter, T				Hunter, T			Oncoprotein networks	CELL			English	Review							ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR PROTEIN; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; MALIGNANT TRANSFORMATION; R-RAS; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; CANCER CELLS; E-CADHERIN				Hunter, T (corresponding author), SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Belliveau MJ, 1995, BIOCHEM CELL BIOL, V73, P733, DOI 10.1139/o95-081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DIRENZO MF, 1995, CANCER RES, V55, P1129; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FORNEROD M, 1995, ONCOGENE, V10, P1739; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gao MH, 1996, CANCER RES, V56, P4229; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HATTORI Y, 1992, CANCER RES, V52, P3367; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; HUANG Y, 1995, ONCOGENE, V11, P1255; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LI J, 1995, CANCER RES, V55, P5540; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lopingco MC, 1996, CURR TOP MICROBIOL, V211, P211; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nusse R, 1996, NATURE, V384, P119, DOI 10.1038/384119a0; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2; OYAMA T, 1994, CANCER RES, V54, P6282; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SAEZ R, 1994, ONCOGENE, V9, P2977; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Shawber C, 1996, DEVELOPMENT, V122, P3765; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SMITH M R, 1990, New Biologist, V2, P648; Spitkovsky D, 1996, ONCOGENE, V12, P2549; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	124	617	645	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1997	88	3					333	346		10.1016/S0092-8674(00)81872-3	http://dx.doi.org/10.1016/S0092-8674(00)81872-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039260	Bronze			2022-12-28	WOS:A1997WG47900006
J	Shann, F				Shann, F			Meta-analysis of trials of prophylactic antibiotics for children with measles: Inadequate evidence	BRITISH MEDICAL JOURNAL			English	Article							PNEUMONIA	Objective: To assess whether antibiotics should be given to all children with measles in communities with a high case fatality rate. Design: Meta-analysis of randomised controlled trials that compared routine antibiotic prophylaxis with no antibiotic treatment or selective treatment of pneumonia or sepsis. Subjects: Six trials of children admitted to hospital with measles: five in Glasgow, London, or New York between 1939 and 1954; and one in India in 1967. Main outcome measures: Incidence of pneumonia or sepsis, and mortality. Results: All but one of the trials were unblinded, and randomisation was either not described or was by alternate allocation. Ln four studies, the incidence of pneumonia or sepsis in the control group was similar to that in the antibiotic prophylaxis group; in the other two studies, the incidence of pneumonia or sepsis was unusually high in the control group so these children had a higher complication rate than the antibiotic group. Four of the 764 children given antibiotics died compared with one of the 637 controls (exact odds ratio 4.0, mid-P corrected 95% confidence interval 0.5 to 101.6). Conclusion: The quality of the trials reviewed was poor, and they provide weak evidence for giving antibiotics to all children with measles. Available evidence suggests that, when mortality from measles is high, all children with measles should be treated with vitamin A but antibiotics should be given only if a child has clinical signs of pneumonia or other evidence of sepsis.			Shann, F (corresponding author), ROYAL CHILDRENS HOSP,INTENS CARE UNIT,PARKVILLE,VIC 3052,AUSTRALIA.		Shann, Frank/C-9510-2011					AABY P, 1995, SOC SCI MED, V41, P673, DOI 10.1016/0277-9536(95)00038-9; Anderson T, 1939, Br Med J, V1, P716; *CYT SOFTW CORP, 1992, STATX TURB; De Buse P J, 1969, East Afr Med J, V46, P46; DOVER AS, 1975, JAMA-J AM MED ASSOC, V234, P612, DOI 10.1001/jama.234.6.612; Ellison J B, 1931, Arch Dis Child, V6, P37; Forbes C E, 1973, East Afr Med J, V50, P159; GADOMSKI AM, 1993, PEDIATR INFECT DIS J, V12, P115, DOI 10.1097/00006454-199302000-00002; Gibel H, 1942, J PEDIATR-US, V21, P315, DOI 10.1016/S0022-3476(42)80023-2; GREMILLION DH, 1981, AM J MED, V71, P539, DOI 10.1016/0002-9343(81)90203-5; Hogarth J C, 1939, Br Med J, V1, P718; HUSSEY GD, 1993, J TROP PEDIATRICS, V39, P342, DOI 10.1093/tropej/39.6.342; KARELITZ S, 1951, PEDIATRICS, V7, P193; KARELITZ S, 1954, J PEDIATR-US, V44, P357, DOI 10.1016/S0022-3476(54)80208-3; KASCHULA ROC, 1983, REV INFECT DIS, V5, P395; LAU YL, 1992, J INFECT DIS, V165, P1111, DOI 10.1093/infdis/165.6.1111; MORTON R, 1986, ANN TROP PAEDIATR, V6, P41, DOI 10.1080/02724936.1986.11748409; OLSON RW, 1975, JAMA-J AM MED ASSOC, V232, P363, DOI 10.1001/jama.232.4.363; Prasad R, 1967, Indian Pediatr, V4, P243; SAMB B, 1995, PEDIATR INFECT DIS J, V14, P695, DOI 10.1097/00006454-199508000-00009; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; THOMPSON AR, 1938, LANCET, V1, P991; WEINSTEIN L, 1955, NEW ENGL J MED, V253, P679, DOI 10.1056/NEJM195510202531602; WESLEY A G, 1971, South African Medical Journal, V45, P1402; *WHO, 1987, WKLY EPIDEMIOL REC, V19, P133; World Health Organization, 1995, WORLD HLTH REP 1995; World Health Organization, 1991, TECHN BAS WHO REC MA	27	10	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					334	336		10.1136/bmj.314.7077.334	http://dx.doi.org/10.1136/bmj.314.7077.334			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040321	Green Published			2022-12-28	WOS:A1997WF86100026
J	Dobson, DP; Richmond, NC; Brodholt, JP				Dobson, DP; Richmond, NC; Brodholt, JP			A high-temperature electrical conduction mechanism in the lower mantle phase (Mg,Fe),O1-x	SCIENCE			English	Article							MAGNESIOWUSTITE; SPECTRA; MGO	Measurements of electrical conductivity at high pressure and temperature were taken on the lower mantle phase magnesiowustite with varying Fe3+ content. Although previous measurements at atmospheric pressure suggest Fe2+-Fe3+ hopping (small polaron) as the dominant conductivity mechanism, the present experiments show a change in charge transport mechanism with temperature. The lower temperature measurements are consistent with small polaron conduction, but at higher temperatures, which are more applicable to the lower mantle, a large polaron mechanism is suggested, Because these mechanisms have different temperature and compositional dependencies, this transition has important implications for extrapolation to mantle conditions.			Dobson, DP (corresponding author), UCL, DEPT GEOL SCI, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.		Brodholt, John P/B-7136-2011	Brodholt, John P/0000-0001-7395-5834; Dobson, David/0000-0002-0890-0121				DUBA AG, 1994, GEOPHYS RES LETT, V21, P1643, DOI 10.1029/94GL01165; GOTO T, 1980, PHYS EARTH PLANET IN, V22, P277, DOI 10.1016/0031-9201(80)90044-8; GUYOT F, 1988, EARTH PLANET SC LETT, V90, P52, DOI 10.1016/0012-821X(88)90110-0; HANSEN KW, 1966, J AM CERAM SOC, V49, P100, DOI 10.1111/j.1151-2916.1966.tb13217.x; IRIFUNE T, 1994, NATURE, V370, P131, DOI 10.1038/370131a0; Katsura T, 1996, GEOPHYS RES LETT, V23, P2005, DOI 10.1029/96GL02086; LI XY, 1990, J GEOPHYS RES-SOLID, V95, P21609, DOI 10.1029/JB095iB13p21609; Mao H.-K, 1973, YB CARNEGIE I WASHIN, V72, P554; MAO HK, 1976, PHYS CHEM MINER, P573; OMURA K, 1991, PHYS EARTH PLANET IN, V65, P292, DOI 10.1016/0031-9201(91)90136-6; ROBERTS J, 1995, EOS, V76, pS156; SHERMAN DM, 1991, J GEOPHYS RES-SOLID, V96, P14299, DOI 10.1029/91JB01202; SHERMAN DM, 1985, PHYS CHEM MINER, V12, P161, DOI 10.1007/BF00308210; TULLER HL, 1985, POINT DEFECTS MINERA, P47; VOLCADO L, 1995, PHYS EARTH PLANET IN, V88, P193; Wood BJ, 1996, SCIENCE, V273, P1522, DOI 10.1126/science.273.5281.1522; WOOD BJ, 1991, NATURE, V351, P309, DOI 10.1038/351309a0; XU YN, 1991, PHYS REV B, V43, P4461, DOI 10.1103/PhysRevB.43.4461	18	49	51	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1779	1781		10.1126/science.275.5307.1779	http://dx.doi.org/10.1126/science.275.5307.1779			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065399				2022-12-28	WOS:A1997WP05600037
J	Brakeman, PR; Lanahan, AA; OBrien, R; Roche, K; Barnes, CA; Huganir, RL; Worley, PF				Brakeman, PR; Lanahan, AA; OBrien, R; Roche, K; Barnes, CA; Huganir, RL; Worley, PF			Homer: A protein that selectively binds metabotropic glutamate receptors	NATURE			English	Article							ACTIVITY-REGULATED GENE; SYNAPTIC ACTIVITY; GROWTH-FACTOR; RAT-BRAIN; TRANSCRIPTION; ACTIVATION; LONG; LOCALIZATION; MEMBRANE; STRIATUM	Spatial localization and clustering of membrane proteins is critical to neuronal development and synaptic plasticity. Recent studies have identified a family of proteins, the PDZ proteins, that contain modular PDZ domains and interact with synaptic ionotropic glutamate receptors(1) and ion channels(2). PDZ proteins are thought to have a role in defining the cellular distribution of the proteins that interact with them, Here we report a novel dendritic protein, Homer, that contains a single, PDZ-like domain and binds specifically to the carboxy terminus of phosphoinositide-linked metabotropic glutamate receptors. Homer is highly divergent from known PDZ proteins and seems to represent a novel family. The Homer gene is also distinct from members of the PDZ family in that its expression is regulated as an immediate early gene and is dynamically responsive to physiological synaptic activity, particularly during cortical development. This dynamic transcriptional control suggests that Homer mediates a novel cellular mechanism that regulates metabotropic glutamate signalling.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOCHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; NIH,BETHESDA,MD 20892; UNIV ARIZONA,DEPT PSYCHOL & NEUROL,TUCSON,AZ; UNIV ARIZONA,DIV NEURONAL SYST MEMORY & AGING,TUCSON,AZ	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; University of Arizona; University of Arizona			Roche, Katherine/W-9893-2019	Roche, Katherine/0000-0001-7282-6539				BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BHAT RV, 1993, J PHARMACOL EXP THER, V267, P496; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Flor PJ, 1996, J NEUROCHEM, V67, P58; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; HYMAN SE, 1995, CHEM SENSES, V20, P257, DOI 10.1093/chemse/20.2.257; JOLY C, 1995, J NEUROSCI, V15, P3970; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NEDIVI E, 1993, NATURE, V363, P713; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; NUSSER Z, 1994, NEUROSCIENCE, V61, P421, DOI 10.1016/0306-4522(94)90421-9; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Tsui CC, 1996, J NEUROSCI, V16, P2463; WORLEY PF, 1993, J NEUROSCI, V13, P4776; WORLEY PF, 1990, COLD SH Q B, V55, P213, DOI 10.1101/SQB.1990.055.01.023; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921	28	887	918	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					284	288		10.1038/386284a0	http://dx.doi.org/10.1038/386284a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069287				2022-12-28	WOS:A1997WP00300052
J	Coley, CM; Barry, MJ; Fleming, C; Mulley, AG				Coley, CM; Barry, MJ; Fleming, C; Mulley, AG			Early detection of prostate cancer .1. Prior probability and effectiveness of tests	ANNALS OF INTERNAL MEDICINE			English	Review							DIGITAL RECTAL EXAMINATION; RANDOMLY SELECTED POPULATION; SYSTEMATIC SEXTANT BIOPSIES; OPERATING CHARACTERISTIC CURVES; DEOXYRIBONUCLEIC-ACID PLOIDY; PREDICT PATHOLOGICAL STAGE; COLLEGE-OF-SURGEONS; TERM FOLLOW-UP; RADICAL PROSTATECTOMY; ANTIGEN LEVELS	Purpose: To estimate the prevalence of clinically important prostate cancer and to evaluate the effectiveness of digital rectal examination and measurement of prostate-specific antigen (PSA) in early detection of prostate cancer. Data Sources: Relevant studies were identified from a structured MEDLINE search (1966 to 1995), reviews, bibliographies of retrieved articles, author files, and abstracts. Study Selection: Articles selected for analysis of test effectiveness were prospective cohort studies of early detection that did not have obvious selection bias. Data Extraction: Likelihood ratios for digital rectal examination and PSA measurement were estimated from studies that specified the age distribution of participants. Data Synthesis: In patients who have abnormalities on digital rectal examination, the risk for a large, intracapsular tumor is increased twofold but the risk for extracapsular disease is increased threefold to ninefold. An elevation in PSA level greater than 4 ng/mL increases the odds of intracapsular tumors by as much as threefold and the odds of extracapsular tumors by threefold to fivefold, For studies in which biopsies were done if results of either test were abnormal, 18% to 26% of screened patients had suspicious results, cancer detection rates were approximately 4%, and the positive predictive Value of the tests combined was 15% to 21%. Men who have lower urinary tract symptoms that are consistent with benign prostatic hyperplasia are not more likely to harbor prostate cancer; the specificity of PSA measurement is considerably lower among these men. Conclusions: Larger-volume tumors of the prostate are common among older men. Available tests for the early detection of cancer have limited specificity, which necessitates a relatively high biopsy rate. The positive predictive value of combined digital rectal examination and PSA measurement has been defined, but the negative predictive value is less clear. Measurement of PSA is the most sensitive noninvasive test for prostate cancer, However, digital rectal examination detects cancer that would otherwise be missed by PSA measurement.	MASSACHUSETTS GEN HOSP, MED PRACTICES EVALUAT CTR, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HLTH OUTCOMES ASSOCIATES, VANCOUVER, WA 98685 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					AHRQ HHS [HS-08397] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAMI HO, 1994, LANCET, V343, P958, DOI 10.1016/S0140-6736(94)90071-X; AIHARA M, 1994, UROLOGY, V43, P60, DOI 10.1016/S0090-4295(94)80264-5; ALEXANDER RB, 1989, J UROLOGY, V141, P880, DOI 10.1016/S0022-5347(17)41038-X; ARONOWITZ R, 1995, J GEN INTERN MED, V10, P295, DOI 10.1007/BF02599892; AUS G, 1993, BRIT J UROL, V71, P457, DOI 10.1111/j.1464-410X.1993.tb15992.x; BABAIAN RJ, 1992, CANCER, V69, P1195; BAQUET CR, 1991, J NATL CANCER I, V83, P551, DOI 10.1093/jnci/83.8.551; BARE R, 1994, UROLOGY, V43, P191, DOI 10.1016/0090-4295(94)90043-4; Baron E, 1941, ARCH PATHOL, V32, P787; BARRY MJ, 1995, J UROLOGY, V153, P99, DOI 10.1097/00005392-199501000-00036; BAZINET M, 1994, UROLOGY, V43, P44, DOI 10.1016/S0090-4295(94)80260-2; BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; BENSON MC, 1992, J UROLOGY, V147, P817, DOI 10.1016/S0022-5347(17)37394-9; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRAWER MK, 1993, J UROLOGY, V150, P369, DOI 10.1016/S0022-5347(17)35485-X; BRAWER MK, 1993, J UROLOGY, V150, P106, DOI 10.1016/S0022-5347(17)35409-5; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; BRAWN PN, 1991, CANCER, V68, P1592, DOI 10.1002/1097-0142(19911001)68:7<1592::AID-CNCR2820680721>3.0.CO;2-M; BRETT AS, 1995, J GEN INTERN MED, V10, P266, DOI 10.1007/BF02599885; BRETTON PR, 1994, SOUTH MED J, V87, P720, DOI 10.1097/00007611-199407000-00009; CARTER HB, 1993, UROL CLIN N AM, V20, P665; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CARTER HB, 1989, J UROLOGY, V142, P1008, DOI 10.1016/S0022-5347(17)38971-1; CATALONA WJ, 1994, J UROLOGY, V152, P2037, DOI 10.1016/S0022-5347(17)32300-5; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; CATALONA WJ, 1994, J UROLOGY, V152, P2031, DOI 10.1016/S0022-5347(17)32299-1; CHANCELLOR MB, 1993, UROLOGY, V41, P590, DOI 10.1016/0090-4295(93)90113-O; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHODAK GW, 1989, J UROLOGY, V141, P1136, DOI 10.1016/S0022-5347(17)41192-X; CHUTE CG, 1993, J UROLOGY, V150, P85, DOI 10.1016/S0022-5347(17)35405-8; COFFIELD KS, 1992, J UROLOGY, V147, P822, DOI 10.1016/S0022-5347(17)37395-0; COLEY CM, 1995, UROLOGY, V46, P125, DOI 10.1016/S0090-4295(99)80181-2; COLLINS GN, 1993, BRIT J UROL, V71, P445, DOI 10.1111/j.1464-410X.1993.tb15990.x; COLLINS GN, 1993, BRIT J UROL, V71, P460, DOI 10.1111/j.1464-410X.1993.tb15993.x; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; CRAWFORD ED, 1992, JAMA-J AM MED ASSOC, V267, P2227, DOI 10.1001/jama.267.16.2227; CUPP MR, 1993, MAYO CLIN PROC, V68, P297, DOI 10.1016/S0025-6196(12)60052-4; DALKIN BL, 1993, J UROLOGY, V150, P1837, DOI 10.1016/S0022-5347(17)35910-4; DEMERS RY, 1994, ARCH INTERN MED, V154, P1211, DOI 10.1001/archinte.154.11.1211; DESMOND PM, 1993, J UROLOGY, V150, P1425, DOI 10.1016/S0022-5347(17)35798-1; DHOM G, 1983, J CANCER RES CLIN, V106, P210, DOI 10.1007/BF00402610; EDWARDS CN, 1953, CANCER, V6, P531, DOI 10.1002/1097-0142(195305)6:3<531::AID-CNCR2820060311>3.0.CO;2-9; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; ERCOLE CJ, 1987, J UROLOGY, V138, P1181, DOI 10.1016/S0022-5347(17)43543-9; FLANIGAN RC, 1994, J UROLOGY, V152, P1506, DOI 10.1016/S0022-5347(17)32457-6; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; FRIEDMAN GD, 1991, LANCET, V337, P1526, DOI 10.1016/0140-6736(91)93207-P; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; GARNETT JE, 1984, J UROLOGY, V131, P690, DOI 10.1016/S0022-5347(17)50583-2; GARNICK MB, 1993, ANN INTERN MED, V118, P804, DOI 10.7326/0003-4819-118-10-199305150-00008; GARRAWAY WM, 1991, LANCET, V338, P469, DOI 10.1016/0140-6736(91)90543-X; Gaynor EP, 1938, VIRCHOWS ARCH A, V301, P602, DOI 10.1007/BF02595173; GERBER GS, 1993, JAMA-J AM MED ASSOC, V269, P61, DOI 10.1001/jama.269.1.61; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GOHAGAN JK, 1994, J UROLOGY, V152, P1905, DOI 10.1016/S0022-5347(17)32412-6; GRAVES HCB, 1990, J UROLOGY, V144, P1516, DOI 10.1016/S0022-5347(17)39789-6; GRAVES HCB, 1993, CANCER, V72, P3141, DOI 10.1002/1097-0142(19931201)72:11<3141::AID-CNCR2820721104>3.0.CO;2-1; GREENE DR, 1994, J UROLOGY, V151, P1301, DOI 10.1016/S0022-5347(17)35236-9; GUESS HA, 1993, EUR J CANCER, V29A, P1055, DOI 10.1016/S0959-8049(05)80223-0; Guinan P, 1987, Prog Clin Biol Res, V243A, P551; GUINAN P, 1980, NEW ENGL J MED, V303, P499, DOI 10.1056/NEJM198008283030906; GUSTAFSSON O, 1992, J UROLOGY, V148, P1827, DOI 10.1016/S0022-5347(17)37041-6; GUTHMAN DA, 1993, UROLOGY, V42, P150, DOI 10.1016/0090-4295(93)90638-Q; HALPERT B, 1966, CANCER-AM CANCER SOC, V19, P695, DOI 10.1002/1097-0142(196605)19:5<695::AID-CNCR2820190515>3.0.CO;2-W; HAMMERER P, 1994, J UROLOGY, V151, P99, DOI 10.1016/S0022-5347(17)34880-2; HAMMERER P, 1992, J UROLOGY, V147, P833, DOI 10.1016/S0022-5347(17)37399-8; HELZLSOUER KJ, 1992, CANCER EPIDEM BIOMAR, V1, P537; HOWARDS SS, 1993, JAMA-J AM MED ASSOC, V269, P913, DOI 10.1001/jama.269.7.913; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; HUDSON MA, 1993, ADV UROL, V6, P157; JACOBSEN SJ, 1994, UROLOGY, V44, P512, DOI 10.1016/S0090-4295(94)80049-9; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; JONLER M, 1994, BRIT J UROL, V74, P352, DOI 10.1111/j.1464-410X.1994.tb16626.x; KABALIN JN, 1989, J UROLOGY, V141, P1091, DOI 10.1016/S0022-5347(17)41178-5; KEETCH DW, 1994, J UROLOGY, V151, P1571, DOI 10.1016/S0022-5347(17)35304-1; KLEER E, 1993, UROLOGY, V41, P207, DOI 10.1016/0090-4295(93)90558-R; KLOMP MLF, 1994, BRIT J UROL, V73, P71, DOI 10.1111/j.1464-410X.1994.tb07459.x; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; LANGE PH, 1989, J UROLOGY, V141, P873; LEE JM, 1993, NEW ENGL J MED, V328, P438, DOI 10.1056/NEJM199302113280613; Lookner David H., 1993, Journal of Urology, V149, p414A; Love R R, 1985, Med Decis Making, V5, P263, DOI 10.1177/0272989X8500500303; LUNDBERG S, 1970, Scandinavian Journal of Urology and Nephrology, V4, P93, DOI 10.3109/00365597009137581; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; Marcus Marci Ann, 1993, Clinical Chemistry, V39, P1193; MCNEAL JE, 1986, LANCET, V1, P60; METTLIN C, 1994, J UROLOGY, V152, P1737, DOI 10.1016/S0022-5347(17)32373-X; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; METTLIN C, 1993, CA-CANCER J CLIN, V43, P83, DOI 10.3322/canjclin.43.2.83; METTLIN C, 1991, CANCER, V67, P2949, DOI 10.1002/1097-0142(19910615)67:12<2949::AID-CNCR2820671202>3.0.CO;2-X; METTLIN C, 1993, CANCER, V71, P891, DOI 10.1002/1097-0142(19930201)71:3+<891::AID-CNCR2820711405>3.0.CO;2-X; MILLS SE, 1986, CANCER, V57, P346, DOI 10.1002/1097-0142(19860115)57:2<346::AID-CNCR2820570226>3.0.CO;2-E; MOLD JW, 1992, J FAM PRACTICE, V34, P561; MONTIE JE, 1989, CANCER, V63, P381, DOI 10.1002/1097-0142(19890115)63:2<381::AID-CNCR2820630230>3.0.CO;2-O; MONTIE JE, 1992, SEMIN UROL, V11, P10; MORRISON AS, 1991, INT J EPIDEMIOL, V20, P642, DOI 10.1093/ije/20.3.642; MUSCHENHEIM F, 1991, ANN CLIN LAB SCI, V21, P371; MYERS RP, 1992, J UROLOGY, V147, P910, DOI 10.1016/S0022-5347(17)37420-7; NAITO S, 1988, EUR UROL, V14, P356; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; OESTERLING JE, 1993, UROL CLIN N AM, V20, P671; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; OESTERLING JE, 1995, J UROLOGY, V153, P1160, DOI 10.1016/S0022-5347(01)67538-4; OESTERLING JE, 1993, UROL CLIN N AM, V20, P687; OESTERLING JE, 1993, UROLOGY, V42, P276, DOI 10.1016/0090-4295(93)90616-I; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; OHORI M, 1994, J UROLOGY, V152, P1714, DOI 10.1016/S0022-5347(17)32369-8; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARTIN AW, 1993, J UROLOGY, V150, P110, DOI 10.1016/S0022-5347(17)35410-1; PARTIN AW, 1990, J UROLOGY, V143, P747, DOI 10.1016/S0022-5347(17)40079-6; PEDERSEN KV, 1990, BRIT MED J, V300, P1041, DOI 10.1136/bmj.300.6731.1041; PIENTA KJ, 1993, ANN INTERN MED, V118, P793, DOI 10.7326/0003-4819-118-10-199305150-00007; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Prorok P, 1994, Can J Oncol, V4 Suppl 1, P98; RAINWATER LM, 1990, MAYO CLIN PROC, V65, P1118, DOI 10.1016/S0025-6196(12)62725-6; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; RICHIE JP, 1993, UROLOGY, V42, P365, DOI 10.1016/0090-4295(93)90359-I; RIEHMANN M, 1993, UROLOGY, V42, P390, DOI 10.1016/0090-4295(93)90364-G; Ries L, 1994, NIH PUBLICATION, V94-2789; RIES LAG, 1991, NIH PUB; ROMMEL FM, 1994, J UROLOGY, V151, P88, DOI 10.1016/S0022-5347(17)34878-4; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; RUCKLE HC, 1994, MAYO CLIN PROC, V69, P69, DOI 10.1016/S0025-6196(12)61615-2; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; SCHMIDT JD, 1986, J UROLOGY, V136, P416, DOI 10.1016/S0022-5347(17)44889-0; Schroder F H, 1994, Can J Oncol, V4 Suppl 1, P102; SCOTT R, 1969, J UROLOGY, V101, P602, DOI 10.1016/S0022-5347(17)62388-7; SEMJONOW A, 1994, BRIT J UROL, V73, P538, DOI 10.1111/j.1464-410X.1994.tb07640.x; SERSHON PD, 1994, EUR UROL, V25, P281; SHINOHARA K, 1989, J UROLOGY, V142, P76, DOI 10.1016/S0022-5347(17)38666-4; SHINOHARA K, 1994, J UROLOGY, V152, P120, DOI 10.1016/S0022-5347(17)32832-X; SMITH DS, 1995, UROLOGY, V45, P70, DOI 10.1016/S0090-4295(95)96812-1; SMITH DS, 1994, J UROLOGY, V152, P1732, DOI 10.1016/S0022-5347(17)32372-8; SOX HC, 1994, NEW ENGL J MED, V330, P1589, DOI 10.1056/NEJM199406023302208; SOX HC, 1994, AM J PREV MED, V10, P187, DOI 10.1016/S0749-3797(18)30589-0; SPITZ MR, 1991, J UROLOGY, V146, P1305, DOI 10.1016/S0022-5347(17)38074-6; STAMEY TA, 1994, J UROLOGY, V152, P1510, DOI 10.1016/S0022-5347(17)32458-8; STAMEY TA, 1995, UROLOGY, V45, P2, DOI 10.1016/S0090-4295(95)96168-2; STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L; STEELE GD, 1993, CA-CANCER J CLIN, V43, P71, DOI 10.3322/canjclin.43.2.71; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; STENMAN UH, 1994, LANCET, V344, P1594, DOI 10.1016/S0140-6736(94)90405-7; STILMANT MM, 1993, CANCER, V71, P2041, DOI 10.1002/1097-0142(19930315)71:6<2041::AID-CNCR2820710619>3.0.CO;2-M; TERRIS MK, 1995, UROLOGY, V45, P75, DOI 10.1016/S0090-4295(95)96858-X; TERRIS MK, 1992, J UROLOGY, V148, P829, DOI 10.1016/S0022-5347(17)36735-6; TERRIS MK, 1994, BRIT J UROL, V73, P61; TERRIS MK, 1991, J UROLOGY, V146, P78, DOI 10.1016/S0022-5347(17)37718-2; THOMPSON IM, 1984, J UROLOGY, V132, P690, DOI 10.1016/S0022-5347(17)49828-4; THOMPSON IM, 1992, J UROLOGY, V148, P326, DOI 10.1016/S0022-5347(17)36585-0; VALLANCIEN G, 1989, EUR UROL, V16, P321; VALLANCIEN G, 1991, J UROLOGY, V146, P1308, DOI 10.1016/S0022-5347(17)38076-X; VANDENOUDEN D, 1993, J UROLOGY, V150, P400, DOI 10.1016/S0022-5347(17)35493-9; VARENHORST E, 1992, ACTA ONCOL, V31, P815, DOI 10.3109/02841869209089713; VARENHORST E, 1993, BRIT J UROL, V72, P173, DOI 10.1111/j.1464-410X.1993.tb00682.x; VESSELLA RL, 1992, CLIN CHEM, V38, P2044; VESSELLA RL, 1993, UROL CLIN N AM, V20, P607; VOSS JD, 1994, J GEN INTERN MED, V9, P468, DOI 10.1007/BF02599070; WALSH PC, 1993, ANN INTERN MED, V119, P948, DOI 10.7326/0003-4819-119-9-199311010-00015; WEBB JAW, 1993, BRIT J UROL, V72, P775, DOI 10.1111/j.1464-410X.1993.tb16266.x; WILT TJ, 1994, J UROLOGY, V152, P1910, DOI 10.1016/S0022-5347(17)32413-8; WINTER HI, 1991, UROLOGY, V38, P202, DOI 10.1016/S0090-4295(91)80344-7; WOLF JS, 1993, UROLOGY, V42, P131; YUAN JJJ, 1992, J UROLOGY, V147, P810, DOI 10.1016/S0022-5347(17)37392-5; ZINCKE H, 1994, J UROLOGY, V151, P435, DOI 10.1016/S0022-5347(17)34978-9; 1991, CAN MED ASSOC J, V145, P413	179	141	147	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					394	406		10.7326/0003-4819-126-5-199703010-00010	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00010			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL104	9054286				2022-12-28	WOS:A1997WL10400010
J	Cookson, B				Cookson, B			Controversies - Is it time to stop searching for MRSA? Screening is still important	BRITISH MEDICAL JOURNAL			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; OUTBREAK; EUROPE				Cookson, B (corresponding author), CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,COLINDALE,LONDON NW9 5HT,ENGLAND.							ABOU YZ, 1995, 957 WHO CDS BVI; Asensio A, 1996, INFECT CONT HOSP EP, V17, P20; AYLIFFE GAJ, 1990, J HOSP INFECT, V16, P351; CASEWELL M, 1996, J HOSP INFECT S, V30, P45; COELLO R, 1994, EUR J CLIN MICROBIOL, V13, P74, DOI 10.1007/BF02026130; COOKSON B, 1995, J CHEMOTHERAPY, V7, P93; COOKSON BD, 1993, J MED MICROBIOL, V38, P309, DOI 10.1099/00222615-38-5-309; Cookson BD, 1993, STANDARDS INFECT CON; COOKSON BD, IN PRESS J MED MICRO; COX RA, 1995, J HOSP INFECT, V29, P87, DOI 10.1016/0195-6701(95)90191-4; GOODMAN DA, 1991, AM J MED, V16, P8; HARTSTEIN AI, 1995, INFECT CONT HOSP EP, V16, P257; JOHNSON AP, IN PRESS J MED MICRO; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; RAHRNAN A, 1995, J HOSP INFECT, V30, P76; RICHET H, 1995, 4 M RAP C MED SCI, P101; SHERIDAN RL, 1994, AM J INFECT CONTROL, V22, P340, DOI 10.1016/0196-6553(94)90032-9; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127; WENZEL RP, 1991, AM J MED S3B, V91, P221; 1996, COMMUN DIS REP CDR W, V23, P197	20	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					664	665		10.1136/bmj.314.7081.664	http://dx.doi.org/10.1136/bmj.314.7081.664			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066484	Green Published			2022-12-28	WOS:A1997WL41800034
J	Markson, L; Bloom, P				Markson, L; Bloom, P			Evidence against a dedicated system for word learning in children	NATURE			English	Article								Children can learn aspects of the meaning of a new word on the basis of only a few incidental exposures and can retain this knowledge for a long period-a process dubbed 'fast mapping'(1-8) It is often maintained that fast mapping is the result of a dedicated language mechanism, but it is possible that this same capacity might apply in domains other than language learning, Here we present two experiments in which three- and four-year-old children and adults were taught a novel name and a novel fact about an object, and were tested on their retention immediately, after a 1-week delay or after a 1-month delay. Our findings show that fast mapping is not limited to word learning, suggesting that the capacity to learn and retain new words is the result of learning and memory abilities that are not specific to language.			Markson, L (corresponding author), UNIV ARIZONA,DEPT PSYCHOL,TUCSON,AZ 85721, USA.							BALDWIN DA, 1991, CHILD DEV, V62, P875, DOI 10.2307/1131140; Bloom PB, 1995, CONTEMPORARY INTERNATIONAL HYPNOSIS, P1, DOI 10.1016/0010-0277(94)00648-5; Carey S., 1978, P STANFORD CHILD LAN, V15, P17; Carey S., 1978, LINGUISTIC THEORY PS, P264; CHOMSKY N, 1980, RULES REPRESENTATION, P1; Curtiss S., 1989, INTERACTION HUMAN DE, P105; DICKINSON DK, 1984, APPL PSYCHOLINGUIST, V5, P359, DOI 10.1017/S0142716400005233; DOLLAGHAN CA, 1987, J SPEECH HEAR DISORD, V52, P218, DOI 10.1044/jshd.5203.218; HEIBECK TH, 1987, CHILD DEV, V58, P1021, DOI 10.1111/j.1467-8624.1987.tb01438.x; MARKMAN EM, 1988, COGNITIVE PSYCHOL, V20, P121, DOI 10.1016/0010-0285(88)90017-5; MARKMAN EM, 1989, CATEGORIZATION NAMIN, P1; NEVILLE HJ, 1991, BRAIN MATURATION COG, P355; NEWPORT EL, 1990, COGNITIVE SCI, V14, P11, DOI 10.1207/s15516709cog1401_2; PINKER S, 1994, LANGUAGE INSTINCT, P1; RICE ML, 1990, J SPEECH HEAR DISORD, V55, P33, DOI 10.1044/jshd.5501.33	15	215	215	3	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					813	815		10.1038/385813a0	http://dx.doi.org/10.1038/385813a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WK570	9039912				2022-12-28	WOS:A1997WK57000052
J	Wantz, GE				Wantz, GE			A 65-year-old man with an inguinal hernia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED PROSPECTIVE TRIAL; LOCAL-ANESTHESIA; GROIN HERNIAS; REPAIR; HERNIORRHAPHY; HERNIOPLASTY		CORNELL UNIV,COLL MED,NEW YORK,NY	Cornell University								BENDAVID R, 1995, HERNIA, P217; CO CV, 1993, IN VIVO, V11, P1; DAVIES N, 1994, BRIT J SURG, V81, P1475; DONAHUE PE, 1996, HERNIA, P73; FITZGIBBONS RJ, 1995, ANN SURG, V221, P3, DOI 10.1097/00000658-199501000-00002; FONG Y, 1992, SURG GYNECOL OBSTET, V174, P399; GALLEGOS NC, 1991, BRIT J SURG, V78, P1171, DOI 10.1002/bjs.1800781007; GEIS WP, 1993, SURGERY, V114, P765; GILBERT AI, 1995, PROBL GEN SURG, V12, P209; GILBERT AI, 1991, PERSPECT GEN SURG, V2, P113; GLASSOW F, 1984, ANN ROY COLL SURG, V66, P382; HAY JM, 1995, ANN SURG, V222, P719, DOI 10.1097/00000658-199512000-00005; Hughson W, 1925, SURG GYNECOL OBSTET, V41, P610; KARK AE, 1995, ANN ROY COLL SURG, V77, P299; KINGSNORTH AN, 1992, BRIT J SURG, V79, P1068, DOI 10.1002/bjs.1800791026; LICHTENSTEIN IL, 1989, AM J SURG, V157, P188, DOI 10.1016/0002-9610(89)90526-6; LICHTENSTEIN IL, 1987, AM J SURG, V153, P553, DOI 10.1016/0002-9610(87)90153-X; Liem MSL, 1996, BRIT J SURG, V83, P1197, DOI 10.1002/bjs.1800830907; *NAT CTR HLTH STAT, 1986, VITAL HLTH STAT PUBL, V13; NEHME AE, 1983, AM J SURG, V146, P257, DOI 10.1016/0002-9610(83)90386-0; PAYNE JH, 1994, ARCH SURG-CHICAGO, V129, P973; PEACOCK EE, 1978, HERNIA, P79; Read R.C., 1989, HERNIA, P3; RUSSELL RH, 1906, LANCET, V3, P1197; RUSSELL RH, 1921, BRIT J SURG, V9, P502; RUTKOW IM, 1995, PROBLEMS GEN SURG; STOKER D, 1994, LANCET, V343, P1243, DOI 10.1016/S0140-6736(94)92148-2; TINGWALD GR, 1982, SURG GYNECOL OBSTET, V154, P704; Wantz G., 1989, HERNIA, P236; Wantz GE, 1996, J AM COLL SURGEONS, V183, P351; WANTZ GE, 1989, WORLD J SURG, V13, P516, DOI 10.1007/BF01658864; WANTZ GE, 1993, SURG CLIN N AM, V73, P571; WANTZ GE, 1994, PRINCIPLES SURG, P1517; WILLIAMS JS, 1966, SURG GYNECOL OBSTETR, V122, P100; WILLIAMS M, 1993, HERNIA REPAIR, P1	35	6	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					663	669						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039886				2022-12-28	WOS:A1997WJ49800036
J	Goldman, AP; Kerr, SJ; Butt, W; Marsh, MJ; Murdoch, IA; Paul, T; Firmin, RK; Tasker, RC; Macrae, DJ				Goldman, AP; Kerr, SJ; Butt, W; Marsh, MJ; Murdoch, IA; Paul, T; Firmin, RK; Tasker, RC; Macrae, DJ			Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease	LANCET			English	Article							PEDIATRIC RESPIRATORY-FAILURE; LIFE-SUPPORT; CHILDREN; MORTALITY	Background Meningococcal disease is still associated with considerable mortality, despite the use of early antibiotics and management in specialised intensive care units, due principally to early refractory myocardial depression and hypotension as well as severe acute respiratory distress syndrome. Extracorporeal membrane oxygenation (ECMO) is a complex technology that uses a modified ''heart-lung'' machine to provide temporary cardiac and respiratory support. We reviewed the UK and Australian experience of the use of ECMO in patients with refractory cardiorespiratory failure due to meningococcal disease. Methods The records from all 12 known patients supported with ECMO for meningococcal disease in the UK and Australia since 1989 were reviewed. Findings 12 patients (aged 4 months to 18 years, median 26 months) with meningococcal disease received ECMO over 8 years. In seven patients, ECMO was required early for cardiac support for intractable shock within 36 h of admission to intensive care. In the other five patients, ECMO was indicated for respiratory failure due to severe adult respiratory distress syndrome, which tended to occur later in the disease. The paediatric risk of mortality score ranged from 13 to 40 (median 29, median predicted risk of mortality 72%). Six of the 12 patients required cardiopulmonary resuscitation before ECMO and the other six were deteriorating despite maximal conventional therapy, Overall, eight of the 12 patients survived, with six leading functionally normal lives at a median of 1 year (range 4 months to 4 years) of follow-up. Interpretation ECMO might be considered to support patients with intractable cardiorespiratory failure due to meningococcal disease who are not responding to conventional treatment.	GUYS HOSP,LONDON,ENGLAND; GLENFIELD GEN HOSP,LEICESTER LE3 9QP,LEICS,ENGLAND; ROYAL CHILDRENS HOSP,MELBOURNE,VIC,AUSTRALIA	Guy's & St Thomas' NHS Foundation Trust; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Royal Children's Hospital Melbourne	Goldman, AP (corresponding author), GREAT ORMOND ST HOSP CHILDREN,CARDIAC INTENS CARE UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.		Macrae, Duncan/AAC-9564-2020; Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113; Macrae, Duncan/0000-0002-7158-6585				BECA J, 1994, PEDIATRICS, V93, P726; BELLOMO R, 1993, CRIT CARE MED, V21, P522, DOI 10.1097/00003246-199304000-00011; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Best C, 1996, LANCET, V347, P202, DOI 10.1016/S0140-6736(96)90389-X; Champion MP, 1996, LANCET, V347, P201, DOI 10.1016/S0140-6736(96)90388-8; GIDELMAN LA, 1995, INTENS CARE MED, V21, pS269; GRIFFIN HD, 1991, BRIT POULTRY SCI, V32, P195, DOI 10.1080/00071669108417340; HEYDERMAN RS, 1993, ARCH DIS CHILD, V68, P621, DOI 10.1136/adc.68.5.621; MELIONES JN, 1991, CIRCULATION, V84, P168; Mok Q, 1996, INTENS CARE MED, V22, P259, DOI 10.1007/BF01712247; MOLER FW, 1994, J PEDIATR-US, V124, P875, DOI 10.1016/S0022-3476(05)83174-9; Parrillo J E, 1993, N Engl J Med, V328, P1471; RIVERA RA, 1990, ANAESTH INTENS CARE, V18, P385, DOI 10.1177/0310057X9001800316; TAMBURRO RF, 1991, J PEDIATR-US, V119, P935, DOI 10.1016/S0022-3476(05)83048-3; THOMSON APJ, 1991, CRIT CARE MED, V19, P26, DOI 10.1097/00003246-199101000-00010; TIMMONS OD, 1991, J PEDIATR-US, V119, P896, DOI 10.1016/S0022-3476(05)83039-2; 1995, CDR REV, V5, pR189	17	84	87	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					466	469		10.1016/S0140-6736(96)12106-1	http://dx.doi.org/10.1016/S0140-6736(96)12106-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040577				2022-12-28	WOS:A1997WH38900012
J	Siewert, JR; Fink, U				Siewert, JR; Fink, U			Commentary: Britain does better than Germany before patients reach hospital	BRITISH MEDICAL JOURNAL			English	Editorial Material											Siewert, JR (corresponding author), TECH UNIV MUNICH,DEPT SURG,SECT SURG ONCOL,D-8000 MUNICH,GERMANY.							SCHONBERGER B, 1996, THESIS TU MUNCHEN	1	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					471	471		10.1136/bmj.314.7079.471	http://dx.doi.org/10.1136/bmj.314.7079.471			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056795	Green Published			2022-12-28	WOS:A1997WJ41900023
J	Ridker, PM; Cushman, M; Stampfer, MJ; Tracy, RP; Hennekens, CH				Ridker, PM; Cushman, M; Stampfer, MJ; Tracy, RP; Hennekens, CH			Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C-REACTIVE PROTEIN; CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION; CHLAMYDIA-PNEUMONIAE; HEART-DISEASE; HELICOBACTER-PYLORI; INFECTION; SERUM; ATHEROSCLEROSIS; PATHOGENESIS	Background Inflammation may be important in the pathogenesis of atherothrombosis. We studied whether inflammation increases the risk of a first thrombotic event and whether treatment with aspirin decreases the risk. Methods We measured plasma C-reactive protein, a marker for systemic inflammation, in 543 apparently healthy men participating in the Physicians' Health Study in whom myocardial infarction, stroke, or venous thrombosis subsequently developed, and in 543 study participants who did not report vascular disease during a follow-up period exceeding eight years. Subjects were randomly assigned to receive aspirin or placebo at the beginning of the trial. Results Base-line plasma C-reactive protein concentrations were higher among men who went on to have myocardial infarction (1.51 vs. 1.13 mg per liter, P<0.001) or ischemic stroke (1.38 vs. 1.13 mg per liter, P=0.02), but not venous th rombosis (1.26 vs. 1.13 mg per liter, P=0.34), than among men without vascular events. The men in the quartile with the highest C-reactive protein values had three times the risk of myocardial infarction (relative risk, 2.9; P<0.001) and two times the risk of ischemic stroke (relative risk, 1.9; P=0.02) of the men in the lowest quartile. Risks were stable over long periods, were not modified by smoking, and were independent of other lipid-related and non-lipid-related risk factors. The use of aspirin was associated with significant reductions in the risk of myocardial infarction (55.7 percent reduction, P=0.02) among men in the highest quartile but with only small, nonsignificant reductions among those in the lowest quartile (13.9 percent, P=0.77). Conclusions The base-line plasma concentration of C-reactive protein predicts the risk of future myocardial infarction and stroke. Moreover, the reduction associated with the use of aspirin in the risk of a first myocardial infarction appears to be directly related to the level of C-reactive protein, raising the possibility that antiinflammatory agents may have clinical benefits in preventing cardiovascular disease. (C) 1997, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC DIS, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; UNIV VERMONT, LAB CLIN BIOCHEM RES, BURLINGTON, VT USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Vermont	Ridker, PM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, 900 COMMONWEALTH AVE E, BOSTON, MA 02215 USA.			Cushman, Mary/0000-0002-7871-6143	NHLBI NIH HHS [HL-46690, HL-34595, HL-26490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595, R01HL046690] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER RW, 1994, NEW ENGL J MED, V331, P468, DOI 10.1056/NEJM199408183310709; BATAILLE R, 1992, ARTHRITIS RHEUM-US, V35, P982, DOI 10.1002/art.1780350824; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; Biasucci LM, 1996, CIRCULATION, V94, P874, DOI 10.1161/01.CIR.94.5.874; Buja LM, 1996, CIRCULATION, V94, P872, DOI 10.1161/01.CIR.94.5.872; CERMAK J, 1993, BLOOD, V82, P513, DOI 10.1182/blood.V82.2.513.513; DAS I, 1985, CLIN CHIM ACTA, V153, P9, DOI 10.1016/0009-8981(85)90133-0; DEBEER FC, 1982, BRIT HEART J, V47, P239; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GRAYSTON JT, 1993, CIRCULATION, V87, P1408, DOI 10.1161/01.CIR.87.4.1408; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Macy EM, 1997, CLIN CHEM, V43, P52; MELNICK JL, 1990, JAMA-J AM MED ASSOC, V263, P2204, DOI 10.1001/jama.263.16.2204; MENDALL MA, 1994, BRIT HEART J, V71, P437; MUNRO JM, 1988, LAB INVEST, V58, P249; NIEMINEN MS, 1993, EUR HEART J, V14, P12; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; PIETILA K, 1993, EUR HEART J, V14, P915, DOI 10.1093/eurheartj/14.7.915; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, CIRCULATION, V90, P2236, DOI 10.1161/01.CIR.90.5.2236; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; RIDKER PM, IN PRESS CIRCULATION; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; VANE J, 1987, DRUGS, V33, P18, DOI 10.2165/00003495-198700331-00005	33	4304	4518	6	297	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	1997	336	14					973	979		10.1056/NEJM199704033361401	http://dx.doi.org/10.1056/NEJM199704033361401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR385	9077376				2022-12-28	WOS:A1997WR38500001
J	Zhang, GY; Liu, Y; Ruoho, AE; Hurley, JH				Zhang, GY; Liu, Y; Ruoho, AE; Hurley, JH			Structure of the adenylyl cyclase catalytic core	NATURE			English	Article							CALMODULIN-BINDING DOMAIN; ELECTRON-DENSITY MAPS; PROTEIN STRUCTURES; FORSKOLIN; TRANSPORTER; MUTAGENESIS; DITERPENE; CALCIUM; MUTANTS; PROGRAM	Mammalian adenylyl cyclases contain two conserved regions, C-1 and C-2, which are responsible for forskolin- and G-protein-stimulated catalysis. The structure of the C-2 catalytic region of type II rat adenylyl cyclase has an alpha/beta class fold in a wreath-like dimer, which has a central cleft. Two forskolin molecules bind in hydrophobic pockets at the ends of cleft. The central part of the cleft is lined by charged residues implicated in ATP binding. Forskolin appears to activate adenylyl cyclase by promoting the assembly of the active dimer and by direct interaction within the catalytic cleft. Other adenylyl cyclase regulators act at the dimer interface or on a flexible C-terminal region.	NIDDKD,MOL BIOL LAB,NIH,BETHESDA,MD 20892; UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Wisconsin System; University of Wisconsin Madison								ARNEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649, DOI 10.1107/S0021889894001858; BRUNGER AT, 1996, XPLOR VERSION 3 8; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; Droste M, 1996, FEBS LETT, V391, P209, DOI 10.1016/0014-5793(96)00735-1; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ERIKSSON AE, 1992, NATURE, V355, P371, DOI 10.1038/355371a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FUREY W, IN PRESS METHODS ENZ; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P510, DOI 10.1038/nsb0696-510; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P219; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MORRIS DI, 1991, J BIOL CHEM, V266, P13377; MURZIN AG, 1994, J MOL BIOL, V242, P309; NICHOLLS A, 1992, GRASP MANUAL; OTWINOWSKI Z, IN PRESS METHODS ENZ; PARENT CA, 1995, J BIOL CHEM, V270, P22693, DOI 10.1074/jbc.270.39.22693; Robbins JD, 1996, J MED CHEM, V39, P2745, DOI 10.1021/jm960191+; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Sutkowski EM, 1996, MOL PHARMACOL, V50, P299; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, IN PRESS ADV SEC MES; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; YAN SZ, IN PRESS J BIOL CHEM; ZHANG G, IN PRESS PROT SCI; 1994, ACTA CRYSTALLOGR D, V50, P670	50	311	318	3	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					247	253		10.1038/386247a0	http://dx.doi.org/10.1038/386247a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069282				2022-12-28	WOS:A1997WP00300042
J	VanSwearingen, P				VanSwearingen, P			Back to basics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					862	862		10.1001/jama.277.11.862	http://dx.doi.org/10.1001/jama.277.11.862			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062308				2022-12-28	WOS:A1997WM77400001
J	Bonneux, L; Looman, CWN; Barendregt, JJ; Van der Maas, PJ				Bonneux, L; Looman, CWN; Barendregt, JJ; Van der Maas, PJ			Regression analysis of recent changes in cardiovascular morbidity and mortality in the Netherlands	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; RISK FACTOR LEVELS; DECLINE; STROKE; POPULATION; FAILURE; TRENDS; RATES; EPIDEMIOLOGY; DEATH	Objectives: To test whether recent declines in mortality from coronary heart disease were associated with increased mortality from other cardiovascular diseases. Design: Poisson regression analysis of national data on causes of death and hospital discharges. Setting and subjects: Population of the Netherlands, 1969-93. Main outcome measures: Annual changes in mortality from coronary heart disease, stroke, and other cardiovascular diseases and annual changes in hospital discharge rates for acute coronary events, stroke, and congestive heart failures. Results: Patterns of cardiovascular mortality changed abruptly in 1987-93. Annual decline in mortality from coronary heart disease increased sharply for women and men: from - 1.9% (95% confidence interval -2.2% to -1.6%) and -1.7% (-1.9% to -1.4%) respectively in 1979-86 to -3.1% (-3.5% to -2.6%) and -4.2% (-4.6% to -3.9%) in 1987-93. The longstanding decline in mortality from stroke levelled off: from annual change of -3.3% (-3.7% to -2.8%) and -3.2% (-3.7% to -2.8%) in 1979-86 to -0.1% (-0.7% to 0.4%) and -1.1% (-1.7% to -0.5%) in 1987-93. Mortality from other cardiovascular diseases, however, started to increase: from -2.0% (-2.4% to -1.6%) and -0.2% (-0.5% to 0.2%) in 1979-86 to 1.5% (1.0% to 2.0%) and 1.9% (1.5% to 2.3%) in 1987-93. Hospital discharge rates for acute coronary heart disease, congestive heart failure, and stroke increased during 1980-6. During 1987-93 discharge rates for stroke and coronary heart disease stabilised but rates for congestive heart failure increased. Conclusion: Improved management of coronary heart disease seems to have reduced mortality, but some of the gains are lost to deaths from stroke and other cardiovascular diseases. The increasing numbers of patients with coronary heart disease who survive will increase demands on health services for long term care.			Bonneux, L (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.		Barendregt, Jan J/F-6895-2010					ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; BRESLOW NE, 1987, DESIGN ANAL COHORT S, P48; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; *CENTR BUR STAT, STAT NETH DEATHS CAU; FRACHEBOUD J, 1987, CORONARY CTR CARE HO; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; Gheorghiade M, 1996, AM HEART J, V131, P250, DOI 10.1016/S0002-8703(96)90349-X; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HACHINSKI V, 1992, LANCET, V340, P645; KANNEL WB, 1991, AM HEART J, V121, P951, DOI 10.1016/0002-8703(91)90225-7; KANNEL WB, 1985, J AM COLL CARDIOL, V5, pB141, DOI 10.1016/S0735-1097(85)80545-3; MACKENBACH JP, 1987, J EPIDEMIOL COMMUN H, V41, P156, DOI 10.1136/jech.41.2.156; MCGOVERN P G, 1992, Journal of the American Medical Association, V268, P753, DOI 10.1001/jama.268.6.753; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; Meeter K, 1993, Ned Tijdschr Geneeskd, V137, P1922; NIESSEN LW, 1993, STROKE, V24, P931, DOI 10.1161/01.STR.24.7.931; Reitsma J B, 1994, Ned Tijdschr Geneeskd, V138, P866; RUWAARD D, 1994, PUBLIC HLTH STATUS D; SIGFUSSON N, 1991, BRIT MED J, V302, P1371, DOI 10.1136/bmj.302.6789.1371; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155; 1994, MORTALITY MORTALITY, V43, P77	25	46	47	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	1997	314	7083					789	792		10.1136/bmj.314.7083.789	http://dx.doi.org/10.1136/bmj.314.7083.789			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080996	Green Published			2022-12-28	WOS:A1997WN64600024
J	Bowen, J; Teri, L; Kukull, W; McCormick, W; McCurry, SM; Larson, EB				Bowen, J; Teri, L; Kukull, W; McCormick, W; McCurry, SM; Larson, EB			Progression to dementia in patients with isolated memory loss	LANCET			English	Article							MILD SENILE DEMENTIA; ALZHEIMERS-DISEASE; CLINICAL-DIAGNOSIS; IMPAIRMENT	Background The diagnosis of dementia requires both memory loss and at least one other type of cognitive impairment. The natural history of patients with severe memory loss but no other type of cognitive impairment is poorly understood. We studied progression to dementia in patients with isolated memory loss. Methods From a registry of 811 patients with cognitive complaints, 21 patients with severe isolated memory loss of unknown cause were identified and followed up for a mean of 48 months. A comparison group of 198 patients on the same register was identified with newly recognised cognitive complaints but without dementia or isolated memory loss (mean follow-up 31 months). We did a range of neuropsychological tests at intake. Findings During follow-up, 48% (n=10) of patients with isolated memory loss developed dementia compared with 18% (n=36) of the comparison group. Life-table analysis showed the mean times to a diagnosis of dementia was 3.77 years (95% CI 2.99-4.56) and 5.96 years (5.60-6.31), respectively (p=0.01). The neuropsychological tests did not predict which patients would progress to dementia. Interpretation Patients with severe isolated memory loss have an increased risk of developing dementia and should be closely followed-up.	WASHINGTON UNIV,DEPT NEUROL,SEATTLE,WA; WASHINGTON UNIV,DEPT MED,SEATTLE,WA; WASHINGTON UNIV,DEPT EPIDEMIOL,SEATTLE,WA; WASHINGTON UNIV,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA				McCurry, Susan M/E-4731-2015	McCurry, Susan M/0000-0001-8624-3772; Kukull, Walter/0000-0001-8761-9014	NATIONAL INSTITUTE ON AGING [U01AG006781] Funding Source: NIH RePORTER; NIA NIH HHS [U01-AG06781] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		A. P. Association, 1987, DIAGN STAT MAN MENT; *AP ASS, 1995, DIAGN STAT MAN MENT; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Colsher Patricia L., 1991, Annals of Epidemiology, V1, P215; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; FLICKER C, 1991, NEUROLOGY, V41, P1006, DOI 10.1212/WNL.41.7.1006; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fuld PA, 1981, FULD OBJECT MEMORY E; HUFF FJ, 1987, NEUROLOGY, V37, P1119, DOI 10.1212/WNL.37.7.1119; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; LARRABEE GJ, 1995, NEUROLOGY, V45, P611, DOI 10.1212/WNL.45.4.611; Larson E B, 1990, Aging (Milano), V2, P404; LINN RT, 1995, ARCH NEUROL-CHICAGO, V52, P485, DOI 10.1001/archneur.1995.00540290075020; MATTIS S, 1989, DEMENTIA RATING SCAL; MCCORMICK WC, 1994, J AM GERIATR SOC, V42, P517, DOI 10.1111/j.1532-5415.1994.tb04974.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1991, NEUROLOGY, V41, P469, DOI 10.1212/WNL.41.4.469; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; PETERSEN RC, 1995, JAMA-J AM MED ASSOC, V273, P1274, DOI 10.1001/jama.273.16.1274; Reitan RM, 1985, HALSTEAD REITAN NEUR; RUBIN EH, 1989, ARCH NEUROL-CHICAGO, V46, P379, DOI 10.1001/archneur.1989.00520400033016; Schmand B, 1996, NEUROLOGY, V46, P121, DOI 10.1212/WNL.46.1.121; STORANDT M, 1989, ARCH NEUROL-CHICAGO, V46, P383, DOI 10.1001/archneur.1989.00520400037017; Tierney MC, 1996, NEUROLOGY, V46, P661, DOI 10.1212/WNL.46.3.661; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223	26	237	245	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					763	765		10.1016/S0140-6736(96)08256-6	http://dx.doi.org/10.1016/S0140-6736(96)08256-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN124	9074575				2022-12-28	WOS:A1997WN12400010
J	Callahan, CM; Kesterson, JG; Tierney, WM				Callahan, CM; Kesterson, JG; Tierney, WM			Association of symptoms of depression with diagnostic test charges among older adults	ANNALS OF INTERNAL MEDICINE			English	Article						aged; depression; primary health care; diagnostic services; cost-benefit analysis	PRIMARY-CARE PATIENTS; MENTAL-HEALTH TREATMENT; PSYCHIATRIC CONSULTATION-LIAISON; MEDICAL-CARE; PSYCHOLOGICAL DISTRESS; SERVICE UTILIZATION; DISORDERS; OFFSET; COST; QUESTIONNAIRE	Background: Previous studies have documented greater use of health services by depressed persons and have postulated that health care costs could be reduced overall through better recognition and treatment of depression. Objective: To determine whether a greater burden of medical illness contributes to excess charges for diagnostic tests among older adults with symptoms of depression. Design: Prospective cohort study. Setting: A primary care group practice at an academic institution. Patients: 3767 patients 60 years of age and older who completed testing on the Centers for Epidemiologic Studies Depression Scale (CES-D) during routine office visits. Measurements: Charges for all inpatient and ambulatory diagnostic testing for 2 years, including clinical pathology, diagnostic imaging, and special procedures; number of visits to the ambulatory care center or emergency department; and number of hospitalizations. The Ambulatory Care Group case-mix approach, which is based on ambulatory diagnoses, was used as a measure of health status and expected resource consumption. Results: Patients with symptoms of depression (CES-D scores greater than or equal to 16) were significantly younger (66.6 compared with 68.1 years; P < 0.001), more likely to be white (50.5% compared with 33.9%; P = 0.001), and more likely to be female (75.8% compared with 67.6%; P = 0.001) than were those without these symptoms (CES-D scores < 16). They also had more nonpsychiatric comorbid conditions, had more visits to the ambulatory care center (9.2 compared with 7.8; P < 0.001), were more likely to use the emergency department (52.3% compared with 40%; P = 0.001), were more likely to be hospitalized (22.4% compared with 17%; P = 0.002), and had greater median total diagnostic test charges for a period of 1 year ($583 compared with $387; P< 0.001). The difference in charges, most of which were clinical pathology charges (54.2%), persisted into the second year. Ambulatory Care Group assignment was independently associated with diagnostic test charges. The CES-D summary score was not independently associated with diagnostic test charges when controlling for Ambulatory Care Group assignment. Conclusions: Patients with symptoms of depression accrue greater average diagnostic test charges. However, these data suggest that such patients also have a greater burden of comorbid nonpsychiatric illness. Efforts to improve outcome and decrease cost for patients who have late-life depression must target interventions to improve the care of psychiatric and medical illness concurrently.	RICHARD L ROUDEBUSH VET AFFAIRS MED CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis	Callahan, CM (corresponding author), REGENSTRIEF INST HLTH CARE, 1001 W 10TH ST, RG6, INDIANAPOLIS, IN 46202 USA.				AHRQ HHS [HS07632, HS07763] Funding Source: Medline; NIA NIH HHS [K08 AG00538-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007763, R01HS007632] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Andersen R, 1977, Med Care, V15, P59, DOI 10.1097/00005650-197705001-00007; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BORSON S, 1986, J AM GERIATR SOC, V34, P341, DOI 10.1111/j.1532-5415.1986.tb04316.x; BORUS JF, 1985, ARCH GEN PSYCHIAT, V42, P573; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; Brown C, 1995, GEN HOSP PSYCHIAT, V17, P414, DOI 10.1016/0163-8343(95)00072-0; CALLAHAN CM, 1995, J AM GERIATR SOC, V43, P1378, DOI 10.1111/j.1532-5415.1995.tb06617.x; Callahan CM, 1996, J GEN INTERN MED, V11, P218, DOI 10.1007/BF02642478; Callahan CM, 1996, INT J PSYCHIAT MED, V26, P155, DOI 10.2190/Q5YB-J2UW-LDAK-G1FX; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; CALLAHAN CM, 1995, J GERONTOL A-BIOL, V50, pM196, DOI 10.1093/gerona/50A.4.M196; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P839, DOI 10.1111/j.1532-5415.1994.tb06555.x; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P833, DOI 10.1111/j.1532-5415.1994.tb06554.x; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; HANKIN JR, 1983, MED CARE, V21, P1099, DOI 10.1097/00005650-198311000-00006; HANKIN JR, 1982, ARCH GEN PSYCHIAT, V39, P225; HANKIN JR, 1979, DHEW PUBLICATION; HOEPER EW, 1980, AM J PSYCHIAT, V137, P207; *INT CLASS DIS, 1989, CLIN MOD; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P237, DOI 10.1016/0163-8343(92)90094-Q; KATON W, 1987, INT J PSYCHIAT MED, V17, P93, DOI 10.2190/XE8W-GLCJ-KEM6-39FH; KATON W, 1986, WESTERN J MED, V144, P564; KATON W, 1994, PSYCHOSOMATICS, V35, P268, DOI 10.1016/S0033-3182(94)71775-8; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P86, DOI 10.1016/0163-8343(92)90033-7; LEVENSON JL, 1992, GEN HOSP PSYCHIAT, V14, pS43; LEVENSON JL, 1992, AM J PSYCHIAT, V149, P631; MANNING WG, 1992, MED CARE, V30, P541, DOI 10.1097/00005650-199206000-00007; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MCDONALD CJ, 1992, M D COMPUT, V9, P206; MECHANIC D, 1978, J HUM STRESS, V4, P26, DOI 10.1080/0097840X.1978.10545983; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; MULROW CD, 1995, ANN INTERN MED, V122, P913, DOI 10.7326/0003-4819-122-12-199506150-00004; MUMFORD E, 1984, AM J PSYCHIAT, V141, P1145; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; OUSLANDER JG, 1982, J AM GERIATR SOC, V30, P593, DOI 10.1111/j.1532-5415.1982.tb05670.x; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAPP SR, 1989, GERONTOLOGIST, V29, P252, DOI 10.1093/geront/29.2.252; REGIER DA, 1978, ARCH GEN PSYCHIAT, V35, P685; SCHLESINGER HJ, 1983, AM J PUBLIC HEALTH, V73, P422, DOI 10.2105/AJPH.73.4.422; SMITH GR, 1986, NEW ENGL J MED, V314, P1407, DOI 10.1056/NEJM198605293142203; SPITZER RL, 1995, JAMA-J AM MED ASSOC, V274, P1511, DOI 10.1001/jama.274.19.1511; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; STRAIN JJ, 1991, AM J PSYCHIAT, V148, P1044; STURM R, 1995, JAMA-J AM MED ASSOC, V273, P51; TESSLER R, 1976, J HEALTH SOC BEHAV, V17, P353, DOI 10.2307/2136713; TIERNEY WM, 1991, MED CARE, V29, pJS57; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WEISMANN MM, 1991, PSYCHIAT DISORDERS A; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WIDMER RB, 1978, J FAM PRACTICE, V7, P293; WOLINSKY FD, 1994, ADV MED SOCIOLOGY, V4, P163; WOLINSKY FD, 1994, FACTS RES GERONTOLOG, P13	54	58	58	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					426	+		10.7326/0003-4819-126-6-199703150-00002	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM530	9072927				2022-12-28	WOS:A1997WM53000002
J	Tuomainen, TP; Salonen, R; Nyyssonen, K; Salonen, JT				Tuomainen, TP; Salonen, R; Nyyssonen, K; Salonen, JT			Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland	BRITISH MEDICAL JOURNAL			English	Article							IRON		UNIV KUOPIO,PUBL HLTH RES INST,FIN-70211 KUOPIO,FINLAND	University of Eastern Finland								SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; Salonen Jukka T., 1996, P293; Salonen Jukka T., 1993, Current Opinion in Lipidology, V4, P277, DOI 10.1097/00041433-199308000-00003; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9	5	109	111	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					793	794		10.1136/bmj.314.7083.793	http://dx.doi.org/10.1136/bmj.314.7083.793			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080998	Green Published			2022-12-28	WOS:A1997WN64600026
J	Schreuder, H; Tardif, C; TrumpKallmeyer, S; Soffientini, A; Sarubbi, E; Akeson, A; Bowlin, T; Yanofsky, S; Barrett, RW				Schreuder, H; Tardif, C; TrumpKallmeyer, S; Soffientini, A; Sarubbi, E; Akeson, A; Bowlin, T; Yanofsky, S; Barrett, RW			A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist	NATURE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; COMPLEX; MUTAGENESIS; REFINEMENT; CLONING; DOMAINS; SITE	Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1). Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1 alpha and IL-1 beta and the IL-1-receptor antagonist IL1RA. (ref. 2). IL-1 is the only cytokine for which a naturally occurring antagonist is known. Here we describe the crystal structure at 2.7 Angstrom resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA. The receptor consists of three immunoglobulin-like domains. Domains 1 and 2 are tightly - linked, but domain three is completely separate and connected by a flexible linker. Residues of all three domains contact the antagonist and include the five critical IL1RA residues which were identified by site-directed mutagenesis(3). A region that is important for biological function in IL-1 beta, the 'receptor trigger site' is not in direct contact with the receptor in the IL1RA complex. Modelling studies suggest that this IL-1 beta trigger site might induce a movement of domain 3.	MARION MERRELL DOW RES INST, F-67080 STRASBOURG, FRANCE; LEPETIT RES CTR, I-21040 GERENZANO, ITALY; HOECHST MARION ROUSSEL INC, CINCINNATI, OH 45215 USA; AFFYMAX, PALO ALTO, CA 94304 USA					Schreuder, Herman/0000-0003-2249-2782				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKY W, 1994, ISOMORPHOUS REPLACEM, P80; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; READ RJ, 1988, J APPL CRYSTALLOGR, V21, P490, DOI 10.1107/S002188988800562X; SCHREUDER H, 1995, FEBS LETT, V373, P39, DOI 10.1016/0014-5793(95)01009-4; SCHREUDER HA, 1995, EUR J BIOCHEM, V227, P838, DOI 10.1111/j.1432-1033.1995.tb20209.x; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; VOS AM, 1992, SCIENCE, V255, P306; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	30	170	185	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 13	1997	386	6621					194	200		10.1038/386194a0	http://dx.doi.org/10.1038/386194a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062194				2022-12-28	WOS:A1997WM97300067
J	Dietrich, RA; Richberg, MH; Schmidt, R; Dean, C; Dangl, JL				Dietrich, RA; Richberg, MH; Schmidt, R; Dean, C; Dangl, JL			A novel zinc finger protein is encoded by the arabidopsis LSD1 gene and functions as a negative regulator of plant cell death	CELL			English	Article							DNA-BINDING DOMAIN; INSULIN-RECEPTOR SUBSTRATE-1; SYSTEMIC ACQUIRED-RESISTANCE; TOBACCO MOSAIC-VIRUS; SALICYLIC-ACID; DISEASE RESISTANCE; TRANSCRIPTION FACTOR; OXIDATIVE BURST; DEFENSE RESPONSES; THALIANA	Arabidopsis Isd1 mutants are hyperresponsive to cell death initiators and fail to limit the extent of cell death. Superoxide is a necessary and sufficient signal for cell death propagation. Thus, LSD1 monitors a superoxide-dependent signal and negatively regulates a plant cell death pathway. We isolated LSD1 via its map position. The predicted LSD1 protein contains three zinc finger domains, defined by CxxCxRxxLMYxxGASxVxCxxC. These domains are present in three additional Arabidopsis genes, suggesting that LSD1 defines a zinc finger protein subclass. LSD1 is constitutively expressed, consistent with the mutant phenotype. Alternate splicing gives rise to a low abundance mRNA encoding an extra five amino-terminal amino acids. We propose that LSD1 regulates transcription, via either repression of a prodeath pathway or activation of an antideath pathway, in response to signals emanating from cells undergoing pathogen-induced hypersensitive cell death.	UNIV N CAROLINA, CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA; JOHN INNES CTR PLANT SCI RES, DEPT MOL GENET, NORWICH NR4 7UH, NORFOLK, ENGLAND; MAX DELBRUCK LAB, D-50829 COLOGNE, GERMANY	University of North Carolina; University of North Carolina Chapel Hill; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dietrich, RA (corresponding author), UNIV N CAROLINA, DEPT BIOL, CB 3280, CHAPEL HILL, NC 27599 USA.			Schmidt, Renate/0000-0002-8037-3581				ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAKER CJ, 1995, ANNU REV PHYTOPATHOL, V33, P299, DOI 10.1146/annurev.py.33.090195.001503; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BENNETZEN JL, 1988, SCIENCE, V241, P208, DOI 10.1126/science.241.4862.208; Bent AF, 1996, PLANT CELL, V8, P1757, DOI 10.1105/tpc.8.10.1757; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; BOLWELL GP, 1995, FREE RADICAL RES, V23, P517, DOI 10.3109/10715769509065273; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DAVIS D, 1993, PHYTOCHEMISTRY, V32, P607, DOI 10.1016/S0031-9422(00)95144-6; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; DePaolis A, 1996, PLANT J, V10, P215, DOI 10.1046/j.1365-313X.1996.10020215.x; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DURNER J, 1995, P NATL ACAD SCI USA, V92, P11312, DOI 10.1073/pnas.92.24.11312; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Goodman R.N., 1994, HYPERSENSITIVE REACT; Gopalan S, 1996, PLANT CELL, V8, P1095, DOI 10.1105/tpc.8.7.1095; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; JABS T, 1997, IN PRESS P NATL ACAD; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; KAPTEIN R, 1991, CURR OPIN STRUC BIOL, V2, P109; KAUSS H, 1992, PLANT J, V2, P655, DOI 10.1111/j.1365-313X.1992.tb00134.x; KAUSS H, 1995, PLANT PHYSIOL, V108, P1171, DOI 10.1104/pp.108.3.1171; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Kosslak RM, 1996, J HERED, V87, P415, DOI 10.1093/oxfordjournals.jhered.a023030; Kosuge T., 1983, GENETIC ENG PLANTS A, P431, DOI [10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_]; LEON J, 1995, PLANT PHYSIOL, V108, P1673, DOI 10.1104/pp.108.4.1673; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; Lippuner V, 1996, J BIOL CHEM, V271, P12859, DOI 10.1074/jbc.271.22.12859; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Low PS, 1996, PHYSIOL PLANTARUM, V96, P533, DOI 10.1111/j.1399-3054.1996.tb00469.x; LUGERT T, 1994, PLANT MOL BIOL, V25, P493, DOI 10.1007/BF00043877; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; Matallana E., 1992, Methods in Arabidopsis research., P144; MauchMani B, 1996, PLANT CELL, V8, P203, DOI 10.1105/tpc.8.2.203; May MJ, 1996, PLANT PHYSIOL, V110, P1367, DOI 10.1104/pp.110.4.1367; MITTLER R, 1995, PLANT CELL, V7, P29, DOI 10.1105/tpc.7.1.29; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Nose K, 1996, BIOCHEM J, V316, P381, DOI 10.1042/bj3160381; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; Reuber TL, 1996, PLANT CELL, V8, P241, DOI 10.1105/tpc.8.2.241; Ritter C, 1996, PLANT CELL, V8, P251, DOI 10.1105/tpc.8.2.251; ROGERS SO, 1985, PLANT MOL BIOL, V5, P69, DOI 10.1007/BF00020088; Rounsley SD, 1996, PLANT PHYSIOL, V112, P1177, DOI 10.1104/pp.112.3.1177; Ruffer M, 1995, FEBS LETT, V377, P175, DOI 10.1016/0014-5793(95)01334-2; Rusterucci C, 1996, PLANT PHYSIOL, V111, P885, DOI 10.1104/pp.111.3.885; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Ryerson DE, 1996, PLANT CELL, V8, P393, DOI 10.1105/tpc.8.3.393; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; UKNES S, 1993, MOL PLANT MICROBE IN, V6, P692, DOI 10.1094/MPMI-6-692; UKNES S, 1993, PLANT CELL, V5, P159, DOI 10.1105/tpc.5.2.159; VandenAckerveken G, 1996, CELL, V87, P1307, DOI 10.1016/S0092-8674(00)81825-5; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; YANAGISAWA S, 1995, NUCLEIC ACIDS RES, V23, P3403, DOI 10.1093/nar/23.17.3403	81	351	415	0	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 7	1997	88	5					685	694		10.1016/S0092-8674(00)81911-X	http://dx.doi.org/10.1016/S0092-8674(00)81911-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054508	Bronze			2022-12-28	WOS:A1997WM41300014
J	Bosma, H; Marmot, MG; Hemingway, H; Nicholson, AC; Brunner, E; Stansfeld, SA				Bosma, H; Marmot, MG; Hemingway, H; Nicholson, AC; Brunner, E; Stansfeld, SA			Low job control and risk of coronary heart disease in Whitehall II (prospective cohort) study	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; CIVIL-SERVANTS; NEGATIVE AFFECTIVITY; DECISION LATITUDE; WORK; STRESS; MEN; HEALTH; INEQUALITIES; DEMANDS	Objective: To determine the association between adverse psychosocial characteristics at work and risk of coronary heart disease among male and female civil servants. Design: Prospective cohort study (Whitehall II study). At the baseline examination (1985-8) and twice during follow up a self report questionnaire provided information on psychosocial factors of the work environment and coronary heart disease, Independent assessments of the work environment were obtained from personnel managers at baseline, Mean length of follow up was 5.3 years. Setting: London based office staff in 20 civil service departments. Subjects: 10 308 civil servants aged 35-55 were examined-6895 men (67%) and 3413 women (33%). Main outcome measures: New: cases of angina (Rose questionnaire), severe pain across the chest, diagnosed ischaemic heart disease, and any coronary event Results: Men and women with low job control, either self reported or independently assessed, had a higher risk of newly reported coronary heart disease during follow up. Job control assessed on two occasions three years apart although intercorrelated, had cumulative effects on newly reported disease, Subjects with low job control on both occasions had an odds ratio for any subsequent coronary event of 1.93 (95% confidence interval 1.34 to 2-77) compared with subjects with high job control at both occasions. This association could not be explained by employment grade, negative affectivity or classic coronary risk factors. Job demands and social support at work were not related to the risk of coronary heart disease. Conclusions: Low control in the work environment is associated with an increased risk of future coronary heart disease among men and women employed in government offices. The cumulative effect of low job control assessed on two occasions indicates that giving employees more variety in tasks and a stranger say in decisions about work may decrease the risk of coronary heart disease.	UCL, SCH MED, INT CTR HLTH & SOC, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND	University of London; University College London; UCL Medical School			Marmot, M G/Y-3920-2019; Hemingway, Harry/C-1219-2009; Bosma, Hans/A-6184-2013; Brunner, Eric/H-2114-2011; Blewett, Verna L/A-5270-2012	Marmot, M G/0000-0002-2431-6419; Hemingway, Harry/0000-0003-2279-0624; Brunner, Eric/0000-0002-0595-4474; 	AHRQ HHS [5 RO1 HS06516] Funding Source: Medline; Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 RO1 HL 36310] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beksinska M, 1995, WHITEHALL 2 STUDY MA; Bradburn N.M., 1969, STRUCTURE PSYCHOL WE, DOI DOI 10.1037/T10756-000; BRIEF AP, 1988, J APPL PSYCHOL, V73, P193, DOI 10.1037/0021-9010.73.2.193; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; CHEN PY, 1991, J APPL PSYCHOL, V76, P398, DOI 10.1037/0021-9010.76.3.398; DEJONGE J, 1996, THESIS U MAASTRICHT; FERRIE JE, 1995, BRIT MED J, V311, P1264, DOI 10.1136/bmj.311.7015.1264; FRESE M, 1985, J APPL PSYCHOL, V70, P314, DOI 10.1037/0021-9010.70.2.314; FRESE M, 1990, CAUSES COPINT CONSEQ, P375; HOUSE JS, 1986, J HEALTH SOC BEHAV, V27, P62, DOI 10.2307/2136503; JOHNSON JV, 1993, SCAND J WORK ENV HEA, V19, P21, DOI 10.5271/sjweh.1508; Johnson JV, 1995, SOC HLTH, P247; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; Karasek R., 1990, HLTH WORK STRESS PRO; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; KASL SV, 1981, AM J PUBLIC HEALTH, V71, P682, DOI 10.2105/AJPH.71.7.682; KASL SV, 1987, STRESS HLTH ISSUES R, P307; KRISTENSEN TS, 1995, STRESS MEDICINE, V11, P17, DOI 10.1002/smi.2460110104; MARMOT M, 1988, INT J HEALTH SERV, V18, P659, DOI 10.2190/KTC1-N5LK-J1PM-9GRQ; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; MCCRAE RR, 1990, STRESS MEDICINE, V6, P237, DOI 10.1002/smi.2460060309; Quinn RP., 1979, 1977 QUALITY EMPLOYM; REID DD, 1974, LANCET, V1, P469; ROSE G, 1977, LANCET, V1, P105; ROSE G, 1968, BRIT J PREV SOC MED, V22, P12; Sauter S. L., 1989, JOB CONTROL WORKER H; SCHNALL PL, 1994, ANNU REV PUBL HEALTH, V15, P381, DOI 10.1146/annurev.pu.15.050194.002121; SIEGRIST J, 1990, SOC SCI MED, V31, P1127, DOI 10.1016/0277-9536(90)90234-J; Spector Paul E, 1992, CONSIDERATION VALIDI; STANSFELD SA, 1995, J EPIDEMIOL COMMUN H, V49, P48, DOI 10.1136/jech.49.1.48; STEPTOE A, 1989, STRESS PERSONAL CONT; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; WILCOSKY T, 1987, AM J EPIDEMIOL, V125, P400, DOI 10.1093/oxfordjournals.aje.a114546	34	622	630	1	56	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					558	565		10.1136/bmj.314.7080.558	http://dx.doi.org/10.1136/bmj.314.7080.558			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK215	9055714	Green Published			2022-12-28	WOS:A1997WK21500023
J	YkiJarvinen, H				YkiJarvinen, H			MODY genes and mutations in hepatocyte nuclear factors	LANCET			English	Editorial Material							GLUCOKINASE; ONSET				YkiJarvinen, H (corresponding author), UNIV HELSINKI,DEPT ENDOCRINOL & DIABETOL,FIN-00290 HELSINKI,FINLAND.							AYAMGATA K, 1996, NATURE, V384, P458; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; LEHTO M, 1997, J CLIN INVEST, V99, P1; MENZEL S, 1995, DIABETES, V44, P1408, DOI 10.2337/diabetes.44.12.1408; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; Todd JA, 1996, NATURE, V384, P407, DOI 10.1038/384407a0; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	11	7	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					516	517		10.1016/S0140-6736(97)80078-5	http://dx.doi.org/10.1016/S0140-6736(97)80078-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048783				2022-12-28	WOS:A1997WJ51200002
J	Kopito, RR				Kopito, RR			ER quality control: The cytoplasmic connection	CELL			English	Review							ENDOPLASMIC-RETICULUM; PROTEIN; TRANSLOCATION; DEGRADATION; PATHWAY				Kopito, RR (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.							Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; SANDVIG K, 1994, FEBS LETT, V346, P99, DOI 10.1016/0014-5793(94)00281-9; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SUZUKI T, 1994, GLYCOBIOLOGY, V4, P777, DOI 10.1093/glycob/4.6.777; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WARD CL, 1996, CYSTIC FIBROSIS CURR, V3, P107; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	20	467	469	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					427	430		10.1016/S0092-8674(00)81881-4	http://dx.doi.org/10.1016/S0092-8674(00)81881-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038332	Bronze			2022-12-28	WOS:A1997WJ69100001
J	Cohn, JA				Cohn, JA			Recent advances - HIV infection .1.	BRITISH MEDICAL JOURNAL			English	Review							ZIDOVUDINE; RITONAVIR; INHIBITOR; PROTEASE				Cohn, JA (corresponding author), WAYNE STATE UNIV,SCH MED,4201 ST ANTOINE,UHC-7D,DETROIT,MI 48201, USA.							*ABB LAB, 1996, NORV RIT CAPS OR SOL; BEISER C, IN PRESS BMJ; BRUNVEZINET F, 1996, 11 INT C AIDS VANC; CAMERON DW, 1996, 11 INT C AIDS VANC; CAMERON W, 1996, 11 INT C AIDS VANC; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CARR A, 1996, 11 INT C AIDS VANC; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P468; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P929; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; CONDRA J, 1996, 11 INT C AIDS VANC; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; DAVEY RT, 1996, 11 INT C AIDS VANC; Deyton L, 1996, JAMA-J AM MED ASSOC, V276, P159, DOI 10.1001/jama.276.2.159; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Fauci AS, 1996, ANN INTERN MED, V124, P654, DOI 10.7326/0003-4819-124-7-199604010-00006; GULICK RM, 1996, 11 INT C AIDS VANC; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; KATALAMA C, 1996, JAMA-J AM MED ASSOC, V276, P118; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Levy JA, 1996, JAMA-J AM MED ASSOC, V276, P161, DOI 10.1001/jama.276.2.161; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MARKOWITZ M, 1996, 11 INT C AIDS VANC; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; *MERCK CO, 1996, CRIX IND SULF PRESCR; MUNOZ A, 1996, 11 INT C AIDS VANC; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PEDERSON C, 1996, 11 INT C AIDS VANC; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PERELSON AS, 1996, 11 INT C AIDS VANC; PHILLIPS AN, 1996, 11 INT C AIDS VANC; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; Staszewski S, 1996, JAMA-J AM MED ASSOC, V276, P111, DOI 10.1001/jama.276.2.111; STASZEWSKI S, 1996, 11 INT C AIDS VANC; Stein DS, 1996, AIDS, V10, P485, DOI 10.1097/00002030-199605000-00006; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; WATHEN LK, 1996, 3 C RETR OPP INF WAS	42	10	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					487	491		10.1136/bmj.314.7079.487	http://dx.doi.org/10.1136/bmj.314.7079.487			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056801	Green Published			2022-12-28	WOS:A1997WJ41900029
J	Klein, R				Klein, R			The rationing debate - Defining a package of healthcare services the NHS is responsible for - The case against	BRITISH MEDICAL JOURNAL			English	Article											Klein, R (corresponding author), KINGS FUND POLICY INST,LONDON W1M 0AN,ENGLAND.							DAY P, 1988, INSPECTING QUALITY S; *DEP HLTH OFF POP, 1992, DEP REP; Klein RDP, 1996, MANAGING SCARCITY PR; NEW B, 1996, RATIONING NHS PRINCI; REDMAYNE S, 1993, BRIT MED J, V306, P1521, DOI 10.1136/bmj.306.6891.1521; REDMAYNE S, 1996, SMALL STEPS BIG GOAL; VEATCH RM, 1992, RATIONING AM MED CAR	7	12	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					506	509						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056806				2022-12-28	WOS:A1997WJ41900036
J	Arber, S; Hunter, JJ; Ross, J; Hongo, M; Sansig, G; Borg, J; Perriard, JC; Chien, KR; Caroni, P				Arber, S; Hunter, JJ; Ross, J; Hongo, M; Sansig, G; Borg, J; Perriard, JC; Chien, KR; Caroni, P			MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure	CELL			English	Article							CYSTEINE-RICH PROTEIN; LIM-PROTEIN; HYPERTROPHY; MYOFIBRILLOGENESIS; INVOLVEMENT; EXPRESSION; MYOCYTES; GROWTH; DOMAIN	MLP is a LIM-only protein of terminally differentiated striated muscle cells, where it accumulates at actin-based structures involved in cytoarchitecture organization. To assess its role in muscle differentiation, we disrupted the MLP gene in mice. MLP (-/-) mice developed dilated cardiomyopathy with hypertrophy and heart failure after birth. Ultrastructural analysis revealed dramatic disruption of cardiomyocyte cytoarchitecture. At birth, these hearts were not hypertrophic, but already abnormally soft, with cell-autonomous and MLP-sensitive alterations in cytoarchitecture. Thus, MLP promotes proper cardiomyocyte cytoarchitecture, whose perturbation can lead to dilated cardiomyopathy. In vivo analysis revealed that MLP-deficient mice reproduce the morphological and clinical picture of dilated cardiomyopathy and heart failure in humans, providing the first model for this condition in a genetically manipulatable organism.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA; CIBA GEIGY AG, PHARMA RES, CH-4002 BASEL, SWITZERLAND; UNIV LOUIS PASTEUR STRASBOURG 1, DEPT PHARMACOL, F-67401 ILLKIRCH GRAFFENSTADEN, FRANCE; SWISS FED INST TECHNOL, INST CELL BIOL, CH-8093 ZURICH, SWITZERLAND	University of California System; University of California San Diego; University of California System; University of California San Diego; Novartis; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Arber, S (corresponding author), FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND.			Arber, Silvia/0000-0002-6261-250X				Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Chien KR, 1996, J CLIN INVEST, V97, P901, DOI 10.1172/JCI118512; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; FUNG YW, 1995, GENOMICS, V28, P602, DOI 10.1006/geno.1995.1200; GONCHAROVA EJ, 1992, DEVELOPMENT, V114, P173; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KUBALAK SW, 1996, METH MOL G, V8, P470; MESSERLI JM, 1993, HISTOCHEMISTRY, V100, P193, DOI 10.1007/BF00269092; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SEN A, 1988, J BIOL CHEM, V263, P19132; SIMPSON DG, 1993, J CELL BIOL, V123, P323, DOI 10.1083/jcb.123.2.323; SOLER AP, 1994, DEV BIOL, V162, P9, DOI 10.1006/dbio.1994.1062; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WANG XK, 1992, J BIOL CHEM, V267, P9176; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; YAMAZAKI T, 1995, J MOL CELL CARDIOL, V27, P133, DOI 10.1016/S0022-2828(08)80013-2; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	26	662	675	3	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1997	88	3					393	403		10.1016/S0092-8674(00)81878-4	http://dx.doi.org/10.1016/S0092-8674(00)81878-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039266	Bronze			2022-12-28	WOS:A1997WG47900012
J	Morrison, SJ; Shah, NM; Anderson, DJ				Morrison, SJ; Shah, NM; Anderson, DJ			Regulatory mechanisms in stem cell biology	CELL			English	Review							PRIMORDIAL GERM-CELLS; MAMMALIAN NEURAL CREST; C-ELEGANS EMBRYOS; LINEAGE COMMITMENT; GROWTH-FACTOR; PROGENITOR CELLS; INTESTINAL CRYPT; NERVOUS-SYSTEM; GENE; PROLIFERATION		CALTECH, HOWARD HUGHES MED INST, PASADENA, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Morrison, SJ (corresponding author), CALTECH, DIV BIOL 21676, PASADENA, CA 91125 USA.		Morrison, Sean/ABD-5326-2021	Morrison, Sean/0000-0003-1587-8329				ABKOWITZ JL, 1990, P NATL ACAD SCI USA, V87, P9062, DOI 10.1073/pnas.87.22.9062; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALVAREZBUYLLA A, 1995, STEM CELLS, V13, P263, DOI 10.1002/stem.5530130307; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; CAGGIANO M, 1994, NEURON, V13, P339, DOI 10.1016/0896-6273(94)90351-4; Campbell K, 1995, NEURON, V15, P1259, DOI 10.1016/0896-6273(95)90006-3; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CONDRON BG, 1994, J NEUROSCI, V14, P5766; Craig CG, 1996, J NEUROSCI, V16, P2649; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DAVIS CB, 1994, CURR OPIN IMMUNOL, V6, P266, DOI 10.1016/0952-7915(94)90100-7; Doe CQ, 1996, CELL, V86, P695, DOI 10.1016/S0092-8674(00)80142-7; DOE CQ, 1995, NEURON, V15, P991, DOI 10.1016/0896-6273(95)90088-8; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1994, CURR TOP DEV BIOL, V29, P189, DOI 10.1016/S0070-2153(08)60551-7; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Felix MA, 1996, DEVELOPMENT, V122, P2129; FLEISCHMAN RA, 1982, CELL, V30, P351, DOI 10.1016/0092-8674(82)90233-1; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; FUJIO K, 1994, LAB INVEST, V70, P511; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; GEOGOPOULOS K, 1994, CELL, V79, P143; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GODIN I, 1991, DEVELOPMENT, V113, P1451; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GRAZIADEI GAM, 1979, J NEUROCYTOL, V8, P197; Grisham JW, 1996, GASTROENTEROLOGY, V110, P1311, DOI 10.1053/gast.1996.v110.agast961311; Gritti A, 1996, J NEUROSCI, V16, P1091; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HALL PA, 1989, DEVELOPMENT, V106, P619; HARRISON DE, 1992, P NATL ACAD SCI USA, V89, P10134, DOI 10.1073/pnas.89.21.10134; HARRISON DE, 1991, BLOOD, V78, P1237; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; IKUTA K, 1991, INT J CELL CLONING, V9, P451; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JOHE KK, 1996, IN PRESS GENES DEV; KEHRL JH, 1995, STEM CELLS, V13, P223, DOI 10.1002/stem.5530130304; KELLER JR, 1995, BLOOD, V86, P1757, DOI 10.1182/blood.V86.5.1757.bloodjournal8651757; KENYON C, 1995, CELL, V82, P171, DOI 10.1016/0092-8674(95)90302-X; KIMBLE J, 1992, COLD SPRING HARB SYM, V57, P401, DOI 10.1101/SQB.1992.057.01.045; KOPAN R, 1994, DEVELOPMENT, V120, P2385; LAVKER RM, 1993, J INVEST DERMATOL, V101, pS16, DOI 10.1111/1523-1747.ep12362556; LEDOUARIN N, 1991, GLIA, V4, P175; LEIGH BR, 1995, RADIAT RES, V142, P12, DOI 10.2307/3578961; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; MAYANI H, 1993, J CELL PHYSIOL, V157, P579, DOI 10.1002/jcp.1041570318; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; Mickey KM, 1996, DEVELOPMENT, V122, P1791; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; MORRISON SJ, 1996, NAT MED, V2, P202; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NYE JS, 1994, DEVELOPMENT, V120, P2421; OGDEN DA, 1976, TRANSPLANTATION, V22, P287, DOI 10.1097/00007890-197609000-00010; PAULUS U, 1992, CELL PROLIFERAT, V25, P559, DOI 10.1111/j.1365-2184.1992.tb01460.x; PODOLSKY DK, 1993, AM J PHYSIOL, V264, pG179, DOI 10.1152/ajpgi.1993.264.2.G179; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; Sechrist J, 1995, DEVELOPMENT, V121, P4103; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; SPANA EP, 1995, DEVELOPMENT, V121, P3489; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; Takahashi T, 1996, J NEUROSCI, V16, P6183; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; Temple S, 1996, CURR OPIN NEUROBIOL, V6, P11, DOI 10.1016/S0959-4388(96)80003-1; Trentin JJ, 1970, REGULATION HEMATOPOI, P161; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; WILLIAMS ED, 1992, AM J PATHOL, V141, P773; Wilson JM, 1996, NAT GENET, V12, P232, DOI 10.1038/ng0396-232; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Wu L, 1996, J EXP MED, V184, P903, DOI 10.1084/jem.184.3.903; Yasumoto S, 1996, ONCOGENE, V13, P433; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; ZIPORI D, 1992, FASEB J, V6, P2691, DOI 10.1096/fasebj.6.9.1612293; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373; ZON LI, 1995, BLOOD, V86, P2876	112	781	894	1	72	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1997	88	3					287	298		10.1016/S0092-8674(00)81867-X	http://dx.doi.org/10.1016/S0092-8674(00)81867-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039255	Bronze			2022-12-28	WOS:A1997WG47900001
J	Allen, G; Buxton, RB; Wong, EC; Courchesne, E				Allen, G; Buxton, RB; Wong, EC; Courchesne, E			Attentional activation of the cerebellum independent of motor involvement	SCIENCE			English	Article							SHIFTING ATTENTION; VERBAL MEMORY; HUMAN BRAIN; MOVEMENT; PATTERNS; AREAS; RAT; MRI	The cerebellum traditionally has been viewed as a neural device dedicated to motor control. Although recent evidence shows that it is involved in nonmotor operations as well, an important question is whether this involvement is independent of motor control and motor guidance, Functional magnetic resonance imaging was used to demonstrate that attention and motor performance independently activate distinct cerebellar regions. These findings support a broader concept of cerebellar function, in which the cerebellum is involved in diverse cognitive and noncognitive neurobehavioral systems, including the attention and motor systems, in order to anticipate imminent information acquisition, analysis, or action.	UNIV CALIF SAN DIEGO, SCH MED, DEPT NEUROSCI, SAN DIEGO, CA 92103 USA; SAN DIEGO STATE UNIV UNIV CALIF, SAN DIEGO JOINT DOCTORAL PROGRAM CLIN PSYCHOL, SAN DIEGO, CA 92120 USA; CHILDRENS HOSP, RES CTR, LAB NEUROSCI AUTISM, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT RADIOL, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego; California State University System; San Diego State University; Children's Hospital Los Angeles; University of California System; University of California San Diego					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH036840] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH36840] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037/0735-7044.106.5.731; AKSHOOMOFF NA, 1994, J COGNITIVE NEUROSCI, V6, P388, DOI 10.1162/jocn.1994.6.4.388; ANDREASEN NC, 1995, P NATL ACAD SCI USA, V92, P5111, DOI 10.1073/pnas.92.11.5111; ARTIGES E, 1995, HUM BRAIN MAPP S, V1, P227; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BLINKENBERG M, 1995, HUMAN BRAIN MAPPIN S, V1, P280; BONDE CT, 1995, HUM BRAIN MAPP S, V1, P313; BOWER JM, 1990, J COMP NEUROL, V302, P768, DOI 10.1002/cne.903020409; BRAITENBERG V, IN PRESS BEHAV BRAIN; Carpenter M.B, 1991, CORE TEXT NEUROANATO; Coenen OJMD, 1996, ADV NEUR IN, V8, P89; Courchesne E, 1995, EEG CL N SU, P315; COURCHESNE E, 1994, BEHAV NEUROSCI, V108, P848, DOI 10.1037/0735-7044.108.5.848; CRISPINO L, 1984, P NATL ACAD SCI-BIOL, V81, P2917, DOI 10.1073/pnas.81.9.2917; Eccles J.C., 1967, CEREBELLUM NEURONAL, DOI [10.1016/0013-4694(69)90099-6, DOI 10.1016/0013-4694(69)90099-6]; ELLERMAN JM, 1994, NMR BIOMED, V7, P63, DOI 10.1002/nbm.1940070110; Fiez JA, 1996, J NEUROSCI, V16, P808; Flament D, 1996, HUM BRAIN MAPP, V4, P210, DOI 10.1002/hbm.460040302; Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545; Gilman, 1981, DISORDERS CEREBELLUM; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; Ito M, 1984, CEREBELLUM NEURAL CO; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; Klingberg T, 1996, EUR J NEUROSCI, V8, P1965, DOI 10.1111/j.1460-9568.1996.tb01340.x; LE TH, 1996, NEUROIMAGE, V3, P246; Llinas R. R., 1992, CEREBELLUM REVISITED; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; NEWMAN PP, 1979, J PHYSIOL-LONDON, V287, P405, DOI 10.1113/jphysiol.1979.sp012667; PAULIN MG, 1993, BRAIN BEHAV EVOLUT, V41, P39, DOI 10.1159/000113822; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; Petit L, 1996, J NEUROSCI, V16, P3714; PRESS GA, 1990, AM J NEURORADIOL, V11, P41; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; RAO SL, 1995, HUM BRAIN MAPP S, V1, P412; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; RYDING E, 1993, COGNITIVE BRAIN RES, V1, P94, DOI 10.1016/0926-6410(93)90015-W; SABATINI U, 1993, J CEREBR BLOOD F MET, V13, P639, DOI 10.1038/jcbfm.1993.82; Schmahmann JD, 1996, HUM BRAIN MAPP, V4, P174, DOI 10.1002/(SICI)1097-0193(1996)4:3<174::AID-HBM3>3.0.CO;2-0; SHIBASAKI H, 1993, BRAIN, V116, P1387, DOI 10.1093/brain/116.6.1387; SNYDER LH, 1992, VISION RES, V32, P569, DOI 10.1016/0042-6989(92)90249-I; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; Townsend J, 1996, DEV PSYCHOPATHOL, V8, P563, DOI 10.1017/S0954579400007276; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.neuro.11.1.423	45	631	644	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1940	1943		10.1126/science.275.5308.1940	http://dx.doi.org/10.1126/science.275.5308.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072973				2022-12-28	WOS:A1997WQ51300048
J	Klarlund, JK; Guilherme, A; Holik, JJ; Virbasius, JV; Chawla, A; Czech, MP				Klarlund, JK; Guilherme, A; Holik, JJ; Virbasius, JV; Chawla, A; Czech, MP			Signaling by phosphoinositide-3,4,5-trisphosphate through proteins containing pleckstrin and Sec7 homology domains	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SH2 DOMAINS; PH DOMAIN; KINASE; RECEPTOR; CLONING; ACTIVATION; WORTMANNIN; BINDING	Signal transmission by many cell surface receptors results in the activation of phosphoinositide (PI) 3-kinases that phosphorylate the 3' position of polyphosphoinositides. From a screen for mouse proteins that bind phosphoinositides, the protein GRP1 was identified. GRP1 binds phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P-3] through a pleckstrin homology (PH) domain and displaysa region of high sequence similarity to the yeast Sec7 protein. The PH domain of the closely related protein cytohesin-1, which, through its Sec7 homology domain, regulates integrin beta 2 and catalyzes guanine nucleotide exchange of the small guanine nucleotide-binding protein ARF1, was also found to specifically bind PtdIns(3,4,5)P-3. GRP1 and cytohesin-1 appear to connect receptor-activated PI 3-kinase signaling pathways with proteins that mediate biological responses such as cell adhesion and membrane trafficking.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester				Virbasius, Joseph/0000-0003-1784-6793	NIDDK NIH HHS [DK30898, DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, R01DK030648, R01DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BONNEMA JD, 1994, J EXP MED, V180, P1427, DOI 10.1084/jem.180.4.1427; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KLARLUND JK, UNPUB; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OKADA T, 1994, J BIOL CHEM, V269, P3568; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; TOKER A, 1994, J BIOL CHEM, V269, P32358; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; YANO H, 1993, J BIOL CHEM, V268, P25846; Zell T, 1996, J IMMUNOL, V156, P883; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	45	353	361	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	1997	275	5308					1927	1930		10.1126/science.275.5308.1927	http://dx.doi.org/10.1126/science.275.5308.1927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072969				2022-12-28	WOS:A1997WQ51300044
J	Wermers, RA; Khosla, S; Atkinson, EJ; Hodgson, SF; OFallon, WM; Melton, LJ				Wermers, RA; Khosla, S; Atkinson, EJ; Hodgson, SF; OFallon, WM; Melton, LJ			The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965-1992	ANNALS OF INTERNAL MEDICINE			English	Article						hyperparathyroidism; calcium; hypercalcemia; parathyroid hormones; population surveillance	RADIATION-INDUCED HYPERPARATHYROIDISM; PRIMARY HYPER-PARATHYROIDISM; NECK IRRADIATION; CALCIUM-ABSORPTION; HYPOCALCIURIC HYPERCALCEMIA; BONE-RESORPTION; VITAMIN-D; AGE; HORMONE; WOMEN	Background: The introduction of routine measurement of serum calcium levels led to a sharp increase in the incidence of primary hyperparathyroidism in the early 1970s. Objective: To evaluate the trends in the incidence of primary hyperparathyroidism since the mid-1970s. Setting: Rochester and Olmsted County, Minnesota. Design: Population-based descriptive study. Patients: All residents of Rochester, Minnesota, who received an initial diagnosis of primary hyperparathyroidism between 1965 and 1992 were identified through the medical records linkage system of the Rochester Epidemiology Project. Included as persons having definite cases (92% of the total) were patients with pathologically confirmed hyperparathyroidism, hypercalcemia with inappropriately elevated parathyroid hormone levels, or hypercalcemia that had lasted for more than a year and had no cause other than primary hyperparathyroidism. Measurements: Incidence rates were calculated and directly standardized to the population structure of white persons in the United States in 1990. Results: From 1965 to June 1974 (the prescreening era), the age- and sex-adjusted incidence of primary hyperparathyroidism in Rochester was 15 cases per 100 000 person-years. After measurement of calcium levels was added to the automated serum chemistry panel in July 1974, the incidence increased to 112 per 100 000 person-years in 1975 and then decreased somewhat, reflecting a sweeping effect. Despite improved case ascertainment, however, the incidence rate has continued to decrease; in 1992, the incidence was 4 per 100 000 person-years. A few patients had complications that might have been caused by hyperparathyroidism (22% between 1965 and June 1974 and 6% thereafter), and survival was not impaired in either period. The maximum serum calcium levels did not change (P = 0.15). Conclusions: The progressive decrease in the incidence of primary hyperparathyroidism is unexpected and suggests a significant change in the epidemiology of this disease.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Mayo Clinic			Khosla, Sundeep/AAE-6170-2020	Khosla, Sundeep/0000-0002-2936-4372	NIAMS NIH HHS [AR 30582] Funding Source: Medline; NIA NIH HHS [AG 04875] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004875] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN RE, 1975, AUST NZ J MED, V5, P224, DOI 10.1111/j.1445-5994.1975.tb04572.x; ARNAUD CD, 1971, J CLIN INVEST, V50, P21, DOI 10.1172/JCI106476; ARNOLD A, 1995, J CLIN INVEST, V95, P2047, DOI 10.1172/JCI117890; AVIS NE, 1990, ANN NY ACAD SCI, V592, P228; BATES B, 1972, J AMER MED ASSOC, V222, P74, DOI 10.1001/jama.222.1.74; BEARD CM, 1989, ARCH INTERN MED, V149, P1887, DOI 10.1001/archinte.149.8.1887; Bergstralh EJ., 1992, CALCULATING INCIDENC; BOONSTRA CE, 1971, AM J CLIN PATHOL, V55, P523; BULLAMORE JR, 1970, LANCET, V2, P535; CHRISTMAS TJ, 1988, BRIT J SURG, V75, P873, DOI 10.1002/bjs.1800750914; DEJONG SA, 1991, SURGERY, V110, P691; DENT DM, 1987, POSTGRAD MED J, V63, P745, DOI 10.1136/pgmj.63.743.745; DERBY CA, 1993, AM J EPIDEMIOL, V137, P1125, DOI 10.1093/oxfordjournals.aje.a116616; EASTELL R, 1992, J CLIN ENDOCR METAB, V74, P487, DOI 10.1210/jc.74.3.487; ESSELSTYN C B JR, 1970, Cleveland Clinic Quarterly, V37, P87; FAVUS MJ, 1976, NEW ENGL J MED, V294, P1019, DOI 10.1056/NEJM197605062941901; FRIEDMAN GD, 1972, ARCH INTERN MED, V129, P91, DOI 10.1001/archinte.129.1.91; FUJIWARA S, 1992, RADIAT RES, V130, P372, DOI 10.2307/3578384; GALLAGHER JC, 1979, J CLIN INVEST, V64, P729, DOI 10.1172/JCI109516; HAFF RC, 1970, ANN SURG, V171, P85, DOI 10.1097/00000658-197001000-00013; HEANEY RP, 1989, J BONE MINER RES, V4, P469; Heaney RP, 1996, J CLIN ENDOCR METAB, V81, P1697, DOI 10.1210/jc.81.5.1697; HEATH H, 1989, ENDOCRIN METAB CLIN, V18, P723, DOI 10.1016/S0889-8529(18)30362-1; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; Heath H 3rd, 1991, J Bone Miner Res, V6 Suppl 2, pS63; HEDMAN I, 1984, WORLD J SURG, V8, P96, DOI 10.1007/BF01658376; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; Innes A, 1987, J R Coll Surg Edinb, V32, P263; JOHANSSON H, 1972, UPSALA J MED SCI, V77, P41, DOI 10.1517/03009734000000008; KAO PC, 1982, CLIN CHEM, V28, P69; KAO PC, 1992, MAYO CLIN PROC, V67, P637, DOI 10.1016/S0025-6196(12)60717-4; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LANDINWILHELMSEN K, 1995, CALCIFIED TISSUE INT, V56, P104, DOI 10.1007/BF00296339; LAW WM, 1985, ANN INTERN MED, V102, P511, DOI 10.7326/0003-4819-102-4-511; LEDGER GA, 1995, J CLIN ENDOCR METAB, V80, P3304, DOI 10.1210/jc.80.11.3304; LEDGER GA, 1994, J CLIN ENDOCR METAB, V79, P211, DOI 10.1210/jc.79.1.211; LINK K, 1984, HUM PATHOL, V15, P75, DOI 10.1016/S0046-8177(84)80333-0; MARCUS R, 1984, J CLIN ENDOCR METAB, V58, P223, DOI 10.1210/jcem-58-2-223; MAYS ET, 1971, SURG GYNECOL OBSTETR, V133, P603; MCGEOWN MG, 1969, LANCET, V1, P887; McKane WR, 1996, J CLIN ENDOCR METAB, V81, P1699, DOI 10.1210/jc.81.5.1699; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MODAN B, 1977, RADIOLOGY, V123, P741, DOI 10.1148/123.3.741; MOLLERUP CL, 1994, EUR J SURG, V160, P485; MULLER H, 1969, LANCET, V1, P449; MUNDY GR, 1980, LANCET, V1, P1317, DOI 10.1016/S0140-6736(80)91783-3; NISHIYAMA RH, 1979, SURG CLIN N AM, V59, P65; NORDIN BEC, 1994, CLIN ENDOCRINOL, V41, P41, DOI 10.1111/j.1365-2265.1994.tb03782.x; PALMER M, 1987, J CHRON DIS, V40, P121, DOI 10.1016/0021-9681(87)90063-4; PREISMAN RA, 1971, ARCH SURG-CHICAGO, V103, P12; PRINCE RL, 1995, J BONE MINER RES, V10, P835; PRINZ RA, 1977, SURGERY, V82, P296; RAO SD, 1980, ARCH INTERN MED, V140, P205, DOI 10.1001/archinte.140.2.205; RUSS JE, 1979, CANCER, V43, P1078, DOI 10.1002/1097-0142(197903)43:3<1078::AID-CNCR2820430344>3.0.CO;2-R; SCALLEY EK, 1993, J WOMENS HEALTH, V2, P289; SCHNEIDER AB, 1995, J CLIN ENDOCR METAB, V80, P254, DOI 10.1210/jc.80.1.254; STENSTROM G, 1974, ACTA MED SCAND, V195, P473; TISELL LE, 1976, ACTA CHIR SCAND, V142, P367; TISELL LE, 1977, CANCER, V40, P846, DOI 10.1002/1097-0142(197708)40:2<846::AID-CNCR2820400238>3.0.CO;2-2; TISELL LE, 1985, CANCER, V56, P1529, DOI 10.1002/1097-0142(19851001)56:7<1529::AID-CNCR2820560710>3.0.CO;2-D; TRIGONIS C, 1983, ACTA CHIR SCAND, V149, P675; WALDENSTROM JG, 1973, ACTA MED SCAND, V193, P145; WEMEAU JL, 1989, HORM RES, V32, P93, DOI 10.1159/000181255; WISKE PS, 1979, NEW ENGL J MED, V300, P1419, DOI 10.1056/NEJM197906213002506	65	206	213	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					433	+		10.7326/0003-4819-126-6-199703150-00003	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM530	9072928				2022-12-28	WOS:A1997WM53000003
J	Andreasen, NC				Andreasen, NC			Linking mind and brain in the study of mental illnesses: A project for a scientific psychopathology	SCIENCE			English	Article							CEREBRAL BLOOD-FLOW; PREFRONTAL CORTEX; SCHIZOPHRENIC-PATIENTS; TEMPORAL-LOBE; FRONTAL-LOBE; AFFECTIVE-DISORDERS; CONDITIONED FEAR; WORKING-MEMORY; ABNORMALITIES; DEPRESSION	Brain research on mental illnesses has made substantial advances in recent years, supported by conceptual and technological developments in cognitive neuroscience. Brain-based cognitive models of illnesses such as schizophrenia and depression have been tested with a variety of techniques, including the lesion method, tract tracing, neuroimaging, animal modeling, single-cell recording, electrophysiology, neuropsychology, and experimental cognitive psychology. A relatively sophisticated picture is emerging that conceptualizes mental illnesses as disorders of mind arising in the brain. Convergent data using multiple neuroscience techniques indicate that the neural mechanisms of mental illnesses can be understood as dysfunctions in specific neural circuits and that their functions and dysfunctions can be influenced or altered by a variety of cognitive and pharmacological factors.	UNIV IOWA,COLL MED,IOWA CITY,IA 52242	University of Iowa	Andreasen, NC (corresponding author), UNIV IOWA HOSP & CLIN,MENTAL HLTH CLIN RES CTR,200 HAWKINS DR,IOWA CITY,IA 52242, USA.				NIMH NIH HHS [MH-CRC43271, MH31593, MH40856] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH031593, R01MH040856, P30MH043271, P50MH043271, R37MH031593] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Andreasen N. C., 1986, CAN SCHIZOPHRENIA BE; Andreasen NC, 1996, NEURON, V16, P697, DOI 10.1016/S0896-6273(00)80090-2; Andreasen NC, 1996, P NATL ACAD SCI USA, V93, P9985, DOI 10.1073/pnas.93.18.9985; ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; ANDREASEN NC, 1994, JAMA-J AM MED ASSOC, V272, P1763, DOI 10.1001/jama.272.22.1763; ANDREASEN NC, 1987, SCHIZOPHRENIA BULL, V13, P9, DOI 10.1093/schbul/13.1.9; [Anonymous], 1983, CANADIAN PSYCHOL; ARMONY JL, 1995, BEHAV NEUROSCI, V109, P246, DOI 10.1037/0735-7044.109.2.246; BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681; BENCH CJ, 1992, PSYCHOL MED, V22, P607, DOI 10.1017/S003329170003806X; BENCH CJ, 1995, PSYCHOL MED, V25, P247, DOI 10.1017/S0033291700036151; Benton A. L., 1969, CONTRIBUTIONS CLIN N; Bleuler E, 1911, DEMENTIA PRAECOX; BOGERTS B, 1993, BIOL PSYCHIAT, V33, P236, DOI 10.1016/0006-3223(93)90289-P; BRAFF DL, 1993, SCHIZOPHRENIA BULL, V19, P233, DOI 10.1093/schbul/19.2.233; BRAFF DL, 1992, ARCH GEN PSYCHIAT, V49, P206; Broadbent D.E., 1958, PERCEPTION COMMUNICA; BUCHANAN RW, 1993, AM J PSYCHIAT, V150, P59; BUCHSBAUM MS, 1982, ARCH GEN PSYCHIAT, V39, P251; COHEN RM, 1989, NEUROPSYCHOPHARMACOL, V2, P241, DOI 10.1016/0893-133X(89)90028-6; CORODIMAS KP, 1995, BEHAV NEUROSCI, V109, P613, DOI 10.1037/0735-7044.109.4.613; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; DELISI LE, 1991, BIOL PSYCHIAT, V29, P159, DOI 10.1016/0006-3223(91)90044-M; Dennett D.C., 1996, UNDERSTANDING CONSCI; DREVETS WC, 1992, J NEUROSCI, V12, P3628; FARB C, 1992, BRAIN RES, V593, P145, DOI 10.1016/0006-8993(92)91303-V; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; Fletcher PC, 1996, J NEUROSCI, V16, P7055; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Friedman H R, 1990, J Cogn Neurosci, V2, P18, DOI 10.1162/jocn.1990.2.1.18; FRITH C, 1995, LANCET, V346, P615, DOI 10.1016/S0140-6736(95)91441-2; FRITH C. D., 1992, COGNITIVE NEUROPSYCH; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; Geschwind N, 1984, CEREBRAL DOMINANCE B; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOLDMANRAKIC PS, 1984, TRENDS NEUROSCI, V7, P425, DOI 10.1016/S0166-2236(84)80147-2; GOLDMANRAKIC PS, 1994, J NEUROPSYCH CLIN N, V6, P348; GOLDMANRAKIC PS, 1984, TRENDS NEUROSCI, V7, P419, DOI 10.1016/S0166-2236(84)80146-0; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; GOLDMANRAKIC PS, 1988, NEUROBIOLOGY NEOCORT; GUPTA S, 1994, SCHIZOPHR RES, V11, P195; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLSBOER F, 1992, HDB AFFECTIVE DISORD; INGVAR DH, 1974, LANCET, V2, P1484, DOI 10.1016/S0140-6736(74)90221-9; JUDD LL, 1992, AM J PSYCHIAT, V149, P448; Kraepelin E., 1919, CUTTING SHEPHERD; LeDoux J E, 1992, Curr Opin Neurobiol, V2, P191, DOI 10.1016/0959-4388(92)90011-9; LEDOUX JE, 1994, SCI AM, V270, P50, DOI 10.1038/scientificamerican0694-50; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; LIPSEY JR, 1984, LANCET, V1, P297; MARTINOT JL, 1990, AM J PSYCHIAT, V147, P1313; MAYBERG HS, 1990, ANN NEUROL, V28, P57, DOI 10.1002/ana.410280111; MCGAUGH JL, 1990, BRAIN ORG MEMORY CEL; MCGHIE A, 1961, BRIT J MED PSYCHOL, V34, P103, DOI 10.1111/j.2044-8341.1961.tb00936.x; McGuire PK, 1996, PSYCHOL MED, V26, P663, DOI 10.1017/S0033291700037673; McGuire PK, 1996, PSYCHOL MED, V26, P29, DOI 10.1017/S0033291700033699; McGuire PK, 1996, BRIT J PSYCHIAT, V169, P148, DOI 10.1192/bjp.169.2.148; Merzenich M M, 1993, Curr Opin Neurobiol, V3, P187, DOI 10.1016/0959-4388(93)90209-H; MILNER B, 1984, TRENDS NEUROSCI, V7, P403, DOI 10.1016/S0166-2236(84)80143-5; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MRZLJAK L, 1996, NATURE, V381, P345; NOPOULOS P, IN PRESS BIOL PSYCHI; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; ROBINS E, 1970, AM J PSYCHIAT, V126, P983, DOI 10.1176/ajp.126.7.983; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; ROBINSON RG, 1979, SCIENCE, V205, P707, DOI 10.1126/science.462179; ROMANSKI LM, 1992, J NEUROSCI, V12, P4501; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Schneider F, 1996, AM J PSYCHIAT, V153, P206; Searle J.R., 1992, REDISCOVERY MIND; SELEMON LD, 1995, ARCH GEN PSYCHIAT, V52, P805; SELIGMAN MEP, 1976, J ABNORM PSYCHOL, V74, P1; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; Squire L.R., 1983, PHYSL BASIS MEMORY; STARKSTEIN SE, 1987, ARCH NEUROL-CHICAGO, V44, P1069, DOI 10.1001/archneur.1987.00520220065019; STARKSTEIN SE, 1989, BRIT J PSYCHIAT, V154, P170, DOI 10.1192/bjp.154.2.170; SWAYZE VW, 1990, ARCH NEUROL-CHICAGO, V47, P805, DOI 10.1001/archneur.1990.00530070103018; SWERDLOW NR, 1994, ARCH GEN PSYCHIAT, V51, P139; TURETSKY B, 1995, ARCH GEN PSYCHIAT, V52, P1061; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769; WALDO MC, 1994, SCHIZOPHR RES, V12, P93, DOI 10.1016/0920-9964(94)90067-1; WEINBERGER DR, 1992, AM J PSYCHIAT, V149, P890; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WIDIGER TA, 1994, DSM 4 SOURCEBROOK, V1; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; ZIPURSKY RB, 1994, BIOL PSYCHIAT, V35, P501, DOI 10.1016/0006-3223(94)90097-3	94	323	333	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1586	1593		10.1126/science.275.5306.1586	http://dx.doi.org/10.1126/science.275.5306.1586			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WN123	9054346				2022-12-28	WOS:A1997WN12300028
J	Woolhandler, S; Himmelstein, DU				Woolhandler, S; Himmelstein, DU			Costs of care and administration at for-profit and other hospitals in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PSYCHIATRIC-HOSPITALS; RELATIVE PERFORMANCE; HEALTH-CARE; OWNERSHIP; EFFICIENCY; SYSTEM	Background In fiscal year 1990, administration accounted for 24.8 percent of total hospital costs in the United States - nearly twice the share in Canada. Studies from the 1970s and early 1980s found high costs, especially for administration, at for-profit hospitals. Methods We calculated administrative costs for 6227 nonfederal hospitals and the total costs of inpatient care for 5201 acute care hospitals in the United States for fiscal year 1994 on the basis of data the hospitals submitted to Medicare. We analyzed similar data for fiscal year 1990. Using multivariate analysis, we assessed the effect of hospital ownership (private not-for-profit, for-profit, and public) on administrative costs, controlling for hospital type, census region, hospital size, and the proportion of revenues derived from outpatient services. We adjusted inpatient costs for local wage levels, hospitals' reporting periods, and case mix. Results Administrative costs accounted for an average of 26.0 percent of total hospital costs in fiscal year 1994, up 1.2 percentage points from 1990. They increased by 2.2 percentage points, to 34.0 percent, for for-profit hospitals; by 1.2 percentage points, to 24.5 percent, for private not-for-profit hospitals; and by 0.6 percentage point, to 22.9 percent, for public hospitals. In 1994, administration accounted for 37.5 percent of total costs at psychiatric hospitals (44.4 percent at for-profit hospitals) and 33.0 percent of total costs at rehabilitation hospitals (37.7 percent at for-profit hospitals). In a multivariate analysis, for-profit ownership was associated with a 7.9 percent absolute (34 percent relative) increase in the proportion of hospital spending devoted to administration as compared with public hospitals and a 5.7 percent absolute (23 percent relative) increase as compared with private not-for-profit hospitals. Among acute care hospitals, for-profit institutions had higher adjusted costs per discharge ($8,115) than did private not-for-profit ($7,490) or public ($6,507) hospitals. Much of the difference was due to higher administrative costs ($2,289, $1,809, and $1,432 per discharge, respectively). Conclusions Administrative costs as a percentage of total hospital costs increased in the United States between 1990 and 1994 and were particularly high at for-profit hospitals. Overall costs of care were also higher at for-profit hospitals. (C) 1997, Massachusetts Medical Society.	HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	Woolhandler, S (corresponding author), CAMBRIDGE HOSP,CTR NATL HLTH PROGRAM STUDIES,1493 CAMBRIDGE ST,CAMBRIDGE,MA 02139, USA.							*BUR CENS, 1996, CURRENT POPULATI P60, V195; *CAN HLTH INS, GEN ACC OFF PUBL; *CHIC AM HOSP ASS, 1995, HOSP STAT EM TRENDS; COELEN CG, 1986, FOR PROFIT ENTERPRIS, P322; *COL HCA HEALTHC, 1995, 10Q REP FIL SEC EXCH; ERMANN D, 1986, FOR PROFIT ENTERPRIS, P474; GRAY BH, 1986, NEW ENGL J MED, V314, P1523, DOI 10.1056/NEJM198606053142335; GRAY BH, 1986, FOR PROFIT ENTERPRIS, P74; Hasan MM, 1996, NEW ENGL J MED, V334, P1055, DOI 10.1056/NEJM199604183341610; Himmelstein DU, 1996, AM J PUBLIC HEALTH, V86, P172, DOI 10.2105/AJPH.86.2.172; JAKLEVIC MC, 1995, MOD HEALTHCARE, V25, P56; LEVIT KR, 1994, HEALTH CARE FINANC R, V16, P247; Levit KR, 1996, HEALTH AFFAIR, V15, P130, DOI 10.1377/hlthaff.15.2.130; MCCUE MJ, 1993, INQUIRY-J HEALTH CAR, V30, P306; MCCUE MJ, 1993, AM J PSYCHIAT, V150, P77; MCCUE MJ, 1995, ARCH PHYS MED REHAB, V76, P413, DOI 10.1016/S0003-9993(95)80569-9; *OECD, 1996, WIND ENV SOFTW PACK; *OFF STAT DAT MAN, 1995, 4774 BUR DAT MAN STR; OZCAN YA, 1992, MED CARE, V30, P781, DOI 10.1097/00005650-199209000-00003; PATTISON RV, 1983, NEW ENGL J MED, V309, P347, DOI 10.1056/NEJM198308113090606; PATTISON RV, 1986, FOR PROFIT ENTERPRIS, P290; *SAS I, 1987, SAS SOFTW VERS 6 04; Sear A M, 1991, Health Care Manage Rev, V16, P31; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302; Sorrentino E A, 1989, Hosp Top, V67, P22; WATT JM, 1986, NEW ENGL J MED, V314, P89, DOI 10.1056/NEJM198601093140206; WATT JM, 1986, FOR PROFIT ENTERPRIS, P260; WOOLHANDLER S, 1994, NEW ENGL J MED, V331, P336, DOI 10.1056/NEJM199408043310520; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; WOOLHANDLER S, 1993, NEW ENGL J MED, V329, P400, DOI 10.1056/NEJM199308053290606; 1996, FED REGISTER, V61, P27453	31	150	150	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					769	774		10.1056/NEJM199703133361106	http://dx.doi.org/10.1056/NEJM199703133361106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM640	9052656				2022-12-28	WOS:A1997WM64000006
J	Black, B				Black, B			Subpoenas and science - When lawyers force their way into the laboratory	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Black, B (corresponding author), HUGHES & LUCE,DALLAS,TX 75201, USA.							Gabriel SE, 1997, NEW ENGL J MED, V336, P677, DOI 10.1056/NEJM199703063361001; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; KOLATA G, 1995, NY TIMES        0516, pD6; ZIMAN J, 1980, INTRO READINGS PHILO	4	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					725	727		10.1056/NEJM199703063361011	http://dx.doi.org/10.1056/NEJM199703063361011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041107				2022-12-28	WOS:A1997WL41900011
J	Conway, JF; Cheng, N; Zlotnick, A; Wingfield, PT; Stahl, SJ; Steven, AC				Conway, JF; Cheng, N; Zlotnick, A; Wingfield, PT; Stahl, SJ; Steven, AC			Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ALPHA-HELICES; CORE ANTIGEN; PROTEIN	Despite the development of vaccines, the hepatitis B virus remains a major cause of human liver disease(1). The virion consists of a lipoprotein envelope surrounding an icosahedral capsid composed of dimers of a 183-residue protein, 'core antigen' (HBcAg)(2). Knowledge of its structure is important for the design of antiviral drugs, but it has yet to be determined. Residues 150-183 are known to form a protamine-like domain required for packaging RNA, and residues 1-149 form the 'assembly domain' that polymerizes into capsids(2) and, unusually for a capsid protein, is highly alpha-helical(3). Density maps calculated from cryo-electron micrographs(4-6) show that the assembly domain dimer is T-shaped: its stem constitutes the dimer interface and the tips of its arms make the polymerization contacts. By refining the procedures used to calculate the map, we have extended the resolution to 9 Angstrom, revealing major elements of secondary structure. In particular, the stem, which protrudes as a spike on the capsid's outer surface, is a 4-helix bundle, formed by the pairing of alpha-helical hairpins from both subunits.	NIAMSD,STRUCT BIOL LAB,NIH,BETHESDA,MD 20892; NIAMSD,PROT EXPRESS LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)			Conway, James F/A-2296-2010	Conway, James F/0000-0002-6581-4748; Zlotnick, Adam/0000-0001-9945-6267; Wingfield, Paul/0000-0002-9515-4752				ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAKER TS, 1989, BIOPHYS J, V55, P243, DOI 10.1016/S0006-3495(89)82799-7; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BAMFORD JKH, 1993, J MOL BIOL, V230, P473, DOI 10.1006/jmbi.1993.1164; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BOOY FP, 1996, P 11 EUR C MICR DUBL; BRINGAS R, IN PRESS J STRUCT; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CONWAY JF, 1993, J STRUCT BIOL, V111, P222, DOI 10.1006/jsbi.1993.1052; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; HOLLINGER FB, 1996, FIELDS VIROLOGY, P2738; JENG TW, 1989, J MOL BIOL, V205, P251, DOI 10.1016/0022-2836(89)90379-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KENNEY JM, 1995, STRUCTURE, V3, P1009, DOI 10.1016/S0969-2126(01)00237-4; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; MORGAN DG, 1995, J MOL BIOL, V249, P88, DOI 10.1006/jmbi.1995.0282; NASSAL M, 1993, VIRUS STRATEGIES, P41; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yu MS, 1996, J VIROL, V70, P7085, DOI 10.1128/JVI.70.10.7085-7091.1996; ZEMLIN F, 1994, MICRON, V25, P223, DOI 10.1016/0968-4328(94)90026-4; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	30	385	409	1	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					91	94		10.1038/386091a0	http://dx.doi.org/10.1038/386091a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052787				2022-12-28	WOS:A1997WL74600058
J	Lurie, P; Drucker, E				Lurie, P; Drucker, E			An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA	LANCET			English	Article							INJECTION-DRUG USERS; SYRINGE; RISK; AIDS	Background Our aim was to estimate the number of HIV infections that could have been prevented had needle-exchange programmes been implemented during the early stages of the AIDS epidemic in the USA. We also estimated the cost to the US health-care system to treat these preventable HIV infections. Methods The formula we used to calculate the annual number of preventable HIV infections accounted for the effectiveness and level of use of needle-exchange programmes, as well as sexual transmission to injection drug users (IDUs) and secondary transmission to their sexual partners and children. Data for the model were obtained from epidemiological and mathematical studies in peer-reviewed published research, government reports, and consultations with experts. Using data from Australia as a model, we calculated the number of HIV infections that could have been prevented by a national needle-exchange programme in the USA between 1987 and 1995. Cost calculations were based on the current US government estimate of the discounted lifetime cost of treating an HIV infection (US$55 640). Findings Our conservative calculation of the number of HIV infections that could have been prevented ranged from 4394 (15% incidence reduction due to needle exchanges) to 9666 (33% incidence reduction). The cost to the US health-care system of treating these preventable HIV infections is between US$ 244 million and US$ 538 million, respectively. If current US policies are not changed. we estimate that an additional 5150-11 329 preventable HIV infections could occur by the year 2000. Interpretation The failure of the federal government in the USA to implement a national needle-exchange programme, despite six government-funded reports in support of needle exchanges, may have led to HIV infection among thousands of IDUs, their sexual partners, and their children. Revoking the US government ban on funding for needle-exchange programmes and accelerating the growth of such programmes in the USA are urgent public-health priorities.	MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Lurie, P (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SUITE 600,SAN FRANCISCO,CA 94105, USA.							*AUSTR NAT AIDS IN, 1991, NEITH BORR NOR LEND; BRACHMAN PS, 1985, PRINCIPLES PRACTICE; *CTR DIS CONTR, 1990, MMWR-MORBID MORTAL W, V39, P8; *CTR DIS CONTR PRE, 1994, HIV AIDS SURVEILLANC, V6, P10; FEACHEM RGA, 1995, VALUING PAST INVESTI; *GEN ACC OFF, 1993, GAOHRD9360; GROSECLOSE SL, 1995, J ACQ IMMUN DEF SYND, V10, P82; GUINAN ME, 1994, AM J PREV MED, V10, P1; HAGAN H, 1995, AM J PUBLIC HEALTH, V85, P1531, DOI 10.2105/AJPH.85.11.1531; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; Jarlais DCD, 1996, LANCET, V348, P987, DOI 10.1016/S0140-6736(96)02536-6; JARLAIS DCD, 1989, JAMA-J AM MED ASSOC, V261, P1008; JARLAIS DCD, 1995, JAMA-J AM MED ASSOC, V274, P1226; KAPLAN EH, 1995, OPER RES, V43, P558, DOI 10.1287/opre.43.4.558; KAPLAN EH, 1994, STAT MED, V13, P2179, DOI 10.1002/sim.4780131923; KOXLEY W, 1995, SAME VEIN 1 REPORT A; Lurie P, 1995, B NEW YORK ACAD MED, V72, P380; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; *NAT COMM ACQ IMM, 1991, TWIN EP SUBS US HIV; NORMAND J, 1995, PREVENTING HIV TRANS; *OFF TECHN ASS, 1995, EFF AIDS PREV EFF; PAONE D, 1995, MMWR-MORBID MORTAL W, V44, P684; SATCHER D, 1993, COMMUNICATION   1210; VANDENHOEK JAR, 1989, AM J PUBLIC HEALTH, V79, P1355, DOI 10.2105/AJPH.79.10.1355; WALDHOLZ M, 1985, WALL STREET J   0903, pA14; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115; 1996, KAISER SURVEY AM AID	27	114	115	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					604	608		10.1016/S0140-6736(96)05439-6	http://dx.doi.org/10.1016/S0140-6736(96)05439-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK915	9057732				2022-12-28	WOS:A1997WK91500010
J	Pine, M; Norusis, M; Jones, B; Rosenthal, GE				Pine, M; Norusis, M; Jones, B; Rosenthal, GE			Predictions of hospital mortality rates: A comparison of data sources	ANNALS OF INTERNAL MEDICINE			English	Article						severity of illness index; myocardial infarction; cerebrovascular disorders; heart failure, congestive; pneumonia	ARTERY BYPASS-SURGERY; OUTCOMES; SEVERITY; MODEL	Background: Comparing hospital mortality rates requires accurate adjustment for patients' intrinsic differences. Commercial severity systems require either administrative data that omit vital clinical facts about patients' conditions at hospital admission or costly, time-consuming abstraction of medical records. The validity of supplementing administrative data with laboratory data has not been assessed. Objective: To compare risk-adjusted mortality predictions using administrative data alone; administrative data plus laboratory values; and the combination of administrative, laboratory, and clinical data. Design: Retrospective cohort study. Setting: 30 acute care hospitals. Patients: 46 769 patients hospitalized with acute myocardial infarction, cerebrovascular accident, congestive heart failure, or pneumonia. Measurements: Each patient's probability of dying was estimated by using administrative data only (unrestricted administrative models), administrative data restricted to secondary diagnoses that are unlikely to be hospital-acquired complications (restricted administrative models), restricted administrative data plus laboratory data (laboratory models), and restricted administrative data plus laboratory and abstracted clinical data (clinical models). Results: The unrestricted administrative models predicted death better than the restricted administrative models (average areas under the receiver-operating characteristic [ROC] curves, 0.87 and 0.75, respectively) and as well as the laboratory models and the clinical models (average areas under the ROC curves, 0.86 and 0.87, respectively). The good mortality predictions obtained by using the unrestricted administrative models result from inclusion of hospital-acquired complications that commonly precede death. The laboratory models ranked 93% of patients and 95% of hospitals in a manner similar to the clinical models; in comparison, rankings provided by the laboratory models were similar to those provided for 75% of patients and 69% of hospitals by the unrestricted administrative models and for 72% of patients and 77% of hospitals by the restricted administrative models. Conclusions: Adding laboratory data (often available electronically) to restricted administrative data sets can provide accurate predictions of inpatient death from acute myocardial infarction, cerebrovascular accident, congestive heart failure, or pneumonia. This alternative avoids the cost of data abstraction and the serious errors associated with using administrative data alone.	CLEVELAND VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, CLEVELAND, OH 44106 USA		Pine, M (corresponding author), MICHAEL PINE & ASSOCIATES INC, 5020 S LAKE SHORE DR, CHICAGO, IL 60615 USA.							ALEMI F, 1990, MED CARE, V28, P762, DOI 10.1097/00005650-199009000-00006; *AM HOSP ASS, 1991, AM HOSP ASS GUID HLT, pA329; Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; DANS PE, 1993, ANN INTERN MED, V119, P855, DOI 10.7326/0003-4819-119-8-199310150-00014; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; GOLDFIELD N, 1994, MEASURING MANAGING S, V3; GREENE J, 1994, MODERN HEALTHCARE, V24, P6; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KRAKAUER H, 1992, HEALTH SERV RES, V27, P317; LEGNINI MW, 1993, ANN REPORT CALIFORNI, V1, P1; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; MOZES B, 1994, HEALTH SERV RES, V28, P689; ROMANO PS, 1994, J CLIN EPIDEMIOL, V47, P249, DOI 10.1016/0895-4356(94)90006-X; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; ROSENTHAL GE, 1994, JOINT COMM J QUAL IM, V20, P425, DOI 10.1016/S1070-3241(16)30088-8; *SAS I INC, 1989, SAS STAT US GUID VER, P1071; SMITH DW, 1991, MED CARE, V29, P1108, DOI 10.1097/00005650-199111000-00004; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; SULLIVAN LW, 1992, MEDICARE HOSP INFORM; WEN SW, 1995, JAMA-J AM MED ASSOC, V274, P1687, DOI 10.1001/jama.274.21.1687	27	112	112	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					347	+		10.7326/0003-4819-126-5-199703010-00002	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL104	9054278				2022-12-28	WOS:A1997WL10400002
J	Zilberstein, M; Feingold, M; Seibel, MM				Zilberstein, M; Feingold, M; Seibel, MM			Umbilical-cord-blood banking: Lessons learned from gamete donation	LANCET			English	Article									BOSTON UNIV,MED CTR,DEPT OBSTET & GYNECOL,BOSTON,MA	Boston University	Zilberstein, M (corresponding author), FAULKNER CTR REPROD MED,HARVARD DEACONESS SURG PROBLEM,1153 CTR ST,BOSTON,MA 02130, USA.							ANDREWS LB, 1994, EXECUTIVE SUMMARY AS; BATES B, 1996, OB GYN NEWS, V31, P1; KONG D, 1996, BOSTON GLOBE    0122, P27; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; MCCULLOUGH J, 1994, BLOOD CELLS, V20, P609; Varadi G, 1995, Obstet Gynecol Surv, V50, P611, DOI 10.1097/00006254-199508000-00022; ZILBERSTEIN M, 1996, UNDERSTANDING FAMILY, P94	7	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					642	643		10.1016/S0140-6736(96)05267-1	http://dx.doi.org/10.1016/S0140-6736(96)05267-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057746	hybrid			2022-12-28	WOS:A1997WK91500043
J	Adzick, NS; Crombleholme, TM; Morgan, MA; Quinn, TM				Adzick, NS; Crombleholme, TM; Morgan, MA; Quinn, TM			A rapidly growing fetal teratoma	LANCET			English	Article							SACROCOCCYGEAL TERATOMA		UNIV PENN,PHILADELPHIA,PA 19104	University of Pennsylvania	Adzick, NS (corresponding author), CHILDRENS HOSP,CTR FETAL DIAG & TREATMENT,PHILADELPHIA,PA 19104, USA.		Crombleholme, Timothy/Y-1477-2019					ADZICK NS, 1994, LANCET, V343, P897, DOI 10.1016/S0140-6736(94)90012-4; ALTMAN RP, 1974, J PEDIATR SURG, V9, P389; Flake A W, 1993, Semin Pediatr Surg, V2, P113; FLAKE AW, 1986, J PEDIATR SURG, V21, P563, DOI 10.1016/S0022-3468(86)80404-3; LANGER JC, 1989, AM J OBSTET GYNECOL, V160, P1145, DOI 10.1016/0002-9378(89)90177-4	5	76	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					538	538		10.1016/S0140-6736(97)80088-8	http://dx.doi.org/10.1016/S0140-6736(97)80088-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048793	hybrid			2022-12-28	WOS:A1997WJ51200012
J	Pringle, M; Heath, I				Pringle, M; Heath, I			Primary care: Opportunities and threats - Distributing primary care fairly	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					595	595						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055724				2022-12-28	WOS:A1997WK21500034
J	Haverkate, F; Thompson, SG; Pyke, SDM; Gallimore, JR; Pepys, MB				Haverkate, F; Thompson, SG; Pyke, SDM; Gallimore, JR; Pepys, MB			Production of C-reactive protein and risk of Coronary events in stable and unstable angina	LANCET			English	Article							SERUM AMYLOID-A; ACUTE-PHASE; MYOCARDIAL-INFARCTION; HEART-DISEASE; ATHEROSCLEROSIS; ASSOCIATION; CYTOMEGALOVIRUS; PATHOGENESIS; COMPLEMENT; HEALTH	Background Inflammation is an important feature of atherosclerotic lesions, and increased production of the acute-phase reactant, C-reactive protein (CRP), is associated with a poor prognosis in severe unstable angina. We have investigated the existence and possible significance of the acute-phase responses of CRP and another sensitive reactant, serum amyloid A protein (SAA), in patients with unstable or stable angina. Methods We used new ultrasensitive immunoassays to measure CRP and SAA concentrations in plasma from 2121 outpatients with angina (1030 unstable, 743 stable, the rest atypical) enrolled in the European Concerted Action on Thrombosis and Disabilities (ECAT) Angina Pectoris Study. All patients underwent coronary angiography and extensive clinical and laboratory assessment at study entry, and were then followed up for 2 years. All suspected coronary events during follow-up were reviewed by an independent endpoint committee. Findings 75 individuals (41 with unstable, 29 with stable, and 5 with atypical angina) had a coronary event during follow-up. Concentrations of CRP at study entry were associated with coronary events in patients with stable or unstable angina: there was about a two-fold increase in the risk of a coronary event in patients whose CRP concentration was in the fifth quintile (>3.6 mg/L), compared with the first four quintiles. A third of the events occurred among patients who had a CRP concentration of more than 3.6 mg/L. CRP concentrations were positively correlated with age, smoking, body-mass index, triglycerides, extent of coronary stenosis, history of myocardial infarction, and lower ejection fraction. By contrast, concentrations of SAA were not associated with risk of a coronary event. Interpretation We found that raised circulating concentrations of CRP are predictors of coronary events in patients with stable or unstable angina. The modest acute-phase responses of CRP were probably not the result of myocardial necrosis. Whatever the underlying mechanisms, the sensitive measurement of CRP as a prognostic marker may be useful in the management of coronary heart diease.	ROYAL POSTGRAD MED SCH,SCH HYG & TROP MED,MED STAT UNIT,LONDON,ENGLAND; ROYAL POSTGRAD MED SCH,IMMUNOL MED UNIT,LONDON,ENGLAND	Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Haverkate, F (corresponding author), TNO PG,GAUBIUS LAB,POB 2215,NL-2301 CE LEIDEN,NETHERLANDS.							BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959; CERMAK J, 1993, BLOOD, V82, P513, DOI 10.1182/blood.V82.2.513.513; *ECAT ANG PECT STU, 1993, EUR HEART J, V14, P8; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Grossman W., 1986, CARDIAC CATHETERIZAT; HEINRICH J, 1995, THROMB HAEMOSTASIS, V73, P374; HENDRIX MGR, 1991, AM J PATHOL, V138, P563; Jespersen J, 1992, ECAT ASSAY PROCEDURE; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Liuzzo G, 1996, CIRCULATION, V94, P2373, DOI 10.1161/01.CIR.94.10.2373; Maseri A, 1996, BRIT MED J, V312, P1049; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; Mendall MA, 1996, BRIT MED J, V312, P1061; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; PEPYS MB, 1985, INT REV EXP PATHOL, V27, P83; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PEPYS MB, 1995, OXFORD TXB MED, P1527; PEPYS MB, 1989, ACUTE PHASE PROTEINS; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SHINE B, 1981, CLIN CHIM ACTA, V117, P13, DOI 10.1016/0009-8981(81)90005-X; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; VANLEEUWEN MA, 1993, BRIT J RHEUMATOL, V32, P9; VIGUSHIN DM, 1993, J CLIN INVEST, V91, P1351, DOI 10.1172/JCI116336; VOLANAKIS JE, 1981, J IMMUNOL, V126, P1820; VOLANAKIS JE, 1982, ANN NY ACAD SCI, V389, P235, DOI 10.1111/j.1749-6632.1982.tb22140.x; WILKINS J, 1994, CLIN CHEM, V40, P1284	30	1243	1337	0	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					462	466						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040576				2022-12-28	WOS:A1997WH38900011
J	Taylor, SJC; Whincup, PH; Cook, DG; Papacosta, O; Walker, M				Taylor, SJC; Whincup, PH; Cook, DG; Papacosta, O; Walker, M			Size at birth and blood pressure: Cross sectional study in 8-11 year old children	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; ADULT LIFE; FETAL INFLUENCES; GROWTH; CHILDHOOD; WEIGHT; HYPERTENSION; DEATH	Objective: To identify which patterns of fetal growth, represented by different measurements of size at birth, are associated with increased blood pressure in children aged 8-11 years. Design and setting: School based, cross sectional survey conducted in 10 towns in England and Wales in 1994, Subjects: 3010 singleton children (response rate 75%) with physical measurements and information on birth weight from parental questionnaires. Hospital birth records were examined for 1573, Main outcome measures: Systolic and diastolic blood pressure at age 8-11 years. Results: In the whole group birth weight was inversely related to systolic pressure (regression coefficient -1.48 mm Hg/kg; 95% confidence interval -2.20 to -0.76) after adjustment for current body size. There was no significant association between birth weight and diastolic pressure, The association with systolic pressure was much stronger in girls (-2.54 mm Hg/kg; -3.60 to -1.48) than in boys (-0,64 mm Hg/kg; -1.58 to 0.30), with a significant difference between the sexes (P=0,006), Among the other neonatal measures, head circumference and placental weight were inversely associated with subsequent blood pressure in girls, and placental ratio (placental weight:birth weight) was positively associated with blood pressure in boys, Neither ponderal index at birth nor length:head circumference ratio was related to blood pressure in either sex. Conclusions: In these contemporary children the association between birth weight and blood pressure was apparent only in girls. There was no evidence that measures of size at birth, which may be related to nutrition at critical periods of pregnancy (thinness at birth or shortness in relation to head circumference), are related to blood pressure in the offspring.			Taylor, SJC (corresponding author), ROYAL FREE HOSP,SCH MED,CARDIOVASC RES GRP,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND.		TAYLOR, STEPHANIE/GYV-4768-2022	Whincup, Peter/0000-0002-5589-4107; Taylor, Stephanie/0000-0001-7454-6354; Cook, Derek/0000-0002-9723-5759; Papacosta, Olia/0000-0001-8781-6747	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; Barker D. J., 1994, MOTHERS BABIES DIS L, P14; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1994, MOTHERS BABIES DIS L, P121; CHANG TC, 1993, EARLY HUM DEV, V35, P37, DOI 10.1016/0378-3782(93)90137-J; CHINN S, 1994, PAEDIATR PERINAT EP, V8, P90, DOI 10.1111/j.1365-3016.1994.tb00438.x; EATONEVANS J, 1986, HUM NUTR-APPL NUTR, V40A, P171; Forrester TE, 1996, BRIT MED J, V312, P156; FROHLICH ED, 1988, CIRCULATION, V77, P502; Hashimoto N, 1996, ACTA PAEDIATR, V85, P132, DOI 10.1111/j.1651-2227.1996.tb13978.x; LAW C, 1995, J HUM HYPERTENS, V9, P649; Law CM, 1996, J HYPERTENS, V14, P935; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MARTYN CN, 1995, BRIT HEART J, V73, P116; Moore VM, 1996, ARCH DIS CHILD, V74, P538, DOI 10.1136/adc.74.6.538; MORLEY R, 1994, ARCH DIS CHILD, V70, P536, DOI 10.1136/adc.70.6.536; MUTCH L, 1995, PEDIATR RES, V38, P447; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; RAMSEY M, 1979, MED BIOL ENG COMPUT, V17, P11, DOI 10.1007/BF02440948; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; Simpson A, 1981, HYPERTENSION YOUNG O, P153; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P164, DOI 10.1136/jech.46.2.164; Whincup PH, 1996, BMJ-BRIT MED J, V313, P79, DOI 10.1136/bmj.313.7049.79; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; [No title captured]	34	105	111	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					475	480		10.1136/bmj.314.7079.475	http://dx.doi.org/10.1136/bmj.314.7079.475			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056797	Green Published			2022-12-28	WOS:A1997WJ41900025
J	Watson, AJM; DuBois, RN				Watson, AJM; DuBois, RN			Lipid metabolism and APC: Implications for colorectal cancer prevention	LANCET			English	Editorial Material									VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37232	Vanderbilt University	Watson, AJM (corresponding author), UNIV MANCHESTER,HOPE HOSP,DEPT MED,ECCLES OLD RD,SALFORD M6 8HD,LANCS,ENGLAND.		DuBois, Raymond N./AAX-8869-2020					DuBois RN, 1996, GASTROENTEROL CLIN N, V25, P773, DOI 10.1016/S0889-8553(05)70274-0; Gould KA, 1996, CELL GROWTH DIFFER, V7, P1361; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pritchard DM, 1996, PHARMACOL THERAPEUT, V72, P149, DOI 10.1016/S0163-7258(96)00102-7; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE J, 1994, NATURE, V367, P243	10	14	14	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					444	445		10.1016/S0140-6736(97)22007-6	http://dx.doi.org/10.1016/S0140-6736(97)22007-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040567				2022-12-28	WOS:A1997WH38900002
J	Bullock, N				Bullock, N			Impotence after sclerotherapy of haemorrhoids: Case reports	BRITISH MEDICAL JOURNAL			English	Article											Bullock, N (corresponding author), ADDENBROOKES NHS TRUST,DEPT UROL,CAMBRIDGE CB2 2QQ,ENGLAND.							BENNANI S, 1994, ANN UROL, V28, P13; Goligher JC., 1984, SURG ANUS RECTUM COL, VVol. 5, P98; MITCHELL AB, 1903, BRIT MED J, V1, P482; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WRIGHT AD, 1950, P ROY SOC MED, V43, P263, DOI 10.1177/003591575004300409	5	28	28	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					419	419		10.1136/bmj.314.7078.419	http://dx.doi.org/10.1136/bmj.314.7078.419			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040388	Green Published			2022-12-28	WOS:A1997WH29500030
J	EarlSlater, A				EarlSlater, A			Regulating the price of the UK's drugs: Second thoughts after the government's first report	BRITISH MEDICAL JOURNAL			English	Article								Few industries in the UK are directly subject to profit regulation by central government One such industry is the pharmaceutical industry supplying drugs to the NHS, which has had its profits regulated since 1969. Yet only in May 1996 did the government produce its first annual report on the regulatory scheme, and even then the report fails to cast much light on the scheme. In particular, there are seven major problems with the regulations and the way they are negotiated: they lack robust reasoning, a theoretical basis, an empirical basis, transparency, accountability, due process, and an analysis of their impact Moreover, patients and health professionals are excluded from the bargaining process. All these problems could be resolved if the political will to debate them emerges.			EarlSlater, A (corresponding author), UNIV KEELE,DEPT MED MANAGEMENT,KEELE ST5 5BG,STAFFS,ENGLAND.							Bailey D., 1994, MAKING TRANSNATIONAL; BISHOP M, 1995, REGULATORY CHALLENGE; *COMM ENQ COST NHS, 1956, CMND9663; *COMM ENQ REL PHAR, 1967, CMND3410; Commonwealth of Australia, 1995, GUID PHARM IND PREP; *DEP HLTH SCOTT HO, 1993, AGR PHARM PRIC REG S; Earl-Slater A., 1997, FINANC ACCOUNT MANAG, V13, P35, DOI [10.1111/1468-0408.00025, DOI 10.1111/1468-0408.00025]; EarlSlater A, 1996, PUBLIC ADMIN, V74, P393, DOI 10.1111/j.1467-9299.1996.tb00877.x; ENTHOVEN AC, 1995, HLTH AFFAIRS     SPR, P105; Hancher L., 1990, REGULATING COMPETITI; HINTON P, 1993, PUBLIC SERVICES 1990; *INT IND DIV, 1996, PHARM PRIC REG SCHEM; *JOINT COMM PRESCR, 1 JOINT COMM PRESCR; *MIN HLTH, 1951, ANN REP YEAR END 195; OGUS A, 1994, REGULATION LEGAL FOR; REDWOOD H, 1993, PRICE REGULATION PHA; SARGENT JA, 1985, PRIVATE INTEREST GOV, P105; SCHERER FM, 1993, J ECON PERSPECT, V7, P97, DOI 10.1257/jep.7.3.97; *SCRIPS PHARM CO L, 1995, SCRIPS 1995 PHARM CO; 1995, CMND2683	20	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					365	368		10.1136/bmj.314.7077.365	http://dx.doi.org/10.1136/bmj.314.7077.365			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040338	Green Published			2022-12-28	WOS:A1997WF86100045
J	Reznick, DN; Shaw, FH; Rodd, FH; Shaw, RG				Reznick, DN; Shaw, FH; Rodd, FH; Shaw, RG			Evaluation of the rate of evolution in natural populations of guppies (Poecilia reticulata)	SCIENCE			English	Article							LIFE-HISTORY EVOLUTION; TRINIDADIAN GUPPIES; SELECTION; PREDATION; MORTALITY; IMPACT	Natural populations of guppies were subjected to an episode of directional selection that mimicked natural processes. The resulting rate of evolution of age and size at maturity was similar to rates typically obtained for traits subjected to artificial selection in laboratory settings and up to seven orders of magnitude greater than rates inferred from the paleontological record. Male traits evolved more rapidly than female traits largely because males had more genetic variation upon which natural selection could act. These results are considered in light of the ongoing debate about the importance of natural selection versus other processes in the paleontological record of evolution.	UNIV MINNESOTA, DEPT ECOL EVOLUT & BEHAV, ST PAUL, MN 55108 USA; UNIV CALIF DAVIS, CTR POPULAT BIOL, DAVIS, CA 95616 USA	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Davis	Reznick, DN (corresponding author), UNIV CALIF RIVERSIDE, DEPT BIOL, RIVERSIDE, CA 92521 USA.		Langerhans, R. Brian/A-7205-2009	reznick, david/0000-0002-1144-0568				CHARLESWORTH B, 1982, EVOLUTION, V36, P474, DOI 10.1111/j.1558-5646.1982.tb05068.x; Charlesworth B., 1994, EVOLUTION AGE STRUCT, DOI [10.1017/CBO9780511525711, DOI 10.1017/CBO9780511525711]; Endler J.A., 1978, Evolutionary Biology (New York), V11, P319; ENDLER JA, 1983, ENVIRON BIOL FISH, V9, P173, DOI 10.1007/BF00690861; Falconer D. S., 1989, Introduction to quantitative genetics.; GADGIL M, 1970, American Naturalist, V104, P1, DOI 10.1086/282637; GIBBS HL, 1987, NATURE, V327, P511, DOI 10.1038/327511a0; GINGERICH PD, 1983, SCIENCE, V222, P159, DOI 10.1126/science.222.4620.159; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; HALDANE JBS, 1949, EVOLUTION, V3, P51, DOI 10.2307/2405451; Haskins C. P., 1961, VERTEBRATE SPECIATIO, P320; Kallman K.D., 1989, P163; Kozlowski J, 1987, EVOL ECOL, V1, P214, DOI 10.1007/BF02067552; LAMBERS H, 1992, ADV ECOL RES, V23, P187, DOI 10.1016/S0065-2504(08)60148-8; LANDE R, 1979, EVOLUTION, V33, P234, DOI [10.2307/2407380, 10.1111/j.1558-5646.1979.tb04678.x]; LAW R, 1979, AM NAT, V114, P399, DOI 10.1086/283488; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Liley NR., 1975, FUNCTION EVOLUTION B, P118; MATTINGLY HT, 1994, OIKOS, V69, P54, DOI 10.2307/3545283; MEYER K, 1983, J DAIRY SCI, V66, P1988, DOI 10.3168/jds.S0022-0302(83)82040-2; MICHOD RE, 1979, AM NAT, V113, P531, DOI 10.1086/283411; MOUSSEAU TA, 1987, HEREDITY, V59, P181, DOI 10.1038/hdy.1987.113; PATTERSON HD, 1971, BIOMETRIKA, V58, P545, DOI 10.1093/biomet/58.3.545; REZNICK D, 1982, EVOLUTION, V36, P1236, DOI 10.1111/j.1558-5646.1982.tb05493.x; REZNICK D, 1982, EVOLUTION, V36, P160, DOI 10.1111/j.1558-5646.1982.tb05021.x; REZNICK DA, 1990, NATURE, V346, P357, DOI 10.1038/346357a0; Reznick DN, 1996, AM NAT, V147, P319, DOI 10.1086/285854; Reznick DN, 1996, AM NAT, V147, P339, DOI 10.1086/285855; REZNICK DN, 1987, EVOLUTION, V41, P1370, DOI 10.1111/j.1558-5646.1987.tb02474.x; Reznick DN, 1996, EVOLUTION, V50, P1651, DOI 10.1111/j.1558-5646.1996.tb03937.x; REZNICK DN, 1989, EVOLUTION, V43, P1285, DOI 10.1111/j.1558-5646.1989.tb02575.x; *SAS I, 1988, SAS STAT US GUID REL, P433; SHAW RG, 1987, EVOLUTION, V41, P812, DOI 10.1111/j.1558-5646.1987.tb05855.x; Stearns S.C., 1992, pi; Travis Joseph, 1994, P205	35	639	652	1	303	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	1997	275	5308					1934	1937		10.1126/science.275.5308.1934	http://dx.doi.org/10.1126/science.275.5308.1934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072971				2022-12-28	WOS:A1997WQ51300046
J	Burke, W; Petersen, G; Lynch, P; Botkin, J; Daly, M; Garber, J; Kahn, MJE; McTiernan, A; Offit, K; Thomson, E; Varricchio, C				Burke, W; Petersen, G; Lynch, P; Botkin, J; Daly, M; Garber, J; Kahn, MJE; McTiernan, A; Offit, K; Thomson, E; Varricchio, C			Recommendations for follow-up care of individuals with an inherited predisposition to cancer .1. Hereditary nonpolyposis colon cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; ENDOMETRIAL CARCINOMA; MOLECULAR-GENETICS; ASPIRIN USE; RISK; SURVEILLANCE; MUTATIONS; KINDREDS; SULINDAC	Objective.-To provide recommendations for cancer surveillance and risk reduction for individuals carrying mutations associated with hereditary nonpolyposis colon cancer (HNPCC). Participants.-A task force with expertise in medical genetics, oncology, primary care, gastroenterology, and epidemiology convened by the Cancer Genetics Studies Consortium (CGSC), organized by the National Human Genome Research Institute (previously the National Center for Human Genome Research). Evidence.-Studies evaluating cancer risk, surveillance, and risk reduction in individuals genetically susceptible to colon cancer were identified using MEDLINE and bibliographies of articles thus identified, Indexing terms used were ''genetics'' in combination with ''colon cancer,'' and ''screening'' in combination with ''cancer family'' and ''HNPCC,'' For studies evaluating specific interventions, quality of evidence was assessed using criteria of the US Preventive Services Task Force. Consensus Process.-The task force developed recommendations through discussions over a 14-month period. Conclusions.-Efficacy of cancer surveillance or other measures to reduce risk in individuals who carry cancer-predisposing mutations is unknown, Based on observational studies, colonoscopy every 1 to 3 years starting at age 25 years is recommended for individuals known to have HNPCC-associated mutations, Endometrial cancer screening is also recommended, based on expert opinion concerning presumptive benefit, No recommendation is made for or against prophylactic surgery (ie, colectomy, hysterectomy); these surgeries are an option for mutation carriers, but evidence of benefit is lacking, It is recommended that individuals considering genetic testing be counseled regarding the unknown efficacy of measures to reduce risk and that care for individuals with cancer-predisposing mutations be provided whenever possible within the context of research protocols designed to evaluate clinical outcomes.	JOHNS HOPKINS UNIV,DEPT EPIDEMIOL,BALTIMORE,MD; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX; UNIV UTAH,UTAH CTR HUMAN GENOME RES,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT; FOX CHASE CANC CTR,PHILADELPHIA,PA 19111; DANA FARBER CANC INST,BOSTON,MA 02115; NATL BREAST CANC COALIT,SEATTLE,WA; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; MEM SLOAN KETTERING INST CANC RES,NEW YORK,NY; NATL HUMAN GENOME RES INST,ETH LEGAL & SOCIAL IMPLICAT BRANCH,BETHESDA,MD; NCI,BETHESDA,MD 20892	Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; Utah System of Higher Education; University of Utah; Fox Chase Cancer Center; Harvard University; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Center; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Burke, W (corresponding author), UNIV WASHINGTON,DEPT MED,4245 ROOSEVELT WAY NE,SEATTLE,WA 98105, USA.							Aarnio M, 1995, INT J CANCER, V64, P430, DOI 10.1002/ijc.2910640613; AHLQUIST DA, 1995, GASTROENTEROLOGY, V108, P1590, DOI 10.1016/0016-5085(95)90711-4; AVERETTE HE, 1993, CANCER, V72, P1043, DOI 10.1002/1097-0142(19930801)72:3+<1043::AID-CNCR2820721317>3.0.CO;2-E; BENBARUCH G, 1994, GYNECOL OBSTET INVES, V37, P260, DOI 10.1159/000292573; BREWER DA, 1994, DIS COLON RECTUM, V37, P1328, DOI 10.1007/BF02257807; BURKE W, IN PRESS JAMA; FITZGIBBONS RJ, 1990, HEREDITARY COLORECTA, P211; FRIEDLANDER M, 1992, CURR OPIN ONCOL, V4, P918; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GIOVANNUCCI E, 1995, ANN INTERN MED, V122, P327, DOI 10.7326/0003-4819-122-5-199503010-00002; HIXSON LJ, 1990, JNCI-J NATL CANCER I, V82, P1769, DOI 10.1093/jnci/82.22.1769; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; JASS JR, 1992, EUR J GASTROEN HEPAT, V4, P523; LIN HH, 1995, BRIT J OBSTET GYNAEC, V102, P148, DOI 10.1111/j.1471-0528.1995.tb09069.x; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LYNCH HT, 1995, TUMORI, V81, P19; LYNCH HT, 1995, J TUMOR MARKER ONCOL, V10, P7; LYNCH HT, 1988, J NATL CANCER I, V80, P278, DOI 10.1093/jnci/80.4.278; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; LYNCH HT, 1994, ANTICANCER RES, V14, P1617; LYNCH HT, 1977, CANCER, V40, P1849, DOI 10.1002/1097-0142(197710)40:4+<1849::AID-CNCR2820400813>3.0.CO;2-U; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MECKLIN JP, 1986, DIS COLON RECTUM, V29, P849, DOI 10.1007/BF02555362; MECKLIN JP, 1986, DIS COLON RECTUM, V29, P160, DOI 10.1007/BF02555012; MECKLIN JP, 1993, DIS COLON RECTUM, V36, P927, DOI 10.1007/BF02050627; *NCI CANC GEN NETW, 1996, SCIENTIST       0722, V10, P1; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; OSMERS R, 1990, LANCET, V335, P1569, DOI 10.1016/0140-6736(90)91387-P; OSMERS RGW, 1994, CURR OPIN OBSTET GYN, V6, P75; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARTRIDGE EE, 1991, SURG CLIN N AM, V71, P991; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; Rhyu MS, 1996, J NATL CANCER I, V88, P240, DOI 10.1093/jnci/88.5.240; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VANDENBOSCH T, 1995, OBSTET GYNECOL, V85, P349, DOI 10.1016/0029-7844(94)00421-9; VASEN HF, 1993, DIS COLON RECTUM, V36, P1, DOI 10.1007/BF02050292; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VASEN HFA, 1995, LANCET, V345, P1183, DOI 10.1016/S0140-6736(95)91016-6; VASEN HFA, 1990, INT J CANCER, V46, P31, DOI 10.1002/ijc.2910460108; Warner EA, 1996, MED CLIN N AM, V80, P45, DOI 10.1016/S0025-7125(05)70426-0; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; WATSON P, 1994, AM J MED, V96, P516, DOI 10.1016/0002-9343(94)90091-4; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; ZORLU CG, 1994, GYNECOL OBSTET INVES, V38, P272	50	374	384	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					915	919		10.1001/jama.277.11.915	http://dx.doi.org/10.1001/jama.277.11.915			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062331				2022-12-28	WOS:A1997WM77400036
J	Dellemijn, PLI; Vanneste, JAL				Dellemijn, PLI; Vanneste, JAL			Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain	LANCET			English	Article							PATIENT-CONTROLLED ANALGESIA; POSTHERPETIC NEURALGIA; IDIOPATHIC FORMS; SENSITIVITY; RESPONSIVENESS; MANAGEMENT; DIAZEPAM; RELIEF	Background The effectiveness of opioid analgesics in noncancer neuropathic pain is unpredictable and can be disappointing. It is not clear whether opioids, when effective, relieve pain by decreasing pain intensity or pain unpleasantness or by their sedative effect. The aim of this prospective randomised double-blind placebo-controlled crossover trial was to assess relief of pain intensity and pain unpleasantness with intravenous infusions of fentanyl. Methods We compared the analgesic effect of intravenous dose titration of fentanyl with diazepam (active placebo) or saline (inert placebo) in 53 patients with different types of neuropathic pain. Patients were randomly assigned two consecutive infusions: fentanyl plus diazepam (27 patients) or fentanyl plus saline (26 patients). Study medication was infused at a constant rate for a maximum of 5 h. Pain, sedation, and side-effects were assessed from the start of infusion for 8 h. The primary outcome measure was maximum relief of pain intensity. Findings One patient in the fentanyl/diazepam group and two in the fentanyl/saline group were withdrawn. Maximum relief of pain intensity was better with fentanyl than with diazepam (66% [95% CI 53-80] vs 23% [12-35]) or with saline (50% [36-63] vs 12% [4-20]). The beneficial effect of fentanyl was independent of the. type of neuropathic pain and the degree of sedation. Fentanyl therapy produced equal relief of pain intensity and pain unpleasantness, whereas diazepam and saline did not reduce either pain index. Patients reported significantly more side-effects while receiving fentanyl than during diazepam or saline infusion (p<0.0001), but none of the side-effects was severe. Interpretation Fentanyl may relieve non-cancer neuropathic pain by its intrinsic analgesic effect. The clinical characteristics of neuropathic pain do not predict response to opioids.	ST JOSEPH HOSP,DEPT CLIN NEUROPHYSIOL,VELDHOVEN,NETHERLANDS; ST LUCAS ANDREAS ZIEKENHUIS,DEPT NEUROL,AMSTERDAM,NETHERLANDS; ST LUCAS ANDREAS ZIEKENHUIS,DEPT CLIN NEUROPHYSIOL,AMSTERDAM,NETHERLANDS	Sint Lucas Andreas Hospital; Sint Lucas Andreas Hospital	Dellemijn, PLI (corresponding author), ST JOSEPH HOSP,DEPT NEUROL,POB 7777,VELDHOVEN,NETHERLANDS.							APPENZELLER O, 1984, BRAIN RES, V304, P383, DOI 10.1016/0006-8993(84)90344-5; ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; ASBURY AK, 1984, NEUROLOGY, V34, P1587, DOI 10.1212/WNL.34.12.1587; CHAPMAN CR, 1973, PSYCHOSOM MED, V35, P330; DELLEMIJN PLI, 1994, EUR J CANCER, V30A, P1244, DOI 10.1016/0959-8049(94)90166-X; DELLEMIJN PLI, 1994, BRAIN, V117, P1475, DOI 10.1093/brain/117.6.1475; DELLEMIJN PLI, 1994, PAIN, V57, P137, DOI 10.1016/0304-3959(94)90217-8; DEVOR M, 1992, NEUROREPORT, V3, P21, DOI 10.1097/00001756-199201000-00005; DEVOR M, 1991, NEW PHARM PAIN, P417; GRACELY RH, 1978, PAIN, V5, P19, DOI 10.1016/0304-3959(78)90021-0; GRACELY RH, 1982, ANESTH ANALG, V61, P751; HROMADA J, 1963, ACTA ANAT, V55, P343; JADAD AR, 1992, LANCET, V339, P1367, DOI 10.1016/0140-6736(92)91194-D; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; KUPERS RC, 1991, PAIN, V47, P5, DOI 10.1016/0304-3959(91)90004-H; MAX MB, 1988, CLIN PHARMACOL THER, V43, P363, DOI 10.1038/clpt.1988.44; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MCQUAY HJ, 1992, ANAESTHESIA, V47, P757, DOI 10.1111/j.1365-2044.1992.tb03253.x; Merskey H, 1994, CLASSIFICATION CHRON, P207; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Portenoy R., 1996, PAIN MANAGEMENT THEO, P83; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; PRICE DD, 1986, PAIN, V24, P197, DOI 10.1016/0304-3959(86)90042-4; PRICE DD, 1985, PAIN, V22, P261, DOI 10.1016/0304-3959(85)90026-0; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; Tasker R., 1991, ADV PAIN RES THER, P241; URBAN BJ, 1986, PAIN, V24, P191, DOI 10.1016/0304-3959(86)90041-2; ZOCHODNE DW, 1993, CAN J NEUROL SCI, V20, P69, DOI 10.1017/S0317167100047466; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	30	160	168	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					753	758		10.1016/S0140-6736(96)09024-1	http://dx.doi.org/10.1016/S0140-6736(96)09024-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074573				2022-12-28	WOS:A1997WN12400008
J	Garrett, GA; Rojo, AG; Sood, AK; Whitaker, JF; Merlin, R				Garrett, GA; Rojo, AG; Sood, AK; Whitaker, JF; Merlin, R			Vacuum squeezing of solids: Macroscopic quantum states driven by light pulses	SCIENCE			English	Article							COHERENT STATES	Femtosecond laser pulses and coherent two-phonon Raman scattering were used to excite KFaO(3) into a squeezed state, nearly periodic in time, in which the variance of the atomic displacements dips below the standard quantum limit for half of a cycle. This nonclassical state involves a continuum of transverse acoustic modes that leads to oscillations in the refractive index associated with the frequency of a van Hove singularity in the phonon density of states.	UNIV MICHIGAN,CTR ULTRAFAST OPT SCI,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PHYS,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Garrett, Gregory A./AAG-2289-2020	Merlin, Roberto/0000-0002-5584-0248				ARTONI M, 1994, OPT COMMUN, V104, P319, DOI 10.1016/0030-4018(94)90563-0; ARTONI M, 1991, PHYS REV B, V44, P3736, DOI 10.1103/PhysRevB.44.3736; BIRMAN JL, 1984, THEORY CRYSTAL SPACE, P282; BORN M, 1954, DYNAMICAL THEORY CRY, P306; COMES R, 1972, PHYS REV B-SOLID ST, V5, P1886, DOI 10.1103/PhysRevB.5.1886; DHAR L, 1994, CHEM REV, V94, P157, DOI 10.1021/cr00025a006; GIACOBINO E, 1992, APPL PHYS B, V55; GLAUBER RJ, 1963, PHYS REV, V131, P2766, DOI 10.1103/PhysRev.131.2766; HU X, 1996, THESIS U MICHIGAN; Hu XD, 1996, PHYS REV LETT, V76, P2294, DOI 10.1103/PhysRevLett.76.2294; Hu XD, 1996, PHYS REV B, V53, P2419, DOI 10.1103/PhysRevB.53.2419; JANSZKY J, 1992, SPECTROCHIM ACTA A, V48, P31, DOI 10.1016/0584-8539(92)80195-3; JANSZKY J, 1990, PHYS REV LETT, V64, P2771, DOI 10.1103/PhysRevLett.64.2771; JANSZKY J, 1988, OPT COMMUN, V59, P151; KIMBLE HJ, 1987, J OPT SOC AM B, P4; LO CF, 1994, PHYS REV B, V50, P418, DOI 10.1103/PhysRevB.50.418; Meekhof DM, 1996, PHYS REV LETT, V76, P1796, DOI 10.1103/PhysRevLett.76.1796; MERTIN R, 1997, SOLID STATE COMMUN, V102, P207; Milburn, 1994, QUANTUM OPT; NATARAJAN V, 1995, PHYS REV LETT, V74, P2855, DOI 10.1103/PhysRevLett.74.2855; NIELSEN WG, 1967, J CHEM PHYS, V47, P1413; RUGAR D, 1991, PHYS REV LETT, V67, P699, DOI 10.1103/PhysRevLett.67.699; SHAPIRO JH, 1979, OPT LETT, V4, P334; SLUSHER RE, 1985, PHYS REV LETT, V55, P2409, DOI 10.1103/PhysRevLett.55.2409; Sonnek M, 1996, PHYS REV B, V53, P3190, DOI 10.1103/PhysRevB.53.3190; WALLS D, 1986, NATURE, V324, P210, DOI 10.1038/324210a0; WU LA, 1986, PHYS REV LETT, V57, P2520, DOI 10.1103/PhysRevLett.57.2520; YUEN HP, 1976, PHYS REV A, V13, P2226, DOI 10.1103/PhysRevA.13.2226	28	147	148	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1638	1640		10.1126/science.275.5306.1638	http://dx.doi.org/10.1126/science.275.5306.1638			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054356	Green Accepted			2022-12-28	WOS:A1997WN12300044
J	Irani, K; Xia, Y; Zweier, JL; Sollott, SJ; Der, CJ; Fearon, ER; Sundaresan, M; Finkel, T; GoldschmidtClermont, PJ				Irani, K; Xia, Y; Zweier, JL; Sollott, SJ; Der, CJ; Fearon, ER; Sundaresan, M; Finkel, T; GoldschmidtClermont, PJ			Mitogenic signaling mediated by oxidants in ras-transformed fibroblasts	SCIENCE			English	Article							GTP-BINDING PROTEIN; GENERATING NADPH OXIDASE; ACTIN STRESS FIBERS; C-JUN; HYDROGEN-PEROXIDE; ENDOTHELIAL-CELLS; REGULATED KINASES; CDC42 GTPASES; GROWTH; ACTIVATION	NIH 3T3 fibroblasts stably transformed with a constitutively active isoform of p21(Ras), H-Ras(V12) (v-H-Ras or EJ-Ras), produced large amounts of the reactive oxygen species superoxide (. O-2-). . O-2(-) production was suppressed by the expression of dominant negative isoforms of Ras or Rac1, as well as by treatment with a farnesyltransferase inhibitor or with diphenylene iodonium, a flavoprotein inhibitor, The mitogenic activity of cells expressing H-Ras(V12) was inhibited by treatment with the chemical antioxidant N-acetyl-L-cysteine. Mitogen-activated protein kinase (MAPK) activity was decreased and c-Jun N-terminal kinase (JNK) was not activated in H-Ras(V12)-transformed cells. Thus, H-Ras(V12)-induced transformation can lead to the production of . O-2(-) through one or more pathways involving a flavoprotein and Rac1. The implication of a reactive oxygen species, probably . O-2(-), as a mediator of Ras-induced cell cycle progression independent of MAPK and JNK suggests a possible mechanism for the effects of antioxidants against Ras-induced cellular transformation.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV MICHIGAN,MED CTR,ANN ARBOR,MI 48109; NHLBI,CARDIOL BRANCH,NIH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University				Der, Channing/0000-0002-7751-2747; Irani, Kaikobad/0000-0001-9194-7387	NHLBI NIH HHS [HL52315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AMES BN, 1988, IARC SCI PUBL, V89, P407; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOS JL, 1989, CANCER RES, V49, P4682; BULKLEY GB, 1994, LANCET, V344, P934, DOI 10.1016/S0140-6736(94)92276-4; Burdon RH, 1996, FREE RADICAL RES, V24, P81, DOI 10.3109/10715769609088004; BURDON RH, 1993, FREE RADICAL RES COM, V19, P203, DOI 10.3109/10715769309111603; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; ERZURUM SC, 1993, NUCLEIC ACIDS RES, V21, P1607, DOI 10.1093/nar/21.7.1607; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; Heldman AW, 1996, CIRC RES, V78, P312, DOI 10.1161/01.RES.78.2.312; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IRANI K, UNPUB; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAUTALAHTI M, 1993, ANN MED, V25, P435; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; SZATROWSKI TP, 1991, CANCER RES, V51, P794; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156	48	1362	1405	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1649	1652		10.1126/science.275.5306.1649	http://dx.doi.org/10.1126/science.275.5306.1649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054359				2022-12-28	WOS:A1997WN12300047
J	Vigers, GPA; Anderson, LJ; Caffes, P; Brandhuber, BJ				Vigers, GPA; Anderson, LJ; Caffes, P; Brandhuber, BJ			Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1 beta	NATURE			English	Article							IDENTIFICATION; ANTAGONIST; RESOLUTION; REFINEMENT; SITE	Interleukin-1 (IL-1) is an important mediator of inflammatory disease. The IL-1 family currently consists of two agonists, IL-1 alpha and IL-1 beta, and one antagonist, IL-1ra. Each of these molecules binds to the type I IL-1 receptor (IL1R)(1). The binding of IL-1 alpha or IL-1 beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs, Here we report the three-dimensional structure of IL-1 beta bound to the extracellular domain of IL1R (s-IL1R) at 2.5 Angstrom resolution. IL-1 beta binds to s-IL1R with a 1:1 stoichiometry. The crystal structure shows that s-IL1R consists of three immunoglobulin-like domains which wrap around IL-1 beta in a manner distinct from the structures of previously described cytokine-receptor complexes. The two receptor-binding regions on IL-1 beta identified by site-directed mutagenesis(2,3) both contact the receptor: one binds to the first two domains of the receptor, while the other binds exclusively to the third domain.	AMGEN INC, BOULDER, CO 80301 USA	Amgen				Vigers, Guy/0000-0003-4451-8453				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; VIGERS GPK, 1994, J BIOL CHEM, V269, P12874; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0	19	214	237	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 13	1997	386	6621					190	194		10.1038/386190a0	http://dx.doi.org/10.1038/386190a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062193				2022-12-28	WOS:A1997WM97300066
J	Dandliker, PJ; Holmlin, RE; Barton, JK				Dandliker, PJ; Holmlin, RE; Barton, JK			Oxidative thymine dimer repair in the DNA helix	SCIENCE			English	Article							PHENANTHRENEQUINONE DIIMINE COMPLEXES; CIS-SYN; DAMAGED DNA; PYRIMIDINE; RECOGNITION; PHOTOLYASE; PHOTOCLEAVAGE; RHODIUM(III); TEMPERATURE; SEQUENCE	The metallointercalator Rh(phi)(2)DMB(3+) (phi, 9,10-phenanthrenequinone diimine; DMB, 4,4'-dimethyl-2,2'-bipyridine) catalyzed the repair of a thymine dimer incorporated site-specifically in a 16-base pair DNA duplex by means of visible light, This repair could be accomplished with rhodium noncovalently bound to the duplex and at long range (16 to 26 angstroms), with the rhodium intercalator tethered to either end of the duplex assembly, This long-range repair was mediated by the DNA helix, Repair efficiency did not decrease with increasing distance between intercalated rhodium and the thymine dimer, but it diminished with disruption of the intervening pi-stack.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology					NIGMS NIH HHS [GM49216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Arkin MR, 1996, J AM CHEM SOC, V118, P2267, DOI 10.1021/ja9532998; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894; BEGLEY TP, 1994, ACCOUNTS CHEM RES, V27, P394, DOI 10.1021/ar00048a002; CARRELL T, 1996, ANGEW CHEM INT EDIT, V35, P620; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; HEELIS PF, 1995, CHEM SOC REV, V24, P289, DOI 10.1039/cs9952400289; HELENE C, 1977, PHOTOCHEM PHOTOBIOL, V25, P429, DOI 10.1111/j.1751-1097.1977.tb09166.x; Holmlin RE, 1996, J AM CHEM SOC, V118, P5236, DOI 10.1021/ja953941y; JACOBSEN JR, 1995, J AM CHEM SOC, V117, P5453, DOI 10.1021/ja00125a004; KALNIK MW, 1990, J BIOL CHEM, V265, P636; KEMMINK J, 1986, PHOTOCHEM PHOTOBIOL, V44, P137, DOI 10.1111/j.1751-1097.1986.tb03577.x; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KIM ST, 1993, PHOTOCHEM PHOTOBIOL, V57, P895, DOI 10.1111/j.1751-1097.1993.tb09232.x; KIM ST, 1990, PHOTOCHEM PHOTOBIOL, V52, P789, DOI 10.1111/j.1751-1097.1990.tb08683.x; MURPHY CJ, 1993, SCIENCE, V262, P1025, DOI 10.1126/science.7802858; PAC CJ, 1990, PHOTOCHEM PHOTOBIOL, V52, P973, DOI 10.1111/j.1751-1097.1990.tb01813.x; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4015, DOI 10.1021/bi00131a017; RSTANDI RR, 1993, J AM CHEM SOC, V115, P2537; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SITLANI A, 1992, J AM CHEM SOC, V114, P2303, DOI 10.1021/ja00033a003; SITLANI A, 1994, BIOCHEMISTRY-US, V33, P12100, DOI 10.1021/bi00206a013; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1994, ACCOUNTS CHEM RES, V27, P76, DOI 10.1021/ar00039a003; Turro C, 1996, INORG CHIM ACTA, V243, P101, DOI 10.1016/0020-1693(95)04896-0; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WACHTER L, 1986, NUCLEIC ACIDS RES, V14, P7985, DOI 10.1093/nar/14.20.7985; YEH SR, 1991, J AM CHEM SOC, V113, P8557, DOI 10.1021/ja00022a072; YOUNG T, 1990, PHOTOCHEM PHOTOBIOL, V52, P661, DOI 10.1111/j.1751-1097.1990.tb08664.x; [No title captured]	33	415	426	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1465	1468		10.1126/science.275.5305.1465	http://dx.doi.org/10.1126/science.275.5305.1465			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045609				2022-12-28	WOS:A1997WM08100042
J	Kirk, KE; Harmon, BP; Reichardt, IK; Sedat, JW; Blackburn, EH				Kirk, KE; Harmon, BP; Reichardt, IK; Sedat, JW; Blackburn, EH			Block in anaphase chromosome separation caused by a telomerase template mutation	SCIENCE			English	Article							TETRAHYMENA-THERMOPHILA; BUDDING YEAST; MITOSIS; REPLICATION; MICROSCOPY	Telomeres are essential for chromosome stability, but their functions at specific cell-cycle stages are unknown. Telomeres are now shown to have a role in chromosome separation during mitosis. In telomeric DNA mutants of Tetrahymena thermophila, created by expression of a telomerase RNA with an altered template sequence, division of the germline nucleus was severely delayed or blocked in anaphase, The mutant chromatids failed to separate completely at the midzone, becoming stretched io up to twice their normal length. These results suggest a physical block in mutant telomere separation.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026259, R01GM026259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adl SM, 1996, J EUKARYOT MICROBIOL, V43, P77, DOI 10.1111/j.1550-7408.1996.tb04484.x; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Blackburn EH, 1995, TELOMERES; BRUNS PJ, 1983, GENETICS, V104, P257; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; DERNBURG AF, 1995, TELOMERES, P295; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; FANG G, 1995, TELOMERES, P69; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GAERTIG J, 1992, P NATL ACAD SCI USA, V89, P9196, DOI 10.1073/pnas.89.19.9196; Gall JG, 1986, MOL BIOL CILIATED PR; Gilley D, 1996, MOL CELL BIOL, V16, P66; HENDERSON E, 1995, TELOMERES, P11; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; KIRK KE, 1995, GENE DEV, V9, P59, DOI 10.1101/gad.9.1.59; KIRK KE, UNPUB; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; ROMERO DP, 1995, J EUKARYOT MICROBIOL, V42, P32, DOI 10.1111/j.1550-7408.1995.tb01537.x; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; WEINERT TA, 1992, RADIAT RES, V132, P141, DOI 10.2307/3578518; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YANAGIDA N, 1995, BIOESSAYS, V17, P519, DOI 10.1002/bies.950170608; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	29	187	192	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 7	1997	275	5305					1478	1481		10.1126/science.275.5305.1478	http://dx.doi.org/10.1126/science.275.5305.1478			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045613				2022-12-28	WOS:A1997WM08100046
J	Bottcher, B; Wynne, SA; Crowther, RA				Bottcher, B; Wynne, SA; Crowther, RA			Determination of the fold of the core protein of hepatitis B virus ky electron cryomicroscopy	NATURE			English	Article							E-ANTIGEN; ESCHERICHIA-COLI; PARTICLES; IDENTIFICATION; MICROSCOPY; EPITOPES; REGIONS; SURFACE	Hepatitis B virus, a major human pathogen with an estimated 300 million carriers worldwide, can lead to cirrhosis and liver cancer in cases of chronic infection. The virus consists of an inner nucleocapsid or core, surrounded by a lipid envelope containing virally encoded surface proteins. The core protein, when expressed in bacteria, assembles into core shell particles, closely resembling the native core of the virus. Here we use electron cryomicroscopy to solve the structure of the core protein to 7.4 Angstrom resolution. Images of about 6,400 individual particles from 34 micrographs at different levels of defocus were combined, imposing icosahedral symmetry. The three-dimensional map reveals the complete fold of the polypeptide chain, which is quite unlike previously solved viral capsid proteins and is largely alpha-helical. The dimer clustering of subunits produces spikes on the surface of the shell, which consist of radial bundles of four long alpha-helices. Our model implies that the sequence corresponding to the immunodominant region of the core protein lies at the tip of the spike and also explains other properties of the core protein.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology			Bottcher, Bettina/E-9397-2010	Bottcher, Bettina/0000-0002-7962-4849				BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; BICHKO V, 1985, FEBS LETT, V185, P208, DOI 10.1016/0014-5793(85)80771-7; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; BORISOVA G, 1993, J VIROL, V67, P3696, DOI 10.1128/JVI.67.6.3696-3701.1993; Bottcher B, 1996, STRUCTURE, V4, P387; BROWN AL, 1991, VACCINE, V9, P595, DOI 10.1016/0264-410X(91)90248-5; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; COHEN BJ, 1982, NATURE, V296, P677, DOI 10.1038/296677a0; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KENNEY JM, 1995, STRUCTURE, V3, P1009, DOI 10.1016/S0969-2126(01)00237-4; Khudyakov YuE, 1991, Biomed Sci, V2, P257; NASSAL M, 1992, J MOL BIOL, V225, P1013, DOI 10.1016/0022-2836(92)90101-O; NASSAL M, 1993, J VIROL, V67, P4307, DOI 10.1128/JVI.67.7.4307-4315.1993; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PUSHKO P, 1994, VIROLOGY, V202, P912, DOI 10.1006/viro.1994.1413; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; SCHODEL F, 1992, J VIROL, V66, P106; TAKAHASHI K, 1991, J IMMUNOL, V147, P3156; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; VIGERS GPA, 1986, THESIS U CAMBRIDGE; WASENAUER G, 1993, J VIROL, V67, P1315, DOI 10.1128/JVI.67.3.1315-1321.1993; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; ZHENG J, 1992, J BIOL CHEM, V267, P9422; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	30	654	693	0	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					88	91		10.1038/386088a0	http://dx.doi.org/10.1038/386088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052786				2022-12-28	WOS:A1997WL74600057
J	Truong, DH; Hedemark, LL; Mickman, JK; Mosher, LB; Dietrich, SE; Lowry, PW				Truong, DH; Hedemark, LL; Mickman, JK; Mosher, LB; Dietrich, SE; Lowry, PW			Tuberculosis among Tibetan immigrants from India and Nepal in Minnesota, 1992-1995	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 15-18, 1996	NEW ORLEANS, LA				MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES; REFUGEES	Objective.-To study screening outcomes among a group of Tibetan immigrants at high risk for developing active tuberculosis (TB) after arrival in Minnesota. Design.-Retrospective cohort study. Participants.-A total of 191 Tibetan immigrants undergoing medical screening. Main Outcome Measures.-Occurrence and treatment outcomes of active TB. Setting.-A health maintenance organization and a public TB clinic in Minneapolis, Minn. Results.-Positive (induration, greater than or equal to 10 mm) tuberculin skin test results were documented in 98% of Tibetans, compared with 44% of Vietnamese, 10% of Hmong, and 51% of Russian refugees in Minnesota (P<.001 for each group). Sixteen active cases (8.4%) were confirmed by isolation of Mycobacterium tuberculosis; however, 5 (31%) were culture-negative on initial screening in Minnesota. Seven cases (44%) were diagnosed during initial screening efforts, and 9 cases (56%) were diagnosed a mean of 19 months (range, 10-27 months) after their initial medical evaluation. Of these 9 cases, 6 (38% of all Tibetan cases) had isolates resistant to 1 or more antituberculous drugs, and 3 (19% of all Tibetan cases) were multidrug resistant (MDR TB). All 3 MDR TB cases were culture-negative on initial screening; these cases constituted 75% of the MDR TB isolates in Minnesota in 1994. The presence of MDR TB was associated with a known history of active TB in Asia (P<.02), Any abnormality on chest radiograph noted either during the Immigration and Naturalization Service screening evaluation in India (relative risk [RR], 5.2; P=.006) or on arrival in Minnesota (RR, 6.8; P=.005) was associated with an increased risk of subsequent active TB. Conclusions.-Tuberculosis infection is nearly universal among Tibetans settling in Minnesota, A single screening evaluation failed to detect the majority of TB cases among Tibetans. Even in the face of negative M tuberculosis cultures, persons with a history of active TB require particularly close follow-up.	UNIV MINNESOTA,SCH PUBL HLTH,INFECT DIS RES UNIT,DIV EPIDEMIOL,MINNEAPOLIS,MN 55454; UNIV MINNESOTA,SCH PUBL HLTH,DEPT MED,MINNEAPOLIS,MN 55454; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55454; HEALTHPARTNERS INC,MINNEAPOLIS,MN; MICHIGAN DEPT COMMUNITY HLTH,LANSING,MI	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; MDHHS - Michigan Department of Health & Human Services								[Anonymous], 1990, MMWR Recomm Rep, V39, P1; BARNHOORN F, 1992, SOC SCI MED, V34, P291, DOI 10.1016/0277-9536(92)90271-Q; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Bloch A.B., 1995, MMWR-MORBID MORTAL W, V44, P18; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P365; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; *NAT OFF NY ASS NE, 1993, SEL NOT ART 1990 199; NOLAN CM, 1986, AM REV RESPIR DIS, V133, P431; NOLAN CM, 1989, AM REV RESPIR DIS, V140, P996, DOI 10.1164/ajrccm/140.4.996; ORMEROD P, 1991, MED INT, V90, P3746; POWELL KE, 1983, JAMA-J AM MED ASSOC, V249, P1455, DOI 10.1001/jama.249.11.1455; RIDZON R, 1993, 34 INT C ANT AG CHEM; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WARES DF, 1995, THORAX S2, V50, pA76	16	31	32	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					735	738		10.1001/jama.277.9.735	http://dx.doi.org/10.1001/jama.277.9.735			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042846				2022-12-28	WOS:A1997WK02600033
J	Hughes, PE; Renshaw, MW; Pfaff, M; Forsyth, J; Keivens, VM; Schwartz, MA; Ginsberg, MH				Hughes, PE; Renshaw, MW; Pfaff, M; Forsyth, J; Keivens, VM; Schwartz, MA; Ginsberg, MH			Suppression of integrin activation: A novel function of a Ras/Raf-initiated MAP kinase pathway	CELL			English	Article							OUT SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; PROTEIN-KINASE; BETA(1) INTEGRIN; CELL-ADHESION; RAS; RECEPTOR; BINDING; TRANSFORMATION; RAF-1	Rapid modulation of ligand binding affinity (''activation'') is a central property of the integrin cell adhesion receptors. Using a screen for suppressors of integrin activation, we identified the small GTP-binding protein, H-Ras, and its effector kinase, Raf-l, as negative regulators of integrin activation. H-Ras inhibited the activation of integrins with three distinct alpha and beta subunit cytoplasmic domains. Suppression was not associated with integrin phosphorylation and was independent of both mRNA transcription and protein synthesis. Furthermore, suppression correlated with activation of the ERK MAP kinase pathway. Thus, regulation of integrin affinity state is a novel, transcription-independent function of a Ras-linked MAP kinase pathway that may mediate a negative feedback loop in integrin function.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				schwartz, martin/0000-0002-2071-1243				ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; COX AD, 1994, ONCOGENE, V9, P3281; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes R O, 1978, Ann N Y Acad Sci, V312, P317, DOI 10.1111/j.1749-6632.1978.tb16811.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VASSBOTN FS, 1994, J BIOL CHEM, V269, P13874; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	46	437	444	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					521	530		10.1016/S0092-8674(00)81892-9	http://dx.doi.org/10.1016/S0092-8674(00)81892-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038343	Bronze			2022-12-28	WOS:A1997WJ69100012
J	Tong, CYW; Potter, FA; Pang, KA; Vora, J				Tong, CYW; Potter, FA; Pang, KA; Vora, J			Severe encephalitis with rapid recovery	LANCET			English	Article							MENINGOENCEPHALITIS		ROYAL LIVERPOOL UNIV HOSP,DEPT ANAESTHESIA,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,DEPT NEUROPHYSIOL,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,DEPT MED,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Tong, CYW (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT MED MICROBIOL,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND.		Tong, Cheuk Yan William/C-1312-2012	Tong, Cheuk Yan William/0000-0001-8401-6832				MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; Rotbart Harley A., 1995, P271; WANG DM, 1993, CHINESE MED J-PEKING, V106, P767; WHITLEY R J, 1990, P1843; WHITLEY RJ, 1995, CLIN INFECT DIS, V20, P414, DOI 10.1093/clinids/20.2.414	5	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					470	470		10.1016/S0140-6736(96)09320-8	http://dx.doi.org/10.1016/S0140-6736(96)09320-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040578				2022-12-28	WOS:A1997WH38900013
J	Woodcock, A				Woodcock, A			Use of spacers with metered dose inhalers	LANCET			English	Editorial Material							DEVICE				Woodcock, A (corresponding author), WYTHENSHAWE HOSP,NW LUNG CTR,MANCHESTER M23 9LT,LANCS,ENGLAND.			Woodcock, Ashley/0000-0002-5428-8578				Barry PW, 1996, THORAX, V51, P835, DOI 10.1136/thx.51.8.835; BARRY PW, 1994, EUR RESPIR J, V7, P1707, DOI 10.1183/09031936.94.07091707; BISGAARD H, 1995, EUR RESPIR J, V8, P856; Clark DJ, 1996, THORAX, V51, P981, DOI 10.1136/thx.51.10.981; KRAEMER R, 1991, AM REV RESPIR DIS, V144, P347, DOI 10.1164/ajrccm/144.2.347; Wildhaber JH, 1996, THORAX, V51, P985, DOI 10.1136/thx.51.10.985	6	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					446	446		10.1016/S0140-6736(05)61178-6	http://dx.doi.org/10.1016/S0140-6736(05)61178-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040569				2022-12-28	WOS:A1997WH38900004
J	Haggard, MP				Haggard, MP			Reduced confusion over ear effusion? Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							OTITIS-MEDIA				Haggard, MP (corresponding author), MRC,INST HEARING RES,NOTTINGHAM NG7 2RD,ENGLAND.							Arason VA, 1996, BMJ-BRIT MED J, V313, P387; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; STEPHENSON H, 1993, AUDIOLOGY, V32, P164; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344; YOUNGSON R, 1995, ROYAL SOC MED ENCY C	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					354	354		10.1136/bmj.314.7077.354	http://dx.doi.org/10.1136/bmj.314.7077.354			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040333	Green Published			2022-12-28	WOS:A1997WF86100039
J	Menon, N; Durian, DJ				Menon, N; Durian, DJ			Diffusing-wave spectroscopy of dynamics in a three-dimensional granular flow	SCIENCE			English	Article							MULTIPLE LIGHT-SCATTERING; VELOCITY FLUCTUATIONS; SUSPENSIONS; SMOOTH	Diffusing-wave spectroscopy was used to measure the microscopic dynamics of grains in the interior of a three-dimensional flow of sand. The correlation functions show that minutely separated grains fly from collision to collision with large random velocities. On a time scale 10(3) to 10(4) times longer than the average time between collisions, the grains displayed slow, collective rearrangements, which, at the long-time limit, produced diffusive dynamics.			Menon, N (corresponding author), UNIV CALIF LOS ANGELES, DEPT PHYS & ASTRON, LOS ANGELES, CA 90095 USA.		Durian, Douglas J./D-7013-2012	Durian, Douglas J./0000-0003-3240-2381				BAGNOLD RA, 1954, PROC R SOC LON SER-A, V225, P49, DOI 10.1098/rspa.1954.0186; BAGNOLD RA, 1966, PROC R SOC LON SER-A, V295, P219, DOI 10.1098/rspa.1966.0236; BERNE B. J., 1976, DYNAMIC LIGHT SCATTE; CAMPBELL CS, 1990, ANNU REV FLUID MECH, V22, P57, DOI 10.1146/annurev.fl.22.010190.000421; Cody GD, 1996, POWDER TECHNOL, V87, P211, DOI 10.1016/0032-5910(96)03087-2; DRAKE TG, 1991, J FLUID MECH, V225, P121, DOI 10.1017/S0022112091001994; EHRICHS EE, 1995, SCIENCE, V267, P1632, DOI 10.1126/science.267.5204.1632; FRADEN S, 1990, PHYS REV LETT, V65, P512, DOI 10.1103/PhysRevLett.65.512; GOLDHIRSCH I, 1993, PHYS REV LETT, V70, P1619, DOI 10.1103/PhysRevLett.70.1619; HAFF PK, 1983, J FLUID MECH, V134, P401, DOI 10.1017/S0022112083003419; HOPKINS MA, 1991, PHYS FLUIDS A-FLUID, V3, P47, DOI 10.1063/1.857863; HSIAU SS, 1993, J FLUID MECH, V251, P299, DOI 10.1017/S0022112093003428; HUI K, 1986, INT J MULTIPHAS FLOW, V12, P289, DOI 10.1016/0301-9322(86)90031-5; JAEGER HM, 1992, SCIENCE, V255, P1523, DOI 10.1126/science.255.5051.1523; Jaeger HM, 1996, PHYS TODAY, V49, P32, DOI 10.1063/1.881494; JENKINS JT, 1983, J FLUID MECH, V130, P187, DOI 10.1017/S0022112083001044; MARET G, 1987, Z PHYS B CON MAT, V65, P409, DOI 10.1007/BF01303762; MCNAMARA S, 1994, PHYS REV E, V50, pR28, DOI 10.1103/PhysRevE.50.R28; NAKAGAWA M, 1993, EXP FLUIDS, V16, P54, DOI 10.1007/BF00188507; Natarajan VVR, 1995, J FLUID MECH, V304, P1, DOI 10.1017/S0022112095004320; OGAWA S, 1979, P US JAP S CONT MECH, P208; PINE DJ, 1988, PHYS REV LETT, V60, P1134, DOI 10.1103/PhysRevLett.60.1134; PINE DJ, 1990, J PHYS-PARIS, V51, P2101, DOI 10.1051/jphys:0199000510180210100; QIU X, 1990, PHYS REV LETT, V65, P516, DOI 10.1103/PhysRevLett.65.516; Reynolds O., 1885, PHILOS MAG, V20, P469, DOI [10.1080/14786448508627791, DOI 10.1080/14786448508627791]; SCHOFIELD J, 1993, PHYSICA A, V196, P209, DOI 10.1016/0378-4371(93)90601-Y; TAGUCHI YH, 1995, EUROPHYS LETT, V30, P499, DOI 10.1209/0295-5075/30/8/010; Williams DRM, 1996, PHYS REV E, V54, pR9, DOI 10.1103/PhysRevE.54.R9; XUE JZ, 1992, PHYS REV LETT, V69, P1715, DOI 10.1103/PhysRevLett.69.1715; ZIK O, 1991, EUROPHYS LETT, V16, P255, DOI 10.1209/0295-5075/16/3/006	30	164	167	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	1997	275	5308					1920	1922		10.1126/science.275.5308.1920	http://dx.doi.org/10.1126/science.275.5308.1920			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072966				2022-12-28	WOS:A1997WQ51300041
J	Korinek, V; Barker, N; Morin, PJ; vanWichen, D; deWeger, R; Kinzler, KW; Vogelstein, B; Clevers, H				Korinek, V; Barker, N; Morin, PJ; vanWichen, D; deWeger, R; Kinzler, KW; Vogelstein, B; Clevers, H			Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC(-/-) colon carcinoma	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; HMG-BOX; ALPHA-ENHANCER; ASSOCIATION; FAMILY	The adenomatous polyposis coli (APC) tumor suppressor protein binds to beta-catenin, a protein recently shown to interact with Tcf and Lef transcription factors, The gene encoding hTcf-4, a Tcf family member that is expressed in colonic epithelium, was cloned and characterized, hTcf-4 transactivates transcription only when associated with beta-catenin. Nuclei of APC(-/-) colon carcinoma cells were found to contain a stable beta-catenin-hTcf-4 complex that was constitutively active, as measured by transcription of a Tcf reporter gene. Reintroduction of APC removed beta-catenin from hTcf-4 and abrogated the transcriptional transactivation, Constitutive transcription of Tcf target genes, caused by loss of APC function, may be a crucial event in the early transformation of colonic epithelium.	UNIV UTRECHT HOSP, DEPT IMMUNOL, NL-3508 GA UTRECHT, NETHERLANDS; JOHNS HOPKINS ONCOL CTR, HOWARD HUGHES MED INST, BALTIMORE, MD 21231 USA; UNIV UTRECHT HOSP, DEPT PATHOL, NL-3508 GA UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Utrecht University; Utrecht University Medical Center			Barker, Nick/AAE-9833-2021; Barker, Nick/A-5535-2011; Barker, Nick/AAS-2774-2020; Korinek, Vladimir/G-6348-2014	Barker, Nick/0000-0003-3566-4475; Korinek, Vladimir/0000-0002-9777-4664	NCI NIH HHS [CA57345] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA057345, R01CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; CASTROP J, 1992, NUCLEIC ACIDS RES, V20, P611, DOI 10.1093/nar/20.3.611; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KORINEK V, UNPUB; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MORIN P, UNPUB; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VanHoffen E, 1996, AM J PATHOL, V149, P1991; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	22	2852	2994	2	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	1997	275	5307					1784	1787		10.1126/science.275.5307.1784	http://dx.doi.org/10.1126/science.275.5307.1784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065401				2022-12-28	WOS:A1997WP05600039
J	Kaupmann, K; Huggel, K; Heid, J; Flor, PJ; Bischoff, S; Mickel, SJ; McMaster, G; Angst, C; Bittiger, H; Froestl, W; Bettler, B				Kaupmann, K; Huggel, K; Heid, J; Flor, PJ; Bischoff, S; Mickel, SJ; McMaster, G; Angst, C; Bittiger, H; Froestl, W; Bettler, B			Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; AMINO-ACID-TRANSPORT; RAT CEREBRAL-CORTEX; HIGH-AFFINITY; B-RECEPTORS; NUCLEOTIDE-SEQUENCES; PHYSIOLOGICAL-ROLE; BINDING-PROTEINS; BRAIN; SITES	GABA (gamma-amino-butyric acid), the principal inhibitory neurotransmitter in the brain, signals through ionotropic (GABA(A)/ GABA(C)) and metabotropic (GABA(B)) receptor systems. Here we report the cloning of GABA(B) receptors. Photoaffinity labelling experiments suggest that the cloned receptors correspond to two highly conserved GABA(B) receptor forms present in the vertebrate nervous system. The cloned receptors negatively couple to adenylyl cyclase and show sequence similarity to the metabotropic receptors for the excitatory neurotransmitter L-glutamate.	NOVARTIS PHARMA INC,RES DEPT,THERAPEUT AREA NERVOUS SYST,CH-4002 BASEL,SWITZERLAND	Novartis			Mickel, Stuart/B-1169-2008; bettler, bernhard/AAO-8018-2020; Mickel, Stuart J./AAN-9800-2020	Mickel, Stuart J./0000-0003-4508-7069; Bettler, Bernhard/0000-0003-0842-8207; Kaupmann, Klemens/0000-0001-8903-2508				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUCHAMPACH JA, 1994, GENE, V145, P251, DOI 10.1016/0378-1119(94)90015-9; BISCHOFF S, IN PRESS J COMP NEUR; BITTIGER H, 1993, TRENDS PHARMACOL SCI, V14, P391, DOI 10.1016/0165-6147(93)90056-P; BONANNO G, 1992, J PHARMACOL EXP THER, V262, P114; BONANNO G, 1993, TRENDS PHARMACOL SCI, V14, P259, DOI 10.1016/0165-6147(93)90124-3; BORMANN J, 1995, TRENDS NEUROSCI, V18, P515, DOI 10.1016/0166-2236(95)98370-E; BOWERY NG, 1993, ANNU REV PHARMACOL, V33, P109, DOI 10.1146/annurev.pa.33.040193.000545; BOWERY NG, 1992, ARZNEIMITTELFORSCH, V42-1, P215; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHU DCM, 1990, NEUROSCIENCE, V34, P341, DOI 10.1016/0306-4522(90)90144-S; Cunningham MD, 1996, BRAIN RES, V720, P220, DOI 10.1016/0006-8993(96)00120-5; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DEERAUSQUIN G, 1992, MOL PHARMACOL, V42, P407; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; FROESTL W, 1995, J MED CHEM, V38, P3297, DOI 10.1021/jm00017a015; FROESTL W, 1996, PHARM REV COMMUN, V8, P127; GEMIGNANI A, 1994, MOL PHARMACOL, V46, P558; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HILL DR, 1984, J NEUROCHEM, V42, P652, DOI 10.1111/j.1471-4159.1984.tb02732.x; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; KARBON EW, 1985, MOL PHARMACOL, V27, P53; Kenakin T, 1996, PHARMACOL REV, V48, P413; KERR DIB, 1995, PHARMACOL THERAPEUT, V67, P187, DOI 10.1016/0163-7258(95)00016-A; Kerr DIB, 1996, DRUG DISCOV TODAY, V1, P371, DOI 10.1016/1359-6446(96)10034-9; Knight AR, 1996, NEUROPHARMACOLOGY, V35, P703, DOI 10.1016/0028-3908(96)84642-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDICK R, 1985, J BIOL CHEM, V260, P8257; LANZA M, 1993, EUR J PHARMACOL, V237, P191, DOI 10.1016/0014-2999(93)90268-M; LAW SF, 1993, J BIOL CHEM, V268, P10721; MISGELD U, 1995, PROG NEUROBIOL, V46, P423, DOI 10.1016/0301-0082(95)00012-K; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NAKAYASU H, 1993, J BIOL CHEM, V268, P8658; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OHNISHI K, 1990, J BIOCHEM-TOKYO, V107, P202, DOI 10.1093/oxfordjournals.jbchem.a123026; OLPE HR, 1993, EXPERIENTIA, V49, P542, DOI 10.1007/BF01955159; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STUART GJ, 1992, J PHYSIOL-LONDON, V447, P675, DOI 10.1113/jphysiol.1992.sp019023; TURGEON SM, 1994, NEUROSCIENCE, V62, P601, DOI 10.1016/0306-4522(94)90392-1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WOJCIK WJ, 1990, NEUROPHARMACOLOGY, V29, P969, DOI 10.1016/0028-3908(90)90150-P; WOJCIK WJ, 1984, MOL PHARMACOL, V25, P24; Zuiderwijk M, 1996, EUR J PHARMACOL, V307, P275, DOI 10.1016/0014-2999(96)00284-1	51	819	885	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					239	246		10.1038/386239a0	http://dx.doi.org/10.1038/386239a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069281				2022-12-28	WOS:A1997WP00300041
J	Donahue, JG; Weiss, ST; Livingston, JM; Goetsch, MA; Greineder, DK; Platt, R				Donahue, JG; Weiss, ST; Livingston, JM; Goetsch, MA; Greineder, DK; Platt, R			Inhaled steroids and the risk of hospitalization for asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIRWAY HYPERRESPONSIVENESS; CORTICOSTEROID-THERAPY; CHILDHOOD ASTHMA; FATAL ASTHMA; BUDESONIDE; DISEASE; ADULTS	Objective.-To determine if anti-inflammatory treatment for asthma reduces the risk of asthma hospitalization. Design.-Retrospective cohort study. Setting.-A health maintenance organization (HMO) in eastern Massachusetts. Participants.-Members of the HMO who were identified during the period October 1991 through September 1994 as having a diagnosis of asthma using a computerized medical record system. Main Outcome.-Hospitalization for asthma. Results.-Of the 16941 eligible persons, 742 (4.4%) were hospitalized for asthma, The overall relative risk (RR) of hospitalization among those who received inhaled steroids was 0.5 (95% confidence interval [CI], 0.4-0.6) after adjustment for beta-agonist dispensing. Additional adjustment for age, race, other asthma medications, and amount and type of ambulatory care for asthma did not substantially affect the inverse relationship between use of inhaled steroids and hospitalization. Cromolyn was similarly associated with reduced risk, especially among children (RR,0.8; 95% CI, 0.7-0.9). In contrast, increasing beta-agonist use was associated with increasing hospitalization risk even after adjustment for other factors and medications. The steroid-associated protection was most marked among individuals who received the largest amount of beta-agonist. Conclusions.-Inhaled steroids and, to a lesser extent, cromolyn confer significant protection against exacerbations of asthma leading to hospitalization. These results support the use of inhaled steroids by individuals who require more than occasional beta-agonist use to control asthma symptoms.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD PILGRIM HLTH CTR,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care								BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1990, AM REV RESPIR DIS, V141, pS70; BARNETT GO, 1979, P IEEE, V67, P1226, DOI 10.1109/PROC.1979.11438; BARRETT TE, 1995, AM J RESP CRIT CARE, V151, P574, DOI 10.1164/ajrccm.151.2.7842223; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; CLARK TJH, 1985, J ALLERGY CLIN IMMUN, V76, P330, DOI 10.1016/0091-6749(85)90649-9; COLLET JP, 1994, PHARMACOEPIDEM DR S, P609; CONOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; DALES RE, 1995, THORAX, V50, P520, DOI 10.1136/thx.50.5.520; DONAHUE JG, IN PRESS J ASTHMA; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HOSMER DW, 1989, APPL LOGISTIC REGRES; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERREBIJN KF, 1990, AM REV RESPIR DIS, V141, pS77; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; *NAT ASTH ED PROGR, 1991, US DHHS PUBLICATION; OBRIENLADNER A, 1994, GERIATRICS, V49, P20; OBRIENLADNER A, 1994, GERIATRICS, V49, P30; REED CE, 1990, AM REV RESPIR DIS, V141, pS82; Rosner B., 2010, FUNDAMENTALS BIOSTAT; SHEFFER AL, 1996, MED CARE, V31, pMS20; SKORODIN MS, 1993, ARCH INTERN MED, V153, P814, DOI 10.1001/archinte.153.7.814; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P477, DOI 10.1016/0091-6749(89)90137-1; SUISSA S, 1994, EUR RESPIR J, V7, P1602, DOI 10.1183/09031936.94.07091602; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1993, BRONCHIAL ASTHMA MEC, P818; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3	35	425	428	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					887	891		10.1001/jama.277.11.887	http://dx.doi.org/10.1001/jama.277.11.887			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062326				2022-12-28	WOS:A1997WM77400031
J	Jones, IR; Urwin, G; Feldman, RA; Banatvala, N				Jones, IR; Urwin, G; Feldman, RA; Banatvala, N			Social deprivation and bacterial meningitis in North East Thames region: Three year study using small area statistics	BRITISH MEDICAL JOURNAL			English	Article									LONDON HOSP,COLL MED,DEPT MED MICROBIOL,LONDON E1 2AD,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London	Jones, IR (corresponding author), UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT GEOG,MILE END RD,LONDON E1 4NS,ENGLAND.			Banatvala, Nick/0000-0001-8130-154X; Jones, Ian/0000-0002-1682-9134				Eachus J, 1996, BMJ-BRIT MED J, V312, P287; ENGLISH D, 1992, GEOGRAPHICAL ENV EPI; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; Townsend PP., 1988, HLTH DEPRIVATION INE; URWIN G, 1994, BRIT MED J, V309, P1412, DOI 10.1136/bmj.309.6966.1412	5	29	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					794	795		10.1136/bmj.314.7083.794	http://dx.doi.org/10.1136/bmj.314.7083.794			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080999	Green Published			2022-12-28	WOS:A1997WN64600027
J	Alter, MJ; Gallagher, M; Morris, TT; Moyer, LA; Meeks, EL; Krawczynski, K; Kim, JP; Margolis, HS				Alter, MJ; Gallagher, M; Morris, TT; Moyer, LA; Meeks, EL; Krawczynski, K; Kim, JP; Margolis, HS			Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B HEPATITIS; POSTTRANSFUSION HEPATITIS; C-HEPATITIS	Background Little is known about the relation of the newly discovered hepatitis G virus (HGV) to the cause and clinical course of acute and chronic viral hepatitis. Methods We selected patients from a surveillance study of acute viral hepatitis in four U.S. counties who had acute disease during 1985 to 1986 or 1991 to 1995. Serum samples were tested for HGV RNA by the polymerase chain reaction. Results HGV RNA was detected in 4 of 45 patients with a diagnosis of non-A-E hepatitis (9 percent), 23 of 116 patients with hepatitis C (20 percent), 25 of 100 patients with hepatitis A (25 percent), and 32 of 100 patients with hepatitis B (32 percent) (P<0.05 for the comparison of hepatitis B with hepatitis non-A-E or C). The clinical characteristics of the acute illness were similar for patients with HGV alone and those with hepatitis A, B, or C with or without HGV infection. During a follow-up period of one to nine years, chronic hepatitis did not develop in any of the patients with HGV alone, but 75 percent were persistently positive for HGV RNA, as were 87 percent of those with both hepatitis C and HGV infection. The rates of chronic hepatitis were similar in patients with hepatitis C alone (60 percent) and those with both hepatitis C and HGV infection (61 percent). Conclusions The evidence from this surveillance study does not implicate HGV as an etiologic agent of non-A-E hepatitis. Persistent infection with HGV was common, but it did not lead to chronic disease and did not affect the clinical course in patients with hepatitis A, B, or C. (C) 1997, Massachusetts Medical Society.	GENELABS TECHNOL, REDWOOD CITY, CA USA		Alter, MJ (corresponding author), CTR DIS CONTROL & PREVENT, HEPATITIS BRANCH, DIV VIRAL & RICKETTSIAL DIS, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; ALTER HJ, 1994, VIRAL HEPATITIS LIVE, P551; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; Favorov MO, 1996, J MED VIROL, V50, P50, DOI 10.1002/(SICI)1096-9071(199609)50:1&lt;50::AID-JMV10&gt;3.0.CO;2-1; Feucht HH, 1996, LANCET, V347, P615, DOI 10.1016/S0140-6736(96)91309-4; Fiordalisi G, 1996, J INFECT DIS, V174, P181, DOI 10.1093/infdis/174.1.181; KORETZ RL, 1993, HEPATOLOGY, V17, P361; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; KRAWCZYNSKI K, 1996, 9 TRIENN INT S VIR H, P39; LEE SR, 1995, TRANSFUSION, V35, P845, DOI 10.1046/j.1537-2995.1995.351096026366.x; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; MCQUILLAN G, 1996, 9 TRIENN INT S VIR H, P8; MCQUILLAN GM, 1989, AM J MED, V3; Moaven LD, 1996, MED J AUSTRALIA, V165, P84, DOI 10.5694/j.1326-5377.1996.tb124854.x; Morris T, 1996, J CLIN MICROBIOL, V34, P2933, DOI 10.1128/JCM.34.12.2933-2936.1996; PilotMatias TJ, 1996, J MED VIROL, V48, P329, DOI 10.1002/(SICI)1096-9071(199604)48:4&lt;329::AID-JMV6&gt;3.0.CO;2-9; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; Tanaka E, 1996, ANN INTERN MED, V125, P740, DOI 10.7326/0003-4819-125-9-199611010-00007; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	24	373	373	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					741	746		10.1056/NEJM199703133361101	http://dx.doi.org/10.1056/NEJM199703133361101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM640	9052651				2022-12-28	WOS:A1997WM64000001
J	Kahn, A				Kahn, A			Clone mammals ... Clone man?	NATURE			English	Editorial Material											Kahn, A (corresponding author), INST COCHIN GENET MOL,INSERM,LAB RES GENET & MOL PATHOL,F-75014 PARIS,FRANCE.							Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	1	33	33	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 13	1997	386	6621					119	119		10.1038/386119a0	http://dx.doi.org/10.1038/386119a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062180				2022-12-28	WOS:A1997WM97300035
J	Watanabe, Y; ShinozakiYabana, S; Chikashige, Y; Hiraoka, Y; Yamamoto, M				Watanabe, Y; ShinozakiYabana, S; Chikashige, Y; Hiraoka, Y; Yamamoto, M			Phosphorylation of RNA-binding protein controls cell cycle switch from mitotic to meiotic in fission yeast	NATURE			English	Article							PREMEIOTIC DNA-SYNTHESIS; SCHIZOSACCHAROMYCES-POMBE; SEXUAL DEVELOPMENT; MEIOSIS; GENE; TRANSCRIPTION; INITIATION; SPORULATION; MUTANTS; PRODUCT	Meiosis generates haploid gametes from diploid cells and is an almost universal feature of eukaryotic organisms. But little is known about how the snitch from mitotic to meiotic cell cycles is molecularly controlled. In the fission yeast Schizosaccharomyces pombe, inactivation of the protein kinase Pat1(Ran1) upon nutrient deprivation triggers entry into the meiotic cell cycle(1-6). Here we show that the RNA-binding protein Mei2 is a substrate of Pat1 kinase and that dephosphorylation of Mei2 is sufficient to switch cells from the mitotic cell cycle into meiosis. Mei2 is localized mainly in the cytoplasm of proliferating cells but is seen as a single spot dose to the microtubule organizing centre in prophase nuclei during meiosis. Our results, and others from a metazoan(7), emphasize the crucial role of RNA-binding proteins in the initiation and execution of meiosis.	UNIV TOKYO, GRAD SCH SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN; KANSAI ADV RES CTR, COMMUN RES LAB, NISHI KU, KOBE, HYOGO 65124, JAPAN	University of Tokyo; National Institute of Information & Communications Technology (NICT) - Japan			Hiraoka, Yasushi/B-5111-2009	Hiraoka, Yasushi/0000-0001-9407-8228; Watanabe, Yoshinori/0000-0002-5488-4812				BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Bohmann K, 1995, J CELL SCI, P107; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Eberhart CG, 1996, NATURE, V381, P783, DOI 10.1038/381783a0; Egel R., 1989, MOL BIOL FISSION YEA, P31; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; IINO Y, 1985, P NATL ACAD SCI USA, V82, P2447, DOI 10.1073/pnas.82.8.2447; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; Li P, 1996, CELL, V87, P869, DOI 10.1016/S0092-8674(00)81994-7; MCLEOD M, 1986, EMBO J, V5, P3665, DOI 10.1002/j.1460-2075.1986.tb04697.x; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MCLEOD M, 1988, NATURE, V332, P509, DOI 10.1038/332509a0; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; NAKASHIMA N, 1995, EMBO J, V14, P4794, DOI 10.1002/j.1460-2075.1995.tb00161.x; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; SHIMODA C, 1987, J BACTERIOL, V169, P93, DOI 10.1128/jb.169.1.93-96.1987; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; SUGIYAMA A, 1994, EMBO J, V13, P1881, DOI 10.1002/j.1460-2075.1994.tb06457.x; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WATANABE Y, 1988, EMBO J, V7, P761, DOI 10.1002/j.1460-2075.1988.tb02873.x; Yamamoto M, 1996, TRENDS BIOCHEM SCI, V21, P18, DOI 10.1016/0968-0004(96)80880-2	29	143	146	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 13	1997	386	6621					187	190		10.1038/386187a0	http://dx.doi.org/10.1038/386187a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062192				2022-12-28	WOS:A1997WM97300065
J	Greene, WL; Craft, J				Greene, WL; Craft, J			A man with fever and petechiae	LANCET			English	Article							INFECTIOUS-MONONUCLEOSIS		YALE UNIV,SCH MED,DEPT INTERNAL MED,RHEUMATOL SECT,NEW HAVEN,CT 06510; YALE NEW HAVEN MED CTR,NEW HAVEN,CT 06504	Yale University; Yale University	Greene, WL (corresponding author), YALE UNIV,SCH MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							CARTER RL, 1965, BLOOD-J HEMATOL, V25, P817, DOI 10.1182/blood.V25.5.817.817; CYRAN EM, 1991, AM J HEMATOL, V38, P124, DOI 10.1002/ajh.2830380210; GINSBURG AD, 1982, CAN MED ASSOC J, V127, P1103; PAPADAKIS MA, 1982, WESTERN J MED, V137, P141; WONG SY, 1982, POSTGRAD MED J, V58, P249, DOI 10.1136/pgmj.58.678.249	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					696	696		10.1016/S0140-6736(96)11204-6	http://dx.doi.org/10.1016/S0140-6736(96)11204-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078202	hybrid			2022-12-28	WOS:A1997WM08000012
J	PritchardJones, K; Hawkins, MM				PritchardJones, K; Hawkins, MM			Biology of Wilms' tumour	LANCET			English	Editorial Material									CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND	University of Oxford	PritchardJones, K (corresponding author), ROYAL MARSDEN NHS TRUST,CANC RES INST,DOWNS RD,SUTTON SM2 5PT,SURREY,ENGLAND.		Pritchard-Jones, Kathy/F-4286-2014	Pritchard-Jones, Kathy/0000-0002-2384-9475				BIRCH JM, 1995, HEMATOL ONCOL CLIN N, V9, P1157, DOI 10.1016/S0889-8588(18)30039-X; Breslow NE, 1996, MED PEDIATR ONCOL, V27, P398; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HAWKINS MM, 1995, J NATL CANCER I, V87, P1323, DOI 10.1093/jnci/87.17.1323; LEISENRING WM, 1994, CANCER RES, V54, P4680; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461	8	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					663	664		10.1016/S0140-6736(05)60129-8	http://dx.doi.org/10.1016/S0140-6736(05)60129-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078193				2022-12-28	WOS:A1997WM08000003
J	Luo, GB; Ducy, P; McKee, MD; Pinero, GJ; Loyer, E; Behringer, RR; Karsenty, G				Luo, GB; Ducy, P; McKee, MD; Pinero, GJ; Loyer, E; Behringer, RR; Karsenty, G			Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein	NATURE			English	Article							TARGETED DISRUPTION; APOLIPOPROTEIN-E; MOUSE EMBRYOS; VITAMIN-K; ATHEROSCLEROSIS; LESIONS; GENE; HYPERCHOLESTEROLEMIA; PROTOONCOGENE; REGION	Calcification of the extracellular matrix (ECM) can be physiological or pathological. Physiological calcification occurs in bone when the soft ECM is converted into a rigid material capable of sustaining mechanical force; pathological calcification can occur in arteries(1) and cartilage(2) and other soft tissues. No molecular determinant regulating ECM calcification has yet been identified. A candidate molecule is matrix GLA protein (Mgp), a mineral-binding ECM protein(3) synthesized by vascular smooth-muscle cells and chondrocytes, two cell types that produce an uncalcified ECM, Mice that lack Mgp develop to term but die within two months as a result of arterial calcification which leads to blood-vessel rupture. Chondrocytes that elaborate a typical cartilage matrix can be seen in the affected arteries. Mgp-deficient mice additionally exhibit inappropriate calcification of various cartilages, including the growth plate, which eventually leads to short stature, osteopenia and fractures. These results indicate that ECM calcification must be actively inhibited in soft tissues. To our knowledge, Mgp is the first inhibitor of calcification of arteries and cartilage to be characterized in vivo.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOL GENET, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT RADIOL, HOUSTON, TX 77030 USA; UNIV MONTREAL, FAC DENT, DEPT STOMATOL, MONTREAL, PQ H3C 3J7, CANADA; UNIV TEXAS, DENT BRANCH, DEPT BASIC SCI, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Universite de Montreal; University of Texas System			McKee, Marc D/E-2187-2011	McKee, Marc D/0000-0001-8349-965X				ANDERSON HC, 1967, J CELL BIOL, V35, P81, DOI 10.1083/jcb.35.1.81; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KOCHHAR DM, 1973, TERATOLOGY, V7, P289, DOI 10.1002/tera.1420070310; LUO GB, 1995, J BONE MINER RES, V10, P325; MANJIN HJ, 1989, PATHOGENESIS OSTEOAR, P1469; McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097-0029(19960201)33:2<141::AID-JEMT5>3.0.CO;2-W; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; QIAO JH, 1994, ARTERIOSCLER THROMB, V14, P1480, DOI 10.1161/01.ATV.14.9.1480; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; REID JD, 1993, ATHEROSCLEROSIS, V101, P213, DOI 10.1016/0021-9150(93)90118-E; ROSS R, 1971, SCI AM, V224, P44; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Singleton E B, 1973, Pediatr Radiol, V1, P2, DOI 10.1007/BF00972817; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; SOLURSH M, 1984, CELL MATRIX INTERACT, P277; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TANIMURA A, 1986, Journal of Experimental Pathology (New York), V2, P261; TANIMURA A, 1983, P SOC EXP BIOL MED, V172, P173; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P257; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	30	1608	1685	1	101	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 6	1997	386	6620					78	81		10.1038/386078a0	http://dx.doi.org/10.1038/386078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052783				2022-12-28	WOS:A1997WL74600054
J	Garbe, E; LeLorier, J; Boivin, JF; Suissa, S				Garbe, E; LeLorier, J; Boivin, JF; Suissa, S			Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPEUTIC EFFICACY; ADRENAL-FUNCTION; BECLOMETHASONE DIPROPIONATE; PHARMACOLOGICAL PROPERTIES; INTRAOCULAR-PRESSURE; DRUG-THERAPY; CORTICOSTEROIDS; ASTHMA; RHINITIS; MANAGEMENT	Objective.-To determine whether the use of inhaled and nasal glucocorticoids is associated with an increased risk of ocular hypertension or open-angle glaucoma. Design.-Case-control study. Setting.-Quebec universal health insurance program for all elderly (registered in the Regie de l'assurance maladie du Quebec [RAMQ] database). Patients.-Enrollees in the RAMQ database aged 66 years and older, The 9793 case patients were ophthalmology patients with a new diagnosis of borderline glaucoma or open-angle glaucoma or were newly started on treatment for ocular hypertension or glaucoma between 1988 and 1994, The 38 325 control patients were randomly selected among noncases with ophthalmologist visits in the same month and year as the case event (index date). Main Outcome Measures.-The odds ratio (OR) of ocular hypertension or open-angle glaucoma was determined in patients using inhaled or nasal glucocorticoids relative to nonusers, using conditional logistic regression analysis, The OR was adjusted for age, sex, diabetes mellitus, systemic hypertension, use of ophthalmic and oral glucocorticoids, and characteristics of health care system use in the year before the index date. Results.-Overall, current use of inhaled and nasal glucocorticoids was not associated with an increased risk of ocular hypertension or open-angle glaucoma, Current users of high doses of inhaled steroids prescribed regularly for 3 or more months were at an increased risk with an OR of 1.44 (95% confidence interval, 1.01-2.06). Conclusion.-Prolonged administration of high doses of inhaled glucocorticoids increases the risk of ocular hypertension or open-angle glaucoma, This finding suggests that in these patients intraocular pressure monitoring may be warranted.	ROYAL VICTORIA HOSP, DIV CLIN EPIDEMIOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MCGILL PHARMACOEPIDEMIOL RES UNIT, MONTREAL, PQ, CANADA; UNIV MONTREAL, CTR RECH, HOTEL DIEU MONTREAL, MONTREAL, PQ, CANADA	McGill University; Royal Victoria Hospital; McGill University; Universite de Montreal								ARMALY MF, 1963, ARCH OPHTHALMOL-CHIC, V70, P482, DOI 10.1001/archopht.1963.00960050484010; ARMALY MF, 1966, DRUG MECHANISMS GLAU, P191; ARMALY MF, 1986, GLAUCOMA, P697; BARNES NC, 1993, RESP MED, V87, P27, DOI 10.1016/S0954-6111(05)80254-9; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BECKER B, 1963, ARCH OPHTHALMOL-CHIC, V70, P500; BROGDEN RN, 1984, DRUGS, V28, P99, DOI 10.2165/00003495-198428020-00002; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; BRUBAKER RF, 1975, MAYO CLIN PROC, V50, P322; BRYSON HM, 1992, DRUGS, V43, P760, DOI 10.2165/00003495-199243050-00009; BURDE RM, 1970, J AMER MED ASSOC, V213, P2075, DOI 10.1001/jama.213.12.2075; BUTCHER JM, 1994, BRIT MED J, V309, P43, DOI 10.1136/bmj.309.6946.43; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851; DREYER EB, 1993, NEW ENGL J MED, V329, P1822, DOI 10.1056/NEJM199312093292420; ESTELLE F, 1989, DRUGS, V38, P313, DOI 10.2165/00003495-198938020-00010; FRANCOIS J, 1954, Ann Ocul (Paris), V187, P805; FRENKEL M, 1969, Illinois Medical Journal, V135, P160; GOLDMANN H, 1962, ARCH OPHTHALMOL-CHIC, V68, P621; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781, DOI 10.1001/jama.272.10.781; HABBICK B, 1995, CAN MED ASSOC J, V153, P1437; HERNANDEZ MR, 1983, INVEST OPHTH VIS SCI, V24, P1612; JACKSON RV, 1995, MED J AUSTRALIA, V162, P663, DOI 10.5694/j.1326-5377.1995.tb126057.x; KASS MA, 1989, GLAUCOMAS, P1161; KITAZAWA Y, 1981, ARCH OPHTHALMOL-CHIC, V99, P813; LESKE MC, 1983, AM J EPIDEMIOL, V118, P166, DOI 10.1093/oxfordjournals.aje.a113626; MABRY RL, 1992, OTOLARYNG HEAD NECK, V107, P855, DOI 10.1177/019459989210700608.2; MCMANUS P, 1993, MED J AUSTRALIA, V159, P832; MYGIND N, 1973, ACTA ALLERGOL, V28, P211, DOI 10.1111/j.1398-9995.1973.tb01327.x; NINAN TK, 1993, THORAX, V48, P599, DOI 10.1136/thx.48.6.599; OPATOWSKY I, 1995, OPHTHALMOLOGY, V102, P177; PAKES GE, 1980, DRUGS, V19, P397, DOI 10.2165/00003495-198019060-00001; PEARCE N, 1995, LANCET, V345, P41, DOI 10.1016/S0140-6736(95)91159-6; REED CE, 1990, AM REV RESPIR DIS, V141, pS82; ROHEN JW, 1973, EXP EYE RES, V17, P19, DOI 10.1016/0014-4835(73)90164-4; ROLL P, 1979, KLIN MONATSBL AUGENH, V174, P421; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P87; *SAS I INC, 1992, P229 SAS I INC, P435; Skuta GL, 1996, GLAUCOMAS, P1177; SMITH MJ, 1983, THORAX, V38, P676, DOI 10.1136/thx.38.9.676; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; WEINREB RN, 1981, INVEST OPHTH VIS SCI, V21, P403; WILSON MR, 1990, INT OPHTHALMOL CLIN, V30, P153; World Health Organization, 1977, INT CLASS DIS; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504	46	265	267	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					722	727		10.1001/jama.277.9.722	http://dx.doi.org/10.1001/jama.277.9.722			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042844				2022-12-28	WOS:A1997WK02600031
J	Blackbourn, DJ; Ambroziak, J; Lennette, E; Adams, M; Ramachandran, B; Levy, JA				Blackbourn, DJ; Ambroziak, J; Lennette, E; Adams, M; Ramachandran, B; Levy, JA			Infectious human herpesvirus 8 in a healthy North American blood donor	LANCET			English	Article							KAPOSIS-SARCOMA; DNA-SEQUENCES; IMMUNODEFICIENCY VIRUS; AIDS; RECOVERY; CELLS	Background Molecular studies have provided strong evidence for the association of human herpesvirus 8 (HHV-8) with Kaposi's sarcoma. These data have been supported by serological studies, which have also suggested that HHV-8 can be found in the healthy population, We report the presence of infectious HHV-8 in a healthy donor to a North American blood bank. Methods We examined the peripheral blood mononuclear cells or CD19 cells of blood donors by PCR for evidence of HHV-8 infection. The CD19 cells were separated from peripheral blood mononuclear cells by immunomagnetic-bead selection. To enhance detection of HHV-8, the CD19 cells from eleven unsystematically selected blood donors were activated with phorbol ester and recombinant interleukin-6; the culture fluid was filtered and inoculated onto HHV-8-negative target CD19 cells that had been prepared from phytohaemagglutinin-stimulated peripheral blood mononuclear cells. These inoculated target cells were cultured for 3 days and then analysed for HHV-8 sequences by PCR. Serum samples were tested for antibodies to HHV-8 by an indirect immunofluorescence assay. Findings One blood donor was consistently found to be infected with HHV-8 by PCR after the cell-culture activation procedure. He was seropositive for the virus, The HHV-8 recovered was infectious, as shown by a reverse-transcription-PCR technique that detected HHV-8 RNA in the inoculated target cells. Interpretation These data provide the first indication that HHV-8 can be recovered from the blood of a healthy individual, a blood donor, and that the virus is infectious, This observation suggests that HHV-8 could be transmitted by blood transfusion, a possibility that merits further study.	UNIV CALIF SAN FRANCISCO,CANC RES INST,DEPT MED,DIV HEMATOL ONCOL,SAN FRANCISCO,CA 94143; VIROLAB INC,BERKELEY,CA; IRWIN MEM BLOOD CTR,SAN FRANCISCO,CA	University of California System; University of California San Francisco				Blackbourn, David/0000-0002-6703-4497				AMADORI A, 1991, J IMMUNOL, V146, P57; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BLACKBOURN DJ, 1992, J VIROL METHODS, V37, P109, DOI 10.1016/0166-0934(92)90038-F; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CALLARD RE, 1991, CYROKINES PRACTICAL; CASTRO BA, 1988, J CLIN MICROBIOL, V26, P2371, DOI 10.1128/JCM.26.11.2371-2376.1988; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; LANDAY AL, 1993, CLIN IMMUNOL IMMUNOP, V69, P106, DOI 10.1006/clin.1993.1157; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; LEVY JA, 1985, J INFECT DIS, V152, P734, DOI 10.1093/infdis/152.4.734; Mesri EA, 1996, J EXP MED, V183, P2385, DOI 10.1084/jem.183.5.2385; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Sambrook J., 2002, MOL CLONING LAB MANU; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5	20	142	149	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					609	611		10.1016/S0140-6736(96)10004-0	http://dx.doi.org/10.1016/S0140-6736(96)10004-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057733				2022-12-28	WOS:A1997WK91500011
J	Cook, DJ; Mulrow, CD; Haynes, RB				Cook, DJ; Mulrow, CD; Haynes, RB			Systematic reviews: Synthesis of best evidence for clinical decisions	ANNALS OF INTERNAL MEDICINE			English	Article							RESPIRATORY-TRACT INFECTIONS; RANDOMIZED CONTROL TRIALS; EVIDENCE-BASED MEDICINE; SELECTIVE DECONTAMINATION; DIGESTIVE-TRACT; HEALTH-CARE; MYOCARDIAL-INFARCTION; USERS GUIDES; METAANALYSIS; RECOMMENDATIONS	Systematic reviews can help practitioners keep abreast of the medical literature by summarizing large bodies of evidence and helping to explain differences among studies on the same question. A systematic review involves the application of scientific strategies, in ways that limit bias, to the assembly, critical appraisal, and synthesis of all relevant studies that address a specific clinical question. A meta-analysis is a type of systematic review that uses statistical methods to combine and summarize the results of several primary studies. Because the review process itself (like any other type of research) is subject to bias, a useful review requires clear reporting of information obtained using rigorous methods. Used increasingly to inform medical decision making, plan future research agendas, and establish clinical policy, systematic reviews may strengthen the link between best research evidence and optimal health care.	MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HLTH INFORMAT RES UNIT, MED CTR, HAMILTON, ON L8N 3Z5, CANADA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX USA; AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX 78284 USA	McMaster University; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital				Haynes, Robert Brian/0000-0002-1453-3196				AERDTS SJA, 1993, BRIT MED J, V307, P525; Allender PS, 1996, ANN INTERN MED, V124, P825, DOI 10.7326/0003-4819-124-9-199605010-00007; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BANGERTDROWNS RL, 1995, EVAL HEALTH PROF, V18, P304, DOI 10.1177/016327879501800305; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1016, DOI 10.1001/jama.275.13.1016; CHALMERS I, 1993, ANN NY ACAD SCI, V703, P153; CHALMERS I, 1995, SYSTEMATIC REV, P86; Chalmers T C, 1993, Stat Methods Med Res, V2, P161; *COCHR COLL, COCHR LIB EL SER PUB; COOK DJ, 1995, CHEST, V108, pS227, DOI 10.1378/chest.108.4_Supplement.227S; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; COOPER HM, 1980, PSYCHOL BULL, V87, P442, DOI 10.1037/0033-2909.87.3.442; DAVIDOFF F, 1995, ANN INTERN MED, V122, P727, DOI 10.7326/0003-4819-122-9-199505010-00012; Dowie J, 1996, J Health Serv Res Policy, V1, P104; GARDNER AW, 1995, JAMA-J AM MED ASSOC, V274, P975, DOI 10.1001/jama.274.12.975; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; HURLEY JC, 1995, ANTIMICROB AGENTS CH, V39, P941, DOI 10.1128/AAC.39.4.941; JADAD A, 1997, IN PRESS CAN MED ASS; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; MILNE R, 1996, EVIDENCE BASED MED, V1, P101; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; NEIHOUSE PF, 1989, DICP ANN PHARMAC, V23, P594, DOI 10.1177/1060028089023007-813; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; Pedrini MT, 1996, ANN INTERN MED, V124, P627, DOI 10.7326/0003-4819-124-7-199604010-00002; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; Richardson WS, 1995, ACP J CLUB, V123, pA12, DOI DOI 10.7326/ACPJC-1995-123-3-A12; Sackett D. L., 1995, EVIDENCE BASED MED, V1, P5; SHIN JH, 1993, CAN MED ASSOC J, V148, P969; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; WILLIAMSON JW, 1989, ANN INTERN MED, V110, P151, DOI 10.7326/0003-4819-110-2-151; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811	44	1107	1163	4	105	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					376	380		10.7326/0003-4819-126-5-199703010-00006	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL104	9054282				2022-12-28	WOS:A1997WL10400006
J	Jejeebhoy, SJ; Cook, RJ				Jejeebhoy, SJ; Cook, RJ			State accountability for wife-beating: The Indian challenge	LANCET			English	Article									UNIV TORONTO,FAC LAW,TORONTO,ON M5S 2C5,CANADA	University of Toronto								BURNS JF, 1996, NY TIMES        0606; Heise L., 1994, 255 WORLD BANK; Jethmalani R., 1995, KALIS YUG EMPOWERMEN; Levinson D., 1989, VIOLENCE CROSS CULTU; PAWAR MS, 1990, VIOLENCE WOMEN; Rao V., 1993, WIFE BEATING ITS CAU; The World Bank, 1993, WORLD DEV REP 1993 I, P50; *UN, 1995, 4 WORLD C WOM NEW YO; *UN, 1992, A4738 UN COMM EL DIS, P5	9	66	66	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR	1997	349			1			S10	S12		10.1016/S0140-6736(97)90004-0	http://dx.doi.org/10.1016/S0140-6736(97)90004-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL568	9057772				2022-12-28	WOS:A1997WL56800005
J	Spruance, SL; Pavia, AT; Mellors, JW; Murphy, R; Gathe, J; Stool, E; Jemsek, JG; Dellamonica, P; Cross, A; Dunkle, L				Spruance, SL; Pavia, AT; Mellors, JW; Murphy, R; Gathe, J; Stool, E; Jemsek, JG; Dellamonica, P; Cross, A; Dunkle, L			Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients - A randomized, double-blind, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	35th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 17-22, 1995	SAN FRANCISCO, CA	Amer Soc Microbiol		human immunodeficiency virus infections; acquired immunodeficiency syndrome; outcome assessment (health care); zidovudine; stavudine	AIDS-RELATED COMPLEX; DIDANOSINE; 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE; D4T	Background: Stavudine is a promising antiretroviral agent, but its clinical efficacy has not been determined. Objective: To evaluate the clinical effect of stavudine (2',3'-didehydro-3'-deoxythymidine) monotherapy in patients with human immunodeficiency virus (HIV) infection. Design: Randomized, controlled, double-blind trial. Setting: 56 outpatient clinics in private practices, universities, and contract research organizations in the United States, France, and Italy. Patients: 822 HIV-infected adults who had 50 to 500 CD4(+) cells/mm(3) and had previously received at least 6 months of zidovudine treatment. Intervention: Monotherapy with peroral stavudine capsules or peroral zidovudine capsules. Measurements: The primary end point was clinical progression, which was defined as all occurrences of acquired immunodeficiency syndrome (AIDS)-defining events or death. Results: Patients receiving stavudine reached clinical end points at a rate of 26 per 100 person-years, compared with 32 per 100 person-years for patients receiving zidovudine (relative risk, 0.75 [95% CI, 0.58 to 0.98]; P = 0.03). The risk for death alone was 26% lower in the stavudine group than in the zidovudine group, but the comparison was not statistically significant (relative risk, 0.74 [CI, 0.53 to 1.02]; P = 0.066). The benefit of stavudine therapy was seen in all CD4(+) cell strata (less than or equal to 100 cells/mm(3), 101 to 300 cells/mm(3), and >300 cells/mm(3)) and clinical stages of HIV disease (asymptomatic, symptomatic, and AIDS). Four weeks after treatment began, CD4(+) cell counts were 30 cells/mm(3) higher in the stavudine group than in the zidovudine group; this difference was sustained for 96 weeks (P < 0.001). Nausea and vomiting were more common in patients receiving zidovudine (P < 0.01), and neuropathy occurred more frequently in those receiving stavudine (12% in the stavudine group compared with 4% in the zidovudine group; Pc 0.001). Neuropathy resolved completely in many patients (63%) after interruption of stavudine treatment; these patients could resume stavudine therapy at a lower dose. Conclusions: Stavudine was well tolerated and delayed progression of HIV disease in patients who had previously received 6 or more months of zidovudine treatment. Benefits were apparent in all CD4(+) cell strata and clinical stages of HIV disease. Stavudine is an important agent to consider for trials of combination chemotherapy.	UNIV PITTSBURGH, MED CTR, PITTSBURGH, PA 15213 USA; HOUSTON CLIN RES NETWORK, HOUSTON, TX 77006 USA; NALLE CLIN, CHARLOTTE, NC 28204 USA; HOP LARCHET, NICE, FRANCE; BRISTOL MYERS SQUIBB CO, WALLINGFORD, CT 06492 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; CHU Nice; Bristol-Myers Squibb	Spruance, SL (corresponding author), UNIV UTAH, SCH MED, HLTH SCI AIDS CTR, DIV INFECT DIS, SALT LAKE CITY, UT 84132 USA.			Murphy, Robert/0000-0003-3936-2052				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Armitage P., 1971, STAT METHODS MED RES, V1; BROWNE MJ, 1993, J INFECT DIS, V167, P21, DOI 10.1093/infdis/167.1.21; Centers for Disease Control and Prevention, 1987, MMWR-MORBID MORTAL W, V36, p1S; DOLIN R, 1995, ARCH INTERN MED, V155, P961, DOI 10.1001/archinte.155.9.961; DUDLEY MN, 1992, J INFECT DIS, V166, P480, DOI 10.1093/infdis/166.3.480; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FLEISS JL, 1973, STATISTICAL METHODS; Fleming TR, 1991, COUNTING PROCESSES S; Griffith BP, 1996, J INFECT DIS, V173, P1252, DOI 10.1093/infdis/173.5.1252; GULICK RM, 1996, 11 INT C AIDS VANC; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KALBFLEISCH JD, 1995, STATISTICAL ANAL FAI; KATLAMA C, 1996, 3 C RETR OPP INF WAS, P196; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MURRAY HW, 1995, J INFECT DIS, V171, pS123, DOI 10.1093/infdis/171.Supplement_2.S123; PETERSEN EA, 1995, J INFECT DIS, V171, pS131, DOI 10.1093/infdis/171.Supplement_2.S131; POLLARD R, 1996, 3 C RETR OPP INF WAS, P197; RICHMAN DD, 1990, AM J MED, V88, pS8, DOI 10.1016/0002-9343(90)90414-9; RIDDLER SA, 1995, ANTIVIR RES, V27, P189, DOI 10.1016/0166-3542(95)00016-F; SKOWRON G, 1995, J INFECT DIS, V171, pS113, DOI 10.1093/infdis/171.Supplement_2.S113; SPRUANCE SL, 1994, ANN INTERN MED, V120, P360, DOI 10.7326/0003-4819-120-5-199403010-00002; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; WEI LJ, 1984, J AM STAT ASSOC, V79, P653, DOI 10.2307/2288413	25	68	69	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					355	+		10.7326/0003-4819-126-5-199703010-00003	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WL104	9054279				2022-12-28	WOS:A1997WL10400003
J	Brunner, E; Peter, O; Schweizer, L; Basler, K				Brunner, E; Peter, O; Schweizer, L; Basler, K			pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in Drosophila	NATURE			English	Article							GENE; EXPRESSION; PROTEIN; MELANOGASTER; MUTATIONS; EMBRYOS; PATHWAY; PATTERN; MARGIN	Members of the Wnt/Wingless (Wg) family of signalling proteins organize many aspects of animal development by regulating the expression of particular target genes in responding cells(1-6). Recent biochemical studies(7-9) indicate that the vertebrate HMG-domain proteins Lef-1 and XTcf-3 can physically interact with beta-catenin, a homologue of Drosophila Armadillo (Arm), the most downstream component known in the Wnt signal transduction pathway(10,11). However, these studies do not address whether the endogenous Lef/Tcf family members are required in vivo to transduce Wnt signals. Using genetic methods in Drosophila, we define a new segment polarity gene, pangolin (pan), and show that its product is required in vivo for Wg signal transduction in embryos and in developing adult tissues. In addition, we show that pan encodes a Lef/Tcf homologue and provide evidence that its protein product binds to the beta-catenin homologue Armadillo in vivo, Finally, we demonstrate that Pan functions downstream of Arm to transduce the Wg signal. Thus, our results indicate that Pan is an essential component of the Wg transduction pathway and suggest that it acts directly to regulate gene transcription in response to Wg signalling.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich				Peter, Oliver/0000-0001-7091-6653; Basler, Konrad/0000-0003-3534-1529				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BAKER NE, 1988, DEVELOPMENT, V102, P489; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BENJUMEA FD, 1995, DEVELOPMENT, V121, P4215; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Cadigan KM, 1996, DEVELOPMENT, V122, P2801; COUSO JP, 1994, DEVELOPMENT, V120, P621; Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; HOCHMAN B, 1964, GENETICA, V35, P109, DOI 10.1007/BF01804879; HOCHMAN B, 1971, GENETICS, V67, P235; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; LOCKE J, 1994, MOL GEN GENET, V243, P234, DOI 10.1007/BF00280321; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Ng M, 1996, NATURE, V381, P316, DOI 10.1038/381316a0; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; PORBES AJ, 1993, DEVELOPMENT, V119, P115; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Shirras AD, 1996, DEV BIOL, V175, P24, DOI 10.1006/dbio.1996.0092; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SLUSARSKI DC, 1995, GENETICS, V139, P229; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Yu X, 1996, DEVELOPMENT, V122, P849; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	35	434	442	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					829	833		10.1038/385829a0	http://dx.doi.org/10.1038/385829a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039917				2022-12-28	WOS:A1997WK57000057
J	Amrein, H; Axel, R				Amrein, H; Axel, R			Genes expressed in neurons of adult male Drosophila	CELL			English	Article							REGULATING SEXUAL-DIFFERENTIATION; DOSAGE COMPENSATION REGULATORS; MUSHROOM BODIES; BINDING PROTEIN; X-CHROMOSOMES; SPLICE SITE; XIST GENE; MELANOGASTER; LETHAL; RNA	We have identified two genes, roX1 and roX2, whose expression in the adult fly is restricted to neurons of males. The two genes reside on the X chromosome, and each encodes an RNA with no apparent open reading frame. Both genes are physically linked to female-specific genes that encode proteins expressed in the ovary: opt1, a novel peptide transporter, and nod, a member of the kinesin family. The male-specific transcripts are positively regulated by the dosage compensation pathway in an all-or-none fashion. Our data suggest that the multimeric complex of dosage compensation proteins may operate in different ways on different sets of X-linked genes.			Amrein, H (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOL BIOPHYS, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.		Amrein, Hubert/AAG-9480-2021	Amrein, Hubert/0000-0001-8799-7250; Axel, Richard/0000-0002-3141-4076	NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029832] Funding Source: NIH RePORTER; NCI NIH HHS [CA 23767] Funding Source: Medline; NINDS NIH HHS [NS 29832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BAKER BS, 1980, GENETICS, V94, P383; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELOTE JM, 1987, P NATL ACAD SCI USA, V84, P8026, DOI 10.1073/pnas.84.22.8026; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BRAND AH, 1993, DEVELOPMENT, V118, P401; BREEN TR, 1986, GENETICS, V112, P483; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CARPENTER AT, 1973, GENETICS, V73, P393; CHASE BA, 1995, GENETICS, V139, P1649; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; CLINE TW, 1984, GENETICS, V107, P231; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEBELLE JS, 1995, NEURON, V15, P245; DIANTONIO A, 1993, J NEUROSCI, V13, P4924; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; GAILEY DA, 1989, GENETICS, V121, P773; GAILEY DA, 1989, GENETICS, V122, P465; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1994, TRENDS GENET, V10, P376, DOI 10.1016/0168-9525(94)90135-X; HALL J C, 1978, P259; HALL JC, 1977, BEHAV GENET, V7, P291, DOI 10.1007/BF01066800; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HEISENBERG M, 1995, J NEUROSCI, V15, P1951, DOI 10.1523/JNEUROSCI.15-03-01951.1995; HILDRETH PE, 1965, GENETICS, V51, P659; HILFIKER A, 1994, EMBO J, V13, P3542, DOI 10.1002/j.1460-2075.1994.tb06661.x; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MORGAN T, 1943, CARNEGIE I WASH YB, V42, P171; MUKHERJEE AS, 1965, NATURE, V207, P785, DOI 10.1038/207785a0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; NOTHIGER R, 1987, GENET RES, V50, P113, DOI 10.1017/S001667230002351X; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; OLIVER B, 1993, DEVELOPMENT, V119, P897; PALMER MJ, 1993, GENETICS, V134, P545; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTELLI L, 1995, MECH DEVELOP, V53, P223, DOI 10.1016/0925-4773(95)00438-7; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Saito H, 1996, BBA-BIOMEMBRANES, V1280, P173, DOI 10.1016/0005-2736(96)00024-7; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STURTEVANT AH, 1945, GENETICS, V30, P297; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; WATANABE TK, 1975, JPN J GENET, V50, P269, DOI 10.1266/jjg.50.269; YANG MY, 1995, NEURON, V15, P45; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	65	178	182	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1997	88	4					459	469		10.1016/S0092-8674(00)81886-3	http://dx.doi.org/10.1016/S0092-8674(00)81886-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038337	hybrid			2022-12-28	WOS:A1997WJ69100006
J	Crawford, DH				Crawford, DH			Personal paper: The scapegoating of a consultant orthopaedic surgeon	BRITISH MEDICAL JOURNAL			English	Article											Crawford, DH (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					435	436		10.1136/bmj.314.7078.435	http://dx.doi.org/10.1136/bmj.314.7078.435			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040393	Green Published			2022-12-28	WOS:A1997WH29500036
J	Schleicher, DG; Lederer, SM; Millis, RL; Farnham, TL				Schleicher, DG; Lederer, SM; Millis, RL; Farnham, TL			Photometric behavior of comet Hale-Bopp (C/1995 O1) before perihelion	SCIENCE			English	Article								Narrowband photometric observations of comet Hale-Bopp (C/1995 O1) between 25 July 1995 and 15 February 1997 indicated gas and dust production rates of 20 and 100 times greater, respectively, than observed at the same heliocentric distances for comet P/Halley in 1985, Hale-Bopp produced dust at a rate greater than has been observed for any other comet at any distance since at least 1977. On the basis of the observed production rate of the hydroxyl molecule, the calculated minimum effective diameter of Hale-Bopp's nucleus is 17 kilometers, but the actual diameter of the nucleus is likely to be at least two to three times larger. The chemical composition of Hale-Bopp is consistent with that of other long-period comets originating from the Oort Cloud.	UNIV FLORIDA,DEPT ASTRON,GAINESVILLE,FL 32611	State University System of Florida; University of Florida	Schleicher, DG (corresponding author), LOWELL OBSERV,1400 W MARS HILL RD,FLAGSTAFF,AZ 86001, USA.							AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; COCHRAN AL, COMMUNICATION; COCHRAN AL, 1996, B AM ASTRON SOC, V28, P1093; COWAN JJ, 1979, MOON PLANETS, V21, P155, DOI 10.1007/BF00897085; Fitzsimmons A, 1996, MON NOT R ASTRON SOC, V278, pL37, DOI 10.1093/mnras/278.2.L37; FITZSIMMONS A, 1995, 6252 IAU; GREEN D, 1995, 6191 IAU; HALE A, 1995, 6187 IAU; HERGENROTHER CW, 1997, 6555 IAU; LECACHEUX J, 1997, 6560 IAU; MARSDEN B, 1995, 6198 IAU; MARSDEN BG, 1995, 6224 IAU; MARSDEN BG, 1996, 6463 IAU; MATTHEWS HE, 1995, 6234 IAU, P6234; Oort J. H., 1950, B ASTRON I NETH, V11, P91; RANDALL CA, UNPUB; RANDALL CE, 1992, B AM ASTRON SOC, V24, P1002; RAUER H, 1995, 6236 IAU; SCHLEICHER DG, 1989, ASTROPHYS J, V339, P1107, DOI 10.1086/167365; SCHLEICHER DG, UNPUB; SEKANINA Z, 1997, 6542 IAU; Wagner RM, 1997, SCIENCE, V275, P1918, DOI 10.1126/science.275.5308.1918; WHIPPLE FL, 1978, MOON PLANETS, V18, P343, DOI 10.1007/BF00896489	23	59	59	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1913	1915		10.1126/science.275.5308.1913	http://dx.doi.org/10.1126/science.275.5308.1913			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072963				2022-12-28	WOS:A1997WQ51300038
J	Valero, FPJ; Collins, WD; Pilewskie, P; Bucholtz, A; Flatau, PJ				Valero, FPJ; Collins, WD; Pilewskie, P; Bucholtz, A; Flatau, PJ			Direct radiometric observations of the water vapor greenhouse effect over the equatorial Pacific ocean	SCIENCE			English	Article							RADIATION BUDGET; TEMPERATURE; CLIMATE; SURFACE; TRENDS	Airborne radiometric measurements were used to determine tropospheric profiles of the clear sky greenhouse effect. At sea surface temperatures (SSTs) larger than 300 kelvin, the clear sky water vapor greenhouse effect was found to increase with SST at a rate of 13 to 15 watts per square meter per kelvin. Satellite measurements of infrared radiances and SSTs indicate that almost 52 percent of the tropical oceans between 20 degrees N and 20 degrees S are affected during all seasons. Current general circulation models suggest that the increase in the clear sky water vapor greenhouse effect with SST may have climatic effects an a planetary scale.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Valero, FPJ (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,CTR ATMOSPHER SCI,ATMOSPHER RES LAB,9500 GILMAN DR,SAN DIEGO,CA 92093, USA.		Collins, William D/J-3147-2014; Flatau, Piotr/E-2219-2011	Collins, William D/0000-0002-4463-9848; 				ANGELL JK, 1990, GEOPHYS RES LETT, V17, P1097; GRAHAM NE, 1995, SCIENCE, V267, P666, DOI 10.1126/science.267.5198.666; HALLBERG R, 1993, J CLIMATE, V6, P920, DOI 10.1175/1520-0442(1993)006<0920:OOSVIA>2.0.CO;2; HAMMER PD, 1991, MON WEATHER REV, V119, P1673, DOI 10.1175/1520-0493(1991)119<1673:TOFCCS>2.0.CO;2; HANSEN J, 1987, J GEOPHYS RES-ATMOS, V92, P13345, DOI 10.1029/JD092iD11p13345; JONES PD, 1986, NATURE, V322, P430, DOI 10.1038/322430a0; KIEHL JT, 1992, J GEOPHYS RES-ATMOS, V97, P10037, DOI 10.1029/92JD00729; King MD, 1996, J ATMOS OCEAN TECH, V13, P777, DOI 10.1175/1520-0426(1996)013<0777:ASSFRS>2.0.CO;2; LAL M, 1984, J ATMOS SCI, V41, P2238, DOI 10.1175/1520-0469(1984)041<2238:TEOMCA>2.0.CO;2; LUBIN D, 1994, SCIENCE, V265, P224, DOI 10.1126/science.265.5169.224; NEWELL RE, 1976, NATURE, V262, P40, DOI 10.1038/262040a0; NEWELL RE, 1976, SCIENCE, V194, P1413, DOI 10.1126/science.194.4272.1413; PAN YH, 1983, MON WEATHER REV, V111, P1244, DOI 10.1175/1520-0493(1983)111<1244:GCVCWS>2.0.CO;2; RAMANATHAN V, 1991, NATURE, V351, P27, DOI 10.1038/351027a0; RAVAL A, 1989, NATURE, V342, P758, DOI 10.1038/342758a0; Reynolds RW, 1988, J CLIMATE, V1, P75, DOI 10.1175/1520-0442(1988)001<0075:ARTGSS>2.0.CO;2; Spinhirne JD, 1996, J ATMOS SCI, V53, P1438, DOI 10.1175/1520-0469(1996)053<1438:CIPASR>2.0.CO;2; STEPHENS GL, 1991, J GEOPHYS RES-ATMOS, V96, P15311, DOI 10.1029/91JD00973; VALERO FPJ, 1982, APPL OPTICS, V21, P831, DOI 10.1364/AO.21.000831; VONDERHAAR TH, 1986, NASA REFER PUBL, V1169, P87; WEAVER CP, 1994, J GEOPHYS RES-ATMOS, V99, P25891, DOI 10.1029/94JD02323	22	16	16	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1773	1776		10.1126/science.275.5307.1773	http://dx.doi.org/10.1126/science.275.5307.1773			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065397				2022-12-28	WOS:A1997WP05600035
J	Neal, KR; Hebden, J; Spiller, R				Neal, KR; Hebden, J; Spiller, R			Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER; SALMONELLA; RAT	Objective: To measure the prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and determine risk factors and associations with postdysenteric symptoms. Design: Postal questionnaire. Setting: Nottingham Health Authority. Subjects: 544 people with microbiologically confirmed bacterial gastroenteritis between July 1994 and December 1994. Main outcome measures: Prevalence of gastrointestinal symptoms and relative risks for development of the irritable bowel syndrome and self reported altered bowel habit. Results: A quarter of subjects reported persistence of altered bowel habit six months after an episode of infective gastroenteritis. Increasing duration of diarrhoea, younger age, and female sex increased this risk, whereas vomiting as part of the illness reduced the risk. One in 14 developed the irritable bowel University of syndrome with an increased risk seen in women Nottingham, (relative risk 3.4; 95% confidence interval 1.2 to 9.8) and with duration of diarrhoea (6.5; 1.3 to 34 for 15-21 days). Conclusions: Persistence of bowel symptoms commonly occurs after bacterial gastroenteritis and is responsible for considerable morbidity and health care costs.	UNIV NOTTINGHAM,QUEENS MED CTR,DEPT GASTROENTEROL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Neal, KR (corresponding author), UNIV NOTTINGHAM,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND.		spiller, robin/ABE-6690-2021	spiller, robin/0000-0001-6371-4500				CHAUDHARY NA, 1962, Q J MED, V31, P307; COLLINS SM, 1994, EUR J GASTROEN HEPAT, V6, P478, DOI 10.1097/00042737-199406000-00005; EVEREST PH, 1992, J MED MICROBIOL, V37, P319, DOI 10.1099/00222615-37-5-319; FELDMAN RA, 1994, EPIDEMIOL INFECT, V113, P41, DOI 10.1017/S095026880005144X; Gwee KA, 1996, LANCET, V347, P150, DOI 10.1016/S0140-6736(96)90341-4; HARVEY RF, 1987, LANCET, V1, P963; KUBOTA Y, 1992, GASTROENTEROLOGY, V102, P1242; MCHUGH KJ, 1993, GASTROENTEROLOGY, V104, pA1051; MCKENDRICK MW, 1994, J INFECTION, V29, P1, DOI 10.1016/S0163-4453(94)94871-2; SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314; SKIRROW MB, 1987, EPIDEMIOL INFECT, V99, P647, DOI 10.1017/S0950268800066504; SWAIN MG, 1991, GASTROENTEROLOGY, V100, P675, DOI 10.1016/0016-5085(91)80011-W; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; Wall P G, 1996, Commun Dis Rep CDR Rev, V6, pR93; WILLIAMS CL, 1995, NEUROGASTROENT MOTIL, V7, P292	15	424	464	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					779	782		10.1136/bmj.314.7083.779	http://dx.doi.org/10.1136/bmj.314.7083.779			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080994	Green Published			2022-12-28	WOS:A1997WN64600021
J	Pearn, J				Pearn, J			Paediatrics .1. Infancy and early childhood	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MALNUTRITION; COUNTRIES; ABUSE				Pearn, J (corresponding author), ROYAL CHILDRENS HOSP, DEPT PAEDIAT & CHILD HLTH, BRISBANE, QLD 4029, AUSTRALIA.			Pearn, John/0000-0002-8815-2994				Abadie V, 1996, ARCH PEDIATRIE, V3, P130, DOI 10.1016/0929-693X(96)85063-9; Ammann AJ, 1997, NEW ENGL J MED, V336, P68; Bart KJ, 1996, B WORLD HEALTH ORGAN, V74, P35; BORTOLUSSI R, 1995, PEDIATR INFECT DIS J, V14, P870, DOI 10.1097/00006454-199510000-00010; Bouffard K, 1995, Mich Med, V94, P26; Burgess M., 1996, Communicable Diseases Intelligence, V20, P192; Butler D, 1996, NATURE, V382, P99, DOI 10.1038/382099a0; Corwin DS, 1996, J AM DIET ASSOC, V96, P874, DOI 10.1016/S0002-8223(96)00239-8; Davies M, 1995, Prof Care Mother Child, V5, P168; Eisensmith RC, 1996, EUR J PEDIATR, V155, pS16, DOI 10.1007/PL00014237; Fonkalsrud EW, 1996, CURR PROB SURG, V33, P6; Friedmann T, 1996, ACTA PAEDIATR, V85, P1261, DOI 10.1111/j.1651-2227.1996.tb13908.x; GELLERT GA, 1995, CHILD ABUSE NEGLECT, V19, P875, DOI 10.1016/0145-2134(95)00043-8; Goretsky MJ, 1996, J AM COLL SURGEONS, V182, P233; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; GROSHEIDE PM, 1995, BMJ-BRIT MED J, V311, P1200, DOI 10.1136/bmj.311.7014.1200; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; Haynes L, 1996, BRIT J DERMATOL, V134, P872; Herceg A, 1995, AUST J PUBLIC HEALTH, V19, P465; HICKS RA, 1995, CHILD ABUSE NEGLECT, V19, P855, DOI 10.1016/0145-2134(95)00044-9; KASIM MS, 1995, CHILD ABUSE NEGLECT, V19, P847, DOI 10.1016/0145-2134(95)00046-B; Kimmel SR, 1996, AM FAM PHYSICIAN, V53, P1648; Kirkwood BR, 1995, B WORLD HEALTH ORGAN, V73, P793; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; Kohn MA, 1996, PEDIATR INFECT DIS J, V15, P535, DOI 10.1097/00006454-199606000-00012; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; Langnas AN, 1996, PEDIATRICS, V97, P443; LEACH CL, 1993, CRIT CARE MED, V21, P1270, DOI 10.1097/00003246-199309000-00008; LEVY FH, 1992, ANESTH ANALG, V75, P1053; Meadow W, 1996, PEDIATRICS, V97, P636; Mitchell EA, 1995, ARCH DIS CHILD, V73, P498, DOI 10.1136/adc.73.6.498; MOTARJEMI Y, 1993, B WORLD HEALTH ORGAN, V71, P79; Muhlemann K, 1996, SCAND J INFECT DIS, V28, P265, DOI 10.3109/00365549609027169; Olliaro PL, 1995, B WORLD HEALTH ORGAN, V73, P735; Pearn J, 1996, J PAEDIATR CHILD H, V32, P290, DOI 10.1111/j.1440-1754.1996.tb02555.x; PELLETIER DL, 1995, B WORLD HEALTH ORGAN, V73, P443; Platt MJ, 1996, ARCH DIS CHILD, V75, P527, DOI 10.1136/adc.75.6.527; Rennie JM, 1996, ARCH DIS CHILD-FETAL, V74, pF214, DOI 10.1136/fn.74.3.F214; Rivara F P, 1996, Inj Prev, V2, P249, DOI 10.1136/ip.2.4.249; Robertson FM, 1996, J AM COLL SURGEONS, V182, P215; Saunders K, 1996, PEDIATRICS, V97, P688; Schmidt P, 1996, FORENSIC SCI INT, V79, P131, DOI 10.1016/0379-0738(96)01900-7; Schneerson R, 1996, LANCET, V348, P1289, DOI 10.1016/S0140-6736(96)05243-9; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SERAFINI G, 1995, EUR J EPIDEMIOL, V11, P349, DOI 10.1007/BF01719442; Shimada T, 1996, ACTA PAEDIATR JAPON, V38, P176; Silberstein LE, 1996, NEW ENGL J MED, V335, P199, DOI 10.1056/NEJM199607183350310; Stiff G, 1996, ANN ROY COLL SURG, V78, P119; TOMASKI SM, 1995, LARYNGOSCOPE, V105, P111, DOI 10.1288/00005537-199502000-00001; Tometzki AJP, 1996, ARCH DIS CHILD-FETAL, V74, pF143, DOI 10.1136/fn.74.2.F143; TULCHINSKY TH, 1993, B WORLD HEALTH ORGAN, V71, P93; TURK J, 1995, ARCH DIS CHILD, V72, P3, DOI 10.1136/adc.72.1.3; Vitiello L, 1996, TRANSFUS SCI, V17, P63; VOWELS M, 1996, BULLETIN, V116, P105; Waugh J, 1996, J PAEDIATR CHILD H, V32, P120, DOI 10.1111/j.1440-1754.1996.tb00907.x; Weinberg KI, 1996, IMMUNOL ALLERGY CLIN, V16, P453, DOI 10.1016/S0889-8561(05)70256-3; White J M, 1995, Commun Dis Rep CDR Rev, V5, pR186; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; WILKEY I, 1982, MED SCI LAW, V22, P31, DOI 10.1177/002580248202200105; Wood DL, 1996, ARCH PEDIAT ADOL MED, V150, P577, DOI 10.1001/archpedi.1996.02170310011001; Woodruff BA, 1996, PEDIATRICS, V97, P798; 1996, B WORLD HEALTH ORGAN, V74, P109	62	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	1997	314	7083					801	805		10.1136/bmj.314.7083.801	http://dx.doi.org/10.1136/bmj.314.7083.801			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9081001	Green Published			2022-12-28	WOS:A1997WN64600031
J	Fei, YW; Bertka, CM; Finger, LW				Fei, YW; Bertka, CM; Finger, LW			High-pressure iron sulfur compound, Fe3S2, and melting relations in the Fe-FeS system	SCIENCE			English	Article							POWDER DIFFRACTION; EARTHS CORE; STATE	An iron-sulfur compound (Fe3S2) was synthesized at pressures greater than 14 gigapascals in the system Fe-FeS. The formation of Fe3S2 changed the melting relations from a simple binary eutectic system to a binary system with an intermediate compound that melted incongruently. The eutectic temperature in the system at 14 gigapascals was about 400 degrees C lower than that extrapolated from Usselman's data, implying that previous thermal models of Fe-rich planetary cores could overestimate core temperature. If it is found in a meteorite, the Fe3S2 phase could also be used to infer the minimum size of a parent body.	CARNEGIE INST WASHINGTON,CTR HIGH PRESSURE RES,WASHINGTON,DC 20015	Carnegie Institution for Science	Fei, YW (corresponding author), CARNEGIE INST WASHINGTON,GEOPHYS LAB,5251 BROAD BRANCH RD NW,WASHINGTON,DC 20015, USA.		Fei, Yingwei/F-3709-2011	Fei, Yingwei/0000-0001-9955-5353				BERTKA CM, IN PRESS J GEOPHYS R; BIRCH F, 1964, J GEOPHYS RES, V69, P4377, DOI 10.1029/JZ069i020p04377; BOEHLER R, 1992, EARTH PLANET SC LETT, V111, P217, DOI 10.1016/0012-821X(92)90180-4; BRETT R, 1969, EARTH PLANET SC LETT, V6, P479, DOI 10.1016/0012-821X(69)90119-8; BROWN JM, 1984, J GEOPHYS RES, V89, P6041, DOI 10.1029/JB089iB07p06041; COX DE, 1988, AUST J PHYS, V41, P117, DOI 10.1071/PH880117; FEI YW, 1995, SCIENCE, V268, P1892, DOI 10.1126/science.268.5219.1892; FLEET ME, 1977, AM MINERAL, V62, P341; Hansen M., 1958, CONSTITUTION BINARY, P704; KULLERUD G, 1962, J PETROL, V3, P126, DOI 10.1093/petrology/3.1.126; LARSON AC, 1986, 86748 LAUR AL NAT LA; LE BAIL A, 1988, MATER RES BULL, V23, P447, DOI 10.1016/0025-5408(88)90019-0; MASON B, 1966, NATURE, V211, P616, DOI 10.1038/211616a0; Murthy V.R., 1970, PHYS EARTH PLANET IN, V2, P276; PARISE JB, 1980, ACTA CRYSTALLOGR B, V36, P1179, DOI 10.1107/S0567740880005523; RYZHENKO B, 1973, AM J SCI, V273, P803, DOI 10.2475/ajs.273.9.803; SHERMAN DM, 1995, EARTH PLANET SC LETT, V132, P87, DOI 10.1016/0012-821X(95)00057-J; USSELMAN TM, 1975, AM J SCI, V275, P278, DOI 10.2475/ajs.275.3.278; WANKE H, 1988, PHILOS T R SOC A, V325, P545, DOI 10.1098/rsta.1988.0067; WERNER PE, 1985, J APPL CRYSTALLOGR, V18, P367, DOI 10.1107/S0021889885010512; WILLIAMS Q, 1990, J GEOPHYS RES-SOLID, V95, P19299, DOI 10.1029/JB095iB12p19299	21	171	174	6	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1621	1623		10.1126/science.275.5306.1621	http://dx.doi.org/10.1126/science.275.5306.1621			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054351				2022-12-28	WOS:A1997WN12300039
J	Miller, A; Wood, D; Ebright, RH; RothmanDenes, OB				Miller, A; Wood, D; Ebright, RH; RothmanDenes, OB			RNA polymerase beta' subunit: A target of DNA binding-independent activation	SCIENCE			English	Article							ESCHERICHIA-COLI; IN-VITRO; TRANSCRIPTION; PROTEIN; DOMAIN; PROMOTER; IDENTIFICATION; NIFA	The bacteriophage N4 single-stranded DNA binding protein (N4SSB) activates transcription by the Escherichia coli sigma 70-RNA polymerase at N4 late promoters. Here it is shown that the single-stranded DNA binding activity of N4SSB is not required for transcriptional activation. N4SSB interacts with the carboxyl terminus of the RNA polymerase beta' subunit in a region that is highly conserved in the largest subunits of prokaryotic and eukaryotic RNA polymerases.	UNIV CHICAGO,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855; RUTGERS STATE UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855	University of Chicago; University of Chicago; Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NIGMS NIH HHS [GM54431, GM35170, GM41376] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BERGER DK, 1994, P NATL ACAD SCI USA, V91, P103, DOI 10.1073/pnas.91.1.103; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CHO NJ, UNPUB; CHO NY, 1995, J MOL BIOL, V246, P461, DOI 10.1006/jmbi.1994.0098; CHOI MY, 1995, J BIOL CHEM, V270, P22541, DOI 10.1074/jbc.270.38.22541; Christie GE, 1996, J BACTERIOL, V178, P6991, DOI 10.1128/jb.178.23.6991-6993.1996; CORDEN JL, 1992, TRANSCRIPTIONAL REGU, P81; DOVE SL, UNPUB; Ebright YW, 1996, BIOCONJUGATE CHEM, V7, P380, DOI 10.1021/bc9600168; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; HUALA E, 1989, J BACTERIOL, V171, P3354, DOI 10.1128/jb.171.6.3354-3365.1989; ISAKSSON LA, 1977, MOL GEN GENET, V156, P233, DOI 10.1007/BF00267177; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; JOSAITIS CA, 1995, P NATL ACAD SCI USA, V92, P1117, DOI 10.1073/pnas.92.4.1117; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KUDELL N, 1994, J BACTERIOL, V176, P2991; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; MARTIN C, 1990, MOL CELL BIOL, V10, P1908, DOI 10.1128/MCB.10.5.1908; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; MILLER A, 1996, METHOD ENZYMOL, V174, P9; Miller A.B., UNPUB; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; NONET ML, 1989, GENETICS, V123, P715; NORTH A, IN PRESS J MOL BIOL; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; SARIS CJM, 1983, ANAL BIOCHEM, V132, P54, DOI 10.1016/0003-2697(83)90425-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; XIAO H, 1994, MOL CELL BIOL, V14, P7507, DOI 10.1128/MCB.14.11.7507; ZIVIN R, 1981, J MOL BIOL, V152, P335, DOI 10.1016/0022-2836(81)90246-1	38	59	60	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1655	1657		10.1126/science.275.5306.1655	http://dx.doi.org/10.1126/science.275.5306.1655			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054361				2022-12-28	WOS:A1997WN12300049
J	Stern, Y; Tang, MX; Albert, MS; Brandt, J; Jacobs, DM; Bell, K; Marder, K; Sano, M; Devanand, D; Albert, SM; Bylsma, F; Tsai, WY				Stern, Y; Tang, MX; Albert, MS; Brandt, J; Jacobs, DM; Bell, K; Marder, K; Sano, M; Devanand, D; Albert, SM; Bylsma, F; Tsai, WY			Predicting time to nursing home care and death in individuals with Alzheimer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APOLIPOPROTEIN-E; EXTRAPYRAMIDAL SIGNS; ONSET; SURVIVAL; PROGRESSION; IMPAIRMENT; DECLINE; MEMORY; ALLELE	Objective.-To develop and validate an approach that uses clinical features that can be determined in a standard patient visit to estimate the length of time before an individual patient with Alzheimer disease (AD) requires care equivalent to nursing home placement or dies. Design.-Prospective cohort study of 236 patients, followed up semiannually for up to 7 years, A second validation cohort of 105 patients was also followed. Setting.-Three AD research centers. Patients.-All patients met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD and had mild dementia at the initial visit. Intervention.-Predictive features, ascertained at the initial visit, were sex, duration of illness, age at onset, modified Mini-Mental State Examination (mMMS) score, and the presence or absence of extrapyramidal signs or psychotic features. Main Outcome Measures.-(1) Requiring the equivalent of nursing home placement and (2) death. Results.-Prediction algorithms were constructed for the 2 outcomes based on Cox proportional hazard models, For each algorithm, a predictor index is calculated based on the status of each predictive feature at the initial visit, A table that specifies the number of months in which 25%, 50%, and 75% of patients with any specific predictor index value are likely to reach the end point is then consulted. Survival curves for time to need for care equivalent to nursing home placement and for time to death derived from the algorithms for selected predictor indexes fell within the 95% confidence bands of actual survival curves for patients. When the predictor variables from the initial visit for the validation cohort patients were entered into the algorithm, the predicted survival curves for time to death fell within the 95% confidence bands of actual survival curves for the patients. Conclusions.-The prediction algorithms are a first but promising step toward providing specific prognoses to patients, families, and practitioners, This approach also has clear implications for the design and interpretation of clinical trials in patients with AD.	COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOSTAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, TAUB CTR ALZHEIMERS DIS RES, NEW YORK, NY 10032 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT PSYCHIAT, BOSTON, MA USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT NEUROL, BOSTON, MA USA	Columbia University; Columbia University; Columbia University; Columbia University; Johns Hopkins University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Stern, Y (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, GERTRUDE H SERGIEVSKY CTR, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Brandt, Jason/0000-0001-7381-6244; Albert, Steven/0000-0001-6786-9956; Jacobs, Diane/0000-0003-0886-6784; Stern, Yaakov/0000-0001-7542-3241	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007370, P01AG007232] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00645] Funding Source: Medline; NIA NIH HHS [AG07232, AG07370] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CHUI HC, 1992, RES PER ALZ, P12; COLLET D, 1994, MODELLING SUVIVAL DA, P153; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; DEVANAND DP, 1992, ARCH NEUROL-CHICAGO, V49, P371, DOI 10.1001/archneur.1992.00530280051022; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRISONI GB, 1995, ANN NEUROL, V37, P596, DOI 10.1002/ana.410370509; HIXSON J, 1991, J LIPID RES, V31, P545; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; JACOBS D, 1994, NEUROLOGY, V44, P1215, DOI 10.1212/WNL.44.7.1215; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; MAYEUX R, 1987, NEUROLOGY, V37, P1130, DOI 10.1212/WNL.37.7.1130; MAYEUX R, 1981, NEUROLOGY, V31, P645, DOI 10.1212/WNL.31.6.645; MAYEUX RP, 1987, NEUROLOGY, V37, P1693, DOI 10.1212/WNL.37.10.1693-a; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORTIMER JA, 1992, NEUROLOGY, V42, P1689, DOI 10.1212/WNL.42.9.1689; RICHARDS M, 1991, ARCH NEUROL-CHICAGO, V48, P1147, DOI 10.1001/archneur.1991.00530230055021; SANO M, 1987, J CLIN EXP NEUROPSYC, V9, P65; STERN MB, 1978, COMPREHENSIVE MANAGE, P3; STERN Y, 1987, Neurology, V37, P179; STERN Y, 1987, NEUROLOGY, V37, P1649, DOI 10.1212/WNL.37.10.1649; STERN Y, 1994, NEUROLOGY, V44, P2300, DOI 10.1212/WNL.44.12.2300; STERN Y, 1993, ALZ DIS ASSOC DIS, V7, P3, DOI 10.1097/00002093-199307010-00002; STERN Y, 1989, B CLIN NEUROSCI, V54, P73; STERN Y, 1994, J GERONTOL, V49, P7216; TYSNES OB, 1994, NEUROEPIDEMIOLOGY, V13, P226, DOI 10.1159/000110384; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; Wechsler D., 2008, WECHSLER ADULT INTEL, P257	29	264	264	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					806	812		10.1001/jama.277.10.806	http://dx.doi.org/10.1001/jama.277.10.806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM082	9052710	Green Submitted			2022-12-28	WOS:A1997WM08200033
J	Wheeler, RT; Shapiro, L				Wheeler, RT; Shapiro, L			Bacterial chromosome segregation: Is there a mitotic apparatus?	CELL			English	Review							ESCHERICHIA-COLI; REPLICATION ORIGIN; DNA-REPLICATION; P1 PLASMID; INITIATION; PARTITION; PROTEIN				Wheeler, RT (corresponding author), STANFORD UNIV,SCH MED,BECKMAN CTR,DEPT DEV BIOL,STANFORD,CA 94305, USA.		Wheeler, Robert/H-3085-2019; Wheeler, Robert/B-9437-2013	Wheeler, Robert/0000-0003-3223-7021; Wheeler, Robert/0000-0003-3223-7021				ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; Firshein W, 1997, MOL MICROBIOL, V23, P1, DOI 10.1046/j.1365-2958.1997.2061569.x; FUNNELL BE, 1994, BIOCHIMIE, V76, P924, DOI 10.1016/0300-9084(94)90017-5; HERRICK J, 1994, EMBO J, V13, P4695, DOI 10.1002/j.1460-2075.1994.tb06793.x; HIRAGA S, 1991, RES MICROBIOL, V142, P189, DOI 10.1016/0923-2508(91)90029-A; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; LIN DC, 1997, IN PRESS P NATL ACAD; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; Sharpe ME, 1996, MOL MICROBIOL, V21, P501, DOI 10.1111/j.1365-2958.1996.tb02559.x; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Wake RG, 1995, ANNU REV GENET, V29, P41; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; WOLDRINGH CL, 1987, J GEN MICROBIOL, V133, P575	18	37	38	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					577	579		10.1016/S0092-8674(00)81898-X	http://dx.doi.org/10.1016/S0092-8674(00)81898-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054496	Bronze			2022-12-28	WOS:A1997WM41300002
J	Kristenson, M; Zieden, B; Kucinskiene, Z; Elinder, LS; Bergdahl, B; Elwing, B; Abaravicius, A; Razinkoviene, L; Calkauskas, H; Olsson, AG				Kristenson, M; Zieden, B; Kucinskiene, Z; Elinder, LS; Bergdahl, B; Elwing, B; Abaravicius, A; Razinkoviene, L; Calkauskas, H; Olsson, AG			Antioxidant state and mortality from coronary heart disease in Lithuanian and Swedish men: Concomitant cross sectional study of men aged 50	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; MYOCARDIAL-INFARCTION; RISK-FACTORS; VITAMIN-C; PLASMA; OXIDATION; CAROTENE; ATHEROSCLEROSIS; SUSCEPTIBILITY		LINKOPING UNIV,FAC HLTH SCI,DEPT MED & CARE,S-58185 LINKOPING,SWEDEN; FAC HLTH SCI,CLIN RES CTR,S-58185 LINKOPING,SWEDEN; FAC MED VILNIUS,DEPT PHYSIOL & BIOCHEM,LT-2021 VILNIUS,LITHUANIA; KAROLINSKA INST,FAC MED,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; CTR PUBL HLTH SCI,DEPT PREVENT MED,S-58185 LINKOPING,SWEDEN; FAC MED VILNIUS,DEPT GASTROENTEROL & DIETET,LT-2021 VILNIUS,LITHUANIA; LINKOPING UNIV,FAC HLTH SCI,DEPT HLTH & ENVIRONM,S-58185 LINKOPING,SWEDEN	Linkoping University; Karolinska Institutet; Linkoping University			Elinder, Liselotte Schäfer/R-4500-2019; Elinder, Liselotte S/J-4677-2012	Elinder, Liselotte Schäfer/0000-0001-7270-1162; Elinder, Liselotte S/0000-0001-7270-1162				ANDREWS B, 1995, ATHEROSCLEROSIS, V112, P77, DOI 10.1016/0021-9150(94)05401-4; BINGHAM SA, 1987, MANUAL METHODOLOGY F, V57, P53; Bobak M, 1996, BRIT MED J, V312, P421; BOSMA H, 1994, INT J EPIDEMIOL, V23, P12, DOI 10.1093/ije/23.1.12; COMINACINI L, 1993, ATHEROSCLEROSIS, V99, P63, DOI 10.1016/0021-9150(93)90051-U; ELINDER LS, 1992, J LIPID RES, V33, P131; EVANS AE, 1995, QJM-INT J MED, V88, P469; FEACHEM R, 1994, NATURE, V367, P313, DOI 10.1038/367313a0; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; KARDINAAL AFM, 1995, ARTERIOSCL THROM VAS, V15, P726, DOI 10.1161/01.ATV.15.6.726; KLEINVELD HA, 1992, CLIN CHEM, V38, P2066; LOGAN RL, 1978, LANCET, V1, P949; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MOLGAARD J, 1988, EUR HEART J, V9, P541; *NAT FOOD ADM, 1993, FOOD COMP TABL EN NU; Ohrvall M, 1996, J INTERN MED, V239, P111, DOI 10.1046/j.1365-2796.1996.410753000.x; OLSSON AG, 1988, ACTA MED SCAND, V223, P3; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PAJAK A, 1988, World Health Statistics Quarterly, V41, P115; REGNSTROM J, 1992, LANCET, V339, P1183, DOI 10.1016/0140-6736(92)91129-V; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SKURIHIN IM, 1987, FOOD CHEM COMPOSITIO; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STREET DA, 1994, CIRCULATION, V90, P1154, DOI 10.1161/01.CIR.90.3.1154; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155; *UN, 1994, CRIS MORT HLTH NUTR; *WHO, 1989, MEAS OB CLASS DESCR; WILLIAMSON DF, 1993, AM J HUM BIOL, V15, P159; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	33	140	143	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					629	633		10.1136/bmj.314.7081.629	http://dx.doi.org/10.1136/bmj.314.7081.629			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066473	Green Published			2022-12-28	WOS:A1997WL41800019
J	Jick, H; Jick, S; Derby, LE; Vasilakis, C; Myers, MW; Meier, CR				Jick, H; Jick, S; Derby, LE; Vasilakis, C; Myers, MW; Meier, CR			Calcium-channel blockers and risk of cancer	LANCET			English	Article							UNITED-KINGDOM	Background Previous studies have been interpreted as suggesting an increase in risk of cancer among users of calcium-channel blockers compared with users of beta-blockers. To explore this issue further, we studied a large group of hypertensive patients to investigate the relation of calcium-channel blockers and cancer. Methods In cohorts of users of calcium-channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, and beta-blockers, we identified all cases of cancer diagnosed in 1995, We used a nested case-control analysis to estimate the risk of cancer among users of calcium-channel blockers and ACE inhibitors, with users of beta-blockers as a reference group. The study was based on information taken from the General Practice Research Database, and the study population was restricted to patients with at least 4 years of medical history recorded on computer. Findings The study was based on 446 cases of cancer and 1750 controls. The relative risk estimates for all cancers combined were 1.27 (95% CI 0.98-1.63) and 0.79 (058-106) for users of calcium-channel blockers and ACE inhibitors, respectively, relative to users of beta-blockers. There was little difference in risk estimates with duration of use of calcium-channel blockers of less than 1.0 year (relative risk 1.46), 1.0-3.9 years (1.26), and 4.0 years or more (1.23). Interpretation The small positive association between calcium-channel blockers and risk of cancer is unlikely to be causal since there is no increase in risk with increasing duration of calcium-channel blocker use.			Jick, H (corresponding author), BOSTON UNIV,CTR MED,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,LEXINGTON,MA 01273, USA.			Jick, Susan/0000-0002-2215-1067; Jick, Hershel/0000-0003-4270-5992				DERBY LE, 1993, MED J AUSTRALIA, V158, P596, DOI 10.5694/j.1326-5377.1993.tb137624.x; JICK H, 1990, PHARMACOTHERAPY, V10, P395; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1996, PHARMACOTHERAPY, V16, P321; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; JICK H, 1995, PHARMACOTHERAPY, V15, P428; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; RODRIGUEZ LAG, 1994, BRIT MED J, V308, P503, DOI 10.1136/bmj.308.6927.503; RODRIQUEZ LAG, 1994, ARCH INTERN MED, V154, P311, DOI 10.1001/archinte.1994.00420030117012; Van Staa TP, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI DOI 10.1002/PDS.2630030106	14	181	182	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					525	528		10.1016/S0140-6736(97)80084-0	http://dx.doi.org/10.1016/S0140-6736(97)80084-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048789	hybrid			2022-12-28	WOS:A1997WJ51200008
J	Neame, R				Neame, R			Smart cards - The key to trustworthy health information systems	BRITISH MEDICAL JOURNAL			English	Article								Some 20 years after they were first developed, ''smart cards'' are set to play a crucial parr in healthcare systems. Last year about a billion were supplied, mainly for use in the financial sector, but their special features make them of particular strategic importance for the health sector, where they offer a ready made solution to some key problems of security and confidentiality This article outlines what smart cards are and why they are so important in managing health information. I discuss some of the unique features of smart cards that are of special importance in the development of secure and trustworthy health information systems. Smart cards would enable individuals' identities to be authenticated and communications to be secured and would provide the mechanisms for implementing strong security, differential access to data, and definitive audit trails. Patient cards can also with complete security carry personal details, data on current health problems and medications, emergency care data, and pointers to where medical records for the patient can be found. Provider cards can in addition carry authorisations and information on computer set up.			Neame, R (corresponding author), HLTH INFORMAT CONSULTING,HOMESTALL HOUSE,FAVERSHAM ME13 8UT,KENT,ENGLAND.							Barrows RC, 1996, J AM MED INFORM ASSN, V3, P139, DOI 10.1136/jamia.1996.96236282; CARTER B, 1996, SMART TECHNOLOGY INT, P14; CIMINO JJ, 1995, J AM MED INFORM ASSN, V2, P273, DOI 10.1136/jamia.1995.96073829; *DAT, 1996, E MED NEWS, V30, P2; ENGELBRECHT R, 1995, P AMICE 95 C AMST VM, P227; HOPKINS R, 1990, EXMOUTH CARE CARD EV; JONES T, 1996, SMART TECHNOLOGY INT, P144; MONOD E, 1996, SMART TECHNOLOGY INT, P186; PESONEN L, 1996, SMART TECHNOLOGY INT, P112	9	17	23	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					573	577		10.1136/bmj.314.7080.573	http://dx.doi.org/10.1136/bmj.314.7080.573			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK215	9055719	Green Published			2022-12-28	WOS:A1997WK21500028
J	Wilmshurst, P				Wilmshurst, P			The code of silence	LANCET			English	Editorial Material							FRAUD				Wilmshurst, P (corresponding author), ROYAL SHREWSBURY HOSP,SHREWSBURY SY3 8XQ,SALOP,ENGLAND.							Broad W, 1985, BETRAYERS TRUTH; BROAD WJ, 1982, SCIENCE, V215, P874, DOI 10.1126/science.7058339; Erlichman J., 1986, GUARDIAN        1103, P6; Greenberg DS, 1996, LANCET, V348, P1303, DOI 10.1016/S0140-6736(05)65768-6; LOCK S, 1995, BRIT MED J, V310, P1547, DOI 10.1136/bmj.310.6994.1547; PETERSDORF RG, 1986, ANN INTERN MED, V104, P252, DOI 10.7326/0003-4819-104-2-252; Smith R, 1996, BRIT MED J, V312, P789; WILMSHURST P, 1987, LANCET, V1, P104; WILMSHURST P, 1986, LANCET, V2, P1280; 1996, LANCET, V347, P843	10	21	21	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					567	569		10.1016/S0140-6736(97)80121-3	http://dx.doi.org/10.1016/S0140-6736(97)80121-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048805				2022-12-28	WOS:A1997WJ51200044
J	Krause, KH; Michalak, M				Krause, KH; Michalak, M			Calreticulin	CELL			English	Editorial Material							CALCIUM-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEIN; GENE-EXPRESSION; CA2+ BINDING; INTEGRIN; IDENTIFICATION; INCREASES; CHAPERONE; CALNEXIN		UNIV HOSP GENEVA,DIV INFECT DIS,CH-1211 GENEVA,SWITZERLAND; UNIV ALBERTA,MOL BIOL MEMBRANES RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA	University of Geneva; University of Alberta; University of Alberta			Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768				BAKSH S, 1991, J BIOL CHEM, V266, P21458; BAKSH S, 1995, J BIOL CHEM, V270, P31333; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Burns Kimberly, 1994, Trends in Cell Biology, V4, P152, DOI 10.1016/0962-8924(94)90190-2; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; KHANNA NC, 1986, BIOCHEMISTRY-US, V25, P1078, DOI 10.1021/bi00353a020; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LIU NG, 1994, J BIOL CHEM, V269, P28635; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MICHALAK M, 1996, CAIRETICULIN; MORI K, 1993, CELL, V74, P743; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OPAS M, 1996, J CELL BIOL, V135, P1, DOI DOI 10.1083/JCB.135.6.1913; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926	27	311	321	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					439	443		10.1016/S0092-8674(00)81884-X	http://dx.doi.org/10.1016/S0092-8674(00)81884-X			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038335	Bronze			2022-12-28	WOS:A1997WJ69100004
J	Hobbs, PV; Reid, JS; Kotchenruther, RA; Ferek, RJ; Weiss, R				Hobbs, PV; Reid, JS; Kotchenruther, RA; Ferek, RJ; Weiss, R			Direct radiative forcing by smoke from biomass burning	SCIENCE			English	Article							AEROSOL; AIRBORNE; BUDGET	Airborne measurements in smoke from biomass burning in Brazil have yielded optical parameters that permit an improved assessment of the effects of smoke on Earth's radiation balance. The global-mean direct radiative forcing due to smoke from biomass burning worldwide is estimated to be no more than about -0.3 watt per square meter (cooling), compared with +2.45 watts per square meter (warming) due to anthropogenic greenhouse gases. On regional scales, direct radiative forcing due to smoke can be large and might indirectly affect global climate.	RADIANCE RES,SEATTLE,WA 98177		Hobbs, PV (corresponding author), UNIV WASHINGTON,DEPT ATMOSPHER SCI,SEATTLE,WA 98195, USA.		Reid, Jeffrey S/B-7633-2014	Reid, Jeffrey S/0000-0002-5147-7955				ARTAXO P, 1994, J GEOPHYS RES-ATMOS, V99, P22857, DOI 10.1029/94JD01023; Boucher O, 1995, J GEOPHYS RES-ATMOS, V100, P26117, DOI 10.1029/95JD02531; BOUCHER O, 1995, TELLUS B, V47, P281, DOI 10.1034/j.1600-0889.47.issue3.1.x; CHYLEK P, 1995, GEOPHYS RES LETT, V22, P929, DOI 10.1029/95GL00800; HANSEN JE, 1969, J ATMOS SCI, V26, P478, DOI 10.1175/1520-0469(1969)026<0478:EAASFM>2.0.CO;2; HAO WM, 1994, GLOBAL BIOGEOCHEM CY, V8, P495, DOI 10.1029/94GB02086; Hegg DA, 1996, J GEOPHYS RES-ATMOS, V101, P12893, DOI 10.1029/96JD00751; HOBBS PV, 1991, J GEOPHYS RES-ATMOS, V96, P18735, DOI 10.1029/91JD01635; Houghton J.T, 1995, SCI CLIMATE CHANGE; HOUGHTON JT, 1994, CLIMATE CHANGE; Houghton JT, 1994, RAD FORCING CLIMATE; Houghton JT, 1995, CLIMATE CHANGE; Kaufman YJ, 1996, J GEOPHYS RES-ATMOS, V101, P19433, DOI 10.1029/95JD02532; KAUFMAN YJ, 1992, J GEOPHYS RES-ATMOS, V97, P14581, DOI 10.1029/92JD00275; LIN C, 1973, APPL OPTICS, V12, P1356, DOI 10.1364/AO.12.001356; PENNER JE, 1992, SCIENCE, V256, P1432, DOI 10.1126/science.256.5062.1432; Radke L. F., 1988, AEROSOLS CLIMATE; RADKE LF, 1991, GLOBAL BIOMASS BURNI; WISCOMBE WJ, 1976, J ATMOS SCI, V33, P2440, DOI 10.1175/1520-0469(1976)033<2440:TBFITS>2.0.CO;2	19	206	207	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1776	1778						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065398				2022-12-28	WOS:A1997WP05600036
J	Madden, K; Sheu, YJ; Baetz, K; Andrews, B; Snyder, M				Madden, K; Sheu, YJ; Baetz, K; Andrews, B; Snyder, M			SBF cell cycle regulator as a target of the yeast PKC-MAP kinase pathway	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; G1 CYCLINS; PROTEIN; GENE; TRANSCRIPTION; HOMOLOG; COMPLEX; GROWTH; CLN1	Protein kinase C (PKC) signaling is highly conserved among eukaryotes and has been implicated in the regulation of cellular processes such as cell proliferation and growth. In the budding yeast, PKC1 functions to activate the SLT2(MPK1) mitogen-activated protein (MAP) kinase cascade, which is required for the maintenance of cell integrity during asymmetric cell growth. Genetic studies, coimmunoprecipitation experiments, and analysis of protein phosphorylation in vivo and in vitro indicate that the SBF transcription factor (composed of Swi4p and Swi6p), an important regulator of gene expression at the G(1) to S phase cell cycle transition, is a target of the Slt2p(Mpk1p) MAP kinase. These studies provide evidence for a direct role of the PKC1 pathway in the regulation of the yeast cell cycle and cell growth and indicate that conserved signaling pathways can act to control key regulators of cell division.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA	Yale University; University of Toronto			Baetz, Kristin/E-6859-2013	Snyder, Michael/0000-0003-0784-7987; Sheu, Yi-Jun/0000-0003-1612-5708	NIGMS NIH HHS [GM36494] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036494] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BAETZ K, UNPUB; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; CLARKWALKER GD, 1974, EUR J BIOCHEM, V41, P359, DOI 10.1111/j.1432-1033.1974.tb03278.x; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; COSTIGAN C, UNPUB; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; ERREDE B, 1995, MOL REPROD DEV, V42, P477, DOI 10.1002/mrd.1080420416; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; Harlow E., 1988, ANTIBODIES LAB MANUA; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Marini NJ, 1996, EMBO J, V15, P3040, DOI 10.1002/j.1460-2075.1996.tb00667.x; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; MICHAK H, 1993, J BIOL CHEM, V268, P20110; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENGURT E, 1984, P NATL ACAD SCI USA, V81, P5748; SHERMAN F, 1986, COLD SPRING HARBOR L; SIDOROVA J, 1993, MOL CELL BIOL, V13, P1069, DOI 10.1128/MCB.13.2.1069; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	52	211	212	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1781	1784		10.1126/science.275.5307.1781	http://dx.doi.org/10.1126/science.275.5307.1781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065400				2022-12-28	WOS:A1997WP05600038
J	Sprunger, PT; Petersen, L; Plummer, EW; Laegsgaard, E; Besenbacher, F				Sprunger, PT; Petersen, L; Plummer, EW; Laegsgaard, E; Besenbacher, F			Giant friedel oscillations on the beryllium(0001) surface	SCIENCE			English	Article							2-DIMENSIONAL ELECTRON-GAS; METAL-SURFACES; SCATTERING; BE(0001); DENSITY; WAVES	Large-amplitude electron density oscillations were observed on a Be(0001) surface by means of variable-temperature scanning tunneling microscopy. Fourier transforms of the images showed a ring of radius 2k(F), where k(F) is the Fermi wave vector of the Be(0001) surface state, This wavelength was expected from Friedel oscillations caused by electronic screening of surface defects, but the amplitude of the waves for energies near the Fermi energy was anomalously large and inconsistent with the Friedel concept of screening. The enhanced amplitude of the waves must be a many-body effect, either in the electron gas (possibly an incipient charge density wave) or in the response of the lattice (electron-phonon coupling).	AARHUS UNIV, INST PHYS & ASTRON, DK-8000 AARHUS C, DENMARK; CTR ATOM SCALE MAT PHYS, DK-8000 AARHUS C, DENMARK; UNIV TENNESSEE, DEPT PHYS & ASTRON, KNOXVILLE, TN 37996 USA; OAK RIDGE NATL LAB, DIV SOLID STATE, OAK RIDGE, TN 37831 USA	Aarhus University; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory			Besenbacher, Flemming/A-9623-2010					Ashcroft N.W., COMMUNICATION; Ashcroft N.W, 1976, SOLID STATE PHYS; AVOURIS P, 1994, J VAC SCI TECHNOL B, V12, P1447, DOI 10.1116/1.587314; BERGER LI, 1994, CRC HDB CHEM PHYSICS, P12; BINNIG G, 1982, HELV PHYS ACTA, V55, P726; Carpinelli JM, 1996, NATURE, V381, P398, DOI 10.1038/381398a0; CHULKOV EV, 1987, SURF SCI, V188, P287, DOI 10.1016/S0039-6028(87)80158-9; CROMMIE MF, 1993, NATURE, V363, P524, DOI 10.1038/363524a0; DAVIS HL, 1992, PHYS REV LETT, V68, P2632, DOI 10.1103/PhysRevLett.68.2632; EINSTEIN TL, 1973, PHYS REV B, V7, P3629, DOI 10.1103/PhysRevB.7.3629; Friedel J, 1958, NUOVO CIM SUPPL, V7, P287, DOI DOI 10.1007/BF02751483; GLOVER RE, 1971, P 12 INT C LOW TEMP, P337; GOLD A, 1994, PHIL MAG LETT, V70, P141, DOI 10.1080/09500839408240967; Gruner G., 1994, DENSITY WAVES SOLIDS; HASEGAWA Y, 1993, PHYS REV LETT, V71, P1071, DOI 10.1103/PhysRevLett.71.1071; HELLER EJ, 1994, NATURE, V369, P464, DOI 10.1038/369464a0; Heller EJ, 1995, AIP CONF PROC, P3; KOHN W, 1959, PHYS REV LETT, V2, P393, DOI 10.1103/PhysRevLett.2.393; LAEGSGAARD E, 1988, J MICROSC-OXFORD, V152, P663, DOI 10.1111/j.1365-2818.1988.tb01435.x; LANG ND, 1970, PHYS REV B, V1, P4555, DOI 10.1103/PhysRevB.1.4555; LAU KH, 1978, SURF SCI, V75, P69, DOI 10.1016/0039-6028(78)90053-5; LINDHARD J, 1954, MAT FYS MEDD DAN VID, V28, P1; MAHAN GD, 1981, MANY PARTICLE PHYSIC; OVERHAUS.AW, 1970, PHYS REV B, V2, P874, DOI 10.1103/PhysRevB.2.874; OVERHAUSER AW, 1986, PHYS REV B, V33, P1468, DOI 10.1103/PhysRevB.33.1468; PEIERLS RE, 1964, QUANTUM THEORY SOLID; PLUMMER EW, 1994, PROG SURF SCI, V46, P149, DOI 10.1016/0079-6816(94)90075-2; RAJAGOPAL AK, 1977, PHYS REV B, V15, P2819, DOI 10.1103/PhysRevB.15.2819; RUDERMAN MA, 1954, PHYS REV, V96, P99, DOI 10.1103/PhysRev.96.99; Schmid M, 1996, PHYS REV LETT, V76, P2298, DOI 10.1103/PhysRevLett.76.2298; Sprunger PT, 1996, PHYS REV B, V54, P8163, DOI 10.1103/PhysRevB.54.8163; STERN F, 1967, PHYS REV LETT, V18, P546, DOI 10.1103/PhysRevLett.18.546; STILES MD, 1993, PHYS REV B, V48, P7238, DOI 10.1103/PhysRevB.48.7238; STUMPF R, 1995, PHYS REV B, V51, P13748, DOI 10.1103/PhysRevB.51.13748; vanderWielen MCMM, 1996, PHYS REV LETT, V76, P1075, DOI 10.1103/PhysRevLett.76.1075	37	209	210	2	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	1997	275	5307					1764	1767		10.1126/science.275.5307.1764	http://dx.doi.org/10.1126/science.275.5307.1764			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065394				2022-12-28	WOS:A1997WP05600032
J	Ardissino, D; Merlini, PA; Ariens, R; Coppola, R; Bramucci, E; Mannucci, PM				Ardissino, D; Merlini, PA; Ariens, R; Coppola, R; Bramucci, E; Mannucci, PM			Tissue-factor antigen and activity in human coronary atherosclerotic plaques	LANCET			English	Article							ARTERY DISEASE; ISCHEMIC DEATH; THROMBOSIS; PATHOGENESIS; MECHANISMS; HEMOSTASIS; EXPRESSION	Background Coronary atherosclerotic-plaque thrombosis is a key event in the pathogenesis of unstable angina and myocardial infarction. Although plaque rupture or fissuring frequently occurs in atherosclerosis, only a small proportion of ruptured plaques develop thromboses. Methods Tissue-factor antigen and activity were measured in atherectomy samples from 50 consecutive patients with coronary artery disease (stable angina n=19, unstable angina n=24, and myocardial infarction n=7). Findings Median tissue-factor antigen and activity concentrations were significantly higher in plaques from patients with unstable angina and myocardial infarction than in those from patients with stable angina (antigen: 66.1 pg/mg [interquartile range 43.8-82.5] vs 32.4 pg/mg [9.8-43.4], p=0.0001; activity: 0.22 mU/mg [0.17-0.41] vs 0.13 mU/mg [0.05-0.16], p=0.0004). Interpretation Tissue-factor, an initiator of the coagulation cascade, may account for the different thrombotic responses to the rupture of human coronary atherosclerotic plaques.	NIGUARDA HOSP,DIV CARDIOL 2,MILAN,ITALY; UNIV MILAN,IRCCS MAGGIORE HOSP,ANGELO BIANCHI BONOMI HAEMOPHILIA & THROMBOSIS CT,I-20122 MILAN,ITALY; UNIV MILAN,IRCCS MAGGIORE HOSP,INST INTERNAL MED,I-20122 MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Ardissino, D (corresponding author), IRCCS POLICLIN SAN MATTEO,DIV CARDIOL,PIAZZALE GOLGI 1,I-27100 PAVIA,ITALY.		Ardissino, Diego/AAC-4041-2022	solinas, emilia/0000-0003-3532-1317; Ariens, Robert/0000-0002-6310-5745				ANNEX BH, 1995, CIRCULATION, V91, P619, DOI 10.1161/01.CIR.91.3.619; DAVIES MJ, 1989, EUR HEART J, V10, P203, DOI 10.1093/oxfordjournals.eurheartj.a059467; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DRAKE TA, 1989, AM J PATHOL, V134, P1087; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; NEMERSON Y, 1988, BLOOD, V71, P1; TOSCHI V, 1995, CIRCULATION S1, V92, P112; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839	12	206	216	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					769	771		10.1016/S0140-6736(96)11189-2	http://dx.doi.org/10.1016/S0140-6736(96)11189-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074577				2022-12-28	WOS:A1997WN12400012
J	Lederle, FA; Johnson, GR; Wilson, SE; Chute, EP; Littooy, FN; Bandyk, D; Krupski, WC; Barone, GW; Acher, CW; Ballard, DJ				Lederle, FA; Johnson, GR; Wilson, SE; Chute, EP; Littooy, FN; Bandyk, D; Krupski, WC; Barone, GW; Acher, CW; Ballard, DJ			Prevalence and associations of abdominal aortic aneurysm detected through screening	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med		aortic aneurysm, abdominal; mass screening; smoking; coronary disease; atherosclerosis	DEPENDENT DIABETES-MELLITUS; MIDDLE-AGED MEN; UNITED-STATES; SMOKING; MANAGEMENT; ATHEROSCLEROSIS; EPIDEMIOLOGY; COMMUNITY; MORTALITY; STIFFNESS	Background: Independent risk factors for abdominal aortic aneurysm (AAA) have not been clearly defined in multivariable analyses of large patient populations. Objective: To identify factors that are independently associated with AAA and to determine the prevalence of previously unrecognized AAA in defined demographic and risk groups. Design: Cross-sectional screening study. Setting: 15 Department of Veterans Affairs medical centers. Participants: 73 451 veterans who were 50 to 79 years of age and had no history of AAA. Measurements: The results of ultrasonographic screening for AAA and a prescreening questionnaire were analyzed using multiple logistic regression. Results: An AAA of 4.0 cm or larger was detected in 1031 participants (1.4%). Smoking was the risk factor most strongly associated with AAA; the odds ratio (OR) for AAAs of 4.0 cm or larger compared with normal aortas (infrarenal aortic diameter < 3.0 cm) was 5.57 (95% CI, 4.24 to 7.31). The association between smoking and AAA increased significantly with the number of years of smoking and decreased significantly with the number of years after quitting smoking. The excess prevalence associated with smoking accounted for 78% of all AAAs that were 4.0 cm or larger in the study sample. Female sex (OR, 0.22 [CI, 0.07 to 0.68]), black race (OR, 0.49 [CI, 0.35 to 0.69]), and presence of diabetes (OR, 0.54 [CI, 0.44 to 0.65]) were negatively associated with AAA. A family history of AAA was positively associated with AAA (OR, 1.95 [CI, 1.56 to 2.43]) but was reported by only 5.1% of participants. Other independently associated factors included age, height, coronary artery disease, any atherosclerosis, high cholesterol levels, and hypertension. Conclusions: Abdominal aortic aneurysm is associated with multiple factors. Smoking was the risk factor most strongly associated with AAA and may be responsible for most clinically important cases of previously undiagnosed AAA.	VET AFFAIRS MED CTR, COOPERAT STUDIES PROGRAM, COORDINATING CTR 151A, West Haven, CT 06516 USA; UNIV CALIF IRVINE, DEPT SURG, MED CTR, ORANGE, CA 92668 USA; VET AFFAIRS MED CTR, HINES, IL 60141 USA; VET AFFAIRS MED CTR, TAMPA, FL 33612 USA; VET AFFAIRS MED CTR, DENVER, CO 80220 USA; VET AFFAIRS MED CTR, LITTLE ROCK, AR 72205 USA; VET AFFAIRS MED CTR, MADISON, WI 53705 USA; EMORY UNIV, CTR CLIN EVALUAT SCI, DECATUR, GA 30030 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Emory University	Lederle, FA (corresponding author), VET AFFAIRS MED CTR, DEPT MED 111 0, 1 VET DR, MINNEAPOLIS, MN 55417 USA.		Ballard, David J/H-1062-2018					[Anonymous], 1995, Eur J Vasc Endovasc Surg, V9, P42; Bengtsson H, 1991, Eur J Vasc Surg, V5, P53; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CHOW WK, 1979, DHEW PUBLICATION; COLLIN J, 1990, ANGIOLOGY, V41, P53, DOI 10.1177/000331979004100108; DARLING RC, 1989, J VASC SURG, V10, P39, DOI 10.1067/mva.1989.vs0100039; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; EVERHART JE, 1988, DIABETOLOGIA, V31, P16; GOLDBERG RJ, 1995, ARCH INTERN MED, V155, P686, DOI 10.1001/archinte.155.7.686; GORE I, 1973, Progress in Cardiovascular Diseases, V16, P113, DOI 10.1016/S0033-0620(73)80011-8; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; JOHANSEN K, 1986, JAMA-J AM MED ASSOC, V256, P1934, DOI 10.1001/jama.256.14.1934; KLEVENS RM, 1995, AM J PREV MED, V11, P245, DOI 10.1016/S0749-3797(18)30453-7; KROHN CD, 1992, EUR J SURG, V158, P527; LAMORTE WW, 1995, J VASC SURG, V21, P422, DOI 10.1016/S0741-5214(95)70284-9; LANNE T, 1992, EUR J VASCULAR SURG, V6, P178, DOI 10.1016/S0950-821X(05)80237-3; LEDERLE FA, 1995, J VASC SURG, V21, P945, DOI 10.1016/S0741-5214(95)70222-9; LEDERLE FA, 1994, J VASC SURG, V20, P296, DOI 10.1016/0741-5214(94)90019-1; LEDERLE FA, 1990, ANN INTERN MED, V113, P731, DOI 10.7326/0003-4819-113-10-731; Lederle FA, 1996, J GEN INTERN MED, V11, P774, DOI 10.1007/BF02599000; LILIENFELD DE, 1987, ARTERIOSCLEROSIS, V7, P637, DOI 10.1161/01.ATV.7.6.637; LINDHOLM L, 1985, ACTA MED SCAND, V218, P305; MACSWEENEY STR, 1994, LANCET, V344, P651, DOI 10.1016/S0140-6736(94)92087-7; MACSWEENEY STR, 1992, BRIT J SURG, V79, P1281, DOI 10.1002/bjs.1800791211; MACSWEENEY STR, 1994, BRIT J SURG, V81, P935, DOI 10.1002/bjs.1800810704; MOHER D, 1992, EUR J VASCULAR SURG, V6, P647, DOI 10.1016/S0950-821X(05)80844-8; NEVITT MP, 1989, NEW ENGL J MED, V321, P1009, DOI 10.1056/NEJM198910123211504; OKELLY TJ, 1989, BRIT J SURG, V76, P479, DOI 10.1002/bjs.1800760517; OXLUND H, 1989, DIABETOLOGIA, V32, P748, DOI 10.1007/BF00274536; PILLARI G, 1988, ARCH SURG-CHICAGO, V123, P727; Pleumeekers HJCM, 1995, AM J EPIDEMIOL, V142, P1291, DOI 10.1093/oxfordjournals.aje.a117596; REED D, 1992, CIRCULATION, V85, P205, DOI 10.1161/01.CIR.85.1.205; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; SALOMAA V, 1995, CIRCULATION, V91, P1432, DOI 10.1161/01.CIR.91.5.1432; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCOTT RAP, 1995, BRIT J SURG, V82, P1066, DOI 10.1002/bjs.1800820821; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; SMITH FCT, 1993, BRIT J SURG, V80, P1406, DOI 10.1002/bjs.1800801117; STRACHAN DP, 1991, BRIT J SURG, V78, P401, DOI 10.1002/bjs.1800780407; TILSON MD, 1992, CIRCULATION, V85, P378, DOI 10.1161/01.CIR.85.1.378; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WOLF YG, 1994, J VASC SURG, V20, P529, DOI 10.1016/0741-5214(94)90277-1	42	622	647	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					441	+		10.7326/0003-4819-126-6-199703150-00004	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WM530	9072929				2022-12-28	WOS:A1997WM53000004
J	Liesner, RJ; Machin, SJ				Liesner, RJ; Machin, SJ			ABC of clinical haematology - Platelet disorders	BRITISH MEDICAL JOURNAL			English	Review								Platelets are produced predominantly by bone marrow megakaryocytes as a result of budding of the cytoplasmic membrane. Megakaryocytes are derived from the haemopoietic stem cell, which is stimulated to differentiate to mature megakaryocytes under the influence of various cytokines, including thrombopoietin. Once released from the bone marrow, young platelets are trapped in the spleen for 36 hours before entering the circulation, where they have a primary haemostatic role.			Liesner, RJ (corresponding author), UCL HOSP, NHS TRUST, DEPT HAEMATOL, LONDON, ENGLAND.								0	6	7	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					809	812		10.1136/bmj.314.7083.809	http://dx.doi.org/10.1136/bmj.314.7083.809			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9081003	Green Published			2022-12-28	WOS:A1997WN64600033
J	Valley, JW; Eiler, JM; Graham, CM; Gibson, EK; Romanek, CS; Stolper, EM				Valley, JW; Eiler, JM; Graham, CM; Gibson, EK; Romanek, CS; Stolper, EM			Low-temperature carbonate concretions in the Martian meteorite ALH84001: Evidence from stable isotopes and mineralogy	SCIENCE			English	Article							MARS VOLATILE EVOLUTION; SNC METEORITES; SYSTEM CACO3-MGCO3-FECO3; OXYGEN; CALCITE; WATER; FRACTIONATION; QUARTZ; MODEL; THERMOMETRY	The martian meteorite ALH84001 contains small, disk-shaped concretions of carbonate with concentric chemical and mineralogical zonation. Oxygen isotope compositions of these concretions, measured by ion microprobe, range from delta(18)O = +9.5 to +20.5 parts per thousand, Most of the core of one concretion is homogeneous (16.7 +/- 1.2 parts per thousand) and over 5 parts per thousand higher in delta(18)O than a second concretion. Orthopyroxene that hosts the secondary carbonates is isotopically homogeneous (delta(18)O = 4.6 +/- 1.2 parts per thousand). Secondary SiO2 has delta(18)O = 20.4 parts per thousand. Carbon isotope ratios measured from the core of one concretion average delta(13)C = 46 +/- 8 parts per thousand, consistent with formation on Mars. The isotopic variations and mineral compositions offer no evidence for high temperature (>650 degrees C) carbonate precipitation and suggest non-equilibrium processes at low temperatures (<similar to 300 degrees C).	CALTECH, DIV GEOL & PLANETARY SCI, PASADENA, CA 91125 USA; UNIV EDINBURGH, DEPT GEOL & GEOPHYS, EDINBURGH EH9 3JW, MIDLOTHIAN, SCOTLAND; NASA, LYNDON B JOHNSON SPACE CTR, HOUSTON, TX 77058 USA; UNIV GEORGIA, SAVANNAH RIVER ECOL LAB, AIKEN, SC 29802 USA	California Institute of Technology; University of Edinburgh; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; United States Department of Energy (DOE); Savannah River Ecology Laboratory; University System of Georgia; University of Georgia	Valley, JW (corresponding author), UNIV WISCONSIN, DEPT GEOL & GEOPHYS, 1215 W DAYTON ST, MADISON, WI 53706 USA.		Valley, John W./B-3466-2011; Facility, Edinburgh Ion Microprobe/AAD-8512-2020	Valley, John W./0000-0003-3530-2722; Facility, Edinburgh Ion Microprobe/0000-0001-6248-6657				Anderson T. F., 1983, STABLE ISOTOPES SEDI, V10, DOI [DOI 10.2110/SCN.83.01.0000, 10.2110/scn.83.01.0000]; ANDERSON TF, 1969, J GEOPHYS RES, V74, P3918, DOI 10.1029/JB074i015p03918; ANOVITZ LM, 1987, J PETROL, V28, P389, DOI 10.1093/petrology/28.2.389; ARUTHUR MA, 1987, ANN REV EARTH PLANET, V15, P47; BARNES I, 1971, GEOCHIM COSMOCHIM AC, V35, P699, DOI 10.1016/0016-7037(71)90068-8; BERMAN RG, 1988, J PETROL, V29, P445, DOI 10.1093/petrology/29.2.445; Bradley JP, 1996, GEOCHIM COSMOCHIM AC, V60, P5149, DOI 10.1016/S0016-7037(96)00383-3; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CHERNIAK DJ, 1995, EOS, V76, pF683; CHIBA H, 1989, GEOCHIM COSMOCHIM AC, V53, P2985, DOI 10.1016/0016-7037(89)90174-9; CLARK ID, 1992, CHEM GEOL, V102, P217, DOI 10.1016/0009-2541(92)90157-Z; CLAYTON RN, 1988, GEOCHIM COSMOCHIM AC, V52, P925, DOI 10.1016/0016-7037(88)90363-8; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; CLAYTON RN, 1972, J GEOPHYS RES, V77, P3057, DOI 10.1029/JB077i017p03057; CLIFFORD SM, 1993, J GEOPHYS RES-PLANET, V98, P10973, DOI 10.1029/93JE00225; CRAIG JR, 1974, REV MINERALOGY MINER, V1; Crank J., 1975, MATH DIFFUSION; DAVIDSON PM, 1994, AM MINERAL, V79, P332; EILER JM, 1993, GEOCHIM COSMOCHIM AC, V57, P2571, DOI 10.1016/0016-7037(93)90418-V; EILER JM, 1995, AM MINERAL, V80, P757; EILER JM, IN PRESS CHEM GEOL; EILER JM, IN PRESS LUNAR PLANE; Farver JR, 1996, CONTRIB MINERAL PETR, V123, P77, DOI 10.1007/s004100050144; FARVER JR, 1994, EARTH PLANET SC LETT, V121, P575, DOI 10.1016/0012-821X(94)90092-2; GALIMOV EM, 1991, GEOCHIM COSMOCHIM AC, V55, P1697, DOI 10.1016/0016-7037(91)90140-Z; GRADY MM, 1994, METEORITICS, V29, P469; Graham CM, 1996, GEOCHIM COSMOCHIM AC, V60, P5101, DOI 10.1016/S0016-7037(96)00286-4; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; HARZMETZ CP, 1992, WORKSH MARS SURF ATM, P94; Hattori K., 1997, STABLE ISOTOPE GEOCH, V1997, p201 pp, DOI [10.1002/qj.49705322213, DOI 10.1002/QJ.49705322213, DOI 10.1007/978-3-662-03377-7]; HAYES JM, 1993, MAR GEOL, V113, P111, DOI 10.1016/0025-3227(93)90153-M; HERVIG RL, 1995, GEOCHIM COSMOCHIM AC, V59, P2537, DOI 10.1016/0016-7037(95)00148-4; JAKOSKY BM, 1993, GEOPHYS RES LETT, V20, P1591, DOI 10.1029/93GL01598; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JOHANNES W, 1969, AM J SCI, V267, P1083, DOI 10.2475/ajs.267.9.1083; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; Kirschvink JL, 1997, SCIENCE, V275, P1629, DOI 10.1126/science.275.5306.1629; KRONENBERG AK, 1984, PHYS CHEM MINER, V11, P101, DOI 10.1007/BF00309248; Leshin LA, 1996, GEOCHIM COSMOCHIM AC, V60, P2635, DOI 10.1016/0016-7037(96)00122-6; MARTINEZ I, 1994, EARTH PLANET SC LETT, V121, P559, DOI 10.1016/0012-821X(94)90091-4; MCCONNAUGHEY T, 1989, GEOCHIM COSMOCHIM AC, V53, P163, DOI 10.1016/0016-7037(89)90283-4; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MCSWIGGEN PL, 1993, PHYS CHEM MINER, V20, P42, DOI 10.1007/BF00202249; MINARIK WG, 1995, EARTH PLANET SC LETT, V133, P423, DOI 10.1016/0012-821X(95)00085-Q; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; MORRISON J, 1991, J GEOL, V99, P559, DOI 10.1086/629517; MORRISON J, 1988, GEOLOGY, V16, P513, DOI 10.1130/0091-7613(1988)016<0513:PGFFII>2.3.CO;2; Morse J. W., 1983, REV MINERAL, V11, P227; ONEIL JR, 1969, J CHEM PHYS, V51, P5547, DOI 10.1063/1.1671982; Reeder R.J., 1983, REV MINERAL, V11; REEDER RJ, 1992, REV MINERAL, V27, P381; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; ROSENBAUM JM, 1994, GEOCHIM COSMOCHIM AC, V58, P2653, DOI 10.1016/0016-7037(94)90135-X; SHARP ZD, 1994, GEOCHIM COSMOCHIM AC, V58, P4491, DOI 10.1016/0016-7037(94)90350-6; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; VALLEY JW, 1993, SCIENCE, V259, P1729, DOI 10.1126/science.259.5102.1729; VALLEY JW, 1991, CONTRIB MINERAL PETR, V109, P38, DOI 10.1007/BF00687199; Valley JW, 1996, CONTRIB MINERAL PETR, V124, P225, DOI 10.1007/s004100050188; VALLEY JW, IN PRESS LUNAR PLANE; VALLEY JW, 1988, CRYSTALLINE BEDROCK, P156; VALLEY JW, IN PRESS REV EC GEOL, V7; VEIZER J, 1980, GEOCHIM COSMOCHIM AC, V44, P579, DOI 10.1016/0016-7037(80)90250-1; WOOD BJ, 1983, SCIENCE, V222, P413, DOI 10.1126/science.222.4622.413; WRIGHT IP, 1990, J GEOPHYS RES-SOLID, V95, P14789, DOI 10.1029/JB095iB09p14789; WRIGHT IP, 1992, GEOCHIM COSMOCHIM AC, V56, P817, DOI 10.1016/0016-7037(92)90100-W	65	147	151	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	1997	275	5306					1633	1638		10.1126/science.275.5306.1633	http://dx.doi.org/10.1126/science.275.5306.1633			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054355				2022-12-28	WOS:A1997WN12300043
J	Moss, EG; Lee, RC; Ambros, V				Moss, EG; Lee, RC; Ambros, V			The cold shock domain protein LIN-28 controls developmental timing in C-elegans and is regulated by the lin-4 RNA	CELL			English	Article							HETEROCHRONIC GENE LIN-14; MURINE LEUKEMIA-VIRUS; ACID BINDING-PROTEINS; Y-BOX PROTEINS; CAENORHABDITIS-ELEGANS; NUCLEOCAPSID PROTEIN; MESSENGER-RNA; ZINC-FINGER; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE	Mutations in the heterochronic gene lin-28 of C. elegans cause precocious development where diverse events specific to the second larval stage are skipped. lin-28 encodes a cytoplasmic protein with a cold shock domain and retroviral-type (CCHC) zinc finger motifs, consistent with a role for LIN-28 in posttranscriptional regulation. The 3'UTR of lin-28 contains a conserved element that is complementary to the 22 nt regulatory RNA product of lin-4 and that resembles seven such elements in the 3'UTR of the heterochronic gene lin-14. Both lin-4 activity and the lin-4-complementaty element (LCE) are necessary for stage-specific regulation of lin-28. Deleting the LCE produces a dominant gain-of-function allele that causes a retarded phenotype, indicating that lin-28 activity is a switch that controls choices of stage-specific fates.			Moss, EG (corresponding author), DARTMOUTH COLL, DEPT BIOL SCI, HANOVER, NH 03755 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AMBROS V, 1994, TRENDS GENET, V10, P123, DOI 10.1016/0168-9525(94)90213-5; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; ARASU P, 1991, GENE DEV, V5, P1825, DOI 10.1101/gad.5.10.1825; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOUVET P, 1995, J BIOL CHEM, V270, P28297; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEOLIVEIRA DE, 1990, PLANT CELL, V2, P427, DOI 10.1105/tpc.2.5.427; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Euling S, 1996, CELL, V84, P667, DOI 10.1016/S0092-8674(00)81045-4; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FITCH DHA, 1995, MOL BIOL EVOL, V12, P346; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; Graumann P, 1996, BIOESSAYS, V18, P309, DOI 10.1002/bies.950180409; Ha I, 1996, GENE DEV, V10, P3041, DOI 10.1101/gad.10.23.3041; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KINGSLEY PD, 1994, PLANT CELL, V6, P1522, DOI 10.1105/tpc.6.11.1522; LADOMERY M, 1994, NUCLEIC ACIDS RES, V22, P5582, DOI 10.1093/nar/22.25.5582; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MERIC C, 1989, J VIROL, V63, P1558; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; OBOKATA J, 1991, PLANT MOL BIOL, V17, P953, DOI 10.1007/BF00037080; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; RUVKUN G, 1991, DEVELOPMENT, P47; SATO SM, 1991, DEVELOPMENT, V112, P747; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SPIRIN AS, 1996, TRANSLATIONAL CONTRO, P319; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Wood WB, 1988, NEMATODE CAENORHABDI	52	658	742	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 7	1997	88	5					637	646		10.1016/S0092-8674(00)81906-6	http://dx.doi.org/10.1016/S0092-8674(00)81906-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054503	hybrid			2022-12-28	WOS:A1997WM41300009
J	Weinberg, RA				Weinberg, RA			The cat and mouse games that genes, viruses, and cells play	CELL			English	Review							APOPTOSIS; P53; E1A; FIBROBLASTS; ONCOGENES; PROTEIN; CANCER; RAS				Weinberg, RA (corresponding author), MIT,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142, USA.							BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; Cristofalo VJ, 1996, EXP GERONTOL, V31, P111, DOI 10.1016/0531-5565(95)02018-7; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIRAMA T, 1995, BLOOD, V86, P841; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; McKenna WG, 1996, ONCOGENE, V12, P237; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITAKER NJ, 1995, ONCOGENE, V11, P971	19	122	128	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					573	575		10.1016/S0092-8674(00)81897-8	http://dx.doi.org/10.1016/S0092-8674(00)81897-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054495	Bronze			2022-12-28	WOS:A1997WM41300001
J	Kendrick, T; Hilton, S				Kendrick, T; Hilton, S			Primary care: Opportunities and threats - Broader teamwork in primary care	BRITISH MEDICAL JOURNAL			English	Article							NEEDS				Kendrick, T (corresponding author), ST GEORGE HOSP,SCH MED,DIV GEN PRACTICE & PRIMARY CARE,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.		Kendrick, Tony/H-8558-2014	Kendrick, Tony/0000-0003-1618-9381				BAKER R, 1995, BRIT J GEN PRACT, V45, P654; *DEP HLTH, 1992, MAK LOND BETT; *DEP HLTH, 1996, CHOIC OPP PRIM CAR F; Department of Health, 1996, NHS SERV AMB; Department of Health, 1996, PRIM CAR DEL FUT; *GEN MED SERV COMM, 1996, COR SERV TAK IN; HOWELLS G, 1986, J ROY COLL GEN PRACT, V36, P449; Howells G, 1996, BRIT J GEN PRACT, V46, P59; *I HLTH POL STUD, 1996, EV PRIM CAR DEV PROJ; ILIFFE S, 1995, BR J HEALTHCARE MANA, V1, P13; INEICHER B, 1980, 4 U DEP MENT HLTH; Kerr M, 1996, BRIT J GEN PRACT, V46, P92; MINIHAN PM, 1990, AM J PUBLIC HEALTH, V80, P1043, DOI 10.2105/AJPH.80.9.1043; PUESCHEL SM, 1995, ACTA PAEDIATR, V84, P823, DOI 10.1111/j.1651-2227.1995.tb13768.x; *ROYAL COLL GEN PR, 1990, 47 RCGP; *ROYAL COLL GEN PR, 1996, 27 RCGP; SMITH FR, 1996, WIDER WORLD ED LONDO; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; WALTERS RM, 1988, J ROY COLL GEN PRACT, V38, P317; *WELSH OFF NHS DIR, 1992, WELSH HLTH PLANN FOR	20	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					672	675		10.1136/bmj.314.7081.672	http://dx.doi.org/10.1136/bmj.314.7081.672			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066488	Green Published			2022-12-28	WOS:A1997WL41800039
J	Osmond, R				Osmond, R			Women's health	LANCET			English	Editorial Material																			0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					588	588		10.1016/S0140-6736(05)61564-4	http://dx.doi.org/10.1016/S0140-6736(05)61564-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057728				2022-12-28	WOS:A1997WK91500006
J	Teare, EL; Barrett, SP				Teare, EL; Barrett, SP			Stop the ritual of tracing colonised people	BRITISH MEDICAL JOURNAL			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; OUTBREAK		ST MARYS HOSP,SCH MED,DEPT MED MICROBIOL,LONDON,ENGLAND	Imperial College London	Teare, EL (corresponding author), CHELMSFORD PUBL HLTH LAB,CHELMSFORD CM2 0YX,ESSEX,ENGLAND.							BARRETT SP, 1993, J HOSP INFECT, V24, P313, DOI 10.1016/0195-6701(93)90064-7; BARRETT SP, 1988, POSTGRAD MED J, V64, P606, DOI 10.1136/pgmj.64.754.606; BENDALL RP, 1994, LANCET, V334, P819; COX RA, 1995, J HOSP INFECT, V29, P87, DOI 10.1016/0195-6701(95)90191-4; *DEP HLTH, 1990, GUID CLIN HLTH CAR W; Jepsen O B, 1980, J Hosp Infect, V1, P363, DOI 10.1016/0195-6701(80)90016-X; Marples R R, 1992, Commun Dis Rep CDR Rev, V2, pR25; MEHTAR S, 1989, J HOSP INFECT, V13, P199, DOI 10.1016/0195-6701(89)90028-5; PERDREAUREMINGTON F, 1995, J HOSP INFECT, V31, P195, DOI 10.1016/0195-6701(95)90066-7; PHILLIPS I, 1991, J HOSP INFECT, V18, P197, DOI 10.1016/0195-6701(91)90024-3; RILEY TV, 1995, J HOSP INFECT, V29, P177, DOI 10.1016/0195-6701(95)90327-5; Riley TV, 1995, MED J AUSTRALIA, V163, P412, DOI 10.5694/j.1326-5377.1995.tb124656.x; RIMIAND D, 1986, J CLIN MICROBIOL, V24, P137; Selkon J B, 1980, J Hosp Infect, V1, P41, DOI 10.1016/0195-6701(80)90030-4; VICKERY AM, 1993, J HOSP INFECT, V24, P139, DOI 10.1016/0195-6701(93)90076-C; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127; 1996, COMMUN DIS REP CDR W, V6, P197	17	51	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					665	666		10.1136/bmj.314.7081.665	http://dx.doi.org/10.1136/bmj.314.7081.665			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066485	Green Published			2022-12-28	WOS:A1997WL41800035
J	Pringle, M				Pringle, M			An opportunity to improve primary care	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER; DOCTORS				Pringle, M (corresponding author), QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							BAKER M, 1995, BRIT MED J, V310, P1301, DOI 10.1136/bmj.310.6990.1301; BAKER R, 1995, BRIT J GEN PRACT, V45, P654; Baker R, 1996, BRIT J GEN PRACT, V46, P601; BLACK DG, 1994, BRIT MED J, V309, P930, DOI 10.1136/bmj.309.6959.930; BOYLE S, 1992, HLTH CARE UK 1991; Campbell JL, 1996, BRIT J GEN PRACT, V46, P465; Carlisle R, 1996, BRIT MED J, V313, P468; CarrHill RA, 1996, BRIT MED J, V312, P1008; COULTER A, 1995, BRIT MED J, V311, P1447, DOI 10.1136/bmj.311.7018.1447; COX J, 1995, RURAL GEN PRACTICAL; DALE J, 1995, BRIT MED J, V311, P423, DOI 10.1136/bmj.311.7002.423; Dale J, 1996, BRIT MED J, V312, P1340, DOI 10.1136/bmj.312.7042.1340; Dunsmuir RA, 1996, BRIT MED J, V313, P1370, DOI 10.1136/bmj.313.7069.1370; Ham C, 1996, BRIT MED J, V312, P70; Harris T, 1996, BRIT MED J, V312, P97; JENKINS C, 1996, BRIT MED J, V312, P1189; *KINGS FUND COMM L, 1992, LOND HLTH CAR 2010; Lattimer V, 1996, BRIT MED J, V312, P352; LEESE B, 1995, BRIT MED J, V311, P546, DOI 10.1136/bmj.311.7004.546; LEESE B, 1995, BRIT MED J, V310, P705, DOI 10.1136/bmj.310.6981.705; *LOND HLTH PLANN C, 1981, PRIM HLTH CAR INN LO; Majeed A, 1996, BRIT MED J, V313, P1274; MURRAY SA, 1995, BRIT MED J, V310, P100, DOI 10.1136/bmj.310.6972.100; *NHS EX, 1994, DEV PURC GP FUNDH; PHAROAH PDP, 1995, BRIT J GEN PRACT, V45, P595; Pringle M, 1996, BRIT MED J, V313, P1026; PRINGLE M, 1995, 68 ROY COLL GEN PRAC; Rivett G, 1986, DEV LONDON HOSP SYST; ROWSELL R, 1995, BRIT J GEN PRACT, V45, P601; RUMBLE RH, 1994, BRIT J GEN PRACT, V44, P571; *SECR STAT HLTH, 1996, PRIM CAR FUT CHOIC O; StewartBrown S, 1996, BRIT MED J, V312, P1311, DOI 10.1136/bmj.312.7042.1311; STURDY P, 1995, BRIT MED J, V311, P1547, DOI 10.1136/bmj.311.7019.1547; SWEENEY KG, 1995, BRIT J GEN PRACT, V45, P133; THOMAS K, 1995, BRIT J GEN PRACT, V45, P581; WILKIN D, 1990, GEN PRACTITIONER REF; Winkens RAG, 1996, BRIT MED J, V312, P490, DOI 10.1136/bmj.312.7029.490; Zermansky AG, 1996, BRIT J GEN PRACT, V46, P643; 1992, REPORT INQUIRY LONDO	39	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					595	597						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055724				2022-12-28	WOS:A1997WK21500035
J	Wilkinson, RG				Wilkinson, RG			Socioeconomic determinants of health - Health inequalities: Relative or absolute material standards?	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; DIFFERENTIALS; WHITEHALL				Wilkinson, RG (corresponding author), UNIV SUSSEX,TRAFFORD CTR MED RES,BRIGHTON BN1 9RY,E SUSSEX,ENGLAND.							[Anonymous], 1995, COMP HLTH STAT; ARBER S, 1987, BRIT MED J, V294, P1069, DOI 10.1136/bmj.294.6579.1069; BERKMAN LF, 1995, PSYCHOSOM MED, V57, P245, DOI 10.1097/00006842-199505000-00006; BLANE D, 1993, SOCIOLOGY HLTH ILLNE, V15, P1, DOI DOI 10.1111/J.1467-9566.1993.TB00328.X; BRUNNER E, 1996, HLTH SOCIAL ORG; *DEP SOC SEC, 1996, HLUS AV INC 1979 199; FOX AJ, 1985, J EPIDEMIOL COMMUN H, V39, P1, DOI 10.1136/jech.39.1.1; GOLDBLATT P, 1990, OPCS SERIES LS, V6; Hertzman C.K.S, 1996, E W LIFE EXPECTANCY; HILLS J, 1994, FUTURE WELFARE; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; Kaplan GA, 1996, BRIT MED J, V312, P999; KAWACHI I, IN PRESS AM J PUBLIC; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Kennedy BP, 1996, BRIT MED J, V312, P1194; Krieger N, 1996, AM J PUBLIC HEALTH, V86, P1370, DOI 10.2105/AJPH.86.10.1370; KUNST A, 1997, SOCIOECONOMIC INEQUA; Lundberg O., 1991, EUR SOCIOL REV, V7, P149, DOI DOI 10.1093/oxfordjournals.esr.a036593; MCISAAC SJ, IN PRESS EUR J PUBL; NORTH F, 1993, BRIT MED J, V306, P361, DOI 10.1136/bmj.306.6874.361; *OFF POP CENS SURV, 1986, REG GEN SUPPL OCC MO; OSTLIN P, 1990, J EPIDEMIOL COMMUN H, V44, P12, DOI 10.1136/jech.44.1.12; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; POWER C, 1990, J R STAT SOC A STAT, V153, P17, DOI 10.2307/2983094; PUTNAM RD, 1993, MAKING DEMOCRACY WOR, V102, P224; SAPOLSKY RM, 1993, RECENT PROG HORM RES, V48, P437; Sennett R., 1973, HIDDEN INJURIES CLAS; Shively C A, 1988, Acta Med Scand Suppl, V723, P71; SHIVELY CA, 1994, ARTERIOSCLER THROMB, V14, P721, DOI 10.1161/01.ATV.14.5.721; SHIVELY CA, IN PRESS BIOL PSYCHI; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P497, DOI 10.2105/AJPH.86.4.497; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; TICKLE L, 1996, POPULATION TRENDS, V86, P21; VANDOORSLAER E, IN PRESS J HLTH EC; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; WILKINSON RG, 1994, DAEDALUS, V123, P61; WILKINSON RG, 1994, SOCIOL HEALTH ILL, V16, P260, DOI 10.1111/1467-9566.ep11347404; *WORLD BANK, 1993, WORLD DEV REP	39	528	543	1	54	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					591	595		10.1136/bmj.314.7080.591	http://dx.doi.org/10.1136/bmj.314.7080.591			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK215	9055723	Green Published			2022-12-28	WOS:A1997WK21500033
J	Golstein, P				Golstein, P			Controlling cell death	SCIENCE			English	Editorial Material											Golstein, P (corresponding author), CNRS MARSEILLE LUMINY,INSERM,CTR IMMUNOL,CASE 906,F-13288 MARSEILLE,FRANCE.		Golstein, Pierre/A-4954-2014	Golstein, Pierre/0000-0003-1750-3483				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	17	284	320	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1081	1082		10.1126/science.275.5303.1081	http://dx.doi.org/10.1126/science.275.5303.1081			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9054009				2022-12-28	WOS:A1997WJ50300033
J	Meeuwisse, EJM; Groen, FC; Dees, A; Smith, GH; Ottervanger, JP				Meeuwisse, EJM; Groen, FC; Dees, A; Smith, GH; Ottervanger, JP			Lethargy with omeprazole	BRITISH MEDICAL JOURNAL			English	Letter									INSPECTORATE HLTH CARE,RIJSWIJK,NETHERLANDS		Meeuwisse, EJM (corresponding author), IKAZIA HOSP,ROTTERDAM,NETHERLANDS.			Dees, Adriaan/0000-0001-9164-4538				ANDERSON T, 1991, THESIS U GOTHENBURG; CASTOT A, 1993, THERAPIE, V48, P469; HAJELA R, 1990, CAN MED ASSOC J, V143, P1207; SIVAKUMAR K, 1994, LANCET, V344, P549; TEARE JP, 1995, SCAND J GASTROENTERO, V30, P216, DOI 10.3109/00365529509093266	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					481	481		10.1136/bmj.314.7079.481a	http://dx.doi.org/10.1136/bmj.314.7079.481a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056799	Green Published			2022-12-28	WOS:A1997WJ41900026
J	Evans, DA; Beckett, LA; Field, TS; Feng, L; Albert, MS; Bennett, DA; Tycko, B; Mayeux, R				Evans, DA; Beckett, LA; Field, TS; Feng, L; Albert, MS; Bennett, DA; Tycko, B; Mayeux, R			Apolipoprotein E epsilon 4 and incidence of Alzheimer disease in a community population of older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							E ALLELE EPSILON-4; E POLYMORPHISM; TYPE-4 ALLELE; FREQUENCIES; ASSOCIATION; GENE; RISK	Objective.-To examine the relation between apolipoprotein E status and risk of Alzheimer disease (AD) in a defined population and estimate the fraction of incident AD attributable to the epsilon 4 allele. Design.-Community-based cohort study. Setting.-East Boston, Mass. Participants.-A random sample of 578 community residents aged 65 years and older free of AD. Main Outcome Measure.-Clinical diagnosis of AD by uniform, structured evaluation. Results.-The increased risk of AD associated with the presence of the epsilon 4 allele was less than that found in most family and case-control studies. Persons with the epsilon 4/epsilon 4 or epsilon 3/epsilon 4 genotypes had 2.27 (95% confidence interval, 1.06-4.89) times the risk of incident disease compared with those with the epsilon 3/epsilon 3 genotype. The epsilon 4 allele accounted for a fairly small fraction of the incidence of AD; if the allele did not exist or had no effect on disease risk, the incidence would be reduced by only 13.7%. The effect of the epsilon 4 allele on risk of AD did not appear to vary with age. Conclusions.-The apolipoprotein E epsilon 4 allele is an important genetic risk factor for AD but accounts for a fairly small fraction of disease occurrence in this population-based study. Continued efforts to identify other environmental and genetic risk factors are warranted.	RUSH UNIV,RUSH ALZHEIMERS DIS CTR,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612; COLUMBIA UNIV COLL PHYS & SURG,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY 10032; BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115	Rush University; Rush University; Columbia University; Columbia University; Columbia University; Columbia University; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Evans, DA (corresponding author), RUSH UNIV,RUSH INST AGING,SUITE 675,1645 W JACKSON BLVD,CHICAGO,IL 60612, USA.				NIA NIH HHS [N01-AG-1-2106, N01-AG-0-2107, AG05362] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG002107, R01AG005362, N01AG012106] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; BREITNER JCS, 1995, ARCH NEUROL-CHICAGO, V52, P763, DOI 10.1001/archneur.1995.00540320035011; BROUSSEAU T, 1994, NEUROLOGY, V44, P342, DOI 10.1212/WNL.44.2.342; CAULEY JA, 1993, GENET EPIDEMIOL, V10, P27, DOI 10.1002/gepi.1370100104; CORBO RM, 1995, ANN HUM GENET, V59, P197, DOI 10.1111/j.1469-1809.1995.tb00741.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; HEBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354, DOI 10.1001/jama.273.17.1354; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HIXSON J, 1991, J LIPID RES, V31, P545; KAMBOH MI, 1995, HUM BIOL, V67, P195; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; ORDOVAS JM, 1987, J LIPID RES, V28, P371; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shah BV, 1997, SOFTWARE STAT ANAL C; SORBI S, 1994, NEUROSCI LETT, V177, P100, DOI 10.1016/0304-3940(94)90054-X; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74	23	154	156	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					822	824		10.1001/jama.277.10.822	http://dx.doi.org/10.1001/jama.277.10.822			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM082	9052713				2022-12-28	WOS:A1997WM08200036
J	Abel, T; Nguyen, PV; Barad, M; Deuel, TAS; Kandel, ER				Abel, T; Nguyen, PV; Barad, M; Deuel, TAS; Kandel, ER			Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory	CELL			English	Article							PROTEIN-SYNTHESIS; CONTEXTUAL FEAR; CA1 REGION; POTENTIATION; LESIONS; MICE; RATS; INDUCTION; AMYGDALA; BINDING	To explore the role of protein kinase A (PKA) in the late phase of long-term potentiation (L-LTP) and memory, we generated transgenic mice that express R(AB), an inhibitory form of the regulatory subunit of PKA, only in the hippocampus and other forebrain regions by using the promoter from the gene encoding Ca2+/calmodulin protein kinase II alpha. In these R(AB) transgenic mice, hippocampal PKA activity was reduced, and L-LTP was significantly decreased in area CA1, without affecting basal synaptic transmission or the early phase of LTP. Moreover, the L-LTP deficit was paralleled by behavioral deficits in spatial memory and in long-term but not short-term memory for contextual fear conditioning. These deficits in long-term memory were similar to those produced by protein synthesis inhibition. Thus, PKA plays a critical role in the consolidation of long-term memory.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Abel, T (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, 722 W 168TH ST, NEW YORK, NY 10032 USA.		Abel, Ted/AAX-2825-2021	Abel, Ted/0000-0003-2423-4592; Nguyen, Peter/0000-0002-1419-5975				Abel T, 1995, MEMORY DISTORTION, P298; ABRAHAM WC, 1993, NEUROSCIENCE, V56, P717, DOI 10.1016/0306-4522(93)90369-Q; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hogan B, 1994, MANIPULATING MOUSE E; Huang Y Y, 1994, Learn Mem, V1, P74; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Muller G. E., 1900, Z PSYCHOLOGIE, V1, P1; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO T, 1994, BEHAV BRAIN RES, V65, P123, DOI 10.1016/0166-4328(94)90097-3	43	957	1001	0	84	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 7	1997	88	5					615	626		10.1016/S0092-8674(00)81904-2	http://dx.doi.org/10.1016/S0092-8674(00)81904-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054501	hybrid			2022-12-28	WOS:A1997WM41300007
J	Nijhawan, R				Nijhawan, R			Visual decomposition of colour through motion extrapolation	NATURE			English	Article							STIMULI; CORTEX; REPRESENTATION; SEGREGATION; PERCEPTION; MOVEMENT; MONKEY	The perception of yellow has played a central role in distinguishing two main theories of colour vision. Hering proposed that yellow results from the activation of a distinct retinal-neural mechanism, whereas according to the Young-Helmholtz-Maxwell view, yellow results from the combined activation of red and green cone mechanisms(1). When red and green images are presented separately to corresponding retinal locations in the two eyes, the resulting sensation is yellow(1,2). As the pathways from the two eyes do not converge until the cortex, this suggests that yellow can indeed arise from the central combining of separate red and green channels(2). I now show that the reverse process can also occur; the visual system can decompose a 'yellow' stimulus into its constituent red and green components. A 'yellow' stimulus was created by optically superimposing a flashed red Line onto a moving green bar. If the bar is visible only briefly, the flashed line appears yellow If the trajectory of the green bar is exposed for sufficient time, however, the line is incorrectly,perceived to trail the bar, and appears red. Motion processing occurs in the cortex rather than the retina in primates, and so the ability of motion cues to affect the perception of colour is consistent with the Young-Helmholtz-Maxwell notion of a 'central synthesis' of yellow.			Nijhawan, R (corresponding author), CORNELL UNIV,DEPT PSYCHOL,URIS HALL,ITHACA,NY 14853, USA.							AHO AC, 1993, J COMP PHYSIOL A, V172, P671; ALPERN M, 1965, J PHYSIOL-LONDON, V176, P473, DOI 10.1113/jphysiol.1965.sp007562; Boynton R. M., 1978, VISUAL PSYCHOPHYSICS, P193; BURR D, 1980, NATURE, V284, P164, DOI 10.1038/284164a0; CAVANAGH P, 1984, J OPT SOC AM A, V1, P893, DOI 10.1364/JOSAA.1.000893; Cropper SJ, 1996, NATURE, V379, P72, DOI 10.1038/379072a0; DILOLLO V, 1987, PERCEPT PSYCHOPHYS, V41, P345, DOI 10.3758/BF03208236; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; EFRON R, 1970, NEUROPSYCHOLOGIA, V8, P57, DOI 10.1016/0028-3932(70)90025-4; Gilchrist A. L., 1979, SCI AM, V24, P88; Hecht S, 1928, P NATL ACAD SCI USA, V14, P237, DOI 10.1073/pnas.14.3.237; HOGBEN JH, 1974, VISION RES, V14, P1059, DOI 10.1016/0042-6989(74)90202-8; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HURVICH LM, 1951, SCIENCE, V114, P199, DOI 10.1126/science.114.2956.199; Hurvich LM., 1981, COLOR VISION; KAHNEMAN D, 1968, PSYCHOL BULL, V70, P404, DOI 10.1037/h0026731; KHURANA B, 1995, NATURE, V378, P565; LAND EH, 1971, J OPT SOC AM, V61, P1, DOI 10.1364/JOSA.61.000001; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; MACKAY DM, 1958, NATURE, V181, P507, DOI 10.1038/181507a0; MORGAN MJ, 1979, VISION RES, V19, P491, DOI 10.1016/0042-6989(79)90133-0; NIJHAWAN R, 1994, NATURE, V370, P256, DOI 10.1038/370256b0; RAMACHANDRAN VS, 1978, NATURE, V275, P55, DOI 10.1038/275055a0; RICHARDS W, 1968, J OPT SOC AM, V58, P1159, DOI 10.1364/JOSA.58.001159; SAITO H, 1989, EXP BRAIN RES, V75, P1; WALRAVEN J, 1973, VISION RES, V13, P1739, DOI 10.1016/0042-6989(73)90091-6; YELLOTT JI, 1976, VISION RES, V16, P1275, DOI 10.1016/0042-6989(76)90053-5; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0; ZEKI SM, 1975, COLD SPRING HARB SYM, V40, P591	29	108	108	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					66	69		10.1038/386066a0	http://dx.doi.org/10.1038/386066a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052780				2022-12-28	WOS:A1997WL74600051
J	Nightingale, SL				Nightingale, SL			Ivermectin approved for strongyloidiasis and onchocerciasis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					703	703						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042830				2022-12-28	WOS:A1997WK02600008
J	Juang, YL; Huang, J; Peters, JM; McLaughlin, ME; Tai, CY; Pellman, D				Juang, YL; Huang, J; Peters, JM; McLaughlin, ME; Tai, CY; Pellman, D			APC-mediated proteolysis of Ase 1 and the morphogenesis of the mitotic spindle	SCIENCE			English	Article							B-TYPE CYCLINS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; MITOSIS; UBIQUITIN; TRANSCRIPTION; DEGRADATION; ANAPHASE; COMPLEX	The molecular mechanisms that link cell-cycle controls to the mitotic apparatus are poorly understood. A component of the Saccharomyces cerevisiae spindle, Ase1, was observed to undergo cell cycle-specific degradation mediated by the cyclosome, or anaphase promoting complex (APC). Ase1 was degraded when cells exited from mitosis and entered G(1). Inappropriate expression of stable Ase1 during G(1) produced a spindle defect that is sensed by the spindle assembly checkpoint. In addition, loss of ASE1 function destabilized telophase spindles, and expression of a nondegradable Ase1 mutant delayed spindle disassembly. APC-mediated proteolysis therefore appears to regulate both spindle assembly and disassembly.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School			Huang, James/W-5976-2019					AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JUANG YD, UNPUB; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MCGARRY T, COMMUNICATION; NEFF MW, 1992, MOL CELL BIOL, V12, P3857, DOI 10.1128/MCB.12.9.3857; PELLMAN D, 1995, J CELL BIOL, V130, P1373, DOI 10.1083/jcb.130.6.1373; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; SCHUYLER S, UNPUB; SIKORSKI RS, 1991, COLD SH Q B, V56, P663; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	34	217	221	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1311	1314		10.1126/science.275.5304.1311	http://dx.doi.org/10.1126/science.275.5304.1311			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036857				2022-12-28	WOS:A1997WK64400044
J	Zhang, F; Endo, S; Cleary, LJ; Eskin, A; Byrne, JH				Zhang, F; Endo, S; Cleary, LJ; Eskin, A; Byrne, JH			Role of transforming growth factor-beta in long-term synaptic facilitation in Aplysia	SCIENCE			English	Article							BONE MORPHOGENETIC PROTEIN-1; SENSORY NEURONS; GILL-WITHDRAWAL; HETEROSYNAPTIC FACILITATION; SIGNAL-TRANSDUCTION; STRUCTURAL-CHANGES; SENSITIZATION; PLASTICITY; KINASE; REQUIRES	The role of transforming growth factor-beta (TGF-beta) in long-term synaptic facilitation was examined in isolated Aplysia ganglia, Treatment with TGF-beta 1 induced long-term facilitation (24 and 48 hours), but not short-term (5 to 15 minutes) or intermediate-term (2 to 4 hours) facilitation. The long-term effects of TGF-beta 1 were not additive with those of serotonin, Moreover, serotonin-induced facilitation was blocked by an inhibitor of TGF-beta. Thus, activation of TGF-beta may be part of the cascade of events underlying long-term sensitization, consistent with the hypothesis that signaling molecules that participate in development also have roles in adult neuronal plasticity.	UNIV TEXAS,SCH MED,DEPT NEUROBIOL & ANAT,HOUSTON,TX 77030; UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204	University of Texas System; University of Houston System; University of Houston					NIMH NIH HHS [K05 MH-00649] Funding Source: Medline; NINDS NIH HHS [R01-NS-19895, R01-NS-28462] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028462, R01NS019895] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; Byrne JH, 1996, J NEUROSCI, V16, P425; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; DALE N, 1987, J NEUROSCI, V7, P2232; Eder IE, 1996, J UROLOGY, V156, P953, DOI 10.1016/S0022-5347(01)65670-2; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; Henderson CE, 1996, CURR OPIN NEUROBIOL, V6, P64, DOI 10.1016/S0959-4388(96)80010-9; KANDEL ER, 1987, SYNAPTIC FUNCTION, P471; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lee W. L., 1996, Society for Neuroscience Abstracts, V22, P441; Lee W. L., 1995, Society for Neuroscience Abstracts, V21, P1680; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu QR, 1997, J NEUROSCI, V17, P755; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; MACKEY SL, 1989, J NEUROSCI, V9, P4227; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin K. C., 1996, Society for Neuroscience Abstracts, V22, P1934; McKay S. E., 1996, Society for Neuroscience Abstracts, V22, P695; Michael D., 1996, Society for Neuroscience Abstracts, V22, P1934; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OLEARY FA, 1995, J NEUROSCI, V15, P3519; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; Stopfer M, 1996, J NEUROSCI, V16, P4933; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TSANG MLS, 1995, CYTOKINE, V7, P389, DOI 10.1006/cyto.1995.0054; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; ZHANG F, 1994, J NEUROPHYSIOL, V72, P778, DOI 10.1152/jn.1994.72.2.778; ZHANG ZS, 1991, J COMP NEUROL, V311, P259, DOI 10.1002/cne.903110207	49	141	146	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1318	1320		10.1126/science.275.5304.1318	http://dx.doi.org/10.1126/science.275.5304.1318			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036859				2022-12-28	WOS:A1997WK64400046
J	Beresford, SAA; Weiss, NS; Voigt, LF; McKnight, B				Beresford, SAA; Weiss, NS; Voigt, LF; McKnight, B			Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; MENOPAUSAL WOMEN; HORMONE USE; PROGESTERONE; RELIABILITY; RECALL	Background Postmenopausal oestrogen therapy reduces the risk of osteoporosis and cardiovascular diseases but is associated with an increased risk of endometrial cancer. We have assessed the impact of a regimen of oestrogen with cyclic progestagen on risk of endometrial cancer for postmenopausal women. Methods We did a population-based case-control study of women aged 45-74 years in western Washington State, USA. Cases were identified from a regional cancer registry as having histologically confirmed endometrial cancer during 1985-91. 832 (72%) of 1154 eligible cases completed interviews. Controls were identified by random digit dialling, screened for intact uterus, frequency matched for age and county, and randomly assigned a reference date within 1985-91. Interviews with 1114 (73%) of 1526 eligible controls were done. The women provided information about use of hormone replacement therapy, and reproductive and medical history before diagnosis date (cases) or reference date (controls). Findings Relative to women who had never used hormones (for >6 months), women who had taken unopposed oestrogen had a four-fold increase (95% CI 3.1-5.1) in risk of endometrial cancer. Women who used a combined therapy of oestrogen with cyclic progestagen leg, medroxyprogesterone acetate) had a relative risk of 1.4 (1.0-1.9). Among women with fewer than 10 days of added progestagen per month, the relative risk was 3.1 (1.7-5.7), whereas that for women with 10-21 days of added progestagen was 1.3 (0.8-2.2). The use of these combined regimens for 5 or more years was associated with risks of 3.7 (1.7-8.2) and 2.5 (1.1-5.5), respectively, relative to non-users of hormones. Interpretation Postmenopausal women who use combined therapy of oestrogen with cyclic progestagen on a longterm basis have an increased risk of endometrial cancer compared with those who are not on hormone replacement, even when progestagen is added for 10 or more days per month. This increase is much smaller than that associated with unopposed oestrogen, but needs to be confirmed.	UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,PROGRAM EPIDEMIOL,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,PROGRAM BIOSTAT,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Beresford, SAA (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,BOX 357236,SEATTLE,WA 98195, USA.				NCI NIH HHS [R35CA39779, R01CA47749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047749, R35CA039779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERESFORD SAA, 1989, AM J EPIDEMIOL, V130, P202, DOI 10.1093/oxfordjournals.aje.a115313; BRESLOW NE, 1980, ANAL CASE CONTROL ST, V1; BRINTON LA, 1993, OBSTET GYNECOL, V81, P265; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; GAMBRELL RD, 1980, OBSTET GYNECOL, V55, P732; GENALO MA, 1988, P SECT SURV RES METH, P552; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P537, DOI 10.1016/0002-9378(79)90289-8; JICK SS, 1993, EPIDEMIOLOGY, V4, P20, DOI 10.1097/00001648-199301000-00005; JICK SS, 1993, EPIDEMIOLOGY, V4, P384, DOI 10.1097/00001648-199307000-00016; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PERSSON I, 1987, INT J EPIDEMIOL, V16, P222, DOI 10.1093/ije/16.2.222; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; ROBINSON D, 1994, J AM GERIATR SOC, V42, P919, DOI 10.1111/j.1532-5415.1994.tb06580.x; STADEL BV, 1975, AM J EPIDEMIOL, V102, P209, DOI 10.1093/oxfordjournals.aje.a112149; STURDEE DW, 1978, BRIT MED J, V1, P1575, DOI 10.1136/bmj.1.6127.1575; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; VOIGT LF, 1992, AM J EPIDEMIOL, V136, P1393, DOI 10.1093/oxfordjournals.aje.a116452; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WHITEHEAD MI, 1987, OBSTET GYN CLIN N AM, V14, P299; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WHITEHEAD MI, 1990, OBSTETRICS GYNECOL S, V75, P59; *WRIT GROUP PEPI T, 1996, JAMA-J AM MED ASSOC, V275, P370; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199	23	361	371	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					458	461		10.1016/S0140-6736(96)07365-5	http://dx.doi.org/10.1016/S0140-6736(96)07365-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040575				2022-12-28	WOS:A1997WH38900010
J	Livingston, MG; Clark, A				Livingston, MG; Clark, A			Curvaceous model of recovery from depression	LANCET			English	Editorial Material							IMIPRAMINE		GREATER GLASGOW COMMUNITY & MENTAL HLTH TRUST,RES & DEV DIRECTORATE,GLASGOW,LANARK,SCOTLAND		Livingston, MG (corresponding author), UNIV GLASGOW,GARTNAVEL ROYAL HOSP,DEPT MED PSYCHOL,GLASGOW G12 0XH,LANARK,SCOTLAND.							ALTMAN DG, 1996, PRACTICAL STAT MED R, P278; KUHN R, 1958, AM J PSYCHIAT, V115, P459, DOI 10.1176/ajp.115.5.459; MONTGOMERY SA, 1991, PHARMACOPSYCHIATRY, V24, P168, DOI 10.1055/s-2007-1014463; Priest RG, 1996, J CLIN PSYCHOPHARM, V16, P420, DOI 10.1097/00004714-199612000-00002; QUITKEN FM, 1984, ARCH GEN PSYCHIAT, V36, P749; SCHWEIZER E, 1994, J CLIN PSYCHIAT, V55, P104; SULSER F, 1978, BIOCHEM PHARMACOL, V27, P257, DOI 10.1016/0006-2952(78)90226-5; 1996, DRUG THER B, V34, P65	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					447	447		10.1016/S0140-6736(05)61179-8	http://dx.doi.org/10.1016/S0140-6736(05)61179-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040570				2022-12-28	WOS:A1997WH38900005
J	Rosewicz, S; Wiedenmann, B				Rosewicz, S; Wiedenmann, B			Pancreatic carcinoma	LANCET			English	Article							ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; COMPUTED-TOMOGRAPHY; K-RAS; BILIARY ENDOPROSTHESIS; BILE-DUCT; CANCER; ADENOCARCINOMA; RESECTION; HEAD; PANCREATICODUODENECTOMY		FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,MED KLIN & POLIKLIN,DEPT GASTROENTEROL,D-12200 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin				Wiedenmann, Bertram/0000-0002-7890-2552				ALLEMA JH, 1994, BRIT J SURG, V81, P1642, DOI 10.1002/bjs.1800811126; ANDERSON JR, 1989, GUT, V30, P1131; BALLINGER AB, 1994, GUT, V35, P467, DOI 10.1136/gut.35.4.467; BARTZ C, 1996, GUT, V38, P423; BAUMEL H, 1994, BRIT J SURG, V81, P102, DOI 10.1002/bjs.1800810138; BORNMAN PC, 1986, LANCET, V1, P69; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CAMERON JL, 1991, AM J SURG, V161, P120, DOI 10.1016/0002-9610(91)90371-J; CHARI ST, 1994, PANCREAS, V9, P62, DOI 10.1097/00006676-199401000-00009; COMPAGNO J, 1978, AM J CLIN PATHOL, V69, P573; CUBILLA AL, 1978, CANCER, V41, P880, DOI 10.1002/1097-0142(197803)41:3<880::AID-CNCR2820410315>3.0.CO;2-J; CUESTA MA, 1993, BRIT J SURG, V80, P1571, DOI 10.1002/bjs.1800801226; DOUGLASS HO, 1995, WORLD J SURG, V19, P270, DOI 10.1007/BF00308637; ECKHAUSER FE, 1995, CURR OPIN GASTROEN, V11, P414, DOI 10.1097/00001574-199509000-00005; FERNANDEZDELCASTILLO C, 1994, CURR OPIN GASTROEN, V10, P507; FREENY PC, 1993, AM J SURG, V165, P600, DOI 10.1016/S0002-9610(05)80443-X; FUHRMAN GM, 1994, AM J SURG, V167, P104, DOI 10.1016/0002-9610(94)90060-4; FURUKAWA T, 1993, ENDOSCOPY, V25, P577, DOI 10.1055/s-2007-1010408; GEER RJ, 1993, AM J SURG, V165, P68, DOI 10.1016/S0002-9610(05)80406-4; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GULLO L, 1994, NEW ENGL J MED, V331, P81, DOI 10.1056/NEJM199407143310203; HAHN SA, 1995, SURG CLIN N AM, V75, P857, DOI 10.1016/S0039-6109(16)46732-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOHNE MW, 1992, CANCER RES, V52, P2616; HRUBAN RH, 1993, AM J PATHOL, V143, P549; KAISER MH, 1985, CANCER, V56, P397; KALTHOFF H, 1993, ONCOGENE, V8, P289; KANEKO T, 1994, SURGERY, V115, P438; KELLY DM, 1995, ANN ONCOL, V6, P19, DOI 10.1093/oxfordjournals.annonc.a059031; KLOPPEL G, 1985, HISTOPATHOLOGY, V9, P841, DOI 10.1111/j.1365-2559.1985.tb02870.x; Kloppel G., 1993, PANCREAS, P871; KLOPPEL G, 1996, WHO INT HISTOLOGICAL; KOHLER H, 1987, PANCREAS, V62, P765; KUBOTA Y, 1993, AM J GASTROENTEROL, V70, P276; LEMOINE NR, 1990, BAILLIERE CLIN GASTR, V4, P815, DOI 10.1016/0950-3528(90)90021-8; LILLEMOE KD, 1995, ANN SURG, V221, P133, DOI 10.1097/00000658-199502000-00003; LIONETTO R, 1995, EUR J CANCER, V31A, P882, DOI 10.1016/0959-8049(94)00445-5; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P433; LYNCH HT, 1990, AM J GASTROENTEROL, V85, P54; MACK TM, 1986, JNCI-J NATL CANCER I, V76, P49; McFarland EG, 1996, AM J ROENTGENOL, V166, P37, DOI 10.2214/ajr.166.1.8571901; MOERTEL CG, 1981, CANCER, V48, P1705, DOI 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4; MOSS AA, 1980, RADIOLOGY, V134, P159, DOI 10.1148/radiology.134.1.6985736; MOTOJIMA K, 1991, AM J GASTROENTEROL, V86, P1784; NAKAO A, 1995, SURGERY, V117, P50, DOI 10.1016/S0039-6060(05)80229-6; NGHIEM HV, 1994, RADIOL CLIN N AM, V32, P71; NITECKI SS, 1995, ANN SURG, V221, P59, DOI 10.1097/00000658-199501000-00007; OUTWATER EK, 1994, RADIOLOGY, V192, P19, DOI 10.1148/radiology.192.1.8208936; Pasricha P J, 1996, Gastroenterology, V110, P311, DOI 10.1053/gast.1996.v110.agast960311; PELLEGATA NS, 1994, CANCER RES, V54, P1556; PERMERT J, 1994, NEW ENGL J MED, V330, P313, DOI 10.1056/NEJM199402033300503; PIETRI F, 1990, BRIT J IND MED, V47, P425; PINTO MM, 1992, AM J GASTROENTEROL, V87, P530; PROCTOR HJ, 1990, AM J SURG, V159, P67, DOI 10.1016/S0002-9610(05)80608-7; RASHLEIGHBELCHER HJC, 1986, BRIT J RADIOL, V59, P182, DOI 10.1259/0007-1285-59-698-182; REZNEK RH, 1993, CLIN RADIOL, V47, P373, DOI 10.1016/S0009-9260(05)81056-6; ROSA JA, 1989, J CLIN GASTROENTEROL, V11, P211, DOI 10.1097/00004836-198904000-00020; ROSCH T, 1992, GASTROENTEROLOGY, V102, P188; ROTHENBERG ML, 1995, P AN M AM SOC CLIN, V14, P198; SATAKE K, 1992, SURG GYNECOL OBSTET, V175, P259; Schnall SF, 1996, SEMIN ONCOL, V23, P220; SELL S, 1994, LAB INVEST, V70, P6; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEMESH E, 1990, CANCER, V65, P893, DOI 10.1002/1097-0142(19900215)65:4<893::AID-CNCR2820650412>3.0.CO;2-G; SHEPHERD HA, 1988, BRIT J SURG, V75, P1166, DOI 10.1002/bjs.1800751207; SHIBATA D, 1990, CANCER RES, V50, P1279; SIKORA K, 1990, BAILLIERE CLIN GASTR, V4, P135, DOI 10.1016/0950-3528(90)90043-G; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; TADA M, 1993, CANCER RES, V53, P2472; TADA M, 1991, GASTROENTEROLOGY, V100, P1037; Thomas PRM, 1996, SEMIN ONCOL, V23, P213; TIO TL, 1993, DIGEST DIS SCI, V38, P59, DOI 10.1007/BF01296774; TREDE M, 1990, ANN SURG, V211, P447, DOI 10.1097/00000658-199004000-00011; TSAO JI, 1994, ARCH SURG-CHICAGO, V129, P405; VENTAFRIDDA GV, 1990, EUR J SURG ONCOL, V16, P1; VIRGOLINI I, 1994, NEW ENGL J MED, V331, P1116, DOI 10.1056/NEJM199410273311703; WARSHAW AL, 1991, AM J SURG, V161, P26, DOI 10.1016/0002-9610(91)90356-I; WARSHAW AL, 1990, ARCH SURG-CHICAGO, V125, P230; WATANAPA P, 1991, PANCREATIC DIS PROGR, P71; WILLETT CG, 1993, ANN SURG, V217, P144, DOI 10.1097/00000658-199302000-00008; WYATT SH, 1994, SEMIN ULTRASOUND CT, V15, P122, DOI 10.1016/S0887-2171(05)80094-0; YANAGISAWA A, 1993, CANCER RES, V53, P953; YEATON P, 1993, AM J CLIN PATHOL, V100, P497, DOI 10.1093/ajcp/100.5.497; Yeo C J, 1996, Surg Oncol Clin N Am, V5, P145; YEO CJ, 1995, ANN SURG, V221, P721, DOI 10.1097/00000658-199506000-00011	86	223	228	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					485	489						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040589				2022-12-28	WOS:A1997WH38900043
J	Ariyaratnam, S; Thakker, NS; Sloan, P; Thornhill, MH				Ariyaratnam, S; Thakker, NS; Sloan, P; Thornhill, MH			Potentiation of warfarin anticoagulant activity by miconazole oral gel	BRITISH MEDICAL JOURNAL			English	Letter							ACENOCOUMAROL				Ariyaratnam, S (corresponding author), UNIV DENT HOSP MANCHESTER,MANCHESTER M15 6FH,LANCS,ENGLAND.			Thornhill, Martin/0000-0003-0681-4083				BRUGMANS J, 1972, EUR J CLIN PHARMACOL, V5, P93, DOI 10.1007/BF00561752; COHEN J, 1982, LANCET, V2, P532; COLQUHOUN MC, 1987, LANCET, V1, P695; DUCROIX JP, 1989, REV MED INTERNE, V10, P557; MAROTEL C, 1986, PRESSE MED, V15, P1684; OREILLY RA, 1992, CLIN PHARMACOL THER, V51, P656, DOI 10.1038/clpt.1992.78; PONGE T, 1987, THERAPIE, V42, P412; SHENFIELD GM, 1991, AUST NZ J MED, V21, P928, DOI 10.1111/j.1445-5994.1991.tb01422.x	8	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					349	349		10.1136/bmj.314.7077.349a	http://dx.doi.org/10.1136/bmj.314.7077.349a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040331	Green Published			2022-12-28	WOS:A1997WF86100037
J	Berlin, JA				Berlin, JA			Summary statistics of poor quality studies must be treated cautiously - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material											Berlin, JA (corresponding author), UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,423 GUARDIAN DR,PHILADELPHIA,PA 19104, USA.							McIntosh MW, 1996, STAT MED, V15, P1713, DOI 10.1002/(SICI)1097-0258(19960830)15:16<1713::AID-SIM331>3.0.CO;2-D	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					337	337		10.1136/bmj.314.7077.337	http://dx.doi.org/10.1136/bmj.314.7077.337			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040322	Green Published			2022-12-28	WOS:A1997WF86100027
J	Frewin, R; Henson, A; Provan, D				Frewin, R; Henson, A; Provan, D			ABC of clinical haematology - Iron deficiency anaemia	BRITISH MEDICAL JOURNAL			English	Review									UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,DEPT PRIMARY CARE,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital	Frewin, R (corresponding author), SOUTHAMPTON UNIV HOSP NHS TRUST,SOUTHAMPTON,HANTS,ENGLAND.		Provan, Drew/AAF-2766-2021	Provan, Drew/0000-0002-5110-8455					0	41	46	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					360	363		10.1136/bmj.314.7077.360	http://dx.doi.org/10.1136/bmj.314.7077.360			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040336	Green Published			2022-12-28	WOS:A1997WF86100043
J	Weaver, HA; Feldman, PD; AHearn, MF; Arpigny, C; Brandt, JC; Festou, MC; Haken, M; McPhate, JB; Stern, SA; Tozzi, GP				Weaver, HA; Feldman, PD; AHearn, MF; Arpigny, C; Brandt, JC; Festou, MC; Haken, M; McPhate, JB; Stern, SA; Tozzi, GP			The activity and size of the nucleus of comet Hale-Bopp (C/1995 01)	SCIENCE			English	Article							HUBBLE-SPACE-TELESCOPE; OH	Analysis of Hubble Space Telescope (HST) images of comet Hale-Bopp (C/1995 O1) suggests that the effective diameter of the nucleus is between 27 to 42 kilometers, which is at least three times larger than that of comet P/Halley, The International Ultraviolet Explorer and HST spectra showed emissions from OH (a tracer of H2O) and CS (a tracer of CS2) starting in April 1996, and from the CO Cameron system (which primarily traces CO2) starting in June 1996. The variation of the H2O production rate with heliocentric distance was consistent with sublimation of an icy body near its subsolar point. The heliocentric variation in the production rates of CS2 and dust was different from that of H2O, which implies that H2O sublimation did not control the CS2 or dust production during these observations.	UNIV MARYLAND,DEPT ASTRON,COLLEGE PK,MD 20742; UNIV LIEGE,INST ASTROPHYS,B-4000 LIEGE,BELGIUM; UNIV COLORADO,ATMOSPHER & SPACE PHYS LAB,BOULDER,CO 80309; OBSERV MIDI PYRENEES,F-31400 TOULOUSE,FRANCE; SW RES INST,DEPT SPACE SCI,BOULDER EXTENS OFF,BOULDER,CO 80302; OSSERV ASTROFIS ARCETRI,I-50125 FLORENCE,ITALY	University System of Maryland; University of Maryland College Park; University of Liege; University of Colorado System; University of Colorado Boulder; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Istituto Nazionale Astrofisica (INAF)	Weaver, HA (corresponding author), JOHNS HOPKINS UNIV,DEPT PHYS & ASTRON,BALTIMORE,MD 21218, USA.		Weaver, Harold A/D-9188-2016	Weaver, Harold A/0000-0003-0951-7762; Tozzi, Gian Paolo/0000-0003-4775-5788; McPhate, Jason/0000-0001-7504-1999				AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; ARPIGNY C, 1997, ATLAS COMETARY SPECT; Biver N, 1996, NATURE, V380, P137, DOI 10.1038/380137a0; BUDZIEN SA, 1994, ICARUS, V107, P164, DOI 10.1006/icar.1994.1014; COWAN JJ, 1979, MOON PLANETS, V21, P155, DOI 10.1007/BF00897085; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; CROVISIER J, 1996, 28 ANN M DIV PLAN SC; FESTOU MC, 1981, ASTRON ASTROPHYS, V95, P69; HALE A, 1995, 6187 IAU; Haser L., 1957, B ACAD ROY SCI BELGI, V43, P740; JACKSON WM, 1982, ASTRON ASTROPHYS, V107, P385; Jewitt D, 1996, SCIENCE, V271, P1110, DOI 10.1126/science.271.5252.1110; Jewitt D, 1991, COMETS POSTHALLEY ER; Kamel L, 1996, ICARUS, V122, P428, DOI 10.1006/icar.1996.0134; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; KIDGER MR, UNPUB ASTROPHYS J LE; LAMY PL, 1995, ASTRON ASTROPHYS, V293, pL43; LAMY PL, UNPUB ASTRON ASTROPH; SCHLEICHER DG, 1988, ASTROPHYS J, V331, P1058, DOI 10.1086/166622; SCHLOERB FP, 1988, ASTROPHYS J, V332, P524, DOI 10.1086/166674; Sekanina Z, 1996, ASTRON ASTROPHYS, V314, P957; WALLACE LV, 1958, ASTRON J, V63, P213, DOI 10.1086/107729; WEAVER HA, 1994, ASTROPHYS J, V422, P374, DOI 10.1086/173732; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; WEAVER HA, 1981, ICARUS, V47, P449, DOI 10.1016/0019-1035(81)90193-7; WEAVER HA, 1996, 6376 IAU	27	95	95	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1900	1904		10.1126/science.275.5308.1900	http://dx.doi.org/10.1126/science.275.5308.1900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072959				2022-12-28	WOS:A1997WQ51300034
J	Morin, PJ; Sparks, AB; Korinek, V; Barker, N; Clevers, H; Vogelstein, B; Kinzler, KW				Morin, PJ; Sparks, AB; Korinek, V; Barker, N; Clevers, H; Vogelstein, B; Kinzler, KW			Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC	SCIENCE			English	Article							GENE-PRODUCT; COLORECTAL-CANCER; WILD-TYPE; PROTEIN; IDENTIFICATION; ASSOCIATION; CHROMOSOME-5Q21; ARMADILLO; ROLES; LOCUS	Inactivation of the adenomatous polyposis coli (APC) tumor suppressor gene initiates colorectal neoplasia. One of the biochemical activities associated with the APC protein is down-regulation of transcriptional activation mediated by beta-catenin and T cell transcription factor 4 (Tcf-4). The protein products of mutant APC genes present in colorectal tumors were found to be defective in this activity. Furthermore, colorectal tumors with intact APC genes were found to contain activating mutations of beta-catenin that altered functionally significant phosphorylation sites. These results indicate that regulation of beta-catenin is critical to APC's tumor suppressive effect and that this regulation can be circumvented by mutations in either APC or beta-catenin.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; HOWARD HUGHES MED INST,BALTIMORE,MD 21231; UNIV UTRECHT HOSP,DEPT IMMUNOL,NL-3508 GA UTRECHT,NETHERLANDS	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Utrecht University; Utrecht University Medical Center			Barker, Nick/A-5535-2011; Korinek, Vladimir/G-6348-2014; Barker, Nick/AAS-2774-2020; Barker, Nick/AAE-9833-2021	Korinek, Vladimir/0000-0002-9777-4664; Barker, Nick/0000-0003-3566-4475	NCI NIH HHS [CA57345] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Friedl W, 1996, HUM GENET, V97, P579; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; JEN J, 1994, CANCER RES, V54, P5523; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Scott RJ, 1996, HUM MOL GENET, V5, P1921, DOI 10.1093/hmg/5.12.1921; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; SU LK, 1995, CANCER RES, V55, P2972; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	37	3416	3559	3	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1787	1790		10.1126/science.275.5307.1787	http://dx.doi.org/10.1126/science.275.5307.1787			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065402				2022-12-28	WOS:A1997WP05600040
J	vanSteveninck, RRD; Lewen, GD; Strong, SP; Koberle, R; Bialek, W				vanSteveninck, RRD; Lewen, GD; Strong, SP; Koberle, R; Bialek, W			Reproducibility and variability in neural spike trains	SCIENCE			English	Article							MOVEMENT-SENSITIVE NEURON; RELIABILITY; EFFICIENCY; ADAPTATION; RESPONSES; SIGNALS; CORTEX; CODE	To provide information about dynamic sensory stimuli, the pattern of action potentials in spiking neurons must be variable, To ensure reliability these variations must be related, reproducibly, to the stimulus, For H1, a motion-sensitive neuron in the fly's visual system, constant-velocity motion produces irregular spike firing patterns, and spike counts typically have a variance comparable to the mean, for cells in the mammalian cortex, But more natural, time-dependent input signals yield patterns of spikes that are much more reproducible, both in terms of timing and of counting precision. Variability and reproducibility are quantified with ideas from information theory, and measured spike sequences in H1 carry more than twice the amount of information they would if they followed the variance-mean relation seen with constant inputs. Thus, models that may accurately account for the neural response to static stimuli can significantly underestimate the reliability of signal transfer under more natural conditions.	PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544; NEC RES INST,PRINCETON,NJ 08540	Princeton University; NEC Corporation								Adrian E.D., 1928, BASIS SENSATION; BAIR W, 1996, NEURAL COMPUT, V8, P1184; BERRY MJ, UNPUB P NATL ACAD SC; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; BRITTEN KH, 1993, VISUAL NEUROSCI, V10, P1157, DOI 10.1017/S0952523800010269; BULLOCK TH, 1970, J GEN PHYSIOL, V55, P565, DOI 10.1085/jgp.55.5.565; Burns BD, 1968, UNCERTAIN NERVOUS SY; DEAR SP, 1993, NATURE, V364, P620, DOI 10.1038/364620a0; FERSTER D, 1995, SCIENCE, V270, P756, DOI 10.1126/science.270.5237.756; Franceschini N., 1989, P360; HAGIWARA S, 1954, Jpn J Physiol, V4, P234; Hausen K., 1989, P391; Holden AV., 1976, MODELS STOCHASTIC AC; Kumar A, 1996, PHYS REV LETT, V76, P2778, DOI 10.1103/PhysRevLett.76.2778; LAND MF, 1974, J COMP PHYSIOL, V89, P331, DOI 10.1007/BF00695351; LEVIN J, 1996, THESIS U CALIFORNIA; MacKAY DONALD M., 1952, BULL MATH BIOPHYS, V14, P127, DOI 10.1007/BF02477711; MADDESS T, 1985, PROC R SOC SER B-BIO, V225, P251, DOI 10.1098/rspb.1985.0061; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MILLER MI, 1992, J ACOUST SOC AM, V92, P202, DOI 10.1121/1.404284; Papoulis A., 1984, PROBABILITY RANDOM V; Perkel DH, 1969, NEUROSCI RES PROG SU, P405; Rieke F, 1995, P ROY SOC B-BIOL SCI, V262, P259, DOI 10.1098/rspb.1995.0204; RIEKE F, 1993, EUROPHYS LETT, V22, P151, DOI 10.1209/0295-5075/22/2/013; Rieke F., 1997, SPIKES EXPLORING NEU; Shadlen M N, 1995, Curr Opin Neurobiol, V5, P248, DOI 10.1016/0959-4388(95)80033-6; Shannon C. E., 1949, MATH THEORY COMMUNIC; Snyder Donald Lee, 1991, RANDOM POINT PROCESS, DOI DOI 10.1007/978-1-4612-3166-0; SOFTKY WR, 1995, NATURE, V376, P21; Stevens CF, 1995, CURR BIOL, V5, P1370, DOI 10.1016/S0960-9822(95)00273-9; TEICH MC, 1989, IEEE T BIO-MED ENG, V36, P150, DOI 10.1109/10.16460; TOLHURST DJ, 1983, VISION RES, V23, P775, DOI 10.1016/0042-6989(83)90200-6; VANSTEVENINCK RD, 1988, PROC R SOC SER B-BIO, V234, P379; VANSTEVENINCK RD, 1995, PHILOS T R SOC B, V348, P321; VANSTEVENINCK RRD, 1986, BIOL CYBERN, V54, P223, DOI 10.1007/BF00318418; vanSteveninck RRD, 1996, NATURAL & ARTIFICIAL PARALLEL COMPUTATION, P21; WAGNER H, 1986, PHILOS T ROY SOC B, V312, P527, DOI 10.1098/rstb.1986.0017; WERNER G, 1963, J NEUROPHYSIOL, V26, P958, DOI 10.1152/jn.1963.26.6.958; ZAAGMAN WH, 1983, IEEE T SYST MAN CYB, V13, P900, DOI 10.1109/TSMC.1983.6313085	39	486	489	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1805	1808		10.1126/science.275.5307.1805	http://dx.doi.org/10.1126/science.275.5307.1805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065407	Green Submitted			2022-12-28	WOS:A1997WP05600045
J	Shelling, AN				Shelling, AN			Role of p53 in drug resistance in ovarian cancer	LANCET			English	Editorial Material											Shelling, AN (corresponding author), NATL WOMENS HOSP,RES CTR REPROD MED,AUCKLAND,NEW ZEALAND.		Shelling, Andrew/E-7496-2010	Shelling, Andrew/0000-0002-5300-1934				Buttitta F, 1997, BRIT J CANCER, V75, P230, DOI 10.1038/bjc.1997.38; Herod JJO, 1996, CANCER RES, V56, P2178; Kristensen GB, 1997, LANCET, V349, P113, DOI 10.1016/S0140-6736(96)06071-0; REESE DM, 1995, NATURE, V378, P532, DOI 10.1038/378532c0; Righetti SC, 1996, CANCER RES, V56, P689; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72	7	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					744	745		10.1016/S0140-6736(05)60195-X	http://dx.doi.org/10.1016/S0140-6736(05)60195-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074569				2022-12-28	WOS:A1997WN12400004
J	Golovina, VA; Blaustein, MP				Golovina, VA; Blaustein, MP			Spatially and functionally distinct Ca2+ stores in sarcoplasmic and endoplasmic reticulum	SCIENCE			English	Article							INTRACELLULAR CALCIUM STORES; CEREBELLAR PURKINJE NEURONS; SMOOTH-MUSCLE CELLS; INOSITOL TRISPHOSPHATE; FLUORESCENT INDICATOR; RYANODINE RECEPTORS; CORTICAL ASTROCYTES; RELEASE CHANNEL; CAFFEINE; THAPSIGARGIN	The organization of calcium (Ca2+) stores in the sarco plasmic and endoplasmic reticulum (S-ER) is poorly understood. The dynamics of the storage and release of calcium in the S-ER of intact, cultured astrocytes and arterial myocytes were studied with high-resolution imaging methods. The S-ER appeared to be a continuous tubular network; nevertheless, calcium stores in the S-ER were organized into small, spatially distinct compartments that functioned as discrete units. Cyclopiazonic acid (an inhibitor of the calcium pump in the S-ER membrane) and caffeine or ryanodine unloaded different, spatially separate compartments. Heterogeneity of calcium stores was also revealed in cells activated by physiological agonists. These results suggest that cells can generate spatially and temporally distinct calcium signals to control individual calcium-dependent processes.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, CTR VASC BIOL & HYPERTENS, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016106] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32276] Funding Source: Medline; NINDS NIH HHS [NS-16106] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN SP, 1993, J MOL CELL CARDIOL, V25, P949, DOI 10.1006/jmcc.1993.1107; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BEZPROZVANNY I, 1994, MOL BIOL CELL, V5, P97, DOI 10.1091/mbc.5.1.97; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; BURGOYNE RD, 1991, TRENDS BIOCHEM SCI, V16, P319, DOI 10.1016/0968-0004(91)90131-E; CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHATTON JY, 1995, FEBS LETT, V368, P165, DOI 10.1016/0014-5793(95)00632-J; CHEEK TR, 1994, BIOCHEM J, V301, P879, DOI 10.1042/bj3010879; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DUCHEN MR, 1992, J PHYSIOL-LONDON, V450, P33, DOI 10.1113/jphysiol.1992.sp019115; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GOLDMAN WF, 1994, J NEUROSCI, V14, P5834; GOLOVINA V, UNPUB; Golovina VA, 1996, GLIA, V16, P296; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HENZI V, 1992, NEUROSCIENCE, V46, P251, DOI 10.1016/0306-4522(92)90049-8; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Hollingworth S, 1996, J GEN PHYSIOL, V108, P455, DOI 10.1085/jgp.108.5.455; INESI G, 1994, J MEMBRANE BIOL, V141, P1; ISENBERG G, 1993, CARDIOVASC RES, V27, P1800, DOI 10.1093/cvr/27.10.1800; JENSEN AM, 1990, J NEUROSCI, V10, P1165; Jung DW, 1996, ARCH BIOCHEM BIOPHYS, V332, P19, DOI 10.1006/abbi.1996.0311; KONISHI M, 1991, J GEN PHYSIOL, V97, P271, DOI 10.1085/jgp.97.2.271; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LONDON RE, 1996, Patent No. 5516911; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MURPHY E, 1993, MINER ELECTROL METAB, V19, P250; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SEYMOURLAURENT KJ, 1995, J NEUROSCI, V15, P2592; SHEU SS, 1994, J BIOENERG BIOMEMBR, V26, P487, DOI 10.1007/BF00762733; SHIMA H, 1992, CIRC RES, V70, P968, DOI 10.1161/01.RES.70.5.968; SIMPSON PB, 1995, TRENDS NEUROSCI, V18, P299, DOI 10.1016/0166-2236(95)93919-O; SLODZINSKI MK, 1995, AM J PHYSIOL-CELL PH, V269, pC1340, DOI 10.1152/ajpcell.1995.269.5.C1340; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SUGIYAMA T, 1995, AM J PHYSIOL-CELL PH, V269, pC698, DOI 10.1152/ajpcell.1995.269.3.C698; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; TERASAKI M, 1989, METHOD CELL BIOL, V29, P125; TERASAKI M, 1994, P NATL ACAD SCI USA, V91, P7510, DOI 10.1073/pnas.91.16.7510; TRIBE RM, 1994, P NATL ACAD SCI USA, V91, P5908, DOI 10.1073/pnas.91.13.5908; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; YAMAZAWA T, 1992, FEBS LETT, V301, P181, DOI 10.1016/0014-5793(92)81243-F; Yuan XJ, 1996, AM J PHYSIOL-CELL PH, V270, pC321, DOI 10.1152/ajpcell.1996.270.1.C321	64	407	410	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	1997	275	5306					1643	1648		10.1126/science.275.5306.1643	http://dx.doi.org/10.1126/science.275.5306.1643			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054358				2022-12-28	WOS:A1997WN12300046
J	Kharitonenkov, A; Chen, ZJ; Sures, I; Wang, HY; Schilling, J; Ullrich, A				Kharitonenkov, A; Chen, ZJ; Sures, I; Wang, HY; Schilling, J; Ullrich, A			A family of proteins that inhibit signalling through tyrosine kinase receptors	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; NEURONAL DIFFERENTIATION; INSULIN-RECEPTOR; PC12 CELLS; MAP KINASE; PHOSPHATASE; EXPRESSION; SH-PTP2; DOWNSTREAM; ACTIVATION	Phosphotyrosine phosphatases are critical negative or positive regulators in the intracellular signalling pathways that result in growth-factor-specific cell responses such as mitosis, differentiation, migration, survival, transformation or death(1-4). The SH2-domain-containing phosphotyrosine phosphatase SHP-2 is a positive signal transducer for several receptor tyrosine kinases (RTKs) and cytokine receptors(5-7). To investigate its mechanism of action we purified a tyrosine-phosphorylated glycoprotein which in different cell types associates tightly with SHP-2 and appears to serve as its substrate. Peptide sequencing in conjunction with complementary DNA cloning revealed a new gene family of at least fifteen members designated signal-regulatory proteins (SIRPs). They consist of two subtypes distinguished by the presence or absence of a cytoplasmic SHP-2-binding domain. The transmembrane polypeptide SIRP alpha 1 is a substrate of activated RTKs and in its tyrosine-phosphorylated form binds SHP-2 through SH2 interactions and acts as its substrate. It also binds SHP-1 and Grb2 in vitro and has negative regulatory effects on cellular responses induced by growth factors, oncogenes or insulin. Our findings indicate that proteins belonging to the SIRP family generally regulate signals defining different physiological and pathological processes.	MAX PLANCK INST BIOCHEM, DEPT MOL BIOL, D-82152 MARTINSRIED, GERMANY; SUGEN INC, REDWOOD CITY, CA 94063 USA	Max Planck Society			Wang, Hongyang/B-1340-2010					BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FENDLY BM, 1990, CANCER RES, V50, P1550; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SAWADA T, 1995, BIOCHEM BIOPH RES CO, V214, P737, DOI 10.1006/bbrc.1995.2347; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	31	537	564	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 13	1997	386	6621					181	186		10.1038/386181a0	http://dx.doi.org/10.1038/386181a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062191				2022-12-28	WOS:A1997WM97300064
J	SustentoReodica, N; Ruiz, P; Rogers, A; Viciana, AL; Conn, HO; Tzakis, AG				SustentoReodica, N; Ruiz, P; Rogers, A; Viciana, AL; Conn, HO; Tzakis, AG			Recurrent Crohn's disease in transplanted bowel	LANCET			English	Article							PANCREAS TRANSPLANTATION	Background Intestinal transplantation is used in patients with short-bowel syndrome after repeated resections for Crohn's disease. We report the apparent clinical recurrence of Crohn's disease in a transplanted intestine. Methods and findings The patient, a 33-year-old Hispanic woman, underwent small-bowel transplantation in December, 1994. Immunosuppression with tacrolimus, methylprednisolone, bone-marrow infusions, and OKT3 was given. In July, 1995, the patient had recurrent abdominal symptoms. The histological diagnosis of Crohn's disease was established by the independent interpretations of four experienced gastrointestinal histopathologists. Interpretation The prompt appearance of this autoimmune disorder (within 6 months of transplantation), despite massive immunosuppression may; provide important insights into the nature of Crohn's disease and of the recurrence of autoimmune disease during immunosuppression.	UNIV MIAMI,SCH MED,DEPT SURG,DIV LIVER & GI TRANSPLANTAT,MIAMI,FL 33101; UNIV MIAMI,JACKSON MEM HOSP,SCH MED,DEPT PATHOL,DIV IMMUNOPATHOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT MED,DIV GASTROENTEROL,MIAMI,FL 33101	University of Miami; University of Miami; University of Miami								BRADFORD WD, 1974, ARCH PATHOL, V98, P17; Deltz E, 1989, CLIN TRANSPLANT, V21, P89; GRANT D, 1990, LANCET, V335, P171; KIRSNER JB, 1991, DIS MONTH, P679; LILLEHEI RC, 1959, ANN SURG, V150, P543, DOI 10.1097/00000658-195910000-00001; ROLANDELLI RH, 1994, INFLAMM BOWEL DIS, P610; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1989, JAMA-J AM MED ASSOC, V261, P1449, DOI 10.1001/jama.261.10.1449; SUTHERLAND DER, 1984, T ASSOC AM PHYSICIAN, V97, P80; TANDON HD, 1972, GUT, V13, P260, DOI 10.1136/gut.13.4.260	10	49	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					688	691		10.1016/S0140-6736(96)09256-2	http://dx.doi.org/10.1016/S0140-6736(96)09256-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078200	hybrid			2022-12-28	WOS:A1997WM08000010
J	Chuang, RY; Weaver, PL; Liu, Z; Chang, TH				Chuang, RY; Weaver, PL; Liu, Z; Chang, TH			Requirement of the DEAD-box protein Ded1p for messenger RNA translation	SCIENCE			English	Article							STEM-LOOP MUTATION; SACCHAROMYCES-CEREVISIAE; INITIATION FACTOR-4A; GENE REGION; DNA-REPAIR; YEAST; HELICASE; TRANSCRIPTION; SUPPRESSOR; SEQUENCE	The DED1 gene, which encodes a putative RNA helicase, has been implicated in nuclear pre-messenger RNA splicing in the yeast Saccharomyces cerevisiae. It is shown here by genetic and biochemical analysis that translation, rather than splicing, is severely impaired in two newly isolated ded1 conditional mutants, Preliminary evidence suggests that the protein Ded1p may be required for the initiation step of translation, as is the distinct DEAD-box protein, eukaryotic initiation factor 4A (eIF4A), The DED1 gene could be functionally replaced by a mouse homolog, PL10, which suggests that the function of Ded1p in translation is evolutionarily conserved.	OHIO STATE UNIV, DEPT MOL GENET, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, MOL CELLULAR & DEV BIOL PROGRAM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NIGMS NIH HHS [GM48752] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048752, R55GM048752] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; CHANG TR, UNPUB; DELACRUZ J, COMMUNICATION; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; GEE SL, 1994, GENE, V140, P171, DOI 10.1016/0378-1119(94)90541-X; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUSSAIN I, 1986, GENE, V46, P13, DOI 10.1016/0378-1119(86)90162-9; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Merrick WC., 1996, TRANSLATION CONTROL, P31; NARANDA T, 1994, J BIOL CHEM, V269, P32286; PAUSE A, 1993, CURR OPIN STRUC BIOL, V3, P953, DOI 10.1016/0959-440X(93)90161-D; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1980, J MOL BIOL, V136, P309, DOI 10.1016/0022-2836(80)90376-9; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	32	268	275	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 7	1997	275	5305					1468	1471		10.1126/science.275.5305.1468	http://dx.doi.org/10.1126/science.275.5305.1468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045610				2022-12-28	WOS:A1997WM08100043
J	Genick, UK; Borgstahl, GEO; Ng, K; Ren, Z; Pradervand, C; Burke, PM; Srajer, V; Teng, TY; Schildkamp, W; McRee, DE; Moffat, K; Getzoff, ED				Genick, UK; Borgstahl, GEO; Ng, K; Ren, Z; Pradervand, C; Burke, PM; Srajer, V; Teng, TY; Schildkamp, W; McRee, DE; Moffat, K; Getzoff, ED			Structure of a protein photocycle intermediate by millisecond time-resolved crystallography	SCIENCE			English	Article							PHOTOACTIVE YELLOW PROTEIN; PURPLE PHOTOTROPHIC BACTERIUM; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; ECTOTHIORHODOSPIRA-HALOPHILA; LAUE DIFFRACTION; PHOSPHORYLASE-B; QUANTUM YIELD; CRYSTALS; MODEL; PHOTORECEPTOR	The blue-light photoreceptor photoactive yellow protein (PYP) undergoes a self-contained light cycle. The atomic structure of the bleached signaling intermediate in the light cycle of PYP was determined by millisecond time-resolved, multiwavelength Laue crystallography and simultaneous optical spectroscopy. Light-induced trans-to-cis isomerization of the 4-hydroxycinnamyl chromophore and coupled protein rearrangements produce a new set of active-site hydrogen bonds. An arginine gateway opens, allowing solvent exposure and protonation of the chromophore's phenolic oxygen. Resulting changes in shape, hydrogen bonding, and electrostatic potential at the protein surface form a likely basis for signal transduction. The structural results suggest a general framework for the interpretation of protein photocycles.	UNIV CHICAGO, DEPT BIOCHEM & MOL BIOL, CHICAGO, IL 60637 USA	University of Chicago	Genick, UK (corresponding author), Scripps Res Inst, DEPT MOL BIOL, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Pradervand, Claude/GPF-4155-2022; Pradervand, Claude P/I-8114-2013; Borgstahl, Gloria/AAZ-4114-2020	Pradervand, Claude/0000-0001-5251-3930; Genick, Ulrich/0000-0002-6526-3552	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036452, R37GM036452] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07707] Funding Source: Medline; NIGMS NIH HHS [GM37684, GM36452] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Bourgeois D, 1996, J SYNCHROTRON RADIAT, V3, P65, DOI 10.1107/S090904959501661X; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Campbell J. W., 1986, INF Q PROTEIN CRYSTA, V18, P23; CAMPBELL JW, 1995, J APPL CRYSTALLOGR, V28, P228, DOI 10.1107/S002188989400991X; CHEN Y, 1994, REV SCI INSTRUM, V65, P1506, DOI 10.1063/1.1144883; Cruickshank D. W. J., 1992, PHILOS T R SOC A, V340, P167; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DUKE EMH, 1994, PROTEIN SCI, V3, P1178, DOI 10.1002/pro.5560030804; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; GENICK U, UNPUB; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; GETZOFF ED, 1994, NUCL INSTRUM METHODS, V79, P1249; GREENHOUGH TJ, 1994, J APPL CRYSTALLOGR, V27, P111, DOI 10.1107/S0021889893006752; HAJDU J, 1987, EMBO J, V6, P539, DOI 10.1002/j.1460-2075.1987.tb04786.x; HELLWELL JR, 1969, J APPL CRYSTALLOGR, V22, P483; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13960; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; MACKERELL AD, 1992, FASEB J, V6, pA143; MACKERELL AD, UNPUB; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MCREE DE, 1986, J BIOL CHEM, V261, P3850; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1993, ARCH BIOCHEM BIOPHYS, V306, P515, DOI 10.1006/abbi.1993.1545; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; MOFFAT K, 1992, PHILOS T R SOC A, V340, P175, DOI 10.1098/rsta.1992.0059; NG K, 1995, BIOCHEMISTRY-US, V34, P879, DOI 10.1021/bi00003a022; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NICHOLLS A, 1990, DELPHI; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; REN Z, 1994, J SYNCHROTRON RADIAT, V1, P78, DOI 10.1107/S0909049594006692; REN Z, 1995, J APPL CRYSTALLOGR, V28, P461, DOI 10.1107/S0021889895003207; Ren Z, 1996, J APPL CRYSTALLOGR, V29, P246, DOI 10.1107/S0021889896000659; REN Z, 1995, J APPL CRYSTALLOGR, V28, P482, DOI 10.1107/S0021889895003219; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SINGER PT, 1993, SCIENCE, V259, P669, DOI 10.1126/science.8430314; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; STODDARD BL, 1991, P NATL ACAD SCI US, V88; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WANG Q, 1994, SCIENCE, V266, P422, DOI 10.1126/science.7939680	52	368	377	3	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1471	1475		10.1126/science.275.5305.1471	http://dx.doi.org/10.1126/science.275.5305.1471			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045611				2022-12-28	WOS:A1997WM08100044
J	Rothfield, LI; Justice, SS				Rothfield, LI; Justice, SS			Bacterial cell division: The cycle of the ring	CELL			English	Review							ESCHERICHIA-COLI; COMPARTMENTALIZATION; SEPTUM; SITES; FTSA				Rothfield, LI (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MICROBIOL,FARMINGTON,CT 06030, USA.		Justice, Sheryl/E-3329-2011	Justice, Sheryl/0000-0002-7059-3759				Addinall SG, 1996, MOL MICROBIOL, V22, P231, DOI 10.1046/j.1365-2958.1996.00100.x; Addinall SG, 1996, J BACTERIOL, V178, P7167, DOI 10.1128/jb.178.24.7167-7172.1996; Addinall SG, 1996, J BACTERIOL, V178, P3877, DOI 10.1128/jb.178.13.3877-3884.1996; BEGG KJ, 1995, J BACTERIOL, V177, P6211, DOI 10.1128/jb.177.21.6211-6222.1995; COOK WR, 1994, MOL MICROBIOL, V14, P485, DOI 10.1111/j.1365-2958.1994.tb02183.x; COOK WR, 1986, J BACTERIOL, V168, P1430, DOI 10.1128/jb.168.3.1430-1438.1986; DAI K, 1996, J BACTERIOL, V175, P1328; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; FOLEY M, 1989, MOL MICROBIOL, V3, P1329, DOI 10.1111/j.1365-2958.1989.tb00114.x; FUNG J, 1978, J BACTERIOL, V133, P1467, DOI 10.1128/JB.133.3.1467-1471.1978; HATE C, 1997, CELL, V88, P175; LUTKENHAUS J, 1996, ESCHERICHIA COLI SAL, P1615; Ma XL, 1996, P NATL ACAD SCI USA, V93, P12998, DOI 10.1073/pnas.93.23.12998; Margolin W, 1996, J BACTERIOL, V178, P1320, DOI 10.1128/jb.178.5.1320-1327.1996; Pogliano J, 1997, P NATL ACAD SCI USA, V94, P559, DOI 10.1073/pnas.94.2.559; SANCHEZ M, 1994, EMBO J, V13, P4919, DOI 10.1002/j.1460-2075.1994.tb06819.x; TORMO A, 1986, J BACTERIOL, V166, P985, DOI 10.1128/jb.166.3.985-992.1986; Wang X, 1996, MOL MICROBIOL, V21, P313, DOI 10.1046/j.1365-2958.1996.6421360.x; Wang X, 1996, J BACTERIOL, V178, P2314, DOI 10.1128/jb.178.8.2314-2319.1996	19	107	114	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					581	584		10.1016/S0092-8674(00)81899-1	http://dx.doi.org/10.1016/S0092-8674(00)81899-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054497	Bronze			2022-12-28	WOS:A1997WM41300003
J	Alderman, MH; Cohen, H; Roque, R; Madhavan, S				Alderman, MH; Cohen, H; Roque, R; Madhavan, S			Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients	LANCET			English	Article							WORK SITE	Background Short-acting calcium antagonists may increase coronary artery morbidity, mortality, and non-cardiovascular complications in hypertensive patients. We assessed whether this association was also true for long-acting calcium antagonists. Methods We did a case-control study, which was nested within a systematic hypertension control programme for a prospective cohort of 4350 people (first seen 1981-94). Cases (n=189) were hypertensive patients who had had a first cardiovascular event, including all cardiovascular deaths and hospitalisations, between 1989 and 1995. Controls (n=189) were individually matched to cases for sex, ethnic origin, age, type of previous antihypertensive treatment, year of entry into the study, and length of follow-up. We collected data on any prescribed drug regimen that was being taken on the event date for cases and on the same date for matched controls. Calcium antagonists were classified by duration of action. Findings Compared with those on beta-blocker monotherapy, patients on long-acting calcium antagonists (n=136) had no increased risk of a cardiovascular event (adjusted odds ratio 0.76 [95% CI 0.41-1.43]), whereas patients on short-acting calcium antagonists (n=27) were at significantly greater risk (adjusted odds ratio 3.88 [1.15-13.11], p=0.029). Among 38 matched pairs who were both on calcium antagonists, the adjusted risk ratio for short-acting versus long-acting was 8.56 (1.88-38.97), p<0.01. Interpretation Long-acting and short-acting calcium antagonists differ in cardiovascular outcomes. Consistent with earlier findings, the use of short-acting calcium antagonists was associated with increased risk of a cardiovascular event. This finding highlights the need to complete on-going clinical trials so that the relative cardiovascular impact of various antihypertensive agents can be assessed.			Alderman, MH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.			Cohen, Hillel/0000-0002-4524-0898	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18323] Funding Source: Medline; OFP OPHS HHS [REQ QIM50053,FPDS:R499] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFP OPHS HHS		Alderman MH, 1996, AM J HYPERTENS, V9, P413, DOI 10.1016/0895-7061(95)00438-6; ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; Barnett AA, 1996, LANCET, V347, P313; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Mancia G, 1996, J HYPERTENS, V14, P13; MEREDITH PA, 1994, J CARDIOVASC PHARM, V23, pS26, DOI 10.1097/00005344-199423005-00006; NAFTILAN AJ, 1990, GUIDE CARDIOLOGY, P409; *NAT HEART LUNG BL, 1995, NEW ANAL REG SAF CAL; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; SIFTON DW, 1995, PHYSICIANS DESK REFE; SWALES JD, 1994, TXB HYPERTENSION, P1111	18	153	155	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	1997	349	9052					594	598		10.1016/S0140-6736(96)08359-6	http://dx.doi.org/10.1016/S0140-6736(96)08359-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057730				2022-12-28	WOS:A1997WK91500008
J	Collee, JG; Bradley, R				Collee, JG; Bradley, R			BSE: A decade on .1.	LANCET			English	Review							BOVINE SPONGIFORM ENCEPHALOPATHY; SCRAPIE; CATTLE; TRANSMISSION; FIBRILS; AGENTS; BRAIN	Bovine spongiform encephalopathy (BSE), popularly known as ''mad cow disease'', was discovered in 1986 and has accounted for the deaths of over 165 000 cattle in the UH (by the end of January, 1997) with about 34 000 (mainly dairy) herds involved. The syndrome in the cow includes changes in posture and temperament, apprehension, and loss of coordination. There are many parallels with scrapie In sheep, with similar neuropathological changes in the hindbrain that give it a spongiform appearance under the microscope. The facts have been broadly reviewed in The Lancet in 1990 and 1993, and in much more detail elsewhere. In a two-part article, the first of which appears here, we now summarise recent developments.	CENT VET LAB,ADDLESTONE,SURREY,ENGLAND		Collee, JG (corresponding author), UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							*ADV COMM DANG PAT, 1994, PL94CO5 ADV COMM DAN; BRADLEY R, 1993, BRIT MED BULL, V49, P932, DOI 10.1093/oxfordjournals.bmb.a072654; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE M, 1994, M OIE AD HOC GROUP B, P29; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; CLARK WW, 1995, AM J VET RES, V56, P606; COLLEE JG, 1990, LANCET, V336, P1300, DOI 10.1016/0140-6736(90)92976-O; COLLEE JG, 1993, LANCET, V342, P790, DOI 10.1016/0140-6736(93)91546-X; CUTLIP RC, 1994, J INFECT DIS, V169, P814, DOI 10.1093/infdis/169.4.814; Dealler S. F., 1995, British Food Journal, V97, P3, DOI 10.1108/00070709510100064; DEALLER S F, 1990, Food Microbiology (London), V7, P253, DOI 10.1016/0740-0020(90)90032-D; *DEP HLTH, 1996, LANCET, V347, P921; DIRINGER H, 1995, LANCET, V346, P1208, DOI 10.1016/S0140-6736(95)92905-3; FOSTER JD, 1993, VET REC, V133, P339, DOI 10.1136/vr.133.14.339; Foster JD, 1996, VET REC, V138, P546, DOI 10.1136/vr.138.22.546; GAJDUSEK DC, 1957, NEW ENGL J MED, V257, P974, DOI 10.1056/NEJM195711142572005; GIBBS CJ, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91336-9; HARRISON PJ, 1992, BMJ-BRIT MED J, V304, P929, DOI 10.1136/bmj.304.6832.929; HARTSOUGH GR, 1965, J INFECT DIS, V115, P387, DOI 10.1093/infdis/115.4.387; HOURRIGAN JL, 1990, J AM VET MED ASSOC, V196, P1678; Kimberlin R H, 1992, Rev Sci Tech, V11, P347; KIMBERLIN RH, 1993, INTERVIROLOGY, V35, P208, DOI 10.1159/000150311; KIMBERLIN RH, 1994, ANN NY ACAD SCI, V724, P210, DOI 10.1111/j.1749-6632.1994.tb38911.x; KIMBERLIN RH, 1990, TOPLEY WILSONS PRINC, V4, P671; KIMBERLIN RH, 1994, TRANSMISSIBLE SPONGI, P455; LACEY R, 1994, MAD COW DIS HIST BSE; Marsh R F, 1992, Rev Sci Tech, V11, P539; MERZ PA, 1981, ACTA NEUROPATHOL, V54, P63, DOI 10.1007/BF00691333; *MIN AGR FISH FOOD, 1996, PROGR REP BOV SPONG; PRUSINER SB, 1994, J R COLL PHYSICIAN S, V28; RIESNER D, 1993, DEV BIOL STAND, V80, P173; SCHREUDER BEC, 1994, LIVEST PROD SCI, V38, P23, DOI 10.1016/0301-6226(94)90239-9; SCOTT AC, 1990, VET MICROBIOL, V23, P295, DOI 10.1016/0378-1135(90)90160-W; *SPONG ENC ADV COM, 1994, TRANSM SPONG ENC SUM; TAYLOR DM, 1994, ARCH VIROL, V139, P313, DOI 10.1007/BF01310794; Taylor DM, 1995, VET REC, V137, P605; TAYLOR DM, 1993, BRIT MED BULL, V49, P810, DOI 10.1093/oxfordjournals.bmb.a072648; TAYLOR DM, 1989, VET REC, V125, P413, DOI 10.1136/vr.125.16.413; Taylor DM, 1995, TRANSMISSIBLE SPONGI; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; WILESMITH JW, 1988, VET REC, V123, P638; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1991, J NEUROL NEUROSUR PS, V54, P761, DOI 10.1136/jnnp.54.9.761; Williams E.S., 1992, Revue Scientifique et Technique Office International des Epizooties, V11, P551	45	101	105	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					636	641		10.1016/S0140-6736(96)01310-4	http://dx.doi.org/10.1016/S0140-6736(96)01310-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057745				2022-12-28	WOS:A1997WK91500042
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Cronbach's alpha	BRITISH MEDICAL JOURNAL			English	Article									IMPERIAL CANC RES FUND,MED STAT RES GRP,CTR STAT MED,INST HLTH SCI,OXFORD OX3 7LF,ENGLAND	University of Oxford	Bland, JM (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; CASEY ATH, IN PRESS ANN RHEUM D; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; McKinley RK, 1997, BMJ-BRIT MED J, V314, P193, DOI 10.1136/bmj.314.7075.193	4	2873	2941	21	192	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					572	572		10.1136/bmj.314.7080.572	http://dx.doi.org/10.1136/bmj.314.7080.572			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK215	9055718	Bronze, Green Published			2022-12-28	WOS:A1997WK21500027
J	Griffiths, C; Sturdy, P; Naish, J; Omar, R; Dolan, S; Feder, G				Griffiths, C; Sturdy, P; Naish, J; Omar, R; Dolan, S; Feder, G			Hospital admissions for asthma in east London: Associations with characteristics of local general practices, prescribing, and population	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; RATES	Objective: To determine the relative importance of appropriate prescribing for asthma in explaining high rates of hospital admission for asthma among east London general practices. Design: Poisson regression analysis describing relation of each general practice's admission rates for asthma with prescribing for asthma and characteristics of general practitioners, practices, and practice populations. Setting: East London, a deprived inner city area with high admission rates for asthma Subjects: All 163 general practices in East London and the City Health Authority (complete data available for 124 practices). Main outcome measures: Admission rates for asthma, excluding readmissions, for ages 5-64 years; ratio of asthma prophylaxis to bronchodilator prescribing; selected characteristics of general practitioners, practices, and practice populations. Results: Median admission rate for asthma was 0.9 (range 0-3.6) per 1000 patients per year. Higher admission rates were most strongly associated with small size of practice partnership: admission rates of singlehanded and two partner practices were higher than those of practices with three or more principals by 1.7 times (95% confidence Interval 1.4 to 2.0, P<0.001) and 1.3 times (1.1 to 1.6, P=0.001) respectively. Practices with higher rates of night visits also had significantly higher admission rates: an increase in night visiting rate by 10 visits per 1000 patients over two years was associated with an increase in admission rates for asthma by 4% (1% to 7%). These associations were independent of asthma prescribing ratios, measures of practice resources, and characteristics of practice populations. Conclusions: Higher asthma admission rates in east London practices were most strongly associated with smaller partnership size and higher rates of night visiting. Evaluating ways of helping smaller partnerships develop structured proactive care for asthma patients at high risk of admission is a priority.	ROYAL LONDON SCH MED & DENT,LONDON E1 4NS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED STAT & EVALUAT,LONDON W12 0NN,ENGLAND; ST MARYS HOSP,SCH MED,IMPERIAL COLL,LONDON W2 1PG,ENGLAND	University of London; Queen Mary University London; Imperial College London; Imperial College London	Griffiths, C (corresponding author), ST BARTHOLOMEWS HOSP,CITY & E LONDON PRACTICE DATABASE PROJECT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND.			Feder, Gene/0000-0002-7890-3926; Omar, Rumana/0000-0003-1483-1932				Altman D.G., 1991, PRACTICAL STAT MED R; ANDERSON HR, 1995, THORAX, V50, P1188, DOI 10.1136/thx.50.11.1188; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; *CHART I PUBL FIN, 1993, HLTH DAT 1993; *CONS ASS, 1993, WHICH           0311, P735; Davidson AC, 1996, BRIT MED J, V312, P601; *DEP HLTH, 1995, ASTHM EP OV; *DEP HLTH, 1992, STAT B, V4, P2; *DEP HLTH, 1995, ID R D PRIOR NHS MAN; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; *E LOND CIT HLTH A, 1996, HLTH E END ANN PUBL; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; GREEN JM, 1993, BRIT MED J, V307, P607, DOI 10.1136/bmj.307.6904.607; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; Hills, 1993, STAT MODELS EPIDEMIO; *HLTH EAST PROJ, 1996, HLTH EAST PROJ ANN R; HOWARD SA, 1996, ASTHMA GEN PRACT, V4, P11; Hull S, 1996, BRIT J GEN PRACT, V46, P375; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; JACKSON SHD, 1981, POSTGRAD MED J, V57, P777, DOI 10.1136/pgmj.57.674.777; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; *N THAM REG HLTH A, 1994, DEV ED LOND IN ZON E; NAISH J, 1995, BRIT MED J, V310, P97, DOI 10.1136/bmj.310.6972.97; ORMEROD LP, 1995, RESP MED, V89, P415, DOI 10.1016/0954-6111(95)90209-0; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163; Shahani A, 1996, BRIT MED J, V313, P1057; SILVERMAN M, 1993, THORAX, V48, P1200, DOI 10.1136/thx.48.12.1200; STORR J, 1988, ARCH DIS CHILD, V63, P778; STURDY P, 1995, BRIT MED J, V311, P1547, DOI 10.1136/bmj.311.7019.1547; Sturdy P, 1996, BRIT J GEN PRACT, V46, P375; VanSchayck CP, 1996, BRIT J GEN PRACT, V46, P193	34	51	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					482	486		10.1136/bmj.314.7079.482	http://dx.doi.org/10.1136/bmj.314.7079.482			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056800	Green Published			2022-12-28	WOS:A1997WJ41900028
J	Groves, T				Groves, T			Primary care: Opportunities and threats - What the changes mean	BRITISH MEDICAL JOURNAL			English	Article													Groves, Trish/A-9119-2009	Groves, Trish/0000-0001-7915-6419				BEECHAM L, 1996, BRIT MED J, V312, P126; BEECHAM L, 1997, BRIT MED J, V314, P233; Bogle I, 1996, BRIT MED J, V312, P1624, DOI 10.1136/bmj.312.7047.1624; Carnall D, 1996, BRIT MED J, V313, P544; Hallam L, 1997, BMJ-BRIT MED J, V314, P157, DOI 10.1136/bmj.314.7075.157; *SECR STAT HLTH, 1996, PRIM CAR DEL FUT; *SECR STAT HLTH, 1996, NAT HLTH SERV SERV A; Secretary of State for Health, 1996, CHOIC OPP PRIM CAR F; [No title captured]	9	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					436	438		10.1136/bmj.314.7078.436	http://dx.doi.org/10.1136/bmj.314.7078.436			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040394	Green Published			2022-12-28	WOS:A1997WH29500037
J	Paulovich, AG; Toczyski, DP; Hartwell, LH				Paulovich, AG; Toczyski, DP; Hartwell, LH			When checkpoints fail	CELL			English	Review							CELL-CYCLE ARREST; WILD-TYPE P53; POLE BODY DUPLICATION; SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; S-PHASE; GENE AMPLIFICATION; REPLICATION FORKS		FRED HUTCHINSON CANC RES CTR,DIV MOL MED,SEATTLE,WA 98109	Fred Hutchinson Cancer Center	Paulovich, AG (corresponding author), UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195, USA.				NCI NIH HHS [CA09437] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009437] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; CAIRNS J, 1966, J MOL BIOL, V17, P418, DOI 10.1016/S0022-2836(66)80152-3; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DURSO G, 1995, CURR OPIN GENET DEV, V5, P12, DOI 10.1016/S0959-437X(95)90047-0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; FAN SJ, 1995, CANCER RES, V55, P1649; FRIEDBERG EC, 1995, DNA REPAIR; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAWN MT, 1995, CANCER RES, V55, P3721; HOLLINGSWORTH RE, 1992, GENETICS, V132, P53; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; KADYK LC, 1992, GENETICS, V132, P387; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KEIL RL, 1984, CELL, V39, P377, DOI 10.1016/0092-8674(84)90016-3; Kiser GL, 1996, MOL BIOL CELL, V7, P703, DOI 10.1091/mbc.7.5.703; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; KUZMINOV A, 1995, BIOESSAYS, V17, P733, DOI 10.1002/bies.950170810; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Longhese MP, 1996, MOL CELL BIOL, V16, P3235; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; McClintock B, 1941, GENETICS, V26, P234; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; NAEGELI H, 1994, BIOESSAYS, V16, P557, DOI 10.1002/bies.950160809; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; PAULOVICH AG, 1997, IN PRESS GENETICS; PETES TD, 1974, NATURE, V251, P637, DOI 10.1038/251637a0; POWELL SN, 1995, CANCER RES, V55, P1643; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAGHURAMAN MK, 1994, GENE DEV, V8, P554, DOI 10.1101/gad.8.5.554; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SIEDE W, 1994, GENETICS, V138, P271; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; Siede W, 1996, NUCLEIC ACIDS RES, V24, P1669, DOI 10.1093/nar/24.9.1669; STEWART N, 1995, ONCOGENE, V10, P109; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; VOELKELMEIMAN K, 1987, CELL, V48, P1071, DOI 10.1016/0092-8674(87)90714-8; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8; Wyllie FS, 1996, ONCOGENE, V12, P1077; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; Zhou P, 1996, CANCER RES, V56, P36	82	560	578	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					315	321		10.1016/S0092-8674(00)81870-X	http://dx.doi.org/10.1016/S0092-8674(00)81870-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039258	Bronze			2022-12-28	WOS:A1997WG47900004
J	Cameron, IC; Beard, JD; Reed, MWR				Cameron, IC; Beard, JD; Reed, MWR			Duplication of surgical research presentations	BRITISH MEDICAL JOURNAL			English	Article									ROYAL HALLAMSHIRE HOSP,DEPT SURG,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; NO GEN HOSP,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	University of Sheffield; Northern General Hospital			Reed, Malcolm Walter/AAG-9219-2020	Reed, Malcolm Walter/0000-0001-7442-2132				WILLIAMSON RCN, 1993, BRIT J SURG, V80, P681	1	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					346	347		10.1136/bmj.314.7077.346	http://dx.doi.org/10.1136/bmj.314.7077.346			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040327	Green Published			2022-12-28	WOS:A1997WF86100033
J	Quan, VA; Saunders, BP; Hicks, BH; Sladen, GE				Quan, VA; Saunders, BP; Hicks, BH; Sladen, GE			Lesson of the week - Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia	BRITISH MEDICAL JOURNAL			English	Review							DOSE COTRIMOXAZOLE PROPHYLAXIS; RENAL-TRANSPLANT RECIPIENTS; THERAPY		LEWISHAM HOSP,DEPT MED,LONDON SE13 6LH,ENGLAND				Saunders, Brian/AAP-4137-2020					BAERT F, 1994, GASTROENTEROLOGY, V106, pA648; BRANTEN AJW, 1995, NEPHROL DIAL TRANSPL, V10, P1194, DOI 10.1093/ndt/10.7.1194; ELINDER CG, 1992, TRANSPLANT INT, V5, P81; HANAUER SB, 1993, LANCET, V342, P412, DOI 10.1016/0140-6736(93)92819-F; HARDY AM, 1984, J INFECT DIS, V149, P143, DOI 10.1093/infdis/149.2.143; HIGGINS RM, 1989, TRANSPLANTATION, V47, P558, DOI 10.1097/00007890-198903000-00032; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601; MOSS RB, 1995, CHEST, V107, P817, DOI 10.1378/chest.107.3.817; SANDBORN WJ, 1995, INFLAMM BOWEL DIS, V1, P48; SATIAGODELPHIN EA, 1988, TRANSPLANT P S1, V20, P462; SMITH MB, 1992, NEW ENGL J MED, V327, P497, DOI 10.1056/NEJM199208133270714; TALSETH T, 1988, TRANSPLANT P, V20, P400; YOCUM DE, 1988, ANN INTERN MED, V109, P863, DOI 10.7326/0003-4819-109-11-863	13	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					363	364		10.1136/bmj.314.7077.363	http://dx.doi.org/10.1136/bmj.314.7077.363			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040337	Green Published			2022-12-28	WOS:A1997WF86100044
J	Biver, N; BockeleeMorvan, D; Colom, P; Crovisier, J; Davies, JK; Dent, WRF; Despois, D; Gerard, E; Lellouch, E; Rauer, H; Moreno, R; Paubert, G				Biver, N; BockeleeMorvan, D; Colom, P; Crovisier, J; Davies, JK; Dent, WRF; Despois, D; Gerard, E; Lellouch, E; Rauer, H; Moreno, R; Paubert, G			Evolution of the outgassing of comet Hale-Bopp (C/1995 O1) from radio observations	SCIENCE			English	Article							ROTATIONAL LINES; P/HALLEY; FORMALDEHYDE; EXCITATION; METHANOL; OH	Spectra obtained from ground-based radio telescopes show the progressive release of CO, CH3OH, HCN, H2O (from OH), H2S, CS, H2CO, CH3CN, and HNC as comet Hale-Bopp (C/1995 O1) approached the sun from 6.9 to 1.4 astronomical units (AU). The more volatile species were relatively more abundant in the coma far from the sun, but there was no direct correlation between overabundance and volatility. Evidence for H2O sublimation from icy grains was seen beyond 3.5 AU from the sun. The change from a GO-driven coma to an H2O-driven coma occurred at about 3 AU. The gas outflow velocity and temperature increased as Hale-Bopp approached the sun.	OBSERV PARIS, F-92195 MEUDON, FRANCE; JOINT ASTRON CTR, HILO, HI 96720 USA; OBSERV BORDEAUX, F-33270 FLOIRAC, FRANCE; INST RADIOASTRON MILLIMETRIQUE, GRANADA 18012, SPAIN	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris								Biver N, 1996, NATURE, V380, P137, DOI 10.1038/380137a0; BIVER N, 1996, 6458 IAU; BIVER N, 1996, 6421 IAU; BIVER N, 1996, 6386 IAU; BOCKELEEMORVAN D, 1990, ASTRON ASTROPHYS, V238, P382; BOCKELEEMORVAN D, 1994, ASTRON ASTROPHYS, V287, P647; BOCKELEEMORVAN D, 1992, ASTRON ASTROPHYS, V264, P282; BOCKELEEMORVAN D, IN PRESS IAU S, V178; BOCKELEEMORVAN D, 1996, 6511 IAU; BUDZIEN SA, 1994, ICARUS, V107, P164, DOI 10.1006/icar.1994.1014; CROVISIER J, 1989, ASTRON ASTROPHYS, V213, P459; Crovisier J, 1996, ASTRON ASTROPHYS, V315, pL385; CROVISIER J, 1995, ICARUS, V115, P213, DOI 10.1006/icar.1995.1091; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; CROVISIER J, 1991, ICARUS, V93, P246, DOI 10.1016/0019-1035(91)90210-K; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; CROVISIER J, 1996, 6394 IAU; DAVIES JK, IN PRESS ICARUS; EBERHARDT P, 1987, ASTRON ASTROPHYS, V187, P481; ENZIAN A, 1997, THESIS U J FOURER GR; GERARD E, UNPUB; GERARD E, 1989, ASTRON ASTROPHYS S, V77, P278; HALE A, 1995, 6187 IAU; Irvine WM, 1996, NATURE, V383, P418, DOI 10.1038/383418a0; Jewitt D, 1996, SCIENCE, V271, P1110, DOI 10.1126/science.271.5252.1110; JEWITT D, 1996, 6377 IAU; LEES RM, 1973, ASTROPHYS J, V184, P763, DOI 10.1086/152368; LIS D, 1996, 6362 IAU; MEIER R, 1993, ASTRON ASTROPHYS, V277, P677; SCHLOERB FP, 1988, ASTROPHYS J, V332, P524, DOI 10.1086/166674; SCHLOERB FP, 1987, ASTRON ASTROPHYS, V187, P475; SENAY MC, 1994, NATURE, V371, P229, DOI 10.1038/371229a0; WEAVER HA, 1996, 6376 IAU; Wilkening L. L, 1982, IAU C 61 COMET DISCO, P85; WOMACK M, 1996, 6382 IAU; WOODNEY LM, 1996, 6408 IAU; WOODNEY LM, 1996, 6344 IAU; WOOTTEN A, 1996, 6362 IAU	38	160	160	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	1997	275	5308					1915	1918		10.1126/science.275.5308.1915	http://dx.doi.org/10.1126/science.275.5308.1915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072964				2022-12-28	WOS:A1997WQ51300039
J	Bruckner, K; Pasquale, EB; Klein, R				Bruckner, K; Pasquale, EB; Klein, R			Tyrosine phosphorylation of transmembrane ligands for Eph receptors	SCIENCE			English	Article							KINASE; FAMILY; AXONOGENESIS; HINDBRAIN; BINDING; CLONING; DOMAIN; AXONS; BRAIN; CEK5	Axonal pathfinding in the nervous system is mediated in part by cell-to-cell signaling events involving members of the Eph receptor tyrosine kinase (RTK) family and their membrane-bound ligands. Genetic evidence suggests that transmembrane ligands may transduce signals in the developing embryo. The cytoplasmic domain of the transmembrane ligand Lerk2 became phosphorylated on tyrosine residues after contact with the Nuk/Cek5 receptor ectodomain, which suggests that Lerk2 has receptorlike intrinsic signaling potential. Moreover, Lerk2 is an in vivo substrate for the platelet-derived growth factor, receptor, which suggests crosstalk between Lerk2 signaling and signaling cascades activated by tyrosine kinases. It is proposed that transmembrane ligands of Eph receptors act not only as conventional RTK ligands but also as receptorlike signaling molecules.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY; BURNHAM INST,LA JOLLA,CA 92037	European Molecular Biology Laboratory (EMBL); Sanford Burnham Prebys Medical Discovery Institute			Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163	NEI NIH HHS [EY10576] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010576] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOGA A, 1995, ONCOGENE, V11, P791; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; OSTMANN A, 1988, J BIOL CHEM, V268, P16202; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0	34	337	361	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1640	1643		10.1126/science.275.5306.1640	http://dx.doi.org/10.1126/science.275.5306.1640			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054357				2022-12-28	WOS:A1997WN12300045
J	Seidenberg, MS				Seidenberg, MS			Language acquisition and use: Learning and applying probabilistic constraints	SCIENCE			English	Article							SYNTACTIC AMBIGUITY RESOLUTION; ERRORS	What kinds of knowledge underlie the use of language and how is this knowledge acquired? Linguists equate knowing a language with knowing a grammar. Classic ''poverty of the stimulus'' arguments suggest that grammar identification is an intractable inductive problem and that acquisition is possible only because children possess innate knowledge of grammatical structure. An alternative view is emerging from studies of statistical and probabilistic aspects of language, connectionist models, and the learning: capacities of infants. This approach emphasizes continuity between how language is acquired and how it is used. It retains the idea that innate capacities constrain language learning, but calls into question whether they include knowledge of grammatical structure.			Seidenberg, MS (corresponding author), UNIV SO CALIF,NEUROSCI PROGRAM,LOS ANGELES,CA 90089, USA.				PHS HHS [P01 47566, KO2 01188] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN J, 1997, THESIS U SO CALIFORN; Aslin RN, 1996, SIGNAL TO SYNTAX: BOOTSTRAPPING FROM SPEECH TO GRAMMAR IN EARLY ACQUISITION, P117; BAKER CL, 1979, LINGUIST INQ, V10, P533; BARLOW H, 1995, COGNITIVE NEUROSCIEN, P1011; BERKO J, 1958, WORD, V14, P150, DOI 10.1080/00437956.1958.11659661; Bishop CM., 1995, NEURAL NETWORKS PATT; BOHANNON JN, 1988, DEV PSYCHOL, V24, P684, DOI 10.1037/0012-1649.24.5.684; Bower G.H., 1981, THEORIES LEARNING; CHOMSKY N, 1959, LANGUAGE, V35, P26, DOI 10.2307/411334; Chomsky N., 1986, KNOWLEDGE LANGUAGE I; CHOMSKY N, 1981, LECT GOVT BINDING, P7; Chomsky Noam, 1957, SYNTACTIC STRUCT, P17; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; CHOMSKY Noam, 1986, KNOWLEDGE LANGUAGE I; CHRISTIANSEN M, IN PRESS LANG COGNIT; Cleeremans A, 1989, NEURAL COMPUT, V1, P372, DOI 10.1162/neco.1989.1.3.372; CRAIN S, 1991, BEHAV BRAIN SCI, V14, P597, DOI 10.1017/S0140525X00071491; DELL GS, 1993, COGNITIVE SCI, V17, P149, DOI 10.1207/s15516709cog1702_1; ELMAN JL, 1990, COGNITIVE SCI, V14, P179, DOI 10.1207/s15516709cog1402_1; Elman JL, 1996, RETHINKING INNATENES; FRAZIER L, 1987, J MEM LANG, V26, P505, DOI 10.1016/0749-596X(87)90137-9; GLEITMAN L, 1988, CAMBRIDGE LINGUISTIC, V3; Gleitman L.R., 1990, LANG ACQUIS, V1, P3, DOI [10.1207/s15327817la0101_2, DOI 10.1207/S15327817LA0101_2, 10.1207/s153278171a0101_2]; GOLD EM, 1967, INFORM CONTROL, V10, P447, DOI 10.1016/S0019-9958(67)91165-5; GORDON P, 1990, DEV PSYCHOL, V26, P215; HINTON GE, 1989, ARTIF INTELL, V40, P185, DOI 10.1016/0004-3702(89)90049-0; HOPFIELD JJ, 1987, P NATL ACAD SCI USA, V84, P8429, DOI 10.1073/pnas.84.23.8429; JELLINEK F, 1990, READINGS SPEECH RECO, P91; Jusczyk P., 1997, DISCOVERY SPOKEN LAN; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KELLY MH, 1994, LINGUA, V92, P105, DOI 10.1016/0024-3841(94)90339-5; LEIN B, 1993, ENGLISH VERB CLASSES; LIGHTFOOT D, 1982, LANGUAGE LOTTERY; Lippmann RP, 1989, NEURAL COMPUT, V1, P1, DOI 10.1162/neco.1989.1.1.1; MACDONALD MC, 1994, PSYCHOL REV, V101, P676, DOI 10.1037/0033-295X.101.4.676; MACDONALD MC, 1994, LANG COGNITIVE PROC, V9, P157, DOI 10.1080/01690969408402115; Mackworth A.K, 1992, ENCYCLOPEDIA, P285; MCCLELLAND JL, 1987, ATTENTION PERFORM, V12, P3; MINTZ T, 1995, P 25 ANN M NE LING S; MOON C, 1993, INFANT BEHAV DEV, V16, P495, DOI 10.1016/0163-6383(93)80007-U; MORGAN JL, 1996, SIGNAL SYNTAX; MUNAKATA Y, IN PRESS PSYCHOL REV; NEWPORT EL, 1990, COGNITIVE SCI, V14, P11, DOI 10.1207/s15516709cog1401_2; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Pinker Steven, 1994, LANGUAGE INSTINCT; Pinker Steven., 1984, LANGUAGE LEARNABILIT; Pinker Steven., 1989, LEARNABILITY COGNITI; PLAUT DC, 1995, PSYCHOL REV, V103, P56; PRINCE A, 1997, OPTIMALITY THEORY; Rakic Pasko, 1995, P127; Roeper T., 1987, PARAMETER SETTING; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, V1; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, P216; RUMELHART DE, 1993, ATTENTION PERFORM, V14, P3; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; SEIDENBERG MS, 1989, PSYCHOL REV, V96, P523, DOI 10.1037/0033-295X.96.4.523; SEIDENBERG MS, 1994, COGNITION, V50, P385, DOI 10.1016/0010-0277(94)90037-X; TANENHAUS MK, 1995, SPEECH LANGUAGE COMM, P217; TRUESWELL JC, 1991, LANG COGNITIVE PROC, V6, P339; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0; 1975, LOGICAL STRUCTURE LI	61	219	222	4	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1599	1603		10.1126/science.275.5306.1599	http://dx.doi.org/10.1126/science.275.5306.1599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WN123	9054348				2022-12-28	WOS:A1997WN12300030
J	Snyder, LH; Batista, AP; Andersen, RA				Snyder, LH; Batista, AP; Andersen, RA			Coding of intention in the posterior parietal cortex	NATURE			English	Article							MONKEY CEREBRAL-CORTEX; ASSOCIATION CORTEX; BEHAVIORAL ENHANCEMENT; VISUAL RESPONSES; REPRESENTATION; ATTENTION; MECHANISMS; MODULATION; PRIMATE; SPACE	To look at or reach for what we see, spatial information from the visual system must be transformed into a motor plan, The posterior parietal cortex (PPC) is well placed to perform this function, because it Lies between visual areas, which encode spatial information(1,2), and motor cortical areas. The PPC contains several subdivisions, which are generally conceived as high-order sensory areas(3,4). Neurons in area 7a and the lateral intraparietal area fire before and during visually guided saccades. Other neurons in areas 7a and 5 are active before and during visually guided arm movements(5-10). These areas are also active during memory tasks in which the animal remembers the location of a target for hundreds of milliseconds before making an eye or arm movement. Such activity could reflect either visual attention(11-15) or the intention to make movements(16-22). This question is difficult to resolve, because even if the animal maintains fixation while directing attention to a peripheral location, the observed neuronal activity could reflect movements that are planned but not executed(22). To address this, we recorded from the PPC while monkeys planned either reaches or saccades to a single remembered location. We now report that, for most neurons, activity before the movement depended on the type of movement being planned. We conclude that PPC contains signals related to what the animal intends to do.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Snyder, Lawrence H/A-4593-2017	Batista, Aaron/0000-0002-1719-0061				ANDERSEN RA, 1987, EXP BRAIN RES, V67, P316; ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; ANDERSEN RA, 1995, CEREB CORTEX, V5, P457, DOI 10.1093/cercor/5.5.457; BON L, 1994, EXP BRAIN RES, V102, P259; Bracewell RM, 1996, J NEUROPHYSIOL, V76, P1457, DOI 10.1152/jn.1996.76.3.1457; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; COLBY CL, 1995, CEREB CORTEX, V5, P470, DOI 10.1093/cercor/5.5.470; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1981, J NEUROPHYSIOL, V46, P773, DOI 10.1152/jn.1981.46.4.773; GOODALE MG, 1992, TRENDS NEUROSCI, V15, P220; HARTJE W, 1974, CORTEX, V9, P346; HYVARINEN J, 1974, BRAIN, V97, P673, DOI 10.1093/brain/97.1.673; KALASKA JF, 1995, CEREB CORTEX, V5, P410, DOI 10.1093/cercor/5.5.410; LYNCH JC, 1977, J NEUROPHYSIOL, V40, P362, DOI 10.1152/jn.1977.40.2.362; Mazzoni P, 1996, J NEUROPHYSIOL, V76, P1439, DOI 10.1152/jn.1996.76.3.1439; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; MURATA A, 1996, NEUROPHYSIOL, V75, P2180; ROBINSON DL, 1978, J NEUROPHYSIOL, V41, P910, DOI 10.1152/jn.1978.41.4.910; SCOTT DW, 1985, ANN STAT, V13, P1024, DOI 10.1214/aos/1176349654; SEAL J, 1985, EXP BRAIN RES, V58, P144; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; SHIBUTANI H, 1984, EXP BRAIN RES, V55, P1; STEINMETZ MA, 1994, J NEUROPHYSIOL, V72, P1020, DOI 10.1152/jn.1994.72.2.1020; Thier P, 1996, P NATL ACAD SCI USA, V93, P4962, DOI 10.1073/pnas.93.10.4962; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; [No title captured]	27	813	820	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 13	1997	386	6621					167	170		10.1038/386167a0	http://dx.doi.org/10.1038/386167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062187				2022-12-28	WOS:A1997WM97300060
J	Garner, P				Garner, P			Do objectives of health-aid programmes impair their effectiveness?	LANCET			English	Editorial Material											Garner, P (corresponding author), UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,INT HLTH DIV,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND.		Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941				Ansoff H. I., 1987, CORPORATE STRATEGY; *COMPTR AUD GEN, 1995, OV DEV ADM HLTH POP; Garner P., 1992, World Health Forum, V13, P244; Long AF, 1996, LANCET, V347, P1572, DOI 10.1016/S0140-6736(96)91072-7; LORENZ N, 1995, WORLD HEALTH FORUM, V16, P280; MAHOMED K, 1996, PREGNANCY CHILDBIRTH; Tarimo E., 1991, HLTH DISTRICT ORG MA; VANNORREN B, 1989, SOC SCI MED, V28, P1091, DOI 10.1016/0277-9536(89)90393-6	8	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					722	723		10.1016/S0140-6736(96)08507-8	http://dx.doi.org/10.1016/S0140-6736(96)08507-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078213				2022-12-28	WOS:A1997WM08000045
J	LawlorSmith, L; LawlorSmith, C				LawlorSmith, L; LawlorSmith, C			Vasospasm of the nipple - A manifestation of Raynaud's phenomenon: Case reports	BRITISH MEDICAL JOURNAL			English	Article																		BELCH J J F, 1991, Current Opinion in Rheumatology, V3, P960, DOI 10.1097/00002281-199112000-00011; BELCH JJF, 1990, THER UPDATE, V6, P253; OLSEN N, 1978, SCAND J CLIN LAB INV, V37, P761; SLOPER KS, 1977, ARCH DIS CHILD, V52, P700, DOI 10.1136/adc.52.9.700; Woolridge M W, 1986, Midwifery, V2, P172, DOI 10.1016/S0266-6138(86)80042-0	5	21	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					644	645		10.1136/bmj.314.7081.644	http://dx.doi.org/10.1136/bmj.314.7081.644			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066478	Green Published			2022-12-28	WOS:A1997WL41800025
J	Zuccala, G; Pahor, M; Landi, F; Gasparini, G; Pagano, F; Carbonin, PU; Cocchi, A				Zuccala, G; Pahor, M; Landi, F; Gasparini, G; Pagano, F; Carbonin, PU; Cocchi, A			Use of calcium antagonists and need for perioperative transfusion in older patients with hip fracture: Observational study	BRITISH MEDICAL JOURNAL			English	Article											Zuccala, G (corresponding author), UNIV CATTOLICA SACRO CUORE, DEPT INTERNAL MED & GERIATR, I-00168 ROME, ITALY.		Zuccalà, Giuseppe/AAC-4677-2022	Zuccalà, Giuseppe/0000-0002-2567-2220				AUDET AM, 1992, ANN INTERN MED, V116, P403, DOI 10.7326/0003-4819-116-5-403; GREER IA, 1985, LANCET, V1, P351; MURRAY GD, 1995, BRIT MED J, V311, P388, DOI 10.1136/bmj.311.7001.388c; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PAHOR M, IN PRESS GASTROENTER	5	36	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					643	644		10.1136/bmj.314.7081.643	http://dx.doi.org/10.1136/bmj.314.7081.643			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066477	Green Published			2022-12-28	WOS:A1997WL41800024
J	Chetverin, AB; Chetverina, HV; Demidenko, AA; Ugarov, VI				Chetverin, AB; Chetverina, HV; Demidenko, AA; Ugarov, VI			Nonhomologous RNA recombination in a cell-free system: Evidence for a transesterification mechanism guided by secondary structure	CELL			English	Article							Q-BETA-REPLICASE; INTERTYPIC POLIOVIRUS RECOMBINANTS; BROME MOSAIC-VIRUS; CROSSOVER REGIONS; SEQUENCES; TEMPLATES; INVITRO; GENOMES; PARTICLES; CLONING	Extensive nonhomologous recombinations occur between the 5' and 3' fragments of a replicable RNA in a cell-free system composed of pure Q beta phage replicase and ribonucleoside triphosphates, providing direct evidence for the ability of RNAs to recombine without DNA intermediates and in the absence of host cell proteins. The recombination events are revealed by the molecular colony technique that allows single RNA molecules to be cloned in vitro. The observed nonhomologous recombinations are entirely dependent on the 3' hydroxyl group of the 5' fragment, and are due to a splicing-like reaction in which RNA secondary structure guides the attack of this 3' hydroxyl on phosphoester bonds within the 3' fragment.			Chetverin, AB (corresponding author), RUSSIAN ACAD SCI, INST PROT RES, PUSHCHINO 142292, MOSCOW REGION, RUSSIA.		Chetverin, Alexander B/AAA-6511-2022; Ugarov, Victor/AAC-6454-2022; Ugarov, Victor/AAC-6502-2022					BERESTOWSKAYA NH, 1988, FEBS LETT, V228, P263, DOI 10.1016/0014-5793(88)80012-7; BIEBRICHER CK, 1992, EMBO J, V11, P5129, DOI 10.1002/j.1460-2075.1992.tb05620.x; BIEBRICHER CK, 1982, J MOL BIOL, V154, P629, DOI 10.1016/S0022-2836(82)80019-3; Blumenthal T, 1979, Methods Enzymol, V60, P628; CARPENTER CD, 1995, J MOL BIOL, V245, P608, DOI 10.1006/jmbi.1994.0050; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CHETVERIN AB, 1991, J MOL BIOL, V222, P3, DOI 10.1016/0022-2836(91)90729-P; CHETVERIN AB, 1995, PROG NUCLEIC ACID RE, V51, P225, DOI 10.1016/S0079-6603(08)60880-6; CHETVERIN AB, 1992, FRONTIERS BIOPROCESS, V2, P44; CHETVERINA HV, 1993, NUCLEIC ACIDS RES, V21, P2349, DOI 10.1093/nar/21.10.2349; DZIANOTT A, 1995, VIROLOGY, V208, P370, DOI 10.1006/viro.1995.1163; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; Hajjou M, 1996, J VIROL, V70, P5153, DOI 10.1128/JVI.70.8.5153-5164.1996; HIRST GK, 1962, COLD SPRING HARB SYM, V27, P303, DOI 10.1101/SQB.1962.027.001.028; IGLOI GL, 1983, ANAL BIOCHEM, V134, P184, DOI 10.1016/0003-2697(83)90281-6; JARVIS TC, 1992, EMBO J, V11, P3135, DOI 10.1002/j.1460-2075.1992.tb05386.x; KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8; KUGE S, 1986, J MOL BIOL, V192, P473, DOI 10.1016/0022-2836(86)90270-6; LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992; LEDINKO N, 1963, VIROLOGY, V20, P107, DOI 10.1016/0042-6822(63)90145-4; MILLIGAN JF, 1989, BIOCHEMISTRY-US, V28, P2849, DOI 10.1021/bi00433a016; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MONROE SS, 1983, P NATL ACAD SCI-BIOL, V80, P3279, DOI 10.1073/pnas.80.11.3279; MOODY MD, 1994, BIOCHEMISTRY-US, V33, P13836, DOI 10.1021/bi00250a038; MOROZOV IY, 1993, P NATL ACAD SCI USA, V90, P9325, DOI 10.1073/pnas.90.20.9325; MUNISHKIN AV, 1991, J MOL BIOL, V221, P463, DOI 10.1016/0022-2836(91)80067-5; MUNISHKIN AV, 1988, NATURE, V333, P473, DOI 10.1038/333473a0; NAGY PD, 1993, P NATL ACAD SCI USA, V90, P6390, DOI 10.1073/pnas.90.14.6390; NEGRONI M, 1995, P NATL ACAD SCI USA, V92, P6971, DOI 10.1073/pnas.92.15.6971; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; PALASINGAM K, 1992, J VIROL, V66, P2435, DOI 10.1128/JVI.66.4.2435-2442.1992; ROMANOVA LI, 1986, VIROLOGY, V155, P202, DOI 10.1016/0042-6822(86)90180-7; STEINSCHNEIDER A, 1966, BIOCHEMISTRY-US, V5, P2729, DOI 10.1021/bi00872a033; STEINSCHNEIDER A, 1966, BIOCHEMISTRY-US, V5, P2735, DOI 10.1021/bi00872a034; TOLSKAYA EA, 1987, VIROLOGY, V161, P54, DOI 10.1016/0042-6822(87)90170-X; WEISSMANN C, 1974, FEBS LETT, V43, pS10; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	37	123	132	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1997	88	4					503	513		10.1016/S0092-8674(00)81890-5	http://dx.doi.org/10.1016/S0092-8674(00)81890-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038341	Green Published, Bronze			2022-12-28	WOS:A1997WJ69100010
J	Fennerty, T				Fennerty, T			Fortnightly review - The diagnosis of pulmonary embolism	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DEEP VENOUS THROMBOSIS; PERFUSION LUNG SCANS; VEIN THROMBOSIS; THROMBOEMBOLISM				Fennerty, T (corresponding author), SO GEN HOSP, CHEST CLIN, GLASGOW G51 4TF, LANARK, SCOTLAND.							BARRITT DW, 1960, LANCET, V1, P1309; BULLER HR, 1991, THROMB HAEMOSTASIS, V66, P133; DALEN JE, 1993, ARCH INTERN MED, V153, P1415, DOI 10.1001/archinte.153.12.1415; FENNERTY A, 1988, BMJ-BRIT MED J, V297, P1285, DOI 10.1136/bmj.297.6659.1285; Henry JW, 1996, CHEST, V109, P462, DOI 10.1378/chest.109.2.462; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1995, ARCH INTERN MED, V155, P1845; HYERS TM, 1995, THORAX, V50, P930, DOI 10.1136/thx.50.9.930; KABOLI P, 1993, POSTGRAD MED J, V69, P851, DOI 10.1136/pgmj.69.817.851; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; MORRELL NW, 1992, BRIT MED J, V304, P1126, DOI 10.1136/bmj.304.6835.1126; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; STEIN PD, 1993, CHEST, V104, P1472, DOI 10.1378/chest.104.5.1472; STEIN PD, 1993, CHEST, V104, P1468, DOI 10.1378/chest.104.5.1468; SUDLOW MF, 1992, LANCET, V340, P873; vanRossum AB, 1996, THORAX, V51, P23, DOI 10.1136/thx.51.1.23; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008; WORSLEY DF, 1995, J NUCL MED, V36, P2380; 1994, BRIT MED J, V309, P1525	23	32	32	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 8	1997	314	7078					425	429		10.1136/bmj.314.7078.425	http://dx.doi.org/10.1136/bmj.314.7078.425			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040390	Green Published			2022-12-28	WOS:A1997WH29500033
J	Allgren, RL; Marbury, TC; Rahman, SN; Weisberg, LS; Fenves, AZ; Lafayette, RA; Sweet, RM; Genter, FC; Kurnik, BRC; Conger, JD; Sayegh, MH				Allgren, RL; Marbury, TC; Rahman, SN; Weisberg, LS; Fenves, AZ; Lafayette, RA; Sweet, RM; Genter, FC; Kurnik, BRC; Conger, JD; Sayegh, MH			Anaritide in acute tubular necrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	27th Annual Meeting of the American-Society-of-Nephrology	NOV 05-08, 1995	SAN DIEGO, CA	Amer Soc Nephrol, NIDDKD, DVA Med Res Funds			ACUTE-RENAL-FAILURE; ATRIAL-NATRIURETIC-PEPTIDE; ATRIOPEPTIN-III; RAT; DOPAMINE	Background Atrial natriuretic peptide, a hormone synthesized by the cardiac atria, increases the glomerular filtration rate by dilating afferent arterioles while constricting efferent arterioles. It has been shown to improve glomerular filtration, urinary output, and renal histopathology in laboratory animals with acute renal dysfunction. Anaritide is a 25-amino-acid synthetic form of atrial natriuretic peptide. Methods We conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial of anaritide in 504 critically ill patients with acute tubular necrosis. The patients received a 24-hour intravenous infusion of either anaritide (0.2 mu g per kilogram of body weight per minute) or placebo. The primary end point was dialysis-free survival for 21 days after treatment. Other end points included the need for dialysis, changes in the serum creatinine concentration, and mortality. Results The rate of dialysis-free survival was 47 percent in the placebo group and 43 percent in the anaritide group (P = 0.35). In the prospectively defined subgroup of 120 patients with oliguria (urinary output, < 400 ml per day), dialysis-free survival was 8 percent in the placebo group (5 of 60 patients) and 27 percent in the anaritide group (16 of 60 patients, P = 0.008). Anaritide-treated patients with oliguria who no longer had oliguria after treatment benefited the most. Conversely, among the 378 patients without oliguria, dialysis-free survival was 59 percent in the placebo group (116 of 195 patients) and 48 percent in the anaritide group (88 of 183 patients, P = 0.03). Conclusions The administration of anaritide did not improve the overall rate of dialysis-free survival in critically ill patients with acute tubular necrosis. However, anaritide may improve dialysis-free survival in patients with oliguria and may worsen it in patients without oliguria who have acute tubular necrosis. (C) 1997, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,DIV RENAL,BOSTON,MA 02115; SCIOS NOVA INC,DIV CLIN RES,MT VIEW,CA 94043; ORLANDO CLIN RES CTR,ORLANDO,FL; UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX; UNIV MED & DENT NEW JERSEY,COOPER HOSP,CAMDEN,NJ 08103; BAYLOR UNIV,MED CTR,DALLAS,TX; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111; KIDNEY DIS & CRIT CARE ASSOCIATES,MINNEAPOLIS,MN; VET AFFAIRS MED CTR,DENVER,CO	Harvard University; Brigham & Women's Hospital; Scios; University of Texas System; University of Texas Health Science Center Houston; Rutgers State University New Brunswick; Rutgers State University Medical Center; Baylor University; Baylor University Medical Center; Tufts Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)								Chertow GM, 1996, AM J MED, V101, P49, DOI 10.1016/S0002-9343(96)00075-7; CONGER JD, 1989, KIDNEY INT, V35, P1126, DOI 10.1038/ki.1989.100; CONGER JD, 1991, KIDNEY INT, V40, P21, DOI 10.1038/ki.1991.174; CORWIN HL, 1987, AM J NEPHROL, V7, P8, DOI 10.1159/000167421; DAVIS CL, 1987, AM J PHYSIOL, V253, pF679, DOI 10.1152/ajprenal.1987.253.4.F679; Fleming TR, 1995, DRUG INF J, V29, p1681S; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; KELLEHER SP, 1987, KIDNEY INT, V31, P725, DOI 10.1038/ki.1987.58; LANESE DM, 1991, AM J PHYSIOL, V261, pF1102, DOI 10.1152/ajprenal.1991.261.6.F1102; LIANO F, 1989, NEPHRON, V51, P307, DOI 10.1159/000185314; MANNS M, 1995, J AM SOC NEPHROL, V6, P470; MARGULIES KB, 1990, AM J PHYSIOL, V259, pR97, DOI 10.1152/ajpregu.1990.259.1.R97; NAKAMOTO M, 1987, J CLIN INVEST, V80, P698, DOI 10.1172/JCI113124; OPGENORTH TJ, 1990, EUR J PHARMACOL, V191, P351, DOI 10.1016/0014-2999(90)94168-W; RAHMAN SN, 1994, KIDNEY INT, V45, P1731, DOI 10.1038/ki.1994.225; ROY DR, 1986, AM J PHYSIOL, V251, pF220, DOI 10.1152/ajprenal.1986.251.2.F220; SCHAFFERHANS K, 1986, NEPHRON, V44, P240, DOI 10.1159/000183994; SHAW SG, 1987, J CLIN INVEST, V80, P1232, DOI 10.1172/JCI113197	18	310	314	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					828	834		10.1056/NEJM199703203361203	http://dx.doi.org/10.1056/NEJM199703203361203			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN371	9062091				2022-12-28	WOS:A1997WN37100003
J	Levin, MC; Lehky, TJ; Flerlage, AN; Katz, D; Kingma, DW; Jaffe, ES; Heiss, JD; Patronas, N; McFarland, HF; Jacobson, S				Levin, MC; Lehky, TJ; Flerlage, AN; Katz, D; Kingma, DW; Jaffe, ES; Heiss, JD; Patronas, N; McFarland, HF; Jacobson, S			Immunologic analysis of a spinal cord-biopsy specimen from a patient with human T-cell lymphotropic virus type I-associated neurologic disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TROPICAL SPASTIC PARAPARESIS; CENTRAL-NERVOUS-SYSTEM; CHRONIC PROGRESSIVE MYELOPATHY; POLYMERASE CHAIN-REACTION; CYTOTOXIC LYMPHOCYTES-T; HTLV-I; PROVIRAL DNA; CEREBROSPINAL-FLUID; INFECTION; LEUKEMIA		NINCDS,NEUROIMMUNOL BRANCH,VIRAL IMMUNOL SECT,NIH,BETHESDA,MD 20892; NINCDS,NEUROSURG BRANCH,NIH,BETHESDA,MD 20892; NINCDS,OFF CLIN DIRECTOR,NIH,BETHESDA,MD 20892; NCI,DEPT HEMATOPATHOL,BETHESDA,MD 20892; NCI,DEPT NEURORADIOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Heiss, John/AAL-8281-2021; Jaffe, Elaine/G-8981-2014	Heiss, John/0000-0002-3890-0165; 				GESSAIN A, 1985, LANCET, V2, P407; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; IWASAKI Y, 1990, J NEUROL SCI, V96, P103, DOI 10.1016/0022-510X(90)90060-Z; JACOBSON S, 1990, ANN NEUROL, V27, P149, DOI 10.1002/ana.410270209; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JACOBSON S, 1992, ANN NEUROL, V32, P651, DOI 10.1002/ana.410320508; JACOBSON S, 1992, SEMIN NEUROSCI, V4, P285; KIRA J, 1992, ANN NEUROL, V31, P39, DOI 10.1002/ana.410310108; KIRA J, 1991, ANN NEUROL, V29, P194, DOI 10.1002/ana.410290214; KIRA J, 1991, ANN NEUROL, V29, P363; KITZE B, 1995, ACTA NEUROL SCAND, V92, P213; KUBOTA R, 1994, J NEUROIMMUNOL, V53, P23, DOI 10.1016/0165-5728(94)90060-4; KWOK S, 1988, J INFECT DIS, V158, P1193, DOI 10.1093/infdis/158.6.1193; LEHKY TJ, 1995, ANN NEUROL, V37, P167, DOI 10.1002/ana.410370206; Levin MC, 1996, J VIROL, V70, P924, DOI 10.1128/JVI.70.2.924-933.1996; LEVIN MC, IN PRESS J NEUROVIRO; LINK H, 1989, NEUROLOGY, V39, P1566, DOI 10.1212/WNL.39.12.1566; MATTSON DH, 1987, LANCET, V2, P49; MOORE GRW, 1989, ANN NEUROL, V26, P523, DOI 10.1002/ana.410260405; Moritoyo T, 1996, ANN NEUROL, V40, P84, DOI 10.1002/ana.410400114; NAKAGAWA M, 1995, J NEUROVIROL, V1, P50, DOI 10.3109/13550289509111010; OHARA Y, 1992, ARCH VIROL, V124, P31, DOI 10.1007/BF01314623; OSAME M, 1986, LANCET, V1, P1031; PICCARDO P, 1988, ANN NEUROL, V23, pS156, DOI 10.1002/ana.410230735; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P617, DOI 10.1097/00005072-199411000-00009; UMEHARA F, 1993, J NEUROPATH EXP NEUR, V52, P424, DOI 10.1097/00005072-199307000-00010; WU E, 1993, ACTA NEUROPATHOL, V86, P224, DOI 10.1007/BF00304136; YOSHIOKA A, 1993, J NEUROL NEUROSUR PS, V56, P1004, DOI 10.1136/jnnp.56.9.1004	30	59	60	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					839	845		10.1056/NEJM199703203361205	http://dx.doi.org/10.1056/NEJM199703203361205			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN371	9062093				2022-12-28	WOS:A1997WN37100005
J	Schneider, E; Hajjeh, RA; Spiegel, RA; Jibson, RW; Harp, EL; Marshall, GA; Gunn, RA; McNeil, MM; Pinner, RW; Baron, RC; Burger, RC; Hutwagner, LC; Crump, C; Kaufman, L; Reef, SE; Feldman, GM; Pappagianis, D; Werner, SB				Schneider, E; Hajjeh, RA; Spiegel, RA; Jibson, RW; Harp, EL; Marshall, GA; Gunn, RA; McNeil, MM; Pinner, RW; Baron, RC; Burger, RC; Hutwagner, LC; Crump, C; Kaufman, L; Reef, SE; Feldman, GM; Pappagianis, D; Werner, SB			A coccidioidomycosis outbreak following the Northridge, Calif, earthquake	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe a coccidioidomycosis outbreak in Ventura County following the January 1994 earthquake, centered in Northridge, Calif, and to identify factors that increased the risk for acquiring acute coccidioidomycosis infection. Design.-Epidemic investigation, population-based skin test survey, and case-control study. Setting.-Ventura County, California. Results.-In Ventura County, between January 24 and March 15, 1994, 203 outbreak-associated coccidioidomycosis cases, including 3 fatalities, were identified (attack rate [AR], 30 cases per 100 000 population). The majority of cases (56%) and the highest AR (114 per 100 000 population) occurred in the town of Simi Valley, a community located at the base of a mountain range that experienced numerous landslides associated with the earthquake. Disease onset for cases peaked 2 weeks after the earthquake. The AR was 2.8 times greater for persons 40 years of age and older than for younger persons (relative risk, 2.8; 95% confidence interval [CI], 2.1-3.7; P<.001). Environmental data indicated that large dust clouds, generated by landslides following the earthquake and strong aftershocks in the Santa Susana Mountains north of Simi Valley, were dispersed into nearby valleys by northeast winds. Simi Valley case-control study data indicated that physically being in a dust cloud (odds ratio, 3.0; 95% CI, 1.6-5.4; P<.001) and time spent in a dust cloud (P<.001) significantly increased the risk for being diagnosed with acute coccidioidomycosis. Conclusions.-Both the location and timing of cases strongly suggest that the coccidioidomycosis outbreak in Ventura County was caused when arthrospores were spread in dust clouds generated by the earthquake. This is the first report of a coccidioidomycosis outbreak following an earthquake. Public and physician awareness, especially in endemic areas following similar dust cloud-generating events, may result in prevention and early recognition of acute coccidioidomycosis.	EPIDEM INTELLIGENCE SERV, COMMUNITY DIS CONTROL, DEPT HLTH SERV, SAN DIEGO, CA USA; CTR DIS CONTROL & PREVENT, DEPT FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA USA; CDC, EPIDEM INTELLIGENCE SERV, DIV BACTERIAL & MYCOT DIS, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA; DEPT INTERIOR, CENT REG GEOL HAZARDS TEAM, US GEOL SURVEY, GOLDEN, CO USA; DEPT INTERIOR, US GEOL SURVEY, MENLO PK, CA USA; CDC, DIV STD HIV PREVENT, NATL CTR HIV STD & TB PREVENT, ATLANTA, GA 30333 USA; DEPT HLTH SERV, COMMUNITY DIS CONTROL, SAN DIEGO, CA USA; CDC, OFF DIRECTOR, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA; CDC, DEPT FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA; CDC, EMERGENCY RESPONSE COORDINAT GRP, NATL CTR ENVIRONM HLTH, ATLANTA, GA 30333 USA; VENTURA CTY PUBL HLTH, HLTH OFF, VENTURA, CA USA; UNIV CALIF DAVIS, SCH MED, DEPT MED MICROBIOL & IMMUNOL, SACRAMENTO, CA 95817 USA; CALIF DEPT HLTH SERV, DIV COMMUNICABLE DIS CONTROL, BERKELEY, CA 94704 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of California System; University of California Davis; California Department of Health Care Services			Crump, Casey/AAO-8802-2021	Crump, Casey/0000-0002-2990-1166; McNeil, Michael/0000-0003-0713-8312				AMPEL NM, 1989, REV INFECT DIS, V11, P897; *CAL GOV OFF EM SE, 1997, FEMADR1008CAPR OES; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P421; Centers for Disease Control and Prevention, 1996, MMWR MORB MORTAL WKL, V45, P1069; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P194; *COUNT LOS ANG DEP, 1994, 1994 COMM DIS MORB R; Dean AG, 1994, EPI INFO VERSION 6 0; DRUTZ DJ, 1978, AM REV RESPIR DIS, V117, P559; DRUTZ DJ, 1978, AM REV RESPIR DIS, V117, P727; EDWARDS PQ, 1957, DIS CHEST, V31, P35, DOI 10.1378/chest.31.1.35; EINSTEIN HE, 1993, CLIN INFECT DIS, V16, P349, DOI 10.1093/clind/16.3.349; Elconin AF, 1967, COCCIDIOIDOMYCOSIS, P319; FIESE MJ, 1958, COCCIDIOIDOMYCOSIS, P53; FLYNN NM, 1979, NEW ENGL J MED, V301, P358, DOI 10.1056/NEJM197908163010705; GALGIANI JN, 1992, CLIN INFECT DIS, V14, pS100, DOI 10.1093/clinids/14.Supplement_1.S100; *HAIN CO INC, 1994, AMERICALIST; Harp EL, 1996, B SEISMOL SOC AM, V86, pS319; JONES L, 1994, SCIENCE, V266, P389, DOI 10.1126/science.266.5184.398; Pappagianis D, 1988, Curr Top Med Mycol, V2, P199; PAPPAGIANIS D, 1994, CLIN INFECT DIS, V19, pS14, DOI 10.1093/clinids/19.Supplement_1.14; PAPPAGIANIS D, 1978, WESTERN J MED, V129, P527; PAPPAGIANIS D, 1990, CLIN MICROBIOL REV, V3, P247, DOI 10.1128/CMR.3.3.247-268.1990; *SAS I, 1993, SAS SOFTW REL 6 08; SMITH CE, 1946, JAMA-J AM MED ASSOC, V132, P833, DOI 10.1001/jama.1946.02870490011003; STEVENS DA, 1995, NEW ENGL J MED, V332, P1077, DOI 10.1056/NEJM199504203321607; STEVENS DA, 1975, CHEST, V68, P697, DOI 10.1378/chest.68.5.697; Swatek F., 1967, P 2 COCCIDIOIDOMYCOS; *US DEP COMM, 1993, 1990 CENS POP HOUS P; WERNER SB, 1972, NEW ENGL J MED, V286, P507, DOI 10.1056/NEJM197203092861003	29	153	154	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					904	908		10.1001/jama.277.11.904	http://dx.doi.org/10.1001/jama.277.11.904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062329				2022-12-28	WOS:A1997WM77400034
J	Westergaard, T; Wohlfahrt, J; Aaby, P; Melbye, M				Westergaard, T; Wohlfahrt, J; Aaby, P; Melbye, M			Population based study of rates of multiple pregnancies in Denmark, 1980-94	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IN-VITRO FERTILIZATION; INFANT-MORTALITY; INDUCTION; OVULATION; TRIPLETS; BIRTHS; RULE	Objective: To study trends in multiple pregnancies not explained by changes in maternal age and parity patterns. Design: Trends in population based figures for multiple pregnancies in Denmark studied from complete national records on parity history and vital status. Population: 497 979 Danish women and 803 019 pregnancies, 1980-94. Main outcome measures: National rates of multiple pregnancies, infant mortality, and stillbirths controlled for maternal age and parity. Special emphasis on primiparous women greater than or equal to 30 years of age, who are most likely to undergo fertility treatment. Results: The national incidence of multiple pregnancies increased 1.7-fold during 1980-94, the increase primarily in 1989-94 and almost exclusively in primiparous women aged greater than or equal to 30 years, for whom the adjusted population based twinning rate increased 2.7-fold and the triplet rate 9.1-fold. During 1989-94, the adjusted yearly increase in multiple pregnancies for these women was 19% (95% confidence interval 16% to 21%) and in dizygotic twin pregnancies 25% (21% to 28%). The proportion of multiple births among infant deaths in primiparous women greater than or equal to 30 years increased from 11.5% to 26.9% during the study period. The total infant mortality, however, did not increase for these women because of a simultaneous significant decrease in infant mortality among singletons. Conclusions: A relatively small group of women has drastically changed the overall national rates of multiple pregnancies. The introduction of ne-cy treatments to enhance fertility has probably caused these changes and has also affected the otherwise decreasing trend in infant mortality. Consequently, the resources, both economical and otherwise, associated with these treatments go well beyond those invested in specific fertility enhancing treatments.	STATE SERUM INST, DANISH EPIDEMIOL SCI CTR, DEPT EPIDEMIOL RES, DK-2300 COPENHAGEN S, DENMARK	Aarhus University; Statens Serum Institut				melbye, mads/0000-0001-8264-6785; Aaby, Peter/0000-0001-8331-1389				[Anonymous], 1994, FERTIL STERIL, V62, P1121; BERAL V, 1990, BMJ-BRIT MED J, V300, P1229; CALLAHAN TL, 1994, NEW ENGL J MED, V331, P244, DOI 10.1056/NEJM199407283310407; DEROM C, 1987, LANCET, V1, P1236; Derom R, 1995, MULTIPLE PREGNANCY E, P145; EDWARDS R G, 1986, Journal of In Vitro Fertilization and Embryo Transfer, V3, P114, DOI 10.1007/BF01139357; FRIEDLER S, 1992, HUM REPROD, V7, P1159, DOI 10.1093/oxfordjournals.humrep.a137813; Hecht B. R., 1995, MULTIPLE PREGNANCY E, P175; JAMES WH, 1992, ACTA GENET MED GEMEL, V41, P33, DOI 10.1017/S0001566000002488; KEITH LG, 1991, INT J GYNECOL OBSTET, V36, P109, DOI 10.1016/0020-7292(91)90764-V; KIELY JL, 1992, AM J DIS CHILD, V146, P862, DOI 10.1001/archpedi.1992.02160190094029; KYVIK KO, 1995, INT J EPIDEMIOL, V24, P589, DOI 10.1093/ije/24.3.589; Little J., 1988, TWINNING TWINS, P37; LUKE B, 1992, J REPROD MED, V37, P661; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; *NAT BOARD HLTH, 1993, VEJL LAEG ANV KUNST; *NAT BOARD HLTH, 1996, NOT IVF BEH 1994 BAS; NEUMANN PJ, 1994, NEW ENGL J MED, V331, P239, DOI 10.1056/NEJM199407283310406; Nygren K G, 1991, Acta Obstet Gynecol Scand, V70, P561, DOI 10.3109/00016349109007917; PETERSEN K, 1995, ACTA OBSTET GYN SCAN, V74, P129, DOI 10.3109/00016349509008921; *SAS I, 1993, GENMOD PROC REL 6 09; SCHENKER JG, 1981, FERTIL STERIL, V35, P105; Taffel SM, 1995, MULTIPLE PREGNANCY E, P133; VANDUIVENBODEN YA, 1991, EUR J OBSTET GYN R B, V42, P201, DOI 10.1016/0028-2243(91)90220-F; VLIETINCK R, 1988, ACTA GENET MED GEMEL, V37, P137, DOI 10.1017/S0001566000004049; Weinberg W, 1901, ARCH GESAMTE PHYSIOL, V88, P346, DOI 10.1007/BF01657695; Westergaard L G, 1993, Ugeskr Laeger, V155, P2511	27	73	73	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	1997	314	7083					775	779		10.1136/bmj.314.7083.775	http://dx.doi.org/10.1136/bmj.314.7083.775			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080993	Green Published			2022-12-28	WOS:A1997WN64600020
J	Gottlieb, SS				Gottlieb, SS			Dead is dead - Artificial definitions are no substitute	LANCET			English	Editorial Material							CONGESTIVE-HEART-FAILURE; AMIODARONE				Gottlieb, SS (corresponding author), UNIV MARYLAND,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21201, USA.							BRITTON M, 1974, ACTA MED SCAND, V196, P203; Britton M, 1993, Qual Assur Health Care, V5, P299; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; Hartikainen JEK, 1996, J AM COLL CARDIOL, V28, P296, DOI 10.1016/0735-1097(96)00169-6; LUU M, 1989, CIRCULATION, V80, P1675, DOI 10.1161/01.CIR.80.6.1675; Narang R, 1996, EUR HEART J, V17, P1390; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; Ziesche S, 1995, J Card Fail, V1, P127, DOI 10.1016/1071-9164(95)90014-4	8	133	135	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					662	663		10.1016/S0140-6736(97)22010-6	http://dx.doi.org/10.1016/S0140-6736(97)22010-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078192				2022-12-28	WOS:A1997WM08000002
J	Kato, M; Mizuno, T; Shimizu, T; Hakoshima, T				Kato, M; Mizuno, T; Shimizu, T; Hakoshima, T			Insights into multistep phosphorelay from the crystal structure of the C-terminal HPt domain of ArcB	CELL			English	Article							3-DIMENSIONAL STRUCTURE; 2-COMPONENT REGULATORS; RESPONSE REGULATOR; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; MAGNESIUM-BINDING; PROTEIN; RESOLUTION; CHEY	The histidine-containing phosphotransfer (HPt) domain is a novel protein module with an active histidine residue that mediates phosphotransfer reactions in the two-component signaling systems. A multistep phosphorelay involving the HPt domain has been suggested for these signaling pathways. The crystal structure of the HPt domain of the anaerobic sensor kinase ArcB has been determined at 2.06 Angstrom resolution. The domain consists of six alpha helices containing a four-helix bundle-folding. The pattern of sequence similarity of the HPt domains of ArcB and components in other signaling systems can be interpreted in light of the three-dimensional structure and supports the conclusion that the HPt domains have a common structural motif both in prokaryotes and eukaryotes.	NARA INST SCI & TECHNOL,DEPT BIOL MOL,NARA 63001,JAPAN; NAGOYA UNIV,SCH AGR SCI,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN	Nara Institute of Science & Technology; Nagoya University								Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; Appleby JL, 1996, CELL, V86, P845, DOI 10.1016/S0092-8674(00)80158-0; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; FEESE M, 1994, P NATL ACAD SCI USA, V91, P3544, DOI 10.1073/pnas.91.9.3544; FEHER VA, 1995, PROTEIN SCI, V4, P1801, DOI 10.1002/pro.5560040915; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; Hoch JA, 1995, 2 COMPONENT SIGNAL T; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; INOUYE M, 1996, CELL, V85, P13; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; JIA Z, 1993, J BIOL CHEM, V30, P22490; JIA ZC, 1993, NATURE, V361, P94, DOI 10.1038/361094a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kato M, 1996, ACTA CRYSTALLOGR D, V52, P1214, DOI 10.1107/S090744499600902X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MCREE DE, 1993, PRACTICAL PROTEIN CR, P303; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; OTWINOWSKI Z, 1994, ISOMORPHOUS REPLACEM, P80; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P1335; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; Tsuzuki M, 1995, MOL MICROBIOL, V18, P953, DOI 10.1111/j.1365-2958.1995.18050953.x; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; VOLKMAN BF, 1995, BIOCHEMISTRY-US, V34, P1413, DOI 10.1021/bi00004a036; VOLZ K, 1991, J BIOL CHEM, V266, P15511; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; ZHOU H, 1995, BIOCHEMISTRY-US, V34, P1358	42	128	133	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					717	723		10.1016/S0092-8674(00)81914-5	http://dx.doi.org/10.1016/S0092-8674(00)81914-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054511	Bronze			2022-12-28	WOS:A1997WM41300017
J	Serrano, M; Lin, AW; McCurrach, ME; Beach, D; Lowe, SW				Serrano, M; Lin, AW; McCurrach, ME; Beach, D; Lowe, SW			Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a)	CELL			English	Article							HUMAN-DIPLOID FIBROBLASTS; CYCLIN-DEPENDENT KINASES; EMBRYO FIBROBLASTS; ALTERED REGULATION; NUCLEAR ONCOGENES; INVITRO LIFESPAN; TUMOR SUPPRESSOR; GROWTH ARREST; SKIN TUMORS; HA-RAS	Oncogenic ras can transform most immortal rodent cells to a tumorigenic state. However, transformation of primary cells by ras requires either a cooperating oncogene or the inactivation of tumor suppressors such as p53 or p16. Here we show that expression of oncogenic ras in primary human or rodent cells results in a permanent G1 arrest The arrest induced by ras is accompanied by accumulation of p53 and p16, and is phenotypically indistinguishable from cellular senescence. Inactivation of either p53 or p16 prevents ras-induced arrest in rodent cells, and E1A achieves a similar effect in human cells. These observations suggest that the onset of cellular senescence does not simply reflect the accumulation of cell divisions, but can be prematurely activated in response to an oncogenic stimulus. Negation of ras-induced senescence may be relevant during multistep tumorigenesis.	COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312	NATIONAL CANCER INSTITUTE [R01CA068040, P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA68040, CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bartkova J, 1996, CANCER RES, V56, P5475; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; FAIRWEATHER DS, 1987, EXP CELL RES, V168, P153, DOI 10.1016/0014-4827(87)90424-1; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; Hara E, 1996, MOL CELL BIOL, V16, P859; HARVEY DM, 1991, GENE DEV, V5, P2357; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HIRAMA T, 1995, BLOOD, V86, P841; HOLLIDAY R, 1986, EXP CELL RES, V166, P543, DOI 10.1016/0014-4827(86)90499-4; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, ONCOGENE, V9, P323; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUMPKIN CK, 1986, MOL CELL BIOL, V6, P2990, DOI 10.1128/MCB.6.8.2990; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCURRACH ME, 1997, IN PRESS P NATL ACAD; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MU XC, 1995, J CELL PHYSIOL, V165, P647, DOI 10.1002/jcp.1041650324; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; QUELLE DE, 1995, ONCOGENE, V11, P635; Reznikoff CA, 1996, CANCER RES, V56, P2886; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; SULLIVAN NF, 1986, CANCER RES, V46, P6427; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOTJA PJ, 1995, BIOCHIM BIOPHYS ACTA, V1242, P29; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINBERG RA, 1989, CANCER RES, V49, P3413; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572	73	3799	3903	11	202	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					593	602		10.1016/S0092-8674(00)81902-9	http://dx.doi.org/10.1016/S0092-8674(00)81902-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054499	Bronze			2022-12-28	WOS:A1997WM41300005
J	Booth, DR; Sunde, M; Bellotti, V; Robinson, CV; Hutchinson, WL; Fraser, PE; Hawkins, PN; Dobson, CM; Radford, SE; Blake, CCF; Pepys, MB				Booth, DR; Sunde, M; Bellotti, V; Robinson, CV; Hutchinson, WL; Fraser, PE; Hawkins, PN; Dobson, CM; Radford, SE; Blake, CCF; Pepys, MB			Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis	NATURE			English	Article							ALPHA-LACTALBUMIN; FIBRIL FORMATION; HEN LYSOZYME; MASS-SPECTROMETRY; MOLTEN GLOBULE; PROTEIN; DISULFIDE; PEPTIDES; DISEASES; SHEET	Tissue deposition of soluble proteins as amyloid fibrils underlies a range of fatal diseases. The two naturally occurring human lysozyme variants are both amyloidogenic, and are shown here to be unstable. They aggregate to form amyloid fibrils with transformation of the mainly helical native fold, observed in crystal structures, to the amyloid fibril cross-beta fold. Biophysical studies suggest that partly folded intermediates are involved in fibrillogenesis, and this may be relevant to amyloidosis generally.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, IMMUNOL MED UNIT, LONDON W12 0NN, ENGLAND; UNIV OXFORD, LAB MOL BIOPHYS, OXFORD OX1 3QT, ENGLAND; UNIV OXFORD, OXFORD CTR MOL SCI, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND; UNIV TORONTO, CTR RES NEURODEGENERAT DIS, TORONTO, ON M5S 3H2, CANADA	Imperial College London; University of Oxford; University of Oxford; University of Toronto			Sunde, Margaret/A-5186-2016; Hawkins, Philip N/C-5573-2008; Sunde, Margaret/ABH-2584-2020; Bellotti, Vittorio/A-6201-2014	Sunde, Margaret/0000-0002-0150-3203; Sunde, Margaret/0000-0002-0150-3203; Bellotti, Vittorio/0000-0001-8678-662X; Radford, Sheena/0000-0002-3079-8039; robinson, carol/0000-0001-7829-5505				ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416; ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BLAKE CCF, 1983, J MOL BIOL, V167, P693, DOI 10.1016/S0022-2836(83)80105-3; Booth DR, 1996, J CLIN INVEST, V97, P2714, DOI 10.1172/JCI118725; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BYCHKOVA VE, 1995, FEBS LETT, V359, P6, DOI 10.1016/0014-5793(95)00004-S; CHUNG LP, 1988, P NATL ACAD SCI USA, V85, P6227, DOI 10.1073/pnas.85.17.6227; DOBSON CM, 1995, NAT STRUCT BIOL, V2, P513, DOI 10.1038/nsb0795-513; EYLES SJ, 1994, BIOCHEMISTRY-US, V33, P13038, DOI 10.1021/bi00248a013; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; Funahashi J, 1996, J BIOCHEM, V120, P1216; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GOLDFARB LG, 1993, P NATL ACAD SCI USA, V90, P4451, DOI 10.1073/pnas.90.10.4451; HAEZEBROUCK P, 1995, J MOL BIOL, V246, P382, DOI 10.1006/jmbi.1994.0093; Harrison RF, 1996, GUT, V38, P151, DOI 10.1136/gut.38.1.151; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; MAURY CPJ, 1994, LAB INVEST, V70, P558; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MCKENZIE HA, 1991, ADV PROTEIN CHEM, V41, P173; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; NANJO F, 1988, J BIOCHEM-TOKYO, V104, P255, DOI 10.1093/oxfordjournals.jbchem.a122453; NELSON SR, 1991, BIOCHEM J, V275, P67, DOI 10.1042/bj2750067; OSSERMAN EF, 1966, J EXP MED, V124, P921, DOI 10.1084/jem.124.5.921; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; PEPYS MB, 1994, SAMTERS IMMUNOLOGIC; PERRY LJ, 1986, BIOCHEMISTRY-US, V25, P733, DOI 10.1021/bi00351a034; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SHIH P, 1995, PROTEIN SCI, V4, P2050, DOI 10.1002/pro.5560041010; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281; YAMADA T, 1994, BBA-MOL BASIS DIS, V1226, P323, DOI 10.1016/0925-4439(94)90044-2; YANG JJ, 1994, BIOCHEMISTRY-US, V33, P7345, DOI 10.1021/bi00189a040	48	954	986	2	179	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 27	1997	385	6619					787	793		10.1038/385787a0	http://dx.doi.org/10.1038/385787a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039909				2022-12-28	WOS:A1997WK57000044
J	McMurdo, MET; Mole, PA; Paterson, CR				McMurdo, MET; Mole, PA; Paterson, CR			Controlled trial of weight bearing exercise in older women in relation to bone density and falls	BRITISH MEDICAL JOURNAL			English	Article								Studies of the effects of different exercise programmes on bone in postmenopausal women have produced different conclusions, but few have targeted elderly women specifically.(1) We report a controlled trial of weight bearing exercise in this clinically important population.			McMurdo, MET (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT MED,SECT AGEING & HLTH,DUNDEE DD1 9SY,SCOTLAND.							FORWOOD MR, 1993, BONE MINER, V21, P89, DOI 10.1016/S0169-6009(08)80012-8; MCMURDO MET, 1992, GERONTOLOGY, V38, P292; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341	3	75	75	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					569	569		10.1136/bmj.314.7080.569	http://dx.doi.org/10.1136/bmj.314.7080.569			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055716	Green Published			2022-12-28	WOS:A1997WK21500025
J	Adams, DH; Lloyd, AR				Adams, DH; Lloyd, AR			Chemokines: Leucocyte recruitment and activation cytokines	LANCET			English	Review							GENE-EXPRESSION; T-CELLS; INTERLEUKIN-8; MIP-1-ALPHA; MIP-1-BETA; RECEPTORS; INJURY; IDENTIFICATION; MIGRATION; SIGNALS	Chemokines are a family of structurally related proteins that share the ability to induce migration of specific subsets of leucocytes. These specialised cytokines play a critical part in the generation of cellular inflammation, both in the protective responses to invading pathogens and in the pathological processes associated with infection and immune-mediated diseases. Chemokines are more than simple chemotactic factors, since they are also implicated in leucocyte activation, angiogenesis, and antimicrobial functions, Including a protective role in HIV infection. These molecules provide potentially valuable targets for therapeutic intervention in a wide range of diseases.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV NEW S WALES,SCH PATHOL,INFLAMMAT RES UNIT,SYDNEY,NSW,AUSTRALIA; PRINCE HENRY HOSP,DEPT INFECT DIS,SYDNEY,NSW,AUSTRALIA	University of Birmingham; University of New South Wales Sydney	Adams, DH (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,LIVER RES LABS,CLIN RES BLOCK,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Lloyd, Andrew/E-7334-2017; Lloyd, Andrew/AAF-6071-2022; Adams, David H/C-9092-2009; Lloyd, Andrew/AFJ-8960-2022	Lloyd, Andrew/0000-0001-6277-8887; Adams, David H/0000-0001-6776-0336; Lloyd, Andrew/0000-0001-6277-8887				Adams DH, 1996, TRANSPLANTATION, V61, P817, DOI 10.1097/00007890-199603150-00024; ADAMS DH, 1994, LANCET, V343, P831, DOI 10.1016/S0140-6736(94)92029-X; AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; ALCAMI A, 1995, IMMUNOL TODAY, V16, P474, DOI 10.1016/0167-5699(95)80030-1; AZUMA H, 1994, CURR OPIN IMMUNOL, V6, P770, DOI 10.1016/0952-7915(94)90083-3; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLETTI LM, 1995, J CLIN INVEST, V95, P134, DOI 10.1172/JCI117630; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; ERGER RA, 1995, AM J PHYSIOL-LUNG C, V12, pL117; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FURIE MB, 1995, AM J PATHOL, V146, P1287; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kunkel SL, 1996, J LEUKOCYTE BIOL, V59, P6, DOI 10.1002/jlb.59.1.6; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUKACS MW, 1996, J LEUKOCYTE BIOL, V59, P13; LUSCINSKAS FW, 1992, J IMMUNOL, V149, P2163; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1994, CYTOKINE HDB, P419; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEITER RM, 1995, SHOCK, V4, P155; STIETER RM, 1995, J BIOL CHEM, V270, P27348; Strieter RM, 1996, J IMMUNOL, V156, P3583; SYLVESTER I, 1993, J IMMUNOL, V151, P3292; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; Taub DD, 1996, J IMMUNOL, V156, P2095; Taub DD, 1996, J LEUKOCYTE BIOL, V59, P81, DOI 10.1002/jlb.59.1.81; Tedla N, 1996, AM J PATHOL, V148, P1367; VANZEE KJ, 1992, J IMMUNOL, V148, P1746; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZHANG YH, 1995, J CLIN INVEST, V95, P586, DOI 10.1172/JCI117702	51	389	395	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					490	495		10.1016/S0140-6736(96)07524-1	http://dx.doi.org/10.1016/S0140-6736(96)07524-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040590				2022-12-28	WOS:A1997WH38900044
J	Adler, MW				Adler, MW			HIV: The other dimension	LANCET			English	Editorial Material											Adler, MW (corresponding author), UCL, SCH MED, DEPT SEXUALLY TRANSMITTED DIS, LONDON WC1E 6AU, ENGLAND.							Ainsworth Martha, 1994, P559; Ankrah E. Maxine, 1994, P547; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; ELLIOT L, 1996, GUARDIAN        0117; *GLOB PROGR AIDS, 1995, CURR GLOB SIT HIV AI; *HARV SCH PUBL HLT, 1993, GLOB AIDS POL COAL N; HILLYARD M, 1995, 95122 HOUS COMM LIB; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; NOVAK R, 1995, SCIENCE, V269, P1332; REID E, 1994, UNDP; *WORLD BANK, 1993, WORLD BANK DEV REP 1	11	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					498	500		10.1016/S0140-6736(96)03233-3	http://dx.doi.org/10.1016/S0140-6736(96)03233-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040592				2022-12-28	WOS:A1997WH38900046
J	Brahams, D				Brahams, D			A unique case of frozen sperm export?	LANCET			English	Editorial Material											Brahams, D (corresponding author), OLD SQUARE CHAMBERS,LONDON WC1R 5LQ,ENGLAND.							1996, LANCET, V348, P1253	1	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					448	448						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040571				2022-12-28	WOS:A1997WH38900006
J	Coulter, A; Mays, N				Coulter, A; Mays, N			Primary care: Opportunities and threats - Deregulating primary care	BRITISH MEDICAL JOURNAL			English	Article									KINGS FUND,KINGS FUND POLICY INST,LONDON W1M 0AN,ENGLAND		Coulter, A (corresponding author), KINGS FUND,KINGS FUND DEV CTR,LONDON W1M 0AN,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				ALLAN G, 1996, HEALTHCARE PARL 1104; BUTLER P, 1996, HLTH SERVICE J  1017, P5; COULTER A, 1995, EUROPEAN J PUBLIC HL, V5, P233; CRAIL M, 1996, HLTH SERVICE J  1024, P10; *DEP HLTH, 1994, DEV NHS PURCH GP FUN; EDMONDS R, 1996, FUTURE OPTIONS GEN P, P109; ELLIOT A, 1996, PULSE           1130, P20; ELLIOT A, 1996, PULSE           1026, P7; ELLIOT A, 1996, PULSE           1109, P1; GOSDEN T, 1996, HLTH SERVICE J  1031, P18; GOULD M, 1996, PULSE           1026, P1; GOULD M, 1996, PULSE           1026, P8; HOLLINGER P, 1996, FINANCIAL TIMES 1209, P1; LINDEN M, 1996, PULSE           1026, P15; Mays N., 1996, TOTAL PURCHASING PRO; *NHS EX, 1996, PRIM CAR FUT; ODOWD A, 1996, PULSE           1109, P15; Reinhardt U E, 1993, Health Econ, V2, P7, DOI 10.1002/hec.4730020103; ROBINSON B, 1996, FUTURE OPTIONS GEN P, P201; SALMON JW, 1987, INT J HEALTH SERV, V17, P1; *SECR STAT HLTH SC, 1996, PRIM CAR FUT; *SECR STAT HLTH SC, 1996, PRIM CAR DEL FUT; STIRLING A, 1996, PULSE           1214, P1; 1996, PULSE           1102, P6; 1996, PULSE           1109, P15; 1996, PULSE           1109, P4; 1996, PULSE           1109, P2	27	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					510	513						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056807				2022-12-28	WOS:A1997WJ41900037
J	Tenenbaum, SA; Rice, JC; Espinoza, LR; Cuellar, ML; Plymale, DR; Sander, DM; Williamson, LL; Haislip, AM; Gluck, OS; Tesser, JRP; Nogy, L; Stribrny, KM; Bevan, JA; Garry, RF				Tenenbaum, SA; Rice, JC; Espinoza, LR; Cuellar, ML; Plymale, DR; Sander, DM; Williamson, LL; Haislip, AM; Gluck, OS; Tesser, JRP; Nogy, L; Stribrny, KM; Bevan, JA; Garry, RF			Use of antipolymer antibody assay in recipients of silicone breast implants	LANCET			English	Article							CONNECTIVE-TISSUE DISEASES; HUMAN ADJUVANT DISEASE; AUGMENTATION MAMMOPLASTY; WOMEN; AUTOANTIBODIES; CONTROVERSY; SYMPTOMS; RISK	Background Local complications (encapsulation, rashes, rupture, and leakage) can occur after placement of silicone-gel-containing breast implants (SBI). Whether SBI exposure results in systemic manifestations in some recipients is controversial. We have carried out a blinded study to assess whether there is any difference between SBI recipients and non-exposed controls in the proportions positive for serum antibodies directed against polymeric substances. Methods We recruited female SBI recipients (including those without symptoms) who presented to a single rheumatology clinic, A physician global assessment was used to classify SBI recipients who did not meet criteria for specific autoimmune diseases according to the severity of local and systemic signs and symptoms. Controls were recruited from among clinic staff and their acquaintances. Results of the antipolymer antibody (APA) assay were compared with those of an assay for antinuclear antibodies (ANA) and with the severity of the signs and symptoms. Findings Positive APA results were found in one (3%) of 34 SBI recipients with limited symptoms, two (8%) of 26 with mild symptoms, seven (44%) of 16 with moderate symptoms, and 13 (68%) of 19 with advanced symptoms. Four (17%) of 23 healthy non-SBI-exposed controls and two (10%) of 20 non-exposed women with classic autoimmune diseases were positive for APA. Thus, women with moderate or advanced symptoms were significantly more likely than those with limited or mild symptoms, or nonexposed controls to have APA (p<0.001). The proportion with positive ANA results was higher for women with classic autoimmune diseases 14 (70%) of 20 than for any SBI-exposed subgroup (0-33%). Interpretation The APA assay can objectively contribute to distinguishing between SBI recipients with limited or mild signs and symptoms, SBI recipients with more severe manifestations, and patients with specific autoimmune diseases. Further studies will be needed to define the signs and symptoms associated with exposure to SBI.	TULANE UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL SL38, NEW ORLEANS, LA 70112 USA; TULANE UNIV, SCH MED, MOL & CELLULAR BIOL PROGRAM, NEW ORLEANS, LA 70112 USA; TULANE UNIV, SCH PUBL HLTH & TROP MED, DEPT BIOSTAT & EPIDEMIOL, NEW ORLEANS, LA 70112 USA; LOUISIANA STATE UNIV, MED CTR, DEPT RHEUMATOL, NEW ORLEANS, LA USA; ARIZONA RHEUMATOL CTR, PHOENIX, AZ USA; AFFINTECH, BENTONVILLE, AR USA	Tulane University; Tulane University; Tulane University; Louisiana State University System			Tenenbaum, Scott A/H-4744-2019	Garry, Robert/0000-0002-5683-3250				ANGELL M, 1994, NEW ENGL J MED, V330, P1748, DOI 10.1056/NEJM199406163302409; Angell M, 1996, NEW ENGL J MED, V334, P1513, DOI 10.1056/NEJM199606063342306; BRAUN G, 1995, CLIN ORAL IMPLAN RES, V6, P1, DOI 10.1034/j.1600-0501.1995.060101.x; Brautbar N., 1995, NATL MED LEG J, V6, P4; BRIDGES AJ, 1994, SEMIN ARTHRITIS RHEU, V24, P54, DOI 10.1016/0049-0172(94)90110-4; BRIDGES AJ, 1994, LANCET, V344, P1451, DOI 10.1016/S0140-6736(94)90284-4; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; BRIDGES AJ, 1993, ARCH INTERN MED, V153, P2638, DOI 10.1001/archinte.153.23.2638; BROZENA SJ, 1988, ARCH DERMATOL, V124, P1383, DOI 10.1001/archderm.124.9.1383; CLAMAN HN, 1994, WESTERN J MED, V160, P225; COOK RR, 1994, JAMA-J AM MED ASSOC, V272, P767, DOI 10.1001/jama.1994.03520100031021; COOK RR, 1994, ARTHRITIS RHEUM, V37, P153, DOI 10.1002/art.1780370202; CUELLAR ML, 1995, J RHEUMATOL, V22, P236; FOX RI, 1986, SCAND J RHEUMATOL, P28; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GERMAIN BF, 1992, B RHEUM DIS, V41, P1; GUILLAUME JC, 1984, ANN DERMATOL VENER, V111, P703; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V270, P2607, DOI 10.1001/jama.270.21.2607; LEVINE MD, 1994, JAMA-J AM MED ASSOC, V272, P769, DOI 10.1001/jama.1994.03520100031025; PRESS RI, 1992, LANCET, V340, P1304, DOI 10.1016/0140-6736(92)92491-W; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SERGOTT TJ, 1986, PLAST RECONSTR SURG, V78, P104, DOI 10.1097/00006534-198607000-00018; Silverman BG, 1996, ANN INTERN MED, V124, P744, DOI 10.7326/0003-4819-124-8-199604150-00008; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; TENENBAUM SA, 1992, ARTHRITIS RHEUM S, V73, P25; TENENBAUM SA, 1993, ARTHRITIS RHEUM S, V118, pA123; TEUBER SS, 1994, INT ARCH ALLERGY IMM, V103, P105, DOI 10.1159/000236613; ZAMBINSKI M, 1989, P 53 GEN M AM COLL R, pS25	30	51	53	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1997	349	9050					449	454		10.1016/S0140-6736(96)07131-0	http://dx.doi.org/10.1016/S0140-6736(96)07131-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040573				2022-12-28	WOS:A1997WH38900008
J	Keeney, S; Giroux, CN; Kleckner, N				Keeney, S; Giroux, CN; Kleckner, N			Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family	CELL			English	Article							SYNAPTONEMAL COMPLEX-FORMATION; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; CHROMOSOME SYNAPSIS; TOPOISOMERASE-II; INITIATION SITE; ESCHERICHIA-COLI; YEAST; GENE; RAD50	Meiotic recombination in S. cerevisiae is initiated by double-strand breaks (DSBs). In certain mutants, breaks accumulate with a covalently attached protein, suggesting that cleavage is catalyzed by the DSB-associated protein via a topoisomerase-like transesterase mechanism. We have purified these protein-DNA complexes and identified the protein as Spo11, one of several proteins required for DSB formation. These findings strongly implicate Spo11 as the catalytic subunit of the meiotic DNA cleavage activity. This is the first identification of a biochemical function for any of the gene products involved in DSB formation. Spo11 defines a protein family with other members in fission yeast, nematodes, and archaebacteria. The S. pombe homolog, rec12p, is also known to be required for meiotic recombination. Thus, these findings provide direct evidence that the mechanism of meiotic recombination initiation is evolutionarily conserved.	WAYNE STATE UNIV, CTR MOL MED & GENET, DETROIT, MI 48202 USA	Wayne State University	Keeney, S (corresponding author), HARVARD UNIV, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.		Keeney, Scott/GVR-8515-2022	Keeney, Scott/0000-0002-1283-6417	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044794] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM44794] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIMURA M, 1993, GENETICS, V133, P51; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BERGERAT A, 1994, J BIOL CHEM, V269, P27663; BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Bullard SA, 1996, P NATL ACAD SCI USA, V93, P13054, DOI 10.1073/pnas.93.23.13054; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; DEMASSY B, 1995, EMBO J, V14, P4589, DOI 10.1002/j.1460-2075.1995.tb00138.x; ESPOSITO MS, 1969, GENETICS, V61, P79; GAME JC, 1989, GENETICS, V123, P695; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; GIROUX CN, 1993, MEIOSIS, V2, P1; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; IVANOV EL, 1992, GENETICS, V132, P651; JOHZUKA K, 1995, GENETICS, V139, P1521; Kaiser C., 1994, METHODS YEAST GENETI; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; Keeney S, 1996, GENES CELLS, V1, P475, DOI 10.1046/j.1365-2443.1996.d01-257.x; KEENEY S, 1995, P NATL ACAD SCI USA, V92, P11274, DOI 10.1073/pnas.92.24.11274; KLAPHOLZ S, 1985, GENETICS, V110, P187; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; LIN YK, 1994, GENETICS, V136, P769; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; LIU LF, 1983, J BIOL CHEM, V258, P5365; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; MaoDraayer Y, 1996, GENETICS, V144, P71; MCKEE AHZ, 1997, IN PRES GENETICS; MCKEE BD, 1993, CHROMOSOMA, V102, P180, DOI 10.1007/BF00387733; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; ORRWEAVER TL, 1995, P NATL ACAD SCI USA, V92, P10443, DOI 10.1073/pnas.92.23.10443; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PRINZ S, 1997, IN PRESS GENETICS; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; ROCA J, 1993, J BIOL CHEM, V268, P14250; Rocco V, 1996, GENES CELLS, V1, P645, DOI 10.1046/j.1365-2443.1996.00256.x; ROCKMILL B, 1995, GENETICS, V141, P49; ROEDER GS, 1995, P NATL ACAD SCI USA, V92, P10450, DOI 10.1073/pnas.92.23.10450; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SCHLESTL RH, 1994, MOL CELL BIOL, V14, P4493; Shabarova Z A, 1970, Prog Nucleic Acid Res Mol Biol, V10, P145; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH AV, 1997, IN PRESS J CELL BIOL; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; WALTER J, 1994, GENE DEV, V8, P1678, DOI 10.1101/gad.8.14.1678; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Xu F, 1996, GENETICS, V143, P1115; XU L, 1997, IN PRESS GENES DEV; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; ZUBENKO GS, 1981, GENETICS, V97, P45	61	1259	1294	4	101	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1997	88	3					375	384		10.1016/S0092-8674(00)81876-0	http://dx.doi.org/10.1016/S0092-8674(00)81876-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039264	Bronze			2022-12-28	WOS:A1997WG47900010
J	Pringle, M				Pringle, M			Interesting idea, but case not proved - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material											Pringle, M (corresponding author), QUEENS MED CTR,SCH MED,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							BRUSTER S, 1994, BRIT MED J, V309, P1542, DOI 10.1136/bmj.309.6968.1542; CAMPBELL LM, 1995, BRIT MED J, V311, P236, DOI 10.1136/bmj.311.6999.236; Kinnersley P, 1996, FAM PRACT, V13, P41, DOI 10.1093/fampra/13.1.41; POULTON B, 1995, BR J GEN PRACT, V46, P26	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					348	348		10.1136/bmj.314.7077.348	http://dx.doi.org/10.1136/bmj.314.7077.348			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040329	Green Published			2022-12-28	WOS:A1997WF86100035
J	Dong, HL; OBrien, RJ; Fung, ET; Lanahan, AA; Worley, PF; Huganir, RL				Dong, HL; OBrien, RJ; Fung, ET; Lanahan, AA; Worley, PF; Huganir, RL			GRIP: A synaptic PDZ domain-containing protein that interacts with AMPA receptors	NATURE			English	Article							GUANYLATE KINASES; NMDA RECEPTOR; GLUTAMATE; CHANNELS; SUBUNIT; SYNAPSES; CLONING; SYSTEM; BRAIN; YEAST	AMPA glutamate receptors mediate the majority of rapid excitatory synaptic transmission in the central nervous system(1,2) and play a role in the synaptic plasticity underlying learning and memory(3,4). AMPA receptors are heteromeric complexes of four homologous subunits (GluR1-4) that differentially combine to form a variety of AMPA receptor subtypes(1,2). These subunits are thought to have a large extracellular amino-terminal domain, three transmembrane domains and an intracellular carboxyterminal domain(5). AMPA receptors are localized at excitatory synapses and are not found on adjacent inhibitory synapses enriched in GABAA receptors(6). The targeting of neurotransmitter receptors, such as AMPA receptors, and ion channels to synapses is essential for efficient transmission(7,8). A protein motif called a PDZ domain is important in the targeting of a variety of membrane proteins to cell-cell junctions including synapses(8-10). Here we identify a synaptic PDZ domain-containing protein GRIP (glutamate receptor interacting protein) that specifically interacts with the C termini of AMPA receptors. GRIP is a new member of the PDZ domain-containing protein family which has seven PDZ domains and no catalytic domain. GRIP appears to serve as an adapter protein that links AMPA receptors to other proteins and may be critical for the clustering of AMPA receptors at excitatory synapses in the brain.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University								Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; EHLERS MD, 1996, CURR OPIN CELL BIOL, V8, P490; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; GALLO V, 1992, J NEUROSCI, V12, P1010; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOHLER M, 1994, J BIOL CHEM, V269, P17367; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; STRICKER NL, IN PRESS NATURE BIOT; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; XIA Z, 1996, J NEUROSCI, V16, P5424	30	711	733	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					279	284		10.1038/386279a0	http://dx.doi.org/10.1038/386279a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069286				2022-12-28	WOS:A1997WP00300051
J	Wyman, C; Rombel, I; North, AK; Bustamante, C; Kustu, S				Wyman, C; Rombel, I; North, AK; Bustamante, C; Kustu, S			Unusual oligomerization required for activity of NtrC, a bacterial enhancer-binding protein	SCIENCE			English	Article							SCANNING FORCE MICROSCOPY; TRANSCRIPTIONAL ACTIVATION; ATPASE ACTIVITY; ENTERIC BACTERIA; ESCHERICHIA-COLI; RNA-POLYMERASE; PHOSPHORYLATION; DETERMINANTS; COMPLEXES; PROMOTER	Nitrogen regulatory protein G (NtrC) contacts a bacterial RNA polymerase from distant enhancers by means of DNA loops and activates transcription by allowing polymerase to gain access to the template DNA strand. It was shown that NtrC from Salmonella typhimurium must build large oligomers to activate transcription. In contrast to eukaryotic enhancer-binding proteins, most of which must bind directly to DNA, some NtrC dimers were bound solely by protein-protein interactions. NtrC oligomers were visualized with scanning force microscopy. Evidence of their functional importance was provided by showing that some inactive non-DNA-binding and DNA-binding mutant forms of NtrC can cooperate to activate transcription.	UNIV OREGON,HOWARD HUGHES MED INST,DEPT CHEM,EUGENE,OR 97403; UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,NL-3000 DR ROTTERDAM,NETHERLANDS; UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of Oregon; University of California System; University of California Berkeley; Erasmus University Rotterdam; University of Oregon; University of California System; University of California Berkeley				Bustamante, Carlos/0000-0002-2970-0073	NIGMS NIH HHS [GM38361, GM17078, GM32543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R01GM032543, R37GM038361, R01GM038361] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BUSTAMANTE C, 1993, CURR OPIN STRUC BIOL, V3, P363, DOI 10.1016/S0959-440X(05)80107-1; BUSTAMANTE C, 1994, CURR OPIN STRUC BIOL, V4, P750, DOI 10.1016/S0959-440X(94)90175-9; BUSTAMANTE C, 1995, PHYS TODAY, V48, P32, DOI 10.1063/1.881478; CHAMBERLIN MJ, 1992, NUCL ACIDS B, V15, P61; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; GREEN MR, 1995, HARVEY LECT, V88, P67; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HOPPER S, 1995, J BACTERIOL, V177, P2798, DOI 10.1128/jb.177.10.2798-2803.1995; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; LEE JH, 1994, J BIOL CHEM, V269, P20401; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MAGASANIK B, 1993, J CELL BIOCHEM, V51, P34, DOI 10.1002/jcb.240510108; Magasanik Boris, 1996, P281; NORTH A, IN PRESS J MOL BIOL; North AK, 1996, J MOL BIOL, V260, P317, DOI 10.1006/jmbi.1996.0403; NORTH AN, UNPUB; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; RANISH A, 1996, CURR OPIN GENE DEV, V6, P151; ROMBEL I, UNPUB; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WYMAN C, 1995, EMBO J, V14, P117, DOI 10.1002/j.1460-2075.1995.tb06981.x; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	36	212	213	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1658	1661		10.1126/science.275.5306.1658	http://dx.doi.org/10.1126/science.275.5306.1658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054362				2022-12-28	WOS:A1997WN12300050
J	Rodionov, VI; Borisy, GG				Rodionov, VI; Borisy, GG			Self-centring activity of cytoplasm	NATURE			English	Article							INTRACELLULAR-TRANSPORT; MICROTUBULE POLARITY; PIGMENT TRANSPORT; FISH MELANOPHORES; KINESIN; PROTEIN; CHROMATOPHORES; ORGANIZATION; DIRECTION; GRANULES	Fish melanophore cells aggregate pigment granules at the centre or redisperse them throughout the cytoplasm. The granules move along radial microtubules by means of molecular motors(1-3) Cytoplasmic fragments of melanophores organize a radial array of microtubules and aggregate pigment at its centre(4-7). Here we report self-centring in microsurgically produced cytoplasmic fragments of black tetra melanophores. We observed rapid (10 min) formation of a radial microtubule array after stimulation of aggregation. Arrangement of microtubules in the fragments returned to random during pigment redispersion. Apparently, formation of the radial array does not depend on a pre-existing microtubule-organizing centre. The array did not form in granule-free fragments nor in fragments treated with inhibitors of the intracellular motor protein cytoplasmic dynein. We conclude that formation of the radial microtubule array is induced by directional motion of pigment granules along microtubules and present evidence that its position is defined by interaction of microtubules with the surface.	UNIV WISCONSIN,MOL BIOL LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Borisy, Gary/0000-0002-0266-8018				BECKERLE MC, 1982, NATURE, V295, P701, DOI 10.1038/295701a0; CLARK TG, 1982, P NATL ACAD SCI-BIOL, V79, P4655, DOI 10.1073/pnas.79.15.4655; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; GYOEVA FK, 1987, J CELL SCI, V88, P649; HAIMO LT, 1994, BIOESSAYS, V16, P727, DOI 10.1002/bies.950161007; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Matthews SA, 1931, J EXP ZOOL, V58, P471, DOI 10.1002/jez.1400580121; MCNIVEN MA, 1988, J CELL BIOL, V106, P1593, DOI 10.1083/jcb.106.5.1593; MCNIVEN MA, 1986, J CELL BIOL, V103, P1547, DOI 10.1083/jcb.103.4.1547; MCNIVEN MA, 1984, CELL, V37, P753, DOI 10.1016/0092-8674(84)90411-2; Oakley Berl R., 1994, V13, P33; OBIKA M, 1986, ZOOL SCI, V3, P1; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; RODIONOV VI, 1994, J CELL BIOL, V126, P1455, DOI 10.1083/jcb.126.6.1455; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; Schliwa M., 1984, Cell and Muscle Motility, V5, P1; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177	20	97	100	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 13	1997	386	6621					170	173		10.1038/386170a0	http://dx.doi.org/10.1038/386170a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062188				2022-12-28	WOS:A1997WM97300061
J	Zerrahn, J; Held, W; Raulet, DH				Zerrahn, J; Held, W; Raulet, DH			The MHC reactivity of the T cell repertoire prior to positive and negative selection	CELL			English	Article							CLASS-II MOLECULES; MICE; THYMOCYTES; ANTIGENS; THYMUS; BETA; SUPERANTIGENS; RECOGNITION; FREQUENCY; ONTOGENY	T cell antigen receptors (TCRs) on mature T cells react with peptide antigens presented by self-MHC proteins and also frequently cross-react with foreign MHC proteins. The fundamental question whether MHC reactivity is inherent in the germline TCR sequences or is imposed by thymic selection was addressed here by inducing nonselective maturation of immature thymocytes in the absence of MHC molecules. MHC reactivity in the preselection repertoire is very high, but no higher than in the normal repertoire. cross-reactivity of clones with multiple MHC molecules occurred to a similar extent in the preselection and MHC-selected repertoires. The results establish the MHC reactivity of the germline TCR repertoire, indicate the minimum fraction of immature thymocytes that must undergo negative selection, and suggest that some TCR-MHC contacts may be conserved.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley				Raulet, David/0000-0002-1257-8649	NIAID NIH HHS [AI31650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; ASHWELL JD, 1986, J IMMUNOL, V136, P389; BEVAN MJ, 1977, P NATL ACAD SCI USA, V74, P2094, DOI 10.1073/pnas.74.5.2094; BIX M, 1992, J EXP MED, V176, P829, DOI 10.1084/jem.176.3.829; BLACKMAN M, 1986, CELL, V47, P349, DOI 10.1016/0092-8674(86)90591-X; BRAUN MY, 1995, EUR J IMMUNOL, V25, P857, DOI 10.1002/eji.1830250334; Brock R, 1996, P NATL ACAD SCI USA, V93, P13108, DOI 10.1073/pnas.93.23.13108; CEREDIG R, 1983, J EXP MED, V158, P1654, DOI 10.1084/jem.158.5.1654; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; EHRICH EW, 1993, J EXP MED, V178, P713, DOI 10.1084/jem.178.2.713; FISCHERLINDAHL K, 1977, J EXP MED, V145, P508; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Gavin MA, 1995, IMMUNITY, V3, P793, DOI 10.1016/1074-7613(95)90068-3; GILFILLAN S, 1994, INT IMMUNOL, V6, P1681, DOI 10.1093/intimm/6.11.1681; GOTZE D, 1980, J IMMUNOL, V124, P2675; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; ITOH T, 1990, THYMUS, V16, P89; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PUNT JA, 1993, J IMMUNOL, V151, P1290; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SCHERER MT, 1995, J EXP MED, V182, P1493, DOI 10.1084/jem.182.5.1493; Sim BC, 1996, SCIENCE, V273, P963, DOI 10.1126/science.273.5277.963; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TAKAHAMA Y, 1994, NATURE, V371, P67, DOI 10.1038/371067a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; WHITE J, 1989, J IMMUNOL, V143, P1822; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	41	261	268	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					627	636		10.1016/S0092-8674(00)81905-4	http://dx.doi.org/10.1016/S0092-8674(00)81905-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054502	Bronze			2022-12-28	WOS:A1997WM41300008
J	Goodrich, J; Puangsomlee, P; Martin, M; Long, D; Meyerowitz, EM; Coupland, G				Goodrich, J; Puangsomlee, P; Martin, M; Long, D; Meyerowitz, EM; Coupland, G			A polycomb-group gene regulates homeotic gene expression in Arabidopsis	NATURE			English	Article							FLORAL ORGAN IDENTITY; FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; DROSOPHILA EMBRYOS; ECTOPIC EXPRESSION; CELL FATE; PROTEIN; ENHANCER; BINDING	Cell fate is determined when the commitment of cells to a particular fate Is autonomously maintained, irrespective of their environment. In Drosophila, fate determination is maintained through the action of the Polycomb-group and trithorax-group genes, which are required so that states of homeotic gene activity are inherited through cell division. It is shown here that the CURLY LEAF gene of Arabidopsis is necessary for stable repression of a floral homeotic gene and encodes a protein with homology to the product of the Polycomb-group gene Enhancer of zeste. We suggest that Polycomb-group genes have a similar role in fate determination in plants and animals.	JOHN INNES CTR PLANT SCI RES,NORWICH NR4 7UH,NORFOLK,ENGLAND; CALTECH,DIV BIOL 15629,PASADENA,CA 91125	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; California Institute of Technology			Meyerowitz, Elliot M/A-7118-2009; Coupland, George/AAP-8609-2020; martin, marta/H-2169-2015; Basanta, Marta Martin/AAI-5459-2020	Coupland, George/0000-0001-6988-4172; martin, marta/0000-0003-2498-9768; Basanta, Marta Martin/0000-0003-2498-9768				Akasaka T, 1996, DEVELOPMENT, V122, P1513; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Bradley D, 1996, DEVELOPMENT, V122, P1535; BREEN TR, 1993, DEVELOPMENT, V117, P119; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; Carrington EA, 1996, DEVELOPMENT, V122, P4073; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; GRINDHART JGJ, 1995, GENETICS, V139, P797; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IRISH EE, 1991, DEVELOPMENT, V112, P891; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; JONES RS, 1990, GENETICS, V126, P185; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence PA, 1976, INSECT DEV, P132; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LIU ZC, 1995, DEVELOPMENT, V121, P975; LONG D, 1993, P NATL ACAD SCI USA, V90, P10370, DOI 10.1073/pnas.90.21.10370; LUTTKE HA, 1987, EMBO J, V6, P43; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; SIMCOX AA, 1983, DEV BIOL, V97, P212, DOI 10.1016/0012-1606(83)90078-7; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; SUTTON WD, 1984, SCIENCE, V223, P1265, DOI 10.1126/science.223.4642.1265; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Weigel D, 1996, CURR BIOL, V6, P10, DOI 10.1016/S0960-9822(02)00408-6; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	50	611	641	4	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					44	51		10.1038/386044a0	http://dx.doi.org/10.1038/386044a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052779				2022-12-28	WOS:A1997WL74600044
J	Allain, JP				Allain, JP			Screening blood donors for markers of new viruses	LANCET			English	Editorial Material											Allain, JP (corresponding author), UNIV CAMBRIDGE,DIV TRANSFUS MED,CAMBRIDGE CB2 2PT,ENGLAND.							Bigoni B, 1996, J INFECT DIS, V173, P542, DOI 10.1093/infdis/173.3.542; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9	6	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					584	585		10.1016/S0140-6736(97)22009-X	http://dx.doi.org/10.1016/S0140-6736(97)22009-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057724				2022-12-28	WOS:A1997WK91500002
J	Hanson, LC; Tulsky, JA; Danis, M				Hanson, LC; Tulsky, JA; Danis, M			Can clinical interventions change care at the end of life?	ANNALS OF INTERNAL MEDICINE			English	Review							CRITICALLY ILL PATIENTS; SELF-DETERMINATION ACT; RANDOMIZED CONTROLLED TRIAL; PROSPECTIVE PAYMENT SYSTEM; ADVANCE DIRECTIVES; SUSTAINING TREATMENTS; RESUSCITATION DECISIONS; RESOURCE UTILIZATION; ELDERLY PATIENTS; TERMINAL CARE	Purpose: To review clinical interventions designed to change care at the end of life. Data Sources: Published results of clinical trials identified by MEDLINE searches, review of abstracts from meetings, and selected bibliographies. Study Selection: Studies were included if data were presented on a clinical intervention designed to change medical care at the end of life. Studies done in nonclinical settings or outside the United States were excluded. Data Extraction: Interventions were classified as targeting patients, physicians, or both and were analyzed by their effect on four common clinical goals: increasing use of patient preferences, decreasing pain and suffering, reducing use of life-sustaining treatments, and reducing costs. Positive and negative trial results were compared for differences in intervention, target group, and strength of study methods. Data Synthesis: Educational interventions usually increased expression of patient treatment preferences. Success rates were higher when more severely ill patients were targeted and when written materials were combined with repeated discussions in clinical encounters. Educational interventions with physicians led to increased use of patient preferences, but sophisticated educational techniques were needed to motivate physicians to change their behavior. Three studies provided limited evidence that physician education reduced the use of life-sustaining treatments. No clinical intervention had an effect on pain, suffering, or cost of medical care. Conclusion: To change care at the end of life, intensive educational interventions for physicians and broad institutional programs seem more promising than advance directives. Future innovations should seek to change physician practices, reduce costs, and improve patient-centered out comes, such as pain control and satisfaction.	VET AFFAIRS MED CTR, DIV GEN MED, DURHAM, NC 27705 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hanson, LC (corresponding author), UNIV N CAROLINA, DIV GEN INTERNAL MED, CB 7110, 5035 OLD CLIN BLDG, CHAPEL HILL, NC 27599 USA.			Hanson, Laura/0000-0001-5120-6058	NATIONAL INSTITUTE ON AGING [P60AG011268] Funding Source: NIH RePORTER; NIA NIH HHS [5-P60-AG11268] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATES DW, 1988, WESTERN J MED, V148, P471; BLACKHALL LJ, 1989, J GEN INTERN MED, V4, P399, DOI 10.1007/BF02599689; CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; DALY BJ, 1991, HEART LUNG, V20, P45; Danis M, 1996, CRIT CARE MED, V24, P1811, DOI 10.1097/00003246-199611000-00009; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Davila F, 1996, ARCH INTERN MED, V156, P405; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DAWSON NJ, 1991, SOC SCI MED, V32, P83, DOI 10.1016/0277-9536(91)90131-U; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; EMANUEL EJ, 1993, AM J MED, V95, P619, DOI 10.1016/0002-9343(93)90358-V; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Fischer G. S., 1996, JGIM, V11, P115; FISCHER GS, 1996, J GEN INTERN MED S4, V10, P115; GAUMER GL, 1992, HEALTH SERV RES, V26, P725; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; Hanson LC, 1996, ARCH INTERN MED, V156, P1018, DOI 10.1001/archinte.156.9.1018; HANSON LC, 1994, AM J MED, V97, P235, DOI 10.1016/0002-9343(94)90006-X; Hanson LC, 1996, ARCH INTERN MED, V156, P785, DOI 10.1001/archinte.156.7.785; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; HESSE KA, 1995, ARCH INTERN MED, V155, P1513, DOI 10.1001/archinte.155.14.1513; HIGGINSON I, 1990, BRIT MED J, V301, P277, DOI 10.1136/bmj.301.6746.277; HIGH DM, 1993, GERONTOLOGIST, V33, P342, DOI 10.1093/geront/33.3.342; HOLLORAN SD, 1995, SURGERY, V118, P294, DOI 10.1016/S0039-6060(05)80337-X; KANE RL, 1984, LANCET, V1, P890; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; LAYSON RT, 1994, J CLIN ETHIC, V5, P195; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LUPTAK MK, 1994, GERONTOLOGIST, V34, P409; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; MAYEROAKES SA, 1988, JAMA-J AM MED ASSOC, V260, P3146, DOI 10.1001/jama.260.21.3146; MCCLISH DK, 1989, MED DECIS MAKING, V9, P125, DOI 10.1177/0272989X8900900207; Meier DE, 1996, J AM GERIATR SOC, V44, P37, DOI 10.1111/j.1532-5415.1996.tb05635.x; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; MILLER DK, 1992, J GEN INTERN MED, V7, P475, DOI 10.1007/BF02599446; MOLLOY DW, 1991, CAN MED ASSOC J, V145, P947; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; NIGHTINGALE SD, 1991, J GEN INTERN MED, V6, P420, DOI 10.1007/BF02598163; PERKINS HS, 1990, AM J MED, V89, P185, DOI 10.1016/0002-9343(90)90298-R; QUILL TE, 1992, ARCH INTERN MED, V152, P569, DOI 10.1001/archinte.152.3.569; RAPOPORT J, 1992, ARCH INTERN MED, V152, P2207, DOI 10.1001/archinte.152.11.2207; REILLY BM, 1995, ARCH INTERN MED, V155, P2202, DOI 10.1001/archinte.155.20.2202; REILLY BM, 1995, ARCH INTERN MED, V155, P2317, DOI 10.1001/archinte.155.21.2317; Richter K P, 1995, Arch Fam Med, V4, P609, DOI 10.1001/archfami.4.7.609; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SILVERMAN HJ, 1995, ARCH INTERN MED, V155, P502, DOI 10.1001/archinte.155.5.502; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; STARR TJ, 1986, J GEN INTERN MED, V1, P373, DOI 10.1007/BF02596420; Sullivan KE, 1996, CHEST, V109, P258, DOI 10.1378/chest.109.1.258; SULMASY DP, 1994, J GEN INTERN MED, V9, P622, DOI 10.1007/BF02600306; TENO JM, 1994, J CLIN ETHIC, V5, P23; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; VOLICER L, 1994, J AM GERIATR SOC, V42, P597, DOI 10.1111/j.1532-5415.1994.tb06856.x; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; YANO EM, 1995, ARCH INTERN MED, V155, P1146, DOI 10.1001/archinte.155.11.1146	65	130	132	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					381	388		10.7326/0003-4819-126-5-199703010-00007	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WL104	9054283				2022-12-28	WOS:A1997WL10400007
J	Jenkins, DR; Rees, JC; Pollitt, C; Cant, A; Craft, AW				Jenkins, DR; Rees, JC; Pollitt, C; Cant, A; Craft, AW			Lesson of the week: Mediterranean spotted fever mimicking Kawasaki disease	BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK	Jenkins, DR (corresponding author), ROYAL VICTORIA INFIRM,CLIN MICROBIOL & PUBL HLTH LAB,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.			Rees, Jon/0000-0002-3295-244X				BACELLAR F, 1991, EUR J EPIDEMIOL, V7, P291, DOI 10.1007/BF00145680; BELTRAN RR, 1992, EUR J CLIN MICROBIOL, V11, P427, DOI 10.1007/BF01961857; JACKSON JL, 1994, ARCH INTERN MED, V154, P1398, DOI 10.1001/archinte.154.12.1398; PARHA S, 1993, EUR J PEDIATR, V152, P1040, DOI 10.1007/BF01957233; RAOULT D, 1986, AM J TROP MED HYG, V35, P845, DOI 10.4269/ajtmh.1986.35.845; WALKER DH, 1991, EUR J EPIDEMIOL, V7, P237, DOI 10.1007/BF00145672; WALKER DH, 1992, AM J TROP MED HYG, V47, P78, DOI 10.4269/ajtmh.1992.47.78; 1982, LANCET, V2, P1441	8	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					655	656		10.1136/bmj.314.7081.655	http://dx.doi.org/10.1136/bmj.314.7081.655			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066481	Green Published			2022-12-28	WOS:A1997WL41800030
J	Finn, JT; Solessio, EC; Yau, KW				Finn, JT; Solessio, EC; Yau, KW			A cGMP-gated cation channel in depolarizing photoreceptors of the lizard parietal eye	NATURE			English	Article							SALAMANDER RETINAL RODS; GMP-ACTIVATED CHANNEL; CYCLIC-GMP; INVERTEBRATE PHOTORECEPTORS; DIVALENT-CATIONS; ION CHANNELS; PINEAL-GLAND; K+ CHANNELS; PERMEATION; CA2+	Rods and cones of the two vertebrate lateral eyes hyperpolarize when illuminated, a response generated by a cyclic GMP cascade leading to cGMP hydrolysis and consequently the closure of cGMP-gated, non-selective cation channels that are open in darkness(1-4). Lizards and other lower vertebrates also have a parietal (third) eye(5), which contains ciliary photoreceptors that under dark-adapted conditions depolarize to light instead(6). Depolarizing Light responses are characteristic of most invertebrate rhabdomeric photoreceptors, and are thought to involve a phosphoinositide signalling pathway (see, for example, refs 7-9). Surprisingly, we have found in excised membrane patches a cGMP-gated channel that is selectively present at high density on the outer segment (the presumptive light-sensitive part) of the parietal eye photoreceptor. Like the light-activated channel of the cell, it is non-selective among cations. Inositol trisphosphate (InsP(3)) had no effect on the same membrane patches. These findings suggest that the photoreceptors of the parietal eye, like rods and cones, use a cGMP cascade and not an InsP(3)-mediated pathway for phototransduction, but in this case light increases cGMP. A unifying principle of evolutionary significance emerges: that phototransductions in various ciliary photoreceptors, whether hyperpolarizing or depolarizing, uniformly use a cGMP cascade and a cGMP-gated channel to generate the Light response, although there are rich variations in the details.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,THOMAS C JENKINS DEPT BIOPHYS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; UNIV UTAH,HLTH SCI CTR,JOHN A MORAN EYE CTR,SALT LAKE CITY,UT 84132	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Utah System of Higher Education; University of Utah								AUTRUM H, 1979, HDB SENSORY PHYSL, V7; Bonigk W, 1996, J NEUROSCI, V16, P7458; BUTLER JN, 1968, BIOPHYS J, V8, P1426, DOI 10.1016/S0006-3495(68)86564-6; COLAMARTINO G, 1991, J PHYSIOL-LONDON, V440, P189, DOI 10.1113/jphysiol.1991.sp018703; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DRYER SE, 1991, NATURE, V353, P756, DOI 10.1038/353756a0; EAKIN RM, 1973, 3 EYE; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; FRINGS S, 1995, NEURON, V15, P169, DOI 10.1016/0896-6273(95)90074-8; GOMEZ M, IN PRESS J PHYSL LON; GOMEZ MD, 1995, NEURON, V15, P607, DOI 10.1016/0896-6273(95)90149-3; GOTOW T, 1994, BRAIN RES, V662, P268, DOI 10.1016/0006-8993(94)90824-9; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HAYNES LW, 1990, J PHYSIOL-LONDON, V429, P451, DOI 10.1113/jphysiol.1990.sp018267; HAYNES LW, 1995, J GEN PHYSIOL, V106, P507, DOI 10.1085/jgp.106.3.507; Hille B., 1992, IONIC CHANNELS EXCIT; KARPEN JW, 1992, J PHYSIOL-LONDON, V448, P257, DOI 10.1113/jphysiol.1992.sp019040; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MARCHIAFAVA PL, 1993, PROG BRAIN RES, V95, P3, DOI 10.1016/S0079-6123(08)60352-0; NEHER E, 1995, SINGLE CHANNEL RECOR, P637; PICONES A, 1995, BIOPHYS J, V69, P120, DOI 10.1016/S0006-3495(95)79881-2; PU GA, 1981, J NEUROPHYSIOL, V46, P1018, DOI 10.1152/jn.1981.46.5.1018; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Robinson R.A., 1959, ELECTROLYTE SOLUTION, DOI DOI 10.1073?PNAS.0305836101; SHIN JH, 1993, NEURON, V11, P845, DOI 10.1016/0896-6273(93)90114-7; SOLESSIO E, 1993, NATURE, V364, P442, DOI 10.1038/364442a0; TAMOTSU S, 1986, J COMP PHYSIOL A, V159, P1, DOI 10.1007/BF00612489; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	31	35	36	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					815	819		10.1038/385815a0	http://dx.doi.org/10.1038/385815a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039913				2022-12-28	WOS:A1997WK57000053
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			An 82-year-old woman with cataracts, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		OBSTBAUM SA, 1996, JAMA-J AM MED ASSOC, V275, P1675	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					669	669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039887				2022-12-28	WOS:A1997WJ49800037
J	Bruning, JC; Winnay, J; BonnerWeir, S; Taylor, SI; Accili, D; Kahn, CR				Bruning, JC; Winnay, J; BonnerWeir, S; Taylor, SI; Accili, D; Kahn, CR			Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles	CELL			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; DEPENDENT DIABETES-MELLITUS; BETA-CELL MASS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; SKELETAL-MUSCLE; KINASE-ACTIVITY; OBESE SUBJECTS; RESISTANCE; GENE	NIDDM is a polygenic disease characterized by insulin resistance in muscle, fat, and liver, followed by a failure of pancreatic beta cells to adequately compensate for this resistance despite increased insulin secretion. Mice double heterozygous for null alleles in the insulin receptor and insulin receptor substrate-1 genes exhibit the expected similar to 50% reduction in expression of these two proteins, but a synergism at a level of insulin resistance with 5- to 50-fold elevated plasma insulin levels and comparable levels of beta cell hyperplasia. At 4-6 months of age, 40% of these double heterozygotes become overtly diabetic. This NIDDM mouse model in which diabetes arises in an age-dependent manner from the interaction between two genetically determined, subclinical defects in the insulin signaling cascade demonstrates the role of epistatic interactions in the pathogenesis of common diseases with non-Mendelian genetics.	HARVARD UNIV,SCH MED,DIV RES,JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; NIDDK,DIABET BRANCH,NATL INST HLTH,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,NATL INST HLTH,BETHESDA,MD 20892	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044523, R01DK033201, R37DK031036, R01DK031036] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 31036, DK 44523, DK 33201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Almind K, 1996, J CLIN INVEST, V97, P2569, DOI 10.1172/JCI118705; ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BAR RS, 1976, J CLIN INVEST, V58, P1123, DOI 10.1172/JCI108565; BISBIS S, 1993, AM J PHYSIOL, V265, pE807, DOI 10.1152/ajpendo.1993.265.5.E807; BONNERWEIR S, 1994, RECENT PROG HORM RES, V49, P91; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; CLAUSEN JO, 1995, LANCET, V346, P397, DOI 10.1016/S0140-6736(95)92779-4; FLIER JS, 1992, DIABETES, V41, P1207, DOI 10.2337/diabetes.41.9.1207; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KAHN CR, 1973, J BIOL CHEM, V248, P244; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350; LAAKSO M, 1994, J CLIN INVEST, V94, P1141, DOI 10.1172/JCI117429; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MONTANA E, 1993, J CLIN INVEST, V91, P780, DOI 10.1172/JCI116297; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; OLEFSKY JM, 1982, AM J PHYSIOL, V243, pE15, DOI 10.1152/ajpendo.1982.243.1.E15; PARSONS JA, 1992, ENDOCRINOLOGY, V130, P1459, DOI 10.1210/en.130.3.1459; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; PRINCE MJ, 1981, DIABETES, V30, P596, DOI 10.2337/diabetes.30.7.596; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; SINHA MK, 1987, DIABETES, V36, P620, DOI 10.2337/diabetes.36.5.620; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; Ura S, 1996, DIABETOLOGIA, V39, P600; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; WARRAM JH, 1995, JOSLINS DIABETES MEL, P201; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WERTHEIMER E, 1993, NAT GENET, V5, P71, DOI 10.1038/ng0993-71; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	52	428	443	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					561	572		10.1016/S0092-8674(00)81896-6	http://dx.doi.org/10.1016/S0092-8674(00)81896-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038347	Bronze			2022-12-28	WOS:A1997WJ69100016
J	Jonkman, MF; Scheffer, H; Stulp, R; Pas, HH; Nijenhuis, M; Heeres, K; Owaribe, K; Pulkkinen, L; Uitto, J				Jonkman, MF; Scheffer, H; Stulp, R; Pas, HH; Nijenhuis, M; Heeres, K; Owaribe, K; Pulkkinen, L; Uitto, J			Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion	CELL			English	Article							SOMATIC REVERSION SUPPRESSION; PEMPHIGOID ANTIGEN; MECHANISMS; COLLAGEN; EXPRESSION; PHENOTYPE; MUTATIONS; BP180; CELLS	Mitotic gene conversion acting as reverse mutation has not been previously demonstrated in human. We report here that the revertant mosaicism of a compound heterozygous proband with an autosomal recessive genodermatosis, generalized atrophic benign epidermolysis bullosa, is caused by mitotic gene conversion of one of the two mutated COL17A1 alleles. Specifically, the maternal allele surrounding the mutation site on COL17A1 (1706delA) showed reversion of the mutation and loss of heterozygosity along a tract of at least 381 bp in revertant keratinocytes derived from clinically unaffected skin patches; the paternal mutation (R1226X) remained present in all cell samples. Revertant mosaicism represents a way of natural gene therapy.	UNIV GRONINGEN,DEPT MED GENET,NL-9713 AW GRONINGEN,NETHERLANDS; NAGOYA UNIV,SCH MED,DEPT BIOL MOL,NAGOYA,AICHI 46401,JAPAN; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL & CUTANEOUS BIOL,PHILADELPHIA,PA 19107	University of Groningen; Nagoya University; Jefferson University	Jonkman, MF (corresponding author), UNIV GRONINGEN HOSP,DEPT DERMATOL,NL-9700 RB GRONINGEN,NETHERLANDS.		Pas, Hendri H/G-9749-2011; Scheffer, Hans/E-4644-2012; Jonkman, Marcel F./H-4647-2011	Pas, Hendri H/0000-0001-8823-2591; Scheffer, Hans/0000-0002-2986-0915; 	NIAMS NIH HHS [P01-AR38923] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHRISTIANO AM, 1994, GENOMICS, V21, P160, DOI 10.1006/geno.1994.1238; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; Gangloff S, 1996, EMBO J, V15, P1715, DOI 10.1002/j.1460-2075.1996.tb00517.x; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Gatalica B, 1997, AM J HUM GENET, V60, P352; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JG, 1988, AM J HUM GENET, V43, P355; HAPPLE R, 1993, ARCH DERMATOL, V129, P1460, DOI 10.1001/archderm.129.11.1460; HINTNER H, 1982, ARCH DERMATOL, V118, P375, DOI 10.1001/archderm.118.6.375; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; Jonkman MF, 1996, ARCH DERMATOL, V132, P145, DOI 10.1001/archderm.132.2.145; JONKMAN MF, 1995, J CLIN INVEST, V95, P1345, DOI 10.1172/JCI117785; JONKMAN MF, 1992, J INVEST DERMATOL, V99, P489, DOI 10.1111/1523-1747.ep12616168; KLEIN CJ, 1992, AM J HUM GENET, V50, P950; KOURILSKY P, 1986, TRENDS GENET, V2, P60, DOI 10.1016/0168-9525(86)90179-4; KVITTINGEN EA, 1994, J CLIN INVEST, V94, P1657, DOI 10.1172/JCI117509; LI K, 1991, J BIOL CHEM, V266, P24064; LI KH, 1993, J BIOL CHEM, V268, P8825; McGrath JA, 1996, J INVEST DERMATOL, V106, P771, DOI 10.1111/1523-1747.ep12345821; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITRA R, 1994, KERATINOCYTE METHODS, P17; NISHIZAWA Y, 1993, J BIOCHEM-TOKYO, V113, P493, DOI 10.1093/oxfordjournals.jbchem.a124072; OWARIBE K, 1991, EXP CELL RES, V192, P622, DOI 10.1016/0014-4827(91)90084-8; PALLER AS, 1994, NEW ENGL J MED, V331, P1408, DOI 10.1056/NEJM199411243312103; Pas H H, 1995, Exp Dermatol, V4, P372, DOI 10.1111/j.1600-0625.1995.tb00062.x; Pohla-Gubo G, 1995, Exp Dermatol, V4, P199, DOI 10.1111/j.1600-0625.1995.tb00245.x; SHERRAT TG, 1993, AM J HUM GENET, V53, P1007; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; UNRAU P, 1995, J THEOR BIOL, V177, P73, DOI 10.1006/jtbi.1995.0226; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VANLEEUWEN F, 1989, P NATL ACAD SCI USA, V86, P6417, DOI 10.1073/pnas.86.16.6417	35	196	200	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					543	551		10.1016/S0092-8674(00)81894-2	http://dx.doi.org/10.1016/S0092-8674(00)81894-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038345	Bronze			2022-12-28	WOS:A1997WJ69100014
J	Martin, IG; Young, S; SueLing, H; Johnston, D				Martin, IG; Young, S; SueLing, H; Johnston, D			Delays in the diagnosis of oesophagogastric cancer: A consecutive case series	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LYMPH-NODE DISSECTION; GASTRIC-CANCER	Objectives: To examine the time taken to diagnose oesophageal or gastric cancer, identify the source of delay, and assess its clinical importance Design: Study of all new patients presenting to one surgical unit with carcinoma of the oesophagus or stomach. Setting: University department of surgery in a large teaching hospital. Subjects: 115 consecutive patients (70 men, mean age 66 years) with carcinoma of the oesophagus (27) or stomach (88). Main outcome measures: Interval from the onset of symptoms to histological diagnosis, final pathological stage of the tumour, and whether potentially curative resection was possible. Results: The median delay from first symptoms to histological diagnosis was 17 weeks (range 1 to 168 weeks). 25% (29/115) of patients had a delay of over 28 weeks (median 39 weeks). Total delay was made up of the following components: delay in consulting a doctor (29%, delay in referral (23%), delay in being seen at hospital (16%), and delay in establishing the diagnosis at the hospital (32%). No relation was found between delay in diagnosis and tumour stage in patients with gastric cancer, but for oesophageal cancer those with stage I and II disease were diagnosed within 7 weeks compared with 21 weeks (P<0.02) for those with stage III and IV disease. Conclusions: Long delays still occur in the diagnosis of patients with cancer of the stomach or oesophagus. Streamlined referral and investigation pathways are needed if patients with gastric and oesophageal carcinomas are to be diagnosed early in the course of the disease.			Martin, IG (corresponding author), GEN INFIRM, CTR DIGEST DIS, DEPT SURG, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND.							AKIYAMA H, 1994, ANN SURG, V220, P364, DOI 10.1097/00000658-199409000-00012; ALLUM WH, 1989, BRIT J SURG, V76, P535, DOI 10.1002/bjs.1800760604; *COMM TNM CLASS, 1987, TNM CLASS MAL TUM, P40; Gear M W, 1980, Br Med J, V280, P1135; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; Haruma K, 1988, Gan No Rinsho, V34, P183; HAUGSTVEDT TK, 1991, SCAND J GASTROENTERO, V26, P611, DOI 10.3109/00365529109043635; ISONO K, 1991, ONCOLOGY, V48, P411; *JAP RES SOC GASTR, 1995, TREATM RES GASTR CAR; KENNEDY BJ, 1987, SCAND J GASTROENTERO, V22, P11, DOI 10.3109/00365528709091007; KOHLI Y, 1981, J CLIN GASTROENTEROL, V3, P129, DOI 10.1097/00004836-198106000-00005; MAY J, 1994, GUT, V35, pS14; POTHE H, 1975, ARCH GESCHWULSTFORSC, V45, P545; SUELING HM, 1992, GUT, V33, P1318, DOI 10.1136/gut.33.10.1318; SUELING HM, 1993, BMJ-BRIT MED J, V307, P591, DOI 10.1136/bmj.307.6904.591	15	93	93	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	1997	314	7079					467	470		10.1136/bmj.314.7079.467	http://dx.doi.org/10.1136/bmj.314.7079.467			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056794	Green Published			2022-12-28	WOS:A1997WJ41900021
J	Guarente, L				Guarente, L			Aging - What makes us tick	SCIENCE			English	Editorial Material							GENE				Guarente, L (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.							Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Finch CE, 1990, LONGEVITY SENESCENCE; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; PROFT M, 1996, EMBO J, V86, P9; SUN JY, 1994, J BIOL CHEM, V269, P18638; WONG A, 1995, GENETICS, V139, P1247; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	12	17	19	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					943	944		10.1126/science.275.5302.943	http://dx.doi.org/10.1126/science.275.5302.943			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9053999				2022-12-28	WOS:A1997WH38800034
J	Rabkin, CS; Janz, S; Lash, A; Coleman, AE; Musaba, E; Liotta, L; Biggar, RJ; Zhuang, ZP				Rabkin, CS; Janz, S; Lash, A; Coleman, AE; Musaba, E; Liotta, L; Biggar, RJ; Zhuang, ZP			Monoclonal origin of multicentric Kaposi's sarcoma lesions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							X-CHROMOSOME INACTIVATION; SPINDLE CELLS; CULTURE; VIRUS; BLOOD	Background Kaposi's sarcoma has features of both hyperplastic proliferation and neoplastic growth. Multiple lesions, in which spindle cells are prominent, often arise synchronously over widely dispersed areas. We tested the hypothesis that the spindle cells in these multicentric lesions originate from a single clone of precursor cells. Methods To determine whether Kaposi's sarcoma is a monoclonal disorder, we assessed the methylation patterns of the androgen-receptor gene (HUMARA) in multiple lesions from women with the acquired immunodeficiency syndrome. In polyclonal tissues, about half the copies of each HUMARA allele are methylated, whereas in cells derived from a single clone all the copies of only one allele are methylated. To minimize contamination by normal DNA, we used microdissection to isolate areas composed primarily of spindle cells, the putative tumor cells. Results Eight patients with a total of 32 tumors were studied. Of these tumors, 28 had highly unbalanced methylation patterns (i.e., predominant methylation of one HUMARA allele). In all the tumors that had unbalanced methylation from a given patient, the same allele predominated. Conclusions These data indicate that Kaposi's sarcoma is a disseminated monoclonal cancer and that the changes that permit the clonal outgrowth of spindle cells occur before the disease spreads. (C) 1997, Massachusetts Medical Society.	NCI,GENET LAB,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892; UNIV TEACHING HOSP,LUSAKA,ZAMBIA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Zambia	Rabkin, CS (corresponding author), NCI,VIRAL EPIDEMIOL BRANCH,EPN 434,BETHESDA,MD 20892, USA.			Lash, Alex/0000-0003-3787-1590				ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BROWNING PJ, 1994, BLOOD, V84, P2711, DOI 10.1182/blood.V84.8.2711.bloodjournal8482711; DICTOR M, 1991, ANAL QUANT CYTOL, V13, P201; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FIALKOW PJ, 1970, LANCET, V1, P384; FUKUNAGA M, 1990, CANCER-AM CANCER SOC, V66, P758, DOI 10.1002/1097-0142(19900815)66:4<758::AID-CNCR2820660427>3.0.CO;2-H; GALE RE, 1994, BLOOD, V83, P2899, DOI 10.1182/blood.V83.10.2899.2899; Jacobson Lisa P., 1995, Current Opinion in Oncology, V7, P450, DOI 10.1097/00001622-199509000-00011; KAAYA EE, 1992, EUR J CANCER, V28A, P1890, DOI 10.1016/0959-8049(92)90030-6; KAAYA EE, 1995, J ACQ IMMUN DEF SYND, V10, P295; KOSTIANOVSKY M, 1992, ULTRASTRUCT PATHOL, V16, P629, DOI 10.3109/01913129209023752; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MULLER JR, 1995, P NATL ACAD SCI USA, V92, P6577, DOI 10.1073/pnas.92.14.6577; NADJI M, 1981, ARCH PATHOL LAB MED, V105, P274; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RABKIN CS, 1995, CLIN CANCER RES, V1, P257; SAFAI B, 1992, AIDS ETIOLOGY DIAGNO, P209; SAIKEVYCH IA, 1988, ARCH PATHOL LAB MED, V112, P825; VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303; Zhuang ZP, 1996, CANCER RES, V56, P1961; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	23	179	185	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	1997	336	14					988	993		10.1056/NEJM199704033361403	http://dx.doi.org/10.1056/NEJM199704033361403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR385	9077377	Bronze			2022-12-28	WOS:A1997WR38500003
J	Hayward, TL; Hanner, MS				Hayward, TL; Hanner, MS			Ground-based thermal infrared observations of comet Hale-Bopp (C/1995 O1) during 1996	SCIENCE			English	Article							EMISSION; GRAINS	Thermal infrared (IR) imaging and spectroscopy of comet Hale-Bopp (C/1995 O1) during June, August, and September 1996 traced the development of the dust coma several months before perihelion, Images revealed nightly variations in the brightness of the inner coma from 1 to 12 June that were correlated with the appearance of a northward-pointing jet. The central IR flux increased by a factor of 8 between 1 June and 30 September, and the September data showed IR jets that corresponded to similar structures that were visible in reflected sunlight at shorter wavelengths. At all epochs, 8- to 13-micrometer spectra of the central coma revealed a strong silicate emission feature, including an 11.2-micrometer feature indicative of crystalline olivine, even when the comet was at a heliocentric distance of 4.1 astronomical units.	CALTECH,JET PROP LAB,PASADENA,CA 91109	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Hayward, TL (corresponding author), CORNELL UNIV,CTR RADIOPHYS & SPACE RES,ITHACA,NY 14853, USA.							AHEARN MF, 1984, ASTRON J, V89, P570; BREGMAN JD, 1987, ASTRON ASTROPHYS, V187, P616; CAMPINS H, 1989, ASTROPHYS J, V341, P1059, DOI 10.1086/167563; HANNER MS, 1994, ASTROPHYS J, V425, P274, DOI 10.1086/173984; HANNER MS, 1994, ICARUS, V112, P490, DOI 10.1006/icar.1994.1200; HANNER MS, 1986, ICARUS, V67, P51, DOI 10.1016/0019-1035(86)90173-9; HAYWARD TL, 1993, P SOC PHOTO-OPT INS, V1946, P334, DOI 10.1117/12.158686; LYNCH DK, 1992, ICARUS, V100, P197, DOI 10.1016/0019-1035(92)90029-7; MORRIS CS, 1993, ASTRON J, V105, P1537, DOI 10.1086/116533; RUSSELL RW, 6448 IAU	10	42	42	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1907	1909		10.1126/science.275.5308.1907	http://dx.doi.org/10.1126/science.275.5308.1907			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072961				2022-12-28	WOS:A1997WQ51300036
J	Bernard, GR; Wheeler, AP; Russell, JA; Schein, R; Summer, WR; Steinberg, KP; Fulkerson, WJ; Wright, PE; Christman, BW; Dupont, WD; Higgins, SB; Swindell, BB				Bernard, GR; Wheeler, AP; Russell, JA; Schein, R; Summer, WR; Steinberg, KP; Fulkerson, WJ; Wright, PE; Christman, BW; Dupont, WD; Higgins, SB; Swindell, BB			The effects of ibuprofen on the physiology and survival of patients with sepsis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; ESCHERICHIA-COLI ENDOTOXIN; ANTI-INFLAMMATORY DRUGS; CRITICALLY ILL PATIENTS; SEPTIC SHOCK; CLINICAL-TRIALS; RENAL-FUNCTION; METHYLPREDNISOLONE; INDOMETHACIN; SHEEP	Background In patients with sepsis the production of arachidonic acid metabolites by cyclooxygenase increases, but the pathophysiologic role of these prostaglandins is unclear. In animal models, inhibition of cyclooxygenase by treatment with ibuprofen before the onset of sepsis reduces physiologic abnormalities and improves survival. In pilot studies of patients with sepsis, treatment with ibuprofen led to improvements in gas exchange and airway mechanics. Methods From October 1989 to March 1995, we conducted a randomized, double-blind, placebo-controlled trial of intravenous ibuprofen (10 mg per kilogram of body weight [maximal dose, 800 mg], given every six hours for eight doses) in 455 patients who had sepsis, defined as fever, tachycardia, tachypnea, and acute failure of at least one organ system. Results In the ibuprofen group, but not the placebo group, there were significant declines in urinary levels of prostacyclin and thromboxane, temperature, heart rate, oxygen consumption, and lactic acidosis. With ibuprofen therapy there was no increased incidence of renal dysfunction, gastrointestinal bleeding, or other adverse events. However, treatment with ibuprofen did not reduce the incidence or duration of shock or the acute respiratory distress syndrome and did not significantly improve the rate of survival at 30 days (mortality, 37 percent with ibuprofen vs. 40 percent with placebo). Conclusions In patients with sepsis, treatment with ibuprofen reduces levels of prostacyclin and thromboxane and decreases fever, tachycardia, oxygen consumption, and lactic acidosis, but it does not prevent the development of shock or the acute respiratory distress syndrome and does not improve survival. (N EnglJ Med 1997;336:912-8.) (C) 1997, Massachusetts Medical Society.	VANDERBILT UNIV, MED CTR, DIV PULM & CRIT CARE MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, DIV BIOSTAT, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, DIV BIOMED ENGN & COMP, NASHVILLE, TN 37232 USA; UNIV BRITISH COLUMBIA, VANCOUVER, BC V5Z 1M9, CANADA; ST PAULS HOSP, DEPT MED, PROGRAM CRIT CARE MED, VANCOUVER, BC V6Z 1Y6, CANADA; UNIV MIAMI, SCH MED, MIAMI, FL USA; DEPT VET AFFAIRS MED CTR, MIAMI, FL USA; LOUISIANA STATE UNIV, MED CTR, DEPT PULM & CRIT CARE MED, NEW ORLEANS, LA USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DIV PULM & CRIT CARE MED, SEATTLE, WA 98104 USA; DUKE UNIV, MED CTR, DIV PULM & CRIT CARE MED, DURHAM, NC USA; METHODIST HOSP, DIV PULM MED, INDIANAPOLIS, IN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of British Columbia; St. Paul's Hospital; University of Saskatchewan; University of Miami; Louisiana State University System; Harborview Medical Center; University of Washington; University of Washington Seattle; Duke University; Indiana University System			Dupont, William D./I-4430-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019153, R01HL043167] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 19153, HL 07123, HL 43167] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMQVIST PM, 1984, CIRC SHOCK, V14, P129; Armitage P., 2001, STAT METHODS MED RES; BERNARD GR, 1991, AM REV RESPIR DIS, V144, P1095, DOI 10.1164/ajrccm/144.5.1095; Bernard GR, 1995, AM J RESP CRIT CARE, V151, pA323; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CHRISTMAN BW, 1993, J IMMUNOL, V151, P2096; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; DELMAS PD, 1995, BRIT J RHEUMATOL, V34, P25; FINK MP, 1984, ANN SURG, V200, P619, DOI 10.1097/00000658-198411000-00011; FINK MP, 1984, J SURG RES, V36, P516, DOI 10.1016/0022-4804(84)90135-5; FLEISS JL, 1981, STATISTICAL METHODS, P13; Fletcher J R, 1980, Adv Prostaglandin Thromboxane Res, V7, P821; FLETCHER JR, 1977, BRIT J PHARMACOL, V61, P175, DOI 10.1111/j.1476-5381.1977.tb08402.x; GALT SW, 1991, J VASC SURG, V13, P876; HALPERIN M, 1982, CONTROL CLIN TRIALS, V3, P311, DOI 10.1016/0197-2456(82)90022-8; HALUSHKA PV, 1985, CRIT CARE MED, V13, P451, DOI 10.1097/00003246-198506000-00001; HANLY PJ, 1987, LANCET, V1, P351; Harris R H, 1980, Adv Prostaglandin Thromboxane Res, V7, P843; HAUPT MT, 1991, CRIT CARE MED, V19, P1339, DOI 10.1097/00003246-199111000-00006; HINSHAW LB, 1967, J PHARMACOL EXP THER, V157, P665; HUBBARD HL, 1987, PROSTAGLANDINS, V33, P149, DOI 10.1016/0090-6980(87)90002-5; HUVAL WV, 1984, ANN SURG, V199, P216, DOI 10.1097/00000658-198402000-00015; JACOBS ER, 1982, J CLIN INVEST, V70, P536, DOI 10.1172/JCI110645; KOPOLOVIC R, 1986, SURGERY, V100, P679; LATOUR D, 1994, GETTING STARTED PROC; LOCKWOOD GF, 1982, J CHROMATOGR, V232, P335, DOI 10.1016/S0378-4347(00)84173-0; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MIZUS I, 1983, CRIT CARE MED, V11, P241; NORTHOVER BJ, 1962, J PATHOL BACTERIOL, V83, P463, DOI 10.1002/path.1700830217; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PARRATT JR, 1975, J PHYSIOL-LONDON, V246, pP79; PARRATT JR, 1975, BRIT J PHARMACOL, V53, P485, DOI 10.1111/j.1476-5381.1975.tb07384.x; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PERKOWSKI SZ, 1983, CIRC RES, V53, P574, DOI 10.1161/01.RES.53.5.574; PHANG PT, 1994, AM J RESP CRIT CARE, V150, P318, DOI 10.1164/ajrccm.150.2.8049809; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; REINES HD, 1982, LANCET, V2, P174; RINALDO JE, 1986, AM J MED SCI, V291, P29, DOI 10.1097/00000441-198601000-00007; RINALDO JE, 1985, CIRC SHOCK, V16, P195; SAS Institute, 1992, SAS STAT SOFTW CHANG; SIELAFF TD, 1987, SURGERY, V102, P350; SNAPPER JR, 1983, J CLIN INVEST, V72, P63, DOI 10.1172/JCI110985; SOULSBY ME, 1984, PROSTA LEUKOTR MED, V13, P295, DOI 10.1016/0262-1746(84)90043-X; WARE JH, 1985, AM J MED, V78, P635, DOI 10.1016/0002-9343(85)90407-3; WRIGHT PE, 1989, AM REV RESPIR DIS, V140, P672, DOI 10.1164/ajrccm/140.3.672	47	560	580	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	1997	336	13					912	918		10.1056/NEJM199703273361303	http://dx.doi.org/10.1056/NEJM199703273361303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP832	9070471				2022-12-28	WOS:A1997WP83200003
J	Rubinfeld, B; Robbins, P; ElGamil, M; Albert, I; Porfiri, E; Polakis, P				Rubinfeld, B; Robbins, P; ElGamil, M; Albert, I; Porfiri, E; Polakis, P			Stabilization of beta-catenin by genetic defects in melanoma cell lines	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; ADHESION; EXPRESSION; CADHERIN; PROTEIN; PRODUCT; WNT-1	Signal transduction by beta-catenin involves its posttranslational stabilization and downstream coupling to the Lef and Tcf transcription factors, Abnormally high amounts of beta-catenin were detected in 7 of 26 human melanoma cell lines, Unusual messenger RNA splicing and missense mutations in the beta-catenin gene (CTNNB1) that result in stabilization of the protein were identified in six of the lines, and the adenomatous polyposis coli tumor suppressor protein (APC) was altered or missing in two others, In the APC-deficient cells, ectopic expression of wild-type APC eliminated the excess beta-catenin, Cells with stabilized beta-catenin contained a constitutive beta-catenin-Lef-1 complex, Thus, genetic defects that result in up-regulation of beta-catenin may play a role in melanoma progression.	ONYX PHARMACEUT,RICHMOND,CA 94806; NCI,SURG BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Rubinfeld, Bonnee/0000-0001-9861-6775	NCI NIH HHS [1R43CA69931] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA069931] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, UNPUB; TOPALIAN SL, 1989, J IMMUNOL, V142, P3714; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	22	1116	1176	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1790	1792		10.1126/science.275.5307.1790	http://dx.doi.org/10.1126/science.275.5307.1790			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065403				2022-12-28	WOS:A1997WP05600041
J	Wood, CS; Bennett, SC; Cho, D; Masterson, BP; Roberts, JL; Tanner, CE; Wieman, CE				Wood, CS; Bennett, SC; Cho, D; Masterson, BP; Roberts, JL; Tanner, CE; Wieman, CE			Measurement of parity nonconservation and an anapole moment in cesium	SCIENCE			English	Article							ELECTRON NUCLEUS INTERACTION; WEAK NEUTRAL CURRENTS; ATOMIC CESIUM; OPTICAL-ROTATION; PRECISION-MEASUREMENT; VIOLATION; PHYSICS; TRANSITION; BEAM; PERTURBATION	The amplitude of the parity-nonconserving transition between the 6S and 7S states of cesium was precisely measured with the use of a spin-polarized atomic beam. This measurement gives Im(E1(pnc))/beta = -1.5935(56) millivolts per centimeter and provides an improved test of the standard model at low energy, including a value for the S parameter of -1.3(3)(exp)(11)(theory). The nuclear spin-dependent contribution was 0.077(11) millivolts per centimeter; this contribution is a manifestation of parity violation in atomic nuclei and is a measurement of the long-sought anapole moment.	JOINT INST LAB ASTROPHYS,BOULDER,CO 80309; UNIV COLORADO,DEPT PHYS,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder				Roberts, Jacob/0000-0002-6243-9233				BLUNDELL SA, 1992, PHYS REV D, V45, P1602, DOI 10.1103/PhysRevD.45.1602; BOUCHIAT C, 1991, Z PHYS C PART FIELDS, V49, P91, DOI 10.1007/BF01570800; BOUCHIAT C, 1991, PHYS LETT B, V269, P195, DOI 10.1016/0370-2693(91)91474-A; BOUCHIAT MA, 1974, J PHYS-PARIS, V35, P899, DOI 10.1051/jphys:019740035012089900; BOUCHIAT MA, 1975, J PHYS-PARIS, V36, P493, DOI 10.1051/jphys:01975003606049300; BOUCHIAT MA, 1986, J PHYS-PARIS, V47, P1709, DOI 10.1051/jphys:0198600470100170900; BOUCHIAT MA, 1981, J PHYS-PARIS, V42, P985, DOI 10.1051/jphys:01981004207098500; Cho D, 1997, PHYS REV A, V55, P1007, DOI 10.1103/PhysRevA.55.1007; DMITRIEV VF, 1994, NUCL PHYS A, V577, P691, DOI 10.1016/0375-9474(94)90940-7; DREVER RWP, 1983, APPL PHYS B-PHOTO, V31, P97, DOI 10.1007/BF00702605; DZUBA VA, 1989, PHYS LETT A, V141, P147, DOI 10.1016/0375-9601(89)90777-9; EDWARDS NH, 1995, PHYS REV LETT, V74, P2654, DOI 10.1103/PhysRevLett.74.2654; Flambaum V. V, 1980, JETP, V52, P835; FRANTSUZOV PA, 1988, Z PHYS D ATOM MOL CL, V7, P297, DOI 10.1007/BF01439798; GILBERT SL, 1986, PHYS REV A, V34, P792, DOI 10.1103/PhysRevA.34.792; GILBERT SL, 1985, PHYS REV LETT, V55, P2680, DOI 10.1103/PhysRevLett.55.2680; HAXTON WC, 1989, PHYS REV LETT, V63, P949, DOI 10.1103/PhysRevLett.63.949; HEMMER PR, 1993, J OPT SOC AM B, V10, P1326, DOI 10.1364/JOSAB.10.001326; KOZLOV MG, 1988, PHYS LETT A, V130, P426, DOI 10.1016/0375-9601(88)90702-5; KRAFTMAKHER AY, 1988, PHYS LETT A, V132, P167, DOI 10.1016/0375-9601(88)90276-9; LANGACKER P, 1992, REV MOD PHYS, V64, P87, DOI 10.1103/RevModPhys.64.87; MACPHERSON MJD, 1991, PHYS REV LETT, V67, P2784, DOI 10.1103/PhysRevLett.67.2784; MAHANTHAPPA KT, 1991, PHYS REV D, V43, P3093, DOI 10.1103/PhysRevD.43.3093; MARCIANO WJ, 1990, PHYS REV LETT, V65, P2963, DOI 10.1103/PhysRevLett.65.2963; MASTERSON BP, 1993, PHYS REV A, V47, P2139, DOI 10.1103/PhysRevA.47.2139; MEEKHOF DM, 1993, PHYS REV LETT, V71, P3442, DOI 10.1103/PhysRevLett.71.3442; NOECKER MC, 1988, PHYS REV LETT, V61, P310, DOI 10.1103/PhysRevLett.61.310; ROSNER J, 1995, PHYS REV D, V53, P2724; SAPIRSTEIN J, 1995, ATOMIC PHYSICS, V14; SUSHKOV OP, 1984, PHYS LETT B, V146, P367; VETTER PA, 1995, PHYS REV LETT, V74, P2658, DOI 10.1103/PhysRevLett.74.2658; WIEMAN CE, 1991, REV SCI INSTRUM, V62, P1, DOI 10.1063/1.1142305; WIEMAN CE, 1987, PHYS REV LETT, V58, P1438; WIEMAN CE, 1994, FRONTIERS LASER SPEC; WU CS, 1957, PHYS REV, V105, P1413, DOI 10.1103/PhysRev.105.1413; Zeldovich Ya. B., 1958, ZH EKSP TEOR FIZ, V6, P1184; 1993, PHYS LETT B, V307, P187	37	956	961	5	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1759	1763		10.1126/science.275.5307.1759	http://dx.doi.org/10.1126/science.275.5307.1759			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065393				2022-12-28	WOS:A1997WP05600031
J	Kremer, H				Kremer, H			A medical mystery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Kremer, H (corresponding author), KREISKRANKENHAUS FUSSEN,D-87629 FUSSEN,GERMANY.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					846	846		10.1056/NEJM199703203361206	http://dx.doi.org/10.1056/NEJM199703203361206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN371	9062094				2022-12-28	WOS:A1997WN37100006
J	deKretser, DM				deKretser, DM			Male infertility	LANCET			English	Article							CYSTIC-FIBROSIS GENE; HUMAN Y-CHROMOSOME; CONGENITAL ABSENCE; VAS-DEFERENS; INVITRO FERTILIZATION; YOUNGS SYNDROME; HUMAN-SPERM; SPERMATOGENESIS; AZOOSPERMIA; MORPHOLOGY				deKretser, DM (corresponding author), MONASH UNIV, MONASH MED CTR, MONASH INST REPROD & DEV, CLAYTON, VIC 3168, AUSTRALIA.							ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; [Anonymous], 1990, Lancet, V336, P955; Baker H W, 1983, Clin Reprod Fertil, V2, P55; BAKER HWG, 1994, ENDOCRINOLOGY, P2404; BELKER AM, 1991, J UROLOGY, V145, P505, DOI 10.1016/S0022-5347(17)38381-7; BROMWICH P, 1994, BRIT MED J, V309, P19, DOI 10.1136/bmj.309.6946.19; CARSEN E, 1992, BRIT MED J, V305, P332; CHEHVAL MJ, 1992, FERTIL STERIL, V57, P174; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; CLARKE GN, 1985, AM J REPROD IM MIC, V7, P118; COMHAIRE FH, 1987, INT J ANDROL, pR3; DEKRETSE.DM, 1974, J CLIN ENDOCR METAB, V38, P787, DOI 10.1210/jcem-38-5-787; DEKRETSER DM, 1985, CLIN OBSTET GYNAECOL, V12, P767; deKretser DM, 1996, BRIT MED J, V312, P457, DOI 10.1136/bmj.312.7029.457; DEKRETSER DM, 1996, REPRODUCTIVE ENDOCRI, P2030; Fisch H, 1996, FERTIL STERIL, V65, P1009, DOI 10.1016/S0015-0282(16)58278-8; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FRIEDMAN KJ, 1995, AM J RESP CRIT CARE, V152, P1353, DOI 10.1164/ajrccm.152.4.7551394; GERVAIS R, 1993, NEW ENGL J MED, V328, P446, DOI 10.1056/NEJM199302113280619; HANDELSMAN DJ, 1984, NEW ENGL J MED, V310, P3, DOI 10.1056/NEJM198401053100102; HAUSER R, 1995, FERTIL STERIL, V63, P631, DOI 10.1016/S0015-0282(16)57437-8; HENDRY WF, 1993, BMJ-BRIT MED J, V307, P1579, DOI 10.1136/bmj.307.6919.1579; HENRY WF, 1990, LANCET, V335, P85; JEQUIER AM, 1985, J ANDROL, V6, P15; KRUGER TF, 1988, FERTIL STERIL, V49, P112; LIU DY, 1992, FERTIL STERIL, V58, P465; LIU DY, 1988, FERTIL STERIL, V50, P288; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MAHADEVAN MM, 1983, FERTIL STERIL, V40, P755; MARRS RP, 1983, AM J OBSTET GYNECOL, V146, P477, DOI 10.1016/0002-9378(83)90783-4; MEACHAM RB, 1993, FERTIL STERIL, V59, P393; Najmabadi H, 1996, J CLIN ENDOCR METAB, V81, P1347, DOI 10.1210/jc.81.4.1347; OEHNINGER S, 1992, REPRODUCTIVE MED REV, V1, P57; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAID SA, 1992, FERTIL STERIL, V57, P1289; SILBER SJ, 1990, NEW ENGL J MED, V323, P1788, DOI 10.1056/NEJM199012273232602; SILBER SJ, 1995, REPROD FERT DEVELOP, V7, P281, DOI 10.1071/RD9950281; SOUTHWICK G J, 1988, Microsurgery, V9, P266, DOI 10.1002/micr.1920090412; STILLMAN RJ, 1982, AM J OBSTET GYNECOL, V142, P905, DOI 10.1016/S0002-9378(16)32540-6; TEMPLE-SMITH P D, 1985, Journal of In Vitro Fertilization and Embryo Transfer, V2, P119, DOI 10.1007/BF01131497; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; TOURNAYE H, 1995, REPROD FERT DEVELOP, V7, P269, DOI 10.1071/RD9950269; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; VOGT P, 1992, HUM GENET, V89, P491; WILTON LJ, 1991, FERTIL STERIL, V55, P144; WILTON LJ, 1988, FERTIL STERIL, V49, P1052; Yanagimachi R., 1994, P189	49	312	324	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	1997	349	9054					787	790		10.1016/S0140-6736(96)08341-9	http://dx.doi.org/10.1016/S0140-6736(96)08341-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074589				2022-12-28	WOS:A1997WN12400043
J	Swerdlow, DL; Griffin, PM				Swerdlow, DL; Griffin, PM			Duration of faecal shedding of Escherichia coli O157:H7 among children in day-care centres	LANCET			English	Editorial Material							HEMOLYTIC-UREMIC SYNDROME				Swerdlow, DL (corresponding author), CTR DIS CONTROL & PREVENT,FOODBOME & DIARRHOEAL DIS BRANCH,ATLANTA,GA 30333, USA.							BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BENENSON AS, 1995, CONTROL COMMUNICABLE, P141; BOYCE TG, 1995, NEW ENGL J MED, V333, P364, DOI 10.1056/NEJM199508103330608; *CDCP, 1996, ABCS SAF HLTH CHILD; CHAPMAN PA, 1994, J MED MICROBIOL, V40, P424, DOI 10.1099/00222615-40-6-424; KARCH H, 1995, J CLIN MICROBIOL, V33, P1602, DOI 10.1128/JCM.33.6.1602-1605.1995; PAI CH, 1988, J INFECT DIS, V157, P1054, DOI 10.1093/infdis/157.5.1054; Shah S, 1996, CLIN INFECT DIS, V23, P835, DOI 10.1093/clinids/23.4.835; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983	10	30	32	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					745	746		10.1016/S0140-6736(05)60196-1	http://dx.doi.org/10.1016/S0140-6736(05)60196-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074570				2022-12-28	WOS:A1997WN12400005
J	Kirschvink, JL; Maine, AT; Vali, H				Kirschvink, JL; Maine, AT; Vali, H			Paleomagnetic evidence of a low-temperature origin of carbonate in the Martian meteorite ALH84001	SCIENCE			English	Article							MAGNETIC-PROPERTIES; NATURAL PYRRHOTITE; SNC METEORITES; GRAIN-SIZE; BEHAVIOR; MARS	Indirect evidence for life on Mars has been reported from the study of meteorite ALH84001. The formation temperature of the carbonates is controversial; some estimates suggest 20 degrees to 80 degrees C, whereas others exceed 650 degrees C. Paleomagnetism can be used to distinguish between these possibilities because heating can remagnetize ferrimagnetic minerals. Study of two adjacent pyroxene grains from the crushed zone of ALH84001 shows that each possesses a stable natural remanent magnetization (NRM), implying that Mars had a substantial magnetic field when the grains cooled. However, NRM directions from these particles differ, implying that the meteorite has not been heated significantly since the formation of the internal crushed zone about 4 billion years ago. The carbonate globules postdate this brecciation, and thus formed at low temperatures.	MCGILL UNIV,DEPT EARTH & PLANETARY SCI,MONTREAL,PQ H3A 2A7,CANADA	McGill University	Kirschvink, JL (corresponding author), CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125, USA.		Vali, Hojatollah/F-3511-2012	Vali, Hojatollah/0000-0003-3464-9943				Ash RD, 1996, NATURE, V380, P57, DOI 10.1038/380057a0; Bradley JP, 1996, GEOCHIM COSMOCHIM AC, V60, P5149, DOI 10.1016/S0016-7037(96)00383-3; Butler R.F., 1992, PALEOMAGNETISM MAGNE; CISOWSKI S, 1981, PHYS EARTH PLANET IN, V26, P56, DOI 10.1016/0031-9201(81)90097-2; CISOWSKI SM, 1986, GEOCHIM COSMOCHIM AC, V50, P1043, DOI 10.1016/0016-7037(86)90386-8; COLLINSON DW, 1986, EARTH PLANET SC LETT, V77, P159, DOI 10.1016/0012-821X(86)90157-3; DEKKERS MJ, 1988, PHYS EARTH PLANET IN, V52, P376, DOI 10.1016/0031-9201(88)90129-X; DEKKERS MJ, 1989, PHYS EARTH PLANET IN, V57, P266, DOI 10.1016/0031-9201(89)90116-7; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; GRIFFITH LL, 1995, NATURE, V377, P406, DOI 10.1038/377406a0; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; JAGOUTZ E, 1994, METEORITICS, V29, P478; JOHNSON HP, 1975, GEOPHYS J ROY ASTR S, V41, P1, DOI 10.1111/j.1365-246X.1975.tb05480.x; Kirschvink J. L., 1983, BIOMAGNETISM, P501; KIRSCHVINK JL, 1980, GEOPHYS J ROY ASTR S, V62, P699, DOI 10.1111/j.1365-246X.1980.tb02601.x; MANN S, 1988, J EXP BIOL, V140, P35; MCFADDEN PL, 1988, EARTH PLANET SC LETT, V87, P161, DOI 10.1016/0012-821X(88)90072-6; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; NYQUIST LE, 1995, LUNAR PLANET SCI, V26, P1065; O'Reilly W, 1984, ROCK MINERAL MAGNETI; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; RUNCORN SK, 1996, GEOCHIM COSMOCHIM AC, V60, P1206; Shearer CK, 1996, GEOCHIM COSMOCHIM AC, V60, P2921, DOI 10.1016/0016-7037(96)00165-2; SWINDLE TD, 1995, GEOCHIM COSMOCHIM AC, V59, P793, DOI 10.1016/0016-7037(94)00359-T; TANAKA H, 1995, GEOPHYS J INT, V120, P97, DOI 10.1111/j.1365-246X.1995.tb05913.x; THOMAS KL, 1996, LUNAR PLANET SCI, V27, P1327; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; VALI H, 1991, IRON BIOMINERALS, P97; WACIHWA M, 1996, METEORIT PLANET SCI, V31, pA145	30	102	107	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1629	1633		10.1126/science.275.5306.1629	http://dx.doi.org/10.1126/science.275.5306.1629			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054354				2022-12-28	WOS:A1997WN12300042
J	Cairns, JA; Connolly, SJ; Roberts, R; Gent, M				Cairns, JA; Connolly, SJ; Roberts, R; Gent, M			Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT	LANCET			English	Article							AMIODARONE; MORTALITY; THERAPY; DRUG	Background Survivors of acute myocardial infarction with frequent or repetitive ventricular premature depolarisations (VPDs) have higher mortality 1-2 years after the event than those without VPDs. Although there is no therapy of proven efficacy for such patients, previous studies of amiodarone have been encouraging. CAMIAT was a randomised double-blind placebo-controlled trial designed to assess the effect of amiodarone on the risk of resuscitated ventricular fibrillation or arrhythmic death among survivors of myocardial infarction with frequent or repetitive VPDs (greater than or equal to 10 VPDs per h or greater than or equal to 1 run of ventricular tachycardia). Methods Patients from 36 Canadian hospitals were randomly assigned amiodarone or placebo; a loading dose of 10 mg/kg daily for 2 weeks, a maintenance dose of 300-400 mg daily for 3.5 months, 200-300 mg daily for 4 months, and 200 mg for 5-7 days per week for 16 months. Patients were followed up for 2 years. The primary outcome was the composite of resuscitated ventricular fibrillation or arrhythmic death. Findings We recruited 1202 patients (606 in the amiodarone group and 596 in the placebo group). The mean follow-up was 1.79 years (SD 0.44). In the efficacy analysis, resuscitated ventricular fibrillation or arrhythmic death occurred in 31 (6.0%) patients in the placebo group and in 15 (3.3%) in the amiodarone group (relative-risk reduction 48.5% [95% CI 4.5 to 7.22], p=0.016). In the intention-to-treat analysis, primary outcome events occurred in 24 (6.9%) patients in the placebo group and in 15 (4.5%) in the amiodarone group (38.2% [95% CI -2.1 to 62.6], p=0.029). The absolute-risk reductions were greatest among patients with congestive heart failure or a history of myocardial infarction. Interpretation Amiodarone reduces the incidence of ventricular fibrillation or arrhythmic death among survivors of acute myocardial infarction with frequent or repetitive VPDs. Treatment decisions for individual survivors should require an assessment of their baseline risk factors and judgments based on the synthesis of our findings with those of related trials.	MCMASTER UNIV, DEPT MED, HAMILTON, ON, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA	McMaster University; McMaster University			Cairns, John/AAI-8744-2021					[Anonymous], 1989, NEW ENGL J MED, V321, P406; BALL SG, 1993, LANCET, V342, P821; BOSI S, 1993, CIRCULATION, V88, P511; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAIRNS JA, 1993, AM J CARDIOL, V72, pF87, DOI 10.1016/0002-9149(93)90969-J; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; FURBERG CD, 1983, AM J CARDIOL, V52, pC32, DOI 10.1016/0002-9149(83)90629-X; LEFEUVRE CA, IN PRESS AM J CARDIO; MOSS AJ, 1979, CIRCULATION, V60, P998, DOI 10.1161/01.CIR.60.5.998; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; PODRID PJ, 1995, ANN INTERN MED, V122, P689, DOI 10.7326/0003-4819-122-9-199505010-00008; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VILLELLA A, 1995, LANCET, V346, P523, DOI 10.1016/S0140-6736(95)91379-3; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6	17	626	654	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	1997	349	9053					675	682		10.1016/S0140-6736(96)08171-8	http://dx.doi.org/10.1016/S0140-6736(96)08171-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078198				2022-12-28	WOS:A1997WM08000008
J	Nyyssonen, K; Parviainen, MT; Salonen, R; Tuomilehto, J; Salonen, JT				Nyyssonen, K; Parviainen, MT; Salonen, R; Tuomilehto, J; Salonen, JT			Vitamin C deficiency and risk of myocardial infarction: Prospective population study of men from eastern Finland	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; FINNISH MEN; LIPID-PEROXIDATION; PHYSICAL-ACTIVITY; BLOOD-PRESSURE; E CONSUMPTION; OXIDIZED LDL; SERUM COPPER; DIETARY FATS	Objective: To examine the association between plasma vitamin C concentrations and the risk of acute myocardial infarction. Design: Prospective population study. Setting: Eastern Finland, Subjects: 1605 randomly selected men aged 42, 48, 54, or 60 who did not have either symptomatic coronary heart disease or ischaemia on exercise testing at entry to the Kuopio ischaemic heart disease risk factor study in between 1984 and 1989. Main outcome measures: Number of acute myocardial infarctions; fasting plasma vitamin C concentrations at baseline. Results: 70 of the men had a fatal or non-fatal myocardial infarction between March 1984 and December 1992. 91 men had vitamin C deficiency (plasma ascorbate <11.4 mu mol/l, or 2.0 mg/l), of whom 12 (13.2%) had a myocardial infarction; 1514 men were not deficient in vitamin C, of whom 58 (3.8%) had a myocardial infarction. In a Cox proportional hazards model adjusted for age, year of examination, and season of the year examined (August to October v rest of the year) men who had vitamin C deficiency had a relative risk of acute myocardial infarction of 3.5 (95% confidence interval 1.8 to 6.7, P = 0.0002) compared with those who were not deficient In another model adjusted additionally for the strongest risk factors for myocardial infarction and for dietary intakes of tea, fibre, carotene, and saturated fats men with a plasma ascorbate concentration <11.4 mu mol/l had a relative risk of 2.5 (1.3 to 5.2, P = 0.0095) compared with men with higher plasma vitamin C concentrations. Conclusion: Vitamin C deficiency, as assessed by low plasma ascorbate concentration, is a risk factor for coronary heart disease.	UNIV KUOPIO,PUBL HLTH RES INST,KUOPIO 70211,FINLAND; KUOPIO UNIV HOSP,DEPT CLIN CHEM,KUOPIO 70211,FINLAND; NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,SF-00300 HELSINKI,FINLAND	University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Finland National Institute for Health & Welfare								BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; COX DR, 1972, J R STAT SOC B, V34, P187; Eichholzer M, 1992, EXS, V62, P398; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1990, ADV EXP MED BIOL, V264, P155; FREI B, 1991, AM J CLIN NUTR, V54, pS1113, DOI 10.1093/ajcn/54.6.1113s; FREYSCHUSS A, 1993, J CLIN INVEST, V91, P1282, DOI 10.1172/JCI116326; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GARRY PJ, 1982, AM J CLIN NUTR, V36, P332, DOI 10.1093/ajcn/36.2.332; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HARATS D, 1990, ATHEROSCLEROSIS, V85, P47, DOI 10.1016/0021-9150(90)90181-H; IHANAINEN M, 1989, NUTR RES, V9, P597, DOI 10.1016/S0271-5317(89)80126-5; JIALAL I, 1991, J CLIN INVEST, V87, P597, DOI 10.1172/JCI115035; KAGAN VE, 1992, J LIPID RES, V33, P385; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; KAUHANEN J, 1992, BEHAV MED, V18, P121, DOI 10.1080/08964289.1992.9936962; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; MAGGI E, 1993, CORONARY ARTERY DIS, V4, P1119, DOI 10.1097/00019501-199312000-00014; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PARVIAINEN MT, 1986, J LIQ CHROMATOGR, V9, P2185, DOI 10.1080/01483918608074142; PARVIAINEN MT, 1990, INT J VITAM NUTR RES, V60, P47; REGNSTROM J, 1992, LANCET, V339, P1183, DOI 10.1016/0140-6736(92)91129-V; RETSKY KL, 1995, BBA-LIPID LIPID MET, V1257, P279, DOI 10.1016/0005-2760(95)00089-U; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALONEN JT, 1994, NEW ENGL J MED, V331, P1159; SALONEN JT, 1988, AM J CLIN NUTR, V48, P1226, DOI 10.1093/ajcn/48.5.1226; SALONEN JT, 1991, AM J EPIDEMIOL, V134, P268, DOI 10.1093/oxfordjournals.aje.a116080; SALONEN JT, 1991, BRIT MED J, V302, P756, DOI 10.1136/bmj.302.6779.756; SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SALONEN JT, 1991, ANN MED, V23, P295, DOI 10.3109/07853899109148063; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SALONEN JT, 1995, FREE RADICALS LIPOPR; SALONEN R, 1994, LIFE CHEM REPORTS, V12, P65; *SPSS, 1993, SPSS UNIX; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TUOMILEHTO J, 1992, EUR HEART J, V13, P577, DOI 10.1093/oxfordjournals.eurheartj.a060219; *WHO, 1989, INT J EPIDEMIOL S1, V18, pS38; WILLIAMS RJ, 1992, ATHEROSCLEROSIS, V94, P153, DOI 10.1016/0021-9150(92)90240-H	49	170	176	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					634	638		10.1136/bmj.314.7081.634	http://dx.doi.org/10.1136/bmj.314.7081.634			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066474	Green Published			2022-12-28	WOS:A1997WL41800021
J	Schuman, E				Schuman, E			Neuroscience - Growth factors sculpt the synapse	SCIENCE			English	Editorial Material							NEUROTROPHIC FACTOR; HIPPOCAMPAL SLICE; NEURONS				Schuman, E (corresponding author), CALTECH,DIV BIOL 216 76,PASADENA,CA 91125, USA.		Schuman, Erin M/D-6204-2011					BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CHANG FLF, 1984, BRAIN RES, V309, P35, DOI 10.1016/0006-8993(84)91008-4; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; HOSOKAWA T, 1995, J NEUROSCI, V15, P5560; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Liu QR, 1997, J NEUROSCI, V17, P755; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Sorra K. E., 1996, Society for Neuroscience Abstracts, V22, P1516; WOJTOWICZ JM, 1994, J NEUROSCI, V14, P3688; Zhang F, 1997, SCIENCE, V275, P1318, DOI 10.1126/science.275.5304.1318	17	22	22	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1277	1278		10.1126/science.275.5304.1277	http://dx.doi.org/10.1126/science.275.5304.1277			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9064784				2022-12-28	WOS:A1997WK64400029
J	Curtis, RE; Rowlings, PA; Deeg, HJ; Shriner, DA; Socie, G; Travis, LB; Horowitz, MM; Witherspoon, RP; Hoover, RN; Sobocinski, KA; Fraumeni, JF; Boice, JD				Curtis, RE; Rowlings, PA; Deeg, HJ; Shriner, DA; Socie, G; Travis, LB; Horowitz, MM; Witherspoon, RP; Hoover, RN; Sobocinski, KA; Fraumeni, JF; Boice, JD			Solid cancers after bone marrow transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							APLASTIC-ANEMIA; SECONDARY MALIGNANCIES; HODGKINS-DISEASE; THYROID-CANCER; TUMORS; CHEMOTHERAPY; RADIOTHERAPY; RADIATION; CHILDHOOD; LEUKEMIA	Background The late effects of bone marrow transplantation, including cancer, need to be determined in a large population at risk. Methods We studied 19,229 patients who received allogeneic transplants (97.2 percent) or syngeneic transplants (2.8 percent) between 1964 and 1992 at 235 centers to evaluate the risk of the development of a new solid cancer. Risk factors relating to the patient, the transplant, and the course after transplantation were evaluated. Results The transplant recipients were at significantly higher risk of new solid cancers than the general population (observed cases, 80; ratio of observed to expected cases, 2.7; P<0.001). The risk was 8.3 times as high as expected among those who survived 10 or more years after transplantation. The cumulative incidence rate was 2.2 percent (95 percent confidence interval, 1.5 to 3.0 percent) at 10 years and 6.7 percent (95 percent confidence interval, 3.7 to 9.6 percent) at 15 years. The risk was significantly elevated (P<0.05) for malignant melanoma (ratio of observed to expected cases, 5.0) and cancers of the buccal cavity (11.1), liver (7.5), brain or other parts of the central nervous system (7.6), thyroid (6.6), bone (13.4), and connective tissue (8.0). The risk was high er for recipients who were younger at the time of transplantation than for those who were older (P for trend, <0.001). In multivariate analyses, higher doses of total-body irradiation were associated with a higher risk of solid cancers. Chronic graft-versus-host disease and male sex were strongly linked with an excess risk of squamous-cell cancers of the buccal cavity and skin. Conclusions Patients undergoing bone marrow transplantation have an increased risk of new solid cancers later in life. The trend toward an increased risk over time after transplantation and the greater risk among younger patients indicate the need for lifelong surveillance. (C) 1997, Massachusetts Medical Society.	MED COLL WISCONSIN,INT BONE MARROW TRANSPLANT REGISTRY,MILWAUKEE,WI 53226; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; HOP ST LOUIS,PARIS,FRANCE; ARMED FORCES INST PATHOL,WASHINGTON,DC 20306; UNIV MUNICH,MUNICH,GERMANY; SALICK HLTH CARE,LOS ANGELES,CA	Medical College of Wisconsin; Fred Hutchinson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; United States Department of Defense; University of Munich	Curtis, RE (corresponding author), NCI,DIV CANC EPIDEMIOL & GENET,EXECUT PLAZA N,SUITE 408,BETHESDA,MD 20892, USA.		horowitz, Mary/ABH-2173-2021		NATIONAL CANCER INSTITUTE [P01CA018029, P01CA047748, P01CA018221] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-18221, P01-CA-18029, P01-CA-47748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhatia S, 1996, BLOOD, V87, P3633, DOI 10.1182/blood.V87.9.3633.bloodjournal8793633; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; COX DR, 1972, J R STAT SOC B, V34, P187; DEEG HJ, 1993, HEMATOL ONCOL CLIN N, V7, P417, DOI 10.1016/S0889-8588(18)30249-1; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; GREENE MH, 1981, LANCET, V1, P1196, DOI 10.1016/S0140-6736(81)92359-X; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; Hawkins MM, 1996, J NATL CANCER I, V88, P270, DOI 10.1093/jnci/88.5.270; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINLEN LJ, 1996, CANC EPIDEMIOLOGY PR, P532; KOLB HJ, 1990, BONE MARROW TRANSPL, V6, P61; KOLB HJ, 1992, BONE MARROW TRANSPL, V10, P135; Land CE, 1996, RADIAT RES, V146, P28, DOI 10.2307/3579392; LOWSKY R, 1994, J CLIN ONCOL, V12, P2187, DOI 10.1200/JCO.1994.12.10.2187; LUSTIG JP, 1995, EUR J CANC B ORAL B, V31, P68; MUIR CS, 1987, IARC SCI PUBLICATION, V88; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PRESTON D. L., 1993, EPICURE USERS GUIDE; RABKIN CS, 1994, J NATL CANCER I, V86, P1711, DOI 10.1093/jnci/86.22.1711; Ries L, 1994, NIH PUBLICATION, V94-2789; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; SHEIL AGR, 1992, TRANSPLANT P, V24, P1275; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SOCIE G, 1992, LEUKEMIA LYMPHOMA, V7, P419, DOI 10.3109/10428199209049797; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; THOMPSON DE, 1994, RADIAT RES, V139, P129; TRAVIS LB, 1991, CANCER-AM CANCER SOC, V67, P2002, DOI 10.1002/1097-0142(19910401)67:7<2002::AID-CNCR2820670729>3.0.CO;2-E; TUCKER MA, 1985, ANN INTERN MED, V102, P37, DOI 10.7326/0003-4819-102-1-37; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; TUCKER MA, 1991, CANCER RES, V51, P2885; *UN SCI COMM EFF T, 1994, UN PUBL; VITTORIO CC, 1995, DERMATOL CLIN, V13, P561, DOI 10.1016/S0733-8635(18)30062-7; VOSE JM, 1992, CANCER, V69, P784, DOI 10.1002/1097-0142(19920201)69:3<784::AID-CNCR2820690328>3.0.CO;2-M; Witherspoon R P, 1994, Transplant Sci, V4, P33; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; WITHERSPOON RP, 1992, BLOOD, V79, P289	41	671	686	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	1997	336	13					897	904		10.1056/NEJM199703273361301	http://dx.doi.org/10.1056/NEJM199703273361301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP832	9070469				2022-12-28	WOS:A1997WP83200001
J	Poulin, P; Stark, H; Lubensky, TC; Weitz, DA				Poulin, P; Stark, H; Lubensky, TC; Weitz, DA			Novel colloidal interactions in anisotropic fluids	SCIENCE			English	Article							PARTICLES	Small water droplets dispersed in a nematic liquid crystal exhibit a novel class of colloidal interactions, arising from the orientational elastic energy of the anisotropic host fluid. These interactions include a short-range repulsion and a long-range dipolar attraction, and they lead to the formation of anisotropic chainlike structures by the colloidal particles, The repulsive interaction can lead to novel mechanisms for colloid stabilization.			Poulin, P (corresponding author), UNIV PENN, DEPT PHYS & ASTRON, PHILADELPHIA, PA 19104 USA.			Poulin, Philippe/0000-0001-7748-8671				Auroux PA, 2002, ANAL CHEM, V74, P2637, DOI 10.1021/ac020239t; Chandrasekhar S., 1992, LIQ CRYST, DOI 10.1017/CBO9780511622496; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; GAST AP, 1989, ADV COLLOID INTERFAC, V30, P153, DOI 10.1016/0001-8686(89)80006-5; Kuksenok OV, 1996, PHYS REV E, V54, P5198, DOI 10.1103/PhysRevE.54.5198; Kurik M. V., 1988, Soviet Physics - Uspekhi, V31, P196, DOI 10.1070/PU1988v031n03ABEH005710; MERMIN ND, 1979, REV MOD PHYS, V51, P591, DOI 10.1103/RevModPhys.51.591; MEYER RB, 1972, MOL CRYST LIQ CRYST, V16, P355, DOI 10.1080/15421407208082796; MEYER RB, 1969, PHYS REV LETT, V22, P918, DOI 10.1103/PhysRevLett.22.918; OSTLUND S, 1981, PHYS REV B, V24, P485, DOI 10.1103/PhysRevB.24.485; POULIN P, 1994, J PHYS II, V4, P1557, DOI 10.1051/jp2:1994217; Ramaswamy S, 1996, MOL CRYST LIQ CRYS A, V288, P175, DOI 10.1080/10587259608034594; TERENTJEV EM, 1995, PHYS REV E, V51, P1330, DOI 10.1103/PhysRevE.51.1330	13	1046	1055	5	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	1997	275	5307					1770	1773		10.1126/science.275.5307.1770	http://dx.doi.org/10.1126/science.275.5307.1770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065396				2022-12-28	WOS:A1997WP05600034
J	Moreno, A; Carreno, V; Cano, A; Gonzalez, C				Moreno, A; Carreno, V; Cano, A; Gonzalez, C			Idiopathic biliary ductopenia in adults without symptoms of liver disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BILE-DUCT SYNDROME; AUTOIMMUNE CHOLANGITIS; CIRRHOSIS; CHOLESTASIS; ACID	Background Idiopathic adulthood ductopenia is a severe cholestatic liver disease of unknown cause characterized by loss of the interlobular bile ducts in more than 50 percent of the portal tracts. In most reported cases, cirrhosis and liver failure develop. Methods We studied 24 adults with abnormal results on liver-function tests but no symptoms of liver disease. All had liver biopsies that showed a lack of bile ducts in many of the portal tracts. Results The 17 women and 7 men had a mean age of 41 years (range, 27 to 57). All were asymptomatic and had high serum gamma-glutamyltransferase concentrations (mean [+/-SD], 179+/-84 U per liter); 75 percent also had abnormal serum alanine aminotransferase concentrations. The proportion of portal tracts that had bile ducts was 62+/-7 percent (range, 55 to 78 percent). Three patients had a second liver biopsy three to nine years after the first; there were no changes over time. In four of the five patients treated with 600 to 900 mg of ursodiol two to three times daily, results of liver-function tests returned to normal. Conclusions Idiopathic biliary ductopenia, with an apparently nonprogressive clinical course, can occur in adults who have no symptoms of biliary disease. (C) 1997, Massachusetts Medical Society.	FDN JIMENEZ DIAZ,DEPT HEPATOL,MADRID 28040,SPAIN; HOSP RAMON Y CAJAL,LIVER UNIT,E-28034 MADRID,SPAIN	Hospital Universitario Ramon y Cajal								ALAGILLE D, 1987, J PEDIATR-US, V110, P195, DOI 10.1016/S0022-3476(87)80153-1; ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2; ALTRAIF I, 1994, AM J GASTROENTEROL, V89, P1230; BENARI Z, 1993, HEPATOLOGY, V18, P10, DOI 10.1016/0270-9139(93)90499-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES MH, 1994, J HEPATOL, V20, P112, DOI 10.1016/S0168-8278(05)80476-3; DEGOTT C, 1992, HEPATOLOGY, V15, P244, DOI 10.1002/hep.1840150212; FAA G, 1991, J HEPATOL, V12, P14, DOI 10.1016/0168-8278(91)90902-N; GOODMAN ZD, 1995, DIGEST DIS SCI, V40, P1232, DOI 10.1007/BF02065530; HAUTEKEETE ML, 1995, J HEPATOL, V22, P71, DOI 10.1016/0168-8278(95)80262-2; ISHII M, 1993, LIVER, V13, P227; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LUDWIG J, 1987, HEPATOLOGY, V7, P476, DOI 10.1002/hep.1840070311; LUDWIG J, 1988, J HEPATOL, V7, P193, DOI 10.1016/S0168-8278(88)80482-3; LUDWIG J, 1981, Hepatology, V1, P632, DOI 10.1002/hep.1840010612; LUDWIG J, 1992, PRACTICAL LIVER BIOP, P203; MICHIELETTI P, 1994, GUT, V35, P260, DOI 10.1136/gut.35.2.260; MULLER C, 1995, LIVER, V15, P213; MURPHY JR, 1990, J CLIN GASTROENTEROL, V12, P555, DOI 10.1097/00004836-199010000-00014; NAKAJIMA K, 1994, ENDOSCOPY, V26, P332, DOI 10.1055/s-2007-1008984; SHERLOCK S, 1987, LANCET, V2, P493; VAZQUEZ JJ, 1993, HEPATOBILIARY DIS, P141; VILLARI D, 1995, VIRCHOWS ARCH, V427, P223, DOI 10.1007/BF00196529; ZAFRANI ES, 1990, GASTROENTEROLOGY, V99, P1823, DOI 10.1016/0016-5085(90)90494-L	24	41	44	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					835	838		10.1056/NEJM199703203361204	http://dx.doi.org/10.1056/NEJM199703203361204			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN371	9062092				2022-12-28	WOS:A1997WN37100004
J	Hall, A				Hall, A			Child mental health services are not medical empires - Comment	BRITISH MEDICAL JOURNAL			English	Editorial Material											Hall, A (corresponding author), TOWER HAMLETS HEALTHCARE TRUST,EMMANUEL MILLER CTR,CHILD MENTAL HLTH SERV,LONDON E14 8HQ,ENGLAND.		Hall, Alistair/K-1953-2019	Hall, Alistair/0000-0003-0306-7887				Bullock R., 1995, CHILD PROTECTION MES; NHS Health Advisory Service, 1995, CHILD AD MENT HLTH S	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					814	815		10.1136/bmj.314.7083.814	http://dx.doi.org/10.1136/bmj.314.7083.814			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9081005	Green Published			2022-12-28	WOS:A1997WN64600036
J	Alter, HJ; Nakatsuji, Y; Melpolder, J; Wages, J; Wesley, R; Shih, JWK; Kim, JP				Alter, HJ; Nakatsuji, Y; Melpolder, J; Wages, J; Wesley, R; Shih, JWK; Kim, JP			The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; C VIRUS; ANTIBODY; BLOOD	Background The role of hepatitis G virus (HGV) in transfusion-associated infection and its relation to liver disease are not well understood. Methods Serum samples collected between 1972 and 1995 from 357 transfusion recipients, 157 controls who did not receive transfusions, 500 randomly selected volunteer blood donors, and 230 donors of blood received by HGV-infected patients were tested for HGV RNA by qualitative and quantitative polymerase-chain-reaction assays. Samples obtained before transfusion and serially after transfusion from 79 of the 81 transfusion recipients who had transfusion-associated non-A, non-B hepatitis were available for testing. Results Of the 79 patients with transfusion-associated hepatitis, 63 (80 percent) had infections related to the hepatitis C virus (HCV) and 3 had preexisting HCV and the cause of their acute hepatitis could not be determined; of the remaining 13 patients, 3 had acute HGV infection, and 10 were infected with unidentified agents. Six of the 63 patients with HCV infection who were tested (10 percent) were also infected with HGV. The three patients infected only with HGV had mild hepatitis (mean peak alanine aminotransferase level, 198 U per liter; none had jaundice); the levels of alanine aminotransferase and HGV RNA were not well correlated. The combined HCV and HGV infections were no more severe than HCV infections alone; the alanine aminotransferase values paralleled the levels of HCV RNA, but not those of HGV RNA, There were 35 HGV infections among the 357 transfusion recipients; only 3 had hepatitis with HGV as the sole viral marker. One of the 157 controls and 7 of the 500 randomly selected blood donors (1.4 percent) had detectable HGV RNA. In all eight instances in which a transfusion recipient had acute HGV infection after transfusion and samples from all donors could be tested, at least one HGV-positive donor was identified. Conclusions HGV was common in a group of volunteer blood donors, and it can be transmitted by transfusion. Most HGV infections were not associated with hepatitis. HGV did not worsen the course of concurrent HCV infection. No causal relation between HGV and hepatitis has been established. (C) 1997, Massachusetts Medical Society.	NIH,WARREN G MAGNUSON CLIN CTR,DEPT INFORMAT SYST,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	Alter, HJ (corresponding author), NIH,WARREN G MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BLDG 10,RM 1C-711,BETHESDA,MD 20892, USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P396; ALTER HJ, 1995, J VIRAL HEPATITIS, V2, P121, DOI 10.1111/j.1365-2893.1995.tb00017.x; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ARMITAGE P, 1971, STATISTICAL METHODS, P135; BICKEL PJ, 1977, MATH STAT BASIC IDEA, P162; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; KOTZ S, 1983, ENCY STAT SCI, P709; KOU G, 1989, SCIENCE, V244, P362; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; TSAREV SA, 1993, J INFECT DIS, V168, P369, DOI 10.1093/infdis/168.2.369; WEINER AJ, 1990, LANCET, V336, P695, DOI 10.1016/0140-6736(90)92194-M	14	501	512	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					747	754		10.1056/NEJM199703133361102	http://dx.doi.org/10.1056/NEJM199703133361102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM640	9052652	Bronze			2022-12-28	WOS:A1997WM64000002
J	Waldmann, R; Champigny, G; Bassilana, F; Heurteaux, C; Lazdunski, M				Waldmann, R; Champigny, G; Bassilana, F; Heurteaux, C; Lazdunski, M			A proton-gated cation channel involved in acid-sensing	NATURE			English	Article							SENSITIVE NA+ CHANNEL; INDUCED SODIUM CURRENT; ROOT GANGLION NEURONS; SENSORY NEURONS; HOMOLOGOUS SUBUNITS; CELLS; ACTIVATION; EXPRESSION; CLONING; CONDUCTANCE	Acid-sensing is associated with both nociception(1) and taste transduction(2). Stimulation of sensory neurons by acid is of particular interest, because acidosis accompanies many painful inflammatory and ischaemic conditions. The pain caused by acids is thought to be mediated by H+-gated cation channels present in sensory neurons(3-5). We have now cloned a H+-gated channel (ASIC, for acid-sensing ionic channel) that belongs to the amiloride-sensitive Na+ channel(6-11)/degenerin(12-14) family of ion channels. Heterologous expression of ASIC induces an amiloride-sensitive cation (Na+ > Ca2+ > K+) channel which is transiently activated by rapid extracellular acidification. The biophysical and pharmacological properties of the ASIC channel closely match the H+-gated cation channel described in sensory neurons(3,15,16). ASIC is expressed in dorsal root ganglia and is also distributed widely throughout the brain. ASIC appears to be the simplest of Ligand-gated channels.	CNRS, INST PHARMACOL MOL & CELLULAIRE, F-06560 VALBONNE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			HEURTEAUX, Catherine/M-4947-2016; Waldmann, Rainer/Q-2108-2016	HEURTEAUX, Catherine/0000-0002-9741-9777; Waldmann, Rainer/0000-0002-4599-2926; Bassilana, Frederic/0000-0003-2063-8450				AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; AKAIKE N, 1990, J NEUROPHYSIOL, V63, P805, DOI 10.1152/jn.1990.63.4.805; Barnard EA, 1996, TRENDS PHARMACOL SCI, V17, P305, DOI 10.1016/0165-6147(96)10041-9; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; DAVIES NW, 1988, J PHYSIOL-LONDON, V400, P159, DOI 10.1113/jphysiol.1988.sp017116; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GRANTYN R, 1989, DEV BRAIN RES, V49, P150, DOI 10.1016/0165-3806(89)90070-9; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KONNERTH A, 1987, J PHYSIOL-LONDON, V386, P603, DOI 10.1113/jphysiol.1987.sp016553; KORKUSHKO A O, 1984, Neirofiziologiya, V16, P557; KOVALCHUK YN, 1990, NEUROSCI LETT, V115, P237, DOI 10.1016/0304-3940(90)90461-H; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Lindemann B, 1996, PHYSIOL REV, V76, P719, DOI 10.1152/physrev.1996.76.3.719; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; OKADA Y, 1994, J EXP BIOL, V187, P19; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RANG HP, 1991, BRIT MED BULL, V47, P534, DOI 10.1093/oxfordjournals.bmb.a072491; RENARD S, 1994, J BIOL CHEM, V269, P12981; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	30	1073	1120	4	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 13	1997	386	6621					173	177		10.1038/386173a0	http://dx.doi.org/10.1038/386173a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062189				2022-12-28	WOS:A1997WM97300062
J	Quagliarello, VJ; Scheld, WM				Quagliarello, VJ; Scheld, WM			Treatment of bacterial meningitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESISTANT STREPTOCOCCUS-PNEUMONIAE; EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; NEGATIVE BACILLARY MENINGITIS; EXPERIMENTAL PENICILLIN-RESISTANT; BETA-LACTAM ANTIBIOTICS; TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER; CEREBROSPINAL-FLUID; NEISSERIA-MENINGITIDIS; DEXAMETHASONE THERAPY		YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06510 USA; UNIV VIRGINIA, SCH MED, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT NEUROSURG, CHARLOTTESVILLE, VA 22908 USA	Yale University; University of Virginia; University of Virginia								ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; BELL WE, 1981, MAJOR PROBLEMS CLIN, V12, P77; BRADLEY JS, 1991, PEDIATR INFECT DIS J, V10, P871; BROOME CV, 1996, 36 INT C ANT AG CHEM, P311; CHERUBIN CE, 1981, AM J MED, V71, P199, DOI 10.1016/0002-9343(81)90106-6; COANT PN, 1992, PEDIATR EMERG CARE, V8, P200, DOI 10.1097/00006565-199208000-00006; COFFEY TJ, 1995, ANTIMICROB AGENTS CH, V39, P1306, DOI 10.1128/AAC.39.6.1306; COWDEN J, 1995, J PUBLIC HEALTH MED, V17, P230; DEVEIKIS A, 1977, ANTIMICROB AGENTS CH, V11, P817, DOI 10.1128/AAC.11.5.817; DILLON JR, 1983, LANCET, V1, P779; DONNELLY JP, 1992, LANCET, V339, P1117; DRYDEN MS, 1991, J INFECT DIS, V164, P1239, DOI 10.1093/infdis/164.6.1239; DUNNE DW, 1993, MEDICINE, V72, P1; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Elmore JG, 1996, AM J MED, V100, P78, DOI 10.1016/S0002-9343(96)90015-7; FEIGIN RD, 1992, PEDIATR INFECT DIS J, V11, P698, DOI 10.1097/00006454-199209000-00003; FELDMAN WE, 1976, J PEDIATR-US, V88, P549, DOI 10.1016/S0022-3476(76)80003-0; FENOLL A, 1991, REV INFECT DIS, V13, P56; Flexner S, 1913, J EXP MED, V17, P553, DOI 10.1084/jem.17.5.553; FONG IW, 1985, REV INFECT DIS, V7, P604; FRIEDLAND IR, 1992, AM J DIS CHILD, V146, P920, DOI 10.1001/archpedi.1992.02160200042023; FRIEDLAND IR, 1993, ANTIMICROB AGENTS CH, V37, P1630, DOI 10.1128/AAC.37.8.1630; FRIEDLAND IR, 1993, PEDIATR INFECT DIS J, V12, P196, DOI 10.1097/00006454-199303000-00004; FRIEDLAND IR, 1992, LANCET, V339, P405, DOI 10.1016/0140-6736(92)90087-J; FRIEDLAND IR, 1993, J INFECT DIS, V168, P1342; FRIEDLAND IR, 1993, LANCET, V342, P240, DOI 10.1016/0140-6736(93)92331-M; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; FRIEDLAND IR, 1993, J INFECT DIS, V168, P657, DOI 10.1093/infdis/168.3.657; GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004; GREEN SDR, 1993, J INFECTION, V26, P253, DOI 10.1016/0163-4453(93)95291-P; HANSMAN D, 1967, LANCET, V2, P264; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; JONES DM, 1993, J ANTIMICROB CHEMOTH, V31, P93, DOI 10.1093/jac/31.suppl_B.93; JONES DM, 1990, LANCET, V335, P863, DOI 10.1016/0140-6736(90)90985-E; JONES RN, 1994, 34 INT C ANT AG CHEM, P87; KANRA GY, 1995, PEDIATR INFECT DIS J, V14, P490, DOI 10.1097/00006454-199506000-00005; KLUGMAN KP, 1995, ANTIMICROB AGENTS CH, V39, P1988, DOI 10.1128/AAC.39.9.1988; LANDESMAN SH, 1981, AM J MED, V71, P693, DOI 10.1016/0002-9343(81)90240-0; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; LEGGIADRO RJ, 1994, PEDIATRICS, V93, P500; LENTNEK AL, 1991, REV INFECT DIS    S7, V3, pS586; LEVITZ RE, 1984, ANN INTERN MED, V100, P881, DOI 10.7326/0003-4819-100-6-881; LIN TY, 1985, JAMA-J AM MED ASSOC, V253, P3559, DOI 10.1001/jama.253.24.3559; MARTIN E, 1990, INFECTION, V18, P70, DOI 10.1007/BF01641418; MARTON A, 1991, J INFECT DIS, V163, P542, DOI 10.1093/infdis/163.3.542; MCCRACKEN GH, 1980, LANCET, V1, P787; MCCRACKEN GH, 1976, J PEDIATR-US, V89, P66, DOI 10.1016/S0022-3476(76)80929-8; MUSTAFA MM, 1989, J INFECT DIS, V160, P818, DOI 10.1093/infdis/160.5.818; NAIRN K, 1995, J ANTIMICROB CHEMOTH, V36, P73, DOI 10.1093/jac/36.suppl_A.73; NARAQI S, 1974, J PEDIATR-US, V85, P671, DOI 10.1016/S0022-3476(74)80513-5; *NAT COMM CLIN LAB, 1995, PERF STAND ANT SUSC, V15; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; ONEILL, 1993, LANCET, V341, P642; ONEILL P, 1993, LANCET, V341, P530, DOI 10.1016/0140-6736(93)90287-Q; PARIS MM, 1994, ANTIMICROB AGENTS CH, V38, P1320, DOI 10.1128/AAC.38.6.1320; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; QUAGLIARELLO VJ, 1986, J CLIN INVEST, V77, P1084, DOI 10.1172/JCI112407; QUAGLIARELLO VJ, 1993, CLIN INFECT DIS, V17, P603, DOI 10.1093/clinids/17.4.603; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; QUAGLIARELLO VJ, 1991, J EXP MED, V174, P657, DOI 10.1084/jem.174.3.657; RADETSKY M, 1992, PEDIATR INFECT DIS J, V11, P694, DOI 10.1097/00006454-199209000-00002; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; RODRIGUEZ WJ, 1990, PEDIATR INFECT DIS J, V9, P83, DOI 10.1097/00006454-199002000-00004; SAEZNIETO JA, 1992, CLIN INFECT DIS, V14, P394, DOI 10.1093/clinids/14.2.394; SANDE MA, 1981, J INFECTION, V3, P33, DOI 10.1016/S0163-4453(81)80006-0; SCHAAD UB, 1993, LANCET, V342, P457, DOI 10.1016/0140-6736(93)91592-A; SCHAAD UB, 1990, NEW ENGL J MED, V322, P141, DOI 10.1056/NEJM199001183220301; SCHELD WM, 1984, JAMA-J AM MED ASSOC, V251, P791, DOI 10.1001/jama.251.6.791; SCHELD WM, 1983, J CLIN INVEST, V71, P411, DOI 10.1172/JCI110785; SCHELD WM, 1979, J INFECT DIS, V140, P287, DOI 10.1093/infdis/140.3.287; Schwentker FF, 1937, J AMER MED ASSOC, V108, P1407, DOI 10.1001/jama.1937.02780170025009; SKOGBERG K, 1992, CLIN INFECT DIS, V14, P815, DOI 10.1093/clinids/14.4.815; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; SMALL PM, 1986, INFECT IMMUN, V52, P484, DOI 10.1128/IAI.52.2.484-487.1986; STRAUSBAUGH LJ, 1978, J INFECT DIS, V137, P251, DOI 10.1093/infdis/137.3.251; SUTCLIFFE EM, 1988, LANCET, V1, P657; SYROGIANNOPOULOS GA, 1994, J INFECT DIS, V169, P853, DOI 10.1093/infdis/169.4.853; SYROGIANNOPOULOS GA, 1987, J INFECT DIS, V155, P213, DOI 10.1093/infdis/155.2.213; TALAN DA, 1993, ANN EMERG MED, V22, P1733, DOI 10.1016/S0196-0644(05)81314-9; TAN TQ, 1994, ANTIMICROB AGENTS CH, V38, P918, DOI 10.1128/AAC.38.5.918; Tauber M G, 1990, Infect Dis Clin North Am, V4, P661; TAUBER MG, 1984, J INFECT DIS, V149, P568, DOI 10.1093/infdis/149.4.568; TAUBER MG, 1985, J INFECT DIS, V151, P528, DOI 10.1093/infdis/151.3.528; TUNKEL AR, 1990, ANN INTERN MED, V112, P610, DOI 10.7326/0003-4819-112-8-610; UNHANAND M, 1993, J PEDIATR-US, V122, P15, DOI 10.1016/S0022-3476(05)83480-8; VANESSO D, 1987, PEDIATR INFECT DIS J, V6, P438, DOI 10.1097/00006454-198705000-00003; VILADRICH PF, 1991, ANTIMICROB AGENTS CH, V35, P2467, DOI 10.1128/AAC.35.12.2467; VILADRICH PF, 1988, AM J MED, V84, P839, DOI 10.1016/0002-9343(88)90061-7; WALD ER, 1995, PEDIATRICS, V95, P21; WALI SS, 1979, T ROY SOC TROP MED H, V73, P698, DOI 10.1016/0035-9203(79)90024-5; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WOLFF MA, 1993, CLIN INFECT DIS, V16, P772, DOI 10.1093/clind/16.6.772; WONG VK, 1991, PEDIATR INFECT DIS J, V10, P122, DOI 10.1097/00006454-199102000-00009; WOODS CR, 1994, J INFECT DIS, V170, P453, DOI 10.1093/infdis/170.2.453; WRIGHT PF, 1981, J INFECT DIS, V143, P141, DOI 10.1093/infdis/143.2.141; YOSHIDA R, 1995, ANTIMICROB AGENTS CH, V39, P1196, DOI 10.1128/AAC.39.5.1196; ZWAHLEN A, 1982, J INFECT DIS, V145, P635, DOI 10.1093/infdis/145.2.635	98	305	319	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					708	716		10.1056/NEJM199703063361007	http://dx.doi.org/10.1056/NEJM199703063361007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041103				2022-12-28	WOS:A1997WL41900007
J	Shaukat, N; Lear, J; Lowy, A; Fletcher, S; deBono, DP; Woods, KL				Shaukat, N; Lear, J; Lowy, A; Fletcher, S; deBono, DP; Woods, KL			RETRACTED: First myocardial infarction in patients of Indian subcontinent and European origin: Comparison of risk factors, management, and long term outcome (Retracted article. See vol 316, pg 116, 1998)	BRITISH MEDICAL JOURNAL			English	Article; Retracted Publication							CORONARY-ARTERY DISEASE; HEART-DISEASE; ASIANS; SURVIVAL; BIRMINGHAM; MORTALITY	Objectives: To compare long term outcome after first myocardial infarction amo Design: Matched pairs study Setting: Coronary care unit in central Leicester. Subjects: 238 pairs of patients admitted during 1987-93 matched for age (within 2 years), sex, date of admission (within 3 months), type of infarction (Q/non-Q), and site of infarction. Main outcome measures: Incidence of angina, reinfarction, or death during follow up of 1-7 years. Results: Patients of Indian subcontinent origin had a higher prevalence of diabetes (35% v 9% in patients of European origin, P<0.001), lower prevalence of smoking (39% v 63%, P < 0.001), longer median delay from symptom onset to admission (5 hours v 3 hows, P<0.01), and lower use of thrombolysis (50% v 66%, P<0.001). During long term follow up (median 39 months), mortality was higher in patients of Indian subcontinent origin (unadjusted hazard ratio=2.1, 95% confidence interval 1.3 to 5.4, P=0.002). After adjustment for smoking, history of diabetes, and thrombolysis the estimated hazard ratio fell slightly to 2.0 (1.1 to 3.6, P=0.02). Patients of Indian subcontinent origin had almost twice the incidence of angina (54% v 29%; P<0.001) and almost three times the risk of reinfarction during follow up (34% v 12.5% at 3 pars, P<0.001). The unadjusted hazard ratio for reinfarction in patients of Indian subcontinent origin was 2.8 (1.8 to 4.4, P<0.001). Adjustment for smoking, history of diabetes, and thrombolysis made little difference to die hazard ratio. Coronary angiography was performed with similar frequency in the two groups; triple vessel disease was the commonest finding in patients of Indian subcontinent origin and single vessel disease the commonest in Europeans (P<0.001). Conclusions: Patients of Indian subcontinent origin are at substantially higher risk of mortality and of further coronary events than Europeans after first myocardial infarction. This is probably due to their higher prevalence of diffuse coronary atheroma Their need for investigation with a view to coronary revascularisation is therefore greater History of diabetes is an inadequate surrogate for ethnic origin as a prognostic indicator.	UNIV LEICESTER, DEPT MED & THERAPEUT & PUBL HLTH, LEICESTER, LEICS, ENGLAND	University of Leicester	Shaukat, N (corresponding author), GEN HOSP KETTERING, NHS TRUST, DEPT CARDIOL, ROTHWELL RD, KETTERING NN16 8UZ, NORTHANTS, ENGLAND.		lear, john/I-5465-2015	lear, john/0000-0002-2969-9922				BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; DHAWAN J, 1994, ATHEROSCLEROSIS, V105, P35, DOI 10.1016/0021-9150(94)90005-1; FEEHALLY J, 1993, Q J MED, V86, P263; HOLT JD, 1974, BIOMETRIKA, V61, P17, DOI 10.1093/biomet/61.1.17; HUGHES LO, 1989, BRIT MED J, V298, P1345, DOI 10.1136/bmj.298.6684.1345; LEAR JT, 1994, J ROY COLL PHYS LOND, V28, P143; LOWRY PJ, 1984, BRIT HEART J, V52, P610, DOI 10.1136/hrt.52.6.610; LOWY AGJ, 1991, J PUBLIC HEALTH MED, V13, P276; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MUKHTAR HT, 1995, BRIT HEART J, V73, P122; SHAUKAT N, 1993, BRIT MED J, V307, P717, DOI 10.1136/bmj.307.6906.717; Wilkinson P, 1996, BMJ-BRIT MED J, V312, P1330, DOI 10.1136/bmj.312.7042.1330; WOODS KL, 1989, BRIT HEART J, V62, P118; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; [No title captured]	16	23	23	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					639	642		10.1136/bmj.314.7081.639	http://dx.doi.org/10.1136/bmj.314.7081.639			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066475	Green Published			2022-12-28	WOS:A1997WL41800022
J	BennettGuerrero, E; Ayuso, L; HamiltonDavies, C; White, WD; Barclay, GR; Smith, PK; King, SA; Muhlbaier, LH; Newman, MF; Mythen, MG				BennettGuerrero, E; Ayuso, L; HamiltonDavies, C; White, WD; Barclay, GR; Smith, PK; King, SA; Muhlbaier, LH; Newman, MF; Mythen, MG			Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR NECROSIS FACTOR; HUMAN SEPTIC SHOCK; BACTERIAL TRANSLOCATION; CARDIOPULMONARY BYPASS; ORGAN FAILURE; INTESTINAL PERMEABILITY; HEMORRHAGIC-SHOCK; ESCHERICHIA-COLI; CONTROLLED TRIAL; ENDOTOXIN	Objective.-To test the hypothesis that low serum antiendotoxin core antibody (EndoCAb) level is an independent predictor of adverse outcome following cardiac surgery, Design.-Prospective, blinded, cohort study. Setting.-Tertiary care medical center. Subjects.-A total of 301 patients undergoing coronary artery bypass graft surgery and/or valvular heart surgery. Design.-Preoperative serum was assayed for IgM EndoCAb, IgG EndoCAb, total IgM, and total IgG levels. Known preoperative risk factors were assessed, and patients were assigned a risk score using a validated method, Main Outcome Measure.-A major complication, defined as either in-hospital death or postoperative length of stay greater than 10 days, Results.-Overall, a major complication occurred in 34 patients (11.3%), Lower IgM EndoCAb level independently predicted (P=.002) increased risk of major complication over and above the effects of preoperative risk score (P=.02), total IgG level (P=.07), and all other known perioperative risk factors. In contrast, IgG EndoCAb and total IgM concentrations did not predict outcome, No association existed between risk score and level of IgM EndoCAb. Conclusion.-There is marked preoperative variability in humoral immunity against endotoxin core, which is not accounted for by differences in known preoperative risk factors. In this study, low levels of IgMEndoCAb were an important independent predictor of adverse postoperative outcome, which supports the theory that endotoxemia is a cause of postoperative morbidity.	HARVARD UNIV,SCH MED,BOSTON,MA; MIDDLESEX HOSP,DEPT ANESTHESIOL,LONDON,ENGLAND; DUKE UNIV,MED CTR,DUKE HEART CTR,DEPT ANESTHESIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DUKE HEART CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DUKE HEART CTR,DEPT COMMUNITY & FAMILY MED,DURHAM,NC 27710; SCOTTISH NATL BLOOD TRANSFUS SERV,EDINBURGH,MIDLOTHIAN,SCOTLAND	Harvard University; Harvard Medical School; University of London; University College London; Duke University; Duke University; Duke University	BennettGuerrero, E (corresponding author), MT SINAI MED CTR,DEPT ANESTHESIOL,BOX 1010,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.		Mythen, Michael G/G-8682-2011					*AM HEART ASS, 1995, HEART STROK FACTS 19, P1; ANDERSEN LW, 1987, J THORAC CARDIOV SUR, V93, P115; BARCLAY GR, 1987, INFECT IMMUN, V55, P2706, DOI 10.1128/IAI.55.11.2706-2714.1987; BARCLAY GR, 1995, BACTERIAL ENDOTOXINS, P263; Baumgartner J D, 1991, Infect Dis Clin North Am, V5, P915; BION JF, 1994, CRIT CARE MED, V22, P40, DOI 10.1097/00003246-199401000-00011; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DECAMP MM, 1988, JAMA-J AM MED ASSOC, V260, P530, DOI 10.1001/jama.260.4.530; Deitch E A, 1987, J Burn Care Rehabil, V8, P475, DOI 10.1097/00004630-198708060-00005; DEITCH EA, 1990, J TRAUMA, V30, pS184; DEITCH EA, 1990, CRIT CARE MED, V18, P529, DOI 10.1097/00003246-199005000-00014; Efron B., 1994, MONOGRAPHS STAT APPL; EVANS ME, 1992, J INFECT DIS, V166, P803, DOI 10.1093/infdis/166.4.803; Fink M P, 1994, Semin Respir Infect, V9, P256; FINK MP, 1991, ARCH SURG-CHICAGO, V126, P211; FONG YM, 1989, J IMMUNOL, V142, P2321; FORD EG, 1991, ANN THORAC SURG, V52, P514, DOI 10.1016/0003-4975(91)90914-C; FREEMAN R, 1985, THORAX, V40, P846, DOI 10.1136/thx.40.11.846; GOLDIE AS, 1995, JAMA-J AM MED ASSOC, V274, P172, DOI 10.1001/jama.274.2.172; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GOULD FK, 1989, AM J OBSTET GYNECOL, V160, P317, DOI 10.1016/0002-9378(89)90433-X; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HAMILTONDAVIES C, 1995, BRIT J ANAESTH, V74, pS34; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V267, P2344, DOI 10.1001/jama.267.17.2344; HOSMER DW, 1989, APPL LOGISTIC REGRES; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUDERITZ O, 1966, BACTERIOL REV, V30, P192; MARTINEZPELLUS AE, 1993, CRIT CARE MED, V21, P1684, DOI 10.1097/00003246-199311000-00017; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MORRISON DC, 1974, J EXP MED, V140, P797, DOI 10.1084/jem.140.3.797; MUNSTER AM, 1993, ANN SURG, V218, P321, DOI 10.1097/00000658-199309000-00011; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; OCONNOR GT, 1992, CIRCULATION, V85, P2110, DOI 10.1161/01.CIR.85.6.2110; PARSONNET V, 1989, CIRCULATION, V79, P3; POXTON IR, 1995, J IMMUNOL METHODS, V186, P1, DOI 10.1016/0022-1759(95)00123-R; QUEZADO ZMN, 1993, JAMA-J AM MED ASSOC, V269, P2221, DOI 10.1001/jama.269.17.2221; Riddington DW, 1996, JAMA-J AM MED ASSOC, V275, P1007, DOI 10.1001/jama.275.13.1007; ROCKE DA, 1987, J THORAC CARDIOV SUR, V93, P832; RUSH BF, 1988, ANN SURG, V207, P549, DOI 10.1097/00000658-198805000-00009; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; TU JV, 1995, CIRCULATION, V91, P677, DOI 10.1161/01.CIR.91.3.677; VOLK WA, 1986, MED MICROBIOLOGY, P396; WARREN HS, 1993, J EXP MED, V177, P89, DOI 10.1084/jem.177.1.89; WATARIDA S, 1994, J THORAC CARDIOV SUR, V108, P620; WHICHER JT, 1978, ANN CLIN BIOCHEM, V15, P77, DOI 10.1177/000456327801500117; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	51	101	104	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					646	650						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039883				2022-12-28	WOS:A1997WJ49800033
J	Axon, ATR; OMorain, CA; Bardhan, KD; Crowe, JP; Beattie, AD; Thompson, RPH; Smith, PM; Hollanders, FD; Baron, JH; Lynch, DAF; Dixon, MF; Tompkins, DS; Birrell, H; Gillon, KRW				Axon, ATR; OMorain, CA; Bardhan, KD; Crowe, JP; Beattie, AD; Thompson, RPH; Smith, PM; Hollanders, FD; Baron, JH; Lynch, DAF; Dixon, MF; Tompkins, DS; Birrell, H; Gillon, KRW			Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection	BRITISH MEDICAL JOURNAL			English	Article								Objective: To determine whether eradication of Helicobacter pylori infection reduces recurrence of benign gastric ulceration. Design: Randomised, double blind, controlled study, Patients were randomised in a 1:2 ratio to either omeprazole 40 mg once daily for eight weeks or the same treatment plus amoxycillin 750 mg twice daily for weeks 7 and 8. A 12 month untreated follow up ensued. Setting: Teaching and district general hospitals between 1991 and 1994. Subjects: 107 patients with benign gastric ulcer associated with H pylori. Main outcome measures: Endoscopically confirmed relapse with gastric ulcer (analysed with life table methods), H pylori eradication, and healing of gastric ulcers (Mantel-Haenszel test). Results: 172 patients were enrolled, Malignancy was diagnosed in 19; 24 were not infected with H pylori; four withdrew because of adverse events; and 18 failed to attend for start of treatment, leaving 107 patients eligible for analysis (35 omeprazole alone; 72 omeprazole plus amoxycillin), In the omeprazole/amoxycillin group 93% (67/72; 95% confidence interval 84% to 98%) of gastric ulcers healed and 83% (29/35; 66% to 94%) in the omeprazole group (P=0.103). Eradication of H pylori was 58% (42/72; 46% to 70%) and 6% (2/35; 1% to 19%) (P<0.001) and relapse after treatment was 22% (16/72) and 49% (17/35) (life table analysis, P<0.001), in the two groups, respectively, The recurrence rates were 7% (3/44) after successful H pylori eradication and 48% (30/63) in those who continued to be infected (P<0.001). Conclusions: Eradication of H pylori reduces relapse with gastric ulcer over one year, Eradication rates achieved with this regimen, however, are too low for it to be recommended for routine use.	MEATH HOSP,DUBLIN 8,IRELAND; ADELAIDE HOSP,DUBLIN 8,IRELAND; ROTHERHAM DIST GEN HOSP,ROTHERHAM S60 2UD,S YORKSHIRE,ENGLAND; MATER MISERICORDIAE HOSP,DUBLIN 7,IRELAND; SO GEN HOSP,GLASGOW G51 4TF,LANARK,SCOTLAND; ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND; LLANDOUGH HOSP,PENARTH CF62 2XX,S GLAM,WALES; OLDCHURCH HOSP,ROMFORD RM7 0BE,ESSEX,ENGLAND; ST MARYS HOSP,LONDON W2 1NY,ENGLAND; LEEDS PUBL HLTH LAB,LEEDS LS15 7PR,W YORKSHIRE,ENGLAND; BLACKBURN HYNDBURN & RIBBLE VALLEY HLTH CARE NHS,BLACKBURN BB2 3LR,LANCS,ENGLAND; ASTRA CLIN RES UNIT,EDINBURGH EH7 4HG,MIDLOTHIAN,SCOTLAND	Trinity College Dublin; Trinity College Dublin; Mater Misericordiae University Hospital; University College Dublin; University of Glasgow; Guy's & St Thomas' NHS Foundation Trust; Imperial College London; AstraZeneca								MARSHALL BJ, 1994, AM J GASTROENTEROL, V89, P5116; NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001; SEPPALA K, 1995, GUT, V36, P834, DOI 10.1136/gut.36.6.834; SUNG JJY, 1995, NEW ENGL J MED, V332, P139, DOI 10.1056/NEJM199501193320302; 1994, JAMA-J AM MED ASSOC, V272, P65	5	48	48	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					565	568		10.1136/bmj.314.7080.565	http://dx.doi.org/10.1136/bmj.314.7080.565			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055715	Green Published			2022-12-28	WOS:A1997WK21500024
J	Beiser, C				Beiser, C			Recent advances - HIV infection .2.	BRITISH MEDICAL JOURNAL			English	Review							NEW-YORK-CITY; MULTIDRUG-RESISTANT TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-AVIUM COMPLEX; 2 CONTROLLED TRIALS; CYTOMEGALOVIRUS RETINITIS; KAPOSIS-SARCOMA; RIFABUTIN PROPHYLAXIS; DNA-SEQUENCES; AIDS		UNIV MARYLAND,MED SYST,ADULT HIV PROGRAM,DIV INFECT DIS,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore	Beiser, C (corresponding author), UNIV MARYLAND,MED SYST,ADULT HIV PROGRAM,INST HUMAN VIROL,BOX 174,BALTIMORE,MD 21201, USA.							ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1995, CLIN INFECT DIS   S1, V21, pS32; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; BROSGART C, 1996, 11 INT C AIDS VANC; CHAISSON RE, 1996, 3 C RETR OPP INF WAS; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; *CHIR GANC IMPL ST, 1995, 35 INT C ANT AG CHEM; COHN DL, 1996, 11 INT C AIDS VANC; DORE G, 1996, 11 INT C AIDS VANC; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; DUBE M, 1996, 3 C RETR OPP INF WAS; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Havlir DV, 1996, NEW ENGL J MED, V335, P392, DOI 10.1056/NEJM199608083350604; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; JONES JL, 1996, 11 INT C AIDS VANC; KUPPERMAN B, 1995, INT S EXP CLIN OC PH; LALEZARI J, 1996, 11 INT C AIDS VANC; LAZEARI J, 1996, 11 INT C AIDS VANC; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; Masur H, 1996, ANN INTERN MED, V125, P126, DOI 10.7326/0003-4819-125-2-199607150-00009; MAY T, 1996, 11 INT C AIDS VANC; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; MONTALBAN C, 1989, REV INFECT DIS, V11, P655; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; MOORE RD, 1995, AIDS, V9, P1337, DOI 10.1097/00002030-199512000-00006; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; NIGHTINGALE SD, 1992, J INFECT DIS, V165, P1082, DOI 10.1093/infdis/165.6.1082; OLDFIELD EC, 1996, 3 C RETR OPP INF WAS; *OR GANC EUR AUSTR, 1995, AIDS, V9, P471; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603; Piscitelli SC, 1996, CLIN INFECT DIS, V23, P685, DOI 10.1093/clinids/23.4.685; Rahhal FM, 1996, ANN INTERN MED, V125, P98, DOI 10.7326/0003-4819-125-2-199607150-00003; ROBINSON NJ, 1996, 11 INT C AIDS VANC; SALOMON N, 1995, CLIN INFECT DIS, V21, P1245, DOI 10.1093/clinids/21.5.1245; SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023; Shafran SD, 1996, NEW ENGL J MED, V335, P377, DOI 10.1056/NEJM199608083350602; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; SQUIRES KE, 1993, 1 NAT C HUM RETR REL; *STUD OC COMPL AID, 1996, ARCH OPHTHALMOL-CHIC, V114, P23; SUPPARATPINYO K, 1994, LANCET, V344, P110, DOI 10.1016/S0140-6736(94)91287-4; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; WAWER MJ, 1996, 11 INT C AIDS VANC; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; 1992, NEW ENGL J MED, V326, P213	56	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					579	583		10.1136/bmj.314.7080.579	http://dx.doi.org/10.1136/bmj.314.7080.579			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055720	Green Published			2022-12-28	WOS:A1997WK21500030
J	Smith, GD; Hart, C; Blane, D; Gillis, C; Hawthorne, V				Smith, GD; Hart, C; Blane, D; Gillis, C; Hawthorne, V			Lifetime socioeconomic position and mortality: Prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; LIVING-CONDITIONS; ADULT MORTALITY; CHILDHOOD; RISK; FINLAND; MORBIDITY; MODELS; WOMEN; BIRTH	Objectives: To assess the influence of socioeconomic position over a lifetime on risk factors for cardiovascular disease, on morbidity, and on mortality from various causes. Design: Prospective observational study with 21 years of follow up. Social class was determined as manual or non-manual at three stages of participants' lives: from the social class of their father's job, the social class of their first job, and the social class of their job at the time of screening. A cumulative social class indicator was constructed, ranging from non-manual social class at all three stages of life to manual social class at all three stages. Setting: 27 workplaces in the west of Scotland. Participants: 5766 men aged 35-64 at the time of examination. Main outcome measures. Prevalence and level of risk factors for cardiovascular disease, morbidity, and mortality from broad causes of death. Results: From non-manual social class locations at all three life stages to manual at all stages there were strong positive trends for blood pressure, body mass index, current cigarette smoking, angina, and bronchitis. Inverse trends were seen for height, cholesterol concentration, lung function, and being an ex-smoker. 1580 men died during follow up. Age adjusted relative death rates in comparison with the men of non-manual social class locations at all three stages of life were 1.29 (95% confidence interval 1.08 to 1.56) in men of two non-manual and one manual social class; 1.45 (1.21 to 1.73) in men of two manual and one non-manual social class; and 1.71 (1.46 to 2.01) in men of manual social class at all three stages. Mortality from cardiovascular disease showed a similar graded association with cumulative social class. Mortality from cancer was mainly raised among men of manual social class at all three stages. Adjustment for a wide range of risk factors caused little attenuation in the association of cumulative social class with mortality from all causes and from cardiovascular disease; greater attenuation was seen in the association with mortality from non-cardiovascular, non-cancer disease, Fathers having a non-manual occupation was strongly associated with mortality from cardiovascular disease: relative rate 1.41 (1.15 to 1.72). Participants' social class at the time of screening was more strongly associated than the other social class indicators with mortality from cancer and from non-cardiovascular, non-cancer causes. Conclusions: Socioeconomic factors acting over the lifetime affect health and risk of premature death. The relative importance of influences at different stages varies for the cause of death, Studies with data on socioeconomic circumstances at only one stage of life are inadequate for fully elucidating the contribution of socioeconomic factors to health and mortality risk.	UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G12 8RZ, LANARK, SCOTLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT PSYCHIAT, LONDON W6 8RP, ENGLAND; RUCHILL HOSP, W SCOTLAND CANC SURVIELLANCE UNIT, GLASGOW G20 9NB, LANARK, SCOTLAND; UNIV MICHIGAN, SCH PUBL HLTH, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA	University of Glasgow; Imperial College London; University of Michigan System; University of Michigan	Smith, GD (corresponding author), UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				ALTER G, 1989, POP STUD-J DEMOG, V43, P25, DOI 10.1080/0032472031000143836; [Anonymous], 1965, LANCET, V1, P775; BARKER DJP, 1995, NUTR CHILD HLTH, P77; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BLANE D, 1993, SOCIOL HEALTH ILL, V15, P2; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; BURNETT JC, 1880, HOMAPATHIC WORL 1001, P437; BURR ML, 1980, J EPIDEMIOL COMMUN H, V34, P93, DOI 10.1136/jech.34.2.93; Carstairs V., 1991, DEPRIVATION HLTH SCO; COX DR, 1972, J R STAT SOC B, V34, P187; *DEP HLTH, 1995, HLTH NAT VAR HLTH WH; Eachus J, 1996, BMJ-BRIT MED J, V312, P287; ELO IT, 1992, POPUL INDEX, V58, P186, DOI 10.2307/3644718; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; GILLUM RF, 1978, AM J EPIDEMIOL, V108, P289, DOI 10.1093/oxfordjournals.aje.a112622; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P163; GUNNELL D, 1996, J EPIDEMIOL COMMUNIT, V50, P580; HASLE H, 1990, BRIT MED J, V300, P512, DOI 10.1136/bmj.300.6723.512; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; JONES H B, 1956, Adv Biol Med Phys, V4, P281; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; KOSKINEN S, 1994, 41 NAWH NAT RES DEV; KUH D, 1993, SOC HIST MED, V6, P101; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; MARE RD, 1990, MEASUREMENT ANAL MOR, P362; Moser K., 1990, LONGITUDINAL STUDY M, P145; NOTKOLA V, 1985, SOC SCI MED, V21, P517, DOI 10.1016/0277-9536(85)90035-8; *OFF POP CENS SURV, 1986, OCC MORT 1979 1980 1; Rose G, 1982, CARDIOVASCULAR SURVE; Salhi M., 1995, ADULT MORTALITY DEV; *SAS I, 1991, SAS LANG PROC US 2 V; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; Smith GD, 1994, EUROPEAN J PUBLIC HL, V4, P131, DOI DOI 10.1093/EURPUB/4.2.131; VAGERO D, 1994, LANCET, V343, P1224, DOI 10.1016/S0140-6736(94)92432-5; VALKONEN T, 1987, EUR J POPUL, V3, P61, DOI 10.1007/BF01797092; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8; Wunsch G, 1996, EUR J POPUL, V12, P167, DOI 10.1007/BF01797082	44	397	398	1	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	1997	314	7080					547	552		10.1136/bmj.314.7080.547	http://dx.doi.org/10.1136/bmj.314.7080.547			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK215	9055712	Green Published			2022-12-28	WOS:A1997WK21500021
J	Mancia, G; Sega, R; Milesi, C; Cesana, G; Zanchetti, A				Mancia, G; Sega, R; Milesi, C; Cesana, G; Zanchetti, A			Blood-pressure control in the hypertensive population	LANCET			English	Article								Background In large-scale surveys of individuals with hypertension those whose clinic blood pressure is reduced to 140/90 mm Hg or less have been found to represent only a small fraction of the hypertensive population. We assessed whether these results arise because of a white-coat effect elevating clinic blood pressure. Methods We randomly selected 2400 individuals from the town of Monza, Italy, and invited them to take part in our study. We measured clinic blood pressure as well as home (morning and evening measurements), and 24 h ambulatory blood pressure-ie, blood pressures largely devoid of a effect. Based on clinic blood pressure were then classified as normotensive, untreated hypertensive (clinic blood pressure>140 mm Hg systolic and/or >90 mm Hg diastolic), or treated hypertensive (having antihypertensive treatment). The mean blood pressures for each group were calculated. Findings 1651 people took part in the study. The clinic blood pressure of treated hypertensives (n=207; 146.9 [SD 18] mm Hg/90.2 [8.6] mm Hg) was only slightly less than in untreated hypertensives (n=402; 148 [15.2] mm Hg/93.3 [8] mm Hg) and in both groups the blood pressure values were much greater than those of normotensive individuals (n=1042; 119.5 [10.3] mm Hg/78.1 [6.6] mm Hg) p<0.001. Averaged home and 24 h blood pressures were lower than clinic blood pressures but similarly higher in untreated and treated hypertensive individuals when compared with normotensive individuals. This was also the case for day and night average blood pressures. The number of treated hypertensive patients found to have blood pressures within the normal limits was small not only when based on clinic blood pressure values but also when based on ambulatory blood-pressure values. Interpretation In the hypertensive population the number of patients with inadequate blood-pressure control is high not only when assessed in the clinic but also when assessed by ambulatory-blood-pressure monitoring or at home. The high blood-pressure values commonly found in treated hypertensive individuals cannot be accounted for by a white-coat effect but by a true lack of daily-life blood-pressure control.	OSPED SAN GERARDO, CTR STUDI PATOL CRONICODEGENERAT, MONZA, ITALY; OSPED SAN GERARDO, CTR FISIOL CLIN & IPERTENS, IST CLIN MED, MONZA, ITALY; UNIV MILAN, MILAN, ITALY; ISTRA, MILAN, ITALY	San Gerardo Hospital; San Gerardo Hospital; University of Milan	Mancia, G (corresponding author), UNIV MILAN, OSPED S GERARDO, CATTEDRA MED INTERNA, I-20052 MONZA, ITALY.		christophe, Milési/AAO-6946-2021	zanchetti, alberto/0000-0003-4796-7959				Assmann G, 1993, LIPID METABOLISM DIS, P19; BEILIN LJ, 1980, HEART, V43, P74; CHATELLIER G, 1987, J HYPERTENS       S5, V5, pS547; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; *GRUPP RIC AR BRIA, 1988, G ITAL CARDIOL, V18, P1034; IMAI Y, 1993, HYPERTENSION, V22, P900, DOI 10.1161/01.HYP.22.6.900; LAURENZI M, 1990, J HYPERTENS, V8, pS7, DOI 10.1097/00004872-199003001-00003; Mancia G, 1995, J HYPERTENS, V13, P1377; MANCIA G, 1983, LANCET, V2, P695; MEJIA AD, 1990, ARCH INTERN MED, V150, P1209, DOI 10.1001/archinte.150.6.1209; PARATI G, 1985, HYPERTENSION, V7, P597, DOI 10.1161/01.HYP.7.4.597; PARATI G, 1991, J HYPERTENS, V9, pS7; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; Staessen, 1996, Blood Press Monit, V1, P13; URQUHART J, 1994, CLIN PHARMACOKINET, V27, P202, DOI 10.2165/00003088-199427030-00004; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]	16	254	258	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1997	349	9050					454	457		10.1016/S0140-6736(96)07099-7	http://dx.doi.org/10.1016/S0140-6736(96)07099-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040574				2022-12-28	WOS:A1997WH38900009
J	McNamee, D				McNamee, D			''Euro-oncocredit'' moves nearer	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					448	448		10.1016/S0140-6736(05)61181-6	http://dx.doi.org/10.1016/S0140-6736(05)61181-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040572				2022-12-28	WOS:A1997WH38900007
J	Piccinelli, M; Tessari, E; Bortolomasi, M; Piasere, O; Semenzin, M; Garzotto, N; Tansella, M				Piccinelli, M; Tessari, E; Bortolomasi, M; Piasere, O; Semenzin, M; Garzotto, N; Tansella, M			Efficacy of the alcohol use disorders identification test as a screening tool for hazardous alcohol intake and related disorders in primary care: A validity study	BRITISH MEDICAL JOURNAL			English	Article							INSTRUMENT; MAST; QUESTIONNAIRE; VALIDATION; ABUSE; CAGE	Objective: To determine the properties of the alcohol use disorders identification test in screening primary care attenders for alcohol problems. Design: A validity study among consecutive primary care attenders aged 18-65 years. Every third subject completed the alcohol use disorders identification test (a 10 item self report questionnaire on alcohol intake and related problems) and nas interviewed by an investigator with the composite international diagnostic interview alcohol use module (a standardised interview for the independent assessment of alcohol intake and related disorders). Setting: 10 primary care clinics in Verona, north eastern Italy. Patients: 500 subjects were approached and 482 (96.4%) completed evaluation. Results: When the alcohol use disorders identification test nas used to detect subjects with alcohol problems the area under the receiver operating characteristic curve was 0.95. The cut off score of 5 was associated with a sensitivity of 0.84, a specificity of 0.90, and a positive predictive value of 0.60. The screening ability of the total score derived from summing the responses to the five items minimising the probability of misclassification between subjects with and without alcohol problems provided an area under the receiver operating characteristic curve of 0.93. A score of 5 or more on the five items was associated with a sensitivity of 0.79, a specificity of 0.95, and a positive predictive value of 0.73. Conclusions: The alcohol use disorders identification test performs well in detecting subjects with formal alcohol disorders and those with hazardous alcohol intake. Using five of the 10 items on the questionnaire gives reasonable accuracy, and these are recommended as questions of choice to screen patients for alcohol problems.	UNIV VERONA,IST PSICHIAT,SERV PSICOL MED,I-37100 VERONA,ITALY	University of Verona	Piccinelli, M (corresponding author), OSPED POLICLIN,SERV PSICOL MED,IST PSICHIAT,I-37134 VERONA,ITALY.		Rao, Rahul/P-7158-2014; Tansella, Michele/B-4106-2010					American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDERSON P, 1990, EUROPEAN SERIES, V32, P44; [Anonymous], 1992, INT CLASS DIS; Babor TF., 1989, ALCOHOL USE DISORDER, V1, P45; CATARINO PA, 1992, ALCOHOL ALCOHOLISM, V27, P465; DORFMAN D, 1966, J MATH PSYCHOL, V6, P487; FEUERLEIN W, 1979, INT J REHABIL RES, V2, P533, DOI 10.1097/00004356-197912000-00023; GOLDBERG D, 1995, MENTAL ILLNESS GEN H, P324; KITCHENS JM, 1994, JAMA-J AM MED ASSOC, V272, P1782, DOI 10.1001/jama.272.22.1782; KRISTENSON H, 1982, BRIT J ADDICT, V77, P297; MAGRUDERHABIB K, 1982, J STUD ALCOHOL, V43, P910, DOI 10.15288/jsa.1982.43.910; MAGRUDERHABIB K, 1993, J CLIN EPIDEMIOL, V46, P435, DOI 10.1016/0895-4356(93)90020-2; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; Metz C. E., 1984, ROCFIT; MODONUTTI G, 1993, ALCOLOGIA ITALIA UNA, P51; NAKAMURA K, 1993, J STUD ALCOHOL, V54, P618, DOI 10.15288/jsa.1993.54.618; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; Rey J., 1992, INT J METHODS PSYCHI, V2, P39; RICE DP, 1991, PUBLIC HEALTH REP, V106, P280; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; Saunders J. B., 1987, WHO COLLABORATIVE PR; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; *WHO, 1990, CIDI COR COMP INT DI; 1995, ALCOHOL ALCOHOLISM, V30, P571; 1991, PRESIDENTS REPORT AC	27	226	229	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					420	424		10.1136/bmj.314.7078.420	http://dx.doi.org/10.1136/bmj.314.7078.420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WH295	9040389	Green Published			2022-12-28	WOS:A1997WH29500031
J	Bockrath, M; Cobden, DH; McEuen, PL; Chopra, NG; Zettl, A; Thess, A; Smalley, RE				Bockrath, M; Cobden, DH; McEuen, PL; Chopra, NG; Zettl, A; Thess, A; Smalley, RE			Single-electron transport in ropes of carbon nanotubes	SCIENCE			English	Article							MICROTUBULES	The electrical properties of individual bundles, or ''ropes,'' of single-walled carbon nanotubes have been measured. Below about 10 kelvin, the low-bias conductance was suppressed for voltages less than a few millivolts. In addition, dramatic peaks were observed in the conductance as a function of a gate voltage that modulated the number of electrons in the rope. These results are interpreted in terms of single-electron charging and resonant tunneling through the quantized energy levels of the nanotubes composing the rope.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,INST MOL DESIGN,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT PHYS,BERKELEY,CA 94720; RICE UNIV,RICE QUANTUM INST,CTR NANOSCALE SCI & TECHNOL,HOUSTON,TX 77251; RICE UNIV,DEPT CHEM,HOUSTON,TX 77251; RICE UNIV,DEPT PHYS,HOUSTON,TX 77251	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Rice University; Rice University; Rice University			Zettl, Alex K/O-4925-2016	Zettl, Alex K/0000-0001-6330-136X				BENEDICT LX, 1995, PHYS REV B, V52, P8541, DOI 10.1103/PhysRevB.52.8541; BERNAERTS D, 1996, PREPRINT; Chico L, 1996, PHYS REV LETT, V76, P971, DOI 10.1103/PhysRevLett.76.971; Chico L, 1996, PHYS REV B, V54, P2600, DOI 10.1103/PhysRevB.54.2600; Cowley JM, 1997, CHEM PHYS LETT, V265, P379, DOI 10.1016/S0009-2614(96)01442-X; Dai HJ, 1996, SCIENCE, V272, P523, DOI 10.1126/science.272.5261.523; Ebbesen TW, 1996, NATURE, V382, P54, DOI 10.1038/382054a0; Ebbesen TW, 1996, PHYS TODAY, V49, P26, DOI 10.1063/1.881603; Fischer JE, 1997, PHYS REV B, V55, pR4921, DOI 10.1103/PhysRevB.55.R4921; Grabert H., 1991, SINGLE CHARGE TUNNEL; HAMADA N, 1992, PHYS REV LETT, V68, P1579, DOI 10.1103/PhysRevLett.68.1579; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; KANE CL, IN PRESS PHYS REV LE; KASTNER MA, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881393; Kasumov AY, 1996, EUROPHYS LETT, V34, P429, DOI 10.1209/epl/i1996-00474-0; Kouwenhoven L. P., NANOSCIENCE TECHNOLO; Langer L, 1996, PHYS REV LETT, V76, P479, DOI 10.1103/PhysRevLett.76.479; SAITO R, 1992, APPL PHYS LETT, V60, P2204, DOI 10.1063/1.107080; TANS S, 1997, PREPRINT; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; ZHU HY, 1996, PREPRINT	21	1213	1239	6	162	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1922	1925		10.1126/science.275.5308.1922	http://dx.doi.org/10.1126/science.275.5308.1922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072967	Green Submitted			2022-12-28	WOS:A1997WQ51300042
J	Herzing, LBK; Romer, JT; Horn, JM; Ashworth, A				Herzing, LBK; Romer, JT; Horn, JM; Ashworth, A			Xist has properties of the X-chromosome inactivation centre	NATURE			English	Article							GENE; EXPRESSION; MICE; RECOMBINATION; CONSERVATION; PROMOTER; EMBRYO; CELLS	X-chromosome inactivation is the process by which female mammals (with two X chromosomes) achieve expression of X-chromosomal genes equivalent to that of males (one X and one Y chromosome)(1,2). This results in the transcriptional silencing of virtually all genes on one of the X chromosomes in female somatic cells, X-chromosome inactivation has been shown to act in cis and to initiate and spread from a single site on the X chromosome known as the X-inactivation centre (Xic)(2,3). The Xic has been localized to a 450-kilobase region of the mouse X chromosome(4). The Xist gene also maps to this region and is expressed exclusively from the inactive X chromosome(3-7). Xist is unusual in that it appears not to code for a protein but produces a nuclear RNA which colocalizes with the inactive X chromosome(4,8). The creation of a null allele of Xist in embryonic stem cells has demonstrated that this gene is required for X inactivation to occur in cis(9). Here we show that Xist, introduced onto an autosome, is sufficient by itself far inactivation in cis and that Xist RNA becomes localized close to the autosome into which the gene is integrated. In addition, the presence of autosomal Xist copies leads to activation of the endogeneous Xist gene in some cells, suggesting that elements required for some aspects of chromosome counting are contained within the construct, Thus the Xist gene exhibits properties of the X-inactivation centre.	INST CANC RES, CHESTER BEATTY LABS, CRC, CTR CELL & MOL BIOL, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; HERZING LBK, 1993, GENE, V137, P163, DOI 10.1016/0378-1119(93)90002-K; HERZING LBK, 1995, NUCLEIC ACIDS RES, V23, P4005, DOI 10.1093/nar/23.19.4005; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEHRACH H., 1990, GENOME ANAL, P39; LYON MF, 1992, ANNU REV GENET, V26, P17, DOI 10.1146/annurev.ge.26.120192.000313; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Matsuura S, 1996, HUM MOL GENET, V5, P451, DOI 10.1093/hmg/5.4.451; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; TAN SS, 1993, NAT GENET, V3, P170, DOI 10.1038/ng0293-170	23	214	216	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	1997	386	6622					272	275		10.1038/386272a0	http://dx.doi.org/10.1038/386272a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069284				2022-12-28	WOS:A1997WP00300049
J	Abzug, MJ				Abzug, MJ			Assault against respiratory syncytial virus: Beginning of an era	LANCET			English	Editorial Material							IMMUNE GLOBULIN; INFANTS		CHILDRENS HOSP,DENVER,CO 80218	Children's Hospital Colorado	Abzug, MJ (corresponding author), UNIV COLORADO,SCH MED,DENVER,CO 80218, USA.							Connor E, 1997, PEDIATRICS, V99, P93; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; GROOTHUIS JR, 1995, PEDIATRICS, V95, P463; HAY JW, 1996, AM J MANAG CARE, V2, P851; Meissner HC, 1996, PEDIATR INFECT DIS J, V15, P1059, DOI 10.1097/00006454-199612000-00001; Nightingale SL, 1996, JAMA-J AM MED ASSOC, V275, P902; Simoes Eric A. F., 1996, Pediatric Research, V39, p113A; WHIMBEY E, 1995, BONE MARROW TRANSPL, V16, P393	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					743	744		10.1016/S0140-6736(05)60194-8	http://dx.doi.org/10.1016/S0140-6736(05)60194-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074568				2022-12-28	WOS:A1997WN12400003
J	Printen, JA; Brady, MJ; Saltiel, AR				Printen, JA; Brady, MJ; Saltiel, AR			PTG, a protein phosphatase 1-binding protein with a role in glycogen metabolism	SCIENCE			English	Article							3T3-L1 ADIPOCYTES; INSULIN; KINASE; STIMULATION; EXPRESSION; ACTIVATION; SUBUNIT; PHOSPHORYLATION; IDENTIFICATION; SUFFICIENT	Protein dephosphorylation by phosphatase PP1 plays a central role in mediating the effects of insulin on glucose and lipid metabolism, A PP1C-targeting protein expressed in 3T3-L1 adipocytes (called PTG, for protein targeting to glycogen) was cloned and characterized. PTG was expressed predominantly in insulin-sensitive tissues. In addition to binding and localizing PP1C to glycogen, PTG formed complexes with phosphorylase kinase, phosphorylase a, and glycogen synthase, the primary enzymes involved in the hormonal regulation of glycogen metabolism. Overexpression of PTG markedly increased basal and insulin-stimulated glycogen synthesis in Chinese hamster ovary cells overexpressing the insulin receptor, which do not express endogenous PTG. These results suggest that PTG is critical for glycogen metabolism, possibly functioning as a molecular scaffold.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT CELL BIOL, ANN ARBOR, MI 48105 USA	University of Michigan System; University of Michigan; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; DONELLADEANA A, 1993, BIOCHIM BIOPHYS ACTA, V1178, P189, DOI 10.1016/0167-4889(93)90008-D; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREBS EG, 1964, BIOCHEMISTRY-US, V3, P1022, DOI 10.1021/bi00896a003; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V194, P930, DOI 10.1006/bbrc.1993.1910; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	26	233	239	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 7	1997	275	5305					1475	1478		10.1126/science.275.5305.1475	http://dx.doi.org/10.1126/science.275.5305.1475			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045612				2022-12-28	WOS:A1997WM08100045
J	Lindor, KD				Lindor, KD			Ursodiol for primary sclerosing cholangitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	1996 Digestive Disease Week Meeting	MAY 19-22, 1996	SAN FRANCISCO, CA	Amer Gastroenterol Assoc			PRIMARY BILIARY-CIRRHOSIS; URSODEOXYCHOLIC ACID; CONTROLLED TRIAL; COLCHICINE; BILE	Background There is no satisfactory medical therapy for patients with primary sclerosing cholangitis. Ursodiol (ursodeoxycholic acid) benefits patients with primary biliary cirrhosis, another cholestatic liver disease. Methods From May 1989 to July 1995, we enrolled 105 patients with well-documented primary sclerosing cholangitis in a randomized, double-blind study comparing ursodiol (13 to 15 mg per kilogram of body weight per day in divided doses) with placebo. The primary outcome was the time to treatment failure, defined as death; liver transplantation; histologic progression by two stages (of four) or progression to cirrhosis; the development of varices, ascites, or encephalopathy; sustained quadrupling of the serum bilirubin concentration; marked worsening of fatigue or pruritus; inability to tolerate the drug; or voluntary withdrawal from the study. Results We analyzed data on the 51 patients in each group with at least 3 months of follow-up; the median follow-up was 2.2 years. There was no significant difference between the groups in time to treatment failure (relative risk of treatment failure in the ursodiol group, 1.01; 95 percent confidence interval, 0.6 to 1.7). During the first two years of followup, treatment was unsuccessful in 17 of 32 patients (53 percent) in the placebo group and 16 of 31 (52 percent)in the ursodiol group. There were also no differences in time to treatment failure for patients with early-stage disease or in time to liver transplantation. Ursodiol, but not placebo, was associated with improvement in serum alkaline phosphatase, aspartate aminotransferase, bilirubin, and albumin levels at one and two years. Conclusions In a group of patients with well-defined primary sclerosing cholangitis, ursodiol provided no clinical benefit. (C) 1997, Massachusetts Medical Society.			Lindor, KD (corresponding author), MAYO CLIN & MAYO FDN,200 1ST ST SW,ROCHESTER,MN 55905, USA.							ALLISON MC, 1986, J HEPATOL, V3, P118, DOI 10.1016/S0168-8278(86)80155-6; BEUERS U, 1992, HEPATOLOGY, V16, P707, DOI 10.1002/hep.1840160315; CHAZOUILLERES O, 1990, J HEPATOL, V11, P120, DOI 10.1016/0168-8278(90)90281-U; DICKSON ER, 1992, GASTROENTEROLOGY, V103, P1893, DOI 10.1016/0016-5085(92)91449-E; GRIJM R, 1986, DIGEST DIS SCI, V31, P792, DOI 10.1007/BF01296045; HASHIMOTO E, 1993, MAYO CLIN PROC, V68, P1049, DOI 10.1016/S0025-6196(12)60897-0; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KNOX TA, 1994, GASTROENTEROLOGY, V106, P494, DOI 10.1016/0016-5085(94)90610-6; LARUSSO NF, 1988, GASTROENTEROLOGY, V95, P1036, DOI 10.1016/0016-5085(88)90180-1; LEE YM, 1995, NEW ENGL J MED, V332, P924, DOI 10.1056/NEJM199504063321406; LINDOR KD, 1991, AM J GASTROENTEROL, V86, P57; LINDOR KD, 1994, GASTROENTEROLOGY, V106, P1284, DOI 10.1016/0016-5085(94)90021-3; LUDWIG J, 1978, VIRCHOWS ARCH A, V379, P103, DOI 10.1007/BF00432479; MANDAL A, 1994, GASTROENTEROLOGY, V106, P185, DOI 10.1016/S0016-5085(94)95271-X; OBRIEN CB, 1992, HEPATOLOGY, V15, P566; OLSSON R, 1995, GASTROENTEROLOGY, V108, P1199, DOI 10.1016/0016-5085(95)90220-1; POUPON RE, 1994, NEW ENGL J MED, V330, P1342, DOI 10.1056/NEJM199405123301903; ROSSI SS, 1987, J LIPID RES, V28, P589; STIEHL A, 1994, J HEPATOL, V20, P57, DOI 10.1016/S0168-8278(05)80467-2; VANTHIEL DH, 1995, AM J GASTROENTEROL, V90, P455; WEISNER RH, 1985, GASTROENTEROLOGY, V88, P108	21	445	460	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					691	695		10.1056/NEJM199703063361003	http://dx.doi.org/10.1056/NEJM199703063361003			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041099				2022-12-28	WOS:A1997WL41900003
J	Alderman, EL; Andrews, K; Brooks, MM; Detre, K; Kelsey, SF; Rosen, AD; SuttonTyrrell, K; Bourassa, M; Chaitman, BR; Faxon, DP; Follmann, D; Sopko, G; Frye, RL; Schaff, H; Hlatky, M; Jones, RH; Sellers, MA; Rogers, WJ; Williams, DO				Alderman, EL; Andrews, K; Brooks, MM; Detre, K; Kelsey, SF; Rosen, AD; SuttonTyrrell, K; Bourassa, M; Chaitman, BR; Faxon, DP; Follmann, D; Sopko, G; Frye, RL; Schaff, H; Hlatky, M; Jones, RH; Sellers, MA; Rogers, WJ; Williams, DO			Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease - A multicenter randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REVASCULARIZATION INVESTIGATION BARI; ARTERY-DISEASE; ANGINA	Objective.-To compare clinical and functional status in patients who had similar 5-year survival after coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA). Design.-Randomized trial of 1829 patients followed for an average 5.4 years. Participants.-Patients with multivessel coronary artery disease suitable for both CABG and PTCA and not previously revascularized. Intervention.-Coronary artery bypass grafting or PTCA within 2 weeks after randomization. Outcome Measures.-Symptoms, exercise test results, medication use, and quality-of-life measures collected at 4 to 14 weeks, and at 1, 3, and 5 years after randomization. Analysis.-Intention to treat. Results.-Differences in angina-free rates between patients assigned to PTCA and CABG decreased from 73% vs 95% at 4 to 14 weeks (P<.001) to 79% vs 85% at 5 years (P=.007). Similar patterns were observed for exercise-induced angina and ischemia, except 5-year differences were not significant. At follow-up of 1 year and later, quality of life, return to work, modification of smoking and exercise behaviors, and cholesterol levels were similar for the 2 treatments. Compared with patients assigned to CABG, use of anti-ischemic medication was higher in patients assigned to PTCA, while smaller differences were observed for other medications. Among patients angina-free at 5 years, 52% of patients who had PTCA required revascularization after the initial procedure vs 6% of patients who had CABG. Conclusions.-The narrowing of treatment differences in angina and exercise-induced ischemia rates can be attributed to a return of symptoms among patients assigned to CABG and incremental surgical procedures among patients assigned to PTCA. Patients assigned to PTCA apparently were able to tolerate higher rates of residual ischemia as evidenced by comparable quality of life and 5-year survival.	UNIV PITTSBURGH, BARI COORDINATING CTR, PITTSBURGH, PA 15261 USA; STANFORD UNIV, CTR MED, CENT RADIOG LAB, STANFORD, CA 94305 USA; MONTREAL HEART INST, MONTREAL, PQ H1T 1C8, CANADA; ST LOUIS UNIV, MED CTR, CENT ELECTROCARDIOG & MYOCARDIAL INFARCT CLASSIFI, ST LOUIS, MO USA; BOSTON UNIV, BOSTON, MA 02215 USA; NHLBI, BETHESDA, MD 20892 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; STANFORD UNIV, SCH MED, STUDY ECON & QUAL LIFE, STANFORD, CA 94305 USA; DUKE UNIV, DURHAM, NC USA; UNIV ALABAMA, BIRMINGHAM, AL USA; BROWN UNIV, RHODE ISL HOSP, PROVIDENCE, RI 02903 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Stanford University; Universite de Montreal; Saint Louis University; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Mayo Clinic; Stanford University; Duke University; University of Alabama System; University of Alabama Birmingham; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL038493, U01HL038509, U01HL038504] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38509, HL38504, HL38493] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alderman EL, 1996, NEW ENGL J MED, V335, P217; [Anonymous], 1995, Lancet, V346, P1179; BOURASSA MG, 1995, AM J CARDIOL, V75, pC3, DOI 10.1016/S0002-9149(99)80389-0; BRUCE RA, 1971, ANN CLIN RES, V3, P323; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; HLATKY MA, 1995, AM J CARDIOL, V75, pC34; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; Pocock SJ, 1996, CIRCULATION, V94, P135, DOI 10.1161/01.CIR.94.2.135; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; ROGERS WJ, 1995, AM J CARDIOL, V75, pC9; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; SCHAFF HV, 1995, AM J CARDIOL, V75, pC18; SIM I, 1995, AM J CARDIOL, V76, P1025, DOI 10.1016/S0002-9149(99)80289-6; WILLIAMS DO, 1995, AM J CARDIOL, V75, pC27	19	168	172	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					715	721						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042843				2022-12-28	WOS:A1997WK02600030
J	Nightingale, SL				Nightingale, SL			Action plan for providing useful prescription information	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1996, JAMA-J AM MED ASSOC, V276, P1128	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					703	703						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042830				2022-12-28	WOS:A1997WK02600009
J	Suchman, AL; Markakis, K; Beckman, HB; Frankel, R				Suchman, AL; Markakis, K; Beckman, HB; Frankel, R			A model of empathic communication in the medical interview	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN; SKILL	Objective.-To formulate an empirically derived model of empathic communication in medical interviews by describing the specific behaviors and patterns of interaction associated with verbal expressions of emotion. Design.-A descriptive, qualitative study of verbal exchanges using 11 transcripts and 12 videotapes of primary care office visits to a total of 21 physicians. Setting.-An urban health maintenence organization (HMO), an urban university-based general medicine clinic, and an urban community hospital general medicine clinic. Analytic Method.-Individual review of transcripts by each research team member to identify instances of expressed or implied emotional themes and to observe the physicians' responses. Individual ratings were compared in group discussions to achieve consensus about the classifications. Similar consensus-based classification was used for review of videotapes. Results.-We observed that patients seldom verbalize their emotions directly and spontaneously, tending to offer clues instead, If invited to elaborate, patients may then express the emotional concern directly, and the physician may respond with an accurate and explicit acknowledgment. In most of the interviews, the physicians allowed both clues and direct expressions of affect to pass without acknowledgment, returning instead to the preceding topic, usually the diagnostic exploration of symptoms, With emotional expression so terminated, some patients attempted to raise the topic again, sometimes repeatedly and with escalating intensity. We noted a parallel dynamic for encounters in which patients sought praise, We summarized the full interactional sequence in a simple descriptive model, Conclusions.-This empirically derived model of empathic communication has practical implications for clinicians and students who want to improve their communication and relationship skills. Based on our observations, the basic empathic skills seem to be recognizing when emotions may be present but not directly expressed, inviting exploration of these unexpressed feelings, and effectively acknowledging these feelings so the patient feels understood, The frequent lack of acknowledgment by physicians of both direct and indirect expressions of affect poses a threat to the patient-physician relationship and warrants further study.	HIGHLAND HOSP,DEPT MED,ROCHESTER,NY 14620; UNIV ROCHESTER,DEPT MED,PROGRAM BIOPSYCHOSOCIAL STUDIES,ROCHESTER,NY; UNIV ROCHESTER,DEPT PSYCHIAT,ROCHESTER,NY	University of Rochester; University of Rochester; University of Rochester	Suchman, AL (corresponding author), HIGHLAND HOSP,PRIMARY CARE INST,1000 S AVE,ROCHESTER,NY 14620, USA.							BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BELLET PS, 1991, JAMA-J AM MED ASSOC, V266, P1831, DOI 10.1001/jama.266.13.1831; BRANCH WT, 1993, JAMA-J AM MED ASSOC, V269, P1667, DOI 10.1001/jama.269.13.1667; CARKHUFF RR, 1974, ART HELPING GUIDE DE; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; COHEN SM, 1991, PROG EXP TUMOR RES, V33, P21; DiMatteo M R, 1980, J Community Health, V6, P18; DIMATTEO MR, 1980, MED CARE, V18, P376, DOI 10.1097/00005650-198004000-00003; DOYLE BJ, 1977, J MED EDUC, V52, P793; Engel G. L, 1988, TASK MED DIALOGUE WI, P113; ENGEL GL, 1987, AM J MED, V82, P107, DOI 10.1016/0002-9343(87)90384-6; GAZDA GM, 1973, HUMAN RELATIONS DEV; Havens L., 1986, MAKING CONTACT USES; INUI TS, 1992, MED SCH MISSION POPU, P23; Kleinman A., 1988, RETHINKING PSYCHIAT, P108; MATTHEWS DA, 1989, J GEN INTERN MED, V4, P14, DOI 10.1007/BF02596484; MILLER WR, 1991, J CLIN PSYCHOL, V47, P444, DOI 10.1002/1097-4679(199105)47:3<444::AID-JCLP2270470320>3.0.CO;2-U; Morse J M, 1992, Image J Nurs Sch, V24, P273; MORSE JM, 1992, J ADV NURS, V17, P809, DOI 10.1111/j.1365-2648.1992.tb02002.x; O'Neil EH, 1993, HLTH PROFESSIONS ED; Olson J K, 1991, Can J Nurs Res, V23, P49; PLATT FW, 1994, J GEN INTERN MED, V9, P222, DOI 10.1007/BF02600129; *PROJ PAN GEN PROF, 1984, J MED EDUC, V59, P1; SPIRO H, 1992, ANN INTERN MED, V116, P843, DOI 10.7326/0003-4819-116-10-843; *SUBC EV HUM QUAL, 1983, ANN INTERN MED, V99, P720; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; TRUAX CB, 1961, PROCESS GROUP PSYCHO; Valentine K L, 1991, J Nurs Qual Assur, V5, P59; ZINN W, 1993, ARCH INTERN MED, V153, P306, DOI 10.1001/archinte.153.3.306	30	492	502	1	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					678	682		10.1001/jama.277.8.678	http://dx.doi.org/10.1001/jama.277.8.678			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039890				2022-12-28	WOS:A1997WJ49800041
J	Quinn, JP				Quinn, JP			Rational antibiotic therapy for intraabdominal infections	LANCET			English	Editorial Material											Quinn, JP (corresponding author), UNIV ILLINOIS,DEPT MED,CHICAGO,IL 60612, USA.							BOHNEN JMA, 1992, ARCH SURG-CHICAGO, V127, P83; Christou NV, 1996, ARCH SURG-CHICAGO, V131, P1193; GORBACH SL, 1993, CLIN INFECT DIS, V17, P961, DOI 10.1093/clinids/17.6.961; Montravers P, 1996, CLIN INFECT DIS, V23, P486, DOI 10.1093/clinids/23.3.486; SCHEIN M, 1994, BRIT J SURG, V81, P989, DOI 10.1002/bjs.1800810720	5	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					517	518		10.1016/S0140-6736(97)80079-7	http://dx.doi.org/10.1016/S0140-6736(97)80079-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048784				2022-12-28	WOS:A1997WJ51200003
J	Richard, F; Helbecque, N; Neuman, E; Guez, D; Levy, R; Amouyel, P				Richard, F; Helbecque, N; Neuman, E; Guez, D; Levy, R; Amouyel, P			APOE genotyping and response to drug treatment in Alzheimer's disease	LANCET			English	Article									INST PASTEUR,INSERM,CJF 9505,F-59019 LILLE,FRANCE; INST RECH INT SERVIER,F-92415 COURBEVOIE,FRANCE; INST PSYCHIAT,OLD AGE PSYCHIAT SECT,LONDON SE5 8AF,ENGLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Servier; Institut de Recherches Internationales Servier; University of London; King's College London				Amouyel, Philippe/0000-0001-9088-234X				ALLAIN H, 1996, JA M GERIATR SOC, V45, P125; GUEZ D, 1995, DEV DEMENTIA FUNCTIO, P69; *NAT I AG ALZH ASS, 1996, LANCET, V347, P1091; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; vanGool WA, 1996, LANCET, V348, P961, DOI 10.1016/S0140-6736(05)65373-1	5	64	72	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					539	539		10.1016/S0140-6736(97)80089-X	http://dx.doi.org/10.1016/S0140-6736(97)80089-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048794				2022-12-28	WOS:A1997WJ51200013
J	Gateley, CA; Bundred, NJ				Gateley, CA; Bundred, NJ			Alopecia and breast disease	BRITISH MEDICAL JOURNAL			English	Letter											Gateley, CA (corresponding author), UNIV S MANCHESTER HOSP,DEPT SURG,NELL LANE,MANCHESTER M20 8LR,LANCS,ENGLAND.							FENTIMAN IS, 1987, LANCET, V1, P1070; HAMED H, 1990, ANN ROY COLL SURG, V72, P221; NICHOLSON RI, 1989, HORM RES, V32, P198, DOI 10.1159/000181345; PARKER F, 1981, TXB ENDOCRINOLOGY, P1080	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					481	481		10.1136/bmj.314.7079.481	http://dx.doi.org/10.1136/bmj.314.7079.481			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056798	Green Published			2022-12-28	WOS:A1997WJ41900027
J	Weatherall, DJ				Weatherall, DJ			ABC of clinical haematology - The hereditary anaemias	BRITISH MEDICAL JOURNAL			English	Review											Weatherall, DJ (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND.							Davies S C, 1991, Baillieres Clin Haematol, V4, P361, DOI 10.1016/S0950-3536(05)80164-7; OLIVIERI NF, 1995, CURRENT THERAPY HEMA, P80; WEATHERALL DJ, IN PRESS WILLIAMS HE; Weatherall DJ, 1994, MOL BASIS BLOOD DIS, P157	4	27	27	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					492	496		10.1136/bmj.314.7079.492	http://dx.doi.org/10.1136/bmj.314.7079.492			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056802	Green Published			2022-12-28	WOS:A1997WJ41900031
J	Beals, CR; Sheridan, CM; Turck, CW; Gardner, P; Crabtree, GR				Beals, CR; Sheridan, CM; Turck, CW; Gardner, P; Crabtree, GR			Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3	SCIENCE			English	Article							T-CELL ACTIVATION; CYCLOSPORINE-A; GENE; FAMILY; IDENTIFICATION; CALCINEURIN; PROMOTER; MEMBERS; PRODUCT; SIGNAL	The transcription factor NF-AT responds to Ca2+-calcineurin signals by translocating to the nucleus, where it participates in the activation of early immune response genes. Calcineurin dephosphorylates conserved serine residues in the amino terminus of NF-AT, resulting in nuclear import. Purification of the NF-AT kinase revealed that it is composed of a priming kinase activity and glycogen synthase kinase-3 (GSK-3). GSK-3 phosphorylates conserved serines necessary for nuclear export, promotes nuclear exit, and thereby opposes Ca2+-calcineurin signaling. Because GSK-3 responds to signals initiated by Wnt and other ligands, NF-AT family members could be effecters of these pathways.	STANFORD UNIV, DEPT MOL PHARMACOL, STANFORD, CA 94305 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	Stanford University; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Beals, CR (corresponding author), STANFORD UNIV, HOWARD HUGHES MED INST, DEPT DEV BIOL, STANFORD, CA 94305 USA.							BEALS CR, UNPUB; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MARY D, 1987, J IMMUNOL, V139, P1179; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564	34	611	639	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	1997	275	5308					1930	1933		10.1126/science.275.5308.1930	http://dx.doi.org/10.1126/science.275.5308.1930			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072970				2022-12-28	WOS:A1997WQ51300045
J	Lawson, TM; Borysiewicz, LK; Camilleri, JP; Jessop, JD; Pritchard, MH; Williams, BD				Lawson, TM; Borysiewicz, LK; Camilleri, JP; Jessop, JD; Pritchard, MH; Williams, BD			Focal myositis mimicking acute psoas abscess - An unusual presentation of systemic lupus erythematosus	BRITISH MEDICAL JOURNAL			English	Editorial Material							LOCALIZED NODULAR MYOSITIS; INCLUSION-BODY MYOSITIS; POLYMYOSITIS; MUSCLE; DERMATOMYOSITIS; DIAGNOSIS; DISEASE	We describe an unusual presentation of severe focal muscle inflammation in a young woman in whom the clinical and radiological findings were suggestive of a psoas abscess, Eighteen months after the onset of her illness, systemic lupus erythematosus was diagnosed.			Lawson, TM (corresponding author), UNIV WALES HOSP,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.							BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; BROWN P, 1989, BRIT J RHEUMATOL, V28, P84; CUMMING WJK, 1977, Q J MED, V184, P531; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DENMAN AM, 1988, POLYMYOSITIS DERMATO, P97; DESANDRE AR, 1995, AM SURGEON, V61, P1087; ESTES D, 1971, MEDICINE, V50, P85, DOI 10.1097/00005792-197103000-00001; FEINGLASS EJ, 1976, MEDICINE, V55, P323, DOI 10.1097/00005792-197607000-00004; FOOTE RA, 1982, MUSCLE NERVE, V5, P65, DOI 10.1002/mus.880050112; HASSELL AB, 1944, BR J RHEUMATOL, V33, P687; HEFFNER RR, 1981, ARCH NEUROL-CHICAGO, V38, P439, DOI 10.1001/archneur.1981.00510070073013; HEFFNER RR, 1977, CANCER-AM CANCER SOC, V40, P301, DOI 10.1002/1097-0142(197707)40:1<301::AID-CNCR2820400142>3.0.CO;2-N; ISENBERG DA, 1981, J RHEUMATOL, V8, P917; LEFF RL, 1992, LANCET, V339, P1192, DOI 10.1016/0140-6736(92)91134-T; LIM KL, 1994, ANN RHEUM DIS, V53, P178, DOI 10.1136/ard.53.3.178; LOTZ BP, 1989, BRAIN, V112, P727, DOI 10.1093/brain/112.3.727; NAUGHTON M, 1993, BRIT J RHEUMATOL, V32, P1101; RUFF RL, 1989, VIRAL DIS HDB CLIN N, P193; Schwartz M M, 1995, Curr Opin Nephrol Hypertens, V4, P162, DOI 10.1097/00041552-199503000-00009; SMITH CA, 1981, J RHEUMATOL, V8, P815; TSOKOS GC, 1981, JAMA-J AM MED ASSOC, V246, P766, DOI 10.1001/jama.246.7.766	22	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					805	808		10.1136/bmj.314.7083.805	http://dx.doi.org/10.1136/bmj.314.7083.805			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9081002	Green Published			2022-12-28	WOS:A1997WN64600032
J	Geiduschek, EP				Geiduschek, EP			Transcription - Paths to activation of transcription	SCIENCE			English	Editorial Material							BINDING PROTEIN NTRC; COLI RNA-POLYMERASE; MECHANISM; CONTACT		UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	Geiduschek, EP (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; JIN RZ, 1995, J BIOL CHEM, V270, P19213, DOI 10.1074/jbc.270.33.19213; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; Miller A, 1997, SCIENCE, V275, P1655, DOI 10.1126/science.275.5306.1655; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; RECORD J, 1996, ESCHERICHIA COLI SAL, P792; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; Wang JT, 1996, J BIOL CHEM, V271, P32707, DOI 10.1074/jbc.271.51.32707; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658	19	6	7	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1614	1616		10.1126/science.275.5306.1614	http://dx.doi.org/10.1126/science.275.5306.1614			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9072826				2022-12-28	WOS:A1997WN12300035
J	Ijaz, T; Jones, K				Ijaz, T; Jones, K			Intramedullary spinal cord metastases	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Ijaz, T (corresponding author), MANITOBA CANC TREATMENT & RES FDN,WINNIPEG,MB R3E 0V9,CANADA.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					768	768		10.1056/NEJM199703133361105	http://dx.doi.org/10.1056/NEJM199703133361105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM640	9052655				2022-12-28	WOS:A1997WM64000005
J	Burnum, JF				Burnum, JF			A physician's hamlet	ANNALS OF INTERNAL MEDICINE			English	Article																		BERTRAM J, 1968, 20 CENTURY INTERPRET, P93; BRADDY H, 1974, HARMLETS WOUNDED NAM, P1; BYNUM WF, 1985, ANATOMY MADNESS ESSA, P289; GOTTSCHALK P, 1972, MEANINGS HAMLET MODE, P25; GOTTSCHALK P, 1972, MEANINGS HAMLET MODE, P142; LEVIN H, 1968, 29 CENTURY INTERPRET, P73; SHAKESPEARE W, 1939, TRAGEDY HAMLET PRINC, P204; WILSON JD, 1956, HAMLET, P200; WILSON JD, 1956, WHAT HAPPENS HAMLET, P49	9	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					412	414		10.7326/0003-4819-126-5-199703010-00025	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00025			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL104	9054297				2022-12-28	WOS:A1997WL10400025
J	Lee, TT; Solomon, NA; Heidenreich, PA; Oehlert, J; Garber, AM				Lee, TT; Solomon, NA; Heidenreich, PA; Oehlert, J; Garber, AM			Cost-effectiveness of screening for carotid stenosis in asymptomatic persons	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Society-of-General-Internal-Medicine Meeting	MAR 10, 1995	SAN DIEGO, CA	Soc Gen Internal Med		endarterectomy, carotid; mass screening; cost-benefit analysis; quality-adjusted life-years; ultrasonography, Doppler, duplex	MYOCARDIAL-INFARCTION; MR-ANGIOGRAPHY; ARTERY DISEASE; RISK-FACTORS; ENDARTERECTOMY; STROKE; PREVALENCE; POPULATION; SURVIVAL; MORTALITY	Background: The Asymptomatic Carotid Atherosclerosis Study (ACAS) showed that carotid endarterectomy was beneficial for symptom-free patients with carotid stenosis of 60% or more. This finding raises the question of whether widespread screening to identify cases of asymptomatic carotid stenosis should be implemented. Objective: To determine whether a screening program to identify cases of asymptomatic carotid stenosis would be a cost-effective strategy for stroke prevention. Design: Cost-effectiveness analysis using published data from clinical trials. Setting: General population of asymptomatic 65-year-old men. Intervention: Patients who were screened for carotid disease with duplex Doppler ultrasonography were compared with patients who were not screened. If ultrasonography found significant carotid stenosis (greater than or equal to 60%), disease was confirmed by angiography before carotid endarterectomy was done. Measurements: Quality-adjusted life-years, costs, and marginal cost-effectiveness ratios. Results: When the conditions and results of ACAS were modeled and it was assumed that the survival advantage produced by endarterectomy would last for 30 years, the lifetime marginal cost-effectiveness of screening relative to no screening was $120 000 per quality-adjusted life-year. Sensitivity analysis showed that marginal cost-effectiveness decreased to $50 000 or less per quality-adjusted life-year only under implausible conditions (for example, if a free screening instrument with perfect test characteristics was used or an asymptomatic population with a 40% prevalence of carotid stenosis was found). Conclusions: Surgery offers a real but modest absolute reduction in the rate of stroke at a substantial cost. A program to identify candidates for endarterectomy by screening asymptomatic populations for carotid stenosis costs more per quality-adjusted life-year than is usually considered acceptable.	KAISER PERMANENTE, OAKLAND, CA 94612 USA; STANFORD UNIV, SCH MED, DIV RHEUMATOL & IMMUNOL, STANFORD, CA 94305 USA	Kaiser Permanente; Stanford University			Heidenreich, Paul/AAU-6864-2021; Garber, Alan M/F-1476-2010	Heidenreich, Paul/0000-0001-7730-8490; 	PHS HHS [28-9, 00028-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barnett H. J. M., 1992, STROKE PATHOPHYSIOLO; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERNSTEIN EF, 1983, ANN SURG, V198, P80, DOI 10.1097/00000658-198307000-00016; BLAKELEY DD, 1995, ANN INTERN MED, V122, P360, DOI 10.7326/0003-4819-122-5-199503010-00007; BLATTER DD, 1993, AM J ROENTGENOL, V161, P1269, DOI 10.2214/ajr.161.6.8249741; *CAL OFF STAT HLTH, 1991, 1991 CAL AC CAR HOSP; CARACCIOLO EA, 1995, CIRCULATION, V91, P2325, DOI 10.1161/01.CIR.91.9.2325; COLGAN MP, 1988, J VASC SURG, V8, P674, DOI 10.1067/mva.1988.avs0080674; COTE R, 1995, ANN INTERN MED, V123, P649, DOI 10.7326/0003-4819-123-9-199511010-00002; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; DIENER HC, 1991, STROKE, V22, P1229; FEUSSNER JR, 1988, ANN INTERN MED, V109, P805, DOI 10.7326/0003-4819-109-10-805; FOWL RJ, 1991, SURG GYNECOL OBSTET, V172, P13; FUCHS VR, 1990, NEW ENGL J MED, V323, P673, DOI 10.1056/NEJM199009063231011; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; GRESHAM GE, 1979, ARCH PHYS MED REHAB, V60, P487; GRZYSKA U, 1990, NEURORADIOLOGY, V32, P296, DOI 10.1007/BF00593048; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; *HEALTHC CONS AM, 1994, PHYS FEE COD GUID; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; HERTZER NR, 1985, J VASC SURG, V2, P661, DOI 10.1067/mva.1985.avs0020661; *HLTH CAR FIN ADM, 1994, HLTH CAR FIN ADM COM; *HLTH CAR INV AN, 1991, MED DRG HDB COMP CLI; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; JENNETT B, 1975, LANCET, V1, P480; JOSSE M O, 1987, Neuroepidemiology, V6, P150, DOI 10.1159/000110110; KEELER EB, 1983, MANAGE SCI, V29, P300, DOI 10.1287/mnsc.29.3.300; KENT KC, 1995, JAMA-J AM MED ASSOC, V274, P888, DOI 10.1001/jama.274.11.888; KRAISS LW, 1995, AM J SURG, V169, P512, DOI 10.1016/S0002-9610(99)80207-4; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lipscomb J., 1996, COST EFFECTIVENESS H; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LUNA G, 1995, AM J SURG, V169, P516, DOI 10.1016/S0002-9610(99)80208-6; MANI RL, 1978, AM J ROENTGENOL, V131, P867, DOI 10.2214/ajr.131.5.867; MATTOS MA, 1992, J CARDIOVASC SURG, V33, P387; MITTL RL, 1994, STROKE, V25, P4, DOI 10.1161/01.STR.25.1.4; MOORE WS, 1979, AM J SURG, V138, P228, DOI 10.1016/0002-9610(79)90375-1; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; PRATI P, 1992, STROKE, V23, P1705, DOI 10.1161/01.STR.23.12.1705; RAMSEY DE, 1987, J VASC SURG, V5, P584, DOI 10.1067/mva.1987.avs0050584; Ricco J B, 1992, Ann Vasc Surg, V6, P408, DOI 10.1007/BF02006994; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; Robins M, 1981, STROKE, V12, pI7; SHRIVER ME, 1993, CURR OPIN NEUROL NEU, V6, P74; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Torrance GW, 1987, METHODS EC EVALUATIO; Torrance GW, 1996, COST EFFECTIVENESS H; TOWNE JB, 1990, J VASC SURG, V11, P252, DOI 10.1067/mva.1990.16484; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; *US DEP HHS, 1990, VIT STAT US; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Weinstein MC, 1980, CLIN DECISION ANAL; WHITE JE, 1994, AM SURGEON, V60, P340; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513; WILLEIT J, 1993, ARTERIOSCLER THROMB, V13, P661, DOI 10.1161/01.ATV.13.5.661; WILSON DL, 1994, MECH AGEING DEV, V74, P15, DOI 10.1016/0047-6374(94)90095-7; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852	62	111	113	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					337	+		10.7326/0003-4819-126-5-199703010-00001	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WL104	9054277				2022-12-28	WOS:A1997WL10400001
J	Petosa, C; Collier, RJ; Klimpel, KR; Leppla, SH; Liddington, RC				Petosa, C; Collier, RJ; Klimpel, KR; Leppla, SH; Liddington, RC			Crystal structure of the anthrax toxin protective antigen	NATURE			English	Article							LETHAL FACTOR; MAMMALIAN-CELLS; MEMBRANE; CHANNELS	Protective antigen (PA) is the central component of the three-part protein toxin secreted by Bacillus anthracis, the organism responsible for anthrax(1). After proteolytic activation on the host cell surface, PA forms a membrane-inserting heptamer that translocates the toxic enzymes, oedema factor and lethal factor, into the cytosol(2-4). PA, which has a relative molecular mass of 83,000 (M(r) 83K), can also translocate heterologous proteins, and is being evaluated for use as a general protein delivery system(5,6). Here we report the crystal structure of monomeric PA at 2.1 Angstrom resolution and the water-soluble heptamer at 4.5 Angstrom resolution, The monomer is organized mainly into antiparallel beta-sheets and has four domains: an amino-terminal domain (domain 1) containing two calcium ions and the cleavage site for activating proteases; a heptamerization domain (domain 2) containing a large flexible loop implicated in membrane insertion; a small domain of unknown function (domain 3); and a carboxy-terminal receptor-binding domain (domain 4). Removal of a 20K amino-terminal fragment from domain 1 allows the assembly of the heptamer, a ring-shaped structure with a negatively charged lumen, and exposes a large hydrophobic surface for binding the toxic enzymes. We propose a model of pH-dependent membrane insertion involving the formation of a porin-like, membrane-spanning beta-barrel.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA; NIDR, MICROBIAL ECOL LAB, NIH, BETHESDA, MD 20982 USA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Petosa, C (corresponding author), UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND.			Collier, R John/0000-0002-2427-4239; Petosa, Carlo/0000-0002-9975-1167				ARORA N, 1993, J BIOL CHEM, V268, P3334; Blanke SR, 1996, P NATL ACAD SCI USA, V93, P8437, DOI 10.1073/pnas.93.16.8437; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P905, DOI 10.1085/jgp.96.5.905; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; KREUSCH A, 1994, PROTEIN SCI, V3, P58; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; Little SF, 1996, MICROBIOL-SGM, V142, P707, DOI 10.1099/13500872-142-3-707; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; Nicholls A., 1992, GRASP GRAPHICAL REPR; NOVAK JM, 1992, J BIOL CHEM, V267, P17186; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; SINGH Y, 1991, J BIOL CHEM, V266, P15493; SINGH Y, 1994, J BIOL CHEM, V269, P29039; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TURNBULL P, 1990, TOPLEY WILSONS PRINC, P365; WARREN G, 1996, Patent No. 10083; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	30	649	704	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 27	1997	385	6619					833	838		10.1038/385833a0	http://dx.doi.org/10.1038/385833a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039918				2022-12-28	WOS:A1997WK57000058
J	Stack, WA; Mann, SD; Roy, AJ; Heath, P; Sopwith, M; Freeman, J; Holmes, G; Long, R; Forbes, A; Kamm, MA; Hawkey, CJ				Stack, WA; Mann, SD; Roy, AJ; Heath, P; Sopwith, M; Freeman, J; Holmes, G; Long, R; Forbes, A; Kamm, MA; Hawkey, CJ			Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease	LANCET			English	Article							CHIMERIC MONOCLONAL-ANTIBODY; DOUBLE-BLIND; CYCLOSPORINE; PLACEBO; CELLS; INDEX; CA2	Background Tumour necrosis factor-alpha (TNF alpha) is thought to have a central role in the pathogenesis of Crohn's disease. We tested the hypothesis that CDP571, a genetically engineered human antibody to TNF alpha, is effective in modifying disease activity in patients with moderately active Crohn's disease. Methods In this double-blind, placebo-controlled study, 31 patients were randomly assigned to CDP571 (n=21) or placebo (n=10). The primary endpoint was change in Crohn's disease activity index 2 weeks after a single infusion of CDP571 (5 mg/kg), or human albumin as placebo. One patient who attended no follow-up assessments was excluded from the analyses (CDP571 group). Findings The median Crohn's disease activity index fell from 263 (IQR 186.5-323.5) at baseline to 167 (137.5-294.0) at 2 weeks in the CDP571-treated patients (p=0.0003); the change in the placebo group (253 [240-334] to 247 [183-256]) was not significant. In the treated group, there were also significant differences between baseline and 2 weeks in Harvey-Bradshaw score (p=0.0005), hey symptom score (p=0.049), alpha 1-glycoprotein concentration (p=0.012), and erythrocyte sedimentation rate (p=0.01); concentrations of C-reactive protein fell, but not significantly (p=0.067). Six patients achieved remission (Crohn's disease activity index less than or equal to 150) and three others had activity indices of 156 or lower. There were no significant changes in the placebo group. Interpretation A single 5 mg/kg infusion of CDP571 reduced disease activity in Crohn's disease at 2 weeks. These data suggest that antibody neutralisation of TNF alpha is a potentially effective strategy in the management of Crohn's disease. The use of CDP571 in Crohn's disease requires further study.	UNIV NOTTINGHAM HOSP,DIV GASTROENTEROL,NOTTINGHAM NG7 2UH,ENGLAND; CITY HOSP NOTTINGHAM,DIV GASTROENTEROL,NOTTINGHAM,ENGLAND; ST MARKS HOSP,LONDON EC1V 2PS,ENGLAND; CELLTECH THERAPEUT LTD,SLOUGH,BERKS,ENGLAND; DERBY CITY & ROYAL INFIRM,DERBY,ENGLAND	University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Imperial College London; Celltech Group Ltd				Forbes, Alastair/0000-0001-7416-9843				BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J; BREESE EJ, 1994, GASTROENTEROLOGY, V106, P1455, DOI 10.1016/0016-5085(94)90398-0; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; DERKX B, 1993, LANCET, V342, P173, DOI 10.1016/0140-6736(93)91375-V; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; FEAGAN BG, 1994, NEW ENGL J MED, V330, P1846, DOI 10.1056/NEJM199406303302602; HARVEY RF, 1980, LANCET, V1, P514; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; LE JM, 1987, LAB INVEST, V56, P234; Lorenz HM, 1996, J IMMUNOL, V156, P1646; LUKACS NW, 1994, J IMMUNOL, V152, P5883; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; RANKIN ECC, 1995, ARTHRITIS RHEUM, V38, pA197; REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174; SINGLETON JW, 1993, GASTROENTEROLOGY, V104, P1293, DOI 10.1016/0016-5085(93)90337-C; STEPHENS S, 1995, IMMUNOLOGY, V85, P668; STRANGE EF, 1995, GASTROENTEROLOGY, V109, P774; STRONKHORST A, 1992, SCAND J GASTROENTERO, V27, P61, DOI 10.3109/00365529209096029; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5	20	357	386	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					521	524		10.1016/S0140-6736(97)80083-9	http://dx.doi.org/10.1016/S0140-6736(97)80083-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048788				2022-12-28	WOS:A1997WJ51200007
J	Goldman, MJ; Anderson, GM; Stolzenberg, ED; Kari, UP; Zasloff, M; Wilson, JM				Goldman, MJ; Anderson, GM; Stolzenberg, ED; Kari, UP; Zasloff, M; Wilson, JM			Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis	CELL			English	Article							HUMAN BRONCHIAL EPITHELIA; ANTIMICROBIAL PEPTIDE; MESSENGER-RNA; GENE-TRANSFER; PANETH CELLS; DEFENSINS; CFTR; INFLAMMATION; XENOGRAFTS; INFECTION	A human bronchial xenograft model was used to characterize the molecular basis for the previously described defect in bacterial killing that is present in the cystic fibrosis (CF) lung. Airway surface fluid from CF grafts contained abnormally high NaCl and failed to kill bacteria, defects that were corrected with adenoviral vectors. A full-length clone for the only known human beta-defensin (i.e., hBD-1) was isolated. This gene is expressed throughout the respiratory epithelia of non-CF and CF lungs, and its protein product shows salt-dependent antimicrobial activity to P. aeruginosa. Antisense oligonucleotides to hBD-1 ablated the antimicrobial activity in airway surface fluid from non-CF grafts. These data suggest that hBD-1 plays an important role in innate immunity that is compromised in CF by its salt-dependent inactivation.	UNIV PENN,MED CTR,WISTAR INST,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,WISTAR INST,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; MAGAININ PHARMACEUT INC,MAGAININ RES INST,PLYMOUTH MEETING,PA 19462	The Wistar Institute; University of Pennsylvania; The Wistar Institute; University of Pennsylvania	Goldman, MJ (corresponding author), UNIV PENN,MED CTR,WISTAR INST,DEPT MED,PHILADELPHIA,PA 19104, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				ARMSTRONG DS, 1995, BRIT MED J, V310, P1571, DOI 10.1136/bmj.310.6994.1571; Armstrong DS, 1996, PEDIATR PULM, V21, P267, DOI 10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3446, DOI 10.1128/IAI.60.8.3446-3447.1992; ENGELHARDT JF, 1995, DEVELOPMENT, V121, P2031; ENGELHARDT JF, 1992, J CLIN INVEST, V90, P2598, DOI 10.1172/JCI116155; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; ENGELHARDT JF, 1993, HUM GENE THER, V4, P759, DOI 10.1089/hum.1993.4.6-759; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8995; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; GILLJAM H, 1989, SCAND J CLIN LAB INV, V49, P121, DOI 10.3109/00365518909105409; GOLDMAN MJ, 1995, NAT GENET, V9, P126, DOI 10.1038/ng0295-126; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; Kellenberger C, 1995, PEPTIDE RES, V8, P321; Mallow EB, 1996, J BIOL CHEM, V271, P4038; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; Russell JP, 1996, INFECT IMMUN, V64, P1565, DOI 10.1128/IAI.64.5.1565-1568.1996; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; TANG H, 1995, INFECT IMMUN, V63, P1278, DOI 10.1128/IAI.63.4.1278-1285.1995; VASCONCELLOS CA, 1994, SCIENCE, V263, P969, DOI 10.1126/science.8310295; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC332, DOI 10.1152/ajpcell.1991.261.2.C332; Zhang YL, 1996, AM J PHYSIOL-CELL PH, V270, pC1326, DOI 10.1152/ajpcell.1996.270.5.C1326	37	863	899	0	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					553	560		10.1016/S0092-8674(00)81895-4	http://dx.doi.org/10.1016/S0092-8674(00)81895-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038346	hybrid			2022-12-28	WOS:A1997WJ69100015
J	MayonWhite, RT				MayonWhite, RT			Assessing the effects of environmental pollution when people know that they have been exposed - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material											MayonWhite, RT (corresponding author), OXFORDSHIRE HLTH AUTHOR,DIRECTORATE PUBL HLTH & HLTH POLICY,OXFORD OX3 7LG,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					343	343		10.1136/bmj.314.7077.343	http://dx.doi.org/10.1136/bmj.314.7077.343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040325	Green Published			2022-12-28	WOS:A1997WF86100031
J	Gray, WA; DuBroff, RJ; White, HJ				Gray, WA; DuBroff, RJ; White, HJ			A common clinical conundrum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	1996 Santa Fe Symposium	1996	SANTA FE, NM				TRANS-LUMINAL ANGIOPLASTY; CAROTID ARTERIES				Gray, WA (corresponding author), PRESBYTERIAN HOSP,SW CARDIOL ASSOCIATES,1101 MED ARTS AVE NE,BLDG 5,ALBUQUERQUE,NM 87102, USA.							AKINS CW, 1995, ANN THORAC SURG, V60, P311, DOI 10.1016/0003-4975(95)00397-4; AUGULAKIS A, 1991, INT ANGIOL, V10, P167; CLARK RE, 1995, ANN THORAC SURG, V59, P1376, DOI 10.1016/0003-4975(95)00288-V; Daily PO, 1996, J THORAC CARDIOV SUR, V111, P1185, DOI 10.1016/S0022-5223(96)70220-9; HASSO AN, 1981, AM J ROENTGENOL, V136, P955, DOI 10.2214/ajr.136.5.955; IYER SS, 1996, CIRCULATION S1, V94, P58; MCCRORY DC, 1993, STROKE, V24, P1285, DOI 10.1161/01.STR.24.9.1285; RIZZO RJ, 1992, ANN THORAC SURG, V54, P1099, DOI 10.1016/0003-4975(92)90076-G; Rothwell PM, 1996, STROKE, V27, P260, DOI 10.1161/01.STR.27.2.260; THERON J, 1987, AM J NEURORADIOL, V8, P495; THERON J, 1984, J NEURORADIOLOGY, V11, P187; TSAI FY, 1986, AM J NEURORADIOL, V7, P349; WIGGLI U, 1983, AM J NEURORADIOL, V4, P793; YADAV JS, 1996, CIRCULATION S1, V94, P58	14	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	1997	336	14					1008	1011		10.1056/NEJM199704033361407	http://dx.doi.org/10.1056/NEJM199704033361407			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR385	9077381				2022-12-28	WOS:A1997WR38500007
J	Katz, MD; Klugman, I; Cai, LQ; Zhu, YS; Fratianni, CM; Zervoudakis, I; Rosenwaks, Z; ImperatoMcGinley, J				Katz, MD; Klugman, I; Cai, LQ; Zhu, YS; Fratianni, CM; Zervoudakis, I; Rosenwaks, Z; ImperatoMcGinley, J			Paternity by intrauterine insemination with sperm from a man with 5 alpha-reductase-2 deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	10th International Congress of Endocrinology	JUN 12-15, 1996	SAN FRANCISCO, CA				STEROID 5ALPHA-REDUCTASE DEFICIENCY; MALE PSEUDOHERMAPHRODITISM; INHIBITOR; PROSTATE; RAT; DIFFERENTIATION		CORNELL UNIV,COLL MED,DEPT MED,DIV ENDOCRINOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT OBSTET & GYNECOL,CTR REPROD MED & INFERTIL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009421] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-00047] Funding Source: Medline; NHLBI NIH HHS [HL-09421-15] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cai LQ, 1996, J CLIN ENDOCR METAB, V81, P1730, DOI 10.1210/jc.81.5.1730; CAI LQ, 1994, J CLIN ENDOCR METAB, V79, P409, DOI 10.1210/jc.79.2.409; CANTU JM, 1976, REV INVEST CLIN, V28, P177; CARPENTER TO, 1990, J CLIN ENDOCR METAB, V71, P318, DOI 10.1210/jcem-71-2-318; FRATIANNI CM, 1994, ENDOCRINOLOGIST, V4, P302, DOI 10.1097/00019616-199407000-00009; GEORGE FW, 1988, ENDOCRINOLOGY, V122, P1159, DOI 10.1210/endo-122-3-1159; GEORGE FW, 1989, ENDOCRINOLOGY, V125, P2434, DOI 10.1210/endo-125-5-2434; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; IMPERATOMCGINLE.J, 1994, CURRENT THERAPY ENDO, P351; IMPERATOMCGINLEY J, 1976, AM J MED, V61, P251, DOI 10.1016/0002-9343(76)90175-3; IMPERATOMCGINLEY J, 1992, ENDOCRINOLOGY, V131, P1149, DOI 10.1210/en.131.3.1149; IMPERATOMCGINLEY J, 1979, NEW ENGL J MED, V300, P1233, DOI 10.1056/NEJM197905313002201; IMPERATOMCGINLEY J, 1980, J CLIN ENDOCR METAB, V50, P15, DOI 10.1210/jcem-50-1-15; IMPERATOMCGINLEY J, 1992, J CLIN ENDOCR METAB, V75, P1022, DOI 10.1210/jc.75.4.1022; IMPERATOMCGINLEY J, 1985, ENDOCRINOLOGY, V116, P807, DOI 10.1210/endo-116-2-807; IMPERATOMCGINLEY J, 1986, J CLIN ENDOCR METAB, V63, P1313, DOI 10.1210/jcem-63-6-1313; KATZ MD, 1995, J CLIN ENDOCR METAB, V80, P3160, DOI 10.1210/jc.80.11.3160; KRUGER TF, 1987, UROLOGY, V30, P248, DOI 10.1016/0090-4295(87)90246-9; Mendonca BB, 1996, MEDICINE, V75, P64, DOI 10.1097/00005792-199603000-00003; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PETERSON RE, 1977, AM J MED, V62, P170, DOI 10.1016/0002-9343(77)90313-8; PRICE P, 1984, J CLIN INVEST, V74, P1496, DOI 10.1172/JCI111563; SAVAGE MO, 1980, CLIN ENDOCRINOL, V12, P397, DOI 10.1111/j.1365-2265.1980.tb02727.x; SIITERI PK, 1974, J CLIN ENDOCR METAB, V38, P113, DOI 10.1210/jcem-38-1-113; THIGPEN AE, 1992, NEW ENGL J MED, V327, P1216, DOI 10.1056/NEJM199210223271706; WALSH PC, 1974, NEW ENGL J MED, V291, P944, DOI 10.1056/NEJM197410312911806; World Health Organization, 1992, WHO LAB MAN EX HUM S	27	58	59	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	1997	336	14					994	997		10.1056/NEJM199704033361404	http://dx.doi.org/10.1056/NEJM199704033361404			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR385	9077378	Bronze			2022-12-28	WOS:A1997WR38500004
J	Li, J; Yen, C; Liaw, D; Podsypanina, K; Bose, S; Wang, SI; Puc, J; Miliaresis, C; Rodgers, L; McCombie, R; Bigner, SH; Giovanella, BC; Ittmann, M; Tycko, B; Hibshoosh, H; Wigler, MH; Parsons, R				Li, J; Yen, C; Liaw, D; Podsypanina, K; Bose, S; Wang, SI; Puc, J; Miliaresis, C; Rodgers, L; McCombie, R; Bigner, SH; Giovanella, BC; Ittmann, M; Tycko, B; Hibshoosh, H; Wigler, MH; Parsons, R			PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer	SCIENCE			English	Article							HUMAN GLIOMAS; REGION; IDENTIFICATION; DELETION; CLONING	Mapping of homozygous deletions on human chromosome 10q23 has led to the isolation of a candidate tumor suppressor gene, PTEN, that appears to be mutated at considerable frequency in human cancers. In preliminary screens, mutations of PTEN were detected in 31% (13/42) of glioblastoma cell lines and xenografts, 100% (4/4) of prostate cancer cell lines, 6% (4/65) of breast cancer cell lines and xenografts, and 17% (3/18) of primary glioblastomas. The predicted PTEN product has a protein tyrosine phosphatase domain and extensive homology to tensin, a protein that interacts with actin filaments at focal adhesions. These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; ST JOSEPH HOSP,STEHLIN FDN CANC RES,HOUSTON,TX 77003; VET ADM MED CTR,NEW YORK,NY 10010; NYU,DEPT PATHOL,NEW YORK,NY 10010	Columbia University; Columbia University; Cold Spring Harbor Laboratory; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); New York University				McCombie, W. Richard/0000-0003-1899-0682; Wigler, Michael/0000-0003-4396-1971; Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R35CA039829] Funding Source: NIH RePORTER; NCI NIH HHS [5R35 CA39829] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; BIGNER SH, 1988, CANCER RES, V48, P405; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHUANG JZ, 1995, J CELL BIOL, V128, P1095, DOI 10.1083/jcb.128.6.1095; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; GRAY IC, 1995, CANCER RES, V55, P4800; Haynie DT, 1996, PROTEIN SCI, V5, P2643, DOI 10.1002/pro.5560051227; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; Hsu SC, 1996, CANCER RES, V56, P5684; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Ittmann M, 1996, CANCER RES, V56, P2143; JAMES CD, 1988, CANCER RES, V48, P5546; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RASHEED BKA, 1995, ONCOGENE, V10, P2243; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Trybus TM, 1996, CANCER RES, V56, P2263; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	31	3981	4421	5	378	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1943	1947		10.1126/science.275.5308.1943	http://dx.doi.org/10.1126/science.275.5308.1943			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072974				2022-12-28	WOS:A1997WQ51300049
J	Versaci, F; Gaspardone, A; Tomai, F; Crea, F; Chiariello, L; Gioffre, PA				Versaci, F; Gaspardone, A; Tomai, F; Crea, F; Chiariello, L; Gioffre, PA			A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	45th Annual Scientific Session of the American-College-of-Cardiology	MAR 24-28, 1996	ORLANDO, FL	Amer Coll Cardiol			INTERNAL MAMMARY ARTERY; BALLOON ANGIOPLASTY; MEDICAL THERAPY; ANGINA-PECTORIS; DISEASE; LESION; TRIAL	Background Randomized studies have shown that the use of coronary-artery stenting as the initial treatment for coronary stenosis is associated with a lower risk of restenosis than is standard coronary angioplasty. We prospectively investigated the efficacy of these two approaches in selected patients with isolated stenosis of the proximal left anterior descending coronary artery. Methods A total of 120 patients with isolated stenosis of the proximal left anterior descending coronary artery were randomly assigned to stent implantation or standard coronary angioplasty. The primary clinical end points were the rate of procedural success (defined as residual stenosis of less than 50 percent and the absence of death, myocardial infarction, and the need for coronary-artery bypass surgery during the hospital stay) and the rate of event-free survival (defined as freedom from death, myocardial infarction, and the recurrence of angina) at 12 months. The angiographic end point was the rate of restenosis 12 months after the procedure. Results The two treatment groups did not differ significantly with respect to demographic, clinical, or angiographic characteristics. The rates of procedural success were similar in the two groups of patients (95 percent in the stenting group vs. 93 percent in the angioplasty group, P = 0.98). The 12-month rates of event-free survival were 87 percent after stenting and 70 percent after angioplasty (P = 0.04). The rates of restenosis were 19 percent after stent implantation and 40 percent after angioplasty (P = 0.02). Conclusions In patients with symptomatic isolated stenosis of the proximal left anterior descending coronary artery, stenting had advantages over standard coronary angioplasty in that it was associated with both a lower rate of restenosis and a better clinical outcome. (C) 1997, Massachusetts Medical Society.	UNIV ROMA TOR VERGATA, SERV SPECIALE DIAG & CURA EMODINAM, DIV CARDIOCHIRURG, I-00149 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, IST CARDIOL, ROME, ITALY	University of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			Versaci, Francesco/AAK-7000-2020; Gaspardone, Achille/AAC-1762-2022	Versaci, Francesco/0000-0003-2413-6693				BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BROOKS N, 1982, BRIT HEART J, V47, P71; Burtt DM, 1996, STRATEGIC APPROACHES, P519; CALIFF RM, 1983, CIRCULATION, V67, P283, DOI 10.1161/01.CIR.67.2.283; Cameron A, 1996, NEW ENGL J MED, V334, P216, DOI 10.1056/NEJM199601253340402; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; CREA F, 1994, J AM COLL CARDIOL, V23, P1472, DOI 10.1016/0735-1097(94)90394-8; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FRIERSON JH, 1992, J AM COLL CARDIOL, V19, P745, DOI 10.1016/0735-1097(92)90512-L; GOY JJ, 1994, LANCET, V343, P1449, DOI 10.1016/S0140-6736(94)92579-8; Heuser R. R., 1995, European Heart Journal, V16, P291; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; HUEB WA, 1995, J AM COLL CARDIOL, V26, P1600, DOI 10.1016/0735-1097(95)00384-3; KALBFLEISCH H, 1977, AM HEART J, V94, P183, DOI 10.1016/S0002-8703(77)80278-0; KLEIN LW, 1986, AM J CARDIOL, V58, P42, DOI 10.1016/0002-9149(86)90238-9; Lablanche JM, 1996, EUR HEART J, V17, P1373; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; MAHMARIAN JJ, 1991, J AM COLL CARDIOL, V17, P355, DOI 10.1016/S0735-1097(10)80099-3; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PUGA J, 1995, EUR HEART J, V16, P21, DOI 10.1093/eurheartj/16.suppl_E.21; RAHIMTOOLA SH, 1984, AM J CARDIOL, V53, P1719, DOI 10.1016/0002-9149(84)90609-X; RYAN T J, 1988, Journal of the American College of Cardiology, V12, P529; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; STRAUSS WE, 1995, CIRCULATION, V92, P1710, DOI 10.1161/01.CIR.92.7.1710; THORNTON MA, 1984, CIRCULATION, V69, P721, DOI 10.1161/01.CIR.69.4.721	27	239	247	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					817	822		10.1056/NEJM199703203361201	http://dx.doi.org/10.1056/NEJM199703203361201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WN371	9062089	Bronze			2022-12-28	WOS:A1997WN37100001
J	ScottSamuel, A				ScottSamuel, A			Health through community co-operation	LANCET			English	Editorial Material											ScottSamuel, A (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3GB,MERSEYSIDE,ENGLAND.							Antonovsky A, 1996, HEALTH PROMOT INT, V11, P11, DOI 10.1093/heapro/11.1.11; Bygren LO, 1996, BRIT MED J, V313, P1577, DOI 10.1136/bmj.313.7072.1577; Gaskin K., 1996, COOPERATING HLTH; WILLIAMSON GS, 1946, LANCET, V1, P393	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					746	746		10.1016/S0140-6736(05)60197-3	http://dx.doi.org/10.1016/S0140-6736(05)60197-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN124	9074571				2022-12-28	WOS:A1997WN12400006
J	Harris, RN; Chapman, DS				Harris, RN; Chapman, DS			Borehole temperatures and a baseline for 20th-century global warming estimates	SCIENCE			English	Article							CHANGING CLIMATE; TRENDS	Lack of a 19th-century baseline temperature against which 20th-century warming can be referenced constitutes a deficiency in understanding recent climate change. Combination of borehole temperature profiles, which contain a memory of surface temperature changes in previous centuries, with the meteorological archive of surface air temperatures can provide a 19th-century baseline temperature tied to the current observational record. A test case in Utah, where boreholes are interspersed with meteorological stations belonging to the Historical Climatological Network, yields a noise reduction in estimates of 20th-century warming and a baseline temperature that is 0.6 degrees +/- 0.1 degrees C below the 1951 to 1970 mean temperature for the region.			Harris, RN (corresponding author), UNIV UTAH,DEPT GEOL & GEOPHYS,SALT LAKE CITY,UT 84112, USA.							BODELL JM, 1982, J GEOPHYS RES, V87, P2869, DOI 10.1029/JB087iB04p02869; Carslaw H.S., 1986, CONDUCTION HEAT SOLI; CHAPMAN DS, 1992, GLOBAL PLANET CHANGE, V98, P269; CHAPMAN DS, 1978, 1408001G341 US GEOL, V2; CHAPMAN DS, 1993, GEOPHYS RES LETT, V18, P1891; CHISHOLM TJ, 1992, J GEOPHYS RES-SOL EA, V97, P14155, DOI 10.1029/92JB00765; CLOW GD, 1992, GLOBAL PLANET CHANGE, V98, P81; DEMING D, 1995, SCIENCE, V268, P1576, DOI 10.1126/science.268.5217.1576; Easterling D.R., 1996, ORNLCDIAC87; ELLSAESSER HW, 1986, REV GEOPHYS, V24, P745, DOI 10.1029/RG024i004p00745; GOSNOLD WD, UNPUB; HANSEN J, 1987, J GEOPHYS RES-ATMOS, V92, P13345, DOI 10.1029/JD092iD11p13345; HARRIS RH, UNPUB; HARRIS RN, 1995, J GEOPHYS RES-SOL EA, V100, P6367, DOI 10.1029/94JB02165; JONES PD, 1994, TRENDS 93 COMPENDIUM, P603; KARL TR, 1987, J CLIM APPL METEOROL, V26, P1744, DOI 10.1175/1520-0450(1987)026<1744:AATACT>2.0.CO;2; KARL TR, 1986, J CLIM APPL METEOROL, V25, P145, DOI 10.1175/1520-0450(1986)025<0145:AMTETT>2.0.CO;2; LACHENBRUCH AH, 1986, SCIENCE, V234, P689, DOI 10.1126/science.234.4777.689; LACHENBRUCH AH, 1988, 5 INT C PERM TRONDH; Pollack HN, 1996, PURE APPL GEOPHYS, V147, P537, DOI 10.1007/BF00878843; POLLACK HN, 1993, SCI AM, V268, P44, DOI 10.1038/scientificamerican0693-44; Putnam SN, 1996, J GEOPHYS RES-SOL EA, V101, P21877, DOI 10.1029/96JB01903; SHEN PY, 1991, J GEOPHYS RES-SOL EA, V96, P19965, DOI 10.1029/91JB01883; SHEN PY, 1995, J GEOPHYS RES-SOL EA, V100, P6383, DOI 10.1029/94JB03136; Wigley TML, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P239	25	77	84	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1618	1621		10.1126/science.275.5306.1618	http://dx.doi.org/10.1126/science.275.5306.1618			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054350				2022-12-28	WOS:A1997WN12300038
J	Peeper, DS; Upton, TM; Ladha, MH; Neuman, E; Zalvide, J; Bernards, R; DeCaprio, JA; Ewen, ME				Peeper, DS; Upton, TM; Ladha, MH; Neuman, E; Zalvide, J; Bernards, R; DeCaprio, JA; Ewen, ME			Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein	NATURE			English	Article							NIH 3T3 CELLS; GROWTH SUPPRESSION; INHIBITION; TRANSFORMATION; PROLIFERATION; D1; MICROINJECTION; NIH-3T3-CELLS; P16(INK4); P16	The Ras proto-oncogene is a central component of mitogenic signal-transduction pathways, and is essential for cells both to leave a quiescent state (G0) and to pass through the G1/S transition of the cell cycle(1-6). The mechanism by which Ras signalling regulates cell-cycle progression is unclear, however. Here we report that the retinoblastoma tumour-suppressor protein (Rb), a regulator of G1 exit(7), functionally Links pas to passage through the G1 phase. Inactivation of Ras in cycling cells-caused a decline in cyclin D1 protein levels, accumulation of the hypophosphorylated, growth-suppressive form of Rb, and G1 arrest. When Rb was disrupted either genetically or biochemically, cells failed to arrest in G1 following Ras inactivation. In contrast, inactivation of Ras in quiescent cells prevented growth-factor induction of both immediate-early gene transcription and exit from G0 in an Rb-independent manner. These data suggest that Rb is an essential G1-specific mediator that links Ras-dependent mitogenic signalling to cell-cycle regulation.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; NETHERLANDS CANC INST,DEPT MOL CARCINOGENESIS,NL-1066 CX AMSTERDAM,NETHERLANDS	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Netherlands Cancer Institute			Zalvide, Juan/ABG-4050-2020; Peeper, Daniel/AAA-2430-2020	Bernards, Rene/0000-0001-8677-3423; Zalvide, Juan/0000-0001-7645-156X				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FILMUS J, 1994, ONCOGENE, V9, P3627; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800	30	316	316	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 13	1997	386	6621					177	181		10.1038/386177a0	http://dx.doi.org/10.1038/386177a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062190	Green Submitted			2022-12-28	WOS:A1997WM97300063
J	Buschges, R; Hollricher, K; Panstruga, R; Simons, G; Wolter, M; Frijters, A; vanDaelen, R; vanderLee, T; Diergaarde, P; Groenendijk, J; Topsch, S; Vos, P; Salamini, F; Schulze-Lefert, P				Buschges, R; Hollricher, K; Panstruga, R; Simons, G; Wolter, M; Frijters, A; vanDaelen, R; vanderLee, T; Diergaarde, P; Groenendijk, J; Topsch, S; Vos, P; Salamini, F; Schulze-Lefert, P			The barley mlo gene: A novel control element of plant pathogen resistance	CELL			English	Article							POWDERY MILDEW RESISTANCE; DISEASE RESISTANCE; INTRAGENIC RECOMBINATION; CELL-DEATH; DNA; ARABIDOPSIS; LOCUS; MEMBRANE; CLONING; INFECTION	Mutation-induced recessive alleles (mlo) of the barley Mlo locus confer a leaf lesion phenotype and broad spectrum resistance to the fungal pathogen, Erysiphe graminis f. sp. hordei. The gene has been isolated using a positional cloning approach. Analysis of 11 mutagen-induced mlo alleles revealed mutations leading in each case to alterations of the deduced Mlo wild-type amino acid sequence. Susceptible intragenic recombinants, isolated from mlo heteroallelic crosses, show restored Mlo wild-type sequences. The deduced 60 kDa protein is predicted to be membrane-anchored by at least six membrane-spanning helices. The findings are compatible with a dual negative control function of the Mlo protein in leaf cell death and in the onset of pathogen defense; absence of Mlo primes the responsiveness for the onset of multiple defense functions.	JOHN INNES CTR PLANT SCI RES, SAINSBURY LAB, NORWICH NR4 7UH, NORFOLK, ENGLAND; RHEIN WESTFAL TH AACHEN, INST BIOL 1, D-52074 AACHEN, GERMANY; KEYGENE NV, NL-6700 AE WAGENINGEN, NETHERLANDS; MAX PLANCK INST ZUCHTUNGSFORSCH, ABT ZUCHTUNGSFORSCH & ERTRAGSPHYSIOL, D-50829 COLOGNE, GERMANY	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; RWTH Aachen University; Keygene N.V.; Max Planck Society			Schulze-Lefert, Paul/B-6707-2011; Schulze-Lefert, Paul/A-7746-2008; Panstruga, Ralph/F-3340-2011; Bruening, Stefan/B-8505-2011; vanderlee, Theo A.J./J-7296-2013	Panstruga, Ralph/0000-0002-3756-8957; 				BAYLES CJ, 1990, PHYSIOL MOL PLANT P, V36, P63, DOI 10.1016/0885-5765(90)90092-C; BECKER J, 1995, MOL GEN GENET, V249, P65, DOI 10.1007/BF00290237; BENNETT MD, 1991, PHILOS T R SOC B, V334, P309, DOI 10.1098/rstb.1991.0120; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHUNWONGSE J, 1993, THEOR APPL GENET, V86, P694, DOI 10.1007/BF00222658; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DOONER HK, 1986, GENETICS, V113, P135; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; FREELING M, 1978, GENETICS, V89, P211; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; GIOVANNONI JJ, 1991, NUCLEIC ACIDS RES, V19, P6553, DOI 10.1093/nar/19.23.6553; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HABEKUSS A, 1988, WISS DDR BERLIN, V272, P229; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HESLOPHARRISON JS, 1991, J CELL SCI, V100, P15; HINZE K, 1991, P NATL ACAD SCI USA, V88, P3691, DOI 10.1073/pnas.88.9.3691; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; JONES JDG, 1994, CURR BIOL, V4, P749, DOI 10.1016/S0960-9822(00)00168-8; JORGENSEN JH, 1977, PHYTOPATHOLOGY, V67, P678; JORGENSEN JH, 1994, CRIT REV PLANT SCI, V13, P97, DOI 10.1080/713608055; JORGENSEN JH, 1992, EUPHYTICA, V63, P141, DOI 10.1007/BF00023919; KOORNNEEF M, 1983, GENET RES, V41, P57, DOI 10.1017/S0016672300021066; Kosslak RM, 1996, J HERED, V87, P415, DOI 10.1093/oxfordjournals.jhered.a023030; Kosuge T., 1983, GENETIC ENG PLANTS A, P431, DOI [10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_]; MOURAD G, 1994, MOL GEN GENET, V243, P178, DOI 10.1007/BF00280315; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; OSBORNE BI, 1995, CURR OPIN CELL BIOL, V7, P406, DOI 10.1016/0955-0674(95)80097-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SALAMINI F, 1970, MOL GEN GENET, V108, P225, DOI 10.1007/BF00283352; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; Stakman EC, 1915, J AGRIC RES, V4, P193; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STEWART CN, 1993, BIOTECHNIQUES, V14, P748; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TANKSLEY SD, 1995, TRENDS GENET, V11, P63, DOI 10.1016/S0168-9525(00)88999-4; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; Weymann K, 1995, PLANT CELL, V7, P2013, DOI 10.1105/tpc.7.12.2013; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	48	799	929	3	159	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 7	1997	88	5					695	705		10.1016/S0092-8674(00)81912-1	http://dx.doi.org/10.1016/S0092-8674(00)81912-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054509	Bronze			2022-12-28	WOS:A1997WM41300015
J	Tondravi, MM; McKercher, SR; Anderson, K; Erdmann, JM; Quiroz, M; Maki, R; Teitelbaum, SL				Tondravi, MM; McKercher, SR; Anderson, K; Erdmann, JM; Quiroz, M; Maki, R; Teitelbaum, SL			Osteopetrosis in mice lacking haematopoietic transcription factor PU.1	NATURE			English	Article							COLONY-STIMULATING FACTOR; C-FOS; MACROPHAGE; BONE; PROMOTER; CELLS; DIFFERENTIATION; OSTEOCLASTS; EXPRESSION; DEFICIENCY	Osteoclasts are multinucleated cells and the principal resorptive cells of bone. Although osteoclasts are of myeloid origin(1), the role of haematopoietic transcription factors in osteoclastogenesis has not been explored. Here we show that messenger RNA for the myeloid- and B-cell-specific transcription factor PU.1 progressively increases as marrow macrophages assume the osteoclast phenotype in vitro. The association between PU.1 and osteoclast differentiation was confirmed by demonstrating that PU.1 expression increased with the induction of osteoclastogenesis by either 1,25-dihydroxyvitamin D-3 or dexamethasone. Consistent with the participation of PU.1 in osteoclastogenesis, we found that the development of both osteoclasts and macrophages is arrested in PU.1-deficient mice. Reflecting the absence of osteoclasts, PU.1(-/-) mice exhibit the classic hallmarks of osteopetrosis, a family of sclerotic bone diseases(2). These animals were rescued by marrow transplantation, with complete restoration of osteoclast and macrophage differentiation, verifying that the PU.1 lesion is intrinsic to haematopoietic cells. The absence of both osteoclasts and macrophages in PU.1-mutant animals suggests that the transcription factor regulates the initial stages of myeloid differentiation, and that its absence represents the earliest developmental osteopetrotic mutant yet described.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute	Tondravi, MM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110, USA.			Teitelbaum, Steven/0000-0002-4054-6679				BEGG SK, 1993, J EXP MED, V177, P237, DOI 10.1084/jem.177.1.237; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; DUONG LT, 1993, J BONE MINER RES, V8, pS378; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; PAHL HL, 1993, J BIOL CHEM, V268, P5014; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIOI A, 1994, CALCIFIED TISSUE INT, V55, P387, DOI 10.1007/BF00299320; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; TAKAHASHI N, 1991, ENDOCRINOLOGY, V128, P1792, DOI 10.1210/endo-128-4-1792; Teitelbaum Steven L., 1996, P61; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YAMAMOTO T, 1993, J CLIN INVEST, V91, P362, DOI 10.1172/JCI116194; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	22	417	434	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					81	84		10.1038/386081a0	http://dx.doi.org/10.1038/386081a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052784				2022-12-28	WOS:A1997WL74600055
J	Ferrucci, L; Guralnik, JM; Pahor, M; Corti, MC; Havlik, RJ				Ferrucci, L; Guralnik, JM; Pahor, M; Corti, MC; Havlik, RJ			Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ELDERLY PATIENTS; MAINTAINING MOBILITY; CORONARY ANGIOPLASTY; PHYSICAL-DISABILITY; BYPASS-SURGERY; LATE-LIFE; AGE; CARE; SURVIVAL	Objective.-To characterize hospital diagnoses, procedures and charges, and nursing home admissions in the year when older persons become severely disabled, comparing those in whom severe disability develops rapidly with those in whom disability develops gradually. Design.-A prospective, population-based cohort study with at least 6 annual interviews beginning in 1982. Setting.-A total of 3 communities: East Boston, Mass, New Haven, Conn, and Iowa and Washington counties in Iowa. Subjects.-A total of 6070 persons at least 70 years old with at least 1 interview after the fourth annual follow-up and without evidence of previous severe disability, defined as disability in 3 or more activities of daily living (ADLs). Main Outcome Measures.-Characteristics associated with development of severe disability after the fourth annual follow-up, in which the disability is classified as catastrophic disability if the individual did not report any ADL disability in the 2 interviews prior to severe disability onset or as progressive disability if the individual had previous disability in 1 or 2 ADLs. Results.-In the year during which severe disability developed, hospitalizations were documented for 72.1% of those developing catastrophic disability and for 48.6% of those developing progressive disability. In the corresponding year, only 14.7% of those who were stable with no disability and 22.3% of those with some disability were hospitalized, The 6 most frequent principal discharge diagnoses included stroke, hip fracture, congestive heart failure, and pneumonia in both severe disability subsets; coronary heart disease and cancer in catastrophic disability; and diabetes and dehydration in progressive disability. These diagnoses occurred in 49% of those with catastrophic disability and 25% of those with progressive disability. In both severe disability subsets, the oldest patients received less intensive hospital care as indicated by charges for surgery, diagnostics, and rehabilitation and by the percentage who received major diagnostic procedures; they were also more often admitted to nursing homes. Conclusions.-In the year when they become severely disabled, a large proportion of older persons are hospitalized for a small group of diseases. Hospital-based interventions aimed at reducing the severity and functional consequences of these diseases could have a large impact on reduction of severe disability.	NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892; NATL RES INST INRCA,DEPT GERIATR,FLORENCE,ITALY; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); IRCCS INRCA; University of Tennessee System; University of Tennessee Health Science Center								ACKERMANN RJ, 1995, J FAM PRACTICE, V40, P129; BEARDEN D, 1994, J AM GERIATR SOC, V42, P1143, DOI 10.1111/j.1532-5415.1994.tb06979.x; BERGMAN L, 1991, BREAST CANCER RES TR, V18, P189, DOI 10.1007/BF01990035; BINSTOCK R, 1991, TOO OLD HLTH CARE; BOULT C, 1994, J GERONTOL, V49, pM28, DOI 10.1093/geronj/49.1.M28; BRACH LG, 1984, AM J PUBLIC HEALTH, V74, P266; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; DEGARA CJ, 1995, HEPATO-GASTROENTEROL, V42, P73; ENSRUD KE, 1994, J AM GERIATR SOC, V42, P481, DOI 10.1111/j.1532-5415.1994.tb04968.x; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FALCONER JA, 1994, J AM GERIATR SOC, V42, P39, DOI 10.1111/j.1532-5415.1994.tb06071.x; Ferrucci L, 1996, J GERONTOL A-BIOL, V51, pM123, DOI 10.1093/gerona/51A.3.M123; FRIED LP, 1992, AGING-CLIN EXP RES, V4, P251, DOI 10.1007/BF03324099; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; GURALNIK JM, 1993, J GERONTOL, V48, P3, DOI 10.1093/geronj/48.Special_Issue.3; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P720; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KOWALSKI LP, 1994, AM J SURG, V168, P485, DOI 10.1016/S0002-9610(05)80107-2; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; MARCHIONNI N, 1995, J AM GERIATR SOC, V43, P389, DOI 10.1111/j.1532-5415.1995.tb05813.x; OKEEFE JH, 1994, J AM COLL CARDIOL, V24, P425, DOI 10.1016/0735-1097(94)90299-2; PALMER RM, 1994, J AM GERIATR SOC, V42, P545, DOI 10.1111/j.1532-5415.1994.tb04978.x; PERLER BA, 1994, SURGERY, V116, P479; ROSENTHAL GE, 1994, J AM GERIATR SOC, V42, P826, DOI 10.1111/j.1532-5415.1994.tb06553.x; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; SHERRY S, 1991, J AM COLL CARDIOL, V17, P1237, DOI 10.1016/0735-1097(91)90859-8; THOMAS DR, 1995, J AM GERIATR SOC, V43, P811, DOI 10.1111/j.1532-5415.1995.tb07058.x; VLADECK BC, 1995, JAMA-J AM MED ASSOC, V274, P259, DOI 10.1001/jama.274.3.259	36	201	205	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					728	734						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK026	9042845				2022-12-28	WOS:A1997WK02600032
J	Davies, PA; Hanna, MC; Hales, TG; Kirkness, EF				Davies, PA; Hanna, MC; Hales, TG; Kirkness, EF			Insensitivity to anaesthetic agents conferred by a class of GABA(A) receptor subunit	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; SUBTHALAMIC NUCLEUS; HIPPOCAMPAL-NEURONS; CHLORIDE CHANNELS; A RECEPTORS; PHARMACOLOGY; CONDUCTANCE; ACTIVATION; EXPRESSION; PROPOFOL	A common feature of general anaesthetic agents is their ability to potentiate neuronal inhibition through GABA(A) (gamma-aminobutyric acid) receptors(1). At concentrations relevant to clinical anaesthesia, these agents cause a dramatic stimulation of the chloride currents that are evoked by the binding of the natural ligand, GABA. Although there is widespread evidence that the sensitivity of GABA(A) receptors to anaesthetic agents is heterogeneous(2-4), the structural basis of these differences is largely unknown. Variations in subunit composition can have profound effects on the sensitivity of GABA(A), receptors to modulatory agents such as benzodiazepines(5). However, strict subunit specificity has not been demonstrated for the potentiating effects of anaesthetic agents(6-10). Here we describe a new class of human GABA(A) receptor subunit (epsilon) that can assemble with alpha- and beta-subunits and confer an insensitivity to the potentiating effects of intravenous anaesthetic agents. The epsilon-subunit also abolishes the normal outward rectification of recombinant receptors in which it assembles. The expression pattern of this subunit in the brain suggests a new target for manipulation of neuronal pathways within the basal ganglia.	INST GENOM RES,ROCKVILLE,MD 20850; UNIV CALIF LOS ANGELES,MED CTR,BRAIN RES INST,DEPT ANESTHESIOL,LOS ANGELES,CA 90095	J. Craig Venter Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center			Davies, Paul A/P-4595-2017	Davies, Paul A/0000-0002-3973-3143				ADAMS MD, 1995, NATURE, V377, P3; ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; BELL K, 1995, SYNAPSE, V20, P10, DOI 10.1002/syn.890200103; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BULLER AL, 1994, MOL PHARMACOL, V46, P858; BUREAU MH, 1993, J NEUROCHEM, V61, P1479, DOI 10.1111/j.1471-4159.1993.tb13643.x; Davies PA, 1997, BRIT J PHARMACOL, V120, P899, DOI 10.1038/sj.bjp.0700987; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GAGE PW, 1994, P ROY SOC B-BIOL SCI, V255, P167, DOI 10.1098/rspb.1994.0024; Goetz CG, 1996, NAT MED, V2, P510, DOI 10.1038/nm0596-510; GRAY R, 1985, J NEUROPHYSIOL, V54, P134, DOI 10.1152/jn.1985.54.1.134; HADINGHAM KL, 1993, MOL PHARMACOL, V44, P1211; HARRIS B, 1993, J PHARMACOL EXP THER, V265, P1392; KORPI ER, 1993, MOL PHARMACOL, V44, P87; MIHAC SJ, 1994, EUR J PHARMACOL, V268, P209; MORROW AL, 1990, MOL PHARMACOL, V37, P263; PETERS JA, 1988, BRIT J PHARMACOL, V94, P1257, DOI 10.1111/j.1476-5381.1988.tb11646.x; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; PUIA G, 1990, NEURON, V4, P759, DOI 10.1016/0896-6273(90)90202-Q; SANNA E, 1995, J PHARMACOL EXP THER, V274, P353; SAXENA NC, 1994, J NEUROSCI, V14, P7077; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SEGAL M, 1984, J NEUROPHYSIOL, V51, P500, DOI 10.1152/jn.1984.51.3.500; Thompson SA, 1996, BRIT J PHARMACOL, V117, P521, DOI 10.1111/j.1476-5381.1996.tb15221.x; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; Whiting PJ, 1995, INT REV NEUROBIOL, V38, P95, DOI 10.1016/S0074-7742(08)60525-5; WISDEN W, 1992, J NEUROSCI, V12, P1040; Zhu WJ, 1996, J NEUROSCI, V16, P6648	30	344	355	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					820	823		10.1038/385820a0	http://dx.doi.org/10.1038/385820a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039914				2022-12-28	WOS:A1997WK57000054
J	Thieme, H				Thieme, H			Lower Palaeolithic hunting spears from Germany	NATURE			English	Article								Little is known about the organic component of Lower and Middle Palaeolithic technologies, particular with respect to wooden tools(1,2). Here I describe some wooden throwing spears about 400,000 years old that were discovered in 1995 at the Pleistocene site at Schoningen, Germany. They are thought to be the oldest complete hunting weapons so far discovered to have been used by humans. Pound in association with stone tools and the butchered remains of more than ten horses, the spears strongly suggest that systematic hunting, involving foresight, planning and the use of appropriate technology, was part of the behavioural repertoire of pre-modern hominids. The use of sophisticated spears as early as the Middle Pleistocene may mean that many current theories on early human behaviour and culture must be revised.			Thieme, H (corresponding author), INST DENKMALPFLEGE,NIEDERSACHS LANDESVERWALTUNGSAMT,SCHARNHORSTSTR 1,D-30175 HANNOVER,GERMANY.		Klein, Richard G/B-5910-2009					Albrecht B., 1991, EISZEITALTER GEGENWA, V41, P85; Gamble C., 1987, PLEISTOCENE OLD WORL, P81; MANIA D, 1993, ARCHAOLOGISCHE AUSGR, V34, P554; Mania D., 1995, EARLIEST OCCUPATION, P85; NITECKI MH, 1987, EVOLUTION HUMAN HUNT, P1; Oakley K.P., 1977, P PREHIST SOC, V43, P13, DOI [10.1017/S0079497X00010343, DOI 10.1017/S0079497X00010343]; ROBERTS MB, 1994, NATURE, V369, P311, DOI 10.1038/369311a0; ROEBROEKS W, 1995, EARLIEST OCCUPATION, P297; Schoch W. H., 1995, ARCHAOLOGISCHE AUSGR, P73; THIEME H, 1992, ARCHAOL DTSCH, V8, P26; Thieme H., 1995, ARCHAOLOGISCHE AUSGR; Thieme H., 1993, ARCHAOL KORRESPONDEN, V23, P147; Thieme H., 1985, KUNDE, V36, P11; Thieme H., 1993, ETHNOGRAPHISCH ARCHA, V34, P610; Thieme H., 1987, ARCHAOL KORRESPONDEN, V17, P445; Urban B., 1995, ARCHAOLOGISCHE AUSGR, P44; Urban B., 1991, Z DTSCH GEOLOGISCHEN, V142, P351; URBAN B., 1993, ETHNOGR ARCHAOL Z, V34, P620; URBAN R, 1988, Z DTSCH GEOL GES, V139, P123; Van Kolfschoten T., 1995, ARCHAOLOGISCHE AUSGR, P85; van Kolfschoten T., 1993, ETHNOGRAPHISCH ARCHA, V34, P623	21	499	511	3	64	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					807	810		10.1038/385807a0	http://dx.doi.org/10.1038/385807a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039910				2022-12-28	WOS:A1997WK57000050
J	HippisleyCox, J				HippisleyCox, J			Newly licensed drugs - Randomised controlled trials are needed in primary care before new drugs are licensed	BMJ-BRITISH MEDICAL JOURNAL			English	Letter											HippisleyCox, J (corresponding author), QUEENS MED CTR, DEPT GEN PRACTICE, FAC MED, SCH MED, NOTTINGHAM NG7 2UH, ENGLAND.		Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283				Ferner RE, 1996, BRIT MED J, V313, P1157, DOI 10.1136/bmj.313.7066.1157; FORBES GM, 1994, LANCET, V343, P258, DOI 10.1016/S0140-6736(94)91111-8; PEDERSEN TR, 1994, LANCET, V344, P1383; SWEENEY KG, 1995, BRIT J GEN PRACT, V45, P153; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	5	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	1997	314	7080					604	605						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055740				2022-12-28	WOS:A1997WK21500051
J	Bada, JL				Bada, JL			Meteoritics - Extraterrestrial handedness?	SCIENCE			English	Editorial Material							AMINO-ACIDS; MURCHISON METEORITE				Bada, JL (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093, USA.							BADA JL, 1995, NATURE, V374, P594, DOI 10.1038/374594a0; BADA JL, 1983, NATURE, V301, P494, DOI 10.1038/301494a0; Becker L, 1996, SCIENCE, V272, P249, DOI 10.1126/science.272.5259.249; CLINA DB, 1996, PHYSICAL ORIGIN HOMO; Cronin J R, 1995, Adv Space Res, V15, P91, DOI 10.1016/S0273-1177(99)80068-4; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; ENGEL MH, 1982, NATURE, V296, P837, DOI 10.1038/296837a0; FLORES JJ, 1977, J AM CHEM SOC, V99, P3622, DOI 10.1021/ja00453a018; KARLE IL, 1990, BIOCHEMISTRY-US, V29, P6747, DOI 10.1021/bi00481a001; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; KVENVOLDEN KA, 1971, P NATL ACAD SCI USA, V68, P486, DOI 10.1073/pnas.68.2.486; MILLER SL, 1974, ORIGINS LIFE EARTH, P83; Peltzer E T, 1984, Adv Space Res, V4, P69, DOI 10.1016/0273-1177(84)90546-5; POLLOCK GE, 1975, GEOCHIM COSMOCHIM AC, V39, P1571, DOI 10.1016/0016-7037(75)90159-3; VALE G, 1989, J AM CHEM SOC, V111, P6828; WOLMAN Y, 1972, P NATL ACAD SCI USA, V69, P809, DOI 10.1073/pnas.69.4.809; ZHAO MX, 1989, NATURE, V339, P463, DOI 10.1038/339463a0	17	26	26	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					942	943		10.1126/science.275.5302.942	http://dx.doi.org/10.1126/science.275.5302.942			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9053998				2022-12-28	WOS:A1997WH38800033
J	Hughes, K; MacKintosh, AM; Hastings, G; Wheeler, C; Watson, J; Inglis, J				Hughes, K; MacKintosh, AM; Hastings, G; Wheeler, C; Watson, J; Inglis, J			Young people, alcohol, and designer drinks: Quantitative and qualitative study	BRITISH MEDICAL JOURNAL			English	Article							ADOLESCENT DRINKING; BRITAIN; EXPERIENCES; BEHAVIOR	Objective: To examine the appeal of ''designer drinks'' to young people Design: Qualitative and quantitative research comprising group discussions and questionnaire led interviews with young people accompanied by a self completion questionnaire. Settings: Argyll and Clyde Health Board area, west Scotland. Subjects: Eight groups aged 12-17 years; 824 aged 12-17 recruited by multistage duster probability sample from the community health index. Results: Young people were familiar with designer drinks, especially MD 20/20 and leading brands of strong white cider. Attitudes towards these drinks varied quite distinctly with age, dearly reflecting their attitudes towards and motivations for drinking in general. The brand imagery of designer drinks-in contrast with that of more mainstream drinks-matched many 14 and 15 year olds' perceptions and expectations of drinking. Popularity of designer drinks peaked between the ages of 13 and 16 while more conventional drinks showed a consistent increase in popularity with age. Consumption of designer drinks tended to be in less controlled circumstances and was associated with heavier alcohol intake and greater drunkenness. Conclusions: Designer drinks are a cause for concern. They appeal to young people, often more so than conventional drinks, and are particularly attractive to 14-16 year olds. Consumption of designer drinks is also associated with drinking in less controlled environments, heavier drinking; and greater drunkenness. There is a need for policy debate to assess the desirability of these drinks and the extent to which further controls on their marketing are required.	UNIV STRATHCLYDE,CTR SOCIAL MKT,GLASGOW G4 0RQ,LANARK,SCOTLAND; UNIV STRATHCLYDE,DEPT MKT,GLASGOW G4 0RQ,LANARK,SCOTLAND; HLTH EDUC BOARD SCOTLAND,EDINBURGH EH10 4SG,MIDLOTHIAN,SCOTLAND	University of Strathclyde; University of Strathclyde								AITKEN P, 1978, 10 14 YEAR OLDS ALCO; BAGNALL G, 1988, DRUG ALCOHOL DEPEN, V22, P241, DOI 10.1016/0376-8716(88)90024-5; BAGNALL G, 1991, ED YOUNG DRINKERS; CASSWELL S, 1993, NZ MED J, V96, P1001; DAVIES JB, 1972, TEENAGERS ALCOHOL; Franzkowiax P., 1987, HEALTH PROMOT INT, V2, P51, DOI [10.1093/ heapro/2.1.51, DOI 10.1093/HEAPRO/2.1.51]; GHODSIAN M, 1987, BRIT J ADDICT, V82, P175; GODDARD E, 1988, DRINKING ENGLAND WAL; HARFORD TC, 1983, J STUD ALCOHOL, V44, P181, DOI 10.15288/jsa.1983.44.181; HASTINGS GB, 1987, BRIT MED J, V294, P48, DOI 10.1136/bmj.294.6563.48; HAWKER A, 1978, ADOLESCENTS ALCOHOL; JAHODA G, 1972, CHILDREN ALCOHOL DEV; KEEFE K, 1994, J STUD ALCOHOL, V55, P46, DOI 10.15288/jsa.1994.55.46; MARSH A, 1986, ADOLESCENT DRINKING; MAY C, 1992, ALCOHOL ALCOHOLISM, V27, P109; MCDERMOT A, 1996, HERALD          0707, P13; McLoone P., 1991, CARSTAIRS SCORES SCO; MILGRAM CG, 1993, J STUD ALCOHOL S11, V11, P53; NEWCOMB MD, 1986, AM J PUBLIC HEALTH, V76, P525, DOI 10.2105/AJPH.76.5.525; NEWCOMBE R, 1995, ADDICT RES, V2, P319, DOI 10.3109/16066359509005552; PLANT MA, 1990, ALCOHOL ALCOHOLISM, V25, P691, DOI 10.1093/oxfordjournals.alcalc.a045067; PLANT MA, 1991, DRUG ALCOHOL DEPEN, V28, P203, DOI 10.1016/0376-8716(91)90077-C; PLANT MA, 1985, ALCOHOL DRUGS SCH LE; SHANKS J, 1990, World Health Forum, V11, P235; SHARP DL, 1994, ALCOHOL ALCOHOLISM, V29, P555; THOMAS RM, 1992, ALCOHOL DRUGS SCOTTI, P34; THOMSON L, 1995, DAILY EXPRESS    JUN, P20; 1995, OFF LICENCE NEW 0420, P12; 1994, OFF LICENCE NEW 0317, P8; 1995, OFF LICENCE NEWS JUN, P12; 1996, DAILY TELEGRAPH 0109, P7	31	70	71	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					414	418		10.1136/bmj.314.7078.414	http://dx.doi.org/10.1136/bmj.314.7078.414			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WH295	9040387	Green Accepted, Green Published			2022-12-28	WOS:A1997WH29500029
J	Yu, S; Mangelsdorf, M; Hewett, D; Hobson, L; Baker, E; Eyre, HJ; Lapsys, N; LePaslier, D; Doggett, NA; Sutherland, GR; Richards, RI				Yu, S; Mangelsdorf, M; Hewett, D; Hobson, L; Baker, E; Eyre, HJ; Lapsys, N; LePaslier, D; Doggett, NA; Sutherland, GR; Richards, RI			Human chromosomal fragile site FRA16B is an amplified AT-rich minisatellite repeat	CELL			English	Article							X-SYNDROME; MYOTONIC-DYSTROPHY; DNA; GENE; MUTATION; LOCUS; SUSCEPTIBILITY; POLYMORPHISM; ASSOCIATION; INSTABILITY	Fragile sites are nonstaining gaps in chromosomes induced by specific tissue culture conditions. They vary both in population frequency and in the culture conditions required for induction. Folate-sensitive fragile sites are due to expansion of p(CCG)(n) trinucleotide repeats; however, the relationship between sequence composition and the chemistry of induction of fragile sites is unclear. To clarify this relationship, the distamycin A-sensitive fragile site FRA16B was isolated by positional cloning and found to be an expanded 33 bp AT-rich minisatellite repeat, p(ATATATTATATATTATATCTAATAATATAT(C)/(A)TA)(n) (consistent with DNA sequence binding preferences of chemicals that induce its cytogenetic expression). Therefore the mutation mechanism associated with trinucleotide repeats is also a property of minisatellite repeats (variable number tandem repeats).	UNIV ADELAIDE,DEPT GENET,ADELAIDE,SA 5000,AUSTRALIA; LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; FDN JEAN DAUSSET,CTR ETUD POLYMORPHISME HUMAIN,PARIS,FRANCE	University of Adelaide; United States Department of Energy (DOE); Los Alamos National Laboratory; Foundation Jean Dausset-CEPH	Yu, S (corresponding author), WOMENS & CHILDRENS HOSP,DEPT CYTOGENET & MOL GENET,CTR MED GENET,ADELAIDE,SA 5006,AUSTRALIA.		Richards, Robert/ABE-6423-2020; Mangelsdorf, Marie E/A-2318-2013; Sutherland, Grant Robert/D-2606-2012	Mangelsdorf, Marie E/0000-0002-7855-7701; Richards, Robert Ian/0000-0002-5978-6453; Le Paslier, Denis/0000-0003-4335-9956				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BERG ES, 1993, GENOMICS, V16, P350, DOI 10.1006/geno.1993.1196; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; DOGGETT NA, 1995, NATURE, V377, P335; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; GARCIASAGREDO JM, 1983, HUM GENET, V65, P211, DOI 10.1007/BF00286668; Igarashi S, 1996, HUM MOL GENET, V5, P923, DOI 10.1093/hmg/5.7.923; JALAL SM, 1993, AM J MED GENET, V46, P441, DOI 10.1002/ajmg.1320460419; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P3296, DOI 10.1021/bi00359a032; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; LINDBLAD K, 1994, NAT GENET, V7, P124, DOI 10.1038/ng0694-124; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; SCHMID M, 1986, HUM GENET, V74, P67; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; SUTHERLAND GR, 1984, AM J HUM GENET, V36, P110; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; YU S, 1992, AM J HUM GENET, V50, P968; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	38	159	162	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					367	374		10.1016/S0092-8674(00)81875-9	http://dx.doi.org/10.1016/S0092-8674(00)81875-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039263	Bronze			2022-12-28	WOS:A1997WG47900009
J	Goodnough, LT; Monk, TG; Andriole, GL				Goodnough, LT; Monk, TG; Andriole, GL			Current concepts: Erythropoietin therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RECOMBINANT-HUMAN-ERYTHROPOIETIN; AUTOLOGOUS BLOOD DONATION; RADICAL RETROPUBIC PROSTATECTOMY; ACUTE NORMOVOLEMIC HEMODILUTION; ELECTIVE ORTHOPEDIC OPERATION; STAGE RENAL-DISEASE; COST-EFFECTIVENESS; MATHEMATICAL-ANALYSIS; SURGERY PATIENTS; TOTAL HIP		WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT ANESTHESIA, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT SURG, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Goodnough, LT (corresponding author), WASHINGTON UNIV, SCH MED,DEPT MED,DIV LAB MED,BOX 8118, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.							ADAMSON JW, 1994, SURGERY, V115, P7; ANDRIOLE GL, 1994, J UROLOGY, V152, P1858, DOI 10.1016/S0022-5347(17)32400-X; BAILEY W, 1993, LANCET, V341, P1227; BERIS P, 1993, VOX SANG, V65, P212, DOI 10.1111/j.1423-0410.1993.tb02152.x; BESARAB A, 1992, J AM SOC NEPHROL, V2, P1405; BIESMA DH, 1994, LANCET, V344, P367, DOI 10.1016/S0140-6736(94)91401-X; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BRECHER ME, 1994, TRANSFUSION, V34, P176, DOI 10.1046/j.1537-2995.1994.34294143950.x; COHEN JA, 1995, TRANSFUSION, V35, P640, DOI 10.1046/j.1537-2995.1995.35895357894.x; DOOLITTLE RF, 1991, NEW ENGL J MED, V324, P1360, DOI 10.1056/NEJM199105093241910; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; Faris PM, 1996, J BONE JOINT SURG AM, V78A, P62, DOI 10.2106/00004623-199601000-00009; Goldberg M A, 1996, Am J Orthop (Belle Mead NJ), V25, P544; Goodnough L T, 1994, Am J Med Qual, V9, P172, DOI 10.1177/0885713X9400900408; GOODNOUGH LT, 1995, J LAB CLIN MED, V126, P57; GOODNOUGH LT, 1993, TRANSFUSION, V33, P944, DOI 10.1046/j.1537-2995.1993.331194082388.x; GOODNOUGH LT, 1993, SURG GYNECOL OBSTET, V176, P235; GOODNOUGH LT, 1994, TRANSFUSION, V34, P66, DOI 10.1046/j.1537-2995.1994.34194098608.x; GOODNOUGH LT, 1994, UROLOGY, V44, P226; GOODNOUGH LT, 1992, VOX SANG, V63, P90, DOI 10.1111/j.1423-0410.1992.tb02492.x; GOODNOUGH LT, 1992, TRANSFUSION, V32, P441, DOI 10.1046/j.1537-2995.1992.32592327718.x; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; GOODNOUGH LT, 1994, AM J CLIN PATHOL, V101, P354; Goodnough LT, 1996, VOX SANG, V71, P133, DOI 10.1046/j.1423-0410.1996.7130133.x; GOODNOUGH LT, 1990, J LAB CLIN MED, V115, P28; GOODNOUGH LT, 1989, TRANSFUSION, V29, P821, DOI 10.1046/j.1537-2995.1989.29990070188.x; GOODNOUGH LT, 1994, J AM COLL SURGEONS, V179, P171; GOODNOUGH LT, 1990, VOX SANG, V59, P65, DOI 10.1111/j.1423-0410.1990.tb05010.x; GOODNOUGH LT, 1994, ANESTH ANALG, V78, P932; *JOINT COUNC AM RE, 1994, CIRC INF US HUM BLOO, P6; KICKLER TS, 1988, JAMA-J AM MED ASSOC, V260, P65, DOI 10.1001/jama.260.1.65; KRANTZ SB, 1991, BLOOD, V77, P419; MCMAHON FG, 1990, BLOOD, V76, P1718; MERCURIALI F, 1993, TRANSFUSION, V33, P55, DOI 10.1046/j.1537-2995.1993.33193142311.x; MESSMER K, 1986, EUR SURG RES, V18, P254, DOI 10.1159/000128533; Monk T. G., 1995, Anesthesia and Analgesia, V80, pS320; MONK TG, 1995, TRANSFUSION, V35, P559, DOI 10.1046/j.1537-2995.1995.35795357877.x; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; Price TH, 1996, TRANSFUSION, V36, P29, DOI 10.1046/j.1537-2995.1996.36196190512.x; RENNER SW, 1992, ARCH PATHOL LAB MED, V116, P613; ROGUS SD, 1990, JAMA-J AM MED ASSOC, V263, P414; Sans T, 1996, TRANSFUSION, V36, P822, DOI 10.1046/j.1537-2995.1996.36996420762.x; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SISK JE, 1991, JAMA-J AM MED ASSOC, V266, P247, DOI 10.1001/jama.266.2.247; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P698, DOI 10.1001/jama.268.6.698; Sowade O, 1997, BLOOD, V89, P411, DOI 10.1182/blood.V89.2.411; TOY PTCY, 1993, TRANSFUSION, V33, P721, DOI 10.1046/j.1537-2995.1993.33994025020.x; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TOY PTCY, 1992, TRANSFUSION, V32, P63, DOI 10.1046/j.1537-2995.1992.32192116435.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; WEISKOPF RB, 1995, TRANSFUSION, V35, P37, DOI 10.1046/j.1537-2995.1995.35195090657.x; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; WINSLOW RM, 1989, TRANSFUSION, V29, P753, DOI 10.1046/j.1537-2995.1989.29990070175.x	56	157	164	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	1997	336	13					933	938		10.1056/NEJM199703273361307	http://dx.doi.org/10.1056/NEJM199703273361307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP832	9070475				2022-12-28	WOS:A1997WP83200007
J	Yazdani, A; Jones, BA; Lutz, CP; Crommie, MF; Eigler, DM				Yazdani, A; Jones, BA; Lutz, CP; Crommie, MF; Eigler, DM			Probing the local effects of magnetic impurities on superconductivity	SCIENCE			English	Article							STATES; VORTEX	The local effects of isolated magnetic adatoms on the electronic properties of the surface of a superconductor were studied with a low-temperature scanning tunneling microscope. Tunneling spectra obtained near magnetic adsorbates reveal the presence of excitations within the superconductor's energy gap that can be detected over a few atomic diameters around the impurity at the surface, These excitations are locally asymmetric with respect to tunneling of electrons and holes, A model calculation based on the Bogoliubov-de Gennes equations can be used to understand the details of the local tunneling spectra.	BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215	Boston University	Yazdani, A (corresponding author), IBM CORP,ALMADEN RES CTR,DIV RES,650 HARRY RD,SAN JOSE,CA 95120, USA.			Yazdani, Ali/0000-0003-4996-8904				ABRIKOSOV AA, 1961, SOV PHYS JETP-USSR, V12, P1243; BAURIEDL W, 1981, PHYS REV LETT, V47, P1163, DOI 10.1103/PhysRevLett.47.1163; FLATTE ME, IN PRESS PHYS REV LE; GYGI F, 1990, PHYS REV B, V41, P822, DOI 10.1103/PhysRevB.41.822; Hayashi N, 1996, PHYS REV LETT, V77, P4074, DOI 10.1103/PhysRevLett.77.4074; HESS HF, 1993, SCANNING TUNNELING M, P427; LANG ND, 1986, PHYS REV LETT, V56, P1164, DOI 10.1103/PhysRevLett.56.1164; Maple M. B., 1973, MAGNETISM, Vv, P289; ROY A, 1985, PHYS REV B, V31, P3003, DOI 10.1103/PhysRevB.31.3003; RUSINOV AI, 1969, ZH EKSP TEOR FIZ, V29, P1101; SAKURAI A, 1970, PROG THEOR PHYS, V44, P1472, DOI 10.1143/PTP.44.1472; SALKOLA MI, IN PRESS PHYS REV B; SCHLOTTMANN P, 1976, PHYS REV B, V13, P1, DOI 10.1103/PhysRevB.13.1; SCHOLTEN PD, 1977, PHYS REV B, V15, P1318, DOI 10.1103/PhysRevB.15.1318; SHIBA H, 1968, PROG THEOR PHYS, V40, P435, DOI 10.1143/PTP.40.435; SHORE JD, 1989, PHYS REV LETT, V62, P3089, DOI 10.1103/PhysRevLett.62.3089; WOOLF MA, 1965, PHYS REV, V137, pA557, DOI 10.1103/PhysRev.137.A557; Yu L., 1965, ACTA PHYS SINICA, V21, P75, DOI DOI 10.7498/APS.21.75; ZITTARTZ J, 1970, Z PHYS, V232, P11, DOI 10.1007/BF01394943; ZITTARTZ J, 1970, Z PHYS, V237, P419, DOI 10.1007/BF01407639	21	394	397	2	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1767	1770		10.1126/science.275.5307.1767	http://dx.doi.org/10.1126/science.275.5307.1767			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065395				2022-12-28	WOS:A1997WP05600033
J	Su, WCS; Kitagawa, M; Xue, NR; Xie, B; Garofalo, S; Cho, J; Deng, CX; Horton, WA; Fu, XY				Su, WCS; Kitagawa, M; Xue, NR; Xie, B; Garofalo, S; Cho, J; Deng, CX; Horton, WA; Fu, XY			Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism	NATURE			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; PROTEIN; SPECIFICITY; MUTATIONS; KINASE; GENE	The achondroplasia class of chondrodysplasias comprises the most common genetic forms of dwarfism in humans and includes achondroplasia, hypochondroplasia and thanatophoric dysplasia types I and II (TDI and TDII), which are caused by different mutations in a fibroblast growth-factor receptor FGFR3 (ref, 1), The molecular mechanism and the mediators of these FGFR3-related growth abnormalities are not known, Here we show that mutant TDII FGFR3 has a constitutive tyrosine kinase activity which can specifically activate the transcription factor Stat1 (for signal transducer and activator of transcription)(2,3). Furthermore, expression of TDII FGFR3 induced nuclear translocation of Stat1, expression of the cell-cycle inhibitor p21(WAF1/CIP1), and growth arrest of the cell. Thus, TDII FGFR3 may use Stat1 as a mediator of growth retardation in bone development, Consistent with this, Stat1 activation and increased p21(WAF1/CIP1) expression was found in the cartilage cells from the TDII fetus, but not in those from the normal fetus, Thus, abnormal STAT activation and p21(WAF1/CIP1) expression by the TDII mutant receptor may be responsible for this FGFR3-related bone disease.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA; SHRINERS HOSP CRIPPLED CHILDRENS, RES DEPT, PORTLAND, OR 97201 USA; NIDDKD, BIOCHEM & METAB LAB, NIH, BETHESDA, MD 20892 USA	Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			deng, chuxia/N-6713-2016; Kitagawa, Motoo/W-8468-2019	Kitagawa, Motoo/0000-0003-1036-840X; Su, Wu-Chou/0000-0003-2953-4105; GAROFALO, SILVIO/0000-0001-7460-3179				Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILLENCE DO, 1979, AM J PATHOL, V96, P813; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016	30	262	272	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	1997	386	6622					288	292		10.1038/386288a0	http://dx.doi.org/10.1038/386288a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069288				2022-12-28	WOS:A1997WP00300053
J	Suzuki, H; Kurihara, Y; Takeya, M; Kamada, N; Kataoka, M; Jishage, K; Ueda, O; Sakaguchi, H; Higashi, T; Suzuki, T; Takashima, Y; Kawabe, Y; Cynshi, O; Wada, Y; Honda, M; Kurihara, H; Aburatani, H; Doi, T; Matsumoto, A; Azuma, S; Noda, T; Toyoda, Y; Itakura, H; Yazaki, Y; Horiuchi, S; Takahashi, K; Kruijt, JK; vanBerkel, TJC; Steinbrecher, UP; Ishibashi, S; Maeda, N; Gordon, S; Kodama, T				Suzuki, H; Kurihara, Y; Takeya, M; Kamada, N; Kataoka, M; Jishage, K; Ueda, O; Sakaguchi, H; Higashi, T; Suzuki, T; Takashima, Y; Kawabe, Y; Cynshi, O; Wada, Y; Honda, M; Kurihara, H; Aburatani, H; Doi, T; Matsumoto, A; Azuma, S; Noda, T; Toyoda, Y; Itakura, H; Yazaki, Y; Horiuchi, S; Takahashi, K; Kruijt, JK; vanBerkel, TJC; Steinbrecher, UP; Ishibashi, S; Maeda, N; Gordon, S; Kodama, T			A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; E-DEFICIENT MICE; APOLIPOPROTEIN-E; CHOLESTEROL; BINDING; HYPERCHOLESTEROLEMIA; MACROSIALIN; BACTERIA; ADHESION; PROTEINS	Macrophage type-I and type-II class-A scavenger receptors (MSR-A) are implicated in the pathological deposition of cholesterol during atherogenesis as a result of receptor-mediated uptake of modified low-density Lipoproteins (mLDL)(1-6). MSR-A can bind an extraordinarily wide range of ligands, including bacterial pathogens(7), and also mediates cation-independent macrophage adhesion in vitro(8). Here we show that targeted disruption of the MSR-A gene in mice results in a reduction in the size of atherosclerotic lesions in an animal deficient in apolipoprotein E. Macrophages from MSR-A-deficient mice show a marked decrease in mLDL uptake in vitro, whereas mLDL clearance from plasma occurs at a normal rate, indicating that there may be alternative mechanisms for removing mLDL from the circulation. In addition, MSR-A-knockout mice show an increased susceptibility to infection with Listeria monocytogenes or herpes simplex virus type-1, indicating that MSR-A may play a part in host defence against pathogens.	UNIV TOKYO,DEPT MOL BIOL & MED,ADV SCI & TECHNOL RES CTR,MEGURO KU,TOKYO 153,JAPAN; CHUGAI PHARMACEUT CO LTD,SHIZUOKA 412,JAPAN; CSK RES PK INC,SHIZUOKA 412,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT PATHOL,KUMAMOTO 860,JAPAN; OSAKA UNIV,FAC PHARMACEUT SCI,OSAKA 565,JAPAN; NATL INST HLTH & NUTR,TOKYO 162,JAPAN; UNIV TOKYO,INST MED SCI,TOKYO 108,JAPAN; JAPANESE FDN CANC RES,INST CANC,TOKYO 170,JAPAN; OBIHIRO UNIV AGR & VET MED,RES CTR PROTOZOAN MOL IMMUNOL,OBIHIRO,HOKKAIDO 080,JAPAN; LEIDEN UNIV,DIV BIOPHARMACEUT,NL-2300 RA LEIDEN,NETHERLANDS; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 4E3,CANADA; UNIV N CAROLINA,SCH MED,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND	University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Tokyo; Kumamoto University; Kumamoto University; Osaka University; National Institute of Health & Nutrition - Japan; University of Tokyo; Japanese Foundation for Cancer Research; Obihiro University of Agriculture & Veterinary Medicine; Leiden University; Leiden University - Excl LUMC; University of British Columbia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Oxford			Noda, Tetsuo/B-1667-2016; Van Berkel, Theo/ABD-7677-2021	Kurihara, Hiroki/0000-0002-6476-5593; Kawabe, Yoshiki/0000-0002-6465-7146				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AZUMA S, 1991, Japanese Journal of Animal Reproduction, V37, P37; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Cynshi O, 1994, J Atheroscler Thromb, V1, P87; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HUGHES DA, 1995, EUR J IMMUNOL, V25, P466, DOI 10.1002/eji.1830250224; IRIE H, 1989, ARCH VIROL, V105, P247, DOI 10.1007/BF01311361; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; NAITO M, 1992, AM J PATHOL, V141, P591; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suzuki Hiroshi, 1994, Journal of Reproduction and Development, V40, P107, DOI 10.1262/jrd.40.107; TAKATA K, 1988, J BIOL CHEM, V263, P14819; VANBERKEL TJC, 1985, J BIOL CHEM, V260, P2203; VANREE JH, 1995, ATHEROSCLEROSIS, V118, P165, DOI 10.1016/0021-9150(95)05602-S; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460	28	957	1017	3	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					292	296		10.1038/386292a0	http://dx.doi.org/10.1038/386292a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069289				2022-12-28	WOS:A1997WP00300054
J	Gass, A; Hennerici, MG; Gaa, J; Schwartz, A				Gass, A; Hennerici, MG; Gaa, J; Schwartz, A			Rapid recovery from left hemiplegia	LANCET			English	Article							DIFFUSION; STROKE		UNIV HEIDELBERG, KLINIKUM MANNHEIM, DEPT RADIOL, D-68137 MANNHEIM, GERMANY	Ruprecht Karls University Heidelberg	Gass, A (corresponding author), UNIV HEIDELBERG, KLINIKUM MANNHEIM, DEPT NEUROL, THEODOR KUTZER UFER 1-3, D-68137 MANNHEIM, GERMANY.							DEROOK FA, 1992, ANN INTERN MED, V117, P922, DOI 10.7326/0003-4819-117-11-922; *FRENCH STUD AORT, 1996, NEW ENGL J MED, V324, P1216; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; Marks MP, 1996, RADIOLOGY, V199, P403, DOI 10.1148/radiology.199.2.8668785; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214	5	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	1997	349	9054					772	772		10.1016/S0140-6736(96)11395-7	http://dx.doi.org/10.1016/S0140-6736(96)11395-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074578				2022-12-28	WOS:A1997WN12400013
J	Tumiati, B; Casoli, P; Parmeggiani, A				Tumiati, B; Casoli, P; Parmeggiani, A			Hearing loss in the Sjogren syndrome	ANNALS OF INTERNAL MEDICINE			English	Article							ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODY; RHEUMATOID-ARTHRITIS; DISEASE; EAR	Background: Ear involvement is not unusual in autoimmune diseases, but few data on this problem in the Sjogren syndrome are available. Objectives: To determine whether the incidence of hearing loss is increased in patients with the Sjogren syndrome and to determine what factors might be involved in the pathogenesis of Sjogren syndrome-related hearing loss. Design: Cross-sectional study. Setting: Secondary referral center in Italy. Patients: 30 women with the Sjogren syndrome were evaluated for evidence of audiovestibular disorder. Their results were compared with those of 40 age-matched healthy women. Measurements: Evaluation techniques included pure tone audiometry thresholds at octave frequencies of 125 Hz to 8000 Hz, tympanometry, and the stapedial reflex test in both ears. The presence of vasculitis, the Raynaud phenomenon, nervous system involvement, and serum anticardiolipin antibodies was recorded. Results: 14 patients with the Sjogren syndrome (46% [95% CI, 28% to 66%]) had sensorineural hearing loss. Only one control (2.5% [CI, 0.06% to 13%]) had a similar hearing impairment (P < 0.001). Nine of the 14 patients who had the Sjogren syndrome and sensorineural hearing loss (64% [CI, 36% to 87%]) had anticardiolipin antibodies compared with only 3 controls (18% [CI, 4% to 45%]) (P = 0.02). Conclusion: The high prevalence of hearing loss in the Sjogren syndrome supports the value of doing audiometric studies before excluding cranial nerve involvement in this disease. The correlation of sensorineural hearing loss with anticardiolipin antibodies must be investigated further.			Tumiati, B (corresponding author), OSPED S MARIA NUOVA, DEPT INTERNAL MED 2, VIALE RISORGIMENTO, I-42100 REGGIO EMILIA, ITALY.							ALEXANDER EL, 1993, RHEUM DIS CLIN N AM, V19, P869; ANDONOPOULOS AP, 1995, CLIN EXP RHEUMATOL, V13, P137; ARROYO R A, 1989, Arthritis and Rheumatism, V32, pS73; ASHERSON RA, 1992, ANN RHEUM DIS, V51, P495, DOI 10.1136/ard.51.4.495; BUCHANAN RRC, 1989, J RHEUMATOL, V16, P757; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; DOIG JA, 1971, BMJ-BRIT MED J, V4, P460, DOI 10.1136/bmj.4.5785.460; ELWANY S, 1986, J RHEUMATOL, V13, P878; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; GUSSEN R, 1977, ARCH OTO-RHINO-LARYN, V217, P263, DOI 10.1007/BF00465544; HARRIS JP, 1989, AM J OTOL, V10, P193; HISASHI K, 1993, AM J OTOLARYNG, V14, P275, DOI 10.1016/0196-0709(93)90075-I; Jerger J, 1980, OTOLARYNG HEAD NECK, V2nd, P1225; KORNBLUT AD, 1982, LARYNGOSCOPE, V92, P713, DOI 10.1288/00005537-198207000-00001; MAGARO M, 1990, CLIN EXP RHEUMATOL, V8, P487; MANOUSSAKIS MN, 1987, CLIN IMMUNOL IMMUNOP, V44, P297, DOI 10.1016/0090-1229(87)90073-0; TUMIATI B, 1995, AM J OTOLARYNG, V16, P220, DOI 10.1016/0196-0709(95)90109-4; VITALI C, 1993, ARTHRITIS RHEUM, V36, P340, DOI 10.1002/art.1780360309; VOLLERTSEN RS, 1990, RHEUM DIS CLIN N AM, V16, P433; YOON TH, 1990, LARYNGOSCOPE, V100, P707	20	88	90	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					450	453		10.7326/0003-4819-126-6-199703150-00005	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM530	9072930				2022-12-28	WOS:A1997WM53000005
J	Pulliam, L; Gascon, R; Stubblebine, M; McGuire, D; McGrath, MS				Pulliam, L; Gascon, R; Stubblebine, M; McGuire, D; McGrath, MS			Unique monocyte subset in patients with AIDS dementia	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; MONONUCLEAR PHAGOCYTES; HIV ENCEPHALITIS; NEOPTERIN; TYPE-1; BRAIN; BLOOD; BETA-2-MICROGLOBULIN	Background 15-30% of patients infected with HIV will develop a debilitating dementia. Whilst HIV enters the brain soon after infection, presumably within monocyte-derived macrophages, not all patients with HIV become demented. Blood monocytes probably cross the blood-brain barrier and give rise ultimately to parenchyma macrophages. We looked for a specific monocyte subset in AIDS patients with dementia. Methods Peripheral blood monocytes from three groups were compared: AIDS patients with (n=12) and without (n=11) dementia, and ten HIV seronegative healthy controls. We used flow cytometry to analyse monocytes, and cell lysis and apoptosis assays to examine monocyte effects on human brain cells in vitro. Findings We found a unique subset of monocytes in patients with AIDS dementia. These monocytes were more dense and granular and expressed CD14/CD16 and CD14/CD69. Means (SD) for CD14/CD16 in HIV-negative controls and in AIDS non-dementia and AIDS dementia patients were 6.5% (4), 16% (13), and 37% (21), respectively (p=0.008 between the two groups of patients). The corresponding means for CD14/CD69 were 7% (6), 8% (10), and 69% (18) (p<0.0001). Interpretation CD69 is a member of the natural-killer-cell gene complex that is expressed after activation. Supernatants from cultures containing these dense cells can trigger apoptosis of human brain cells in vitro. The monocyte subset we found in patients with AIDS dementia might enter the brain and expose neural cells to toxic factors.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; NEUREX CORP,MENLO PK,CA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Pulliam, L (corresponding author), VET AFFAIRS MED CTR 113A,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NCI NIH HHS [R01CA6738] Funding Source: Medline; NINDS NIH HHS [R01 NS30311S] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030311] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHIM CL, 1993, J CLIN INVEST, V91, P2769, DOI 10.1172/JCI116518; ADLEBIASSETTE H, 1995, NEUROPATH APPL NEURO, V21, P218, DOI 10.1111/j.1365-2990.1995.tb01053.x; BOGNER JR, 1992, CLIN INVESTIGATOR, V70, P665; Brew BJ, 1996, J INFECT DIS, V174, P294, DOI 10.1093/infdis/174.2.294; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999; Frankenberger M, 1996, BLOOD, V87, P373; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; HAGBERG L, 1993, J INFECT DIS, V168, P1285, DOI 10.1093/infdis/168.5.1285; HEYES MP, 1992, J NEUROIMMUNOL, V40, P71, DOI 10.1016/0165-5728(92)90214-6; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; NOKTA MA, 1995, VIROLOGY, V208, P590, DOI 10.1006/viro.1995.1190; Nottet HSLM, 1996, J NEUROVIROL, V2, P111, DOI 10.3109/13550289609146544; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; PETITO CK, 1995, AM J PATHOL, V146, P1121; PRICE RW, 1988, J INFECT DIS, V158, P1079, DOI 10.1093/infdis/158.5.1079; PULLIAM L, 1991, J CLIN INVEST, V87, P503, DOI 10.1172/JCI115024; PULLIAM L, 1988, J NEUROSCI RES, V21, P521, DOI 10.1002/jnr.490210243; Pulliam L, 1996, AIDS, V10, P1495, DOI 10.1097/00002030-199611000-00006; Thieblemont N, 1995, EUR J IMMUNOL, V25, P3418, DOI 10.1002/eji.1830251232; WILEY CA, 1992, AIDS, V6, P1299, DOI 10.1097/00002030-199211000-00010; ZIEGLER SF, 1994, STEM CELLS, V2, P456; ZIEGLERHEITBROCK HWL, 1992, BLOOD, V79, P503; ZIEGLERHEITBROCK HWL, 1993, EUR J IMMUNOL, V23, P2053, DOI 10.1002/eji.1830230902	30	299	314	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					692	695		10.1016/S0140-6736(96)10178-1	http://dx.doi.org/10.1016/S0140-6736(96)10178-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078201				2022-12-28	WOS:A1997WM08000011
J	Greegor, RB; Pingitore, NE; Lytle, FW				Greegor, RB; Pingitore, NE; Lytle, FW			Strontianite in coral skeletal aragonite	SCIENCE			English	Article							SR/CA; REEF	An x-ray spectroscopic study of scleractinian coral skeletons indicated that, although some strontium substitutes for calcium in the aragonite structure, at concentrations of about 7500 parts per million, as much as 40 percent of the strontium resides in strontianite (SrCO3). A doubler peak in the Fourier transform of the extended x-ray absorption fine structure of the coral corresponded to six metal and 13 oxygen neighbors surrounding strontium at about 4.05 angstroms in strontium-substituted aragonite and at about 4.21 angstroms in strontianite. Thus, the mechanism of the temperature-sensitive partitioning of strontium between seawater and coral skeleton used for paleothermometry is unexpectedly complex.	UNIV TEXAS,DEPT GEOL SCI,EL PASO,TX 79968; BOEING CO,SEATTLE,WA 98124; EXAFS CO,PIOCHE,NV 89043	University of Texas System; University of Texas El Paso; Boeing								AMIEL AJ, 1973, SEDIMENTOLOGY, V20, P47, DOI 10.1111/j.1365-3091.1973.tb01606.x; Barnes DJ, 1995, J EXP MAR BIOL ECOL, V194, P251, DOI 10.1016/0022-0981(95)00091-7; Bathurst R. G. C., 1971, CARBONATE SEDIMENTS; DEVILLIERS JP, 1971, AM MINERAL, V56, P758; DEVILLIERS S, 1994, GEOCHIM COSMOCHIM AC, V58, P197, DOI 10.1016/0016-7037(94)90457-X; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; Hart SR, 1996, GEOCHIM COSMOCHIM AC, V60, P3075, DOI 10.1016/0016-7037(96)00154-8; HOLLAND HD, 1963, GEOCHIM COSMOCHIM AC, V27, P957, DOI 10.1016/0016-7037(63)90105-4; LEE T, 1995, EOS, V76, P180; LYTLE FW, 1989, APPLICATIONS SYNCHRO, P135; McCulloch M, 1996, EARTH PLANET SC LETT, V138, P169, DOI 10.1016/0012-821X(95)00230-A; MCCULLOCH MT, 1994, GEOCHIM COSMOCHIM AC, V58, P2747, DOI 10.1016/0016-7037(94)90142-2; Morse J. W., 1990, GEOCHEMISTRY SEDIMEN; PLUMMER LN, 1987, GEOCHIM COSMOCHIM AC, V51, P1393, DOI 10.1016/0016-7037(87)90324-3; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SMITH SV, 1979, SCIENCE, V204, P404, DOI 10.1126/science.204.4391.404; SPEER JA, 1983, CARBONATES MINERALOG, P145; WEBER JN, 1973, GEOCHIM COSMOCHIM AC, V37, P2173, DOI 10.1016/0016-7037(73)90015-X; Wyckoff R.W.G, 1963, CRYST STRUCT	19	83	87	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1452	1454		10.1126/science.275.5305.1452	http://dx.doi.org/10.1126/science.275.5305.1452			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9072808				2022-12-28	WOS:A1997WM08100037
J	Sawamura, T; Kume, N; Aoyama, T; Moriwaki, H; Hoshikawa, H; Aiba, Y; Tanaka, T; Miwa, S; Katsura, Y; Kita, T; Masaki, T				Sawamura, T; Kume, N; Aoyama, T; Moriwaki, H; Hoshikawa, H; Aiba, Y; Tanaka, T; Miwa, S; Katsura, Y; Kita, T; Masaki, T			An endothelial receptor for oxidized low-density lipoprotein	NATURE			English	Article							SCAVENGER RECEPTOR; MACROPHAGE; CELLS; ATHEROSCLEROSIS; RECOGNITION; EXPRESSION; CHOLESTEROL; BINDING; DOMAINS; CLONING	Endothelial dysfunction or activation elicited by oxidatively modified low-density lipoprotein (Ox-LDL) has been implicated in the pathogenesis of atherosclerosis(1-4), characterized by intimal thickening and lipid deposition in the arteries. Ox-LDL and its lipid constituents impair endothelial production of nitric oxide, and induce the endothelial expression of leukocyte adhesion molecules and smooth-muscle growth factors, which may be involved in atherogenesis(5-7). Vascular endothelial cells in culture(8,9) and in vivo(10,11) internalize and degrade Ox-LDL through a putative receptor-mediated pathway that does not involve macrophage scavenger receptors(12-15). Here we report the molecular cloning, using expression cloning strategy, of an Ox-LDL receptor from vascular endothelial cells. The cloned receptor is a membrane protein that belongs structurally to the C-type lectin family, and is expressed in vivo in vascular endothelium and vascular-rich organs.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT GERIATR MED,KYOTO 606,JAPAN; KYOTO UNIV,CHEST DIS RES INST,DEPT IMMUNOL,KYOTO 606,JAPAN; JAPANESE RED CROSS SAITAMA BRANCH,YONO,SAITAMA 338,JAPAN	Kyoto University; Kyoto University; Kyoto University			Miwa, Soichi/D-8468-2012; Sawamura, Tatsuya/E-7103-2010	Marchini, Julio/0000-0002-2279-1945				ACTON SL, 1994, J BIOL CHEM, V269, P21003; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIMBRONE MA, 1995, ANN NY ACAD SCI, V748, P122; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IKURA T, 1994, BIOCHEM BIOPH RES CO, V203, P1417, DOI 10.1006/bbrc.1994.2343; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUME N, 1991, BIOCHIM BIOPHYS ACTA, V1091, P63, DOI 10.1016/0167-4889(91)90223-K; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHOW G, 1986, CELL, V46, P659; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEIN O, 1980, BIOCHIM BIOPHYS ACTA, V620, P631, DOI 10.1016/0005-2760(80)90155-1; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEPHAN ZF, 1993, J LIPID RES, V34, P325; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282	27	1101	1241	2	68	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					73	77		10.1038/386073a0	http://dx.doi.org/10.1038/386073a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052782				2022-12-28	WOS:A1997WL74600053
J	Fazekas, F; Deisenhammer, F; StrasserFuchs, S; Nahler, G; Mamoli, B				Fazekas, F; Deisenhammer, F; StrasserFuchs, S; Nahler, G; Mamoli, B			Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis	LANCET			English	Article							IMMUNE GLOBULIN; DOUBLE-BLIND; IMMUNOTHERAPY; GUIDELINES; DISABILITY; IGG; MS	Background Multiple sclerosis is an autoimmune disorder characterised by the repeated occurrence of demyelinating lesions within the central nervous system. Uncontrolled studies and experimental evidence suggest beneficial effects of repeated administration of intravenous immunoglobulin (IVIg) by immunomodulating mechanisms and induction or remyelination. We aimed to investigate the efficacy of IVIg in a randomised double-blind multicentre study. Methods Patients with relapsing-remitting multiple sclerosis were randomly assigned a monthly dose of IVlg (0.15-0.2 g/kg bodyweight) or placebo. Duration of treatment was 2 years, The primary outcome measures were the effect of treatment on clinical disability-measured by the absolute change in Kurtzke's expanded disability status scale (EDSS) score-and the proportion of patients with improved, stable, or worse clinical disability(greater than or equal to 1.0 grade on EDSS score). Findings Of the 243 patients screened, 150 met our eligibility criteria and were randomly assigned to IVIg or placebo. Before the start of treatment two patients in the placebo group dropped out, so there were 75 patients in the IVIg group and 73 in the placebo group. Intention-to-treat analysis showed that IVIg treatment had a beneficial effect on the course of clinical disability. The EDSS score decreased in the IVIg-treated patients and increased in the placebo group (-0.23 [95% CI -0.43 to -0.03] vs 0.12 [-0.13 to 0.37], p=0.008). In the IVIg group, the numbers of patients with improved, stable, or worse clinical disability were 23 (31%), 40 (53%), and 12 (16%) compared with ten (14%), 46 (63%), and 17 (23%) in the placebo group. Side-effects were reported in three (4%) IVIg-treated patients and in four (5%) placebo-group patients, but were not directly linked to study medication. Interpretation Monthly IVIg is an effective and well-tolerated treatment for patients with relapsing-remitting multiple sclerosis.	LEOPOLD FRANZENS UNIV, DEPT NEUROL, INNSBRUCK, AUSTRIA; CIS CLIN INVEST SUPPORT GMBH & CO KG, VIENNA, AUSTRIA; HOSP ROSENHUGEL, DEPT NEUROL 2, VIENNA, AUSTRIA	University of Innsbruck	Fazekas, F (corresponding author), KARL FRANZENS UNIV GRAZ, DEPT NEUROL, ANENBRUGGERPL 22, A-8036 GRAZ, AUSTRIA.		Macedo, Ana/L-9912-2018	Macedo, Ana/0000-0002-6978-8989				ACHIRON A, 1992, ARCH NEUROL-CHICAGO, V49, P1233, DOI 10.1001/archneur.1992.00530360031013; ACHIRON A, 1994, J NEUROL NEUROSUR PS, V57, P57, DOI 10.1136/jnnp.57.Suppl.57; ANDERSSON UG, 1993, IMMUNOLOGY, V79, P211; BERRY DA, 1990, STAT METHODOLOGY PHA, V104; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; CHERIN P, 1994, J NEUROL NEUROSUR PS, V57, P50, DOI 10.1136/jnnp.57.Suppl.50; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; FRANK MM, 1992, CLIN IMMUNOL IMMUNOP, V62, pS82, DOI 10.1016/0090-1229(92)90045-P; HAFLER DA, 1989, IMMUNOL TODAY, V10, P104, DOI 10.1016/0167-5699(89)90236-3; HAUSER SL, 1994, HARRISONS PRINCIPLES, V2, P2287; IPPOLITI G, 1984, LANCET, V2, P809; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; JUNGI TW, 1990, CLIN EXP IMMUNOL, V82, P163; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Miller DH, 1996, ANN NEUROL, V39, P6, DOI 10.1002/ana.410390104; MILLER DH, 1991, J NEUROL NEUROSUR PS, V54, P683, DOI 10.1136/jnnp.54.8.683; NOSEWORTHY JH, 1994, J NEUROL NEUROSUR PS, V57, P11, DOI 10.1136/jnnp.57.Suppl.11; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; REDER AT, 1985, HDB CLIN NEUROLOGY, V2, P337; REINHART WH, 1992, LANCET, V339, P662, DOI 10.1016/0140-6736(92)90806-E; RODRIGUEZ M, 1990, ANN NEUROL, V27, P12, DOI 10.1002/ana.410270104; ROTHFELDER U, 1982, MUNCHEN MED WOCHEN, V124, P74; SCHULLER E, 1983, EUR NEUROL, V22, P205, DOI 10.1159/000115560; SORENSEN PS, 1994, J NEUROL NEUROSUR PS, V57, P62, DOI 10.1136/jnnp.57.Suppl.62; SOUKOP W, 1986, WIEN MED WOCHENSCHR, V136, P477; TENSER RB, 1993, ARCH NEUROL-CHICAGO, V50, P417, DOI 10.1001/archneur.1993.00540040069017; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; VANDOORN PA, 1994, J NEUROL NEUROSUR PS, V57, P38, DOI 10.1136/jnnp.57.Suppl.38; VANENGELEN BGM, 1992, ANN NEUROL, V32, P834, DOI 10.1002/ana.410320624; VERMEULEN M, 1993, J NEUROL NEUROSUR PS, V56, P36, DOI 10.1136/jnnp.56.1.36; WEINER HL, 1988, ANN NEUROL, V23, P211, DOI 10.1002/ana.410230302; YAN J, 1990, LANCET, V336, P692, DOI 10.1016/0140-6736(90)92188-N	34	331	340	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	1997	349	9052					589	593		10.1016/S0140-6736(96)09377-4	http://dx.doi.org/10.1016/S0140-6736(96)09377-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057729				2022-12-28	WOS:A1997WK91500007
J	Johnson, A				Johnson, A			Laparoscopic surgery	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; OPEN INGUINAL HERNIORRHAPHY; OPEN APPENDECTOMY; HERNIA REPAIR; CHOLECYSTECTOMY; METASTASES; INJURY				Johnson, A (corresponding author), UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT SURG & ANAESTHET SCI,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							Antia NH, 1996, LANCET, V347, P985, DOI 10.1016/S0140-6736(96)90138-5; BARKUN JS, 1995, SURGERY, V118, P703, DOI 10.1016/S0039-6060(05)80038-8; BERNARD HR, 1993, AM J SURG, V165, P533, DOI 10.1016/S0002-9610(05)80956-0; Cohen MM, 1996, CAN MED ASSOC J, V154, P491; CUSCHIERI A, 1995, AM J SURG, V169, P9, DOI 10.1016/S0002-9610(99)80104-4; FLETCHER DR, 1995, MED J AUSTRALIA, V163, P535, DOI 10.5694/j.1326-5377.1995.tb124722.x; Gotley DC, 1996, GUT, V38, P487, DOI 10.1136/gut.38.4.487; GOUMA DJ, 1994, J AM COLL SURGEONS, V178, P229; Hansen JB, 1996, WORLD J SURG, V20, P17, DOI 10.1007/s002689900003; Johnson AG, 1996, LANCET, V347, P1623; KITANO S, 1993, SURG ENDOSC-ULTRAS, V7, P311, DOI 10.1007/BF00725947; Koivusalo AM, 1996, BRIT J SURG, V83, P1532, DOI 10.1002/bjs.1800831112; KUM CK, 1993, BRIT J SURG, V80, P1599, DOI 10.1002/bjs.1800801236; Lau WY, 1996, ANN SURG, V224, P131, DOI 10.1097/00000658-199608000-00004; LAWRENCE K, 1995, BRIT MED J, V311, P981; Lejus C, 1996, ANESTHESIOLOGY, V84, P801, DOI 10.1097/00000542-199604000-00006; Majeed AW, 1996, LANCET, V347, P989, DOI 10.1016/S0140-6736(96)90143-9; MARTIN LC, 1995, ANN SURG, V222, P256, DOI 10.1097/00000658-199509000-00004; MATTHEW G, 1996, BRIT J SURG, V83, P1087; MCGINN FP, 1995, BRIT J SURG, V82, P1374, DOI 10.1002/bjs.1800821027; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; MONSONJRT, 1995, BRIT J SURG, V82, P295; Mutter D, 1996, SURGERY, V120, P71, DOI 10.1016/S0039-6060(96)80243-1; Naude G P, 1995, Endosc Surg Allied Technol, V3, P183; NDUKA CC, 1994, BRIT J SURG, V81, P648, DOI 10.1002/bjs.1800810506; ORTEGA AE, 1995, AM J SURG, V169, P208, DOI 10.1016/S0002-9610(99)80138-X; Ortega AE, 1996, J AM COLL SURGEONS, V183, P249; PAYNE JH, 1994, ARCH SURG-CHICAGO, V129, P973; REDMOND HP, 1994, ARCH SURG-CHICAGO, V129, P1240; RUTKOW IM, 1992, ARCH SURG-CHICAGO, V127, P1271; STOKER D, 1994, LANCET, V343, P1243, DOI 10.1016/S0140-6736(94)92148-2; STRASBERG SM, 1995, J AM COLL SURGEONS, V180, P101; TATE JJT, 1993, LANCET, V342, P633, DOI 10.1016/0140-6736(93)91757-D; Terpstra OT, 1996, BRIT MED J, V312, P1375; Watson DI, 1996, ANN SURG, V224, P198, DOI 10.1097/00000658-199608000-00013; WEXNER SD, 1995, BRIT J SURG, V82, P295, DOI 10.1002/bjs.1800820305; [No title captured]; 1995, LOTHIAN SURG AUDIT	38	98	99	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					631	635		10.1016/S0140-6736(96)10032-5	http://dx.doi.org/10.1016/S0140-6736(96)10032-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057744				2022-12-28	WOS:A1997WK91500041
J	Wilmut, I; Schnieke, AE; McWhir, J; Kind, AJ; Campbell, KHS				Wilmut, I; Schnieke, AE; McWhir, J; Kind, AJ; Campbell, KHS			Viable offspring derived from fetal and adult mammalian cells	NATURE			English	Article							BOVINE EMBRYOS; NUCLEAR TRANSPLANTATION; RECIPIENT OOCYTE; CYCLE-STAGE; SHEEP; INVITRO; ZYGOTES	Fertilization of mammalian eggs is followed by successive cell divisions and progressive differentiation, first into the early embryo and subsequently into all of the cell types that make up the adult animal. Transfer of a single nucleus at a specific stage of development, to an enucleated unfertilized egg, provided an opportunity to investigate whether cellular differentiation to that stage involved irreversible genetic modification. The first offspring to develop from a differentiated cell were born after nuclear transfer from an embryo-derived cell line that had been induced to become quiescent(1). Using the same procedure, we now report the birth of live lambs from three new cell populations established from adult mammary gland, fetus and embryo. The fact that a lamb was derived from an adult cell confirms that differentiation of that cell did not involve the irreversible modification of genetic material required for development to term, The birth of lambs from differentiated fetal and adult cells also reinforces previous speculation(1,2) that by inducing donor cells to become quiescent it will be possible to obtain normal development from a wide variety of differentiated cells.	PPL THERAPEUT,ROSLIN EH25 9PP,MIDLOTHIAN,SCOTLAND		Wilmut, I (corresponding author), ROSLIN INST,ROSLIN EH25 9PS,MIDLOTHIAN,SCOTLAND.		王, 士勇/B-5170-2012	Schnieke, Angelika/0000-0002-5761-9635				BARNES FL, 1993, MOL REPROD DEV, V36, P33, DOI 10.1002/mrd.1080360106; BRADFORD GE, 1972, J REPROD FERTIL, V30, P459, DOI 10.1530/jrf.0.0300459; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; BUCHANAN FC, 1993, MAMM GENOME, V4, P258, DOI 10.1007/BF00417432; Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CAMPBELL KHS, 1993, BIOL REPROD, V49, P933, DOI 10.1095/biolreprod49.5.933; CHEONG HT, 1993, BIOL REPROD, V48, P958, DOI 10.1095/biolreprod48.5.958; Finch LMB, 1996, BIOCHEM SOC T, V24, pS369, DOI 10.1042/bst024369s; GARDNER DK, 1994, BIOL REPROD, V50, P390, DOI 10.1095/biolreprod50.2.390; GURDON JB, 1975, J EMBRYOL EXP MORPH, V34, P93; GURDON JB, 1974, CONTROL GENE EXPRESS; KWON OY, 1996, J REPROD FERTIL, V17, P30; MCGRATH J, 1984, SCIENCE, V226, P1317, DOI 10.1126/science.6542249; Nash ML, 1996, VET REC, V139, P64, DOI 10.1136/vr.139.3.64; PRATHER RS, 1987, BIOL REPROD, V37, P859, DOI 10.1095/biolreprod37.4.859; QUINLIVAN TD, 1966, J REPROD FERTIL, V11, P379, DOI 10.1530/jrf.0.0110379; ROBL JM, 1987, J ANIM SCI, V64, P642, DOI 10.2527/jas1987.642642x; Solter D, 1996, NATURE, V380, P24, DOI 10.1038/380024a0; WALKER SK, 1992, THERIOGENOLOGY, V37, P111, DOI 10.1016/0093-691X(92)90250-U; Walton A, 1938, PROC R SOC SER B-BIO, V125, P311, DOI 10.1098/rspb.1938.0029; WHITTEN WK, 1968, J REPROD FERTIL, V17, P399, DOI 10.1530/jrf.0.0170399	22	3470	4128	5	478	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					810	813		10.1038/385810a0	http://dx.doi.org/10.1038/385810a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039911				2022-12-28	WOS:A1997WK57000051
J	Katz, J				Katz, J			Prevention of phantom limb pain by regional anaesthesia	LANCET			English	Editorial Material							POSTOPERATIVE PAIN; AMPUTATION; ANALGESIA; NEUROPLASTICITY; SURGERY; BLOCK		TORONTO HOSP,ACUTE PAIN RES UNIT,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT BEHAV SCI,TORONTO,ON,CANADA; UNIV TORONTO,DEPT ANAESTHESIA,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Katz, J (corresponding author), TORONTO HOSP,DEPT PSYCHOL,TORONTO,ON M5T 2S8,CANADA.		Katz, Joel/HDO-1635-2022; Katz, Joel/J-7015-2014	Katz, Joel/0000-0002-8686-447X				BACH S, 1988, PAIN, V33, P297, DOI 10.1016/0304-3959(88)90288-6; Bonn D, 1996, LANCET, V347, P530, DOI 10.1016/S0140-6736(96)91154-X; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Devor M, 1994, TXB PAIN, P79; ELIZAGA AM, 1994, J REHABIL RES DEV, V31, P179; FISHER A, 1991, ANESTH ANALG, V72, P300; JAHANGIRI M, 1994, ANN ROY COLL SURG, V76, P324; KATZ J, 1994, PAIN, V59, P395, DOI 10.1016/0304-3959(94)90026-4; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; MALAWER MM, 1991, CLIN ORTHOPAEDICS, V266, P227; Pinzur MS, 1996, J BONE JOINT SURG AM, V78A, P1501, DOI 10.2106/00004623-199610000-00007; SCHUG SA, 1995, REGION ANESTH, V20, P256; Sherman RA, 1997, PHANTOM PAIN	13	40	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					519	520		10.1016/S0140-6736(97)80081-5	http://dx.doi.org/10.1016/S0140-6736(97)80081-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048786	Green Submitted			2022-12-28	WOS:A1997WJ51200005
J	Messinezy, M; Pearson, TC				Messinezy, M; Pearson, TC			ABC of clinical haematology - Polycythaemia, primary (essential) thrombocythaemia and myelofibrosis	BRITISH MEDICAL JOURNAL			English	Review											Messinezy, M (corresponding author), UNITED MED & DENT SCH,LONDON SE1 9RT,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					587	590		10.1136/bmj.314.7080.587	http://dx.doi.org/10.1136/bmj.314.7080.587			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055722	Green Published			2022-12-28	WOS:A1997WK21500032
J	Vale, L; Silcock, J; Rawles, J				Vale, L; Silcock, J; Rawles, J			An economic evaluation of thrombolysis in a remote rural community	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To assess the cost effectiveness of community thrombolysis relative to hospital thrombolysis by investigating the extra costs and benefits of a policy of community thrombolysis. Design: Economic evaluation based an the results of the Grampian region early anistreplase trial. Setting: 29 rural general practices and one secondary care provider in Grampian, Scotland. Subjects: 311 patients recruited to the Grampian region early anistreplase trial. Interventions: Intravenous anistreplase given either by general practitioners or secondary care clinicians. Main outcome measures: Survival at 4 years and costs of administration of thrombolysis. Results: Relative to hospital thrombolysis, community thrombolysis gives an additional probability of survival at 4 years of 11% (95% confidence Interval 1% to 22%) at an additional cost of f425 per patient. This gives a marginal cost of life saved at 4 years of f3890 (f1990 to f42 820). Conclusions: The cost per life saved by community thrombolysis is modest compared with for example, the cost of changing the thrombolytic drug used in hospital from streptokinase to alteplase.	UNIV ABERDEEN,MED ASSESSMENT RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen	Vale, L (corresponding author), UNIV ABERDEEN,HLTH ECON RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND.		Silcock, Jonathan/AAB-1856-2020	Silcock, Jonathan/0000-0002-4920-9249; Vale, Luke/0000-0001-8574-8429				BARRADELL LB, 1995, PHARMACOECONOMICS, V8, P428, DOI 10.2165/00019053-199508050-00006; *BRIT HEART FDN WO, 1994, BRIT MED J, V308, P767; *FIBR THER TRIAL C, 1994, LANCET, V343, P311; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; Rawles J, 1996, BMJ-BRIT MED J, V312, P212; RAWLES J, 1994, HLTH B, V52, P106	6	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					570	572		10.1136/bmj.314.7080.570	http://dx.doi.org/10.1136/bmj.314.7080.570			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055717	Green Published			2022-12-28	WOS:A1997WK21500026
J	Schneiter, R; Kohlwein, SD				Schneiter, R; Kohlwein, SD			Organelle structure, function, and inheritance in yeast: A role for fatty acid synthesis?	CELL			English	Review							SACCHAROMYCES-CEREVISIAE				Schneiter, R (corresponding author), GRAZ TECH UNIV,SFB BIOMEMBRANE RES CTR,INST BIOCHEM & LEBENSMITTELCHEM,PETERSGASSE 12,A-8010 GRAZ,AUSTRIA.			Schneiter, Roger/0000-0002-9102-8396; Kohlwein, Sepp Dieter/0000-0002-1030-0598				CHEMOMORDIK LV, 1997, J CELL BIOL, V136, P81; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; Kohlwein SD, 1996, TRENDS CELL BIOL, V6, P260, DOI 10.1016/0962-8924(96)10025-8; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; LESTER RL, 1993, J BIOL CHEM, V268, P845; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; ROGGENKAMP R, 1980, P NATL ACAD SCI-BIOL, V77, P1814, DOI 10.1073/pnas.77.4.1814; Saitoh S, 1996, J CELL BIOL, V134, P949, DOI 10.1083/jcb.134.4.949; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; SCHULLER HJ, 1992, EUR J BIOCHEM, V203, P607, DOI 10.1111/j.1432-1033.1992.tb16590.x; STEWART LC, 1991, J CELL BIOL, V115, P1249, DOI 10.1083/jcb.115.5.1249; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	13	69	71	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					431	434		10.1016/S0092-8674(00)81882-6	http://dx.doi.org/10.1016/S0092-8674(00)81882-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038333	Bronze			2022-12-28	WOS:A1997WJ69100002
J	Crossman, D				Crossman, D			Science, medicine, and the future - The future of the management of ischaemic heart disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CORONARY-ARTERY DISEASE; ANGIOPLASTY	Ischaemic heart disease will kill over 150 000 people in the next year in Britain, more than any other single disease process, and cost more than pound 1.4bn in health care alone. Faced with the continuing problems arising from ischaemic heart disease cardiological clinician scientists are moving from technology based solutions to basic sciences. This article explains how basic science may contribute to new understanding and treatments for patients with ischaemic heart disease. Highlighted are three problems which face any clinical cardiologist on a daily basis and for which basic science may provide solutions: the uncertainty of plaque stability in coronary disease; restenosis after percutaneous transluminal angioplasty; and the shortage of organs for cardiac transplant programmes for patients with heart failure.			Crossman, D (corresponding author), UNIV SHEFFIELD, NO GEN HOSP, CTR CLIN SCI, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND.							Appelman YEA, 1996, LANCET, V347, P79, DOI 10.1016/S0140-6736(96)90209-3; BALCON R, 1992, CIRCULATION, V86, P100; Duff GW, 1994, CYTOKINE HDB, P21; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; HAMON M, 1995, EUR HEART J, V16, P33, DOI 10.1093/eurheartj/16.suppl_I.33; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; *LOND OFF HLTH EC, 1995, COMP HLTH STAT; Maseri A, 1996, BRIT MED J, V312, P1049; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; SAVILL J, BRIT MED J, V314, P126; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; Wang XK, 1996, TRENDS PHARMACOL SCI, V17, P276, DOI 10.1016/0165-6147(96)40001-3; Warrens AN, 1996, QJM-INT J MED, V89, P885	18	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 1	1997	314	7077					356	359		10.1136/bmj.314.7077.356	http://dx.doi.org/10.1136/bmj.314.7077.356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040335	Green Published			2022-12-28	WOS:A1997WF86100042
J	Taubenberger, JK; Reid, AH; Krafft, AE; Bijwaard, KE; Fanning, TG				Taubenberger, JK; Reid, AH; Krafft, AE; Bijwaard, KE; Fanning, TG			Initial genetic characterization of the 1918 ''Spanish'' influenza virus	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; A VIRUS; EVOLUTION; LINEAGES; SWINE	The ''Spanish'' influenza pandemic killed at least 20 million people in 1918-1919, making it the worst infectious pandemic in history. Understanding the origins of the 1918 virus and the basis for its exceptional virulence may aid in the prediction of future influenza pandemics. RNA from a victim of the 1918 pandemic was isolated from a formalin-fixed, paraffin-embedded, lung tissue sample. Nine fragments of viral RNA were sequenced from the coding regions of hemagglutinin, neuraminidase, nucleoprotein, matrix protein 1, and matrix protein 2. The sequences are consistent with a novel H1N1 influenza A virus that belongs to the subgroup of strains that infect humans and swine, not the avian subgroup.			Taubenberger, JK (corresponding author), ARMED FORCES INST PATHOL,DEPT CELLULAR PATHOL,DIV MOL PATHOL,WASHINGTON,DC 20306, USA.		Taubenberger, Jeffery/AAQ-1407-2021	Reid, Ann/0000-0002-8899-5246				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRAUDE AI, 1986, INFECT DIS MED MICRO, P783; CHMEL H, 1994, PULMONARY INFECT IMM, P286; CROSBY W, 1989, AM FORGOTTEN PANDEMI, P205; Francis T, 1934, SCIENCE, V80, P457, DOI 10.1126/science.80.2081.457-a; Frost W.H., 1920, PUB HLTH REP, V35, P584, DOI DOI 10.2307/4575511; GORMAN OT, 1991, J VIROL, V65, P3704, DOI 10.1128/JVI.65.7.3704-3714.1991; GROVE RD, 1968, VITAL STAT RATES US, P309; HORIMOTO T, 1994, J VIROL, V68, P3120, DOI 10.1128/JVI.68.5.3120-3128.1994; KANEGAE Y, 1994, ARCH VIROL, V134, P17, DOI 10.1007/BF01379103; KRAFFT A, 1995, J WILDLIFE DIS, V31, P410, DOI 10.7589/0090-3558-31.3.410; Kumar S, 1993, MOL EVOLUTIONARY GEN; LeCount ER, 1919, J AMER MED ASSOC, V72, P650, DOI 10.1001/jama.1919.02610090034009; LINDER FE, 1947, VITAL STAT RATES US, P254; MARKS G, 1976, EPIDEMICS, P274; PHILIP RN, 1962, AM J HYG, V75, P322, DOI 10.1093/oxfordjournals.aje.a120253; REID AH, 1993, AM J PATHOL, V142, P395; ROHM C, 1995, VIROLOGY, V209, P664, DOI 10.1006/viro.1995.1301; ROSENAU MJ, 1980, MAXCY ROSENAU PREVEN, P116; SHOPE RE, 1958, PUBLIC HEALTH REP, V73, P165, DOI 10.2307/4590072; Shope RE, 1936, J EXP MED, V63, P669, DOI 10.1084/jem.63.5.669; SMITH WILSON, 1933, LANCET, V225, P66; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; Wolbach SB, 1919, B JOHNS HOPKINS HOSP, V30, P104	25	470	514	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1793	1796		10.1126/science.275.5307.1793	http://dx.doi.org/10.1126/science.275.5307.1793			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065404	Green Submitted			2022-12-28	WOS:A1997WP05600042
J	Saris, DBF; vanRinsum, AC; Dhert, WJA; Roosendaal, G; Mali, WPTM				Saris, DBF; vanRinsum, AC; Dhert, WJA; Roosendaal, G; Mali, WPTM			Periarticular aneurysm formation in haemophilia	LANCET			English	Article							PATHOGENESIS	Background Spontaneous bleeding into the joints is common in haemophilia.(4) Recurrent intra-articular bleeding leads to joint destruction. In the past 4 years we have carried out sixteen total knee replacements for haemophilic arthropathy. In three patients there was persistent bleeding with haemarthrosis, manifest skin discolouration, severe pain, and swelling, which was caused by a periarticular aneurysm. Methods Using angiography as part of the preoperative preparation, we initiated a prospective study. Ten angiographic examinations (six preoperative, two postoperative, one both) were carried out in seven patients without major complications. Findings In seven of the ten angiographic examinations, three preoperative and four postoperative, we found aneurysms around the knee. Since the patients with a positive postoperative finding did not have preoperative studies, we do not know whether the aneurysms existed before surgery. Interpretation Aneurysms can cause increased bleeding and other complications. The occurrence of spontaneous periarticular aneurysms in haemophilia has not been explored. In these cases, the resultant bleeding led to serious clinical symptoms that were not responsive to conservative measures. This new finding is relevant to those who surgically treat haemophilia patients, Angiography-and, when indicated, embolisation-before total knee replacement proved simple and effective as a diagnostic and therapeutic procedure.	UNIV UTRECHT HOSP, VAN CREVELD CLIN, NL-3508 GA UTRECHT, NETHERLANDS; UNIV UTRECHT HOSP, DEPT RADIOL, NL-3508 GA UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Saris, DBF (corresponding author), UNIV UTRECHT HOSP, UNIV CLUSTER ORTHOPAED, POB 85500, NL-3508 GA UTRECHT, NETHERLANDS.		Mali, Willem PThM/I-1123-2014	Mali, Willem PThM/0000-0003-4391-0904				ARNOLD WD, 1977, J BONE JOINT SURG AM, V59, P287, DOI 10.2106/00004623-197759030-00001; BENNETT FS, 1994, J ORTHOP TRAUMA, V8, P73, DOI 10.1097/00005131-199402000-00016; BERRIDGE DC, 1988, ANN ROY COLL SURG, V70, P253; COHEN B, 1992, ARTHROSCOPY, V8, P373, DOI 10.1016/0749-8063(92)90072-J; EDWARDS H, 1982, J TRAUMA, V22, P323, DOI 10.1097/00005373-198204000-00011; FIGGIE MP, 1989, CLIN ORTHOP RELAT R, P98; GAYLIS H, 1981, SURGERY, V90, P509; GRAHAM ANJ, 1991, INJURY, V22, P179, DOI 10.1016/0020-1383(91)90035-D; Juhan C, 1992, Chirurgie, V118, P55; KARTHAUS RP, 1988, J BONE JOINT SURG BR, V70, P382, DOI 10.1302/0301-620X.70B3.3131346; KJAERSGAARDANDERSEN P, 1990, CLIN ORTHOP RELAT R, P137; LACHIEWICZ PF, 1985, J BONE JOINT SURG AM, V67A, P1361, DOI 10.2106/00004623-198567090-00009; OMARY R, 1991, J BONE JOINT SURG AM, V73A, P1257, DOI 10.2106/00004623-199173080-00018; PETTERSSON H, 1980, CLIN ORTHOP RELAT R, P153; SATIANI B, 1980, ANN SURG, V192, P674; SCAPINEL.R, 1968, ACTA ANAT, V70, P305; SCOLES PV, 1980, CLIN ORTHOP RELAT R, V149, P153; STEIN H, 1981, J BONE JOINT SURG BR, V63, P601, DOI 10.1302/0301-620X.63B4.7298694; TRUBEL W, 1993, WIEN KLIN WOCHENSCHR, V105, P139	19	24	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	1997	349	9054					766	768		10.1016/S0140-6736(96)09177-5	http://dx.doi.org/10.1016/S0140-6736(96)09177-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074576				2022-12-28	WOS:A1997WN12400011
J	Lopera, F; Ardilla, A; Martinez, A; Madrigal, L; ArangoViana, JC; Lemere, CA; ArangoLasprilla, JC; Hincapie, L; ArcosBurgos, M; Ossa, JE; Behrens, IM; Norton, J; Lendon, C; Goate, AM; RuizLinares, A; Rosselli, M; Kosik, KS				Lopera, F; Ardilla, A; Martinez, A; Madrigal, L; ArangoViana, JC; Lemere, CA; ArangoLasprilla, JC; Hincapie, L; ArcosBurgos, M; Ossa, JE; Behrens, IM; Norton, J; Lendon, C; Goate, AM; RuizLinares, A; Rosselli, M; Kosik, KS			Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRECURSOR PROTEIN GENE; NEUROPSYCHOLOGICAL ASSESSMENT; CEREBRAL-HEMORRHAGE; MISSENSE MUTATIONS; DIAGNOSIS; ABILITIES; DEMENTIA; SEIZURES; CONSORTIUM; ESTABLISH	Objectives.-To characterize clinical features of a very large pedigree with early-onset Alzheimer disease (AD) in which all affected individuals carry the identical glutamic acid-to-alanine mutation at codon 280 in the presenilin-1 gene. Design.-Clinical histories were obtained by patient and family interviews and through medical or civil records. Using standard diagnostic criteria, a case series of 128 individuals was identified, of which 6 have definitive (autopsy-proven) early-onset AD, 93 have probable early-onset AD, and 29 have possible early-onset AD. Setting.-Community based in Antioquia, Colombia. Patients.-A population-based sample in which all members of 5 extended families (nearly 3000 individuals) were surveyed. Criteria for inclusion required obtaining sufficient information to categorize the individual as affected. Main Outcome Measures.-Age at onset, neuropsychological profile, neurologic history, and examination, Results.-The patients had a mean age at onset of 46.8 years (range, 34-62 years). The average interval until death was 8 years. Headache was noted in affected individuals significantly more frequently than in those not affected. The most frequent presentation was memory loss followed by behavior and personality changes and progressive loss of language ability. In the final stages, gait disturbances, seizures, and myoclonus were frequent. Conclusions.-Other than the early onset, this clinical phenotype is indistinguishable from sporadic AD except that affected individuals frequently complained of headache preceding and during the disease; Despite the uniform genetic basis for the disease, there was significant variability in the age at onset, suggesting an important role for environmental factors or genetic modifiers in determining the age at onset.	ANTIOQUIA UNIV,SCH MED,DEPT NEUROL,MEDELLIN,COLOMBIA; ANTIOQUIA UNIV,SCH MED,DEPT PATHOL,MEDELLIN,COLOMBIA; ANTIOQUIA UNIV,SCH MED,DEPT MICROBIOL & PARASITOL,MEDELLIN,COLOMBIA; ANTIOQUIA UNIV,SCH MED,DEPT BIOCHEM,MEDELLIN,COLOMBIA; MIAMI INST PSYCHOL,MIAMI,FL; FLORIDA ATLANTIC UNIV,MIAMI,FL; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115	Universidad de Antioquia; Universidad de Antioquia; Universidad de Antioquia; Universidad de Antioquia; State University System of Florida; Florida Atlantic University; Washington University (WUSTL); Harvard University; Harvard Medical School			Ruiz-Linares, Andres/AAR-1104-2021; Behrens, Maria I I/I-1083-2013; LOPERA, FRANCISCO/AAR-5968-2021; Arcos-Burgos, Mauricio/H-1326-2017	Ruiz-Linares, Andres/0000-0001-8372-1011; Behrens, Maria I I/0000-0003-0964-426X; Goate, Alison/0000-0002-0576-2472; Arcos-Burgos, Mauricio/0000-0002-8529-0574				[Anonymous], 1994, NEUROPSYCHOLOGICAL E; ARCOS OM, 1992, EPIDEMIOLOGIA GENETI; ARDILA A, 1995, J CLIN EXP NEUROPSYC, V17, P143, DOI 10.1080/13803399508406589; ARDILA A, 1994, DEV NEUROPSYCHOL, V10, P97, DOI 10.1080/87565649409540571; ARDILA A, 1989, DEV NEUROPSYCHOL, V5, P307, DOI 10.1080/87565648909540441; ARDILA A, 1989, BRAIN COGNITION, V11, P147, DOI 10.1016/0278-2626(89)90015-8; Bird T D, 1989, Prog Clin Biol Res, V317, P229; BIRD TD, 1994, ANN NEUROL, V36, P335, DOI 10.1002/ana.410360303; CAMPION D, 1995, NEUROLOGY, V45, P80, DOI 10.1212/WNL.45.1.80; CHEN X, 1996, ANN NEUROL, V40, P50; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cornejo W, 1987, ACTA MED COLOMB, V12, P55; ERKINJUNTTI T, 1987, ACTA NEUROL SCAND, V76, P433, DOI 10.1111/j.1600-0404.1987.tb03599.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOMEZ JR, 1985, ESTUDIO ESTRUCTURA G, pH93; Goodglass H., 1983, BOSTON NAMING TEST; GOODGLASS H, 1983, EVALUACION AFASIAS T; HALTIA M, 1994, ANN NEUROL, V36, P362, DOI 10.1002/ana.410360307; HAUSER WA, 1986, NEUROLOGY, V36, P1226, DOI 10.1212/WNL.36.9.1226; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; KENNEDY AM, 1995, BRAIN, V118, P185, DOI 10.1093/brain/118.1.185; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; Koss E, 1996, NEUROLOGY, V46, P136, DOI 10.1212/WNL.46.1.136; LAMPE TH, 1994, ANN NEUROL, V36, P368, DOI 10.1002/ana.410360308; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; LENDON CL, IN PRESS HUM MUTAT; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; Lopera F, 1994, ACTA NEUROL COLOMB, V10, P173; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; MCAREAVEY MJ, 1992, EPILEPSIA, V33, P657, DOI 10.1111/j.1528-1157.1992.tb02343.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mega MS, 1996, NEUROLOGY, V46, P130, DOI 10.1212/WNL.46.1.130; Mendez M F, 1994, J Geriatr Psychiatry Neurol, V7, P230; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; MULLAN M, 1993, NEUROBIOL AGING, V14, P407, DOI 10.1016/0197-4580(93)90099-W; Muller U, 1996, NEUROLOGY, V47, P1575, DOI 10.1212/WNL.47.6.1575; Nacmias B, 1996, ANN NEUROL, V40, P678, DOI 10.1002/ana.410400420; RAVEN JC, 1976, REV MANUAL RAVENS PR; Reitan R.M., 1993, HALSTEADREITAN NEURO; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROGERS JD, 1985, ANN NEUROL, V17, P163, DOI 10.1002/ana.410170210; ROSSELLI M, 1990, J CLIN EXP NEUROPSYC, V12, P313, DOI 10.1080/01688639008400977; ROSSELLI M, 1990, BRAIN COGNITION, V12, P281, DOI 10.1016/0278-2626(90)90020-O; ROSSELLI M, 1991, CLIN NEUROPSYCHOL, V5, P370; Schottky J, 1932, Z GESAMTE NEUROL PSY, V140, P333, DOI 10.1007/BF02864363; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Taylor EM.., 1995, PSYCHOL APPRAISAL CH; Van Broeckhoven C, 1995, NAT GENET, V11, P230; Wechsler D., 1945, WECHSLER MEMORY SCAL; White L, 1996, JAMA-J AM MED ASSOC, V276, P955, DOI 10.1001/jama.276.12.955; Wragg M, 1996, LANCET, V347, P509, DOI 10.1016/S0140-6736(96)91140-X	57	245	254	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					793	799		10.1001/jama.277.10.793	http://dx.doi.org/10.1001/jama.277.10.793			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM082	9052708				2022-12-28	WOS:A1997WM08200031
J	vanBuchem, FL; Knottnerus, JA; Schrijnemaekers, VJJ; Peeters, MF				vanBuchem, FL; Knottnerus, JA; Schrijnemaekers, VJJ; Peeters, MF			Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis	LANCET			English	Article							ETIOLOGY	Background The value of antibiotics in acute rhinosinusitis is uncertain. Although maxillary sinusitis is commonly diagnosed and treated in general practice, no effectiveness studies have been done on unselected primary-care patients. We used a randomised, placebo-controlled design to test the hypothesis that there would be an improvement associated with amoxycillin treatment for acute maxillary sinusitis patients presenting to general practice. Methods Adult patients with suspected acute maxillary sinusitis were referred by general practitioners for radiographs of the maxillary sinus. Those with radiographic abnormalities (n=214) were randomly assigned treatment with amoxycillin (750 mg three times daily for 7 days; n=108) or placebo (n=106). Clinical course was assessed after 1 week and 2 weeks, and reported relapses and complications were recorded during the following year. Findings After 2 weeks, symptoms had improved substantially or disappeared in 83% of patients in the study group and 77% of patients taking placebo. Amoxycillin did not influence the clinical course of maxillary sinusitis nor the frequency of relapses during the 1-year follow-up. Radiographs had no prognostic value, nor were they an effect modifier. Side-effects were recorded in 28% of patients given amoxycillin and in 9% of those taking placebo (p<0.01). The occurrence of relapses was similar in both groups (21 vs 17%) during the follow-up year. Interpretation Antibiotic treatment did not improve the clinical course of acute maxillary sinusitis presenting to general practice. For these patients, an initial radiographic examination is not necessary and initial management can be limited to symptomatic treatment. Whether antibiotics are necessary in more severe cases warrants further study.	ST ELIZABETH HOSP,DEPT MED MICROBIOL,NL-5000 LC TILBURG,NETHERLANDS; UNIV LIMBURG,DEPT GEN PRACTICE,NL-6200 MD MAASTRICHT,NETHERLANDS	Elisabeth-TweeSteden Ziekenhuis (ETZ); Hasselt University; Maastricht University	vanBuchem, FL (corresponding author), ST ELIZABETH HOSP,DEPT OTORHINOLARYNGOL,POB 90151,NL-5000 LC TILBURG,NETHERLANDS.		Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009					AXELSSON A, 1976, ORL J OTO-RHINO-LARY, V38, P298, DOI 10.1159/000275288; Beaumont J, 1995, EUR J GEN PRACT, V1, P155, DOI 10.3109/13814789509161629; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; Kaiser L, 1996, LANCET, V347, P1507, DOI 10.1016/S0140-6736(96)90670-4; KARMA P, 1991, J ANTIMICROB CHEMOTH, V27, P83, DOI 10.1093/jac/27.suppl_A.83; KENNEDY DW, 1990, OTOLARYNG HEAD NECK, V103, P847, DOI 10.1177/01945998901030S502; KNOTTNERUS JA, 1991, FAM PRACT, V8, P305, DOI 10.1093/fampra/8.4.305; LAMBERTS H, 1991, HET HUIS HUISARTS; MANN W, 1981, HNO, V29, P92; MATTUCCI KF, 1986, ARCH OTOLARYNGOL, V112, P73; SYDNOR A, 1989, ARCH OTOLARYNGOL, V115, P1430; VANDELISDONK EH, 1994, ZIEKTEN HUISARTSPRAK; von Sydow C, 1982, Rhinology, V20, P223	15	176	178	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					683	687		10.1016/S0140-6736(96)07585-X	http://dx.doi.org/10.1016/S0140-6736(96)07585-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078199				2022-12-28	WOS:A1997WM08000009
J	Fan, H; Sakulich, AL; Goodier, JL; Zhang, XL; Qin, J; Maraia, RJ				Fan, H; Sakulich, AL; Goodier, JL; Zhang, XL; Qin, J; Maraia, RJ			Phosphorylation of the human La antigen on serine 366 can regulate recycling of RNA polymerase III transcription complexes	CELL			English	Article							CASEIN KINASE-II; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; EXPRESSION; INVITRO; TFIIIB; GENES; AUTOANTIGEN; TERMINATION; INITIATION	The human La antigen is an RNA-binding protein that facilitates transcriptional termination and reinitiation by RNA polymerase III. Native La protein fractionates into transcriptionally active and inactive forms that are unphosphorylated and phosphorylated at serine 366, respectively, as determined by enzymatic and mass spectrometric analyses. Serine 366 comprises a casein kinase II phosphorylation site that resides within a conserved region in the La proteins from several species. RNA synthesis from isolated transcription complexes is inhibited by casein kinase Ii-mediated phosphorylation of La serine 366 and is reversible by dephosphorylation. This work demonstrates a novel mechanism of transcriptional control at the level of recycling of stable transcription complexes.	NHLBI,BIOPHYS CHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Fan, H (corresponding author), NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892, USA.		Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066				ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BARSH GS, 1981, P NATL ACAD SCI-BIOL, V78, P5142, DOI 10.1073/pnas.78.8.5142; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; CHU WM, 1995, NUCLEIC ACIDS RES, V23, P1750, DOI 10.1093/nar/23.10.1750; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; DIECI G, 1993, J BIOL CHEM, V268, P11199; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FRANCOEUR AM, 1985, MOL CELL BIOL, V5, P586, DOI 10.1128/MCB.5.3.586; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; Hockman DJ, 1996, MOL CELL BIOL, V16, P892; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KENAN DJ, 1995, THESIS DUKE U RALEIG; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; McBryant SJ, 1996, MOL CELL BIOL, V16, P4639; PFEIFLE J, 1987, BIOCHIM BIOPHYS ACTA, V928, P217, DOI 10.1016/0167-4889(87)90124-8; PIZER LI, 1983, MOL CELL BIOL, V3, P1235, DOI 10.1128/MCB.3.7.1235; SKLAR VEF, 1976, J BIOL CHEM, V251, P1064; SRUTH J, 1996, EMBO J, V15, P1941; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wang ZX, 1996, MOL CELL BIOL, V16, P6841; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585	40	97	98	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					707	715		10.1016/S0092-8674(00)81913-3	http://dx.doi.org/10.1016/S0092-8674(00)81913-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054510	Bronze			2022-12-28	WOS:A1997WM41300016
J	Gabriel, SE; Woods, JE; OFallon, M; Beard, CM; Kurland, LT; Melton, LJ				Gabriel, SE; Woods, JE; OFallon, M; Beard, CM; Kurland, LT; Melton, LJ			Complications leading to surgery after breast implantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE DISEASES; AUGMENTATION MAMMAPLASTY; CLINICAL-EXPERIENCE; RECONSTRUCTION; CANCER; RISK	Background Local complications that require additional surgical procedures are an important problem for women with breast implants. Methods We studied 749 women who lived in Olmsted County, Minnesota, and received a first breast implant at the Mayo Clinic between 1964 and 1991. We identified complications that occurred after the initial procedure and after any subsequent implantation. A complication was defined as a surgical procedure performed for any of the following reasons: capsular contracture; rupture of the implant; hematoma or bleeding; infection or seroma of the wound; chronic pain; extrusion, leakage, or sweating of the implant; necrosis of the nipple, areola, or flap; malfunction of the filler port of a tissue expander; and wound dehiscence. Results During follow-up (mean, 7.8 years; range, 0 to 25.8), 208 (27.8 percent) of the women underwent 450 additional implant-related surgical procedures. Ninety-one (20.2 percent) were anticipated, staged procedures or were done because the patient requested a size change or aesthetic improvement, and 359 procedures (79.8 percent) had at least one clinical indication (thus constituting a complication). Complications occurred in 178 (23.8 percent) of the 749 women and involved 274 (18.8 percent) of the 1454 breasts with implants and 321 (18.8 percent) of the 1703 implants. The most frequent problem was capsular contraction (131 women), followed by implant rupture (43 [5.7 percent]), hematoma (43), and wound infection (19). The rate of complications was significantly lower (P<0.001) among women with cosmetic implants (6.5 percent at one year, 12 percent at five years) than among those who received implants after mastectomy for breast cancer (21.8 percent at one year, 34 percent at five years) or prophylactic mastectomy (17.3 percent at one year, 30.4 percent at five years). Conclusions Women who have had breast implantation frequently experience local complications during the subsequent five years. Complications were significantly less frequent among patients who received implants for cosmetic reasons than among those who received implants after mastectomy for cancer or for cancer prophylaxis. (C) 1997, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN,DIV RHEUMATOL & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV PLAST SURG,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	Gabriel, SE (corresponding author), MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker JL, 1979, PLASTIC SURGERY, P719; Baker JL, 1978, P S ED FDN AM SOC PL, P256; BURNS CG, 1994, THESIS U MICHIGAN; DEAPEN DM, 1986, PLAST RECONSTR SURG, V77, P361, DOI 10.1097/00006534-198603000-00001; DECAMARA DL, 1993, PLAST RECONSTR SURG, V91, P828, DOI 10.1097/00006534-199304001-00012; DUFFY MJ, 1994, PLAST RECONSTR SURG, V94, P295, DOI 10.1097/00006534-199408000-00012; ENGLERT HJ, 1994, AUST NZ J MED, V24, P74, DOI 10.1111/j.1445-5994.1994.tb04439.x; GABRIEL SE, 1995, J CLIN EPIDEMIOL, V48, P527, DOI 10.1016/0895-4356(94)00209-9; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GABRIEL SE, 1993, ARTHRITIS RHEUM, V36, pS70; Hagerty R C, 1990, J S C Med Assoc, V86, P545; Hochberg M. C., 1994, Arthritis and Rheumatism, V37, pS369; HOLLEY DT, 1995, AM SURGEON, V61, P60; KROLL SS, 1989, PLAST RECONSTR SURG, V84, P886, DOI 10.1097/00006534-198912000-00003; LeRoy E C, 1990, J S C Med Assoc, V86, P556; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; MAY DS, 1991, PLAST RECONSTR SURG, V87, P193, DOI 10.1097/00006534-199101000-00045; MCGRATH MH, 1984, PLAST RECONSTR SURG, V74, P550, DOI 10.1097/00006534-198410000-00019; MELTON LJ, 1996, MAYO CLIN P, V71, P1266; OBRIEN W, 1993, AM J SURG, V166, P1, DOI 10.1016/S0002-9610(05)80572-0; PETERS W, 1994, ANN PLAS SURG, V32, P449, DOI 10.1097/00000637-199405000-00001; PICKERING PP, 1978, S AESTH SURG BREAST, P293; ROBINSON OG, 1995, ANN PLAS SURG, V34, P1, DOI 10.1097/00000637-199501000-00001; ROSEN PB, 1990, ANN PLAS SURG, V25, P249, DOI 10.1097/00000637-199010000-00002; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; Therneau TM, 1996, TECHNICAL REPORT SER, V58; TRUPPMAN ES, 1978, S AESTHETIC SURGERY, P344; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; WORSEG A, 1995, BR J PLAST SURG, V48, P153	30	305	312	1	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					677	682		10.1056/NEJM199703063361001	http://dx.doi.org/10.1056/NEJM199703063361001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041097	Bronze			2022-12-28	WOS:A1997WL41900001
J	Koh, KK; Mincemoyer, R; Bui, MN; Csako, G; Pucino, F; Guetta, V; Waclawiw, M; Cannon, RO				Koh, KK; Mincemoyer, R; Bui, MN; Csako, G; Pucino, F; Guetta, V; Waclawiw, M; Cannon, RO			Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; LOW-DENSITY-LIPOPROTEIN; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; MYOCARDIAL-INFARCTION; ESTROGEN REPLACEMENT; ENDOTHELIAL-CELLS; HEART-DISEASE; FOLLOW-UP; TYPE-1; PLASMA	Background Plasma levels of plasminogen-activator inhibitor type 1 (PAI-1), an essential inhibitor of fibrinolysis in humans, increase in women after menopause, and this may contribute to the risk of cardiovascular disease. We studied the effects of hormone-replacement therapy on PAI-1 levels. Methods In a randomized, crossover study, we investigated the effects of oral conjugated estrogen (0.625 mg per day) in 30 postmenopausal women and transdermal estradiol (0.1 mg per day) in 20 postmenopausal women, either alone or in combination with medroxyprogesterone acetate (2.5 mg daily) for one month, on plasma PAI-1 antigen levels. Degradation products of cross-linked fibrin (D-dimer) were measured in serum as an index of fibrinolysis. Results PAI-1 levels were inversely associated with D-dimer levels at base line (r=-0.540, P=0.002). Conjugated estrogen, both alone and in combination with medroxyprogesterone acetate, reduced mean (+/-SD) plasma levels of PAI-1 from 32+/-34 ng per milliliter to 14+/-10 ng per milliliter (P<0.001) and from 31+/-29 ng per milliliter to 15+/-11 ng per milliliter (P=0.003), respectively; there was a significant inverse correlation between pretreatment PAI-1 levels and the degree of reduction in these levels during therapy (r=-0.631, P<0.001 for conjugated estrogen; r=-0.507, P=0.004 for combined therapy). The degree of reduction in PAI-1 levels was associated with increases in D-dimer levels both when conjugated estrogen was given alone (r=-0.572, P=0.001) and when combined hormone therapy was given (r=-0.541, P=0.002). Transdermal estradiol caused no significant changes in PAI-1 levels from base-line values. Conclusions Conjugated estrogen, alone or combined with progestin therapy, reduced PAI-1 levels by approximately 50 percent in postmenopausal women and was associated with enhanced systemic fibrinolysis. These findings may partly explain the protective effect of hormone-replacement therapy with respect to coronary artery disease. (C) 1997, Massachusetts Medical Society.	NHLBI, CARDIOL BRANCH, NIH, BETHESDA, MD 20892 USA; NIH, DEPT CLIN PATHOL, CTR CLIN, BETHESDA, MD 20892 USA; NIH, DEPT PHARMACOL, CTR CLIN, BETHESDA, MD 20892 USA; NHLBI, OFF BIOSTAT RES, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BEEBE DP, 1986, THROMB RES, V43, P663, DOI 10.1016/0049-3848(86)90103-9; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CAINE YG, 1992, THROMB HAEMOSTASIS, V68, P392; CORTELLARO M, 1993, ARTERIOSCLER THROMB, V13, P1412, DOI 10.1161/01.ATV.13.10.1412; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DECLERCK PJ, 1988, BLOOD, V71, P220; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; ETINGIN OR, 1991, J BIOL CHEM, V266, P2459; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEBARA OCE, 1995, CIRCULATION, V91, P1952, DOI 10.1161/01.CIR.91.7.1952; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAMSTEN A, 1987, LANCET, V2, P3; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; JuhanVague I, 1996, CIRCULATION, V94, P2057, DOI 10.1161/01.CIR.94.9.2057; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KEBER I, 1992, HAEMOSTASIS, V22, P187; KOOISTRA T, 1990, FIBRINOLYSIS, V4, P33, DOI 10.1016/0268-9499(90)90352-K; KORNINGER C, 1981, THROMB HAEMOSTASIS, V46, P658; KROON UB, 1994, THROMB HAEMOSTASIS, V71, P420; KUGIYAMA K, 1993, CIRC RES, V73, P335, DOI 10.1161/01.RES.73.2.335; LEVINE DM, 1992, INT J CLIN LAB RES, V22, P173, DOI 10.1007/BF02591419; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLOFSSON BO, 1989, EUR HEART J, V10, P77; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; QUAX PHA, 1990, J BIOL CHEM, V265, P15560; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; RIJPKEMA AHM, 1990, MATURITAS, V12, P259, DOI 10.1016/0378-5122(90)90007-S; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SCARABIN PY, 1993, THROMB HAEMOSTASIS, V70, P584; SCHNEIDER DJ, 1991, P NATL ACAD SCI USA, V88, P9959, DOI 10.1073/pnas.88.22.9959; SCHNEIDER DJ, 1992, P NATL ACAD SCI USA, V89, P1148; Shahar E, 1996, CIRCULATION, V93, P1970, DOI 10.1161/01.CIR.93.11.1970; SPORRONG T, 1990, BRIT J OBSTET GYNAEC, V97, P939, DOI 10.1111/j.1471-0528.1990.tb02451.x; SPRENGERS ED, 1987, BLOOD, V69, P381; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; VANWERSCH JWJ, 1994, EUR J CLIN CHEM CLIN, V32, P449; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WINDLER EET, 1980, J BIOL CHEM, V255, P464	46	321	331	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					683	690		10.1056/NEJM199703063361002	http://dx.doi.org/10.1056/NEJM199703063361002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041098				2022-12-28	WOS:A1997WL41900002
J	Sandborn, WJ; Tremaine, WJ; Offord, KP; Lawson, GM; Petersen, BT; Batts, KP; Croghan, IT; Dale, LC; Schroeder, DR; Hurt, RD				Sandborn, WJ; Tremaine, WJ; Offord, KP; Lawson, GM; Petersen, BT; Batts, KP; Croghan, IT; Dale, LC; Schroeder, DR; Hurt, RD			Transdermal nicotine for mildly to moderately active ulcerative colitis - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	97th Annual Meeting of the American-Gastroenterological-Association	MAY 18-23, 1996	SAN FRANCISCO, CA	Amer Gastroenterol Assoc		colitis, ulcerative; administration, cutaneous; nicotine; cotinine; smoking	CIGARETTE-SMOKING; THERAPY	Background: Ulcerative colitis is predominantly a disease of nonsmokers. Transdermal nicotine may help control clinical manifestations of this condition. Objective: Tb determine the efficacy of transdermal nicotine for controlling clinical disease activity in active ulcerative colitis. Design: Randomized, double-blind, placebo-controlled, single-center clinical trial. Setting: Multispecialty group serving as an academic tertiary referral center. Patients: 64 nonsmoking patients with mildly to moderately active ulcerative colitis despite the use of medication. Intervention: Patients were stratified on the basis of smoking history, extent of disease, and concomitant medical therapy. After stratification, patients were randomly assigned to daily treatment with transdermal nicotine (n = 31) at the highest tolerated dose (11 mg for 1 week and then less than or equal to 22 mg for 3 weeks) or placebo (n = 33). Measurements: Clinical features were assessed at baseline and 4 weeks by endoscopy, physician assessment, and a patient diary of daily symptoms. Serum concentrations of nicotine were determined by using gas chromatography and mass spectrometry, and plasma concentrations of cotinine were measured by using high-performance liquid chromatography. Results: At 4 weeks, 12 of 31 patients (39%) who received nicotine showed clinical improvement compared with 3 of 33 patients (9%) who received placebo (P = 0.007). Four patients receiving nicotine discontinued therapy because of side effects (contact dermatitis [n = 2], nausea [n = 1], and acute pancreatitis [n = 1]). At week 4, the nicotine group had a mean (+/-SD) trough serum nicotine concentration of 12.3 +/- 8.4 ng/mL and a mean trough plasma cotinine concentration of 192 +/- 95 ng/mL. Conclusions: Transdermal nicotine administered at the highest tolerated dosage (less than or equal to 22 mg/d) for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active ulcerative colitis.			Sandborn, WJ (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Sandborn, William/ABE-8342-2020; qin, zhen/F-1263-2014					BASKIN LB, 1991, CLIN CHEM, V37, P467; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BOYKO EJ, 1987, NEW ENGL J MED, V316, P707, DOI 10.1056/NEJM198703193161202; Green JT, 1996, GASTROENTEROLOGY, V110, pA917; HARRIES AD, 1982, BRIT MED J, V284, P706, DOI 10.1136/bmj.284.6317.706; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; JARVIS MJ, 1980, BRIT MED J, V281, P484, DOI 10.1136/bmj.281.6238.484; JICK H, 1983, NEW ENGL J MED, V308, P261, DOI 10.1056/NEJM198302033080507; LASHNER BA, 1990, DIGEST DIS SCI, V35, P827, DOI 10.1007/BF01536795; MACHACEK DA, 1986, CLIN CHEM, V32, P979; MOTLEY RJ, 1987, DIGESTION, V37, P125, DOI 10.1159/000199478; PULLAN RD, 1994, NEW ENGL J MED, V330, P811, DOI 10.1056/NEJM199403243301202; RUDRA T, 1989, SCAND J GASTROENTERO, V24, P61, DOI 10.3109/00365528909091354; SANDBORN WJ, 1994, GASTROENTEROLOGY, V106, P1429, DOI 10.1016/0016-5085(94)90394-8; SAS Institute, 1990, SAS STAT US GUID VER; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; SINGLETON JW, 1995, INFLAMM BOWEL DIS, P335; SOMERVILLE KW, 1984, BRIT MED J, V289, P954, DOI 10.1136/bmj.289.6450.954; SRIVASTAVA ED, 1991, EUR J GASTROEN HEPAT, V3, P815; Thomas GAO, 1996, EUR J GASTROEN HEPAT, V8, P769; THOMAS GAO, 1995, NEW ENGL J MED, V332, P988, DOI 10.1056/NEJM199504133321503	21	204	205	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					364	+		10.7326/0003-4819-126-5-199703010-00004	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WL104	9054280				2022-12-28	WOS:A1997WL10400004
J	Halfon, N; Wood, DL; Valdez, RB; Pereyra, M; Duan, NH				Halfon, N; Wood, DL; Valdez, RB; Pereyra, M; Duan, NH			Medicaid enrollment and health services access by Latino children in inner-city Los Angeles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	First Annual Meeting of the Academic-Pediatric-Societies	MAY   04, 1995	SAN DIEGO, CA	Amer Pediatr Soc, Soc Pediatr Res			PREVENTIVE SERVICES; MEXICAN-AMERICANS; PUERTO-RICAN; CARE; INSURANCE; BARRIERS; ACCULTURATION; CALIFORNIA; BLACK	Objectives.-To understand the role of parental immigration status on Medicaid enrollment and access to health services for young Latino children. Design.-A cross-sectional household survey of the parents of inner-city Latino children. Setting.-South Central and East Los Angeles, Calif, 1992. Population.-Children 12 to 36 months old and their parents from 817 Latino families, Main Outcome Variables.-Continuous Medicaid enrollment, continuity of care, deferral of care, and number of visits. Methods.-Univariate analysis, logistic and linear regression by demographic and socioeconomic characteristics, residency status, and language use, Results.-Children were primarily born in the United States (96%), but most parents were not citizens (80%). Only 40.0% of eligible children had continuous Medicaid coverage since birth, 18.6% had never been insured, and 20.7% had received episodic Medicaid coverage, Continuous Medicaid coverage was negatively associated with either the caregiver (odds ratio [OR], 0.32; 95% confidence interval [CI], 0.19-0.56) or their partner (OR=0.33, 95% Cl=0.20-0,55) working, Residency status, language preference, and length of US residency were not associated with continuous Medicaid enrollment. Insurance coverage was associated with more physician visits, greater continuity of care, and fewer deferrals of care. Conclusion.-While most (84%) young Latino children in inner-city Los Angeles were eligible for Medicaid, a substantial proportion (39.3%) have episodic or no coverage. Insurance status and provider type were more consistently associated with access rather than residency and language preference. In the aftermath of California's Proposition 187 and federal welfare reform, insurance status and access are likely to worsen for these young children unless the wave of anti-immigration sentiments is held in check.	UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT HLTH SERV,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT HLTH SERV,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024; RAND CORP,HLTH SCI PROGRAM,SANTA MONICA,CA; CEDARS SINAI MED CTR,SPEILBERG PEDIAT RES CTR,AHMANSON DEPT PEDIAT,LOS ANGELES,CA 90048	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation; Cedars Sinai Medical Center	Halfon, N (corresponding author), UNIV CALIF LOS ANGELES,SCH PUBL HLTH,CTR HEALTHIER CHILDREN FAMILIES & COMMUNITIES,LOS ANGELES,CA 90095, USA.			Duan, Naihua/0000-0001-9411-2924	PHS HHS [5 MCJ-069500-02-0, 200-91-0942] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSEN R, 1981, J HEALTH SOC BEHAV, V22, P78, DOI 10.2307/2136370; BERKANOVIC E, 1974, J HEALTH SOC BEHAV, V15, P93, DOI 10.2307/2137188; BROWN ER, 1996, 830000 CALIFORNIA IM; BURNAM AM, 1989, VALIDITY HHANES ACCU; CHESNEY AP, 1982, MED CARE, V20, P883, DOI 10.1097/00005650-198209000-00002; *COMP RES CTR, 1992, STATA TECHN MAN VERS; *COUNC SCI AFF, 1991, JAMA-J AM MED ASSOC, V265, P248; Cuellar I., 1980, HISP J BEHAV SCI, V2, P199, DOI DOI 10.1177/07399863950173001; DEMING WE, 1953, J AM STAT ASSOC, V48, P743, DOI 10.2307/2281069; GUENDELMAN S, 1986, MED CARE, V24, P925, DOI 10.1097/00005650-198610000-00006; HALFON N, 1995, ANNU REV PUBL HEALTH, V16, P447, DOI 10.1146/annurev.pu.16.050195.002311; Helmstadter G. C., 1964, PRINCIPLES PSYCHOL M; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUBBELL FA, 1991, WESTERN J MED, V154, P414; Huber P., 1965, P 5 BERK S MATH STAT, P221; LEWINEPSTEIN N, 1991, MED CARE, V29, P543, DOI 10.1097/00005650-199106000-00013; MENDOZA FS, 1991, JAMA-J AM MED ASSOC, V265, P227, DOI 10.1001/jama.265.2.227; MOORE P, 1994, JAMA-J AM MED ASSOC, V272, P297, DOI 10.1001/jama.272.4.297; *NAT HLTH FDN CTR, 1995, BARR HLTH CAR US CIT; NEWACHECK PW, 1988, PEDIATRICS, V82, P462; NEWACHECK PW, 1995, HEALTH AFFAIR, V14, P244, DOI 10.1377/hlthaff.14.1.244; POTTHOFF RF, 1993, J AM STAT ASSOC, V88, P1197, DOI 10.2307/2291258; QUESADA GM, 1976, SOC SCI MED, V10, P323, DOI 10.1016/0037-7856(76)90078-0; ROWLAND D, 1992, MEDICAID CROSSROADS; Searle S.R., 1971, LINEAR MODELS; SHORT PF, 1992, MED CARE, V30, P766, DOI 10.1097/00005650-199209000-00002; SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI 10.2105/AJPH.80.Suppl.11; STODDARD JJ, 1994, NEW ENGL J MED, V330, P1421, DOI 10.1056/NEJM199405193302006; STPETER RF, 1992, JAMA-J AM MED ASSOC, V267, P2760, DOI 10.1001/jama.267.20.2760; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; *US BUR CENS, 1992, CURR POP REP SER P60, V181; VALDEZ RB, 1993, PUBLIC HEALTH REP, V108, P534; VALDEZ RB, 1993, JAMA-J AM MED ASSOC, V269, P889, DOI 10.1001/jama.269.7.889; Wood D, 1994, J Health Care Poor Underserved, V5, P112; WOOD D, 1993, LOS ANGELES IMMUNIZA; WOOD DL, 1990, PEDIATRICS, V86, P666; ZIV TA, 1995, NEW ENGL J MED, V332, P1095, DOI 10.1056/NEJM199504203321612; [No title captured]	38	55	56	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					636	641		10.1001/jama.277.8.636	http://dx.doi.org/10.1001/jama.277.8.636			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WJ498	9039881				2022-12-28	WOS:A1997WJ49800031
J	Brown, P				Brown, P			Muscle sounds in Parkinson's disease	LANCET			English	Article								Background A sound with a frequency of around 40 Hz can be heard, with a stethoscope, in the muscles of the hand and forearm during tonic contraction or movement. This sound is the acoustic correlate of the Piper rhythm seen in electromyographic records of muscle activity. The way in which motor activity is organised at the cortical level may determine the frequency of the sound heard. Methods The wrist extensor muscles in the forearm of seven patients with idiopathic Parkinson's disease, studied with and without antiparkinsonian treatment, and a control group of seven healthy men were auscultated during very strong extension of the wrist and during repeated slow flexion and extension of this joint. Findings In healthy people, the Piper-band sound made by muscle activity is 40-50 Hz. In all seven parkinsonian patients, when off medication, the normal Piper-band sound was replaced by a pulsatile muscle activity of 10 Hz during strong wrist extension, and in four patients during repeated flexion and extension of the wrist. After treatment. with dopaminergic drugs, the Piper mode of muscle discharge was restored and motor performance was improved. Interpretation The Piper mode of muscle discharge is dependent on the normal functioning of pallidal projections to the motor areas of the cortex. In abnormal function a muscle discharge of 10 Hz dominates, which is suboptimal when fast or powerful contractions are necessary.	UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1 3BG, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Brown, P (corresponding author), INST NEUROL, MRC, HUMAN MOVEMENT & BALANCE UNIT, LONDON WC1 3BG, ENGLAND.		Brown, Peter/J-4307-2016	Brown, Peter/0000-0002-5201-3044				Brown P, 1996, BRAIN, V119, P1307, DOI 10.1093/brain/119.4.1307; Brown P, 1996, J PHYSIOL-LONDON, V494P, pP68; BROWN P, 1995, LANCET, V346, P306, DOI 10.1016/S0140-6736(95)92190-7; BROWN P, 1996, BRAIN, V11, P171; BROWN P, 1996, MOV DISORD S, V11, P171; Crick F, 1995, ASTONISHING HYPOTHES; FEX J, 1957, ACTA PSYCHIAT NEUROL, V33, P54; HAGBARTH KE, 1983, ACTA PHYSIOL SCAND, V117, P263, DOI 10.1111/j.1748-1716.1983.tb07205.x; HILL AV, 1921, J PHYSL, V55, pP14; LANCE JW, 1963, BRAIN, V86, P95, DOI 10.1093/brain/86.1.95; MARSDEN CD, 1970, J PHYSIOL-LONDON, V207, P429, DOI 10.1113/jphysiol.1970.sp009071; MERTON PA, 1981, J NEUROL NEUROSUR PS, V44, P861, DOI 10.1136/jnnp.44.10.861; Piper H.E., 1912, ELEKTROPHYSIOLOGIE M; Rutherford W, 1886, J Anat Physiol, V21, P166; STOKES MJ, 1992, J APPL PHYSIOL, V72, P1908, DOI 10.1152/jappl.1992.72.5.1908	15	38	39	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					533	535		10.1016/S0140-6736(97)80086-4	http://dx.doi.org/10.1016/S0140-6736(97)80086-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048791				2022-12-28	WOS:A1997WJ51200010
J	Rowe, PM				Rowe, PM			Changing the risky behaviour of politicians	LANCET			English	Editorial Material																		Coates TJ, 1996, LANCET, V348, P1143, DOI 10.1016/S0140-6736(96)02307-0	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					520	520		10.1016/S0140-6736(97)80082-7	http://dx.doi.org/10.1016/S0140-6736(97)80082-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048787				2022-12-28	WOS:A1997WJ51200006
J	vanDonselaar, CA; Brouwer, OF; Geerts, AT; Arts, WFM; Stroink, H; Peters, ACB				vanDonselaar, CA; Brouwer, OF; Geerts, AT; Arts, WFM; Stroink, H; Peters, ACB			Clinical course of untreated tonic-clonic seizures in childhood: Prospective, hospital based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	21st International Epilepsy Congress	SEP 03-08, 1995	SYDNEY, AUSTRALIA				EPILEPSY; PROGNOSIS	Objective: To assess decleration and acceleration in the disease process in the initial phase of epilepsy in children with new onset tonic-clonic seizures. Study design:Hospital based follow up study. Setting: Two university hospitals, a general hospital, and a children's hospital in the Netherlands. Patients: 204 children aged 1 month to 16 years with idiopathic or remote symptomatic, newly diagnosed, tonic-clonic seizures, of whom 123 were enrolled at time of their first ever seizure; all children were followed until the start of drug treatment (78 children), the occurrence of the fourth untreated seizure (41 children), or the end of the follow up period of two years (85 untreated children). Main outcome measures: Analysis of disease pattern from first ever seizure. The pattern was categorised as decelerating if the child became free of seizures despite treatment being withheld. In cases with four seizures, the pattern was categorised as decelerating if successive intervals increased or as accelerating if intervals decreased. Patterns in the remaining children were classified as uncertain. Results: A decelerating pattern was found in 83 of 85 children who became free of seizures without treatment. Three of the 41 children with four or more untreated seizures showed a decelerating pattern and eight an accelerating pattern. In 110 children the disease process could not be classified, mostly because drug treatment was started after the first, second,or third seizure. The proportion of children with a decelerating pattern (42%, 95% confidence interval 35% to 49%) may be a minimum estimate because of the large number of patients with an uncertain disease pattern. Conclusions: Though untreated epilepsy is commonly considered to be a progressive disorder with decreasing intervals between seizures, a large proportion of children with newly diagnosed, unprovoked tonic-clonic seizures have a decelerating disease process. The fear that tonic-clonic seizures commonly evolve into a progressive disease should not be used as an argument in favour of early drug treatment in children with epilepsy.	UNIV HOSP ROTTERDAM DIJKZIGT & SOPHIA, DEPT NEUROL, NL-3015 GJ ROTTERDAM, NETHERLANDS; LEIDEN UNIV HOSP, DEPT NEUROL, NL-2333 AA LEIDEN, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, NL-3000 DR ROTTERDAM, NETHERLANDS; JULIANA CHILDRENS HOSP, NL-2566 ER THE HAGUE, NETHERLANDS; WESTEINDE ZIEKENHUIS, NL-2566 ER THE HAGUE, NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Erasmus University Rotterdam								[Anonymous], 1981, Epilepsia, V22, P489; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; ELWES RDC, 1988, BRIT MED J, V297, P948, DOI 10.1136/bmj.297.6654.948; GASTAUT H, 1969, EPILEPSIA, VS 10, pS14; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; REYNOLDS EH, 1995, BRIT MED J, V310, P176, DOI 10.1136/bmj.310.6973.176; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; REYNOLDS EH, 1983, LANCET, V2, P952; VANDONSELAAR CA, 1989, NEUROLOGY, V39, P267, DOI 10.1212/WNL.39.2.267	9	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 8	1997	314	7078					401	404						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WH295	9040384				2022-12-28	WOS:A1997WH29500026
J	Hogan, SC; Stratford, KJ; Moore, DR				Hogan, SC; Stratford, KJ; Moore, DR			Duration and recurrence of otitis media with effusion in children from birth to 3 years: Prospective study using monthly otoscopy and tympanometry	BRITISH MEDICAL JOURNAL			English	Article							LIFE	Objective: To monitor the natural course of otitis media with effusion. Design: Prospective, longitudinal assessment of the state of the middle ear by otoscopy and tympanometry at monthly intervals from birth to 3 years. Setting: Domiciliary visits to family homes. Subjects: 95 full term infants born between August 1991 and November 1993. Main outcome measures: Observed and simulated data (Monte Carlo) for the duration of single episodes of otitis media with effusion. Results: 17 of the children had unilateral or bilateral otitis media with effusion for more than half of their first three years of life. Thirty three of the 95 children had tympanograms suggestive of otitis media with effusion at more than a third of observations; the remaining 62 had such tympanograms at less than a third of observations. The data of each group were described by a first order Markov model, yielding a mean duration of unilateral effusion episodes of 5-6 weeks in both groups; the mean duration of bilateral effusion was 6 and 10 weeks in the low and high incidence groups, respectively. However, the main difference between the groups was the time spent between episodes of effusion: effusion free periods were, on average, three times longer in the children who experienced less otitis media with effusion. Conclusion: Children who are susceptible to otitis media with effusion tend to have more separate episodes of effusion rather than an increased overall duration of episodes. Such children are primarily distinguished by the likelihood with which they acquire the disease than by their ability to recover from it.			Hogan, SC (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		FIELLAUNIKOLAJSEN M, 1980, ANN OTO RHINOL LARYN, V89, P223, DOI 10.1177/00034894800890S351; HAGGARD M, 1993, OBJECTIVES VALUES ME; HOLTE L, 1990, AUDIOLOGY, V29, P1; Karlin S., 1975, 1 COURSE STOCHASTIC, V2; MOORE DR, 1991, AUDIOLOGY, V30, P91; MOORE DR, 1997, SPRINGER HDB AUDITOR, V8; ODIO CM, 1985, PEDIATRICS, V75, P819; PARADISE JL, 1981, PEDIATRICS, V68, P869; PILLSBURY HC, 1991, ARCH OTOLARYNGOL, V117, P718; PRESS WH, 1986, NUMERICAL RECIPES AR; SHURIN PA, 1979, NEW ENGL J MED, V300, P1121, DOI 10.1056/NEJM197905173002001; TEELE DW, 1984, PEDIATRICS, V74, P282; TOS M, 1980, ARCH OTOLARYNGOL, V106, P345; ZIELHUIS GA, 1989, LANCET, V1, P311	14	40	41	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					350	353		10.1136/bmj.314.7077.350	http://dx.doi.org/10.1136/bmj.314.7077.350			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040332	Green Published			2022-12-28	WOS:A1997WF86100038
J	Fuchs, VR				Fuchs, VR			Managed care and merger mania	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									STANFORD UNIV,DEPT ECON,STANFORD,CA 94305; STANFORD UNIV,DEPT HLTH RES & POLICY,STANFORD,CA 94305	Stanford University; Stanford University								BENVENISTE L, 1988, CAPITAL ISSUES BANKI, P27; MERGERS MG, 1987, NEW PALGRAVE DICT EC, V3, P450; Nelson Ralph L., 1959, MERGER MOVEMENTS AM, P89; SACK K, 1993, NY TIMES        0223, pA1; SACK K, 1993, NY TIMES        0408, pB5	5	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					920	921		10.1001/jama.277.11.920	http://dx.doi.org/10.1001/jama.277.11.920			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062332				2022-12-28	WOS:A1997WM77400037
J	Gutthann, SP; Rodriguez, LAG; Castellsague, J; Oliart, AD				Gutthann, SP; Rodriguez, LAG; Castellsague, J; Oliart, AD			Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective: To evaluate the association between use of hormone replacement therapy and the risk of idiopathic venous thromboembolism. Design: Population based case-control study. Setting: Population enrolled in the General Practice Research Database, United Kingdom. Subjects: A cohort of 347 253 women aged 50 to 79 without major risk factors for venous thromboembolism was identified. Cases were 292 women admitted to hospital for a first episode of pulmonary embolism or deep venous thrombosis; 10 000 controls were randomly selected from the source cohort. Main outcome measures: Adjusted relative risks estimated from unconditional logistic regression. Results: The adjusted odds ratio of venous thromboembolism for current use of hormone replacement therapy compared with non-users, with odds ratios of 4.6 (2.5 to 8.4) during the first six months and 3.0 (1.4 to 6.5) 6-12 months after starting treatment. No major risk differences were observed between users of low and high doses of oestrogens, unopposed and opposed treatment, and oral and transdermal preparations. The risk of idiopathic venous thromboembolism among non-users, idiopathic venous thromboembolism occurs at two to three times the rate in non-users, resulting in one to two additional cases per 10 000 women per year. Conclusions: Current use of hormone replacement therapy was associated with a higher risk of venous thromboembolism, although the risk seemed to be restricted to the first year of use.	UNIV COMPLUTENSE MADRID, CTR ESPANOL INVEST FARMACOEPIDEMIOL, MADRID 28003, SPAIN	Complutense University of Madrid	Gutthann, SP (corresponding author), NOVARTIS PHARMACEUT, DEPT MED, GRAN VIA CORTS CATALANES 764, BARCELONA 08013, SPAIN.			Perez-Gutthann, Susana/0000-0001-5798-3691				[Anonymous], 1974, NEW ENGL J MED, V290, P15; *COMM SAF MED, 1996, CURRENT PROBLEMS PHA, V22, P9; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; FEINSTEIN AR, 1978, CANCER RES, V38, P4001; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; *SAS I, 1992, SAS SYST PERS COMP R; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; Walker AM, 1991, OBSERVATION INFERENC	18	288	293	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	1997	314	7083					796	800		10.1136/bmj.314.7083.796	http://dx.doi.org/10.1136/bmj.314.7083.796			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9081000	Green Published			2022-12-28	WOS:A1997WN64600029
J	Peterson, HB; Xia, ZS; Hughes, JM; Wilcox, LS; Tylor, LR; Trussell, J				Peterson, HB; Xia, ZS; Hughes, JM; Wilcox, LS; Tylor, LR; Trussell, J			The risk of ectopic pregnancy after tubal sterilization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEMALE STERILIZATION; LAPAROSCOPIC STERILIZATION; FAILURES	Background Tubal sterilization is an increasingly common method of contraception in the United States. Although pregnancy after sterilization is uncommon, it can occur and may be ectopic. We used data from the U.S. Collaborative Review of Sterilization to estimate the risk of ectopic pregnancy in women who had undergone the common types of tubal sterilization. Methods A total of 10,685 women undergoing tubal sterilization were followed in a multicenter, prospective cohort study. We intended to follow all the women for 5 years by means of annual telephone interviews; for women enrolled early in the study, we attempted an additional follow-up telephone interview 8 to 14 years after sterilization. To assess the risk of ectopic pregnancy in these women, we used cumulative life-table probabilities and proportional-hazards analysis. Results There were 47 ectopic pregnancies in the 10,685 women; the 10-year cumulative probability of ectopic pregnancy for all methods of tubal sterilization combined was 7.3 per 1000 procedures. The cumulative probability varied substantially according to the method of sterilization and the woman's age at the time of sterilization. Women sterilized by bipolar tubal coagulation before the age of 30 years had a probability of ectopic pregnancy that was 27 times as high as that among women of similar age who underwent postpartum partial salpingectomy (31.9 vs. 1.2 ectopic pregnancies per 1000 procedures). The annual rate of ectopic pregnancy for all methods combined in the 4th through 10th years after sterilization was no lower than that in the first 3 years. Conclusions A history of tubal sterilization does not rule out the possibility of ectopic pregnancy, even many years after the procedure. (C) 1997, Massachusetts Medical Society.	PRINCETON UNIV,OFF POPULAT RES,PRINCETON,NJ 08544	Princeton University	Peterson, HB (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV REPROD HLTH,ATLANTA,GA 30341, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041075] Funding Source: NIH RePORTER; NICHD NIH HHS [3-Y02-HD41075-10] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHENG MCE, 1977, STUD FAMILY PLANN, V8, P109, DOI 10.2307/1966115; CHI IC, 1980, AM J OBSTET GYNECOL, V136, P768, DOI 10.1016/0002-9378(80)90454-8; KJER JJ, 1989, AM J OBSTET GYNECOL, V160, P1202, DOI 10.1016/0002-9378(89)90190-7; MAKAR AP, 1990, EUR J OBSTET GYN R B, V37, P237, DOI 10.1016/0028-2243(90)90030-5; MCCAUSLAND A, 1980, AM J OBSTET GYNECOL, V136, P97, DOI 10.1016/0002-9378(80)90573-6; MENKEN J, 1986, SCIENCE, V234, P413; MENKEN J, 1986, SCIENCE, V233, P1389, DOI 10.1126/science.3755843; PETERSON HB, 1983, AM J OBSTET GYNECOL, V146, P131, DOI 10.1016/0002-9378(83)91040-2; PETERSON HB, 1993, J REPROD MED, V38, P574; Peterson HB, 1996, AM J OBSTET GYNECOL, V174, P1161, DOI 10.1016/S0002-9378(96)70658-0; PETERSON LS, 1995, ADV DATA VITAL HLTH, V260; *SAS I, 1992, P229 SAS I; SIEGLER AM, 1985, FERTIL STERIL, V43, P499; SODERSTROM RM, 1989, OBSTET GYNECOL, V74, P60; STOVALL TG, 1990, OBSTET GYNECOL, V76, P461; WILCOX LS, 1991, FERTIL STERIL, V55, P927; 1995, MMWR-MORBID MORTAL W, V44, P46	17	123	126	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					762	767		10.1056/NEJM199703133361104	http://dx.doi.org/10.1056/NEJM199703133361104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM640	9052654				2022-12-28	WOS:A1997WM64000004
J	Mirza, DF; Gunson, BK; Soonawalla, Z; Pirenne, J; Mayer, AD; Buckels, JAC; McMaster, P				Mirza, DF; Gunson, BK; Soonawalla, Z; Pirenne, J; Mayer, AD; Buckels, JAC; McMaster, P			Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression	LANCET			English	Article									FREEMAN RD HOSP,LIVER UNIT,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND	Newcastle Freeman Hospital	Mirza, DF (corresponding author), QUEEN ELIZABETH HOSP,LIVER & HEPATOBILIARY UNIT,BIRMINGHAM,W MIDLANDS,ENGLAND.		Pirenne, Jacques/I-3728-2018	Pirenne, Jacques/0000-0002-8147-8801; Gunson, Bridget/0000-0001-6149-9915				CANDINAS D, 1995, LANCET, V346, P1117, DOI 10.1016/S0140-6736(95)91797-7; *EUR FK506 MULT LI, 1994, LANCET, V344, P423; Hubscher S G, 1994, Transpl Immunol, V2, P118, DOI 10.1016/0966-3274(94)90040-X; NOBLE S, 1995, DRUGS, V50, P924, DOI 10.2165/00003495-199550050-00009	4	40	40	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					701	702		10.1016/S0140-6736(05)60138-9	http://dx.doi.org/10.1016/S0140-6736(05)60138-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078209				2022-12-28	WOS:A1997WM08000019
J	Danilevskaya, ON; Arkhipova, IR; Traverse, KL; Pardue, ML				Danilevskaya, ON; Arkhipova, IR; Traverse, KL; Pardue, ML			Promoting in tandem: The promoter for telomere transposon HeT-A and implications for the evolution of retroviral LTRs	CELL			English	Article							INACTIVE X-CHROMOSOME; DROSOPHILA-MELANOGASTER; REVERSE TRANSCRIPTION; INTERNAL PROMOTER; ELEMENT; GENE; SEQUENCES; DNA; RNA; RETROTRANSPOSONS	HeT-A elements are non-long terminal repeat (non-LTR) retrotransposons found in head-to-tail arrays on Drosophila chromosome ends, where they form telomeres. We report that HeT-A promoter activity is located in the 3' end of the element, unlike the 5' location seen for other non-LTR retrotransposons. In HeT-A arrays the 3' sequence of one element directs transcription of its downstream neighbor. Because the upstream promoter has the same sequence as the 3' end of the transcribed element, the HeT-A promoter is effectively equivalent to a 5' LTR in both structure and function. Retroviruses and LTR retrotransposons have their promoters and transcription initiation sites in their 5' LTRs. Thus HeT-A appears to have the structure of an evolutionary intermediate between non-LTR and LTR retrotransposons.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Massachusetts Institute of Technology (MIT); Harvard University				Arkhipova, Irina/0000-0002-4805-1339	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050315] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50315] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKHIPOVA IR, 1995, GENETICS, V139, P1359; Arkhipova IR, 1995, DROSOPHILA RETROTRAN; BIESSMANN H, 1992, EMBO J, V11, P4459, DOI 10.1002/j.1460-2075.1992.tb05547.x; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BIESSMANN H, 1994, CHROMOSOMA, V103, P90, DOI 10.1007/BF00352317; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; DANILEVSKAYA O, 1994, CHROMOSOMA, V103, P215, DOI 10.1007/s004120050027; DANILEVSKAYA ON, 1994, P NATL ACAD SCI USA, V91, P6679, DOI 10.1073/pnas.91.14.6679; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Eickbush Thomas H., 1994, P121; HENNIG W, 1993, P NATL ACAD SCI USA, V90, P10904, DOI 10.1073/pnas.90.23.10904; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; MCCLURE MA, 1991, MOL BIOL EVOL, V8, P835; MCLEAN C, 1993, MOL CELL BIOL, V13, P1042, DOI 10.1128/MCB.13.2.1042; MILLER JH, 1974, EXPT MOL GENETICS, P352; MINCHIOTTI G, 1991, MOL CELL BIOL, V11, P5171, DOI 10.1128/MCB.11.10.5171; MIZROKHI LJ, 1988, CELL, V54, P685, DOI 10.1016/S0092-8674(88)80013-8; MULLER HJ, 1938, COLLECTING NET, V13, P182; Pardue ML, 1996, J MOL EVOL, V43, P572, DOI 10.1007/BF02202105; Pardue ML, 1996, TRENDS GENET, V12, P48, DOI 10.1016/0168-9525(96)81399-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARZSOMMER Z, 1987, EMBO J, V6, P3873, DOI 10.1002/j.1460-2075.1987.tb02727.x; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VALGEIRSDOTTIR K, 1990, P NATL ACAD SCI USA, V87, P7998, DOI 10.1073/pnas.87.20.7998; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	33	107	111	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					647	655		10.1016/S0092-8674(00)81907-8	http://dx.doi.org/10.1016/S0092-8674(00)81907-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054504	Bronze			2022-12-28	WOS:A1997WM41300010
J	Hawley, RS				Hawley, RS			Cell biology - Unresolvable endings: Defective telomeres and failed separation	SCIENCE			English	Editorial Material							DNA-SEQUENCES; DROSOPHILA; YEAST				Hawley, RS (corresponding author), UNIV CALIF DAVIS,DEPT GENET,SECT MOL & CELLULAR BIOL,DAVIS,CA 95616, USA.			Hawley, R. Scott/0000-0002-6478-0494				BIESSMANN H, 1988, EMBO J, V7, P1081, DOI 10.1002/j.1460-2075.1988.tb02916.x; BIESSMANN H, 1990, P NATL ACAD SCI USA, V87, P1758, DOI 10.1073/pnas.87.5.1758; Blackburn E.H., 1996, TELOMERES; CENCI G, IN PRESS GENES DEV; DERNBURG AF, 1996, TELOMERES, P295; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; MASON JM, 1984, P NATL ACAD SCI-BIOL, V81, P6090, DOI 10.1073/pnas.81.19.6090; PARDUE ML, 1996, TELOMERES, P339; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0	13	5	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1441	1443						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9072807				2022-12-28	WOS:A1997WM08100032
J	Jansen, PHP; Veenhuizen, KCW; Wesseling, AIM; deBoo, T; Verbeek, ALM				Jansen, PHP; Veenhuizen, KCW; Wesseling, AIM; deBoo, T; Verbeek, ALM			Randomised controlled trial of hydroquinine in muscle cramps	LANCET			English	Article							NOCTURNAL LEG CRAMPS; QUININE	Background Although quinine and hydroquinine are commonly prescribed for muscle cramps, controlled clinical trials of these drugs have reported mixed findings about efficacy. We investigated hydroquinine therapy in otherwise healthy adults who had frequent, ordinary muscle cramps. Methods This randomised, double-blind, placebo-controlled, parallel-group trial consisted of three consecutive 2-week periods: qualification, treatment, and washout. 68 women and 44 men who had at least three muscle cramps per week were enrolled. During the treatment period, participants were randomly assigned 300 mg daily dose of hydroquinine hydrobromide dihydrate (54 participants) or placebo (58). The frequency, severity (1-10), duration, and location of muscle cramps, as well as any side-effects, were recorded by participants in daily diaries. The primary outcome measures were the number of muscle cramps and the number of days during which the participants had muscle cramps (cramp-days). Findings We excluded five participants from both groups from the analysis. Thus, data from 49 hydroquinine-group participants and 53 placebo-group participants were analysed. In both groups the total number of muscle cramps and the number of cramp-days decreased during the treatment period compared with the qualification period. However, these improvements were greater in the hydroquinine group than in the placebo group. The hydroquinine-group participants reported a median of 8 (95% CI 7-12) fewer cramps and median of 3 (1-4) fewer cramp-days, whereas those on placebo reported only 3 (0-5) fewer cramps and 1 (0-5) fewer cramp-days. 32 (65%) of participants in the hydroquinine group had a 50% or greater reduction in the number of muscle cramps. After the onset of cramps, hydroquinine did not reduce the severity or duration of cramps. We also found a sustained effect after treatment had stopped. Hydroquinine was well tolerated, and resulted in only mild side-effects. Interpretation In our study, 300 mg hydroquinine was safe to take in the short-term and significantly more effective than placebo in the prevention of frequent, ordinary muscle cramps. this therapeutic effect outlasted the duration of treatment.	CATHOLIC UNIV NIJMEGEN,DEPT MED INFORMAT EPIDEMIOL & STAT,NL-6500 HB NIJMEGEN,NETHERLANDS; ZIEKENHUIS GELDERSE VALLEI,DEPT NEUROL,EDE,NETHERLANDS; ASTA MED BV,DEPT MED,DIEMEN,NETHERLANDS	Radboud University Nijmegen; Gelderse Vallei Hospital			Verbeek, A.L.M./H-8103-2014	Verbeek, A.L.M./0000-0002-2319-5002				BARR E, 1990, BRIT MED J, V301, P323, DOI 10.1136/bmj.301.6747.323; BOLAND ME, 1985, LANCET, V1, P384; CONNOLLY PS, 1992, ARCH INTERN MED, V152, P1877, DOI 10.1001/archinte.152.9.1877; De Vries H A, 1966, Am J Phys Med, V45, P119; DUNN NR, 1995, LBMJ, V310, P1136; DUNN NR, 1993, BR J GEN PRACT, V3, P127; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; FUNG MC, 1989, WESTERN J MED, V151, P42; GORLICH HD, 1991, ARZNEIMITTEL-FORSCH, V41-1, P167; HARATS N, 1984, NEW ENGL J MED, V310, P1331; HING M, 1995, BRIT MED J, V310, P13; JANSEN PHP, 1991, EUR ARCH PSY CLIN N, V241, P98, DOI 10.1007/BF02191149; JANSEN PHP, 1994, J NEUROL SCI, V122, P157, DOI 10.1016/0022-510X(94)90294-1; JANSEN PHP, 1990, EUR ARCH PSY CLIN N, V239, P337, DOI 10.1007/BF01735062; JANSEN PHP, 1993, MOTOR UNIT HYPERACTI, P125; KETZ E, 1987, MUSKELKRAMPFE, P59; LAYZER RB, 1994, MUSCLE NERVE, V17, P1243, DOI 10.1002/mus.880171102; LJUNGGREN B, 1988, PHOTODERMATOLOGY, V5, P133; NAYLOR JR, 1994, AGE AGEING, V23, P418, DOI 10.1093/ageing/23.5.418; PUNUKOLLU RC, 1990, ARCH INTERN MED, V150, P1112, DOI 10.1001/archinte.150.5.1112; SIMCHAK AC, 1991, SEMIN NEUROL, V11, P281, DOI 10.1055/s-2008-1041233	21	43	43	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					528	532		10.1016/S0140-6736(97)80085-2	http://dx.doi.org/10.1016/S0140-6736(97)80085-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048790	Green Submitted			2022-12-28	WOS:A1997WJ51200009
J	Nan, XS; Campoy, FJ; Bird, A				Nan, XS; Campoy, FJ; Bird, A			MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin	CELL			English	Article							MAJOR LATE PROMOTER; THYMIDINE KINASE GENE; DNA METHYLATION; HISTONE H1; CHROMOSOMAL PROTEIN; INVITRO METHYLATION; CPG SEQUENCES; POLYMERASE-II; EXPRESSION; INHIBITION	MeCP2 is an abundant mammalian protein that binds to methylated CpG. We have found that native and recombinant MeCP2 repress transcription in vitro from methylated promoters but do not repress nonmethylated promoters. Repression is nonlinearly dependent on the local density of methylation, becoming significant at the density found in bulk vertebrate genomic DNA. Transient transfection using fusions with the GAL4 DNA binding domain identified a region of MeCP2 that is capable of long-range repression in vivo. Moreover, MeCP2 is able to displace histone H1 from preassembled chromatin that contains methyl-CpG These properties, together with the abundance of MeCP2 and the high frequency of its 2 bp binding site, suggest a role as a global transcriptional repressor in vertebrate genomes.			Nan, XS (corresponding author), UNIV EDINBURGH, INST CELL & MOL BIOL, EDINBURGH EH9 3JR, MIDLOTHIAN, SCOTLAND.			Nan, Xinsheng/0000-0002-0865-7934; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bird A, 1995, J CELL SCI, P37; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; BUSCHHAUSEN G, 1985, NUCLEIC ACIDS RES, V13, P5503, DOI 10.1093/nar/13.15.5503; CAMPOY FJ, 1995, J BIOL CHEM, V270, P26473, DOI 10.1074/jbc.270.44.26473; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; HIGURASHI M, 1991, J BIOL CHEM, V266, P8619; HOCK R, 1993, DEV BIOL, V158, P510, DOI 10.1006/dbio.1993.1209; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; Hug M, 1996, FEBS LETT, V379, P251, DOI 10.1016/0014-5793(95)01521-3; JOHNSON CA, 1995, BIOCHEM J, V305, P791, DOI 10.1042/bj3050791; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; LEVINE A, 1993, J BIOL CHEM, V268, P21754; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI BY, 1994, J BIOL CHEM, V269, P7756; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; NAN X, 1996, NUCLEIC ACIDS RES, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REACH M, 1990, J VIROL, V64, P5851, DOI 10.1128/JVI.64.12.5851-5860.1990; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tweedie S, 1997, MOL CELL BIOL, V17, P1469, DOI 10.1128/MCB.17.3.1469; VARDIMON L, 1982, P NATL ACAD SCI-BIOL, V79, P1073, DOI 10.1073/pnas.79.4.1073; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136	48	983	1017	1	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1997	88	4					471	481		10.1016/S0092-8674(00)81887-5	http://dx.doi.org/10.1016/S0092-8674(00)81887-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038338	Bronze			2022-12-28	WOS:A1997WJ69100007
J	Follette, PJ; OFarrell, PH				Follette, PJ; OFarrell, PH			Connecting cell behavior to patterning: Lessons from the cell cycle	CELL			English	Review							BUD SITE SELECTION; GENETIC-CONTROL; DROSOPHILA EMBRYOGENESIS; ASYMMETRIC SEGREGATION; DEVELOPMENTAL CONTROL; PROSPERO; DIVISION; PROTEIN; GASTRULATION; EMBRYOS				Follette, PJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			O'Farrell, Patrick/0000-0003-0011-2734; Follette, Peter/0000-0003-1791-4960	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM037193, R01 GM037193-10] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Edgar BA, 1996, GENE DEV, V10, P1966, DOI 10.1101/gad.10.15.1966; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FOE VE, 1989, DEVELOPMENT, V107, P1; FOLLETTE PJ, 1997, CURR OPIN GENET DEV; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Guillemin K, 1996, DEVELOPMENT, V122, P1353; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; SPANA EP, 1995, DEVELOPMENT, V121, P3187; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805	34	31	32	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					309	314		10.1016/S0092-8674(00)81869-3	http://dx.doi.org/10.1016/S0092-8674(00)81869-3			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039257	Green Accepted, Bronze			2022-12-28	WOS:A1997WG47900003
J	Sarnthein, J; Pasquarello, A; Car, R				Sarnthein, J; Pasquarello, A; Car, R			Origin of the high-frequency doublet in the vibrational spectrum of vitreous SiO2	SCIENCE			English	Article							MOLECULAR-DYNAMICS; ALPHA-QUARTZ; AMORPHOUS SIO2; GLASSES; SILICA; RAMAN; SPLITTINGS; NEUTRON; PHONONS; DENSITY	The vibrational properties of amorphous SiO2 were studied within first-principles density functional theory. The calculated spectrum is in good agreement with neutron data, showing, in particular, a double peak in the high-frequency region. This doublet results from different local modes of the tetrahedral subunits and cannot be ascribed to a longitudinal-optic-transverse-optic (LO-TO) effect. This solves a long-standing controversy about the origin of the doublet in neutron spectra. A LO-TO splitting is recovered only when the long-wavelength limit is probed, as in optical experiments. These findings should be a general feature of tetrahedral AX(2) amorphous networks.	IN ECUBIENS,INST ROMAND RECH NUMER PHYS MAT,CH-1015 LAUSANNE,SWITZERLAND; UNIV GENEVA,DEPT CONDENSED MATTER PHYS,CH-1211 GENEVA,SWITZERLAND	University of Geneva			Sarnthein, Johannes/E-7959-2010; Pasquarello, Alfredo/G-2883-2011	Sarnthein, Johannes/0000-0001-9141-381X; Pasquarello, Alfredo/0000-0002-9142-2799				ALMEIDA RM, 1992, PHYS REV B, V45, P161, DOI 10.1103/PhysRevB.45.161; ARAI M, 1992, PHYSICA B, V180, P779, DOI 10.1016/0921-4526(92)90465-5; BELL RJ, 1975, J PHYS C SOLID STATE, V8, P787, DOI 10.1088/0022-3719/8/6/009; CARPENTER JM, 1985, PHYS REV LETT, V54, P441, DOI 10.1103/PhysRevLett.54.441; DELEEUW SW, 1985, PHYS REV LETT, V55, P2879, DOI 10.1103/PhysRevLett.55.2879; DELLAVALLE RG, 1994, CHEM PHYS, V179, P411, DOI 10.1016/0301-0104(94)87017-9; DENISOV VN, 1984, J NON-CRYST SOLIDS, V64, P195, DOI 10.1016/0022-3093(84)90216-3; GALEENER FL, 1976, PHYS REV LETT, V37, P1474, DOI 10.1103/PhysRevLett.37.1474; GALEENER FL, 1979, PHYS REV B, V19, P4292, DOI 10.1103/PhysRevB.19.4292; GALEENER FL, 1983, PHYS REV B, V27, P1052, DOI 10.1103/PhysRevB.27.1052; GONZE X, 1994, PHYS REV B, V50, P13035, DOI 10.1103/PhysRevB.50.13035; GONZE X, 1992, PHYS REV LETT, V68, P3603, DOI 10.1103/PhysRevLett.68.3603; HANNON AC, 1992, J NON-CRYST SOLIDS, V150, P239, DOI 10.1016/0022-3093(92)90129-8; JIN W, 1993, PHYS REV B, V48, P9359, DOI 10.1103/PhysRevB.48.9359; KIRK CT, 1988, PHYS REV B, V38, P1255, DOI 10.1103/PhysRevB.38.1255; LAASONEN K, 1993, PHYS REV B, V47, P10142, DOI 10.1103/PhysRevB.47.10142; LEE C, 1995, PHYS REV B, V51, P8610, DOI 10.1103/PhysRevB.51.8610; LEE CY, 1994, PHYS REV LETT, V72, P1686, DOI 10.1103/PhysRevLett.72.1686; LEHMANN A, 1983, PHYS STATUS SOLIDI B, V117, P689, DOI 10.1002/pssb.2221170231; MARTINET C, 1995, J APPL PHYS, V77, P4343, DOI 10.1063/1.359459; MCMILLAN P, 1982, GEOCHIM COSMOCHIM AC, V46, P2021, DOI 10.1016/0016-7037(82)90182-X; MCMILLAN PF, 1994, GEOCHIM COSMOCHIM AC, V58, P3653, DOI 10.1016/0016-7037(94)90156-2; PASQUARELLO A, 1992, PHYS REV LETT, V69, P1982, DOI 10.1103/PhysRevLett.69.1982; PAYNE MC, 1984, J NON-CRYST SOLIDS, V68, P351, DOI 10.1016/0022-3093(84)90016-4; PICK RM, 1977, LATTICE DYNAMICS, P459; PRICE DL, 1987, J NON-CRYST SOLIDS, V92, P153, DOI 10.1016/S0022-3093(87)80366-6; SARNTHEIN J, 1995, PHYS REV LETT, V74, P4682, DOI 10.1103/PhysRevLett.74.4682; SARNTHEIN J, 1995, PHYS REV B, V52, P12690, DOI 10.1103/PhysRevB.52.12690; SEN PN, 1977, PHYS REV B, V15, P4030, DOI 10.1103/PhysRevB.15.4030; STRAUCH D, 1993, J PHYS-CONDENS MAT, V5, P6149, DOI 10.1088/0953-8984/5/34/003; SUSMAN S, 1991, PHYS REV B, V43, P1194, DOI 10.1103/PhysRevB.43.1194; THORPE MF, 1986, PHYS REV B, V33, P8490, DOI 10.1103/PhysRevB.33.8490; WALRAFEN GE, 1990, J CHEM PHYS, V92, P6987, DOI 10.1063/1.458239; Wilson M, 1996, PHYS REV LETT, V77, P4023, DOI 10.1103/PhysRevLett.77.4023	35	123	123	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1925	1927		10.1126/science.275.5308.1925	http://dx.doi.org/10.1126/science.275.5308.1925			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072968				2022-12-28	WOS:A1997WQ51300043
J	Ridzon, R; Gallagher, K; Ciesielski, C; Mast, EE; Ginsberg, MB; Robertson, BJ; Luo, CC; DeMaria, A				Ridzon, R; Gallagher, K; Ciesielski, C; Mast, EE; Ginsberg, MB; Robertson, BJ; Luo, CC; DeMaria, A			Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE WORKERS; OCCUPATIONAL EXPOSURES; INFANT TRANSMISSION; NATURAL-HISTORY; INFECTION; BLOOD; RISK; IDENTIFICATION; ANTIBODY		CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,EPIDEM INTELLIGENCE SERV,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HEPATITIS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HIV LAB INVESTIGAT BRANCH,ATLANTA,GA 30333; MASSACHUSETTS DEPT PUBL HLTH,BUR COMMUNICABLE DIS CONTROL,BOSTON,MA; NEPONSET VALLEY HLTH SYST,NORWOOD,MA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Massachusetts Department of Public Health								ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1993, INFECT AGENT DIS, V2, P155; BEACH MJ, 1992, J MED VIROL, V36, P226, DOI 10.1002/jmv.1890360314; *CDC, 1996, HIV AIDS SURV REP, V8, P15; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; Felsenstein J., 1993, PHYLIP PHYLOGENETIC; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; Heptonstall J, 1995, OCCUPATIONAL TRANSMI; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; LANPHEAR BP, 1994, INFECT CONT HOSP EP, V15, P745; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; OU CY, 1988, SCIENCE, V240, P240; PURO V, 1995, AM J INFECT CONTROL, V23, P273, DOI 10.1016/0196-6553(95)90056-X; SanchezQuijano A, 1995, EUR J CLIN MICROBIOL, V14, P949, DOI 10.1007/BF01691375; Seeff L B, 1995, Semin Gastrointest Dis, V6, P20; SEEFF LB, 1994, ANN INTERN MED, V120, P807, DOI 10.7326/0003-4819-120-9-199405010-00014; SIMMONDS P, 1994, J GEN VIROL, V75, P1053, DOI 10.1099/0022-1317-75-5-1053; TSUDE K, 1992, HEPATO-GASTROENTEROL, V39, P73; WORMSER GP, 1991, AM J INFECT CONTROL, V19, P237, DOI 10.1016/S0196-6553(05)80255-X; ZANETTI AR, 1995, LANCET, V345, P289, DOI 10.1016/S0140-6736(95)90277-5; 1996, MMWR-MORBID MORTAL W, V45, P468	27	109	110	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	1997	336	13					919	922		10.1056/NEJM199703273361304	http://dx.doi.org/10.1056/NEJM199703273361304			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP832	9070472				2022-12-28	WOS:A1997WP83200004
J	Benatar, SR				Benatar, SR			Health care reform in the new South Africa	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICINE		GROOTE SCHUUR HOSP,ZA-7925 CAPE TOWN,SOUTH AFRICA	University of Cape Town	Benatar, SR (corresponding author), UNIV CAPE TOWN,DEPT MED,ZA-7925 CAPE TOWN,SOUTH AFRICA.							Adam H., 1993, NEGOTIATED REVOLUTIO; African National Congress, 1994, NAT HLTH PLAN S AFR; African National Congress, 1994, REC DEV PROGR; BENATAR SR, 1991, NEW ENGL J MED, V325, P30, DOI 10.1056/NEJM199107043250106; BENATAR SR, 1990, S AFR MED J, V77, P441; BENATAR SR, 1986, NEW ENGL J MED, V315, P527, DOI 10.1056/NEJM198608213150829; BENATAR SR, 1995, HASTINGS CENT REP, V25, P16, DOI 10.2307/3562156; Braudel F., 1994, HIST CIVILIZATIONS; BUCHANAN A, 1995, BIOETHICS, V9, P220, DOI 10.1111/j.1467-8519.1995.tb00357.x; Cherry M, 1996, NATURE, V384, P11; COUGHLAN FJ, 1995, S AFR J SOCIOL, V26, P9; *HLTH SYS TRUST HJ, 1995, S AFR HLTH REV 1995; *HLTH SYST TRUST, 1995, DIR HLTH SYST RES 19; Hobsbawm Eric, 1994, AGE EXTREMES; LEWIS A, 1995, ANN SURV INT COMP LA, V2, P1; Lyman PN, 1996, FOREIGN POLICY, P105, DOI 10.2307/1149262; MALCOLM L, 1994, SOC SCI MED, V39, P455, DOI 10.1016/0277-9536(94)90088-4; MCINTYRE D, 1995, S AFR MED J, V85, P133; RIFKIN SB, 1986, SOC SCI MED, V23, P559, DOI 10.1016/0277-9536(86)90149-8; SPARKS A, 1994, TOMORROW ANOTHER COU; VANRENSBURG HCJ, 1996, DEMOGRAPHIC TRANSITI, P363; VANRENSBURG HCJ, 1993, S AFRICAN J SOCIOLOG, V24, P99	22	28	29	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					891	895		10.1056/NEJM199703203361224	http://dx.doi.org/10.1056/NEJM199703203361224			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN371	9062099				2022-12-28	WOS:A1997WN37100030
J	Lee, JT; Jaenisch, R				Lee, JT; Jaenisch, R			Long-range cis effects of ectopic X-inactivation centres on a mouse autosome	NATURE			English	Article							CHROMOSOME INACTIVATION; INSITU HYBRIDIZATION; XIST GENE; EXPRESSION; REPLICATION; EMBRYOS; NUCLEUS; RNA	In mammals, the X chromosome is unique in being capable of complete inactivation. Such X inactivation evolved to compensate for gene dosage differences between females with two X chromosomes and males with one(1). Transcriptional silencing of a, single female X chromosome is controlled in cis by Xist(2), whose RNA product coats the inactive X chromosome (X(i))(3), and the X-inactivation centre (Xic)(4). A transgenic study limited the Xic to 450 kilobases including Xist, and demonstrated that it is sufficient to initiate X inactivation(5). Here we report that ectopic Xist RNA completely coats transgenic chromosome 12. Expression of genes over 50 centimorgans was reduced two-fold and was detected only from the normal homologue in fibroblasts. Moreover, ectopic Xic action resulted in chromosome-wide changes that are characteristic of the X(i): DNA replication was delayed, and histone H4 was markedly hypoacetylated. Our findings suggest long-range cis effects on the autosome similar to those of X inactivation, and imply that the Xic can both initiate X inactivation and drive heterochromatin formation, Thus, the potential for chromosome-wide gene regulation is not intrinsic to X-chromosome DNA, but can also occur on autosomes possessing the Xic.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	Lee, JT (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carrel L, 1996, HUM MOL GENET, V5, P1361, DOI 10.1093/hmg/5.9.1361; CLEMSON CM, 1996, J CELL BIOL, V132, P1; DEUSTACHIO P, 1994, GENOME, V5, pS181; EICHER EM, 1970, ADV GENET, V15, P175, DOI 10.1016/S0065-2660(08)60074-7; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GE, 1993, CELL, V72, P161; KEITGES EA, 1986, HUM GENET, V72, P230; KRUMLAUF R, 1986, NATURE, V319, P224, DOI 10.1038/319224a0; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; PRAVTCHEVA DD, 1991, DEVELOPMENT, V111, P1109; PRIEST JH, 1967, J CELL BIOL, V35, P483, DOI 10.1083/jcb.35.2.483; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; SCHEMPP W, 1985, Y CHROMOSOME, P357; SHEARDOWN S, HUM MOL GENET, V5, P1355; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; VOGEL W, 1986, HUM GENET, V72, P129; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4	30	224	230	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					275	279		10.1038/386275a0	http://dx.doi.org/10.1038/386275a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069285				2022-12-28	WOS:A1997WP00300050
J	Raisz, LG				Raisz, LG			The osteoporosis revolution	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HORMONE-REPLACEMENT THERAPY; RECEPTOR GENE ALLELES; BONE-MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; LUMBAR-SPINE; ESTABLISHED OSTEOPOROSIS; ESTROGEN REPLACEMENT; COST-EFFECTIVENESS; SODIUM-FLUORIDE; HIP-FRACTURES	Our concepts of the pathogenesis, diagnosis, prevention, and treatment of osteoporosis are radically changing. Some changes, such as the study of genetic determinants of bone mass and turnover and the identification of local factors in pathogenesis, have just begun. The use of bone densitometry to diagnose and predict fracture risk is well developed but not yet widely applied. Measurement of bone turnover done by using biochemical markers is a promising new diagnostic method that has already proved useful in assessing a patient's response to therapy. Options for prevention and treatment have increased substantially with the Food and Drug Administration's recent approval of alendronate (a bisphosphonate) and nasal calcitonin for treatment of osteoporosis. Some are concerned that these new agents will unduly reduce the use of estrogen, which should remain the mainstay for prevention of bone loss and fractures in postmenopausal women. New therapeutic approaches are needed to treat the established disease. Our goal should be to develop inexpensive and widely applicable methods for diagnosis, prevention, and treatment to limit the enormous increase in osteoporotic fractures that has been predicted as the aging population expands worldwide.			Raisz, LG (corresponding author), UNIV CONNECTICUT, CTR HLTH, DIV ENDOCRINOL & METAB, FARMINGTON, CT 06030 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-06192] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; BISMAR H, 1995, J CLIN ENDOCR METAB, V80, P3351, DOI 10.1210/jc.80.11.3351; BLACK DM, 1995, AM J MED, V98, pS67, DOI 10.1016/S0002-9343(05)80050-6; BONDE M, 1995, J CLIN ENDOCR METAB, V80, P864, DOI 10.1210/jc.80.3.864; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; CHRISCHILLES E, 1994, BONE, V15, P377, DOI 10.1016/8756-3282(94)90813-3; CLARK AP, 1992, OSTEOPOROSIS INT, V2, P195, DOI 10.1007/BF01623926; CUMMINGS SR, 1995, AM J MED, V98, pS24, DOI 10.1016/S0002-9343(05)80041-5; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DAVIDSON NE, 1995, NEW ENGL J MED, V332, P1638, DOI 10.1056/NEJM199506153322409; DELMAS PD, 1993, J BONE MINER RES, V8, pS549; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; DIAMOND T, 1995, AM J MED, V98, P459, DOI 10.1016/S0002-9343(99)80345-3; EISMAN JA, 1995, J BONE MINER RES, V10, P1289; FERRARI S, 1995, LANCET, V345, P423, DOI 10.1016/S0140-6736(95)90404-2; FUCHSYOUNG R, 1995, ANN NY ACAD SCI, V761, P355, DOI 10.1111/j.1749-6632.1995.tb31392.x; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693; GEELHOED E, 1994, AUST J PUBLIC HEALTH, V18, P153; Gonnelli S, 1995, OSTEOPOROSIS INT, V5, P413, DOI 10.1007/BF01626601; HANSEN MA, 1991, BMJ-BRIT MED J, V303, P961, DOI 10.1136/bmj.303.6808.961; JACOBSEN SJ, 1992, EPIDEMIOLOGY, V3, P515, DOI 10.1097/00001648-199211000-00009; JONSSON B, 1995, OSTEOPOROSIS INT, V5, P136, DOI 10.1007/BF01623315; KANIS JA, 1995, AM J MED, V98, pS60; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KASSEM M, 1994, EUR J ENDOCRINOL, V131, P150, DOI 10.1530/eje.0.1310150; Kassem M, 1996, J CLIN ENDOCR METAB, V81, P513, DOI 10.1210/jc.81.2.513; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P539, DOI 10.1172/JCI118066; KE HZ, 1995, ENDOCRINOLOGY, V136, P2435, DOI 10.1210/en.136.6.2435; KENNY AM, 1995, J CLIN ENDOCR METAB, V80, P3287, DOI 10.1210/jc.80.11.3287; KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054; KLEEREKOPER M, 1993, ENDOCR REV, V14, P312, DOI 10.1210/er.14.3.312; KRALL EA, 1995, J BONE MINER RES, V10, P978; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LINDSAY R, 1995, AM J MED, V98, pS9, DOI 10.1016/S0002-9343(05)80038-5; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; LUKERT BP, 1992, J BONE MINER RES, V7, P1063; MELTON LJ, 1993, BONE, V14, pS1; PAK CYC, 1995, ANN INTERN MED, V123, P401, DOI 10.7326/0003-4819-123-6-199509150-00001; PEACOCK M, 1995, J BONE MINER RES, V10, P1294; PRESTWOOD KM, 1995, ANNU REV MED, V46, P249; PRESTWOOD KM, 1994, J CLIN ENDOCR METAB, V79, P366, DOI 10.1210/jc.79.2.366; Raisz LG, 1996, J CLIN ENDOCR METAB, V81, P37, DOI 10.1210/jc.81.1.37; RAISZ LG, 1988, NEW ENGL J MED, V318, P818; RALSTON SH, 1994, J BONE MINER RES, V9, P883; RAVN P, 1995, EUR J ENDOCRINOL, V132, P313, DOI 10.1530/eje.0.1320313; REGINSTER JY, 1995, AM J MED, V98, P452, DOI 10.1016/S0002-9343(99)80344-1; RIIS BJ, 1995, AM J MED, V98, pS29, DOI 10.1016/S0002-9343(05)80042-7; RIZZOLI R, 1995, AM J MED, V98, pS33, DOI 10.1016/S0002-9343(05)80043-9; RODAN GA, 1994, OSTEOPOROSIS INT, V4, P5; SAMBROOK P, 1993, OSTEOPOROSIS INT, V3, pS141; SEEMAN E, 1994, J BONE MINER RES, V9, P739; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; TOKITA A, 1994, J CLIN ENDOCR METAB, V78, P1461, DOI 10.1210/jc.78.6.1461; WHITE CP, 1994, J CELL BIOCHEM, V56, P307, DOI 10.1002/jcb.240560306	55	78	86	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					458	462		10.7326/0003-4819-126-6-199703150-00007	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM530	9072932				2022-12-28	WOS:A1997WM53000007
J	Warren, P; Warren, F				Warren, P; Warren, F			Window on the breast: 19th century English developments in pulmonary diagnosis	LANCET			English	Article									UNIV MANITOBA,DEPT MED,WINNIPEG,MB,CANADA	University of Manitoba								ARMSTRONG, 1825, LANCET, V6, P137; AUENBRUGGER L, 1922, INVENTUM NOVUM 1761; BEIGEL H, 1864, LANCET, P243; BENNETT H, 1843, LANCET, V1, P461; BISHOP PJ, 1980, J ROY SOC MED, V73, P448, DOI 10.1177/014107688007300611; CORRIGAN DJ, 1829, LANCET, V1, P586; CORVISART JN, 1962, ESSAY ORGANIC DIS LE; DAMADOR, 1995, MED MANDARINS FRENCH, P164; DAVIES A, 1850, LANCET, V11, P123; DAVIES A, 1850, LANCET, V11, P547; DAVIES A, 1850, LANCET, V12, P234; DAVIES A, 1850, LANCET, V12, P22; DAVIES A, 1850, LANCET, V11, P417; DAVIES A, 1850, LANCET, V11, P304; Eliot George, 1965, MIDDLEMARCH 1871 72; FENOGLIO GC, 1823, LANCET, V1, P435; FORBES J, 1824, REV ORIGINAL CASES D, P145; FOX F, 1829, LANCET, P509; HARRISON JB, 1842, LANCET, V1, P118; HUTCHINSON J, 1844, LANCET, P594; HUTCHINSON J, 1844, LANCET, P390; HUTCHINSON J, 1844, LANCET, P567; KAY JP, 1827, LANCET, V1, P754; Keele K. D., 1963, EVOLUTION CLIN METHO; LAENNEC THR, 1962, TREATISE DIS CHEST; LOUIS PCA, 1844, RES PHTHISIS ANATOMI; MARTINET L, 1824, LANCET, V3, P658; Newman C, 1957, EVOLUTION MED ED 19; NICOLSON M, 1993, MED 5 SENSES; OSLER W, 1904, MED 19 CENTURY AEQUA; Pollock JamesE, 1856, LANCET, V1, P398; Reiser S., 1978, MED REIGN TECHNOLOGY; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; SAKULA A, 1981, J ROY SOC MED, V74, P759, DOI 10.1177/014107688107401010; SALTER H, 1866, LANCET, V1, P84; SALTER H, 1866, LANCET, V1, P1; SALTER H, 1866, LANCET, V1, P153; SPRAGGE SS, 1974, LIFE TIMES T WAKLEY; STOKES W, 1826, LANCET, V9, P471; STOKES W, 1855, MED SESS 1855 56 U D; TIFFENEAU R, 1952, PRESSE MED, V60, P640; 1826, LANCET, V11, P372; 1826, LANCET, V10, P667; 1878, LANCET, V1, P766	44	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					798	801		10.1016/S0140-6736(96)10510-9	http://dx.doi.org/10.1016/S0140-6736(96)10510-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074591				2022-12-28	WOS:A1997WN12400050
J	Goldberg, LH				Goldberg, LH			Basal-cell carcinoma as predictor for other cancers	LANCET			English	Editorial Material							NON-HODGKINS-LYMPHOMA; SKIN-CANCER				Goldberg, LH (corresponding author), BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030, USA.		Goldberg, Leonard/AGR-0657-2022					ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; Frisch M, 1996, ANN INTERN MED, V125, P815, DOI 10.7326/0003-4819-125-10-199611150-00005; FRISCH M, 1995, AM J EPIDEMIOL, V141, P916, DOI 10.1093/oxfordjournals.aje.a117358; HALL P, 1995, INT J CANCER, V62, P19; Hjalgrim H, 1996, BRIT J CANCER, V73, P951, DOI 10.1038/bjc.1996.170; KRIPKE ML, 1994, CANCER RES, V54, P6102; McMichael AJ, 1996, BRIT J CANCER, V73, P945, DOI 10.1038/bjc.1996.169; Schottenfeld D, 1996, ANN INTERN MED, V125, P852, DOI 10.7326/0003-4819-125-10-199611150-00011; Wassberg C, 1996, BRIT J CANCER, V73, P255, DOI 10.1038/bjc.1996.45	10	6	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					664	665		10.1016/S0140-6736(05)60130-4	http://dx.doi.org/10.1016/S0140-6736(05)60130-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078194				2022-12-28	WOS:A1997WM08000004
J	Muller, U; Wang, DN; Denda, S; Meneses, JJ; Pedersen, RA; Reichardt, LF				Muller, U; Wang, DN; Denda, S; Meneses, JJ; Pedersen, RA; Reichardt, LF			Integrin alpha 8 beta 1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis	CELL			English	Article							RECEPTOR; TENASCIN; FIBRONECTIN; EXPRESSION; MICE; VITRONECTIN; ANTIBODIES; MIGRATION; ADHESION; SUBUNIT	We present genetic evidence that integrins regulate epithelial-mesenchymal interactions during organogenesis. Mice with a mutation in the alpha 8 gene do not express the integrin alpha 8 beta 1 and exhibit profound deficits in kidney morphogenesis. In wild-type animals, inductive interactions between the ureteric epithelium and metanephric mesenchyme are essential for kidney morphogenesis. In alpha 8 mutant homozygotes, growth and branching of the ureteric bud and recruitment of mesenchymal cells into epithelial structures are defective. Consistent with these phenotypes, alpha 8 expression is induced in mesenchymal cells upon contact with the ureter. Since none of its previously identified ligands appears likely to mediate the essential functions of alpha 8 beta 1 in kidney morphogenesis, we have used an alpha 8 beta 1-alkaline phosphatase chimera to localize novel ligand(s) in the growing ureter. The distribution of these ligand(s) makes them strong candidates for regulators of kidney morphogenesis.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,REPROD GENET UNIT,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Muller, U (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,BOX 0444,SAN FRANCISCO,CA 94143, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD026732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019090] Funding Source: NIH RePORTER; NICHD NIH HHS [P01-HD26732] Funding Source: Medline; NINDS NIH HHS [R01 NS019090, R01 NS019090-14] Funding Source: Medline; PHS HHS [P01-16033] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; EKBLOM P, 1981, J CELL BIOL, V91, P1, DOI 10.1083/jcb.91.1.1; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P700, DOI 10.1016/S0955-0674(96)80112-8; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GETTNER S, 1994, THESIS U CALIFORNIA; GROBSTEIN C, 1953, SCIENCE, V118, P52, DOI 10.1126/science.118.3054.52; GROBSTEIN C, 1956, ADV CANCER RES, V4, P187, DOI 10.1016/S0065-230X(08)60725-3; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; Holtfreter Johannes, 1944, REV CANADIENNE BIOL, V3, P220; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Joyner AL, 1993, GENE TARGETING PRACT; KADOYA Y, 1995, J CELL BIOL, V129, P521, DOI 10.1083/jcb.129.2.521; Kispert A, 1996, DEVELOPMENT, V122, P3627; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Liu ZZ, 1996, DEV BIOL, V178, P133, DOI 10.1006/dbio.1996.0204; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MULLER U, 1995, MOL BIOL CELL, V6, P433; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; POOLE TJ, 1981, J EMBRYOL EXP MORPH, V63, P1; POOLE TJ, 1982, DEV BIOL, V92, P144, DOI 10.1016/0012-1606(82)90159-2; Roelink H, 1996, CURR OPIN NEUROBIOL, V6, P33, DOI 10.1016/S0959-4388(96)80006-7; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SPERMANN H, 1924, ARCH ENTW MECH ORG, V100, P599; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Torres M, 1995, DEVELOPMENT, V121, P4057; Tung TC, 1944, J ANAT, V78, P52; VARNUMFINNEY B, 1995, NEURON, V14, P1213, DOI 10.1016/0896-6273(95)90268-6; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; ZHANG X, 1995, P NATL ACAD SCI USA, V92, P12426	52	276	284	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					603	613		10.1016/S0092-8674(00)81903-0	http://dx.doi.org/10.1016/S0092-8674(00)81903-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054500	Green Accepted, Bronze			2022-12-28	WOS:A1997WM41300006
J	Webb, CD; Teleman, A; Gordon, S; Straight, A; Belmont, A; Lin, DCH; Grossman, AD; Wright, A; Losick, R				Webb, CD; Teleman, A; Gordon, S; Straight, A; Belmont, A; Lin, DCH; Grossman, AD; Wright, A; Losick, R			Bipolar localization of the replication origin regions of chromosomes in vegetative and sporulating cells of B-subtilis	CELL			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; GENE-EXPRESSION; TRANSCRIPTION; PROTEINS; DNA; IMMUNOFLUORESCENCE; IDENTIFICATION; VISUALIZATION; CONDENSATION	To investigate chromosome segregation in B. subtilis, we introduced tandem copies of the lactose operon operator into the chromosome near the replication origin or terminus. We then visualized the position of the operator cassettes with green fluorescent protein fused to the Lad repressor. In sporulating bacteria, which undergo asymmetric cell division, origins localized near each pole of the cell whereas termini were restricted to the middle. In growing cells, which undergo binary fission, origins were observed at various positions but preferentially toward the poles early in the cell cycle. In contrast, termini showed little preference for the poles. These results indicate the existence of a mitotic-like apparatus that is responsible for moving the origin regions of newly formed chromosomes toward opposite ends of the cell.	TUFTS UNIV,DEPT MOL BIOL & MICROBIOL,BOSTON,MA 02111; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Tufts University; University of California System; University of California San Francisco; University of Illinois System; University of Illinois Urbana-Champaign; Massachusetts Institute of Technology (MIT)	Webb, CD (corresponding author), HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.		Teleman, Aurelio/V-8470-2019; Teleman, Aurelio A/E-6864-2013	Teleman, Aurelio/0000-0002-4237-9368; Teleman, Aurelio A/0000-0002-4237-9368; Straight, Aaron/0000-0001-5885-7881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018568, R01GM038035, R01GM018568, R01GM042516] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38035, GM18568, R01 GM042516] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BONE EJ, 1985, J BACTERIOL, V164, P192, DOI 10.1128/JB.164.1.192-200.1985; COOPER S, 1991, BACTERIAL GROWTH DIV, P279; Cutting S., 1990, MOL BIOL METHODS BAC; DRIKS A, 1994, GENE DEV, V8, P234, DOI 10.1101/gad.8.2.234; DUBNAU E, 1988, J BACTERIOL, V170, P1054, DOI 10.1128/jb.170.3.1054-1062.1988; EBERLE H, 1966, J MOL BIOL, V22, P183, DOI 10.1016/0022-2836(66)90190-2; FORT P, 1985, J GEN MICROBIOL, V131, P1091; GARTNER D, 1988, J BACTERIOL, V170, P3102; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; HYMAN AA, 1995, CURR BIOL, V5, P483, DOI 10.1016/S0960-9822(95)00097-2; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; JAACKS KJ, 1989, J BACTERIOL, V171, P4121, DOI 10.1128/JB.171.8.4121-4129.1989; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; LEDEAUX JR, 1995, J BACTERIOL, V177, P166, DOI 10.1128/jb.177.1.166-175.1995; MOBLEY HLT, 1984, J BACTERIOL, V158, P169, DOI 10.1128/JB.158.1.169-179.1984; MOHL DA, 1997, CELL; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; POGLIANO K, 1995, MOL MICROBIOL, V18, P459, DOI 10.1111/j.1365-2958.1995.mmi_18030459.x; Resnekov O, 1996, GENES CELLS, V1, P529, DOI 10.1046/j.1365-2443.1996.d01-262.x; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; ROELS S, 1995, J BACTERIOL, V177, P6263, DOI 10.1128/jb.177.21.6263-6275.1995; SANDLER N, 1988, J GEN MICROBIOL, V134, P1155; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; Sharpe ME, 1996, MOL MICROBIOL, V21, P501, DOI 10.1111/j.1365-2958.1996.tb02559.x; SHARPE ME, 1995, P NATL ACAD SCI USA, V92, P8630, DOI 10.1073/pnas.92.19.8630; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; Wake RG, 1995, ANNU REV GENET, V29, P41; WEBB CD, 1995, J BACTERIOL, V177, P5906, DOI 10.1128/jb.177.20.5906-5911.1995; WOLDRINGH CL, 1987, J GEN MICROBIOL, V133, P575; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014; YOUNGMAN P, 1984, PLASMID, V12, P1, DOI 10.1016/0147-619X(84)90061-1; ZUBER P, 1983, CELL, V35, P275, DOI 10.1016/0092-8674(83)90230-1	39	314	317	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					667	674		10.1016/S0092-8674(00)81909-1	http://dx.doi.org/10.1016/S0092-8674(00)81909-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054506	Bronze, Green Published			2022-12-28	WOS:A1997WM41300012
J	Gomez, R; Buescher, ES				Gomez, R; Buescher, ES			Meningococcemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Gomez, R (corresponding author), CHILDRENS HOSP KINGS DAUGHTERS,NORFOLK,VA 23507, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					707	707		10.1056/NEJM199703063361006	http://dx.doi.org/10.1056/NEJM199703063361006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041102				2022-12-28	WOS:A1997WL41900006
J	Psaty, BM; Smith, NL; Siscovick, DS; Koepsell, TD; Weiss, NS; Heckbert, SR; Lemaitre, RN; Wagner, EH; Furberg, CD				Psaty, BM; Smith, NL; Siscovick, DS; Koepsell, TD; Weiss, NS; Heckbert, SR; Lemaitre, RN; Wagner, EH; Furberg, CD			Health outcomes associated with antihypertensive therapies used as first-line agents - A systematic review and meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; MILD HYPERTENSION; CALCIUM-ANTAGONISTS; BLOOD-PRESSURE; BETA-BLOCKERS; CARDIOVASCULAR-DISEASE; SYSTOLIC HYPERTENSION; RANDOMIZED TRIALS; STOP-HYPERTENSION	Objective.-To review the scientific evidence concerning the safety and efficacy of various antihypertensive therapies used as first-line agents and evaluated in terms of major disease end points. Data Sources.-MEDLINE searches and previous meta-analyses for 1980 to 1995. Data Selection.-We selected long-term studies that assessed major disease end points as an outcome. For the meta-analysis, we chose placebo-controlled randomized trials. For randomized trials using surrogate end points such as blood pressure, we selected the largest studies that evaluated multiple drugs. Where clinical trial evidence was lacking, we relied on information from observational studies. Data Synthesis.-Diuretics and beta-blockers have been evaluated in 18 long-term randomized trials. Compared with placebo, beta-blocker therapy was effective in preventing stroke (relative risk [RR], 0.71; 95% confidence interval [CI], 0.59-0.86) and congestive heart failure (RR, 0.58; 95% CI, 0.40-0.84). The findings were similar for high-dose diuretic therapy (for stroke, RR, 0.49; 95% CI, 0.39-0.62; and for congestive heart failure, RR, 0.17; 95% CI, 0.07-0.41). Low-dose diuretic therapy prevented not only stroke (RR, 0.66; 95% CI, 0.55-0.78) and congestive heart failure (RR, 0.58; 95% CI, 0.44-0.76) but also coronary disease (RR, 0.72; 95% CI, 0.61-0.85) and total mortality (RR, 0.90; 95% CI, 0.81-0.99). Although calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors reduce blood pressure in hypertensive patients, the clinical trial evidence in terms of health outcomes is meager. For several short-acting dihydropyridine calcium channel blockers, the available evidence suggests the possibility of harm. Whether the long-acting formulations and the nondihydropyridine calcium channel blockers are safe and prevent major cardiovascular events in patients with hypertension remains untested and therefore unknown. Conclusion.-Until the results of large long-term clinical trials evaluating the effects of calcium channel blockers and ACE inhibitors on cardiovascular disease incidence are completed, the available scientific evidence provides strong support for the current national guidelines, which recommend diuretics and beta-blockers as first-line agents and low-dose therapy for all antihypertensive agents.	UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98101 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98101 USA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA 98101 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; Wake Forest University; Wake Forest Baptist Medical Center	Psaty, BM (corresponding author), UNIV WASHINGTON, CARDIOVASC HLTH RES UNIT, DEPT MED, SUITE 1360, 1730 MINOR AVE, SEATTLE, WA 98101 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040628, R29HL040628, R01HL043201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40628, HL43201] Funding Source: Medline; NIA NIH HHS [AG09556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1985, J Hypertens, V3, P379; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1973, BMJ-BRIT MED J, V3, P434; [Anonymous], 1995, Hypertens Res, V18, P235; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1974, JAMA-J AM MED ASSOC, V229, P409; [Anonymous], 1982, JAMA-J AM MED ASSOC, V247, P633; [Anonymous], 1993, ARCH INTERN MED, V153, P154, DOI DOI 10.1001/archinte.1993.00410020010002; Aursnes Vvar I. Litleskare, 1995, Blood Pressure, V4, P157, DOI 10.3109/08037059509077588; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BLACK H, 1993, JAMA-J AM MED ASSOC, V270, P757, DOI 10.1001/jama.270.6.757; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; CARTER AB, 1970, LANCET, V1, P485; CASIGLIA E, 1994, JPN HEART J, V35, P589; Chatellier G, 1996, BRIT MED J, V312, P426; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; Cutler Jeffrey A., 1995, P253; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; EKBOM T, 1992, J HYPERTENS, V10, P1525, DOI 10.1097/00004872-199210120-00013; EPSTEIN M, 1995, ARCH INTERN MED, V155, P2150, DOI 10.1001/archinte.155.20.2150; FALLOWFIELD JM, 1993, BRIT J CLIN PRACT, V47, P296; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; FRIEDMAN LM, 1996, FUNDAMENTALS CLIN TR; Furberg CD, 1996, CIRCULATION, V93, P1475; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GHEORGHIADE M, 1989, EUR HEART J, V10, P695, DOI 10.1093/oxfordjournals.eurheartj.a059553; GOLDBOURT U, 1993, ARCH INTERN MED, V153, P345, DOI 10.1001/archinte.153.3.345; Gong LS, 1996, J HYPERTENS, V14, P1237, DOI 10.1097/00004872-199610000-00013; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Grimm RH, 1996, JAMA-J AM MED ASSOC, V275, P1549, DOI 10.1001/jama.275.20.1549; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; HEGELAND A, 1980, AM J MED, V0069, P00725; HELD PH, 1994, CORONARY ARTERY DIS, V5, P21, DOI 10.1097/00019501-199401000-00004; HOES AW, 1995, ANN INTERN MED, V123, P481, DOI 10.7326/0003-4819-123-7-199510010-00001; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2562; Hypertension Detection and Follow-Up Program Cooperative Group, 1984, HYPERTENSION S1, V6; Jick H, 1996, PHARMACOTHERAPY, V16, P321; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; KASISKE BL, 1995, ANN INTERN MED, V122, P133, DOI 10.7326/0003-4819-122-2-199501150-00010; KENDALL MJ, 1995, ANN INTERN MED, V123, P358, DOI 10.7326/0003-4819-123-5-199509010-00007; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KURAMOTO K, 1981, JPN HEART J, V22, P75; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; LINDQVIST M, 1994, HYPERTENSION, V24, P287, DOI 10.1161/01.HYP.24.3.287; LUBSEN J, 1986, BRIT HEART J, V56, P400; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; *MAN COMM AUSTR NA, 1980, LANCET, V1, P1262; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; *NAT HEART LUNG BL, 1995, AN REG SAF CALC CHAN; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PERRY HM, 1989, STROKE, V20, P4, DOI 10.1161/01.STR.20.1.4; PERRY HM, 1978, ANN NY ACAD SCI, V304, P267; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Psaty BM, 1996, AM J HYPERTENS, V9, P178, DOI 10.1016/0895-7061(96)00015-5; PSATY BM, 1990, J CLIN EPIDEMIOL, V43, P961, DOI 10.1016/0895-4356(90)90079-5; Rothman K, 1986, MODERN EPIDEMIOLOGY; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SCHEIDT S, 1986, AM J CARDIOL, V58, P715, DOI 10.1016/0002-9149(86)90343-7; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SEWESTER CS, 1996, DRUG FACTS COMP; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; SLOVICK DI, 1993, J HUM HYPERTENS, V7, P201; SMITH WM, 1977, CIRC RES, V40, P98; SPRACKLING ME, 1981, BRIT MED J, V283, P1151, DOI 10.1136/bmj.283.6300.1151; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; THADANI U, 1991, CIRCULATION, V84, P2398, DOI 10.1161/01.CIR.84.6.2398; TOBIAN L, 1994, AM J HYPERTENS, V7, P859, DOI 10.1093/ajh/7.10.859; Veterans Administration Cooperative Study Group on Antihypertensive Agents, 1967, JAMA-J AM MED ASSOC, V202, P116, DOI DOI 10.1001/JAMA.1967.03130150084015; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; WOLFF FW, 1966, J CHRON DIS, V19, P227, DOI 10.1016/0021-9681(66)90128-7; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G	90	685	718	1	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					739	745		10.1001/jama.277.9.739	http://dx.doi.org/10.1001/jama.277.9.739			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042847				2022-12-28	WOS:A1997WK02600034
J	Alpern, RJ; Sakhaee, K				Alpern, RJ; Sakhaee, K			Does hyperphosphaturia underlie hypercalciuria?	LANCET			English	Editorial Material							ABSORPTIVE HYPERCALCIURIA; AMBULATORY EVALUATION; 1,25-DIHYDROXYVITAMIN-D; NEPHROLITHIASIS; PHOSPHATE				Alpern, RJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235, USA.							BARILLA DE, 1979, MINER ELECTROL METAB, V2, P302; BRESLAU NA, 1992, J CLIN ENDOCR METAB, V75, P1446, DOI 10.1210/jc.75.6.1446; BROADUS AE, 1984, NEW ENGL J MED, V311, P73, DOI 10.1056/NEJM198407123110201; GRAY RW, 1977, J CLIN ENDOCR METAB, V45, P299, DOI 10.1210/jcem-45-2-299; INSOGNA KL, 1985, J CLIN ENDOCR METAB, V61, P490, DOI 10.1210/jcem-61-3-490; LEVY FL, 1995, AM J MED, V98, P50, DOI 10.1016/S0002-9343(99)80080-1; PAK CYC, 1991, AM J KIDNEY DIS, V18, P624, DOI 10.1016/S0272-6386(12)80602-0; PAK CYC, 1980, AM J MED, V69, P19, DOI 10.1016/0002-9343(80)90495-7; SAKHAEE K, 1985, J CLIN ENDOCR METAB, V61, P825, DOI 10.1210/jcem-61-5-825; WILLIAMS CP, 1995, J CLIN PATHOL, V49, P881	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					518	519		10.1016/S0140-6736(97)80080-3	http://dx.doi.org/10.1016/S0140-6736(97)80080-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048785				2022-12-28	WOS:A1997WJ51200004
J	McLellan, MF				McLellan, MF			Literature and medicine: Physician-writers	LANCET			English	Editorial Material							WISDOM; PAIN		UNIV TEXAS,MED BRANCH,INST MED HUMANITIES,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	McLellan, MF (corresponding author), UNIV TEXAS,MED BRANCH,DEPT ANESTHESIOL,GALVESTON,TX 77555, USA.			McLellan, Faith/0000-0003-0744-1450				BRYANT DC, 1994, LIT MED, V13, P284, DOI 10.1353/lm.2010.0003; CARSON RA, 1995, ENCY BIOETHICS, V3, P1283; CHARON R, 1989, SOUNDINGS, V72, P137; CHARON R, 1989, PERSPECTIVES MED SOC, P527; CHEKHOV A, 1979, A CHEKHOVS SHORT STO, P270; CHEKHOV A, 1965, WARD 6 OTHER STORIES; CHEKHOV A, 1979, A CHEKHOVS SHORT STO, P271; CHEKOV A, 1979, A CHEKHOVS SHORT STO, P267; Connelly Julia E, 1994, EMPATHIC PRACTITIONE, P171; CREMEENS C, 1968, SO REV, V4, P271; DILTHEY W, 1972, NEW LITERARY HIST, V3, P229, DOI DOI 10.2307/468313; Eichenbaum Boris, 1967, CHEKHOV COLLECTION C, P21; FOUCAULT M, 1963, BIRTH CLIN ARCHAEOLO, P14; FREUD, 3 CASE HIST; FREUD, DORA ANAL CASE HYSTE; Gadamer Hans-Georg, 1982, REASON AGE SCI; GORDAN JD, 1964, DOCTORS MEN LETT ENG; GRAHAM PW, 1981, PERSPECT BIOL MED, V24, P229; GREEN JP, 1993, MT SINAI J MED, V60, P132; HEFFERNAN M, 1985, MIDWEST Q, V26, P189; HODGES HW, 1927, INTRODUCTION, pR7; HORTON RC, 1995, DIFFICLT HYPERTENSIO, P265; Jones AH, 1997, LANCET, V349, P275, DOI 10.1016/S0140-6736(96)12240-6; JOSYPH P, 1994, WHAT ONE MAN SAID AN, P252; JOURNET D, 1990, WRIT COMMUN, V7, P171, DOI 10.1177/0741088390007002001; JOURNET D, 1990, MOSAIC, V23, P87; KLASS P, 1994, EMPATHIC PRACTITIONE, P157; Lawson L, 1972, S ATLANTIC B, V37, P58; LEDER D, 1990, THEOR MED, V11, P9, DOI 10.1007/BF00489234; LURIA AR, MAN SHATTERED WORLD; LURIA AR, MIND MNEMONIST; MITCHELL SW, H WYNNE; MITCHELL SW, 1915, AUTOBIOGRAPHY QUACK, P83; MITCHELL SW, DR NORTH; MITCHELL SW, CHARACTERISTICS; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; MORRELL RC, 1986, PHAROS, V59, P26; Osler W., 1903, MED NEWS NEW YORK, V82, P49; Pellegrino E. D., 1982, LIT MED, V1, P19; POIRIER SUSAN, 1985, LIT MED, V4, P21; PRICE R, 1985, PALPABLE GOD, P3; SACKS O, AWAKENINGS MAN WHO M; SCHLEIERMACHER F, 1986, INTERPRETATION TEXTS, V1; SELZER R, 1986, TAKING WORLD REPAIRS; SELZER R, LETT YOUNG DOCTOR; SELZER R, MORTAL LESSONS; SELZER R, TAKING WORLD REPAIRS; SELZER R, CONFESSIONS KNIFE; SIMMONS EJ, 1962, CHEKHOV BIOGRAPHY, P73; SMITHERS DW, 1989, THIS IDLE TRADE DOCT; STONE J, 1990, LIT MED, V9, P142; TERRY JS, 1987, LIT MED, V6, P43, DOI 10.1353/lm.2011.0012; WOLFF S, 1990, LIT MED, V9, P134	53	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					564	567		10.1016/S0140-6736(97)80120-1	http://dx.doi.org/10.1016/S0140-6736(97)80120-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	WJ512	9048804				2022-12-28	WOS:A1997WJ51200043
J	Jacobson, MD; Weil, M; Raff, MC				Jacobson, MD; Weil, M; Raff, MC			Programmed cell death in animal development	CELL			English	Review							GROWTH-FACTOR; C-ELEGANS; CAENORHABDITIS-ELEGANS; ELECTRON-MICROSCOPE; GENETIC-CONTROL; NEURONAL DEATH; RNA-SYNTHESIS; APOPTOSIS; SURVIVAL; BCL-2				Jacobson, MD (corresponding author), UNIV LONDON UNIV COLL,MRC,MOL CELL BIOL LAB,DEV NEUROBIOL PROGRAMME,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.							Allan D.J., 1987, P229; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BIGGERS J. D., 1971, Methods in mammalian embryology, P86; BOSCH TCG, 1984, DEV BIOL, V104, P161, DOI 10.1016/0012-1606(84)90045-9; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clarke PGH, 1996, ANAT EMBRYOL, V193, P81; COLES HSR, 1993, DEVELOPMENT, V118, P777; CORNILLON S, 1994, J CELL SCI, V107, P2691; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ELSHERSH.AM, 1974, J EMBRYOL EXP MORPH, V31, P643; Frade JM, 1996, NATURE, V383, P166; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Ganan Y, 1996, DEVELOPMENT, V122, P2349; GLUCKSMANN A, 1951, BIOL REV, V26, P5986; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; ISHIZAKI Y, 1994, J CELL BIOL, V126, P1069, DOI 10.1083/jcb.126.4.1069; ISHIZAKI Y, 1995, MOL BIOL CELL, V6, P1443, DOI 10.1091/mbc.6.11.1443; ISHIZAKI Y, 1993, J CELL BIOL, V121, P899, DOI 10.1083/jcb.121.4.899; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1974, J CELL SCI, V14, P571; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; LOCKSHIN RA, 1964, J INSECT PHYSIOL, V10, P643, DOI 10.1016/0022-1910(64)90034-4; Loomis WF, 1995, EXPERIENTIA, V51, P1110, DOI 10.1007/BF01944728; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NATARAJ A, 1994, INT J ONCOL, V4, P1211; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SHUB DA, 1994, CURR BIOL, V4, P555, DOI 10.1016/S0960-9822(00)00124-X; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SNYDER L, 1995, MOL MICROBIOL, V15, P415, DOI 10.1111/j.1365-2958.1995.tb02255.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VOGT C, 1942, UNTERSUCHUNGEN ENTWI; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; YU YTN, 1994, P NATL ACAD SCI USA, V91, P802, DOI 10.1073/pnas.91.2.802; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	70	2261	2385	5	124	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					347	354		10.1016/S0092-8674(00)81873-5	http://dx.doi.org/10.1016/S0092-8674(00)81873-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039261	Bronze			2022-12-28	WOS:A1997WG47900007
J	Nagata, S				Nagata, S			Apoptosis by death factor	CELL			English	Review							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; FAS ANTIGEN; FACTOR RECEPTOR; LYMPHOPROLIFERATIVE SYNDROME; MONOCLONAL-ANTIBODY; ICE/CED-3 PROTEASE; MOLECULAR-CLONING; DEFICIENT MICE; LIGAND		OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN		Nagata, S (corresponding author), OSAKA UNIV,SCH MED,DEPT GENET,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Calabrese, Massimiliano/I-6195-2012; Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gamen S, 1996, FEBS LETT, V390, P233, DOI 10.1016/0014-5793(96)00666-7; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KISTON J, 1996, NATURE, V384, P372; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; RODRIGUEZ I, 1996, IN PRESS J EXP MED; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SPLEGEL S, 1996, CURR OPIN CELL BIOL, V8, P159; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TANAKA M, 1997, IN PRESS J IMMUNOL; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WU JG, 1994, P NATL ACAD SCI USA, V91, P2344, DOI 10.1073/pnas.91.6.2344; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMBAMI N, 1996, J EXP MED, V183, P1533; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	84	4335	4535	1	246	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					355	365		10.1016/S0092-8674(00)81874-7	http://dx.doi.org/10.1016/S0092-8674(00)81874-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039262	Bronze			2022-12-28	WOS:A1997WG47900008
J	Rauer, H; Arpigny, C; Boehnhardt, H; Colas, F; Crovisier, J; Jorda, L; Kuppers, M; Manfroid, J; Rembor, K; Thomas, N				Rauer, H; Arpigny, C; Boehnhardt, H; Colas, F; Crovisier, J; Jorda, L; Kuppers, M; Manfroid, J; Rembor, K; Thomas, N			Optical observations of comet Hale-Bopp (C/1995 O1) at large heliocentric distances before perihelion	SCIENCE			English	Article							GAS-PRODUCTION; 17 COMETS; P/HALLEY; HALLEY	The activity of comet Hale-Bopp (C/1995 O1) was monitored monthly by optical imaging and long-slit spectroscopy of its dust and gas distribution over heliocentric distances of 4.6 to 2.9 astronomical units, The observed band intensities of the NH2 radical and the H2O+ ion cannot be explained by existing models of fluorescence excitation, warranting a reexamination of the corresponding production rates, at least at large heliocentric distances, Comparing the production rate of the CN radical to its proposed parent, HCN, shows no evidence for the need of a major additional source for CN in Hale-Bopp at large heliocentric distances, The dust and CN production rates are consistent with a significant amount of sublimation occurring from icy dust grains surrounding Hale-Bopp.	INST ASTROPHYS, B-4000 LIEGE, BELGIUM; UNIV MUNICH, INST ASTRON & ASTROPHYS, D-81679 MUNICH, GERMANY; BUR LONGITUDES, F-75014 PARIS, FRANCE; MAX PLANCK INST AERON, D-37191 KATLENBURG DUHM, GERMANY	University of Munich; Max Planck Society	Rauer, H (corresponding author), OBSERV PARIS, 5 PL JULES JANSSEN, F-92190 MEUDON, FRANCE.		Jorda, Laurent/AAA-1718-2021; Thomas, Nicolas/G-4693-2015	Thomas, Nicolas/0000-0002-0146-0071				AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; AHEARN MF, 1985, ICARUS, V64, P1, DOI 10.1016/0019-1035(85)90033-8; AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; AHEARN MF, 1986, NATURE, V324, P649, DOI 10.1038/324649a0; ARPIGNY C, 1994, AIP C P, V312, P205; Biver N, 1996, NATURE, V380, P137, DOI 10.1038/380137a0; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; COCHRAN AL, 1992, ICARUS, V98, P151, DOI 10.1016/0019-1035(92)90086-M; CRIFO JF, 1987, ASTRON ASTROPHYS, V187, P438; Crovisier J, 1996, ASTRON ASTROPHYS, V315, pL385; DAVIES JK, 1995, IN PRESS ICARUS, V118; DUTREY A, 1996, 6364 IAU; Fink U, 1996, ASTROPHYS J, V459, P729, DOI 10.1086/176938; Fitzsimmons A, 1996, MON NOT R ASTRON SOC, V278, pL37, DOI 10.1093/mnras/278.2.L37; FITZSIMMONS A, 1996, 6361 IAU; HASER L, 1957, B ACAD R BELG, V5, P43; Irvine WM, 1996, NATURE, V383, P418, DOI 10.1038/383418a0; JEWITT D, 1991, ASTROPHYS SPACE SC L, V167, P19; Jewitt D, 1996, SCIENCE, V271, P1110, DOI 10.1126/science.271.5252.1110; JOCKERS K, 1996, 6468 IAU; KIDGER MR, UNPUB; Kurucz R. L., 1984, SUNSPOT; LECACHEUX J, 1997, 6560 IAU; LUTZ BL, 1987, ASTROPHYS J, V315, pL147, DOI 10.1086/184877; MEECH KJ, 1987, ASTRON ASTROPHYS, V187, P585; NEWBURN RL, 1985, ASTRON J, V90, P2591, DOI 10.1086/113965; SCHLEICHER DG, 1983, THESIS U MARYLAND; SEKANINA Z, 1997, 6542 IAU; TEGLER S, 1989, ASTROPHYS J, V343, P445, DOI 10.1086/167717; WEAVER HA, 1996, 6376 IAU; WOMACK M, 1996, B AM ASTRON SOC, V28, P1091; YAMAMOTO T, 1985, ASTRON ASTROPHYS, V142, P31	32	58	58	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1909	1912		10.1126/science.275.5308.1909	http://dx.doi.org/10.1126/science.275.5308.1909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072962				2022-12-28	WOS:A1997WQ51300037
J	Collins, R; Peto, R; Baigent, C; Sleight, P				Collins, R; Peto, R; Baigent, C; Sleight, P			Drug therapy: Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TISSUE-PLASMINOGEN-ACTIVATOR; RANDOMIZED CLINICAL-TRIALS; THROMBOLYTIC THERAPY; ANTITHROMBOTIC THERAPY; CORONARY THROMBOLYSIS; INTRAVENOUS HEPARIN; UNSTABLE ANGINA; PLATELET ACTIVATION; GUSTO TRIAL; STREPTOKINASE		RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, EPIDEMIOL STUDIES UNIT, OXFORD OX2 6HE, ENGLAND	Radcliffe Infirmary; University of Oxford	Collins, R (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON HV, 1993, NEW ENGL J MED, V329, P703; [Anonymous], 1987, Eur Heart J, V8, P634; [Anonymous], 1988, Lancet, V1, P545; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1993, Lancet, V342, P767; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; *ANT SEC PREV EV C, 1994, MEIJ, V343, P499; ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ARNOUT J, 1992, J AM COLL CARDIOL, V20, P513, DOI 10.1016/0735-1097(92)90001-4; BAIGENT C, 1993, CIRCULATION, V88, P291; BATES ER, 1991, J AM COLL CARDIOL, V18, P1077, DOI 10.1016/0735-1097(91)90770-A; BERGLUND U, 1991, EUR HEART J, V12, P428, DOI 10.1093/oxfordjournals.eurheartj.a059912; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; CAIRNS JA, 1994, LANCET, V343, P497, DOI 10.1016/S0140-6736(94)91457-5; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; COHEN M, 1990, AM J CARDIOL, V66, P1287, DOI 10.1016/0002-9149(90)91155-Y; COL J, 1992, CIRCULATION, V86, P259; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; COLLINS R, 1993, AM J CARDIOL, V71, P1127, DOI 10.1016/0002-9149(93)90591-Y; Collins R, 1996, BMJ-BRIT MED J, V313, P652; COLLINS R, 1996, OXFORD TXB MED, V1, P21; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; DEBONO DP, 1992, BRIT HEART J, V67, P122; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; ELLIS S, 1996, AM COLL CARD SCI SES; *FIBR THER TRIAL C, 1994, LANCET, V343, P742; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; FITZGERALD DJ, 1989, CIRC RES, V65, P83, DOI 10.1161/01.RES.65.1.83; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; GRANGER CB, 1994, AM J CARDIOL, V74, P1220, DOI 10.1016/0002-9149(94)90552-5; GRANGER CB, 1992, CIRCULATION, V86, P258; Grines C L, 1991, J Interv Cardiol, V4, P149; GRINES CL, 1991, CIRCULATION, V84, P540, DOI 10.1161/01.CIR.84.2.540; GRINES CL, 1995, BRIT HEART J, V73, P405; GURFINKEL EP, 1995, J AM COLL CARDIOL, V26, P313, DOI 10.1016/0735-1097(95)80001-W; HAMPTON J, 1993, LANCET, V342, P759; HENNEKENS CH, 1995, EUR HEART J, V16, P2, DOI 10.1093/eurheartj/16.suppl_D.2; HOLDRIGHT D, 1994, J AM COLL CARDIOL, V24, P39, DOI 10.1016/0735-1097(94)90539-8; HOLMES DR, 1995, J AM COLL CARDIOL, V25, pS10; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; HSIA J, 1992, J AM COLL CARDIOL, V20, P31, DOI 10.1016/0735-1097(92)90133-8; HUNT D, 1992, LANCET, V339, P753; *INT JOINT EFF COM, 1995, LANCET, V346, P980; *INT JOINT EFF COM, 1995, LANCET, V346, P329; KERINS DM, 1989, CIRCULATION, V80, P1718, DOI 10.1161/01.CIR.80.6.1718; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LANGE RA, 1993, NEW ENGL J MED, V328, P726, DOI 10.1056/NEJM199303113281010; Leizorovicz A, 1996, BRIT MED J, V312, P215; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; Mahaffey KW, 1996, AM J CARDIOL, V77, P551, DOI 10.1016/S0002-9149(97)89305-8; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; MARK DB, 1995, NEW ENGL J MED, V333, P267; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; NEUHAUS KL, 1994, CIRCULATION, V90, P1638, DOI 10.1161/01.CIR.90.4.1638; OCONNOR CM, 1994, J AM COLL CARDIOL, V23, P11, DOI 10.1016/0735-1097(94)90496-0; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PEDERSEN TR, 1994, LANCET, V344, P1383; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRINS MH, 1991, AM J CARDIOL, V67, pA3; REILLY IAG, 1987, BLOOD, V69, P180; RIDKER PM, 1993, LANCET, V341, P1574, DOI 10.1016/0140-6736(93)90707-N; ROBERTS R, 1991, CLIN CHALLENGES ACUT, V1, P1; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROSS AM, 1994, J MYOCARDIAL ISCHEMI, V6, P11; ROSSI P, 1991, AM J CARDIOL, V68, P585, DOI 10.1016/0002-9149(91)90348-O; SCHEIDT S, 1991, CVR R            SEP, P37; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; Sleight Peter, 1995, Am J Ther, V2, P128, DOI 10.1097/00045391-199502000-00009; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SOBEL BE, 1992, AM J CARDIOL, V70, P385, DOI 10.1016/0002-9149(92)90624-8; SOBEL BE, 1991, AM J CARDIOL, V68, P382, DOI 10.1016/0002-9149(91)90836-A; Speizer, 1976, NATURAL HIST CHRONIC, P218; The GUSTO Angiographic Investigators, 1994, NEW ENGL J MED, V330, P516; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; TIEFENBRUNN AJ, 1991, FIBRINOLYSIS, V5, P1, DOI 10.1016/0268-9499(91)90073-D; TOPOL E, 1994, CIRCULATION, V90, P1631; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1990, LANCET, V336, P71; VANDEWERF F, 1995, EUR HEART J, V16, P1024; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586; Wallentin L, 1996, LANCET, V347, P561; WALLENTIN L, 1990, LANCET, V336, P827; WARREN KS, 1993, ANN NY ACAD SCI, V703, P1, DOI 10.1111/j.1749-6632.1993.tb26327.x; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WILCOX RG, 1988, LANCET, V2, P525; Woods KL, 1996, LANCET, V347, P1203, DOI 10.1016/S0140-6736(96)90732-1; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	102	235	241	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					847	860		10.1056/NEJM199703203361207	http://dx.doi.org/10.1056/NEJM199703203361207			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN371	9062095				2022-12-28	WOS:A1997WN37100007
J	Hannan, EL; Racz, M; Ryan, TJ; McCallister, BD; Johnson, LW; Arani, DT; Guerci, AD; Sosa, J; Topol, EJ				Hannan, EL; Racz, M; Ryan, TJ; McCallister, BD; Johnson, LW; Arani, DT; Guerci, AD; Sosa, J; Topol, EJ			Coronary angioplasty volume-outcome relationships for hospitals and cardiologists	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; BYPASS GRAFT-SURGERY; SURGICAL VOLUME; MORTALITY; OPERATIONS; QUALITY; MODELS	Objective.-To assess the relationship between each of 2 provider volume measures (annual hospital volume and annual cardiologist volume) for percutaneous transluminal coronary angioplasty (PTCA) and 2 outcomes of PTCA (in-hospital mortality and same-stay coronary artery bypass graft [CABG] surgery). Design.-Cohort study, using data from January 1, 1991, through December 31, 1994, from the Coronary Angioplasty Reporting System of the New York State Department of Health. Setting.-Thirty-one hospitals in New York State in which PTCA was performed during 1991-1994. Patients.-All 62 670 patients discharged after undergoing PTCA in these hospitals during 1991-1994. Main Outcome Measures.-Rates of in-hospital mortality and CABG surgery during the same stay as the PTCA. Results.-The overall in-hospital mortality rate for patients undergoing PTCA in New York during 1991-1994 was 0.90%, and the same-stay CABG surgery rate was 3.43%. Patients undergoing PTCA in hospitals with annual PTCA volumes less than 600 experienced a significantly higher risk-adjusted in-hospital mortality rate of 0.96% (95% confidence interval [CI], 0.91%-1.01%) and risk-adjusted same-stay CABG surgery rate of 3.92% (95% CI, 3.76%-4.08%). Patients undergoing PTCA by cardiologists with annual PTCA volumes less than 75 had mortality rates of 1.03% (95% CI, 0.91%-1.17%) and same-stay CABG surgery rates of 3.93% (95% CI, 3.65%-4.24%); both of these rates were also significantly higher than the rates for all patients. Also, same-stay CABG surgery rates for patients undergoing PTCA in hospitals with annual volumes of 600 to 999 performed by cardiologists with annual volumes of 75 to 174 (2.99%; 95% CI, 2.69%-3.31%) and 175 or more (2.84%; 95% CI, 2.57%-3.14%) were significantly lower than the overall statewide rate (3.43%). Conclusions.-In New York State, both hospital PTCA volume and cardiologist PTCA volume are significantly inversely related to in-hospital mortality rate and same-stay CABG surgery rate for patients undergoing PTCA.	BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; ST LUKES HOSP, MID AMER HEART INST, KANSAS CITY, MO 64111 USA; SUNY SYRACUSE, HLTH SCI CTR, SYRACUSE, NY 13210 USA; ST JOSEPHS HOSP, SYRACUSE, NY USA; SUNY BUFFALO, BUFFALO, NY USA; BUFFALO GEN HOSP, BUFFALO, NY 14203 USA; ST FRANCIS HOSP, ROSLYN, NY USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA	Boston University; Saint Luke's Hospital - Missouri; Saint Luke's Mid America Heart Institute; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center; Cleveland Clinic Foundation	Hannan, EL (corresponding author), SUNY ALBANY, DEPT HLTH POLICY, 1 UNIV PL, RENSSELAER, NY 12144 USA.			Topol, Eric/0000-0002-1478-4729	AHRQ HHS [HS06503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM COLL CARD AM H, 1993, J AM COLL CARDIOL, V12, P2033; *AM HEART ASS, 1992, HEART STROK FACTS 19; DELONG ER, IN PRESS STAT MED; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1992, HEALTH SERV RES, V27, P517; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HOSMER DW, 1995, STAT MED, V14, P2161, DOI 10.1002/sim.4780141909; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; KELLY JV, 1987, HEALTH SERV RES, V22, P369; KIMMEL SE, 1995, JAMA-J AM MED ASSOC, V274, P1137, DOI 10.1001/jama.274.14.1137; LUFT HS, 1980, MED CARE, V18, P940, DOI 10.1097/00005650-198009000-00006; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LUFT HS, 1990, HOSPITAL VOLUME PHYS; MAERKI SC, 1986, MED CARE, V24, P148, DOI 10.1097/00005650-198602000-00006; RITCHIE JL, 1993, CIRCULATION, V88, P2735, DOI 10.1161/01.CIR.88.6.2735; *SAS I INC, 1986, STAT AN SYST SAS; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SLOAN FA, 1986, SURGERY, V99, P446	23	324	326	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					892	898		10.1001/jama.277.11.892	http://dx.doi.org/10.1001/jama.277.11.892			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062327				2022-12-28	WOS:A1997WM77400032
J	Makarov, VL; Hirose, Y; Langmore, JP				Makarov, VL; Hirose, Y; Langmore, JP			Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening	CELL			English	Article							AQUATICUS DNA-POLYMERASE; MACRONUCLEAR DNA; 3' TERMINUS; S-PHASE; CELLS; ELONGATION; ORIGIN; YEAST; ORGANIZATION; TETRAHYMENA	The chromosomes of lower eukaryotes have short telomeric 3' extensions. Using a primer-extension/nick-translation technique and nondenaturing hybridization, we find long 3' G-rich tails at human chromosome ends in mortal primary fibroblasts, umbilical vein endothelial cells, and leukocytes, as well as in immortalized fibroblasts. For all cells tested, >80% of the telomeres have long G-rich overhangs, averaging 130-210 bases in length, in disagreement with the conventional model for incomplete lagging-strand replication, which predicts overhangs on 50% of the chromosome ends. The observed G tails must exist during most of the cell cycle and probably result from degradation of both chromosome ends. The average lengths of the G tails are quantitatively consistent with the observed rates of human chromosome shortening.	UNIV MICHIGAN,DEPT BIOL SCI,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Makarov, VL (corresponding author), UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109, USA.							ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; BIESSMANN H, 1988, EMBO J, V7, P1081, DOI 10.1002/j.1460-2075.1988.tb02916.x; Birren BW, 1993, PULSED FIELD GEL ELE, DOI [10.1016/B978-0-12-101290-8.50002-X, DOI 10.1016/B978-0-12-101290-8.50002-X]; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CARDENAS ME, 1993, GENE DEV, V7, P870; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Greider Carol W., 1995, Cold Spring Harbor Monograph Series, V29, P35; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; HARLEY CB, 1995, COLD SPRING HARBOR M, V29, P247; HENDERSON E, 1988, EUKARYOTIC DNA REPLI, V6, P453; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Henderson Eric, 1995, Cold Spring Harbor Monograph Series, V29, P11; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LONGLEY MJ, 1990, NUCLEIC ACIDS RES, V18, P7317, DOI 10.1093/nar/18.24.7317; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; MAKAROV VL, 1993, CELL, V73, P775, DOI 10.1016/0092-8674(93)90256-P; Maniatis T., 1982, MOL CLONING; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PLUTA AF, 1982, NUCLEIC ACIDS RES, V10, P8145, DOI 10.1093/nar/10.24.8145; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SHAY JW, 1994, METH MOL G, V5, P263; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; Strahl C, 1996, MOL CELL BIOL, V16, P53; TSENG BY, 1979, J MOL BIOL, V129, P531, DOI 10.1016/0022-2836(79)90467-4; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	54	719	751	0	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					657	666		10.1016/S0092-8674(00)81908-X	http://dx.doi.org/10.1016/S0092-8674(00)81908-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054505	Bronze			2022-12-28	WOS:A1997WM41300011
J	Jones, DG; Harris, RJ				Jones, DG; Harris, RJ			Contending for the dead	NATURE			English	Editorial Material											Jones, DG (corresponding author), UNIV OTAGO,DEPT ANAT & STRUCT BIOL,POB 913,DUNEDIN,NEW ZEALAND.								0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					15	16		10.1038/386015a0	http://dx.doi.org/10.1038/386015a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052772				2022-12-28	WOS:A1997WL74600022
J	Sethi, T				Sethi, T			Science, medicine, and the future - Lung cancer	BRITISH MEDICAL JOURNAL			English	Review							CARCINOMA		UNIV EDINBURGH,SCH MED,RESP MED UNIT,RAYNE LAB,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh								AQUAYO SM, 1989, J CLIN INVEST, V84, P1105; MANDELBOIM O, 1995, NAT MED, V1, P1179, DOI 10.1038/nm1195-1179; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SCHULOF R S, 1988, Molecular Biotherapy, V1, P30; SETHI T, 1992, CANCER RES, V52, pS2737; STRIETER RM, 1995, J LEUKOCYTE BIOL, V57, P752, DOI 10.1002/jlb.57.5.752; TAKITA H, 1991, J SURG ONCOL, V46, P9, DOI 10.1002/jso.2930460104; Tallett A, 1996, CANCER RES, V56, P4255; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3	9	8	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					652	655		10.1136/bmj.314.7081.652	http://dx.doi.org/10.1136/bmj.314.7081.652			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066480	Green Published			2022-12-28	WOS:A1997WL41800029
J	Madhani, HD; Fink, GR				Madhani, HD; Fink, GR			Combinatorial control required for the specificity of yeast MAPK signaling	SCIENCE			English	Article							DNA-BINDING DOMAIN; SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; STE12 PROTEIN; CELL-TYPE; TRANSCRIPTION; ELEMENTS; GENE; ACTIVATION; EXPRESSION	In yeast, an overlapping set of mitogen-activated protein kinase (MAPK) signaling components controls mating, haploid invasion, and pseudohyphal development. Paradoxically, a single downstream transcription factor, Ste12, is necessary for the execution of these distinct programs. Developmental specificity was found to require a transcription factor of the TEA/ATTS family, Tec1, which cooperates with Ste12 during filamentous and invasive growth. Purified derivatives of Ste12 and Tec1 bind cooperatively to enhancer elements called filamentation and invasion response elements (FREs), which program transcription that is specifically responsive to the MAPK signaling components required for filamentous growth. An FRE in the TEC1 promoter functions in a positive feedback loop required for pseudohyphal development.			Madhani, HD (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Madhani, Hiten/0000-0001-7400-6657				ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; ANDRIANOPOULOS A, 1994, MOL CELL BIOL, V14, P2503, DOI 10.1128/MCB.14.4.2503; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MADHANI HD, UNPUB; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; MOSCH HU, IN PRESS GENETICS; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wittenberg C, 1996, CURR OPIN CELL BIOL, V8, P223, DOI 10.1016/S0955-0674(96)80069-X; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YUAN YLO, 1991, MOL CELL BIOL, V11, P5910, DOI 10.1128/MCB.11.12.5910	22	326	335	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1997	275	5304					1314	1317		10.1126/science.275.5304.1314	http://dx.doi.org/10.1126/science.275.5304.1314			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036858				2022-12-28	WOS:A1997WK64400045
J	Bregeon, F; Papazian, L; Visconti, A; Gregoire, R; Thirion, X; Gouin, F				Bregeon, F; Papazian, L; Visconti, A; Gregoire, R; Thirion, X; Gouin, F			Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilator-associated pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTECTED SPECIMEN BRUSH; INTENSIVE-CARE UNITS; CONTINUOUS MECHANICAL VENTILATION; QUANTITATIVE CULTURE TECHNIQUES; RANDOMIZED CONTROLLED TRIAL; CRITICALLY ILL PATIENTS; NOSOCOMIAL PNEUMONIA; ATTRIBUTABLE MORTALITY; BACTERIAL PNEUMONIA; HOSPITAL STAY	Objective.-To evaluate whether the mortality and the morbidity of ventilator-associated pneumonia, defined by positive result of protected specimen brush culture, was different from that defined by other methods, Design.-Matched-cohort study. All patients with clinical suspicion of pneumonia were investigated with protected specimen brush, bronchoalveolar lavage, and blind bronchial samplings. Two groups were defined: brush-positive patients (positive culture of the protected specimen brush) and brush-negative patients (negative culture of the protected specimen brush, but positive culture with another method). Setting.-A 14-bed medicosurgical intensive care unit (ICU) in an 850-bed teaching hospital, Patients.-All patients with documented ventilator-associated pneumonia over 4 years 9 months, A total of 102 cases documented by protected specimen brush culture and 223 documented by another sampling procedure, Patients were matched according to diagnosis on admission, age, sex, date of admission, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and date of onset of pneumonia, Main Outcome Measures.-Mortality rate, duration of mechanical ventilation, duration of ICU stay, duration of hospital stay, sampling methods, and microbiologic cultures, Results.-A total of 76 pairs were submitted for analysis, The effectiveness of matching was 81.85%, There was no difference in mortality between brush-positive patients and brush-negative patients, The ICU fatality rate was 38% in the brush-positive group and 39.4% in the brush-negative group (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.46-1.93), The hospital fatality rate was 41% (OR, 1;95% CI, 0.5-2.01), The mean (SD) duration of ventilation was 26 (23) days in the 2 groups (range, 3-132 days). The duration of ICU stay was 33 (27.4) days in the 2 groups (range, 3-152 days), Conclusions.-When confounding factors are controlled, patient outcome is the same if ventilator-associated pneumonia has been diagnosed by protected specimen brush or by another sampling method.	HOP ST MARGUERITE, DEPT ANESTHESIA & INTENS CARE, MARSEILLE, FRANCE; HOP ST MARGUERITE, DEPT MED INFORMAT, MARSEILLE, FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille								ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; AUBAS S, 1994, AM J RESP CRIT CARE, V149, P860, DOI 10.1164/ajrccm.149.4.8143047; BAKER AM, 1995, CHEST, V107, P85, DOI 10.1378/chest.107.1.85; Baker AM, 1996, AM J RESP CRIT CARE, V153, P343, DOI 10.1164/ajrccm.153.1.8542141; CHASTRE J, 1984, AM REV RESPIR DIS, V130, P924; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; COHEN IL, 1995, CHEST, V107, P1673, DOI 10.1378/chest.107.6.1673; CRAIG CP, 1984, AM J INFECT CONTROL, V12, P233, DOI 10.1016/0196-6553(84)90114-7; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DJEDAINI K, 1995, AM J RESP CRIT CARE, V152, P1562, DOI 10.1164/ajrccm.152.5.7582295; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; GROSS PA, 1983, AM J MED, V75, P658, DOI 10.1016/0002-9343(83)90453-9; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; KAPPSTEIN I, 1992, EUR J CLIN MICROBIOL, V11, P504, DOI 10.1007/BF01960804; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KNAUS W A, 1989, American Review of Respiratory Disease, V140, pS8; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; KOLLEF MH, 1995, ANN INTERN MED, V123, P168, DOI 10.7326/0003-4819-123-3-199508010-00002; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; LANGER M, 1987, INTENS CARE MED, V13, P342; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MOORE RD, 1984, AM J MED, V77, P657, DOI 10.1016/0002-9343(84)90358-9; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; PAPAZIAN L, 1995, AM J RESP CRIT CARE, V152, P1982, DOI 10.1164/ajrccm.152.6.8520766; PHAM LH, 1991, AM REV RESPIR DIS, V143, P1055, DOI 10.1164/ajrccm/143.5_Pt_1.1055; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; PRODHOM G, 1994, ANN INTERN MED, V120, P653, DOI 10.7326/0003-4819-120-8-199404150-00005; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; RELLO J, 1994, AM J RESP CRIT CARE, V150, P1545, DOI 10.1164/ajrccm.150.6.7952612; RELLO J, 1991, CHEST, V100, P439, DOI 10.1378/chest.100.2.439; ROUBY JJ, 1994, INTENS CARE MED, V20, P187, DOI 10.1007/BF01704698; ROUBY JJ, 1989, ANESTHESIOLOGY, V71, P679, DOI 10.1097/00000542-198911000-00010; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; *SAS I INC, 1988, SAS US GUID, P126; TORRES A, 1994, AM J RESP CRIT CARE, V149, P324, DOI 10.1164/ajrccm.149.2.8306025; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; VANSAENE HKF, 1992, REAN URG, V1, P385; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; WAYNE WD, 1995, BIOSTATISTICS FDN AN, P235; WIMBERLEY N, 1979, AM REV RESPIR DIS, V119, P337	51	45	47	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					655	662		10.1001/jama.277.8.655	http://dx.doi.org/10.1001/jama.277.8.655			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039885				2022-12-28	WOS:A1997WJ49800035
J	Levy, JA				Levy, JA			Three new human herpesviruses (HHV6, 7, and 8)	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; EPSTEIN-BARR-VIRUS; POTENTIAL ANIMAL-MODEL; KAPOSIS-SARCOMA; LYMPHOCYTES-T; DNA-SEQUENCES; TYPE-1 REPLICATION; PERIPHERAL-BLOOD; INFECTION	Three new human herpesviruses have been recognised in the past decade, and add further to our knowledge of human diseases with potential viral aetiologies, These viruses can be included with the other known human herpesviruses found in normal body secretions, particularly saliva, HHV6 and HHV7 have been associated with febrile illnesses and the childhood disease, exanthem subitum, HHV8 seems to resemble Epstein-Barr virus in its possible transforming properties and poses challenging questions for researchers directed at determining its potential role in lymphomas and Kaposi's sarcoma, Research on these herpesviruses can provide valuable new insights into virus/host relationships and mechanisms involved in replicative and latent stages of virus infection.			Levy, JA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,DIV HEMATOL ONCOL,SAN FRANCISCO,CA 94143, USA.							ABLASHI DV, 1995, CLIN DIAGN VIROL, V4, P1, DOI 10.1016/0928-0197(95)00005-S; ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; Blackbourn D. J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P564; Blackbourn DJ, 1997, AIDS, V11, P249, DOI 10.1097/00002030-199702000-00016; BLACKBOURN DJ, 1997, IN PRESS LANCET, V349; Boldogh I, 1996, CLIN INFECT DIS, V23, P406, DOI 10.1093/clinids/23.2.406; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CARRIGAN DR, 1990, J INFECT DIS, V162, P844, DOI 10.1093/infdis/162.4.844; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; CHEN M, 1994, J VIROL, V68, P1173, DOI 10.1128/JVI.68.2.1173-1178.1994; Cone RW, 1996, J CLIN MICROBIOL, V34, P877, DOI 10.1128/JCM.34.4.877-881.1996; Corbellino M, 1996, NEW ENGL J MED, V334, P1341, DOI 10.1056/NEJM199605163342019; Decker LL, 1996, J EXP MED, V184, P283, DOI 10.1084/jem.184.1.283; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; FLAMAND L, 1993, J VIROL, V67, P6768, DOI 10.1128/JVI.67.11.6768-6777.1993; FLAMAND L, 1995, BLOOD, V85, P1263, DOI 10.1182/blood.V85.5.1263.bloodjournal8551263; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; FRENKEL N, 1990, P NATL ACAD SCI USA, V87, P748, DOI 10.1073/pnas.87.2.748; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; Gyulai R, 1996, LANCET, V347, P1837, DOI 10.1016/S0140-6736(96)91658-X; HALL CB, 1994, NEW ENGL J MED, V331, P432, DOI 10.1056/NEJM199408183310703; He J, 1996, J VIROL, V70, P1296, DOI 10.1128/JVI.70.2.1296-1300.1996; HORVAT RT, 1989, J VIROL, V63, P970, DOI 10.1128/JVI.63.2.970-973.1989; Huang YQ, 1996, J CLIN INVEST, V97, P2803, DOI 10.1172/JCI118735; Katsafanas GC, 1996, P NATL ACAD SCI USA, V93, P9788, DOI 10.1073/pnas.93.18.9788; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Knox KK, 1996, J ACQ IMMUN DEF SYND, V11, P370, DOI 10.1097/00042560-199604010-00007; KONDO K, 1993, J INFECT DIS, V167, P1197, DOI 10.1093/infdis/167.5.1197; LEACH CT, 1994, J INFECT DIS, V169, P1281, DOI 10.1093/infdis/169.6.1281; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; LEVY JA, 1990, VIROLOGY, V178, P113, DOI 10.1016/0042-6822(90)90384-4; LEVY JA, 1990, LANCET, V335, P1047, DOI 10.1016/0140-6736(90)92628-U; LEVY JA, 1990, J CLIN MICROBIOL, V28, P2362, DOI 10.1128/JCM.28.10.2362-2364.1990; LEVY JA, 1995, LANCET, V346, P786, DOI 10.1016/S0140-6736(95)91611-3; Li JJ, 1996, AM J PATHOL, V148, P1741; LUPPI M, 1995, J MED VIROL, V47, P105, DOI 10.1002/jmv.1890470119; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUSSO P, 1990, J VIROL, V64, P2751, DOI 10.1128/JVI.64.6.2751-2758.1990; LUSSO P, 1994, AIDS RES HUM RETROV, V10, P181, DOI 10.1089/aid.1994.10.181; LUSSO P, 1993, NATURE, V362, P458, DOI 10.1038/362458a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1994, P NATL ACAD SCI USA, V91, P3872, DOI 10.1073/pnas.91.9.3872; MILLER G, 1971, P SOC EXP BIOL MED, V137, P1459; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; OKUNO T, 1995, J CLIN MICROBIOL, V33, P1968, DOI 10.1128/JCM.33.7.1968-1970.1995; OKUNO T, 1989, J CLIN MICROBIOL, V27, P651, DOI 10.1128/JCM.27.4.651-653.1989; PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201; RAZZAQUE A, 1993, VIROLOGY, V195, P113, DOI 10.1006/viro.1993.1351; Renne R, 1996, J VIROL, V70, P8151, DOI 10.1128/JVI.70.11.8151-8154.1996; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; REUX I, 1992, AM J OPHTHALMOL, V114, P375, DOI 10.1016/S0002-9394(14)71814-8; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sada E, 1996, J CLIN MICROBIOL, V34, P2320, DOI 10.1128/JCM.34.9.2320-2321.1996; Said JW, 1996, BLOOD, V87, P4937, DOI 10.1182/blood.V87.12.4937.bloodjournal87124937; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Singh N, 1996, ANN INTERN MED, V124, P1065, DOI 10.7326/0003-4819-124-12-199606150-00007; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SPIRA TJ, 1990, J INFECT DIS, V161, P567, DOI 10.1093/infdis/161.3.567; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; STEEPER TA, 1990, AM J CLIN PATHOL, V93, P776, DOI 10.1093/ajcp/93.6.776; TAKAHASHI K, 1989, J VIROL, V63, P3161, DOI 10.1128/JVI.63.7.3161-3163.1989; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; WYATT LS, 1992, J VIROL, V66, P3206, DOI 10.1128/JVI.66.5.3206-3209.1992; WYATT LS, 1991, J VIROL, V65, P6260, DOI 10.1128/JVI.65.11.6260-6265.1991; YADAV M, 1994, J NATL CANCER I, V86, P1792, DOI 10.1093/jnci/86.23.1792; YALCIN S, 1994, MICROBIOL IMMUNOL, V38, P587, DOI 10.1111/j.1348-0421.1994.tb01827.x; YAMANISHI K, 1988, LANCET, V1, P1065; YASUKAWA M, 1993, J VIROL, V67, P6259, DOI 10.1128/JVI.67.10.6259-6264.1993; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641	82	95	102	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					558	563		10.1016/S0140-6736(97)80119-5	http://dx.doi.org/10.1016/S0140-6736(97)80119-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048803				2022-12-28	WOS:A1997WJ51200042
J	Schmidt, A; Bickle, M; Beck, T; Hall, MN				Schmidt, A; Bickle, M; Beck, T; Hall, MN			The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2	CELL			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE GENE; RAS SUPERFAMILY GENES; CELL POLARITY; BUDDING YEAST; BUD FORMATION; CDC42; RAPAMYCIN; ENCODES; GROWTH	The Saccharomyces cerevisiae phosphatidylinositol kinase homolog TOR2 is required for organization of the actin cytoskeleton. Overexpression of RHO1 or RHO2, encoding Rho-like GTPases, or ROM2, encoding a GDP/GTP exchange factor for RHO1 and RHO2, suppresses a tor2 mutation. Deletion of SAC7, a gene originally identified as a suppressor of an actin mutation, also suppresses a tor2 mutation. SAC7 is a novel GTPase-activating protein for RHO1. ROM2 exchange activity is reduced in a tor2 mutant, and overexpression of ROM2 lacking its PH domain can no longer suppress a tor2 mutation. Thus, TOR2 signals to the actin cytoskeleton through a GTPase switch composed of RHO1, RHO2, ROM2, and SAC7. TOR2 activates this switch via ROM2, possibly via the ROM2 PH domain.	UNIV BASEL, DEPT BIOCHEM, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of Basel				Hall, Michael N/0000-0002-2998-0757				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Chen GC, 1996, MOL CELL BIOL, V16, P1376; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; DUNN TM, 1990, MOL CELL BIOL, V10, P2308, DOI 10.1128/MCB.10.5.2308; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Imai J, 1996, GENETICS, V142, P359; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KRON SJ, 1995, CURR OPIN CELL BIOL, V7, P845, DOI 10.1016/0955-0674(95)80069-7; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; MULLER L, 1994, NUCLEIC ACIDS RES, V22, P3151, DOI 10.1093/nar/22.15.3151; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1993, J BIOL CHEM, V268, P24629; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	69	257	267	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1997	88	4					531	542		10.1016/S0092-8674(00)81893-0	http://dx.doi.org/10.1016/S0092-8674(00)81893-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038344	Bronze			2022-12-28	WOS:A1997WJ69100013
J	Seglen, PO				Seglen, PO			Why the impact factor of journals should not be used for evaluating research	BRITISH MEDICAL JOURNAL			English	Article							CITATION ANALYSIS; SCIENCE; FIELD				Seglen, PO (corresponding author), INST STUDIES RES & HIGHER EDUC,HEGDENHAUGSVEIEN 31,N-0352 OSLO,NORWAY.							Andersen H, 1996, DANSK SOCIOLOGI, V2, P72; ANDERSEN H, 1996, BIBLIOTEKSARBEJDE, V17, P19; Artus HM, 1996, SCIENTOMETRICS, V37, P297, DOI 10.1007/BF02093626; BAUIN S, 1992, REPRESENTATIONS SCI, P225; Bourke P, 1996, SCIENTOMETRICS, V35, P199, DOI 10.1007/BF02018478; BRAUN T, 1995, SCIENTOMETRICS, V34, P207, DOI 10.1007/BF02020421; Brenner, 1995, NATURE, V375, P624; CALZA L, 1995, NATURE, V374, P492, DOI 10.1038/374492a0; COLE S, 1981, SCIENCE, V214, P881, DOI 10.1126/science.7302566; Drettner B, 1994, Lakartidningen, V91, P744; ERNST E, 1993, NATURE, V363, P296, DOI 10.1038/363296a0; FOLLY G, 1981, SCIENTOMETRICS, V3, P135, DOI 10.1007/BF02025636; GARFIELD E, 1972, SCIENCE, V178, P471, DOI 10.1126/science.178.4060.471; GOMPERTS MC, 1968, J DOC, V24, P113, DOI 10.1108/eb026448; GORDON MD, 1984, SOC STUD SCI, V14, P27, DOI 10.1177/030631284014001003; Gotzsche P C, 1995, Ugeskr Laeger, V157, P5075; HAMILTON DP, 1991, SCIENCE, V251, P25, DOI 10.1126/science.1986409; HAMILTON DP, 1990, SCIENCE, V250, P1331, DOI 10.1126/science.2255902; Hansen H. F., 1995, STYRING FORSKNING KA; HARGENS LL, 1984, AM SOCIOL REV, V49, P685, DOI 10.2307/2095425; Korevaar JC, 1996, SCIENTOMETRICS, V37, P117, DOI 10.1007/BF02093488; LANGE L, 1985, SCIENTOMETRICS, V8, P205, DOI 10.1007/BF02016936; LEWISON G, 1995, NATURE, V377, P671, DOI 10.1038/377671a0; MACROBERTS MH, 1989, J AM SOC INFORM SCI, V40, P342, DOI 10.1002/(SICI)1097-4571(198909)40:5<342::AID-ASI7>3.0.CO;2-U; MAFFULLI N, 1995, NATURE, V378, P760, DOI 10.1038/378760b0; Magri M, 1996, SCIENTOMETRICS, V35, P93, DOI 10.1007/BF02018235; Martin BR, 1996, SCIENTOMETRICS, V36, P343, DOI 10.1007/BF02129599; MARTON J, 1985, SCIENTOMETRICS, V7, P145, DOI 10.1007/BF02017142; Moed HF, 1996, SCIENTOMETRICS, V37, P105, DOI 10.1007/BF02093487; MOED HF, 1985, SCIENTOMETRICS, V8, P177, DOI 10.1007/BF02016935; Moed HF, 1996, NATURE, V381, P186, DOI 10.1038/381186a0; MOED HF, 1987, MEASUREMENT RES PERF; MOLLER AP, 1990, NATURE, V348, P480, DOI 10.1038/348480c0; NARIN F, 1976, J AM SOC INFORM SCI, V27, P25, DOI 10.1002/asi.4630270104; NARIN F, 1996, SCIENTOMETRICS, V6, P293; Schubert A, 1996, SCIENTOMETRICS, V36, P311, DOI 10.1007/BF02129597; Seglen P O, 1989, Nord Med, V104, P331; Seglen P.O., 1995, KLINISK KEMI NORDEN, V7, P59; SEGLEN PO, 1992, J AM SOC INFORM SCI, V43, P628, DOI 10.1002/(SICI)1097-4571(199210)43:9<628::AID-ASI5>3.0.CO;2-0; SEGLEN PO, 1994, J AM SOC INFORM SCI, V45, P1, DOI 10.1002/(SICI)1097-4571(199401)45:1<1::AID-ASI1>3.0.CO;2-Y; Seglen PO., 1989, TIDSSKR NOR LAEGEFOR, V31, P3229; SEGLEN PO, 1992, RES EVALUAT, V2, P143, DOI DOI 10.1093/REV/2.3.143; SEGLEN PO, 1989, NOP NYTT HELSINGFORS, V15, P2; SEGLEN PO, 1992, REPRESENTATIONS SCI, P240; Semenza G, 1996, FEBS LETT, V389, P1, DOI 10.1016/S0014-5793(96)90932-1; SENGUPTA IN, 1986, SCIENTOMETRICS, V10, P235, DOI 10.1007/BF02016772; SIVERTSEN G, 1991, NORSK FORSKNING INTE; Sorokin NI, 1996, NATURE, V380, P578, DOI 10.1038/380578c0; TAUBES G, 1993, SCIENCE, V260, P884, DOI 10.1126/science.8493516; Vinkler P, 1996, SCIENTOMETRICS, V36, P223, DOI 10.1007/BF02017315; Vinkler P, 1996, SCIENTOMETRICS, V35, P375, DOI 10.1007/BF02016908; VINKLER P, 1986, SCIENTOMETRICS, V10, P157, DOI 10.1007/BF02026039; [No title captured]	53	1485	1519	1	285	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					498	502						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WJ419	9056804	Green Published			2022-12-28	WOS:A1997WJ41900034
J	Mocroft, A; Youle, M; Morcinek, J; Sabin, CA; Gazzard, B; Johnson, MA; Phillips, AN				Mocroft, A; Youle, M; Morcinek, J; Sabin, CA; Gazzard, B; Johnson, MA; Phillips, AN			Survival after diagnosis of AIDS: A prospective observational study of 2625 patients	BRITISH MEDICAL JOURNAL			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; NEW-YORK-CITY; EUROPEAN PATIENTS; CONTROLLED TRIAL; ZIDOVUDINE; TRENDS; EXPERIENCE; PATTERNS; EFFICACY	Objective: To estimate median survival and changes in survival in patients diagnosed as having AIDS. Design: Prospective observational study. Setting: Clinics in two large London hospitals. Subjects: 2625 patients with AIDS seen between 1982 and July 1995. Main outcome measures: Survival, estimated using lifetable analyses, and factors associated with survival, identified from Cox proportional hazards models. Results: Median survival (20 months) was longer than previous estimates. The CD4 lymphocyte count at or before initial AIDS defining illness decreased significantly over time from 90 x 10(6)/l during 1987 or earlier to 40x10(6)/l during 1994 and 1995 (P < 0.0001). In the first three months after diagnosis, patients in whom AIDS was diagnosed after 1987 had a much lower risk of death (relative risk 0.44, 95% confidence interval 0.22 to 0.86; P=0.0.017) than patients diagnosed before 1987. When the diagnosis was based on oesophageal candidiasis or Kaposi's sarcoma, patients had a lower risk of death than when the diagnosis was based on Pneumocystis carinii pneumonia (0.21 (0.07 to 0.59), P=0.0030 and 0.37 (0.16 to 0.83), P=0.016). Three months after AIDS diagnosis, the risk of death was similar in patients whose diagnosis was made after and before 1987 (1.02 (0.79 to 1.31), P=0.91). There were no differences in survival between patients diagnosed during 1958-90, 1991-3, or 1994-5. Conclusions:In later years, patients were much more likely to survive their initial illness, but long term survival has remained poor. The decrease in CD4 lymphocyte count at AIDS diagnosis indicates that patients are being diagnosed as having AIDS at ever more advanced stages of immunodeficiency.	ROYAL FREE HOSP,DEPT THORAC MED,LONDON NW3 2PF,ENGLAND; CHELSEA & WESTMINSTER HOSP,KOBLER CTR,ST STEPHENS CLIN,LONDON SW10 9TH,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Imperial College London	Mocroft, A (corresponding author), ROYAL FREE HOSP,SCH MED,HIV RES UNIT,DEPT PRIMARY CARE & POPULAT,LONDON NW3 2PF,ENGLAND.		Mocroft, Amanda/G-8748-2011; Phillips, Andrew N/B-4427-2008; Mocroft, Amanda/C-1527-2008; Sabin, Caroline/C-2464-2008	Mocroft, Amanda/0000-0001-8316-1122; Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760				BLUM S, 1994, AM J EPIDEMIOL, V139, P351, DOI 10.1093/oxfordjournals.aje.a117007; Centers for Disease Control, 1987, MMWR-MORBID MORTAL W, V21, p1S; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; CHANG HGH, 1993, AM J EPIDEMIOL, V138, P341, DOI 10.1093/oxfordjournals.aje.a116864; CHEQUER P, 1992, AIDS, V6, P483, DOI 10.1097/00002030-199205000-00007; DOURNON E, 1988, LANCET, V2, P1297; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HILL AB, 1984, SHORT TXB MED STATIS; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LUNDGREN JD, 1995, ARCH INTERN MED, V155, P822, DOI 10.1001/archinte.155.8.822; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; LUO KH, 1995, AIDS, V9, P57, DOI 10.1097/00002030-199501000-00008; MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; PAYNE SF, 1990, J ACQ IMMUN DEF SYND, V3, pS14; PIETTE J, 1991, HEALTH SERV RES, V26, P75; PIETTE JD, 1992, EPIDEMIOLOGY, V3, P310, DOI 10.1097/00001648-199207000-00006; Rogers PA, 1996, AIDS, V10, P1571, DOI 10.1097/00002030-199611000-00017; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; *SAS I, 1990, SAS US GUID; SCHWARTLANDER B, 1992, AIDS, V6, P413, DOI 10.1097/00002030-199204000-00009; SEAGE GR, 1993, AM J PUBLIC HEALTH, V83, P72, DOI 10.2105/AJPH.83.1.72; TURNER BJ, 1991, J ACQ IMMUN DEF SYND, V4, P1059; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WHITMOREOVERTON SE, 1993, AIDS, V7, P415, DOI 10.1097/00002030-199303000-00017; 1996, COMMUN DI SREP CDR W, V6, P141	31	50	56	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					409	413		10.1136/bmj.314.7078.409	http://dx.doi.org/10.1136/bmj.314.7078.409			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040386	Green Published			2022-12-28	WOS:A1997WH29500028
J	Jin, FY; Nathan, C; Radzioch, D; Ding, A				Jin, FY; Nathan, C; Radzioch, D; Ding, A			Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide	CELL			English	Article							STABLE PROTEINASE-INHIBITOR; AIRWAY EPITHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; AMINO-ACID SEQUENCE; LEUKOPROTEASE INHIBITOR; MONOCLONAL-ANTIBODIES; ENDOTOXIN RESISTANCE; DIFFERENTIAL DISPLAY; INDUCED EMPHYSEMA; GAMMA-INTERFERON	To explore regulation of potentially lethal responses to bacterial lipopolysaccharide (LPS), we used differential display under LPS-free conditions to compare macrophage cell lines from two strains of mice congenic for a locus affecting LPS sensitivity. LPS-hyporesponsive cells, primary macrophages, and polymorphonuclear leukocytes transcribed secretory leukocyte protease inhibitor (SLPI), a known epithelial cell-derived inhibitor of leukocyte serine proteases. Transfection of macrophages with SLPI suppressed LPS-induced activation of NF-kappa B and production of nitric oxide and TNF alpha. The ability of interferon-gamma (IFN gamma) to restore LPS responsiveness is a hallmark of the LPS-hyporesponsive phenotype. IFN gamma suppressed expression of SLPI and restored LPS responsiveness to SLPI-producing cells. Thus, SLPI is an LPS-induced IFN gamma-suppressible phagocyte product that serves to inhibit LPS responses.	MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1A4, CANADA	McGill University	Jin, FY (corresponding author), CORNELL UNIV, COLL MED, BEATRICE & SAMUEL A SEAVER LAB, DEPT MED, NEW YORK, NY 10021 USA.			Radzioch, Danuta/0000-0002-1601-2757	NIAID NIH HHS [AI34543, AI30165] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030165, R01AI030165, R01AI034543, R21AI034543] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBINANTENISSEN JM, 1993, AM J PHYSIOL, V265, pL286, DOI 10.1152/ajplung.1993.265.3.L286; ABBINANTENISSEN JM, 1995, AM J PHYSIOL-LUNG C, V268, pL601, DOI 10.1152/ajplung.1995.268.4.L601; ABE T, 1991, J CLIN INVEST, V87, P2207, DOI 10.1172/JCI115255; BEESON PB, 1947, J EXP MED, V86, P29, DOI 10.1084/jem.86.1.29; BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BLASI E, 1987, EUR J IMMUNOL, V17, P1491, DOI 10.1002/eji.1830171016; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOHM B, 1992, EUR J BIOCHEM, V207, P773, DOI 10.1111/j.1432-1033.1992.tb17108.x; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Brandtzaeg P, 1996, J EXP MED, V184, P51, DOI 10.1084/jem.184.1.51; COSTA TE, 1992, J EXP MED, V175, P1669, DOI 10.1084/jem.175.6.1669; COUTINHO A, 1975, SCAND J IMMUNOL, V4, P129; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; DEWATER R, 1986, AM REV RESPIR DIS, V133, P882; DING A, 1990, J IMMUNOL, V145, P940; DING AH, 1995, J LEUKOCYTE BIOL, V57, P174, DOI 10.1002/jlb.57.1.174; DING AH, 1987, J EXP MED, V165, P733, DOI 10.1084/jem.165.3.733; DING AH, 1987, J IMMUNOL, V139, P1971; DRENTH J, 1980, J BIOL CHEM, V255, P2652; EISENBERG SP, 1990, J BIOL CHEM, V265, P7976; FINK E, 1986, BIOL CHEM H-S, V367, P567, DOI 10.1515/bchm3.1986.367.2.567; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; HELMIG R, 1995, EUR J OBSTET GYN R B, V59, P95, DOI 10.1016/0028-2243(94)02023-8; HOGAN MM, 1988, J IMMUNOL, V140, P513; Hutchison D C, 1987, Eur J Respir Dis Suppl, V153, P78; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; KANAYAMA N, 1995, BIOCHEM BIOPH RES CO, V207, P324, DOI 10.1006/bbrc.1995.1191; KRAMPS JA, 1989, AM REV RESPIR DIS, V140, P471, DOI 10.1164/ajrccm/140.2.471; KU GSB, 1981, J IMMUNOL, V126, P2209; KUUSREICHEL K, 1986, J IMMUNOL, V137, P472; LEE CH, 1993, AM REV RESPIR DIS, V147, P710, DOI 10.1164/ajrccm/147.3.710; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LUCEY EC, 1990, J LAB CLIN MED, V115, P224; MARUYAMA M, 1994, J CLIN INVEST, V94, P368, DOI 10.1172/JCI117331; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Ohlsson K, 1988, Adv Exp Med Biol, V240, P123; OHLSSON K, 1995, J ANDROL, V16, P64; PARKER MM, 1983, JAMA-J AM MED ASSOC, V250, P3324, DOI 10.1001/jama.250.24.3324; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; ROSENSTREICH DL, 1975, J IMMUNOL, V115, P777; RUDOLPHUS A, 1993, AM REV RESPIR DIS, V147, P442, DOI 10.1164/ajrccm/147.2.442; SALLENAVE JM, 1993, AM J RESP CELL MOL, V8, P126, DOI 10.1165/ajrcmb/8.2.126; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; STOLK J, 1993, PULM PHARMACOL, V6, P33, DOI 10.1006/pulp.1993.1006; SULTZER BM, 1993, IMMUNOBIOLOGY, V187, P257, DOI 10.1016/S0171-2985(11)80343-8; SULTZER BM, 1968, NATURE, V219, P1253, DOI 10.1038/2191253a0; SULTZER BM, 1976, INFECT IMMUN, V13, P1579, DOI 10.1128/IAI.13.6.1579-1584.1976; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TEGNER H, 1978, ACTA OTO-LARYNGOL, V85, P282, DOI 10.3109/00016487809111936; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; Tomova Svetlana, 1994, Journal of Molecular Recognition, V7, P31, DOI 10.1002/jmr.300070105; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; WATSON J, 1977, J IMMUNOL, V120, P422; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	68	317	334	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1997	88	3					417	426		10.1016/S0092-8674(00)81880-2	http://dx.doi.org/10.1016/S0092-8674(00)81880-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039268	hybrid			2022-12-28	WOS:A1997WG47900014
